



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 109354

**TO: Terra Gibbs
Location: CM1/12A12/11E12
Art Unit: 1635
Monday, December 01, 2003**

Case Serial Number: 09/954556

**From: David Schreiber
Location: Biotech-Chem Library
CM1-6A03
Phone: 308-4292**

david.schreiber@uspto.gov

Search Notes

THIS PAGE BLANK (USPTO)

SEARCH REQUEST FORM

Requestor's

Name: _____

Serial

Number: _____

Date: _____

Phone: _____

Art Unit: _____

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

ALL INFORMATION CONTAINED
HEREIN IS UNCLASSIFIED

STAFF USE ONLY

Date completed: 12/1

Searcher: P. Schreiber 308-4792

Terminal time: 93

Elapsed time: 17

CPU time: _____

Total time: _____

Number of Searches: _____

Number of Databases: _____

Search Site

____ STIC
____ ☒ CM-1 6A03
____ Pre-S

Type of Search

85 N.A. Sequence
____ A.A. Sequence
____ Structure
____ Bibliographic

Vendors

____ IG
____ STN
____ Dialog
____ APS
____ Geninfo
____ SDC
____ DARC/Questel
✓ Other CompuLink

This Page Blank (uspto)

Schreiber, David

109354

From: Gibbs, Terra
Sent: Friday, November 21, 2003 12:14 PM
To: Schreiber, David
Subject: Sequence search request...

Hi David,

Doug Schultz and Karen LaCourcie recommended that I send you this search request.

I have a request for a score over length search:

I need a length limited nucleotide sequence search against nucleobases 1317-2720 of SEQ ID NO:3 of USSN 09/954,556, where the returns are rank ordered based on the score over length/ratio as we've discussed. I need the lengths limited to hits between 8 and 50 nucleotides, and I'll take as many hits as you can import into excel (64,000?), and alignments for anything above .75 on the above ratio. Hope this is clear, please call me if it's not.

Terra Cotta Gibbs, Ph.D.
Art Unit 1635
CM1, 12A12
703-306-3221

THIS PAGE BLANK (USPTO)

Schreiber, David

From: Fredman, Jeffrey
Sent: Tuesday, November 25, 2003 7:06 AM
To: Schreiber, David
Cc: Gibbs, Terra
Subject: FW: Sequence search request (RUSH)...

PLEASE RUSH

I Approve.

Jeff Fredman

-----Original Message-----

From: Gibbs, Terra
Sent: Monday, November 24, 2003 10:40 AM
To: Fredman, Jeffrey
Subject: FW: Sequence search request (RUSH)...

This case is an AF. I need an immediate sequence search.
Could you please approve the RUSH?

Also, this sequence search request has to be sent to David Schreiber, instead of STIC-Biotech in general.

Thanks.

-----Original Message-----

From: Gibbs, Terra
Sent: Friday, November 21, 2003 12:14 PM
To: Schreiber, David
Subject: Sequence search request...

Hi David,


Doug Schultz and Karen LaCourcie recommended that I send you this search request.

I have a request for a score over length search:

I need a length limited nucleotide sequence search against nucleobases 1317-2720 of SEQ ID NO:3 of USSN 09/954,556, where the returns are rank ordered based on the score over length/ratio as we've discussed. I need the lengths limited to hits between 8 and 50 nucleotides, and I'll take as many hits as you can import into excel (64,000?), and alignments for anything above .75 on the above ratio. Hope this is clear, please call me if it's not.

Terra Cotta Gibbs, Ph.D.
Art Unit 1635
CM1, 12A12
703-306-3221

THIS PAGE BLANK (USPTO)



STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact *the searcher or contact*:

Mary Hale, Information Branch Supervisor
308-4258, CM1-1E01

Voluntary Results Feedback Form

➤ I am an examiner in Workgroup: Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC/Biotech-Chem Library CM1 – Circ. Desk



THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Comugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 1, 2003, 11:51:18 ; Search time 4 Seconds
(without alignments)
4.409 Million cell updates/sec

Title: us-09-954-556-3

Perfect score: 1404
Sequence: 1 tggagatattcttctactctg.....ccctcagtatccacacataaa 1404

Scoring table: IDENTITY_NTC
Gapop 10.0 , Gapext 0.5

Searched: 353 seqs, 6280 residues

Total number of hits satisfying chosen parameters: 706

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database : rge.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	33	2.4	39	1	AR007163
C 2	27.4	2.0	36	1	ACCESION:AR007163
C 3	27.4	2.0	36	1	ACCESION:AR007163
C 4	25.8	1.8	30	1	ACCESION:AR007163
C 5	25.8	1.8	30	1	ACCESION:AR007163
C 6	22.4	1.6	28	1	ACCESION:AR007163
C 7	21.4	1.5	25	1	ACCESION:AR007163
C 8	21	1.5	21	1	ACCESION:AR007163
C 9	21	1.5	21	1	ACCESION:AR007163
C 10	21	1.5	21	1	ACCESION:AR007163
C 11	20	1.4	20	1	ACCESION:AR007163
C 12	19.6	1.4	26	1	ACCESION:AR007163
C 13	18.8	1.3	22	1	ACCESION:AR007163
C 14	18.8	1.3	22	1	ACCESION:AR007163
C 15	18.8	1.3	22	1	ACCESION:AR007163
C 16	18.8	1.3	22	1	ACCESION:AR007163
C 17	18.8	1.3	23	1	ACCESION:AR007163
C 18	18.8	1.3	23	1	ACCESION:AR007163
C 19	18.6	1.3	20	1	ACCESION:AR007163
C 20	18.2	1.3	24	1	ACCESION:AR007163
C 21	18.2	1.3	24	1	ACCESION:AR007163
C 22	18.2	1.3	24	1	ACCESION:AR007163
C 23	18.2	1.3	24	1	ACCESION:AR007163
C 24	18.2	1.3	24	1	ACCESION:AR007163
C 25	17.8	1.3	21	1	ACCESION:AR007163
C 26	17.8	1.3	21	1	ACCESION:AR007163
C 27	17.4	1.2	19	1	ACCESION:AR007163
C 28	17.4	1.2	19	1	ACCESION:AR007163
C 29	17	1.2	20	1	ACCESION:AR007163
C 30	17	1.2	20	1	ACCESION:AR007163
C 31	17	1.2	20	1	ACCESION:AR007163
C 32	16.8	1.2	20	1	ACCESION:AR007163
C 33	16.8	1.2	20	1	ACCESION:AR007163

C 34	16.8	1.2	20	1	E23735	ACCESION:E23735
C 35	16.2	1.2	21	1	AR084555	ACCESION:AR084555
C 36	16.2	1.2	21	1	AR084576	ACCESION:AR084576
C 37	15.8	1.1	19	1	AX129010	ACCESION:AX129010
C 38	15.8	1.1	20	1	AR079558	ACCESION:AR079558
C 39	15.8	1.1	20	1	AR139522	ACCESION:AR139522
C 40	15.8	1.1	20	1	AR266054	ACCESION:AR266054
C 41	15.8	1.1	21	1	AX590585	ACCESION:AX590585
C 42	15.4	1.1	17	1	AR192109	ACCESION:AR192109
C 43	15.4	1.1	18	1	AX482165	ACCESION:AX482165
C 44	15.4	1.1	18	1	AX511404	ACCESION:AX511404
C 45	15.4	1.1	18	1	AX721765	ACCESION:AX721765
C 46	15.4	1.1	19	1	A95063	ACCESION:A95063
C 47	15.4	1.1	19	1	AR222435	ACCESION:AR222435
C 48	15.4	1.1	19	1	BD102783	ACCESION:BD102783
C 49	15.4	1.1	20	1	AR103195	ACCESION:AR103195
C 50	15.4	1.1	20	1	AX147705	ACCESION:AX147705
C 51	15.4	1.1	20	1	AX298917	ACCESION:AX298917
C 52	15.4	1.1	20	1	E44090	ACCESION:E44090
C 53	15.2	1.1	20	1	AR050627	ACCESION:AR050627
C 54	15.2	1.1	20	1	AR268232	ACCESION:AR268232
C 55	15.2	1.1	20	1	AR314742	ACCESION:AR314742
C 56	15.2	1.1	20	1	AX020769	ACCESION:AX020769
C 57	15.2	1.1	20	1	AX020775	ACCESION:AX020775
C 58	15.2	1.1	20	1	AX326944	ACCESION:AX326944
C 59	15.2	1.1	20	1	AX397785	ACCESION:AX397785
C 60	15.2	1.1	20	1	E12301	ACCESION:E12301
C 61	15.2	1.1	20	1	ATH527748	ACCESION:ATH527748
C 62	15.2	1.1	20	1	ATH527822	ACCESION:ATH527822
C 63	15.2	1.1	20	1	DOGH07B	ACCESION:DOGH07B
C 64	15.2	1.1	20	1	DOGITTA	ACCESION:DOGITTA
C 65	15	1.1	15	1	AR133380	ACCESION:AR133380
C 66	15	1.1	15	1	AR133381	ACCESION:AR133381
C 67	15	1.1	15	1	AR133382	ACCESION:AR133382
C 68	15	1.1	20	1	AX553634	ACCESION:AX553634
C 69	14.8	1.1	18	1	AR106794	ACCESION:AR106794
C 70	14.8	1.1	18	1	AR160861	ACCESION:AR160861
C 71	14.8	1.1	19	1	AX132279	ACCESION:AX132279
C 72	14.8	1.1	19	1	AX132280	ACCESION:AX132280
C 73	14.6	1.0	17	1	I23857	ACCESION:I23857
C 74	14.6	1.0	17	1	I25016	ACCESION:I25016
C 75	14.6	1.0	18	1	AX118055	ACCESION:AX118055
C 76	14.4	1.0	16	1	AX133183	ACCESION:AX133183
C 77	14.4	1.0	16	1	BD002055	ACCESION:BD002055
C 78	14.4	1.0	17	1	AR048076	ACCESION:AR048076
C 79	14.4	1.0	17	1	AR048079	ACCESION:AR048079
C 80	14.4	1.0	17	1	AR108979	ACCESION:AR108979
C 81	14.4	1.0	17	1	AR108982	ACCESION:AR108982
C 82	14.4	1.0	17	1	AR190227	ACCESION:AR190227
C 83	14.4	1.0	18	1	AR048082	ACCESION:AR048082
C 84	14.4	1.0	18	1	AR073390	ACCESION:AR073390
C 85	14.4	1.0	18	1	AR108985	ACCESION:AR108985
C 86	14.4	1.0	18	1	AR220012	ACCESION:AR220012
C 87	14	1.0	17	1	AX227662	ACCESION:AX227662
C 88	14	1.0	17	1	AX227663	ACCESION:AX227663
C 89	14	1.0	17	1	AX227664	ACCESION:AX227664
C 90	13.8	1.0	17	1	A20708	ACCESION:A20708
C 91	13.8	1.0	17	1	A21027	ACCESION:A21027
C 92	13.8	1.0	17	1	A95626	ACCESION:A95626
C 93	13.8	1.0	17	1	AR188717	ACCESION:AR188717
C 94	13.8	1.0	17	1	AR188718	ACCESION:AR188718
C 95	13.8	1.0	17	1	AR188719	ACCESION:AR188719
C 96	13.8	1.0	17	1	AR188869	ACCESION:AR188869
C 97	13.8	1.0	17	1	AR190226	ACCESION:AR190226
C 98	13.8	1.0	17	1	AR190291	ACCESION:AR190291
C 99	13.8	1.0	17	1	AR190292	ACCESION:AR190292
C 100	13.8	1.0	17	1	AR190329	ACCESION:AR190329
C 101	13.8	1.0	17	1	AR192186	ACCESION:AR192186
C 102	13.8	1.0	17	1	AR192196	ACCESION:AR192196
C 103	13.8	1.0	17	1	AR192197	ACCESION:AR192197
C 104	13.8	1.0	17	1	AR192198	ACCESION:AR192198
C 105	13.8	1.0	17	1	AR192199	ACCESION:AR192199
C 106	13.8	1.0	17	1	AR286013	ACCESION:AR286013

107	13.8	1.0	17	1	AR286406	ACCESSION:AR286406	180	13.4	1.0	17	1	194270	ACCESSION:194270
108	13.8	1.0	17	1	AX008727	ACCESSION:AX008727	181	13	0.9	14	1	AR119016	ACCESSION:AR119016
109	13.8	1.0	17	1	AX215402	ACCESSION:AX215402	182	13	0.9	15	1	AX328242	ACCESSION:AX328242
110	13.8	1.0	17	1	AX218180	ACCESSION:AX218180	183	13	0.9	17	1	AR030682	ACCESSION:AR030682
111	13.8	1.0	17	1	AX218315	ACCESSION:AX218315	184	13	0.9	17	1	AR196283	ACCESSION:AR196283
112	13.8	1.0	17	1	AX227058	ACCESSION:AX227058	185	13	0.9	17	1	AX216364	ACCESSION:AX216364
113	13.8	1.0	17	1	AX325661	ACCESSION:AX325661	186	13	0.9	17	1	AX227661	ACCESSION:AX227661
114	13.8	1.0	17	1	AX325662	ACCESSION:AX325662	187	13	0.9	17	1	AX688031	ACCESSION:AX688031
115	13.8	1.0	17	1	AX498838	ACCESSION:AX498838	188	13	0.9	17	1	AX688032	ACCESSION:AX688032
116	13.8	1.0	17	1	AX500369	ACCESSION:AX500369	189	13	0.9	17	1	AX688033	ACCESSION:AX688033
117	13.8	1.0	17	1	AX530613	ACCESSION:AX530613	190	13	0.9	17	1	AX688034	ACCESSION:AX688034
118	13.8	1.0	17	1	AX530614	ACCESSION:AX530614	191	13	0.9	17	1	AX688035	ACCESSION:AX688035
119	13.8	1.0	17	1	AX673357	ACCESSION:AX673357	192	13	0.9	17	1	137553	ACCESSION:137553
120	13.8	1.0	17	1	AX687587	ACCESSION:AX687587	193	13	0.9	17	1	137554	ACCESSION:137554
121	13.8	1.0	17	1	AX726093	ACCESSION:AX726093	194	13	0.9	17	1	194403	ACCESSION:194403
122	13.8	1.0	17	1	AX729373	ACCESSION:AX729373	195	13	0.9	17	1	194404	ACCESSION:194404
123	13.8	1.0	17	1	AX733343	ACCESSION:AX733343	196	12.8	0.9	16	1	AX282045	ACCESSION:AX282045
124	13.8	1.0	17	1	AX744528	ACCESSION:AX744528	197	12.8	0.9	16	1	AX284081	ACCESSION:AX284081
125	13.8	1.0	17	1	BD091430	ACCESSION:BD091430	198	12.8	0.9	16	1	AX284082	ACCESSION:AX284082
126	13.8	1.0	18	1	AR21030	ACCESSION:AR21030	199	12.8	0.9	17	1	AR19468	ACCESSION:AR19468
127	13.8	1.0	18	1	AR46964	ACCESSION:AR46964	200	12.8	0.9	17	1	AR024071	ACCESSION:AR024071
128	13.8	1.0	18	1	AR8187	ACCESSION:AR8187	201	12.8	0.9	17	1	AR036431	ACCESSION:AR036431
129	13.8	1.0	18	1	AR90154	ACCESSION:AR90154	202	12.8	0.9	17	1	AR039275	ACCESSION:AR039275
130	13.8	1.0	18	1	AR92272	ACCESSION:AR92272	203	12.8	0.9	17	1	AR045623	ACCESSION:AR045623
131	13.8	1.0	18	1	AR036682	ACCESSION:AR036682	204	12.8	0.9	17	1	AR045741	ACCESSION:AR045741
132	13.8	1.0	18	1	AR048072	ACCESSION:AR048072	205	12.8	0.9	17	1	AR046321	ACCESSION:AR046321
133	13.8	1.0	18	1	AR077364	ACCESSION:AR077364	206	12.8	0.9	17	1	AR046323	ACCESSION:AR046323
134	13.8	1.0	18	1	AR096633	ACCESSION:AR096633	207	12.8	0.9	17	1	AR047630	ACCESSION:AR047630
135	13.8	1.0	18	1	AR102333	ACCESSION:AR102333	208	12.8	0.9	17	1	AR048077	ACCESSION:AR048077
136	13.8	1.0	18	1	AR106793	ACCESSION:AR106793	209	12.8	0.9	17	1	AR048078	ACCESSION:AR048078
137	13.8	1.0	18	1	AR108975	ACCESSION:AR108975	210	12.8	0.9	17	1	AR048080	ACCESSION:AR048080
138	13.8	1.0	18	1	AR117984	ACCESSION:AR117984	211	12.8	0.9	17	1	AR048081	ACCESSION:AR048081
139	13.8	1.0	18	1	AR198571	ACCESSION:AR198571	212	12.8	0.9	17	1	AR108980	ACCESSION:AR108980
140	13.8	1.0	18	1	AR265427	ACCESSION:AR265427	213	12.8	0.9	17	1	AR108981	ACCESSION:AR108981
141	13.8	1.0	18	1	AR274624	ACCESSION:AR274624	214	12.8	0.9	17	1	AR108983	ACCESSION:AR108983
142	13.8	1.0	18	1	AR274625	ACCESSION:AR274625	215	12.8	0.9	17	1	AR108984	ACCESSION:AR108984
143	13.8	1.0	18	1	AX008729	ACCESSION:AX008729	216	12.8	0.9	17	1	AR186504	ACCESSION:AR186504
144	13.8	1.0	18	1	AX076043	ACCESSION:AX076043	217	12.8	0.9	17	1	AR186521	ACCESSION:AR186521
145	13.8	1.0	18	1	AX084246	ACCESSION:AX084246	218	12.8	0.9	17	1	AR187273	ACCESSION:AR187273
146	13.8	1.0	18	1	AX084249	ACCESSION:AX084249	219	12.8	0.9	17	1	AR188652	ACCESSION:AR188652
147	13.8	1.0	18	1	AX708786	ACCESSION:AX708786	220	12.8	0.9	17	1	AR190328	ACCESSION:AR190328
148	13.8	1.0	18	1	AX713201	ACCESSION:AX713201	221	12.8	0.9	17	1	AR192483	ACCESSION:AR192483
149	13.8	1.0	18	1	BD065700	ACCESSION:BD065700	222	12.8	0.9	17	1	AR192618	ACCESSION:AR192618
150	13.8	1.0	18	1	BD103233	ACCESSION:BD103233	223	12.8	0.9	17	1	AR224290	ACCESSION:AR224290
151	13.8	1.0	18	1	BD104044	ACCESSION:BD104044	224	12.8	0.9	17	1	AR275226	ACCESSION:AR275226
152	13.8	1.0	18	1	E39157	ACCESSION:E39157	225	12.8	0.9	17	1	AR286411	ACCESSION:AR286411
153	13.8	1.0	18	1	E39158	ACCESSION:E39158	226	12.8	0.9	17	1	AX215401	ACCESSION:AX215401
154	13.8	1.0	18	1	166360	ACCESSION:166360	227	12.8	0.9	17	1	AX215403	ACCESSION:AX215403
155	13.8	1.0	18	1	195705	ACCESSION:195705	228	12.8	0.9	17	1	AX216650	ACCESSION:AX216650
156	13.4	1.0	15	1	AR180165	ACCESSION:AR180165	229	12.8	0.9	17	1	AX216661	ACCESSION:AX216661
157	13.4	1.0	16	1	AB8174	ACCESSION:AB8174	230	12.8	0.9	17	1	AX216899	ACCESSION:AX216899
158	13.4	1.0	16	1	AB90141	ACCESSION:AB90141	231	12.8	0.9	17	1	AX217484	ACCESSION:AX217484
159	13.4	1.0	16	1	BD065687	ACCESSION:BD065687	232	12.8	0.9	17	1	AX217829	ACCESSION:AX217829
160	13.4	1.0	17	1	AA8870	ACCESSION:AA8870	233	12.8	0.9	17	1	AX217853	ACCESSION:AX217853
161	13.4	1.0	17	1	AR085293	ACCESSION:AR085293	234	12.8	0.9	17	1	AX226704	ACCESSION:AX226704
162	13.4	1.0	17	1	AR127158	ACCESSION:AR127158	235	12.8	0.9	17	1	AX227307	ACCESSION:AX227307
163	13.4	1.0	17	1	AR188867	ACCESSION:AR188867	236	12.8	0.9	17	1	AX227715	ACCESSION:AX227715
164	13.4	1.0	17	1	AR188868	ACCESSION:AR188868	237	12.8	0.9	17	1	AX264368	ACCESSION:AX264368
165	13.4	1.0	17	1	AR286277	ACCESSION:AR286277	238	12.8	0.9	17	1	AX264369	ACCESSION:AX264369
166	13.4	1.0	17	1	AX216933	ACCESSION:AX216933	239	12.8	0.9	17	1	AX265923	ACCESSION:AX265923
167	13.4	1.0	17	1	AX216934	ACCESSION:AX216934	240	12.8	0.9	17	1	AX265924	ACCESSION:AX265924
168	13.4	1.0	17	1	AX272527	ACCESSION:AX272527	241	12.8	0.9	17	1	AX272714	ACCESSION:AX272714
169	13.4	1.0	17	1	AX272715	ACCESSION:AX272715	242	12.8	0.9	17	1	AX422196	ACCESSION:AX422196
170	13.4	1.0	17	1	AX673499	ACCESSION:AX673499	243	12.8	0.9	17	1	AX422876	ACCESSION:AX422876
171	13.4	1.0	17	1	AX673500	ACCESSION:AX673500	244	12.8	0.9	17	1	AX423045	ACCESSION:AX423045
172	13.4	1.0	17	1	AX674421	ACCESSION:AX674421	245	12.8	0.9	17	1	AX498837	ACCESSION:AX498837
173	13.4	1.0	17	1	AX726400	ACCESSION:AX726400	246	12.8	0.9	17	1	AX498839	ACCESSION:AX498839
174	13.4	1.0	17	1	AX727626	ACCESSION:AX727626	247	12.8	0.9	17	1	AX500368	ACCESSION:AX500368
175	13.4	1.0	17	1	AX732816	ACCESSION:AX732816	248	12.8	0.9	17	1	AX500370	ACCESSION:AX500370
176	13.4	1.0	17	1	AX732843	ACCESSION:AX732843	249	12.8	0.9	17	1	AX530612	ACCESSION:AX530612
177	13.4	1.0	17	1	AX739491	ACCESSION:AX739491	250	12.8	0.9	17	1	AX530615	ACCESSION:AX530615
178	13.4	1.0	17	1	137420	ACCESSION:137420	251	12.8	0.9	17	1	AX615893	ACCESSION:AX615893
179	13.4	1.0	17	1	164698	ACCESSION:164698	252	12.8	0.9	17	1	AX615894	ACCESSION:AX615894

C 253	12.8	0.9	17	1	AX648748	ACCESSION:AX648748
C 254	12.8	0.9	17	1	AX648749	ACCESSION:AX648749
C 255	12.8	0.9	17	1	AX672107	ACCESSION:AX672107
C 256	12.8	0.9	17	1	AX672299	ACCESSION:AX672299
C 257	12.8	0.9	17	1	AX672663	ACCESSION:AX672663
C 258	12.8	0.9	17	1	AX673076	ACCESSION:AX673076
C 259	12.8	0.9	17	1	AX673485	ACCESSION:AX673485
C 260	12.8	0.9	17	1	AX674784	ACCESSION:AX674784
C 261	12.8	0.9	17	1	AX687397	ACCESSION:AX687397
C 262	12.8	0.9	17	1	AX687398	ACCESSION:AX687398
C 263	12.8	0.9	17	1	AX687586	ACCESSION:AX687586
C 264	12.8	0.9	17	1	AX687588	ACCESSION:AX687588
C 265	12.8	0.9	17	1	AX687609	ACCESSION:AX687609
C 266	12.8	0.9	17	1	AX687610	ACCESSION:AX687610
C 267	12.8	0.9	17	1	AX688397	ACCESSION:AX688397
C 268	12.8	0.9	17	1	AX688398	ACCESSION:AX688398
C 269	12.8	0.9	17	1	AX692517	ACCESSION:AX692517
C 270	12.8	0.9	17	1	AX692518	ACCESSION:AX692518
C 271	12.8	0.9	17	1	AX711055	ACCESSION:AX711055
C 272	12.8	0.9	17	1	AX723358	ACCESSION:AX723358
C 273	12.8	0.9	17	1	AX722882	ACCESSION:AX722882
C 274	12.8	0.9	17	1	AX723196	ACCESSION:AX723196
C 275	12.8	0.9	17	1	AX724155	ACCESSION:AX724155
C 276	12.8	0.9	17	1	AX724673	ACCESSION:AX724673
C 277	12.8	0.9	17	1	AX724703	ACCESSION:AX724703
C 278	12.8	0.9	17	1	AX725084	ACCESSION:AX725084
C 279	12.8	0.9	17	1	AX725777	ACCESSION:AX725777
C 280	12.8	0.9	17	1	AX725869	ACCESSION:AX725869
C 281	12.8	0.9	17	1	AX726992	ACCESSION:AX726992
C 282	12.8	0.9	17	1	AX727138	ACCESSION:AX727138
C 283	12.8	0.9	17	1	AX727199	ACCESSION:AX727199
C 284	12.8	0.9	17	1	AX727780	ACCESSION:AX727780
C 285	12.8	0.9	17	1	AX728341	ACCESSION:AX728341
C 286	12.8	0.9	17	1	AX728422	ACCESSION:AX728422
C 287	12.8	0.9	17	1	AX728590	ACCESSION:AX728590
C 288	12.8	0.9	17	1	AX728851	ACCESSION:AX728851
C 289	12.8	0.9	17	1	AX729046	ACCESSION:AX729046
C 290	12.8	0.9	17	1	AX729296	ACCESSION:AX729296
C 291	12.8	0.9	17	1	AX729326	ACCESSION:AX729326
C 292	12.8	0.9	17	1	AX729354	ACCESSION:AX729354
C 293	12.8	0.9	17	1	AX729580	ACCESSION:AX729580
C 294	12.8	0.9	17	1	AX730392	ACCESSION:AX730392
C 295	12.8	0.9	17	1	AX731487	ACCESSION:AX731487
C 296	12.8	0.9	17	1	AX731824	ACCESSION:AX731824
C 297	12.8	0.9	17	1	AX732003	ACCESSION:AX732003
C 298	12.8	0.9	17	1	AX732048	ACCESSION:AX732048
C 299	12.8	0.9	17	1	AX732049	ACCESSION:AX732049
C 300	12.8	0.9	17	1	AX733473	ACCESSION:AX733473
C 301	12.8	0.9	17	1	AX733774	ACCESSION:AX733774
C 302	12.8	0.9	17	1	AX733950	ACCESSION:AX733950
C 303	12.8	0.9	17	1	AX734767	ACCESSION:AX734767
C 304	12.8	0.9	17	1	AX734878	ACCESSION:AX734878
C 305	12.8	0.9	17	1	AX735178	ACCESSION:AX735178
C 306	12.8	0.9	17	1	AX735178	ACCESSION:AX735178
C 307	12.8	0.9	17	1	AX738552	ACCESSION:AX738552
C 308	12.8	0.9	17	1	AX738641	ACCESSION:AX738641
C 309	12.8	0.9	17	1	AX744527	ACCESSION:AX744527
C 310	12.8	0.9	17	1	AX744529	ACCESSION:AX744529
C 311	12.8	0.9	17	1	BD001175	ACCESSION:BD001175
C 312	12.8	0.9	17	1	BD001604	ACCESSION:BD001604
C 313	12.8	0.9	17	1	BD067344	ACCESSION:BD067344
C 314	12.8	0.9	17	1	BD067486	ACCESSION:BD067486
C 315	12.8	0.9	17	1	BD104906	ACCESSION:BD104906
C 316	12.8	0.9	17	1	BD107297	ACCESSION:BD107297
C 317	12.8	0.9	17	1	129872	ACCESSION:129872
C 318	12.8	0.9	17	1	137681	ACCESSION:137681
C 319	12.8	0.9	17	1	137682	ACCESSION:137682
C 320	12.8	0.9	17	1	152675	ACCESSION:152675
C 321	12.8	0.9	17	1	152793	ACCESSION:152793
C 322	12.8	0.9	17	1	153373	ACCESSION:153373
C 323	12.8	0.9	17	1	153375	ACCESSION:153375
C 324	12.8	0.9	17	1	154682	ACCESSION:154682
C 325	12.8	0.9	17	1	194531	ACCESSION:194531

ALIGNMENTS

326	12.8	0.9	17	1	194532	ACCESSION:194532
327	12.4	0.9	14	1	AR105805	ACCESSION:AR105805
328	12.4	0.9	14	1	AR214947	ACCESSION:AR214947
329	12.4	0.9	14	1	AR214949	ACCESSION:AR214949
C 330	12.4	0.9	14	1	BD123479	ACCESSION:BD123479
C 331	12.4	0.9	15	1	A12791	ACCESSION:A12791
C 332	12.4	0.9	15	1	A40008	ACCESSION:A40008
C 333	12.4	0.9	15	1	A46520	ACCESSION:A46520
C 334	12.4	0.9	15	1	A64369	ACCESSION:A64369
C 335	12.4	0.9	15	1	AR028988	ACCESSION:AR028988
C 336	12.4	0.9	15	1	AR028992	ACCESSION:AR028992
C 337	12.4	0.9	15	1	AR102668	ACCESSION:AR102668
C 338	12.4	0.9	15	1	AR133690	ACCESSION:AR133690
C 339	12.4	0.9	15	1	AR156870	ACCESSION:AR156870
C 340	12.4	0.9	15	1	AR156874	ACCESSION:AR156874
C 341	12.4	0.9	15	1	AR192985	ACCESSION:AR192985
C 342	12.4	0.9	15	1	AR262971	ACCESSION:AR262971
C 343	12.4	0.9	15	1	AX598512	ACCESSION:AX598512
C 344	12.4	0.9	15	1	AX598514	ACCESSION:AX598514
C 345	12.4	0.9	15	1	AX637907	ACCESSION:AX637907
C 346	12.4	0.9	15	1	E07289	ACCESSION:E07289
C 347	12.4	0.9	15	1	E11942	ACCESSION:E11942
C 348	12.4	0.9	15	1	I77589	ACCESSION:I77589
C 349	12.4	0.9	16	1	AR054087	ACCESSION:AR054087
C 350	12.4	0.9	16	1	AX132931	ACCESSION:AX132931
C 351	12.4	0.9	16	1	AX133152	ACCESSION:AX133152
C 352	12.4	0.9	16	1	AX320908	ACCESSION:AX320908
C 353	12.4	0.9	16	1	AX708809	ACCESSION:AX708809

RESULT 1

AR007163/c
LOCUS AR007163 Sequence 15 from patent US 5750371. 39 bp. DNA linear PAT 04-DEC-1998

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

FEATURES

BASE COUNT

Query Match

Best Local Similarity

Matches

Conservative

MisMatches

Indels

Gaps

0;

0;

REFERENCE 1 (bases 1 to 36)
 AUTHORS Champion-Arnaud,P., Ronsin,C., Gilbert,E., Gesnel,M.C.,
 Housseaint,E. and Breathnach,R.
 TITLE Multiple mRNAs code for proteins related to the BEK fibroblast
 growth factor receptor
 JOURNAL Oncogene 6 (6), 979-987 (1991)
 MEDLINE 91296403
 PUBMED 1648704
 REMARK GenBank staff at the National Library of Medicine created this
 entry [NCBI glibbsg 41355] from the original journal article.
 This sequence comes from Fig. 4b.
 FEATURES
 source location/Qualifiers
 1..36
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 /cell_type="leukocyte"
 BASE COUNT 13 a 9 c 5 g 9 t
 Query Match 2.0%; Score 27.4; DB 1; Length 36;
 Best Local Similarity 96.6%; Pred. No. 4.6;
 Matches 28; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2549 GAATTCACCTCTCAACCAATGAGGA 2577
 DB 1 GAATTCACCTCTCAACCAATGAGGA 29

RESULT 3
 LOCUS S41845S1 36 bp DNA linear PRI 09-MAY-2000
 DEFINITION TK25-fibroblast growth factor receptor {3, region} [human, normal
 leukocyte DNA, genomic, 36 nt, segment 1 of 2].
 ACCESSION S41845
 VERSION S41845.1 GI:232806
 KEYWORDS
 ORGANISM
 SOURCE
 1 of 2
 Homo sapiens (human)
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (bases 1 to 36)
 AUTHORS Champion-Arnaud,P., Ronsin,C., Gilbert,E., Gesnel,M.C.,
 Housseaint,E. and Breathnach,R.
 TITLE Multiple mRNAs code for proteins related to the BEK fibroblast
 growth factor receptor
 JOURNAL Oncogene 6 (6), 979-987 (1991)
 MEDLINE 91296403
 PUBMED 1648704
 REMARK GenBank staff at the National Library of Medicine created this
 entry [NCBI glibbsg 41845] from the original journal article.
 This sequence comes from Fig. 4b.
 FEATURES
 source location/Qualifiers
 1..36
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 /cell_type="leukocyte"
 BASE COUNT 13 a 9 c 5 g 9 t
 Query Match 2.0%; Score 27.4; DB 1; Length 36;
 Best Local Similarity 96.6%; Pred. No. 4.6;
 Matches 28; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2549 GAATTCACCTCTCAACCAATGAGGA 2577
 DB 1 GAATTCACCTCTCAACCAATGAGGA 29

RESULT 4
 LOCUS A29208/c 30 bp DNA linear PAT 30-JUN-1995
 A29208 30 bp DNA linear PAT 30-JUN-1995

DEFINITION DNA probe from patent WO9111459.
 ACCESSION A29208
 VERSION A29208.1 GI:1248929
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE 1 (bases 1 to 30)
 AUTHORS
 TITLE
 JOURNAL
 PATent: WO 911459-A 2 08-AUG-1991;
 FEATURES
 source location/Qualifiers
 1..30
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"
 BASE COUNT 5 a 8 c 11 g 6 t
 Query Match 1.8%; Score 25.8; DB 1; Length 30;
 Best Local Similarity 93.1%; Pred. No. 6;
 Matches 27; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2488 TGTTGCATGCAGTGCCTCCAGAGACC 2516
 DB 30 TGCTGGCATGCAGTGCCTCCAGAGACC 2

RESULT 5
 LOCUS A29211/c 30 bp DNA linear PAT 30-JUN-1995
 DEFINITION Oligonucleotide OAB984 from patent WO9111459.
 ACCESSION A29211
 VERSION A29211.1 GI:1248932
 KEYWORDS
 ORGANISM
 SOURCE
 1 (bases 1 to 30)
 REFERENCE 1 (bases 1 to 30)
 AUTHORS
 TITLE
 JOURNAL
 PATent: WO 911459-A 6 08-AUG-1991;
 FEATURES
 source location/Qualifiers
 1..30
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"
 BASE COUNT 5 a 8 c 11 g 6 t
 Query Match 1.8%; Score 25.8; DB 1; Length 30;
 Best Local Similarity 93.1%; Pred. No. 6;
 Matches 27; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2488 TGTTGCATGCAGTGCCTCCAGAGACC 2516
 DB 30 TGCTGGCATGCAGTGCCTCCAGAGACC 2

RESULT 6
 LOCUS AR020621/c 28 bp DNA linear PAT 05-DEC-1998
 DEFINITION Sequence 5 from patent US 5789182.
 ACCESSION AR020621
 VERSION AR020621.1 GI:3975236
 KEYWORDS
 ORGANISM
 SOURCE
 Unknown.
 Unclassified.
 REFERENCE 1 (bases 1 to 28)
 AUTHORS Yayon,A., Ornitz,D.M., Klagsbrun,M., Leder,P. and Flanagan,J.G.
 TITLE System for assaying binding to a heparin-binding growth factor
 receptor
 JOURNAL Patent: US 5789182-A 5 04-AUG-1998;
 FEATURES location/Qualifiers

```

source      1. .28
            /organism="unknown"
BASE COUNT      6 a      11 c      1 g      10 t

Query Match      1.6%; Score 22.4; DB 1; Length 28;
Best Local Similarity 95.8%; Pred. No. 17;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1873 GAGATGGAGATGATGATGATT 1896
Db      28 GAGATGGAGATGATGATGATGAT 5

RESULT 7
LOCUS      AR028294/c      25 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION      Sequence 4 from patent US 5858662.
ACCESSION      AR028294
VERSION      AR028294.1 GI:5940267
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 25)
AUTHORS      Keating,M.T. and Morris,C.A.
TITLE      Diagnosis of Williams syndrome and Williams syndrome cognitive
JOURNAL      profile by analysis of the presence or absence of a LIM-kinase gene
FEATURES      Patent: US 5858662-A 4 12-JAN-1999;
SOURCE      Location/Qualifiers
            1. .25
            /organism="unknown"
BASE COUNT      4 a      10 c      6 g      5 t

Query Match      1.5%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 20;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2269 CCACTCAAGTGGAGTCCGCA 2291
Db      24 CCACTCAAGTGGAGTCCGCA 2

RESULT 8
LOCUS      AR007164      21 bp      DNA      linear      PAT 04-DEC-1998
DEFINITION      Sequence 16 from patent US 5750371.
ACCESSION      AR007164
VERSION      AR007164.1 GI:3966648
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 21)
AUTHORS      Senoo,M., Watanabe,T. and Igataashi,K.
TITLE      Water-soluble mutein of FGF receptor. DNA and production thereof
JOURNAL      Patent: US 5750371-A 16 12-MAY-1998;
FEATURES      Location/Qualifiers
            1. .21
            /organism="unknown"
BASE COUNT      8 a      1 c      8 g      4 t

Query Match      1.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1870 TCAGAGATGAGATGATGAAG 1890
Db      1 TCAGAGATGAGATGATGAAG 21

RESULT 9
LOCUS      132953      21 bp      DNA      linear      PAT 06-FEB-1997

```

```

DEFINITION      Sequence 14 from patent US 5589451.
ACCESSION      I32953
VERSION      I32953.1 GI:1823744
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 21)
AUTHORS      Wilson,S.E.
TITLE      Methods and treatments for corneal healing with hepatocyte and
JOURNAL      keratinocyte growth factors
FEATURES      Patent: US 5589451-A 14 31-DEC-1996;
SOURCE      Location/Qualifiers
            1. .21
            /organism="unknown"
BASE COUNT      9 a      3 c      6 g      3 t

Query Match      1.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1322 TATCCTTCACTCTGCATGCT 1342
Db      21 TATCCTTCACTCTGCATGCT 1

RESULT 10
LOCUS      I87099      21 bp      DNA      linear      PAT 10-JUN-1998
DEFINITION      Sequence 13 from patent US 5703047.
ACCESSION      I87099
VERSION      I87099.1 GI:3206817
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 21)
AUTHORS      Wilson,S.E.
TITLE      Methods and treatments for corneal healing with growth factors
JOURNAL      Patent: US 5703047-A 13 30-DEC-1997;
FEATURES      Location/Qualifiers
            1. .21
            /organism="unknown"
BASE COUNT      9 a      3 c      6 g      3 t

Query Match      1.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1322 TATCCTTCACTCTGCATGCT 1342
Db      21 TATCCTTCACTCTGCATGCT 1

RESULT 11
LOCUS      E23733      20 bp      DNA      linear      PAT 18-JUN-2001
DEFINITION      Immobilized human papilla pilli cell and method for evaluating hair
ACCESSION      E23733
VERSION      E23733.1 GI:13024481
KEYWORDS      growth stimulants with the use of the same.
SOURCE      JP 1999089565-A/22.
ORGANISM      unidentified
REFERENCE      1 (bases 1 to 20)
AUTHORS      Jun,S., Briko,T., Chika,H., Akihiro,I., Masahiro,T. and Hiroshi,H.
TITLE      Immobilized human papilla pilli cell and method for evaluating hair
JOURNAL      growth stimulants with the use of the same
SHISEIDO CO LTD      Patent: JP 1999089565-A 22 06-APR-1999;
OS      unidentified
COMMENT      PN      JP 1999089565-A/22

```

```

PD      06-APR-1999
PF      19-SEP-1997  JP 1997271927
PR
PI      JUN SUZUKI, ERIKO TAKEOKA, CHIKA HAMADA, AKIHIRO ISHINO, PI
MASAHIRO TAJIMA,
PI      HIROSHI HANDA
PC      C12N5/10, A61K7/06, C12N15/09, C12P21/02, C12Q1/02// (C12N5/10, PC
C12R1:91),
PC      (C12P21/02, C12N1:91), C12N5/00, C12N15/00, (C12N5/00, C12R1:91) CC
Strandedness: Single;
CC      Topology: Linear;
FH      Key          Location/Qualifiers
FT      source          1..20
                        /organism='Unidentified'.
FEATURES
    source          Location/Qualifiers
                        1..20
                        /organism="unidentified"
                        /mol_type="genomic DNA"
                        /db_xref="taxon:32644"
BASE COUNT          1 a      4 c      4 g      11 t

Query Match          1.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 20; Conservative 0; Mismatches 0; Gaps 0;

QY      1470 AATGAGACACGACCCAGA 1489
DB      20 AATGAGACACGACCCAGA 1
|||||
REFERENCE
LOCUS      AR007165      26 bp      DNA      linear      PAT 04-DEC-1998
DEFINITION      Sequence 17 from patent US 5750371.
ACCESSION      AR007165
VERSION      AR007165.1 GI:3966649
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE
    AUTHORS      Senoo, M., Matanabe, T. and Igarashi, K.
    TITLE      Water-soluble mutcin of FgR receptor, DNA and production thereof
    JOURNAL      Patent: US 5750371-A 17 12-MAY-1998;
    FEATURES
        source          1..26
                        /organism="unknown"
BASE COUNT          5 a      4 c      10 g      7 t

Query Match          1.4%; Score 19.6; DB 1; Length 26;
Best Local Similarity 84.6%; Pred. No. 40;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      1388 CCCGAGTACTGTGAGATAGCAATT 1413
DB      26 CCCGAGTACTGTGATCCAGCAATT 1
|||||
REFERENCE
LOCUS      AS9560      22 bp      DNA      linear      PAT 06-MAR-1998
DEFINITION      Sequence 13 from Patent WO9705278.
ACCESSION      AS9560
VERSION      AS9560.1 GI:3714872
KEYWORDS
SOURCE      unidentified
ORGANISM      unidentified
REFERENCE
    AUTHORS      Andersson, L., Moller, M. J., Wales, R., Siggens, K. W. and Plastow, G. S.
    TITLE      METHODS FOR DETERMINING THE COAT COLOUR GENOTYPE OF A PIG
    JOURNAL      Patent: WO 9705278-A 13 13-FEB-1997;
    PATENT      PLC (GB)

```

[illegible]

Db 1 TGTGGAGCTCTTCTTTAGG 22

RESULT 16
LOCUS BD135486 22 bp DNA linear PAT 18-SEP-2002
DEFINITION Methods for analyzing animal products.
ACCESSION BD135486
VERSION BD135486.1 GI:23230431
KEYWORDS JP 2002504814-A/24.
SOURCE unclassified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 22)
AUTHORS Anderson,L., Kijae,J., Giuffra,E., Jon,G., Evans, Wales,R. and Plastow,G.S.
TITLE Methods for analyzing animal products
JOURNAL Patent: JP 2002504814-A 24 12-FEB-2002;
OS Unidentified
COMMENT OS Unidentified
PN JP 2002504814-A/24
PD 12-FEB-2002
PR 27-MAY-1998 JP 199500368
PR 30-MAY-1997 GB 9711214.8,31-JAN-1998 GB 9801990.4 PI
LEIF ANDERSSON,JAMES KIJAS,ELISABETTA GIUFFRA,GARY JON PI
EVANS,RICHARD WALES,
PI GRAHAM STUART PLASTOW
PC C1Q1/68
CC Strandedness: Single;
CC Topology: Linear;
CC Primer
FH Key
FT source
FT 1.22
Location/Qualifiers
FEATURES
source 1.22
/organism="unclassified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

BASE COUNT 2 a 4 c 7 g 9 t

Query Match 1.3%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 40;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2351 TGTGGAGATCTTCACTTAGG 2372
Db 1 TGTGGAGCTCTTCTTTAGG 22

RESULT 17
LOCUS AX203707 23 bp DNA linear PAT 30-AUG-2001
DEFINITION Sequence 42 from Patent WO0152904.
ACCESSION AX203707
VERSION AX203707.1 GI:15393156
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Gill,P.S. and Masood,R.
TITLE Methods and compositions for antisense vegf oligonucleotides
JOURNAL Patent: WO 0152904-A 42 26-JUL-2001;
Gill, Parkash, S. (US)
FEATURES
source 1.23
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="VEGFR-1 gene specific primers for RT-PCR"

BASE COUNT 6 a 4 c 9 g 4 t

Query Match 1.3%; Score 18.8; DB 1; Length 23;
Best Local Similarity 90.9%; Pred. No. 43;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2098 CAGCTGCCAGAGCATGAGT 2119
Db 1 CAGTGCCAGAGCATGAGT 22

RESULT 18
LOCUS AX203708 23 bp DNA linear PAT 30-AUG-2001
DEFINITION Sequence 43 from Patent WO0152904.
ACCESSION AX203708
VERSION AX203708.1 GI:15393157
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Gill,P.S. and Masood,R.
TITLE Methods and compositions for antisense vegf oligonucleotides
JOURNAL Patent: WO 0152904-A 43 26-JUL-2001;
Gill, Parkash, S. (US)
FEATURES
source 1.23
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="VEGFR-1 gene specific primers for RT-PCR"

BASE COUNT 6 a 4 c 9 g 4 t

Query Match 1.3%; Score 18.8; DB 1; Length 23;
Best Local Similarity 90.9%; Pred. No. 43;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2098 CAGCTGCCAGAGCATGAGT 2119
Db 1 CAGTGCCAGAGCATGAGT 22

RESULT 19
LOCUS AR177699 20 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 39 from patent US 6312949.
ACCESSION AR177699
VERSION AR177699.1 GI:17920054
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sakurada,K., Palmer,T. and Gage,F.H.
TITLE Regulation of tyrosine hydroxylase expression
JOURNAL Patent: US 6312949-A 39 06-NOV-2001;
FEATURES
source 1.20
/organism="unknown"

BASE COUNT 6 a 1 c 7 g 4 t 2 others

Query Match 1.3%; Score 18.6; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 38;
Matches 18; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1870 TCAGAGATGAGATGAA 1889
Db 1 TCAGAGATGAGATGAA 20

RESULT 20
LOCUS AR019576 24 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 61 from patent US 5783666.

[illegible]

source	1..24	/organism="unknown"			
BASE COUNT	10 a	3 c	4 g	7 t	
Query Match	1.3%;	Score 18.2;	DB 1;	Length 24;	
Best Local Similarity	87.0%;	Pred. No. 56;			
Matches	20;	Conservative	0;	Mismatches	3;
Indels			0;	Gaps	0;
OY	2645	CTTCAGAGATGATTCGTGTTT	2667		
DB	23	CTTCAGACATGATTCGTATTT	1		
RESULT 23					
155708/c					
DEFINITION	155708	Sequence 61 from patent US 5648212.	24 bp	DNA	linear
ACCESSION	155708				
VERSION	155708.1	GI:2476502			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 24)				
	Albersen,H., Anand,R., Carlson,M., Groden,J., Hedge,P.,John.,				
	Joeljn,G., Kinzler,K., Markham,A., Nakamura,Y., Thliveris,A.,				
	Vogelstein,B. and White,R.L.				
	Detection of inherited and somatic mutations of APC gene in				
	colorectal cancer of humans				
	Patent: US 5648212-A 61 15-JUL-1997;				
TITLE	location/Qualifiers				
JOURNAL	1..24				
FEATURES	/organism="unknown"				
source					
BASE COUNT	10 a	3 c	4 g	7 t	
Query Match	1.3%;	Score 18.2;	DB 1;	Length 24;	
Best Local Similarity	87.0%;	Pred. No. 56;			
Matches	20;	Conservative	0;	Mismatches	3;
Indels			0;	Gaps	0;
OY	2645	CTTCAGAGATGATTCGTGTTT	2667		
DB	23	CTTCAGACATGATTCGTATTT	1		
RESULT 24					
LOCUS	176485	24 bp	DNA	linear	PAT 03-APR-1998
DEFINITION	Sequence 61 from patent US 5691454.				
ACCESSION	176485				
VERSION	176485.1	GI:3012639			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 24)				
	Albersen,H., Anand,R., Carlson,M., Groden,J., Hedge,P.,John.,				
	Joeljn,G., Kinzler,K., Markham,A.,Fred., Nakamura,Y., Thliveris,A.,				
	Vogelstein,B. and White,R.L.				
	APC antibodies				
	Patent: US 5691454-A 61 25-NOV-1997;				
TITLE	location/Qualifiers				
JOURNAL	1..24				
FEATURES	/organism="unknown"				
source					
BASE COUNT	10 a	3 c	4 g	7 t	
Query Match	1.3%;	Score 18.2;	DB 1;	Length 24;	
Best Local Similarity	87.0%;	Pred. No. 56;			
Matches	20;	Conservative	0;	Mismatches	3;
Indels			0;	Gaps	0;
OY	2645	CTTCAGAGATGATTCGTGTTT	2667		
DB	23	CTTCAGACATGATTCGTATTT	1		

RESULT 25
AX020546/c
LOCUS AX020546 21 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 46 from Patent WO934016.
ACCESSION AX020546
VERSION AX020546.1 GI:10044236
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1
TITLE A method for identifying and characterizing cells and tissues
JOURNAL Patent: WO 934016-A 46 08-JUL-1999;
GENENA LTD (IL); VIDER BEN ZION (IL)
FEATURES
source 1..21
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 9 c 4 g 2 t
Query Match 1.3%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 53;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2323 AGTGATGCTGGTCTTCGGG 2343
Db 21 AGCGATGCTGGTCTTCGGG 1
RESULT 26
AX020772/c
LOCUS AX020772 21 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 272 from Patent WO934016.
ACCESSION AX020772
VERSION AX020772.1 GI:10044471
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1
TITLE A method for identifying and characterizing cells and tissues
JOURNAL Patent: WO 934016-A 272 08-JUL-1999;
GENENA LTD (IL); VIDER BEN ZION (IL)
FEATURES
source 1..21
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 7 a 8 c 3 g 3 t
Query Match 1.3%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 53;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2323 AGTGATGCTGGTCTTCGGG 2343
Db 21 AGTGATGCTGGTCTTCGGG 1
RESULT 27
AX129008
LOCUS AX129008 19 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 226 from Patent WO0130362.
ACCESSION AX129008
VERSION AX129008.1 GI:14135313
KEYWORDS
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1
TITLE Robbins,J.M. and Tiltz,R.
JOURNAL Ribozyme therapy for the treatment of proliferative skin and eye diseases
Patent: WO 0130362-A 226 03-MAY-2001;
IMMUSOL, INC.(US)
FEATURES
source 1..19
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/note="Cdk2 ribozyme binding site"
BASE COUNT 5 a 4 c 5 g 5 t
Query Match 1.2%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 52;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2198 TAGCAGACTTGGACTGCGC 2216
Db 1 TAGCAGACTTGGACTGAC 19
RESULT 28
AX129009
LOCUS AX129009 19 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 227 from Patent WO0130362.
ACCESSION AX129009
VERSION AX129009.1 GI:14135314
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1
TITLE Robbins,J.M. and Tiltz,R.
JOURNAL Ribozyme therapy for the treatment of proliferative skin and eye diseases
Patent: WO 0130362-A 227 03-MAY-2001;
IMMUSOL, INC.(US)
FEATURES
source 1..19
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/note="Cdk2 ribozyme binding site"
BASE COUNT 5 a 5 c 5 g 4 t
Query Match 1.2%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 52;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2199 AGCAGACTTGGACTGACC 2217
Db 1 AGCAGACTTGGACTGACC 19
RESULT 29
AR116481/c
LOCUS AR116481 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 62 from Patent US 6133246.
ACCESSION AR116481
VERSION AR116481.1 GI:14096803
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
AUTHORS 1 (bases 1 to 20)
TITLE McKay,R., Dean,N., Monia,B.P., Nero,P.S. and Garde,W.A.
Antisense oligonucleotide compositions and methods for the

modulation of JNK proteins
 JOURNAL Patent: US 6133246-A 6217-OCT-2000;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"

BASE COUNT 6 a 6 c 3 g 5 t

Query Match 1.2%; Score 17; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 64;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2642 GTTCTCAGAGATGAT 2658
 Db 17 GTTCTCAGAGATGAT 1

RESULT 30
 AX020776 20 bp DNA linear PAT 07-SEP-2000
 LOCUS Sequence 276 from Patent WO9334016.
 ACCESSION AX020776
 VERSION AX020776.1 GI:10044475
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens (human)
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
 Vidler B.Z.
 A method for identifying and characterizing cells and tissues
 TITLE Patent: WO 9334016-A 276 08-UTL-1999;
 JOURNAL GENENIA LTD (IL); VIDER BEN ZION (IL)
 FEATURES Location/Qualifiers
 source 1..20
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

BASE COUNT 7 a 3 c 4 g 6 t

Query Match 1.2%; Score 17; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 64;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2194 AAAATAGCAGCTTTGG 2210
 Db 1 AAAATAGCAGCTTTGG 17

RESULT 31
 BD074638 20 bp DNA linear PAT 27-AUG-2002
 LOCUS Antisense oligonucleotide composition and modulation method of JNK
 DEFINITION protein.
 ACCESSION BD074638
 VERSION BD074638.1 GI:22620241
 KEYWORDS JP 2001514905-A/62.
 SOURCE JP 2001514905-A/62.
 ORGANISM synthetic construct
 artificial sequences.
 1 (bases 1 to 20)
 McKay,R., Dean,N., Monia,B.P., Scott,P., Nero and Gaarde,W.A.
 Antisense oligonucleotide composition and modulation method of JNK
 TITLE Patent: JP 2001514905-A 62 18-SEP-2001;
 JOURNAL SITS PHARMACEUTICALS INC
 OS Artificial Sequence
 PN JP 2001514905-A/62
 PD 18-SEP-2001
 PF 07-AUG-1998 JP 2000509875
 PI 13-AUG-1997 US 08/910629
 PI ROBERT MCKAY, NICHOLAS DEAN, BRETT P MONIA, PAMELA SCOTT PI
 NERO WILLIAM A GAARDE
 PC C12Q1/66,A61K31/7088,A61K48/00,A61P35/00,C12N15/09,C12P19/34,

PC C12N15/00
 CC antisense sequence
 FH Key Location/Qualifiers
 FT source 1..20
 FT /organism="Artificial Sequence".

FEATURES Location/Qualifiers
 source 1..20
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

BASE COUNT 6 a 6 c 3 g 5 t

Query Match 1.2%; Score 17; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 64;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2642 GTTCTCAGAGATGAT 2658
 Db 17 GTTCTCAGAGATGAT 1

RESULT 32
 AR177700 20 bp DNA linear PAT 17-DEC-2001
 LOCUS Sequence 40 from patent US 6312949.
 ACCESSION AR177700
 VERSION AR177700.1 GI:11792055
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 Unclassified.

REFERENCE 1 (bases 1 to 20)
 Sakurada,K., Palmer,T. and Gage,F.H.
 Regulation of tyrosine hydroxylase expression
 TITLE Patent: US 6312949-A 40 06-NOV-2001;
 JOURNAL Location/Qualifiers
 FEATURES source 1..20
 /organism="unknown"

BASE COUNT 5 a 6 c 2 g 5 t 2 others

Query Match 1.2%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 68;
 Matches 17; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 2191 ATGAAATACGACCTTTGG 2210
 Db 20 ATGAAATACGACCTTTGG 1

RESULT 33
 AR211982 20 bp DNA linear PAT 20-JUN-2002
 LOCUS Sequence 38 from patent US 6399378.
 DEFINITION AR211982
 ACCESSION AR211982
 VERSION AR211982.1 GI:21515448
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unknown.
 Unclassified.

REFERENCE 1 (bases 1 to 20)
 Ward,D.T. and Watt,A.T.
 Antisense modulation of RECG12 expression
 TITLE Patent: US 6399378-A 38 04-JUN-2002;
 JOURNAL Location/Qualifiers
 FEATURES source 1..20
 /organism="unknown"

BASE COUNT 5 a 7 c 1 g 7 t

Query Match 1.2%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 68;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1882 ATGATGAAGATGATTGGAA 1901

Db 20 ATGATGATGATGACTGGAA 1

RESULT 34
E23735/c
LOCUS
DEFINITION
E23735 20 bp DNA linear PAT 18-JUN-2001
Immortalized human papilla cell and method for evaluating hair
growth stimulants with the use of the same.

ACCESSION
E23735.1 GI:13024483
VERSION
JP 199089565-A/24.
KEYWORDS
unidentified
SOURCE
unidentified
ORGANISM
unclassified.

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
OS Unidentified
PN JP 199089565-A/24
PD 06-APR-1999
PF 19-SEP-1997 JP 1997271927
PR JUN SUZUKI, ERIKO TAKEOKA, CHIKA HAMADA, AKIHIRO ISHINO, PI
MASAHIRO TAJIMA,
PI HIROSHI HANDA
PC C12N5/10,A61K7/06,C12N15/09,C12P21/02,C12Q1/02//C12N5/10, PC
C12R1:91),
PC (C12P21/02,C12R1:91), C12N5/00,C12N15/00, (C12N5/00,C12R1:91) CC
Strandedness: Single;
CC Topology: Linear;
FH Key
FT source 1..20
Location/Qualifiers
/organism='Unidentified'.

FEATURES
source
1..20
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 3 a 6 c 3 g 8 t

Query Match 1.2%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 68;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1822 AAGATGTTGAAGATGATGC 1841
Db 20 AAGATGCTGAAGACGATGC 1

RESULT 35
AR084555/c
LOCUS
DEFINITION
AR084555 21 bp DNA linear PAT 01-SEP-2000
Sequence 44 from patent US 5981185.
ACCESSION
AR084555.1 GI:10011326
VERSION
AR084555.1
KEYWORDS
Unknown.
SOURCE
Unknown.
ORGANISM
Unclassified.

REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
1 (bases 1 to 21)
Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
Oligonucleotide repeat arrays
Patent: US 5981185-A 44 09-NOV-1999;
Location/Qualifiers
1..21
source
/organism="unknown"

BASE COUNT 7 a 7 c 0 g 7 t
Query Match 1.2%; Score 16.2; DB 1; Length 21;

Best Local Similarity 85.7%; Pred. No. 89;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1875 GATGAGATGATGAAGATGAT 1895
Db 21 GATGATGATGATGATGATGAT 1

RESULT 36
AR084576
LOCUS
DEFINITION
AR084576 21 bp DNA linear PAT 01-SEP-2000
Sequence 65 from patent US 5981185.
ACCESSION
AR084576
VERSION
AR084576.1 GI:10011347
KEYWORDS
Unknown.
SOURCE
Unknown.
ORGANISM
Unclassified.

REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
1 (bases 1 to 21)
Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
Oligonucleotide repeat arrays
Patent: US 5981185-A 65 09-NOV-1999;
Location/Qualifiers
1..21
source
/organism="unknown"

BASE COUNT 7 a 0 c 7 g 7 t
Query Match 1.2%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 89;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1875 GATGAGATGATGAAGATGAT 1895
Db 1 GATGATGATGATGATGATGAT 21

RESULT 37
AX129010
LOCUS
DEFINITION
AX129010 19 bp DNA linear PAT 15-MAY-2001
Sequence 228 from Patent WO0130362.
ACCESSION
AX129010
VERSION
AX129010.1 GI:14135315
KEYWORDS
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
1 Robbins,J.M. and Tritz,R.
Ribozyme therapy for the treatment of proliferative skin and eye
diseases
Patent: WO 0130362-A 228 03-MAY-2001;
IMMUSOL, INC. (US)
Location/Qualifiers
1..19
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/note="Cdk2 ribozyme binding site"

BASE COUNT 4 a 5 c 5 g 5 t
Query Match 1.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 88;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2205 CTTTGACGCGCAGAGAT 2223
Db 1 CTTTGACGCTAGCCAGAGCT 19

RESULT 38
AR079558/c
LOCUS
AR079558 20 bp DNA linear PAT 31-AUG-2000

```

DEFINITION Sequence 2 from patent US 5965712.
ACCESSION AR079558
VERSION AR079558.1 GI:10006302
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 20)
  Unclassified.
AUTHORS Conrad,D.H. and Kelly,A.E.
TITLE L2-CD3 chimera for inhibition of IGE-mediated allergic disease
JOURNAL Patent: US 5965712-A 2 12-OCT-1999;
FEATURES
  source
    1..20
    /organism="unknown"
BASE COUNT      4 a      6 c      0 g      10 t

Query Match      1.1%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1819 GTGAGATGTTGAAGATG 1837
Db      19 GTGAAATGTTGAAAGAG 1

RESULT 39
LOCUS AR139522/c
DEFINITION Sequence 39 from patent US 6207383.
ACCESSION AR139522
VERSION AR139522.1 GI:14482018
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 20)
  Unclassified.
AUTHORS Keating,M.T. and Splawski,I.
TITLE Mutations in and genomic structure of HERG--a long QT syndrome gene
JOURNAL Patent: US 6207383-A 39 27-MAR-2001;
FEATURES
  source
    1..20
    /organism="unknown"
BASE COUNT      2 a      4 c      7 g      7 t

Query Match      1.1%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2556 CACTCTCACAACCATGAG 2574
Db      19 CACACTCACACCATGAG 1

RESULT 40
LOCUS AR266054
DEFINITION Sequence 61 from patent US 6492171.
ACCESSION AR266054
VERSION AR266054.1 GI:29694900
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 20)
  Unclassified.
AUTHORS Monia,B.P., Gaarde,W.A., Freier,S.M. and Wanciewicz,E.
TITLE Antisense modulation of TERT expression
JOURNAL Patent: US 6492171-A 61 10-DEC-2002;
FEATURES
  source
    1..20
    /organism="unknown"
BASE COUNT      4 a      3 c      6 g      7 t

Query Match      1.1%; Score 15.8; DB 1; Length 20;

```

```

Best Local Similarity 89.5%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2020 GCGATGAGTACTCTATG 2038
Db      1 GCGATGAGTACTCTATG 19

RESULT 41
LOCUS AX590585
DEFINITION Sequence 25 from Patent WO02086113.
ACCESSION AX590585
VERSION AX590585.1 GI:27949194
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1
  Unclassified.
AUTHORS Cookson,W.O., Moffat,M.F., Allen,M. and Lench,N.
TITLE Enzyme and snp marker for disease
JOURNAL Patent: WO 02086113-A 25 31-OCT-2002;
FEATURES
  source
    1..21
    /organism="synthetic construct"
    /mol_type="genomic DNA"
    /db_xref="taxon:32630"
    /note="Primer"
BASE COUNT      2 a      10 c      4 g      5 t

Query Match      1.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1e+02; 2; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1565 CGGCTGAGTCCAGCTCCTC 1583
Db      3 CGGCTGCTCCAGCTCCTC 21

RESULT 42
LOCUS AR192109
DEFINITION Sequence 7597 from patent US 6346398.
ACCESSION AR192109
VERSION AR192109.1 GI:20238074
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 17)
  Unclassified.
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7597 12-FEB-2002;
FEATURES
  source
    1..17
    /organism="unknown"
BASE COUNT      7 a      0 c      7 g      3 t

Query Match      1.1%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 85;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1821 GAAGATGTTGAAGATG 1837
Db      1 GAAGATGTTGAAGAGG 17

RESULT 43
LOCUS AX482165/c
DEFINITION Sequence 142 from Patent EP1225233.

```

ACCESSION AX482165
 VERSION AX482165.1 GI:22316887
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 1
 AUTHORS van der Kuyl,A.C. and Cornelissen,M.
 TITLE Means and methods for treatment evaluation
 JOURNAL Patent: EP 1225233-A 142 24-JUL-2002;
 Amsterdam Support Diagnostics B.V. (NL)
 FEATURES
 source
 1.18
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"
 /note="3'TAG019GENE-2"
 BASE COUNT 2 a 8 c 3 g 5 t

Query Match 1.1%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 93;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2413 AAGCTGCTGAAGGAGG 2429
 |||||
 18 AAGCTGCTGAAGGAGG 2

RESULT 44
 AX511404/c 18 bp DNA linear PAT 27-SEP-2002
 LOCUS AX511404
 DEFINITION Sequence 142 from Patent WO02059558.
 ACCESSION AX511404
 VERSION AX511404.1 GI:23392281
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 1
 AUTHORS van der Kuyl,A.C. and Cornelissen,M.
 TITLE Means and methods for treatment evaluation
 JOURNAL Patent: WO 02059558-A 142 01-AUG-2002;
 Amsterdam Support Diagnostics B.V. (NL)
 FEATURES
 source
 1.18
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"
 /note="3'TAG019GENE-2"
 BASE COUNT 2 a 8 c 3 g 5 t

Query Match 1.1%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 93;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2413 AAGCTGCTGAAGGAGG 2429
 |||||
 18 AAGCTGCTGAAGGAGG 2

RESULT 45
 AX721765/c 18 bp DNA linear PAT 07-MAY-2003
 LOCUS AX721765
 DEFINITION Sequence 144 from Patent EP1298221.
 ACCESSION AX721765
 VERSION AX721765.1 GI:30422356
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 1
 AUTHORS van der Kuyl,A.C. and Cornelissen,M.
 TITLE Means and methods for treatment evaluation

JOURNAL Patent: EP 1298221-A 144 02-APR-2003;
 Primagen Holding B.V. (NL)
 FEATURES
 source
 1.18
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"
 /note="primer 3'TAG019GENE-2"
 BASE COUNT 2 a 8 c 3 g 5 t

Query Match 1.1%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 93;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2413 AAGCTGCTGAAGGAGG 2429
 |||||
 18 AAGCTGCTGAAGGAGG 2

RESULT 46
 A95063/c 19 bp DNA linear PAT 26-JAN-2000
 LOCUS A95063
 DEFINITION Sequence 5 from Patent WO929866.
 ACCESSION A95063
 VERSION A95063.1 GI:6779218
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 1 (bases 1 to 19)
 AUTHORS Bowler,C. and Mustilli,A.C.
 TITLE NUCLEOTIDE SEQUENCES ENCODING THE TOMATO LIGHT HYPERSENSITIVE
 JOURNAL PHENOTYPE, ENCODED PROTEINS AND USES THEREOF
 PATENT: WO 9929866-A 5 17-JUN-1999;
 BOWLER CHRIS (GB); STAZIONE ZOOLOGIA ANTON DOHRN (IT)
 FEATURES
 source
 1.19
 /organism="unidentified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"
 BASE COUNT 4 a 6 c 3 g 6 t

Query Match 1.1%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1816 GCCGTGAAGATGTGAA 1832
 |||||
 19 GCCGTGAAGATGTGAA 3

RESULT 47
 AR222435/c 19 bp DNA linear PAT 26-SEP-2002
 LOCUS AR222435
 DEFINITION Sequence 5 from patent US 6429259.
 ACCESSION AR222435
 VERSION AR222435.1 GI:23329965
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 1 (bases 1 to 19)
 AUTHORS Bowler,C. and Mustilli,A.C.
 TITLE Nucleotide sequences encoding the tomato light hypersensitive
 JOURNAL phenotype, encoded proteins and uses thereof
 PATENT: US 6429259-A 5 06-AUG-2002;
 FEATURES
 source
 1.19
 /organism="unknown"
 BASE COUNT 4 a 6 c 3 g 6 t

Query Match 1.1%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 1e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1816 GCCGTGAAGATGTTGAA 1832
|||||
Db 19 GCCGTGAAGATGATGAA 3

RESULT 48
BD102783/c 19 bp DNA linear PAT 27-AUG-2002
LOCUS Nucleotide sequence encoding tomato photosensitive phenotype,
DEFINITION protein encoded thereby and utilization thereof.
ACCESSION BD102783
VERSION BD102783.1 GI:22648357
KEYWORDS JP 2001526034-A/4.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Bowler,C. and Mustilli,A.C.
TITLE Nucleotide sequence encoding tomato photosensitive phenotype,
JOURNAL Protein encoded thereby and utilization thereof
COMMENT Patent: JP 2001526034-A 4 18-DEC-2001;
STAZIONE ZOOLOGICA ANTON DOHRN
OS Artificial Sequence
PN JP 2001526034-A/4
PD 18-DEC-2001
PF 07-DEC-1998 JP 2000524438
PI 09-DEC-1997 IT RM97A000760
PR CHLIS BOWLER,ANNA CHITARA MUSTILLI
PC C12N15/09,A01H5/00,C07K14/415,C12N15/00
CC Nucleotide sequence encoding tomato photosensitive phenotype,
CC protein
CC encoded thereby and utilization thereof
FH Key Location/Qualifiers
FT source 1..19
Location/Qualifiers
1..19 /organism='Artificial Sequence'

FEATURES
source

BASE COUNT 4 a 6 c 3 g 6 t

Query Match 1.1%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1816 GCCGTGAAGATGTTGAA 1832
|||||
Db 19 GCCGTGAAGATGATGAA 3

RESULT 49
AR103195/c 20 bp DNA linear PAT 14-FEB-2001
LOCUS Sequence 89 from patent US 6087160.
DEFINITION AR103195
ACCESSION AR103195
VERSION AR103195.1 GI:12814783
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Yuan,J. and Mura,M.
TITLE Programmed cell death genes and proteins
JOURNAL Patent: US 6087160-A 89 11-JUL-2000;
FEATURES Location/Qualifiers
source 1..20
/organism='unknown'

BASE COUNT 4 a 8 c 1 g 7 t

Query Match 1.1%; Score 15.4; DB 1; Length 20;

Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1878 GGAGATGATGAGATGA 1894
|||||
Db 20 GGAGTTGATGAGATGA 4

RESULT 50
AX147705 20 bp DNA linear PAT 08-JUN-2001
LOCUS AX147705
DEFINITION Sequence 7 from Patent WO0136673.
ACCESSION AX147705
VERSION AX147705.1 GI:14346750
KEYWORDS
SOURCE Clostridium perfringens
ORGANISM Clostridium perfringens
Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;
Clostridium.

REFERENCE 1
AUTHORS Apfel,H., Heesemann,J., Trebesius,K. and Autenrieth,I.
TITLE Test for micro-organisms
JOURNAL Patent: WO 0136673-A 7 25-MAY-2001;
Creatogen Aktiengesellschaft (DE)
FEATURES Location/Qualifiers
source 1..20
/organism='Clostridium perfringens'
/mol_type='genomic DNA'
/db_xref='taxon:1502'

BASE COUNT 5 a 3 c 6 g 6 t

Query Match 1.1%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1827 GTTGAAGATGATGCCA 1843
|||||
Db 2 GTTGAATGATGATGCCA 18

RESULT 51
AX298917 20 bp DNA linear PAT 26-NOV-2001
LOCUS AX298917
DEFINITION Sequence 551 from Patent WO0183749.
ACCESSION AX298917
VERSION AX298917.1 GI:17128907
KEYWORDS
SOURCE Mus sp.
ORGANISM Mus sp.
REFERENCE 1
AUTHORS Bachmanov,A.A., Beauchamp,G.K., Chatterjee,A., de Jong,P.J., Li,S.,
TITLE Li,X., Ohmen,J.D., Reed,D.R., Ross,D. and Tordoff,M.G.
JOURNAL Gene and sequence variation associated with sensing carbohydrate
compounds and other sweeteners
PATENT: WO 0183749-A 551 08-NOV-2001;
WARNER-LAMBERT COMPANY (US) ; The Monell Chemical Senses Center
(US)
FEATURES Location/Qualifiers
source 1..20
/organism='Mus sp.'
/mol_type='genomic DNA'
/db_xref='taxon:10095'

BASE COUNT 7 a 6 c 5 g 2 t

Query Match 1.1%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2418 GCTGAAGAGACACA 2434
|||||
Db 1 GCTCAAGAGACACA 17

RESULT 52
E44090/c
LOCUS E44090 20 bp DNA linear PAT 27-AUG-2002
DEFINITION Primer for enteric bacteria and detection method with the use of the primer.
ACCESSION E44090
VERSION E44090.1 GI:22553262
KEYWORDS JP 2001112485-A/11.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 20)
AUTHORS Ito, K., Kikuchi, E., Matsuki, T. and Miyamoto, Y.
TITLE Primer for enteric bacteria and detection method with the use of the primer.
JOURNAL Patent: JP 2001112485-A 11 24-APR-2001;
YAKULT HONSHA CO LTD, YAKULT BIOSCIENCE KENKYU ZAIDAN
OS Artificial Sequence
PN JP 2001112485-A/11
PD 24-APR-2001
PF 19-OCT-1999 JP 1999296815
PI KIKUCHI ITO, EISAKU KIKUCHI, TAKAHIRO MATSUKI, YUKIKO MIYAMOTO PC
C12N15/09, C12Q1/68, C12N15/00
CC

FEATURES
source Location/Qualifiers
1..20 /organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
BASE COUNT 7 a 5 c 3 g 5 t

Query Match 1.1%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1827 GTTGAAGATGATGCCA 1843
DB 20 GTTGAAGATGATGCCA 4

RESULT 53
AR050627
LOCUS AR050627 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 3 from patent US 5827726.
ACCESSION AR050627
VERSION AR050627.1 GI:5973352
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Nezu, J.-I.
TITLE DNA coding protein kinase
JOURNAL Patent: US 5827726-A 3 27-OCT-1998;
FEATURES Location/Qualifiers
source 1..20 /organism="unknown"

BASE COUNT 5 a 1 c 4 g 4 t 6 others

Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 70.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

OY 1813 GTGGCCGGAAGATGTGA 1832
DB 1 GTGGCCGGAAGATGTGA 20

RESULT 54
AR268232
LOCUS AR268232 20 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 24 from patent US 6498035.
ACCESSION AR268232
VERSION AR268232.1 GI:29698506
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Wyatt, J.
TITLE Antisense modulation of MEK3 expression
JOURNAL Patent: US 6498035-A 24 24-DEC-2002;
FEATURES Location/Qualifiers
source 1..20 /organism="unknown"

BASE COUNT 6 a 5 c 5 g 4 t

Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2258 ATGGCGGCTTCAGTCAG 2277
DB 1 ATGGCGGCTTCAGTCAG 20

RESULT 55
AR314742
LOCUS AR314742 20 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 5279 from patent US 6559294.
ACCESSION AR314742
VERSION AR314742.1 GI:31708168
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Griffiths, R., Hoiseh, S.K., Zagursky, R.J., Metcalf, B.J., Peek, J.A., Sankaran, B. and Fletcher, L.D.
TITLE Chlamydia pneumoniae polynucleotides and uses thereof
JOURNAL Patent: US 6559294-A 5279 06-MAY-2003;
FEATURES Location/Qualifiers
source 1..20 /organism="unknown"

BASE COUNT 5 a 5 c 4 g 6 t

Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2633 GAAGTCTTGTCTTCAGCA 2652
DB 1 GAAGTCTTGTCTTCAGCA 20

RESULT 56
AX020769
LOCUS AX020769 20 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 269 from Patent WO9934016.
ACCESSION AX020769
VERSION AX020769.1 GI:10044468
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens (human)
REFERENCE 1
AUTHORS Vidar, B.Z.
TITLE A method for identifying and characterizing cells and tissues
JOURNAL Patent: WO 9934016-A 269 08-JUL-1999;
GENENA LTD (IL); VIDAR BEN ZION (IL)
FEATURES Location/Qualifiers
source 1..20

LOCUS AR268232 20 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 24 from patent US 6498035.
ACCESSION AR268232
VERSION AR268232.1 GI:29698506
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Wyatt, J.
TITLE Antisense modulation of MEK3 expression
JOURNAL Patent: US 6498035-A 24 24-DEC-2002;
FEATURES Location/Qualifiers
source 1..20 /organism="unknown"

BASE COUNT 6 a 5 c 5 g 4 t

Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2258 ATGGCGGCTTCAGTCAG 2277
DB 1 ATGGCGGCTTCAGTCAG 20

RESULT 55
AR314742
LOCUS AR314742 20 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 5279 from patent US 6559294.
ACCESSION AR314742
VERSION AR314742.1 GI:31708168
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Griffiths, R., Hoiseh, S.K., Zagursky, R.J., Metcalf, B.J., Peek, J.A., Sankaran, B. and Fletcher, L.D.
TITLE Chlamydia pneumoniae polynucleotides and uses thereof
JOURNAL Patent: US 6559294-A 5279 06-MAY-2003;
FEATURES Location/Qualifiers
source 1..20 /organism="unknown"

BASE COUNT 5 a 5 c 4 g 6 t

Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2633 GAAGTCTTGTCTTCAGCA 2652
DB 1 GAAGTCTTGTCTTCAGCA 20

RESULT 56
AX020769
LOCUS AX020769 20 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 269 from Patent WO9934016.
ACCESSION AX020769
VERSION AX020769.1 GI:10044468
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens (human)
REFERENCE 1
AUTHORS Vidar, B.Z.
TITLE A method for identifying and characterizing cells and tissues
JOURNAL Patent: WO 9934016-A 269 08-JUL-1999;
GENENA LTD (IL); VIDAR BEN ZION (IL)
FEATURES Location/Qualifiers
source 1..20

```

BASE COUNT      8 a      1 c      5 g      6 t

Query Match      1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2194 AAATAGCAGACTTTGACT 2213
Db      1 AAATGAGAGCTTGGAT 20

/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

RESULT 57
AX020775      20 bp      DNA      linear      PAT 07-SEP-2000
DEFINITION    Sequence 275 from Patent WO9934016.
ACCESSION     AX020775
VERSION       AX020775.1 GI:10044474
KEYWORDS
SOURCE        Homo sapiens (human)
ORGANISM      Homo sapiens
AUTHORS       Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1
              Vidar,B.2.
              A method for identifying and characterizing cells and tissues
              Patent: WO 9934016-A 275 08-JUL-1999;
              GENENA LTD (IL); VIDAR BEN ZION (IL)
FEATURES
  source
    1..20
    /organism="Homo sapiens"
    /mol_type="genomic DNA"
    /db_xref="taxon:9606"

BASE COUNT      6 a      3 c      4 g      7 t

Query Match      1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2194 AAATAGCAGACTTTGACT 2213
Db      1 AAATGAGAGCTTGGCT 20

/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

RESULT 58
AX326944      20 bp      DNA      linear      PAT 07-JAN-2002
DEFINITION    Sequence 140 from Patent WO017894.
ACCESSION     AX326944
VERSION       AX326944.1 GI:18097655
KEYWORDS
SOURCE        synthetic construct
ORGANISM      artificial sequences.
REFERENCE     1
              Keith,T.
              Novel human gene relating to respiratory diseases, obesity, and
              inflammatory bowel disease
              Patent: WO 0178894-A 140 25-OCT-2001;
              Genome Therapeutics Corp. (US)
FEATURES
  source
    1..20
    /organism="synthetic construct"
    /mol_type="genomic DNA"
    /db_xref="taxon:32630"
    /note="Primer"

BASE COUNT      5 a      4 c      7 g      4 t

Query Match      1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY      2098 CAGCTGCCAGAGCATGGA 2117
Db      1 CAGCTGACAGTGTATGGA 20

/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

RESULT 59
AX397785      20 bp      DNA      linear      PAT 27-MAY-2002
DEFINITION    Sequence 19 from Patent WO0220852.
ACCESSION     AX397785
VERSION       AX397785.1 GI:21260659
KEYWORDS
SOURCE        synthetic construct
ORGANISM      artificial sequences.
REFERENCE     1
              Yang,Y.Y., Brentano,S.T., Babola,O., Tran,N. and Vernet,G.
              Amplification of hiv-1 sequences for detection of sequences
              associated with drug-resistance mutations
              Patent: WO 0220852-A 19 14-MAR-2002;
              Gen-Probe Incorporated Patent Dept (US) ; Biomerieux S.A. (FR)
FEATURES
  source
    1..20
    /organism="synthetic construct"
    /mol_type="genomic DNA"
    /db_xref="taxon:32630"
    /note="Oligonucleotide primer for Protease target
    sequence"
    1..2
    /note="2'-O-methyladenosine"
    /mod_base=OTHER
    modified_base
      3..4
      /mod_base=gm

BASE COUNT      11 a      3 c      5 g      1 t

Query Match      1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2422 AAGGAGACACAGATGGA 2441
Db      1 AAGGAGACACCAATGAA 20

/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

RESULT 60
EI2301      20 bp      DNA      linear      PAT 27-APR-1998
DEFINITION    Primer.
ACCESSION     EI2301
VERSION       EI2301.1 GI:3251135
KEYWORDS      JP 1996308586-A/2.
SOURCE        unidentified
ORGANISM      unidentified
REFERENCE     1
              Nezu,J.
              DNA CODING PROTEIN KINASE
              Patent: JP 1996308586-A 2 26-NOV-1996;
              CHUGAI PHARMACEUT CO LTD
COMMENT       OS None
              OC Artificial sequences.
              PN JP 1996308586-A/2
              PD 26-NOV-1996
              PF 15-MAR-1996 JP 1996087498
              PR 16-MAR-1995 JP 95P 57104
              PT NEZU JUNICHI
              PC C12N15/09,C07H21/04,C12N1/21,C12N9/12/C07K7/06,C07K7/08, PC
              C07K14/47,
              PC C12Q1/68,(C12N1/21,C12R1:19),(C12N9/12,C12R1:19); CC
              CC C12Q1/68,(C12N1/21,C12R1:19),(C12N9/12,C12R1:19); CC
              CC topology: Linear;
              CC strandedness: Single;
              CC hypothetical: No;

```

```

FH Key Location/Qualifiers
FH source 1.20
FH FT /organism='Artificial sequences'
FEATURES
source
1..20
/location/Qualifiers
/mol_type='unidentified'
/db_xref='taxon:32644'
BASE COUNT 5 a 1 c 4 g 4 t 6 others
Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 70.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1813 GTGGCCCTGAAGATGTTGAA 1832
Db 1 GTTGCCTGTTAATATGATGTTAA 20

RESULT 61
ATHS27748/c 20 bp DNA linear PLN 29-MAR-2003
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone 146F12.
ACCESSION AJ527748.1 GI:26796008
VERSION AJ527748.1
KEYWORDS left border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE
1 Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F., Chauvin, S., Bechtold, N., Cruaud, C., Derose, R., Pelletier, G., Lepoint, L., Caboche, M. and Lecharny, A. T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites EMBO Rep. 3 (12), 1152-1157 (2002)
JOURNAL MEDLINE 22363535
PUBMED 12446565
REFERENCE 2 (bases 1 to 20)
AUTHORS Balzerque, S.
TITLE Direct Submission
COMMENT Submitted (21-NOV-2002) Balzerque S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at http://dbsgap.versailles.inra.fr/publiclines/. This sequence has been generated in the framework of the French plant genomics program 'Genoplatane' (http://www.genoplatane.com and http://genoplatane-info.inbio.gen.fr).
location/Qualifiers
1..20
/organism='Arabidopsis thaliana'
/mol_type='genomic DNA'
/cultivar='Massiliaewskija'
/db_xref='taxon:3702'
/clone='146F12'
/clone_1tb='Arabidopsis thaliana T-DNA insertion lines'
misc_feature 1..20
/notes='T-DNA flanking sequence left border'
BASE COUNT 7 a 2 c 2 g 9 t
Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

FEATURES
source
1..20
/organism='Arabidopsis thaliana'
/mol_type='genomic DNA'
/cultivar='Massiliaewskija'
/db_xref='taxon:3702'
/clone='149B02'
/clone_1tb='Arabidopsis thaliana T-DNA insertion lines'
misc_feature 1..20
/notes='T-DNA flanking sequence left border'
BASE COUNT 7 a 2 c 2 g 9 t
Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

RESULT 63
DOGH0X7B/c 20 bp DNA linear STS 11-APR-1996
LOCUS DOGH0X7B
DEFINITION Canis familiaris Homeobox 7 (HOX7) STS DNA, 3' primer, sequence tagged site.
ACCESSION L77371

```

```

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2132 AAAATGATTCATCGAGAT 2151
Db 20 AAACATGTATTCATTAAGAT 1

RESULT 62
ATHS27822/c 20 bp DNA linear PLN 29-MAR-2003
LOCUS Arabidopsis thaliana T-DNA flanking sequence, left border, clone 149B02.
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone 149B02.
ACCESSION AJ527822.1 GI:26796082
VERSION AJ527822.1
KEYWORDS left border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE
1 Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F., Chauvin, S., Bechtold, N., Cruaud, C., Derose, R., Pelletier, G., Lepoint, L., Caboche, M. and Lecharny, A. T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites EMBO Rep. 3 (12), 1152-1157 (2002)
JOURNAL MEDLINE 22363535
PUBMED 12446565
REFERENCE 2 (bases 1 to 20)
AUTHORS Balzerque, S.
TITLE Direct Submission
COMMENT Submitted (21-NOV-2002) Balzerque S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at http://dbsgap.versailles.inra.fr/publiclines/. This sequence has been generated in the framework of the French plant genomics program 'Genoplatane' (http://www.genoplatane.com and http://genoplatane-info.inbio.gen.fr).
location/Qualifiers
1..20
/organism='Arabidopsis thaliana'
/mol_type='genomic DNA'
/cultivar='Massiliaewskija'
/db_xref='taxon:3702'
/clone='149B02'
/clone_1tb='Arabidopsis thaliana T-DNA insertion lines'
misc_feature 1..20
/notes='T-DNA flanking sequence left border'
BASE COUNT 7 a 2 c 2 g 9 t
Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

FEATURES
source
1..20
/organism='Arabidopsis thaliana'
/mol_type='genomic DNA'
/cultivar='Massiliaewskija'
/db_xref='taxon:3702'
/clone='149B02'
/clone_1tb='Arabidopsis thaliana T-DNA insertion lines'
misc_feature 1..20
/notes='T-DNA flanking sequence left border'
BASE COUNT 7 a 2 c 2 g 9 t
Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

RESULT 63
DOGH0X7B/c 20 bp DNA linear STS 11-APR-1996
LOCUS DOGH0X7B
DEFINITION Canis familiaris Homeobox 7 (HOX7) STS DNA, 3' primer, sequence tagged site.
ACCESSION L77371

```

```

VERSION      L77371.1 GI:1261709
KEYWORDS     STS; Homobox 7; PCR identification; PCR primer; sequence tagged
SOURCE       Canis, universal mammalian STS.
ORGANISM     Canis familiaris (dog)
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
REFERENCE    1 (bases 1 to 20)
AUTHORS      Venta, P.J., Brouillette, J.A., Yuzbasiyan-Gurkan, V. and Brewer, G.J.
TITLE        Gene-specific universal mammalian sequence-tagged sites:
              application to the canine genome
JOURNAL      Unpublished (1996)
COMMENT      Original source text: Canis familiaris DNA.
              Gene-specific universal mammalian sequence-tagged site for HOX7.
              Primer for the 3' end is in exon 2. Human product is 151 bp. Canine
              product is 151 bp. PCR conditions: 1 min, 94 C, 2 min, 57 C, 3 min,
              72 C, 35 cycles.
FEATURES     location/Qualifiers
              1..20
              /organism="Canis familiaris"
              /mol_type="genomic DNA"
              /db_xref="taxon:9615"
              primer_bind
                1..20
                /note="PCR primer binding site"
                /evidence=experimental
                1..20
                8 c      2 g      7 t
BASE COUNT   3 a      8 c      2 g      7 t
STS
Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1873 GAGATGGAGATGATGAGAT 1892
Db 20 GAGCTGGAGAGCTGAGAGAT 1

RESULT 64
LOCUS       DOGKIT1A                20 bp      DNA          linear      STS 11-APR-1996
DEFINITION  Canis familiaris c-KIT Protooncogene (KIT1) STS DNA, 5' primer,
sequence tagged site.
ACCESSION   L77376
VERSION     L77376.1 GI:1261721
KEYWORDS    STS; PCR identification; PCR primer; c-KIT Protooncogene; sequence
              tagged site; universal mammalian STS.
SOURCE      Canis familiaris (dog)
ORGANISM    Canis familiaris
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
REFERENCE    1 (bases 1 to 20)
AUTHORS      Venta, P.J., Brouillette, J.A., Yuzbasiyan-Gurkan, V. and Brewer, G.J.
TITLE        Gene-specific universal mammalian sequence-tagged sites:
              application to the canine genome
JOURNAL      Unpublished (1996)
COMMENT      Original source text: Canis familiaris DNA.
              Gene-specific universal mammalian sequence-tagged site for KIT1.
              Primer for the 5' end is in exon 18. Human product is 650 bp.
              Canine product is 650 bp. PCR conditions: 1 min, 94 C, 2 min, 57 C,
              3 min, 72 C, 35 cycles.
FEATURES     location/Qualifiers
              1..20
              /organism="Canis familiaris"
              /mol_type="genomic DNA"
              /db_xref="taxon:9615"
              1..20
              complement(1..20)
              /note="PCR primer binding site"
              /evidence=experimental
              5 c      7 g      4 t
BASE COUNT   4 a      5 c      7 g      4 t

Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1373 AGGAGATTACAGCTT 1387
Db 1 AGGAGATTACAGCTT 15

RESULT 66
LOCUS       AR133381                15 bp      DNA          linear      PAT 16-MAY-2001
DEFINITION  Sequence 1806 from patent US 6194150.
ACCESSION   AR133381
VERSION     AR133381.1 GI:14122286
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE    1 (bases 1 to 15)
AUTHORS      Stinchcomb, D.T., Jarvis, T. and McSwiggen, J.
TITLE        Nucleic acid based inhibition of CD40
JOURNAL      Patent: US 6194150-A 1805 27-FEB-2001;
              Location/Qualifiers
              1..15
              /organism="unknown"
              5 a      2 c      4 g      4 t
BASE COUNT   5 a      2 c      4 g      4 t

Query Match 1.1%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1373 AGGAGATTACAGCTT 1387
Db 1 AGGAGATTACAGCTT 15

RESULT 67
LOCUS       AR133382                15 bp      DNA          linear      PAT 16-MAY-2001
DEFINITION  Sequence 1807 from patent US 6194150.
ACCESSION   AR133382
VERSION     AR133382.1 GI:14122287
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1373 AGGAGATTACAGCTT 1387
Db 1 AGGAGATTACAGCTT 15
```

```

REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of Cpd40
JOURNAL Patent: US 6194150-A 1807 27-FEB-2001;
FEATURES
    SOURCE
        1..15
            Location/Qualifiers
                ORGANISM= "unknown"
BASE COUNT      4 a      3 c      4 g      4 t
Query Match
Best Local Similarity 100.0%; Pred. No. 82; Length 15;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1374 GGAGATTACAGCTTC 1388
Db      1 GGAGATTACAGCTTC 15

RESULT 68
LOCUS AX553634/c
DEFINITION Sequence 38 from Patent WO02074946.
ACCESSION AX553634
VERSION AX553634.1 GI:25897632
KEYWORDS
SOURCE
    ORGANISM Homo sapiens (human)
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Setup,P., Heimberg,H. and Gradwohl,G.
TITLE Method for generating insulin-secreting cells suitable for
JOURNAL transplation
PATENT: WO 02074946-A 38 26-SEP-2002;
NOVO NORDISK A/S (DK)
FEATURES
    source
        1..20
            Location/Qualifiers
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"
BASE COUNT      7 a      6 c      6 g      1 t
Query Match
Best Local Similarity 100.0%; Pred. No. 1.2e+02; Length 20;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1807 GTCACCGTGGCCGTG 1821
Db      16 GTCACCGTGGCCGTG 2

RESULT 69
LOCUS AR106794/c
DEFINITION Sequence 42 from patent US 6107091.
ACCESSION AR106794
VERSION AR106794.1 GI:12821324
KEYWORDS
SOURCE
    ORGANISM Unknown.
    UNCLASSIFIED.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cowsebt,L.M.
TITLE Antisense inhibition of G-alpha-16 expression
JOURNAL Patent: US 6107091-A 42 22-AUG-2000;
FEATURES
    source
        1..18
            Location/Qualifiers
                /organism="unknown"
BASE COUNT      2 a      7 c      4 g      5 t
Query Match
Best Local Similarity 88.9%; Pred. No. 1.1e+02; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Qy      1354 CCAGCGCTGGAGAGAA 1371
Db      18 CCAGTGGCTGGAGAGAA 1

RESULT 70
LOCUS AR160861/c
DEFINITION Sequence 65 from patent US 6255111.
ACCESSION AR160861
VERSION AR160861.1 GI:16225723
KEYWORDS
SOURCE
    ORGANISM Unknown.
    UNCLASSIFIED.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank. and Cowsebt,L.M.
TITLE Antisense modulation of Her-4 expression
JOURNAL Patent: US 6255111-A 65 03-JUL-2001;
FEATURES
    source
        1..18
            Location/Qualifiers
                /organism="unknown"
BASE COUNT      4 a      7 c      0 g      7 t
Query Match
Best Local Similarity 88.9%; Pred. No. 1.1e+02; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1884 GATGAGATGATTGGAA 1901
Db      18 GATGAGAGATTGGAA 1

RESULT 71
LOCUS AX132279
DEFINITION Sequence 3497 from Patent WO0130362.
ACCESSION AX132279
VERSION AX132279.1 GI:14138584
KEYWORDS
SOURCE
    ORGANISM Homo sapiens (human)
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye
JOURNAL diseases
PATENT: WO 0130362-A 3497 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES
    source
        1..19
            Location/Qualifiers
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"
                /note="Cdc25 hs ribozyme binding site"
BASE COUNT      3 a      5 c      2 g      9 t
Query Match
Best Local Similarity 88.9%; Pred. No. 1.2e+02; Length 19;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1320 GATATCCTTCACTCTGC 1337
Db      2 GATTCTTCACTCTGC 19

RESULT 72
LOCUS AX132280
DEFINITION Sequence 3498 from Patent WO0130362.
ACCESSION AX132280

```

VERSION AX132280.1 GI:14138585
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Robbins,J.M. and Tiltz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 3498 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES Location/Qualifiers
source 1..19
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/note="Cdc25 hs ribozyme binding site"

BASE COUNT 2 a 5 c 2 g 10 t

Query Match 1.1%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1320 GATATCCTTCACCTGC 1337
Db 1 GATTTCCTTCATCTGC 18

RESULT 73
LOCUS 123857 17 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 10 from patent US 5538892.
ACCESSION 123857
VERSION 123857.1 GI:1603727
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Donahoe,P.K., Gustafson,M., He,W.-W. and Wang,X.-F.
TITLE Nucleic acids encoding a TGF-beta type 1 receptor
JOURNAL Patent: US 5538892-A 10 23-JUL-1996;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"

BASE COUNT 3 a 2 c 4 g 5 t 3 others

Query Match 1.0%; Score 14.6; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 1.1e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1813 GTGGCCGTGAAGATGTT 1829
Db 1 GTGGCCGTSAARATYTT 17

RESULT 74
LOCUS 125016 17 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 10 from patent US 5547854.
ACCESSION 125016
VERSION 125016.1 GI:1604886
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Donahoe,P.K., Gustafson,M. and He,W.W.
TITLE DNA encoding a receptor for Mullerian inhibitory substance, misrl,
and corresponding vectors, cells, probes, and recombinant methods
JOURNAL Patent: US 5547854-A 10 20-AUG-1996;
FEATURES Location/Qualifiers

source 1..17
/organism="unknown"

BASE COUNT 3 a 2 c 4 g 5 t 3 others

Query Match 1.0%; Score 14.6; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 1.1e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1813 GTGGCCGTGAAGATGTT 1829
Db 1 GTGGCCGTSAARATYTT 17

RESULT 75
LOCUS AX118055/c 18 bp DNA linear PAT 11-MAY-2001
DEFINITION Sequence 3178 from Patent W00129262.
ACCESSION AX118055
VERSION AX118055.1 GI:14035006
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Picoult-Newburg,L. and Pohl,M.
TITLE Genotyping reagents, kits and methods of use thereof
JOURNAL Patent: WO 0129262-A 3178 26-APR-2001;
Orchid Biosciences, Inc. (US)
FEATURES Location/Qualifiers
source 1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Primer"

BASE COUNT 3 a 3 c 9 g 2 t 1 others

Query Match 1.0%; Score 14.6; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1382 CAGCTTCCCGAGCT 1396
Db 16 CAGCTTCCCGAGCT 2

RESULT 76
LOCUS AX133183 16 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 4401 from Patent W00130362.
ACCESSION AX133183
VERSION AX133183.1 GI:14139493
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Robbins,J.M. and Tiltz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 4401 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES Location/Qualifiers
source 1..16
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/note="IL-1 beta ribozyme recognition site"

BASE COUNT 2 a 3 c 5 g 6 t

Query Match 1.0%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2324 GTGATGCTGTGCTCT 2339
 |||||
 Db 1 GTGATGCTGTGCTCAT 16

RESULT 77
 BD002055/c 16 bp DNA linear PAT 31-JAN-2002
 LOCUS Agent for retarding the conversion of hormone-dependent cancer info
 DEFINITION hormone-independent cancer.
 ACCESSION BD002055
 VERSION BD002055.1 GI:18628795
 KEYWORDS JP 2000178202-A/6,
 SOURCE synthetic construct
 ORGANISM synthetic construct
 REFERENCE 1 (bases 1 to 16)
 AUTHORS Matsutani, T. and Naito, K.
 TITLE Agent for retarding the conversion of hormone-dependent cancer into
 hormone-independent cancer.
 JOURNAL Patent: JP 2000178202-A 6 27-JUN-2000;
 COMMENT TAKEDA CHEMICAL INDUSTRIES LTD
 OS Artificial Sequence
 PN JP 2000178202-A/6
 PD 27-JUN-2000
 PF 07-OCT-1999 JP 1999286856
 PR
 PI TOSHIVA MATSUTANI, KENICHIRO NAITO
 PC A61K38/04, A61K38/22, A61K45/00, A61P13/08, A61P35/00//COTK7/23 CC

FEATURES
 source 1.16
 FT Location/Qualifiers
 Location/Qualifiers
 1.16
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

BASE COUNT 4 a 5 c 1 g 2 t 4 others

QY 2323 AGTGATGCTGTGCTCT 2338
 |||||
 Db 16 AGYGAVGTGTGCTCT 1

RESULT 78
 AR048076 17 bp DNA linear PAT 29-SEP-1999
 LOCUS Sequence 17 from patent US 5821046.
 DEFINITION AR048076
 ACCESSION AR048076
 VERSION AR048076.1 GI:5970419
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Karn, J., Galt, M., John, S., Heaphy, S. and Dingwall, C.
 TITLE RNA oligonucleotides that bind HIV tat protein
 JOURNAL Patent: US 5821046-A 17 13-OCT-1998;
 FEATURES Location/Qualifiers
 source 1.17
 /organism="unknown"

BASE COUNT 5 a 4 c 5 g 2 t 1 others

Query Match 1.0%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1490 AGCCAGACTTCAGCAGC 1506
 |||||
 Db 1 AGCCAGANTTGAGCAGC 17

RESULT 79
 AR048079 17 bp DNA linear PAT 29-SEP-1999
 LOCUS Sequence 20 from patent US 5821046.
 DEFINITION AR048079
 ACCESSION AR048079
 VERSION AR048079.1 GI:5970422
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Karn, J., Galt, M., John, S., Heaphy, S. and Dingwall, C.
 TITLE RNA oligonucleotides that bind HIV tat protein
 JOURNAL Patent: US 5821046-A 20 13-OCT-1998;
 FEATURES Location/Qualifiers
 source 1.17
 /organism="unknown"

BASE COUNT 5 a 4 c 5 g 2 t 1 others

QY 1490 AGCCAGACTTCAGCAGC 1506
 |||||
 Db 1 AGCCAGANTTGAGCAGC 17

RESULT 80
 AR108979 17 bp DNA linear PAT 14-FEB-2001
 LOCUS Sequence 17 from patent US 6114109.
 DEFINITION AR108979
 ACCESSION AR108979
 VERSION AR108979.1 GI:12825255
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Karn, J., Galt, M., John, S., Heaphy, S. and Dingwall, C.
 TITLE Viral (HIV) growth inhibition
 JOURNAL Patent: US 6114109-A 17 05-SEP-2000;
 FEATURES Location/Qualifiers
 source 1.17
 /organism="unknown"

BASE COUNT 5 a 4 c 5 g 2 t 1 others

QY 1490 AGCCAGACTTCAGCAGC 1506
 |||||
 Db 1 AGCCAGANTTGAGCAGC 17

RESULT 81
 AR108982 17 bp DNA linear PAT 14-FEB-2001
 LOCUS Sequence 20 from patent US 6114109.
 DEFINITION AR108982
 ACCESSION AR108982
 VERSION AR108982.1 GI:12825258
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Karn, J., Galt, M., John, S., Heaphy, S. and Dingwall, C.

Query Match 1.0%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

TITLE      Viral (HIV) growth inhibition
JOURNAL    Patent: US 614109-A 20 05-SEP-2000;
FEATURES    Location/Qualifiers
SOURCE      1. .17
            /organism="unknown"
BASE COUNT      5 a      4 c      5 g      2 t      1 others

Query Match      1.0%; Score 14.4; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1490 AGCCAGACTTCAGCAGC 1506
        |||||
        1 AGCCAGANTTGACGAGC 17

Db

RESULT 82
LOCUS      AR190227      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION Sequence 5715 from patent US 6346398.
ACCESSION  AR190227
VERSION     AR190227.1 GI:20236192
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE    1 (bases 1 to 17)
AUTHORS     Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE       Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
JOURNAL     Patent: US 6346398-A 5715 12-FEB-2002;
FEATURES     Location/Qualifiers
SOURCE      1. .17
            /organism="unknown"
BASE COUNT      8 a      1 c      5 g      3 t

Query Match      1.0%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1822 AAGATGTTGAAAGATG 1837
        |||||
        2 AAGATGTTGAAAGAG 17

Db

RESULT 83
LOCUS      AR048082      18 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 23 from patent US 5821046.
ACCESSION  AR048082
VERSION     AR048082.1 GI:5970425
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE    1 (bases 1 to 18)
AUTHORS     Karn,J., Galt,M.,John., Heaphy,S. and Dingwall,C.
TITLE       RNA oligonucleotides that bind HIV tat protein
JOURNAL     Patent: US 5821046-A 23 13-OCT-1998;
FEATURES     Location/Qualifiers
SOURCE      1. .18
            /organism="unknown"
BASE COUNT      5 a      4 c      5 g      3 t      1 others

Query Match      1.0%; Score 14.4; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1490 AGCCAGACTTCAGCAGC 1506
        |||||
        1 AGCCAGANTTGACGAGC 17

Db

```

```

RESULT 84
LOCUS      AR073390      18 bp      DNA      linear      PAT 28-AUG-2000
DEFINITION Sequence 30 from patent US 5951455.
ACCESSION  AR073390
VERSION     AR073390.1 GI:10000154
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE    1 (bases 1 to 18)
AUTHORS     Cowser,L.M.
TITLE       Antisense modulation of G-alpha-11 expression
JOURNAL     Patent: US 5951455-A 30 14-SEP-1999;
FEATURES     Location/Qualifiers
SOURCE      1. .18
            /organism="unknown"
BASE COUNT      3 a      2 c      7 g      6 t

Query Match      1.0%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1814 TGGCGGTGAAGATGTT 1829
        |||||
        1 TGGCGGTGAAGATGTT 16

Db

RESULT 85
LOCUS      AR108985      18 bp      DNA      linear      PAT 14-FEB-2001
DEFINITION Sequence 23 from patent US 6114109.
ACCESSION  AR108985
VERSION     AR108985.1 GI:12825261
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE    1 (bases 1 to 18)
AUTHORS     Karn,J., Galt,M.J., Heaphy,S. and Dingwall,C.
TITLE       Viral (HIV) growth inhibition
JOURNAL     Patent: US 6114109-A 23 05-SEP-2000;
FEATURES     Location/Qualifiers
SOURCE      1. .18
            /organism="unknown"
BASE COUNT      5 a      4 c      5 g      3 t      1 others

Query Match      1.0%; Score 14.4; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1490 AGCCAGACTTCAGCAGC 1506
        |||||
        1 AGCCAGANTTGACGAGC 17

Db

RESULT 86
LOCUS      AR220012      18 bp      DNA      linear      PAT 26-SEP-2002
DEFINITION Sequence 5 from patent US 6423518.
ACCESSION  AR220012
VERSION     AR220012.1 GI:23324417
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE    1 (bases 1 to 18)
AUTHORS     Anderson,S. and Banta,S.
TITLE       Design and production of mutant 2,5-dihydro-D-gluconic acid
            reductase enzymes with altered cofactor dependency
JOURNAL     Patent: US 6423518-A 5 23-JUL-2002;
FEATURES     Location/Qualifiers
SOURCE      1. .18

```

BASE COUNT 6 a 5 c 6 g 1 t
/organism="unknown"

Query Match 1.0%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1356 AGCGCTGAGAGAA 1371
|||||
2 AGCCCTCGAAGAGAA 17

RESULT 87
AX227662 17 bp mRNA linear PAT 10-SEP-2001
LOCUS
DEFINITION Sequence 1034 from Patent WO0157206.
AX227662
VERSION AX227662.1 GI:15556803
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Fattaey,A.R., Jarvis,T., Mcswiggen,J., Bocher,R.N. and Holman,P.S.
TITLE Method and reagent for the inhibition of checkpoint kinase-1 (chk
1) enzyme
JOURNAL Patent: WO 0157206-A 1034 09-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"

BASE COUNT 6 a 3 c 6 g 2 t

Query Match 1.0%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1730 CCCTGGAGAGGT 1743
|||||
4 CCCTGGAGAGGT 17

RESULT 88
AX227663 17 bp mRNA linear PAT 10-SEP-2001
LOCUS
DEFINITION Sequence 1035 from Patent WO0157206.
AX227663
VERSION AX227663.1 GI:15556804
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Fattaey,A.R., Jarvis,T., Mcswiggen,J., Bocher,R.N. and Holman,P.S.
TITLE Method and reagent for the inhibition of checkpoint kinase-1 (chk
1) enzyme
JOURNAL Patent: WO 0157206-A 1035 09-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"

BASE COUNT 5 a 3 c 7 g 2 t

Query Match 1.0%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1730 CCCTGGAGAGGT 1743
|||||

DB 3 CCCTGGAGAGGT 16

RESULT 89
AX227664 17 bp mRNA linear PAT 10-SEP-2001
LOCUS
DEFINITION Sequence 1036 from Patent WO0157206.
AX227664
VERSION AX227664.1 GI:15556805
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Fattaey,A.R., Jarvis,T., Mcswiggen,J., Bocher,R.N. and Holman,P.S.
TITLE Method and reagent for the inhibition of checkpoint kinase-1 (chk
1) enzyme
JOURNAL Patent: WO 0157206-A 1036 09-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"

BASE COUNT 3 a 5 c 7 g 2 t

Query Match 1.0%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1730 CCCTGGAGAGGT 1743
|||||
1 CCCTGGAGAGGT 14

RESULT 90
A20708 17 bp mRNA linear PAT 03-OCT-1994
LOCUS
DEFINITION Oligoribonucleotide 17-mer.
A20708
VERSION A20708.1 GI:641287
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 17)
AUTHORS
TITLE VIRAL (HIV) GROWTH INHIBITION
JOURNAL Patent: WO 9202228-A 2 20-FEB-1992;
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"

BASE COUNT 5 a 4 c 5 g 3 t

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1490 AGCCAGACTTCAGCAGC 1506
|||||
1 AGCCAGATTTCAGCAGC 17

RESULT 91
A21027 17 bp mRNA linear PAT 03-OCT-1994
LOCUS
DEFINITION Oligoribonucleotide.
A21027
VERSION A21027.1 GI:641329
KEYWORDS
SOURCE
synthetic construct

ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 17)
AUTHORS
TITLE VIRAL (HIV) GROWTH INHIBITION
JOURNAL Patent: WO 9202228-A 17 20-FEB-1992;
FEATURES Location/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="mrna"
/db_xref="taxon:32630"

BASE COUNT 5 a 4 c 5 g 3 t

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1490 AGCCAGACTTCAGCAGC 1506
Db 1 AGCCAGATTTCAGCAGC 17
|||||
|

RESULT 92
LOCUS A95626 17 bp DNA linear PAT 26-JAN-2000
DEFINITION Sequence 28 from Patent WO925815.
ACCESSION A95626
VERSION A95626.1 GI:6779563
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS Herrmann, B. and Kispert, A.
TITLE NUCLEIC ACIDS INVOLVED IN THE RESPONDER PHENOTYPE AND APPLICATIONS
JOURNAL Patent: WO 925815-A 28 27-MAY-1999;
FEATURES Location/Qualifiers
source 1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

BASE COUNT 3 a 7 c 3 g 4 t

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2272 GTCAAGTCGATGCTCC 2288
Db 17 GTGAAGTCGATGCGACC 1
|||||
|

RESULT 93
LOCUS ARI88717 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4205 from patent US 6346398.
ACCESSION ARI88717
VERSION ARI88717.1 GI:20234682
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL Patent: US 6346398-A 4205 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"

BASE COUNT 3 a 3 c 5 g 6 t

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2112 CATGAGTACTTGCTT 2128
Db 1 CATGAGTCTTGGCAT 17
|||||
|

RESULT 94
LOCUS ARI88718 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4206 from patent US 6346398.
ACCESSION ARI88718
VERSION ARI88718.1 GI:20234683
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL Patent: US 6346398-A 4206 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"

BASE COUNT 3 a 3 c 5 g 6 t

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2113 ATGAGTACTTGCTTC 2129
Db 1 ATGAGTCTTGGCATC 17
|||||
|

RESULT 95
LOCUS ARI88754 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4242 from patent US 6346398.
ACCESSION ARI88754
VERSION ARI88754.1 GI:20234719
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL Patent: US 6346398-A 4242 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"

BASE COUNT 2 a 3 c 5 g 7 t

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2323 AGTGATCTGCTGCTT 2339
Db 1 AGTGAGCTCTGCTCTT 17
|||||
|

RESULT 96
LOCUS ARI88869 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4357 from patent US 6346398.
ACCESSION ARI88869

```

VERSION      AR188869.1  GI:20234834
KEYWORDS
SOURCE       Unknown.
ORGANISM     Unknown.
REFERENCE    1 (bases 1 to 17)
AUTHORS      Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE        Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6346398-A 4357 12-FEB-2002;
FEATURES
  source      1. .17
              /organism="unknown"
BASE COUNT   6 a      2 c      3 g      6 t

Query Match  1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 2404 GAACTTTTAACTGCT 2420
Db 1 GAACTTTTAACTGAT 17

RESULT 97
LOCUS      AR190226      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION Sequence 5714 from patent US 6346398.
ACCESSION  AR190226
VERSION     AR190226.1  GI:20236191
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    1 (bases 1 to 17)
AUTHORS      Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE        Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6346398-A 5714 12-FEB-2002;
FEATURES
  source      1. .17
              /organism="unknown"
BASE COUNT   4 a      3 c      5 g      5 t

Query Match  1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 1813 GTGCGCGTGAAGATGT 1829
Db 1 GTAGCGGTCAAGATGT 17

RESULT 98
LOCUS      AR190291      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION Sequence 5779 from patent US 6346398.
ACCESSION  AR190291
VERSION     AR190291.1  GI:20236256
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    1 (bases 1 to 17)
AUTHORS      Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE        Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6346398-A 5779 12-FEB-2002;
FEATURES
  source      1. .17
              /organism="unknown"
BASE COUNT   3 a      3 c      5 g      6 t

BASE COUNT   3 a      3 c      5 g      6 t

```

```

Query Match  1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 2112 CATGAGTACTTGCGCTT 2128
Db 1 CATGAGTCTTGCGCAT 17

RESULT 99
LOCUS      AR190292      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION Sequence 5780 from patent US 6346398.
ACCESSION  AR190292
VERSION     AR190292.1  GI:20236257
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    1 (bases 1 to 17)
AUTHORS      Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE        Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6346398-A 5780 12-FEB-2002;
FEATURES
  source      1. .17
              /organism="unknown"
BASE COUNT   3 a      3 c      5 g      6 t

Query Match  1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 2113 ATGAGTACTTGCGCTTC 2129
Db 1 ATGAGTCTTGCGCATC 17

RESULT 100
LOCUS      AR190329      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION Sequence 5817 from patent US 6346398.
ACCESSION  AR190329
VERSION     AR190329.1  GI:20236294
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    1 (bases 1 to 17)
AUTHORS      Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE        Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6346398-A 5817 12-FEB-2002;
FEATURES
  source      1. .17
              /organism="unknown"
BASE COUNT   0 a      2 c      6 g      9 t

Query Match  1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 2332 TGGTCTTGGGGGTGT 2348
Db 1 TGGTCTTGGGTGT 17

RESULT 101
LOCUS      AR192186      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION Sequence 7674 from patent US 6346398.
ACCESSION  AR192186
VERSION     AR192186.1  GI:20238151

```

KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7674 12-FEB-2002;
FEATURES
source 1..17
location/Qualifiers
BASE COUNT 3 a 5 c 5 g 4 t

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2279 GGATGGCTCCAGAGCC 2295
Db 1 GGATGGCTCCTGATCC 17

RESULT 102
LOCUS AR192196 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 7684 from patent US 6346398.
ACCESSION AR192196
VERSION AR192196.1 GI:20238161
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7684 12-FEB-2002;
FEATURES
source 1..17
location/Qualifiers
BASE COUNT 2 a 4 c 4 g 7 t

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2353 TGGGAGATCTTCACTT 2369
Db 1 TGGGAGATCTTCTCCTT 17

RESULT 103
LOCUS AR192197 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 7685 from patent US 6346398.
ACCESSION AR192197
VERSION AR192197.1 GI:20238162
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7685 12-FEB-2002;
FEATURES
source 1..17
location/Qualifiers
BASE COUNT 3 a 4 c 4 g 6 t

Query Match 1.0%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2355 GGAGATCTTCACCTTAG 2371
Db 1 GGAGATCTTCTCCTTAG 17

RESULT 104
LOCUS AR192198 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 7686 from patent US 6346398.
ACCESSION AR192198
VERSION AR192198.1 GI:20238163
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7686 12-FEB-2002;
FEATURES
source 1..17
location/Qualifiers
BASE COUNT 3 a 4 c 4 g 6 t

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2356 GAGATCTTCACTTAGG 2372
Db 1 GAGATCTTCTCCTTAGG 17

RESULT 105
LOCUS AR192199 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 7687 from patent US 6346398.
ACCESSION AR192199
VERSION AR192199.1 GI:20238164
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7687 12-FEB-2002;
FEATURES
source 1..17
location/Qualifiers
BASE COUNT 2 a 4 c 5 g 6 t

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2358 GATCTTCACCTTAGGGG 2374
Db 1 GATCTTCTCCTTAGGGG 17

RESULT 106
LOCUS AR286013 17 bp RNA linear PAT 10-APR-2003
DEFINITION Sequence 385 from patent US 6528640.
ACCESSION AR286013
VERSION AR286013.1 GI:29723609
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
TITLE Beigelman, L., Burgin, A., Beaudry, A., Karpeisky, A.,
Matulic-Adamc, J., Sweedler, D. and Zinnen, S.
JOURNAL Synthetic ribonucleic acids with RNase activity
Patent: US 6528640-A 385 04-MAR-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 5 a 3 c 6 g 3 t
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1920 TCTTCTTGAGCCTGCA 1936
Db 17 TCTTCTTGAGCCTGCA 1
RESULT 107 17 bp RNA linear PAT 10-APR-2003
AR286406
LOCUS AR286406
DEFINITION Sequence 778 from patent US 6528640.
ACCESSION AR286406
VERSION AR286406.1 GI:29724002
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
TITLE Beigelman, L., Burgin, A., Beaudry, A., Karpeisky, A.,
Matulic-Adamc, J., Sweedler, D. and Zinnen, S.
JOURNAL Synthetic ribonucleic acids with RNase activity
Patent: US 6528640-A 778 04-MAR-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 4 a 5 c 5 g 3 t
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2269 CCAGTCAAGTGATGGC 2285
Db 1 CCAGTCAAGTGATGGC 17
RESULT 108 17 bp RNA linear PAT 06-SEP-2000
AX008727
LOCUS AX008727
DEFINITION Sequence 1 from Patent WO9964625.
ACCESSION AX008727
VERSION AX008727.1 GI:9996224
KEYWORDS
SOURCE Human immunodeficiency virus
ORGANISM Human immunodeficiency virus
REFERENCE Human immunodeficiency virus
AUTHORS Viruses; Retrovirdae; Lentivirus; Primate
TITLE Prescott, C.D. and Karn, J.
JOURNAL Methods and kits for discovery of rna-binding compounds
Patent: WO 9964625-A 1 16-DEC-1999;
FEATURES Location/Qualifiers
source 1..17
/organism="Human immunodeficiency virus"
/mol_type="genomic RNA"
/db_xref="taxon:12721"
BASE COUNT 5 a 4 c 5 g 3 t

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1490 AGCCAGACTTCAGCAGC 1506
Db 1 AGCCAGACTTCAGCAGC 17
RESULT 109 17 bp mRNA linear PAT 07-SEP-2001
AX215402/c
LOCUS AX215402
DEFINITION Sequence 844 from Patent WO0159103.
ACCESSION AX215402
VERSION AX215402.1 GI:15525445
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE artificial sequences.
AUTHORS 1
TITLE Blatt, L., McSwiggen, J. and Chowrira, B.M.
JOURNAL Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
Patent: WO 0159103-A 844 16-AUG-2001;
FEATURES RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
Location/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
BASE COUNT 6 a 4 c 4 g 3 t
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1650 GCTGCGAGGGGTCTCCG 1666
Db 17 GCTGCGAGGGGTCTCCG 1
RESULT 110 17 bp mRNA linear PAT 07-SEP-2001
AX218180
LOCUS AX218180
DEFINITION Sequence 3622 from Patent WO0159103.
ACCESSION AX218180
VERSION AX218180.1 GI:15528241
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE artificial sequences.
AUTHORS 1
TITLE Blatt, L., McSwiggen, J. and Chowrira, B.M.
JOURNAL Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
Patent: WO 0159103-A 3622 16-AUG-2001;
FEATURES RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
Location/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

QY 1701 TCCAGAGATTAAGCTGA 1717
|||||
Db 1 TCCAGAGAGACTGCTGA 17

RESULT 111
AX218315

LOCUS AX218315 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 3757 from Patent WO0159103.
ACCESSION AX218315
VERSION AX218315.1 GI:15528376
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Blatt, L., Mcswigen, J. and Chowitra, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 3757 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
Mcswigen, James (US) ; Chowitra, Bharat M. (US)
LOCATION/Qualifiers

FEATURES
source 1..17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

BASE COUNT 5 a 4 c 4 g 4 t

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1700 TTCAGAGATTAAGCTG 1716
|||||
Db 1 TCCAGAGAGACTGCTG 17

RESULT 112
AX227058 17 bp mRNA linear PAT 10-SEP-2001
LOCUS AX227058
DEFINITION Sequence 430 from Patent WO0157206.
ACCESSION AX227058
VERSION AX227058.1 GI:15556199
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Fattaey, A.R., Jarvis, T., Mcswigen, J., Bocher, R.N. and Holman, P.S.
TITLE Method and reagent for the inhibition of checkpoint kinase-1 (chk
1) enzyme
JOURNAL Patent: WO 0157206-A 430 09-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)
LOCATION/Qualifiers

FEATURES
source 1..17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"

BASE COUNT 6 a 3 c 3 g 5 t

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2194 AAAATAGCAGCTTTGG 2210
|||||
Db 1 AAAATCTCAGACTTTGG 17

RESULT 113
AX325661

LOCUS AX325661 17 bp DNA linear PAT 02-SEP-2002
DEFINITION Sequence 1799 from Patent WO0192512.
ACCESSION AX325661
VERSION AX325661.1 GI:18096420
KEYWORDS
SOURCE Solanum tuberosum (potato)
ORGANISM Solanum tuberosum
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B., Rice, M.C. and Kim, J.
TITLE Targeted chromosomal genomic alterations in plants using modified
single stranded oligonucleotides
JOURNAL Patent: WO 0192512-A 1799 06-DEC-2001;
UNIVERSITY OF DELAWARE (US)
LOCATION/Qualifiers

FEATURES
source 1..17
/organism="Solanum tuberosum"
/mol_type="genomic DNA"
/db_xref="taxon:4113"

BASE COUNT 8 a 4 c 2 g 3 t

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1485 CAGAGACCACTTCA 1501
|||||
Db 1 CAGAGACTTAACCTTCA 17

RESULT 114
AX325662 17 bp DNA linear PAT 02-SEP-2002
LOCUS AX325662/C
DEFINITION Sequence 1800 from Patent WO0192512.
ACCESSION AX325662
VERSION AX325662.1 GI:18096421
KEYWORDS
SOURCE Solanum tuberosum (potato)
ORGANISM Solanum tuberosum
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B., Rice, M.C. and Kim, J.
TITLE Targeted chromosomal genomic alterations in plants using modified
single stranded oligonucleotides
JOURNAL Patent: WO 0192512-A 1800 06-DEC-2001;
UNIVERSITY OF DELAWARE (US)
LOCATION/Qualifiers

FEATURES
source 1..17
/organism="Solanum tuberosum"
/mol_type="genomic DNA"
/db_xref="taxon:4113"

BASE COUNT 3 a 2 c 4 g 8 t

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1485 CAGAGACCACTTCA 1501
|||||
Db 17 CAGAGACTTAACCTTCA 1

RESULT 115
AX498838 17 bp DNA linear PAT 27-SEP-2002
LOCUS AX498838
DEFINITION Sequence 145 from Patent EP1229046.
ACCESSION AX498838
VERSION AX498838.1 GI:23381120
KEYWORDS

SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1
AUTHORS Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 145 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 8 c 2 g 1 t
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1518 GCACAGCTGACCAAC 1534
DB 1 GCCCAGCTCACCAC 17
RESULT 116
AX500369/c 17 bp DNA linear PAT 27-SEP-2002
LOCUS Sequence 1676 from Patent EP1229046.
DEFINITION AX500369
ACCESSION AX500369.1 GI:23382662
VERSION AX500369.1
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1
AUTHORS Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 1676 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 2 c 1 g 9 t
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2186 ATGTGATGAAATAGCA 2202
DB 17 ATGTTATTAATAATAGCA 1
RESULT 117
AX530613/c 17 bp DNA linear PAT 22-NOV-2002
LOCUS Sequence 122 from Patent EP1239051.
DEFINITION AX530613
ACCESSION AX530613
VERSION AX530613.1 GI:25253033
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1
AUTHORS Shannon, M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 122 11-SEP-2002;
Aeomica, Inc. (US)

FEATURES Location/Qualifiers
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 4 c 5 g 2 t
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1564 TCGGCTGAGTCCAGCTC 1580
DB 17 TCTGCTGAGTCCAGCTC 1
RESULT 118
AX530614/c 17 bp DNA linear PAT 22-NOV-2002
LOCUS Sequence 123 from Patent EP1239051.
DEFINITION AX530614
ACCESSION AX530614
VERSION AX530614.1 GI:25253035
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1
AUTHORS Shannon, M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 123 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 7 a 4 c 4 g 2 t
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1563 TTCGCTGAGTCCAGCT 1579
DB 17 TTCGCTGAGTCCAGCT 1
RESULT 119
AX673357 17 bp DNA linear PAT 27-MAR-2003
LOCUS Sequence 1802 from Patent WO03004526.
DEFINITION AX673357
ACCESSION AX673357
VERSION AX673357.1 GI:29331705
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1
AUTHORS Telerman, A., Anson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 1802 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 4 a 6 c 2 g 5 t

Query Match 1.0%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1577 GCTCTCATGACTCC 1593
 DB 1 GATCTCTATGACTCC 17

RESULT 120
 LOCUS AX687587 17 bp DNA linear PAT 31-MAR-2003
 DEFINITION Sequence 319 from Patent EP1281758.
 ACCESSION AX687587
 VERSION AX687587.1 GI:29410283
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

REFERENCE
 AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
 TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
 JOURNAL Patent: EP 1281758-A 319 05-FEB-2003;
 FEATURES
 source Location/Qualifiers

1. .17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

BASE COUNT 2 a 5 c 6 g 4 t

Query Match 1.0%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2283 GGCTCCAGAACCTCTGT 2299
 DB 1 GGCTCCAGAGCTCTGT 17

RESULT 121
 LOCUS AX726093/c 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 3780 from Patent WO03025176.
 ACCESSION AX726093
 VERSION AX726093.1 GI:30505436
 KEYWORDS
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus

REFERENCE
 AUTHORS Telerman, A., Anson, R. and Tuijnder, M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
 JOURNAL Patent: WO 03025176-A 3780 27-MAR-2003;
 FEATURES
 source Location/Qualifiers

1. .17
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /db_xref="taxon:10090"

BASE COUNT 5 a 5 c 3 g 4 t

Query Match 1.0%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2532 GGTAGAGACTTGATC 2548
 DB 1 GGTAGAGACTTGATC 2548

DB 17 GGTAGAGACTTGATC 1

RESULT 122
 LOCUS AX729373/c 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 1007 from Patent WO03025175.
 ACCESSION AX729373
 VERSION AX729373.1 GI:30508716
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

REFERENCE
 AUTHORS Telerman, A., Anson, R. and Tuijnder, M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
 JOURNAL Patent: WO 03025175-A 1007 27-MAR-2003;
 FEATURES
 source Location/Qualifiers

1. .17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

BASE COUNT 6 a 4 c 2 g 5 t

Query Match 1.0%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1848 GAAAGACCTTGTGATC 1864
 DB 17 GAAAGACTTGTGATC 1

RESULT 123
 LOCUS AX733343/c 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 4977 from Patent WO03025175.
 ACCESSION AX733343
 VERSION AX733343.1 GI:30512686
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

REFERENCE
 AUTHORS Telerman, A., Anson, R. and Tuijnder, M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
 JOURNAL Patent: WO 03025175-A 4977 27-MAR-2003;
 FEATURES
 source Location/Qualifiers

1. .17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

BASE COUNT 2 a 4 c 3 g 8 t

Query Match 1.0%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1898 GGAACACAGATATC 1914
 DB 17 GGAATCACAGAGATC 1

RESULT 124
 AX744528

LOCUS AX744528 17 bp DNA linear PAT 14-MAY-2003
DEFINITION Sequence 493 from Patent WO03031621.
ACCESSION AX744528
VERSION AX744528.1 GI:30723195
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Zhang, J.
TITLE A human G protein coupled receptor
JOURNAL Patent: WO 03031621-A 493 17-APR-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 4 a 7 c 1 g 5 t
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2585 ACCCTGACCACTCTC 2601
Db 1 ACTTCAGTCAACTCTC 17
RESULT 125
LOCUS BD091430 17 bp DNA linear PAT 27-AUG-2002
DEFINITION Nucleic acids involved in the responder phenotype and applications thereof.
ACCESSION BD091430
VERSION BD091430.1 GI:22637041
KEYWORDS JP 2001523449-A/19.
SOURCE JP 2001523449-A/19.
ORGANISM
synthetic construct
artificial sequences.
1 (bases 1 to 17)
REFERENCE Hermann, B., Koschorz, B. and Kispert, A.
AUTHORS Nucleic acids involved in the responder phenotype and applications thereof
TITLE
JOURNAL Patent: JP 2001523449-A 19 27-NOV-2001;
COMMENTS MAX PLANCK GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
OS Artificial Sequence
PN JP 2001523449-A/19
PD 27-NOV-2001
PF 18-NOV-1998 JP 2000521181
PR 18-NOV-1997 EP 97120190.0, 02-MAR-1998 EP 98103596.7 PI
BERNHARD HERMANN, BIRGIT KOSCHORZ, ANDREAS KISPERT PC
C12N15/09, A01K67/027, A61K31/7088, A61K38/45, A61K39/395, A61K48/PC
00, A61P15/16,
PC C07K16/40, C12N1/15, C12N1/19, C12N1/21, C12N5/10, C12N9/12 PC
, C12Q1/68/A61K35/12,
CC C12P21/08, C12N15/00, A61K37/52, C12N5/00
Description of Artificial Sequence: synthetic no-natural CC
FH Key Location/Qualifiers
FT source 1..17
/organism="Artificial Sequence".
location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
BASE COUNT 3 a 7 c 3 g 4 t
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2272 GTCAAGTGATGCTCC 2288
Db 17 GTCAAGTGATGCTCC 1
RESULT 126
LOCUS A21030 18 bp mRNA linear PAT 03-OCT-1994
DEFINITION Oligoribonucleotide 18-mer.
ACCESSION A21030
VERSION A21030.1 GI:641332
KEYWORDS
SOURCE
ORGANISM
synthetic construct
artificial sequences.
1 (bases 1 to 18)
REFERENCE 1
AUTHORS VIRAL (HIV) GROWTH INHIBITION
TITLE Patent: WO 9202228-A 20 20-FEB-1992;
JOURNAL Location/Qualifiers
FEATURES
source 1..18
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
BASE COUNT 5 a 4 c 5 g 4 t
Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1490 AGCCAGACTTCAGCAGC 1506
Db 1 AGCCAGATTGAGCAGC 17
RESULT 127
LOCUS A46964 18 bp DNA linear PAT 07-MAR-1997
DEFINITION Sequence 4 from Patent WO9529259.
ACCESSION A46964
VERSION A46964.1 GI:2300984
KEYWORDS
SOURCE
ORGANISM
unidentified
unclassified.
1 (bases 1 to 18)
REFERENCE Voordberg, J.J., Van, M.J. and Mertens, K.
AUTHORS METHOD AND MEANS FOR DETECTING AND TREATING DISORDERS IN THE BLOOD
TITLE COAGULATION CASCADE
JOURNAL Patent: WO 9529259-A 4 02-NOV-1995;
COMMENTS STICHTING CENTRAAL LAB (NL)
Other publication AU 2319495 951116.
FEATURES
source 1..18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 7 a 2 c 4 g 5 t
Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2531 TGGTGAAGACTTGAT 2547
Db 2 TGGTGAAGACTTGAT 18
RESULT 128
LOCUS A88187 18 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 335 from Patent WO9833904.

```

ACCESSION  A88187
VERSION     A88187.1  GI:6736757
KEYWORDS
SOURCE      unidentified
ORGANISM    unidentified
            unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Brysch, W. and Schlingensiepen, K.
TITLE       AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL     Patent: WO 9833904-A 335 06-AUG-1998;
            BIOGENSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES
  source
    1..18
    /organism="unidentified"
    /mol_type="genomic DNA"
    /db_xref="taxon:32644"

BASE COUNT  4 a 6 c 4 g 4 t

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2317 CATCAGAGTGATGCTG 2333
Db 17 CACCAGAGTGATGCTG 1

RESULT 129
LOCUS      A90154
DEFINITION Sequence 335 from Patent EP0856579.
ACCESSION  A90154
VERSION     A90154.1  GI:6738668
KEYWORDS
SOURCE      unidentified
ORGANISM    unidentified
            unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Brysch, W.D. and Schlingensiepen, K.D.
TITLE       An antisense oligonucleotide preparation method
JOURNAL     Patent: EP 0856579-A 335 05-AUG-1998;
            BIOGENSTIK GES (DE)
FEATURES
  source
    1..18
    /organism="unidentified"
    /mol_type="genomic DNA"
    /db_xref="taxon:32644"

BASE COUNT  4 a 6 c 4 g 4 t

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2317 CATCAGAGTGATGCTG 2333
Db 17 CACCAGAGTGATGCTG 1

RESULT 130
LOCUS      A99272
DEFINITION Sequence 48 from Patent WO9907839.
ACCESSION  A99272
VERSION     A99272.1  GI:6782201
KEYWORDS
SOURCE      unidentified
ORGANISM    unidentified
            unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Min, J.W. and Fiers, W.
TITLE       NEW IMMUNOPROTECTIVE INFLUENZA ANTIGEN AND ITS USE IN VACCINATION
JOURNAL     Patent: WO 9907839-A 48 18-FEB-1999;
            VLAAMS INTERUNIV INST BIOTECH (BE); MIN JOU WILLY (BE)

```

```

FEATURES
  source
    1..18
    /organism="unidentified"
    /mol_type="genomic DNA"
    /db_xref="taxon:32644"

BASE COUNT  7 a 0 c 6 g 5 t

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1821 GAAGATGTTGAAGATG 1837
Db 2 GTAGATATTGAAGATG 18

RESULT 131
LOCUS      AR036682/c
DEFINITION Sequence 21 from patent US 5800811.
ACCESSION  AR036682
VERSION     AR036682.1  GI:5954538
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
            unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Hall, F.L., Nimml, M.E., Tuan, T.-L., Wu, L. and Cheung, D.T.
TITLE       Artificial skin prepared from collagen matrix containing
            transforming growth factor-beta, having a collagen binding site
JOURNAL     Patent: US 5800811-A 21 01-SEP-1998;
            Location/Qualifiers
            1..18
            /organism="unknown"

BASE COUNT  6 a 7 c 0 g 5 t

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1879 GAGATGATGAAGATGAT 1895
Db 18 GTGATGATGATGATGAT 2

RESULT 132
LOCUS      AR048072
DEFINITION Sequence 13 from patent US 5821046.
ACCESSION  AR048072
VERSION     AR048072.1  GI:5970415
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
            unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Karn, J., Galt, M., John, S. and Dingwall, C.
TITLE       RNA oligonucleotides that bind HIV tat protein
JOURNAL     Patent: US 5821046-A 13 13-OCT-1998;
            Location/Qualifiers
            1..18
            /organism="unknown"

BASE COUNT  5 a 4 c 5 g 4 t

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1490 AGCCAGACTTGACGACG 1506
Db 1 AGCCAGATTGACGACG 17

```

```

RESULT 133
AR077364      18 bp      DNA      linear      PAT 31-AUG-2000
LOCUS         AR077364
DEFINITION    Sequence 79 from patent US 5962255.
ACCESSION     AR077364
VERSION       AR077364.1 GI:10004110
KEYWORDS
SOURCE        Unknown.
ORGANISM      Unknown.
REFERENCE     1 (bases 1 to 18)
AUTHORS      Griffiths,A.David., Williams,S.Cameron., Waterhouse,P.Michael.,
             Nissim,A., Winter,G.Paul., Johnson,K.Stuart. and
             Smith,A.John.Hammond.
TITLE        Methode for producing recombinant vectors
JOURNAL      Patent: US 5962255-A 79 05-OCT-1999;
FEATURES
SOURCE       1..18
              /organism="unknown"
BASE COUNT   7 a      6 c      3 g      2 t

Query Match   1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No.1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1673 AACTTCGAGAGACCCA 1689
Db 1 AACATCCAGATGACCCA 17

RESULT 134
AR096633/c    18 bp      DNA      linear      PAT 08-SEP-2000
LOCUS         AR096633
DEFINITION    Sequence 17 from patent US 6008048.
ACCESSION     AR096633
VERSION       AR096633.1 GI:10025602
KEYWORDS
SOURCE        Unknown.
ORGANISM      Unknown.
REFERENCE     1 (bases 1 to 18)
AUTHORS      Montu,B.P. and Cowser,L.M.
TITLE        Antisense inhibition of EGR-1 expression
JOURNAL      Patent: US 6008048-A 17 26-DEC-1999;
FEATURES
SOURCE       1..18
              /organism="unknown"
BASE COUNT   2 a      4 c      9 g      3 t

Query Match   1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No.1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1924 CTTGAGCCTGCACACA 1940
Db 17 CTTGAGCCTGCACCCA 1

RESULT 135
AR102333      18 bp      DNA      linear      PAT 14-FEB-2001
LOCUS         AR102333
DEFINITION    Sequence 4 from patent US 6083905.
ACCESSION     AR102333
VERSION       AR102333.1 GI:12813131
KEYWORDS
SOURCE        Unknown.
ORGANISM      Unknown.
REFERENCE     1 (bases 1 to 18)
AUTHORS      Voorberg,J.Jacobus., van Mourik,J.Aart. and Mertens,K.
TITLE        Method and means for detecting and treating disorders in the blood
JOURNAL      Patent: US 6083905-A 4 04-JUL-2000;

```

```

FEATURES
SOURCE       1..18
              /organism="unknown"
BASE COUNT   7 a      2 c      4 g      5 t

Query Match   1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No.1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2531 TGTGAGAACTTGCAAT 2547
Db 2 TGTGAAAAGACTTGCAAT 18

RESULT 136
AR106793/c    18 bp      DNA      linear      PAT 14-FEB-2001
LOCUS         AR106793
DEFINITION    Sequence 41 from patent US 6107091.
ACCESSION     AR106793
VERSION       AR106793.1 GI:12821323
KEYWORDS
SOURCE        Unknown.
ORGANISM      Unknown.
REFERENCE     1 (bases 1 to 18)
AUTHORS      Cowser,L.M.
TITLE        Antisense inhibition of G-alpha-16 expression
JOURNAL      Patent: US 6107091-A 41 22-AUG-2000;
FEATURES
SOURCE       1..18
              /organism="unknown"
BASE COUNT   2 a      7 c      4 g      5 t

Query Match   1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No.1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1354 CCAGCGCTGGAAGACA 1370
Db 17 CCAGTGCCTGGAAGACA 1

RESULT 137
AR108975      18 bp      DNA      linear      PAT 14-FEB-2001
LOCUS         AR108975
DEFINITION    Sequence 13 from patent US 6114109.
ACCESSION     AR108975
VERSION       AR108975.1 GI:12825251
KEYWORDS
SOURCE        Unknown.
ORGANISM      Unknown.
REFERENCE     1 (bases 1 to 18)
AUTHORS      Karn,J., Galt,M.J., Heaphy,S. and Dingwall,C.
TITLE        Viral (HIV) growth inhibition
JOURNAL      Patent: US 6114109-A 13 05-SEP-2000;
FEATURES
SOURCE       1..18
              /organism="unknown"
BASE COUNT   5 a      4 c      5 g      4 t

Query Match   1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No.1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1490 AGCCAGACTTCAGAGC 1506
Db 1 AGCCAGATTGAGCAGC 17

RESULT 138
AR117984      18 bp      DNA      linear      PAT 16-MAY-2001
LOCUS         AR117984

```

DEFINITION	Sequence 33 from patent US 6140471.
ACCESSION	AR117984
VERSION	AR117984.1
KEYWORDS	GI:14098890
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	Unclassified.
AUTHORS	1 (bases 1 to 18)
TITLE	Johnson,K.Stuart., Winter,G.Paul., Griffiths,A.David.,
JOURNAL	Smith,A.John.Hammond. and Waterhouse,P.Michael.
FEATURES	Methods for producing members of specific binding pairs
source	Patent: US 6140471-A 33 31-OCT-2000;
	Location/Qualifiers
	1..18
	/organism="unknown"
BASE COUNT	7 a 6 c 3 g 2 t
Query Match	1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity	88.2%; Pred.No.1.5e+02;
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY	1673 AACCTCCAGAGACCCA 1689
Db	1 AACATCCAGATGACCCA 17
RESULT 139	
LOCUS	AR198571 18 bp DNA linear PAT 20-APR-2002
DEFINITION	Sequence 21 from patent US 6352972.
ACCESSION	AR198571
VERSION	AR198571.1
KEYWORDS	GI:20248420
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	Unclassified.
AUTHORS	1 (bases 1 to 18)
TITLE	Nimmi,M.E., Hall,F.L., Wu,L., Han,B. and Shore,E.C.
JOURNAL	Bone morphogenetic proteins and their use in bone growth
FEATURES	Patent: US 6352972-A 21 05-MAR-2002;
source	Location/Qualifiers
	1..18
	/organism="unknown"
BASE COUNT	6 a 7 c 0 g 5 t
Query Match	1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity	88.2%; Pred.No.1.5e+02;
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY	1879 GAGATGATGAGATGAT 1895
Db	18 GTGATGATGATGATGAT 2
RESULT 140	
LOCUS	AR265427 18 bp DNA linear PAT 10-APR-2003
DEFINITION	Sequence 79 from patent US 6492160.
ACCESSION	AR265427
VERSION	AR265427.1
KEYWORDS	GI:29693959
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	Unclassified.
AUTHORS	1 (bases 1 to 18)
TITLE	Griffiths,A.D., Williams,S.C., Waterhouse,P.M., Nissim,A.,
JOURNAL	Winter,G.P., Johnson,K.S. and Smith,A.J.H.
FEATURES	Methods for producing members of specific binding pairs
source	Patent: US 6492160-A 79 10-DEC-2002;
	Location/Qualifiers
	1..18
	/organism="unknown"
BASE COUNT	7 a 6 c 3 g 2 t

Query Match	Best Local Similarity	1.0%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		
<p>RESULT 141</p> <p>LOCUS AR274624 18 bp DNA PAT 10-APR-2003</p> <p>DEFINITION Sequence 8 from patent US 6506595.</p> <p>ACCESSION AR274624</p> <p>VERSION AR274624.1 GI:29707158</p> <p>KEYWORDS</p> <p>SOURCE Unknown.</p> <p>ORGANISM Unknown.</p> <p>REFERENCE Unclassified.</p> <p>AUTHORS 1 (bases 1 to 18)</p> <p>TITLE Sato,S., Higashikuni,N., Kudo,T. and Kondo,M.</p> <p>JOURNAL DNAs encoding new fusion proteins and processes for preparing useful polypeptides through expression of the DNAs</p> <p>FEATURES Patent: US 6506595-A 8 14-JAN-2003;</p> <p>source Location/Qualifiers</p> <p>1..18</p> <p>/organism="unknown"</p>		
<p>BASE COUNT 6 a 7 c 0 g 5 t</p> <p>Query Match 1.0%; Score 13.8; DB 1; Length 18;</p> <p>Best Local Similarity 88.2%; Pred. No. 1.5e+02;</p> <p>Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;</p>		
<p>CY 1879 GAGATGATGAAGATGAT 1895</p> <p>DB 18 GTGATGATGATGATGAT 2</p>		
<p>RESULT 142</p> <p>LOCUS AR274625 18 bp DNA PAT 10-APR-2003</p> <p>DEFINITION Sequence 9 from patent US 6506595.</p> <p>ACCESSION AR274625</p> <p>VERSION AR274625.1 GI:29707159</p> <p>KEYWORDS</p> <p>SOURCE Unknown.</p> <p>ORGANISM Unknown.</p> <p>REFERENCE Unclassified.</p> <p>AUTHORS 1 (bases 1 to 18)</p> <p>TITLE Sato,S., Higashikuni,N., Kudo,T. and Kondo,M.</p> <p>JOURNAL DNAs encoding new fusion proteins and processes for preparing useful polypeptides through expression of the DNAs</p> <p>FEATURES Patent: US 6506595-A 9 14-JAN-2003;</p> <p>source Location/Qualifiers</p> <p>1..18</p> <p>/organism="unknown"</p>		
<p>BASE COUNT 5 a 0 c 7 g 6 t</p> <p>Query Match 1.0%; Score 13.8; DB 1; Length 18;</p> <p>Best Local Similarity 88.2%; Pred. No. 1.5e+02;</p> <p>Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;</p>		
<p>CY 1879 GAGATGATGAAGATGAT 1895</p> <p>DB 1 GTGATGATGATGATGAT 17</p>		
<p>RESULT 143</p> <p>LOCUS AX008729 18 bp RNA PAT 06-SEP-2000</p> <p>DEFINITION Sequence 3 from Patent W09964625.</p> <p>ACCESSION AX008729</p>		

VERSION	AX008729.1	GI:9996226
KEYWORDS		
SOURCE	Human immunodeficiency virus	
ORGANISM	Human immunodeficiency virus	
REFERENCE	Vitruces; Retrovid viruses; Retroviridae; Lentivirus; Primate lentivirus group.	
AUTHORS	Prescott,C.D. and Karn,J.	
TITLE	Methods and kits for discovery of rna-binding compounds	
JOURNAL	Patent: WO 9964625-A 3 16-DEC-1999; RIBOTARGETS LIMITED (GB)	
FEATURES	Location/Qualifiers	
source	1..18 /organism="Human immunodeficiency virus" /mol_type="Genomic RNA" /db_xref="taxon:12721"	
BASE COUNT	5 a 4 c 6 g 3 t	
Query Match	1.0%; Score 13.8; DB 1;	Length 18;
Best Local Similarity	88.2%; Pred.No.1.5e+02;	
Matches	15; Conservative 0; Mismatches 2;	Indels 0; Gaps 0;
OY	1490 AGCCAGACTTCAGCAGC 1506	
Db	1 AGCCAGATTGACGAC 17	
RESULT 144		
AX076043	18 bp DNA linear PAT 06-FEB-2001	
LOCUS	AX076043	
DEFINITION	Sequence 19 from Patent W00104358.	
ACCESSION	AX076043	
VERSION	AX076043.1 GI:12710696	
KEYWORDS	Hepatitis B virus	
SOURCE	Hepatitis B virus	
ORGANISM	Hepatitis B virus	
REFERENCE	Vitruces; Retrovid viruses; Hepadnaviridae; Orthohepadnavirus.	
AUTHORS	Stuyver,L., Maertens,G. and van Geyt,C.	
TITLE	Detection of anti-hepatitis b drug resistance	
JOURNAL	Patent: WO 0104358-A 19 18-JAN-2001; INNOGENETICS N.V. (BE)	
FEATURES	Location/Qualifiers	
Source	1..18 /organism="Hepatitis B virus" /mol_type="Genomic DNA" /db_xref="taxon:10407"	
BASE COUNT	4 a 2 c 5 g 7 t	
Query Match	1.0%; Score 13.8; DB 1;	Length 18;
Best Local Similarity	88.2%; Pred.No.1.5e+02;	
Matches	15; Conservative 0; Mismatches 2;	Indels 0; Gaps 0;
OY	2267 TTCACGTCAATGGATG 2283	
Db	1 TTTCAGTCATGTGATG 17	
RESULT 145		
AX084246	18 bp DNA linear PAT 28-FEB-2001	
LOCUS	AX084246	
DEFINITION	Sequence 40 from Patent W00110902.	
ACCESSION	AX084246	
VERSION	AX084246.1 GI:13185749	
KEYWORDS	synthetic construct	
SOURCE	synthetic construct	
ORGANISM	artificial sequences.	
REFERENCE	Shimkets,R.A. and Fernandes,E.	
AUTHORS	Nucleic acids and secreted polypeptides encoded thereby	
TITLE	Patent: WO 0110902-A 40 15-FEB-2001;	
JOURNAL	Cutagen Corporation (US)	

FEATURES		location/Qualifiers	
source		1..18	
ORGANISM		/organism="synthetic construct"	
LOCUS		/mol_type="genomic DNA"	
DEFINITION		/db_xref="taxon:32630"	
VERSION		/note="PCR PRIMER"	
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
FEATURES			
source			
BASE COUNT			
Query Match			
Best Local Similarity			
Matches			
QY			
Db			
RESULT 147			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
FEATURES			
source			
BASE COUNT			
Query Match			
Best Local Similarity			
Matches			
QY			
Db			
RESULT 147			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
FEATURES			
source			
BASE COUNT			
Query Match			
Best Local Similarity			
Matches			
QY			
Db			
RESULT 147			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
FEATURES			
source			
BASE COUNT			
Query Match			
Best Local Similarity			
Matches			
QY			
Db			
RESULT 147			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
FEATURES			
source			
BASE COUNT			
Query Match			
Best Local Similarity			
Matches			
QY			
Db			
RESULT 147			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
FEATURES			
source			
BASE COUNT			
Query Match			
Best Local Similarity			
Matches			
QY			
Db			
RESULT 147			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
FEATURES			
source			
BASE COUNT			
Query Match			
Best Local Similarity			
Matches			
QY			
Db			
RESULT 147			
LOCUS			
DEFINITION			

Query Match 1.0%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1987 CTCCGAGAACTCTCCG 2003
 |||||
 18 CTCCGTGAACACTCCG 2

RESULT 148
 AX713201 18 bp DNA linear PAT 11-APR-2003
 LOCUS Sequence 87 from Patent WO03018837.
 DEFINITION AX713201
 ACCESSION AX713201 GI:29823790
 VERSION
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 1
 AUTHORS
 TITLE
 JOURNAL
 Adnagen AG (DE)
 Location/Qualifiers

1.18
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"
 /note="Oligonucleotide"

BASE COUNT 2 a 9 c 0 g 7 t

Query Match 1.0%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1872 AGAGATGGAGTATGA 1888
 |||||
 18 AGAGATGGAGAGGTGA 2

RESULT 149
 BD065700/c 18 bp DNA linear PAT 27-AUG-2002
 LOCUS BD065700
 DEFINITION An antisense oligonucleotide preparation method.
 ACCESSION BD065700
 VERSION BD065700.1 GI:22611303
 KEYWORDS JP 2001511000-A/335.
 SOURCE unidentified
 ORGANISM unclassified.

REFERENCE
 1 (bases 1 to 18)
 AUTHORS Schlingensiepen,K.H. and Brysch,W.
 TITLE An antisense oligonucleotide preparation method
 JOURNAL Patent: JP 2001511000-A 335 07-AUG-2001;
 BIOLOGISTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK MBH
 OS Unknown
 PN JP 2001511000-A/335
 PD 07-AUG-2001
 PF 30-JAN-1998 JP 1998532533
 PR 31-JAN-1997 EP 97101531.8
 PI KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
 PC C12N15/11,C07H21/04,A61K31/70
 CC An antisense oligonucleotide preparation method FH Key
 Location/Qualifiers

FT source 1.18
 /organism='Unknown'.
 Location/Qualifiers

FEATURES
 source 1.18
 /organism="unidentified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

BASE COUNT 4 a 6 c 4 g 4 t

Query Match 1.0%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2317 CACGAGTGTCTG 2333
 |||||
 17 CACGAGTGTCTGTG 1

RESULT 150
 BD103233 18 bp DNA linear PAT 27-AUG-2002
 LOCUS BD103233
 DEFINITION Novel insulin/IGF/relaxin family polypeptide and its DNA.
 ACCESSION BD103233
 VERSION BD103233.1 GI:22648807
 KEYWORDS WO 0181562-A/10.
 SOURCE
 ORGANISM
 REFERENCE
 1 (bases 1 to 18)
 AUTHORS Ito,Y., Suzuki,N., Nishi,K., Kizawa,H., Harada,M. and Ogi,K.
 TITLE Novel insulin/IGF/relaxin family polypeptide and its DNA
 JOURNAL Patent: WO 0181562-A 10 01-NOV-2001;
 TAKEDA CHEMICAL INDUSTRIES LTD,YASUOKI ITO,NOBUHIRO SUZUKI,
 KAZUNORI NISHI, HIDEKI KIZAWA,MASATKA HARADA,KAZUHIRO OGI

COMMENT
 OS Artificial Sequence
 PN WO 0181562-A/10
 PD 01-NOV-2001
 PF 20-APR-2001 WO 2001JP003399
 PR 21-APR-2000 JP 00P 126340,03-JUL-2000 JP 00P 205587 PR
 10-AUG-2000 JP 00P 247962,22-DEC-2000 JP 00P 395050 PI
 YASUOKI ITO,NOBUHIRO SUZUKI,KAZUNORI NISHI,HIDEKI KIZAWA, PI
 MASATKA HARADA, PI
 KAZUHIRO OGI
 PC C12N15/09,C07K14/65,C07K16/26,C12N1/15,C12N1/19,C12N1/21 PC
 C12N5/00,C12Q1/68,
 PC C12P21/02,C12P21/08,A61K38/17,A61K38/28,A61K38/30,A61K39/395,
 PC A61K45/00,
 PC A61P43/00,A61P3/00,A61P9/00,A61P9/00,A61P5/00,A61P25/00, PC
 A61P37/00,
 PC A61P1/16,A61P11/00,A61P17/00,G01N33/50,G01N33/15 CC Primer
 FH Key
 FT source 1.18
 Location/Qualifiers

FEATURES
 source 1.18
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

BASE COUNT 1 a 3 c 9 g 5 t

Query Match 1.0%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1653 GCGAGGCTCTCCGAGT 1669
 |||||
 2 GCGAGGCTCTCTGTG 18

RESULT 151
 BD104044/c 18 bp DNA linear PAT 27-AUG-2002
 LOCUS BD104044
 DEFINITION Kit and method for determining HLA type.
 ACCESSION BD104044
 VERSION BD104044.1 GI:22649618
 KEYWORDS WO 0192572-A/148.
 SOURCE
 ORGANISM
 REFERENCE
 1 (bases 1 to 18)
 Location/Qualifiers

FEATURES
 source 1.18
 /organism="unidentified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

AUTHORS Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and Nishida,M.
TITLE Kit and method for determining HLA type
JOURNAL Patent: WO 0192572-A 148 06-DEC-2001;
 NISSHINBO INDUSTRIES INC, SYSTEM RESEARCH INC, HIDEOTOSHI INOKO, TAEKO KAGIYA, TATSUO ICHIHARA, YOSHIYUKI MATSUMURA, SHOGO MORIYA, MICHIO NISHIDA

COMMENT
 OS Artificial Sequence
 PN WO 0192572-A/148
 PD 06-DEC-2001
 PF 01-JUN-2001 WO 2001JP004662
 PR 01-JUN-2000 JP 00P 164798
 PI HIDEOTOSHI INOKO, TAEKO KAGIYA, TATSUO ICHIHARA, YOSHIYUKI MATSUMURA, PI

FEATURES
 source
 1.18 Location/Qualifiers
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

BASE COUNT
 3 a 3 c 6 g 6 t

Query Match
 Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2619 TTACCCGTGACACAGAA 2635
 Db 18 TTACCCGTGACACAGAA 2

RESULT 152
LOCUS E39157/c 18 bp DNA linear PAT 18-JUN-2001
DEFINITION DNA encoding novel fused protein and process for producing useful protein mediating the expression thereof.
ACCESSION E39157
VERSION E39157.1 GI:13019231
KEYWORDS JP 1999341991-A/3.
SOURCE JP 1999341991-A/3.
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 18)
AUTHORS Seiji,S., Masahiko,H., Toshiyuki,K. and Masaaki,K.
TITLE DNA encoding novel fused protein and process for producing useful protein mediating the expression thereof
JOURNAL Patent: JP 1999341991-A 3 14-DEC-1999;
 ITO HAM KK,UZO UDAKA
COMMENT
 OS Artificial Sequence
 PN JP 1999341991-A/3
 PD 14-DEC-1999
 PF 30-MAR-1999 JP 1999089488
 PR

FEATURES
 source
 1.18 Location/Qualifiers
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

BASE COUNT 6 a 7 c 0 g 5 t

Query Match
 Best Local Similarity 1.0%; Score 13.8; DB 1; Length 18;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1879 GAGATGATGATGAT 1895
 Db 18 GTGATGATGATGAT 2

RESULT 153
LOCUS E39158 18 bp DNA linear PAT 18-JUN-2001
DEFINITION DNA encoding novel fused protein and process for producing useful protein mediating the expression thereof.
ACCESSION E39158
VERSION E39158.1 GI:13019232
KEYWORDS JP 1999341991-A/4.
SOURCE JP 1999341991-A/4.
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 18)
AUTHORS Seiji,S., Masahiko,H., Toshiyuki,K. and Masaaki,K.
TITLE DNA encoding novel fused protein and process for producing useful protein mediating the expression thereof
JOURNAL Patent: JP 1999341991-A 4 14-DEC-1999;
 ITO HAM KK,UZO UDAKA
COMMENT
 OS Artificial Sequence
 PN JP 1999341991-A/4
 PD 14-DEC-1999
 PF 30-MAR-1999 JP 1999089488
 PR

FEATURES
 source
 1.18 Location/Qualifiers
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

BASE COUNT 5 a 0 c 7 g 6 t

Query Match
 Best Local Similarity 1.0%; Score 13.8; DB 1; Length 18;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1879 GAGATGATGATGAT 1895
 Db 1 GTGATGATGATGAT 17

RESULT 154
LOCUS E39160 18 bp DNA linear PAT 28-DEC-1997
DEFINITION Sequence 19 from patent US 5670330.
ACCESSION E39160
VERSION E39160.1 GI:2724337
KEYWORDS US 5670330
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Sonenberg,N., Katze,M.G., Roy,S., Koromilas,A.E. and Barber,G.H.
TITLE Anti-tumor agent assay using PKR
JOURNAL Patent: US 5670330-A 19 23-SEP-1997;

```

FEATURES
  source
    location/Qualifiers
      1. 18
      /organism="unknown"
BASE COUNT      4 a      2 c      5 g      7 t

Query Match
  Best Local Similarity 88.2%; Pred. No. 1.5e+02;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2197 ATAGCAGACTTTGGACT 2213
Db      1 ATGAGAGACTTTGGACT 17

RESULT 155
195705 LOCUS      18 bp      DNA      linear      PAT 01-DEC-1998
DEFINITION Sequence 33 from patent US 5733743.
ACCESSION 195705
VERSION 195705.1 GI:3940175
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 18)
  Johnson,K.Stuart., Winter,G.Paul., Griffiths,A.David.,
  Smith,A.John.Hammond. and Waterhouse,P.Michael.
  Methods for producing members of specific binding pairs
  JOURNAL
  TITLE Patent: US 5733743-A 33 31-MAR-1998;
  FEATURES
    source
      1. 18
      /organism="unknown"
BASE COUNT      7 a      6 c      3 g      2 t

Query Match
  Best Local Similarity 88.2%; Pred. No. 1.5e+02;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1673 AACTTCAGAGACCCA 1689
Db      1 AACATCCAGATGACCCA 17

RESULT 156
AR180165/c LOCUS      15 bp      DNA      linear      PAT 20-APR-2002
DEFINITION Sequence 233 from patent US 6333152.
ACCESSION AR180165
VERSION AR180165.1 GI:20222198
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 15)
  Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
  Gene expression profiles in normal and cancer cells
  JOURNAL
  TITLE Patent: US 6333152-A 233 25-DEC-2001;
  FEATURES
    source
      1. 15
      /organism="unknown"
BASE COUNT      4 a      3 c      6 g      2 t

Query Match
  Best Local Similarity 93.3%; Pred. No. 1.4e+02;
  Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1573 TCCAGCTCTCCAGT 1587
Db      15 TCCAGCTCTCCAGT 1

RESULT 157
A88174/c

```

```

LOCUS      A88174      16 bp      DNA      linear      PAT 22-JAN-2000
DEFINITION Sequence 322 from Patent WO9833904.
ACCESSION A88174
VERSION A88174.1 GI:6736744
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 16)
  Brysch,W. and Schlingensiepen,K.
  AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL
  TITLE Patent: WO 9833904-A 322 06-AUG-1998;
  BIOGOSTIK GBS (DE); BRYSCH WOLFGANG (DE)
  FEATURES
    source
      1. 16
      /organism="unidentified"
      /mol_type="genomic DNA"
      /db_xref="taxon:32644"
BASE COUNT      4 a      7 c      2 g      3 t

Query Match
  Best Local Similarity 93.3%; Pred. No. 1.5e+02;
  Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2320 CAGAGTGATGCTGG 2334
Db      15 CAGAGTGATGCTGG 1

RESULT 158
A90141/c LOCUS      16 bp      DNA      linear      PAT 22-JAN-2000
DEFINITION Sequence 322 from Patent EP0856579.
ACCESSION A90141
VERSION A90141.1 GI:6738655
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 16)
  Brysch,W.D. and Schlingensiepen,K.D.
  An antisense oligonucleotide preparation method
  JOURNAL
  TITLE Patent: EP 0856579-A 322 05-AUG-1998;
  BIOGOSTIK GBS (DE)
  FEATURES
    source
      1. 16
      /organism="unidentified"
      /mol_type="genomic DNA"
      /db_xref="taxon:32644"
BASE COUNT      4 a      7 c      2 g      3 t

Query Match
  Best Local Similarity 93.3%; Pred. No. 1.5e+02;
  Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2320 CAGAGTGATGCTGG 2334
Db      15 CAGAGTGATGCTGG 1

RESULT 159
BD065687/c LOCUS      16 bp      DNA      linear      PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD065687
VERSION BD065687.1 GI:22611290
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 16)
  Schlingensiepen,K.H. and Brysch,W.
  An antisense oligonucleotide preparation method
  TITLE

```

JOURNAL Patent: JP 2001511000-A 322 07-AUG-2001;
BIOGENOSITIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK MBH

COMMENT OS Unknown
PN 07-AUG-2001
PD 30-JAN-1998 JP 1998532533
PF 31-JAN-1997 EP 97101531.8
PI KARL, HERMANN SCHLINGENSIEPEN, WOLFGANG BRYSCH
PC C12N15/11, C07H21/04, A61K31/70
CC An antisense oligonucleotide preparation method FH Key

FEATURES
FT source
Location/Qualifiers
1. .16
/organism="Unknown".
/mol_type="genomic DNA"
/db_xref="taxon:32644"

BASE COUNT 4 a 7 c 2 g 3 t

Query Match 1.0%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2320 CAGAGTGATGCTGCG 2334
15 CAGAGTGATGCTGCG 1

Db 15 CAGAGTGATGCTGCG 1

RESULT 160
LOCUS A48870 17 bp DNA linear PAT 07-MAR-1997
DEFINITION Sequence 10 from Patent WO9604387.
ACCESSION A48870
VERSION A48870.1 GI:2302532
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS Du,A., Faucheu,C., Hercend,T., Lalanne,J., Livingston,D.J. and Su,M.S.
TITLE DNA SEQUENCES CODING FOR THE HUMAN PROTEINS TX AND TY RELATED TO THE INTERLEUKIN-1BETA CONVERTING ENZYME
JOURNAL Patent: WO 9604387-A 10 15-FEB-1996;
ROUSSEL UCLAF (FR)
COMMENT Other publication AU 3118095 960304
Other publication FR 2723378 960209.
FEATURES
source
1. .17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

BASE COUNT 6 a 2 c 5 g 4 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2465 AACTGTACATGATGA 2479
1 AACTGTGATGATGA 15

Db 1 AACTGTGATGATGA 15

RESULT 161
LOCUS AR085293 17 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 5 from patent US 5981705.
ACCESSION AR085293
VERSION AR085293.1 GI:10012062
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Kornbluth,J.
TITLE Natural killer lytic associated protein
JOURNAL Patent: US 5981705-A 5 09-NOV-1999;
FEATURES
source
1. .17
/organism="Unknown"

BASE COUNT 6 a 3 c 4 g 4 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1375 GAGATTACAGCTTCC 1389
16 GTGATTACAGCTTCC 2

Db 16 GTGATTACAGCTTCC 2

RESULT 162
LOCUS AR127158 17 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 10 from patent US 6180386.
ACCESSION AR127158
VERSION AR127158.1 GI:14113751
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Du,A., Faucheu,C., Hercend,T., Lalanne,J., Louis., Livingston,D.J. and Su,M.S.
TITLE DNA sequences coding for the human proteins TX and TY related to the interleukin-1beta converting enzyme
JOURNAL Patent: US 6180386-A 10 30-JAN-2001;
FEATURES
source
1. .17
/organism="Unknown"

BASE COUNT 6 a 2 c 5 g 4 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2465 AACTGTACATGATGA 2479
1 AACTGTGATGATGA 15

Db 1 AACTGTGATGATGA 15

RESULT 163
LOCUS AR188867 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4355 from patent US 6346398.
ACCESSION AR188867
VERSION AR188867.1 GI:20234832
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Rayco,P., Mcswisgen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 4355 12-FEB-2002;
FEATURES
source
1. .17
/organism="Unknown"

BASE COUNT 6 a 3 c 3 g 5 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2404 GAACCTTTTAAAGCTG 2418
 |||||
 Db 3 GAACCTTTTAAAGCTG 17

RESULT 164
 ARI88868
 LOCUS ARI88868 17 bp DNA linear PAT 20-APR-2002
 DEFINITION Sequence 4356 from patent US 6346398.
 ACCESSION ARI88868
 VERSION ARI88868.1 GI:20234833
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Patco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
 TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
 JOURNAL Patent: US 6346398-A 4356 12-FEB-2002;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"

BASE COUNT 7 a 2 c 3 g 5 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.6e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2404 GAACCTTTTAAAGCTG 2418
 |||||
 Db 2 GAACCTTTTAAAGCTG 16

RESULT 165
 AR286277
 LOCUS AR286277 17 bp RNA linear PAT 10-APR-2003
 DEFINITION Sequence 649 from patent US 6528640.
 ACCESSION AR286277
 VERSION AR286277.1 GI:29723873
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Beigelman, L., Burghin, A., Beaudry, A., Karpetsky, A.,
 Matulic-Adamic, J., Sweedler, D. and Zinnen, S.
 TITLE Synthetic ribonucleic acids with RNase activity
 JOURNAL Patent: US 6528640-A 649 04-MAR-2003;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"

BASE COUNT 3 a 4 c 7 g 3 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.6e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2110 GGCGATGGAGTACTGG 2124
 |||||
 Db 1 GGCGATGGAGTACTGG 15

RESULT 166
 AX216933/c
 LOCUS AX216933 17 bp mRNA linear PAT 07-SEP-2001
 DEFINITION Sequence 2375 from Patent WO0159103.
 ACCESSION AX216933
 VERSION AX216933.1 GI:15526994
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 TITLE artificial sequences.

REFERENCE 1
 AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
 TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
 JOURNAL Patent: WO 0159103-A 2375 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
 McSwiggen, James (US) ; Chowrira, Bharat M. (US)
 FEATURES Location/Qualifiers
 source 1..17
 /organism="synthetic construct"
 /mol_type="mRNA"
 /db_xref="taxon:32630"
 /note="Nucleic Acid"

BASE COUNT 4 a 3 c 8 g 2 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.6e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1573 TCCAGCTCTCCATG 1587
 |||||
 Db 17 TCCAGCTCTCCATG 3

RESULT 167
 AX216934/c
 LOCUS AX216934 17 bp mRNA linear PAT 07-SEP-2001
 DEFINITION Sequence 2376 from Patent WO0159103.
 ACCESSION AX216934
 VERSION AX216934.1 GI:15526995
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 REFERENCE 1
 AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
 TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
 JOURNAL Patent: WO 0159103-A 2376 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
 McSwiggen, James (US) ; Chowrira, Bharat M. (US)
 FEATURES Location/Qualifiers
 source 1..17
 /organism="synthetic construct"
 /mol_type="mRNA"
 /db_xref="taxon:32630"
 /note="Nucleic Acid"

BASE COUNT 4 a 3 c 8 g 2 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.6e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1573 TCCAGCTCTCCATG 1587
 |||||
 Db 16 TCCAGCTCTCCATG 2

RESULT 168
 AX272527/c
 LOCUS AX272527 17 bp mRNA linear PAT 29-OCT-2001
 DEFINITION Sequence 96 from Patent WO0162911.
 ACCESSION AX272527
 VERSION AX272527.1 GI:16545264
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 REFERENCE 1
 AUTHORS Jarvis, T., von Carlowitz, I., McSwiggen, J.A., Hamblin, P.A. and Ellis, J.H.
 TITLE Method and reagent for the inhibition of grid

JOURNAL Patent: WO 0162911-A 96 30-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)

FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"

BASE COUNT 2 a 6 c 2 g 7 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1868 TGTGAGATGAGAGA 1882

Db 16 TGACAGAGATGAGAGA 2

RESULT 169
LOCUS AX272715 17 bp mRNA linear PAT 29-OCT-2001
DEFINITION Sequence 284 from Patent WO0162911.
ACCESSION AX272715
VERSION AX272715.1 GI:16545452
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Jarvis,T., von Carlowitz,I., Mcswigen,J.A., Hamlin,P.A. and Ellis,J.H.
TITLE Method and reagent for the inhibition of grid
JOURNAL Patent: WO 0162911-A 284 30-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"

BASE COUNT 2 a 6 c 3 g 6 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1868 TGTGAGATGAGAGA 1882

Db 15 TGACAGAGATGAGAGA 1

RESULT 170
LOCUS AX673499 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 1944 from Patent WO03004526.
ACCESSION AX673499
VERSION AX673499.1 GI:29331847
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 1944 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 2 a 3 c 2 g 10 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2656 GATTCGTGTTTCT 2670

Db 1 GATTCGTGTTTCT 15

RESULT 171
LOCUS AX673500 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 1945 from Patent WO03004526.
ACCESSION AX673500
VERSION AX673500.1 GI:29331848
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 1945 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 1 a 3 c 2 g 11 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2656 GATTCGTGTTTCT 2670

Db 1 GATTCGTGTTTCT 15

RESULT 172
LOCUS AX674421 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 2866 from Patent WO03004526.
ACCESSION AX674421
VERSION AX674421.1 GI:29332769
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 2866 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 2 a 4 c 8 g 3 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2498 CAGTCCCTCCGACA 2512
Db 17 CAGGCCCTCCGACA 3

RESULT 173
AX726400/c 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 4087 from Patent WO03025176.
ACCESSION AX726400
VERSION AX726400.1 GI:30505743
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversal, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 4087 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1..17
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"

BASE COUNT 4 a 3 c 4 g 6 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1329 TCACTGTGATGTT 1343
Db 3 TCACTGTGATGTT 17

RESULT 174
AX727626 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 5313 from Patent WO03025176.
ACCESSION AX727626
VERSION AX727626.1 GI:30506969
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversal, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 5313 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1..17
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"

BASE COUNT 4 a 3 c 4 g 6 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1329 TCACTGTGATGTT 1343
Db 3 TCACTGTGATGTT 17

RESULT 175
AX732816/c 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 4450 from Patent WO03025175.
ACCESSION AX732816
VERSION AX732816.1 GI:30512159
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversal, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 4450 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 3 a 3 c 6 g 5 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1930 GCCTGCACACGAT 1944
Db 16 GCCTGCACACGAT 2

RESULT 176
AX732843 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 4477 from Patent WO03025175.
ACCESSION AX732843
VERSION AX732843.1 GI:30512186
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversal, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 4477 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 4 a 2 c 8 g 3 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1861 GATCTGCTCAGAG 1875
Db 1 GATCTGCTCAGAG 15

RESULT 177
AX739491 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 4477 from Patent WO03025175.
ACCESSION AX739491
VERSION AX739491.1 GI:30512186
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversal, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 4477 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 4 a 2 c 8 g 3 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1861 GATCTGCTCAGAG 1875
Db 1 GATCTGCTCAGAG 15

DEFINITION Sequence 5081 from Patent WO03025177.
 AX739491
 VERSION AX739491.1 GI:30518788
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
 AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
 TITL Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
 JOURNAL Patent: WO 03025177-A 5081 27-MAR-2003;
 FEATURES Molecular Engines Laboratories (FR)
 SOURCE Location/Qualifiers
 1. .17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

BASE COUNT 2 a 3 c 2 g 10 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.6e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2656 GATCTGTTTCTTCT 2670
 |||
 1 GATCTGTTTCTTCT 15

RESULT 178
 LOCUS 137420 17 bp DNA linear PAT 13-MAY-1997
 DEFINITION Sequence 433 from patent US 5612215.
 ACCESSION 137420
 VERSION 137420.1 GI:2085380
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 UNCLASSIFIED.
 1 (bases 1 to 17)
 REFERENCE 1
 AUTHORS Draper, K.G., Pavco, P., McSwiggen, J., Gustofson, J. and Stinchcomb, D.T.
 TITL Stromelysin targeted ribozymes
 JOURNAL Patent: US 5612215-A 433 18-MAR-1997;
 FEATURES Location/Qualifiers
 1. .17
 /organism="unknown"

BASE COUNT 4 a 8 c 3 g 2 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.6e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1586 TGAAGTCCACACCC 1600
 |||
 3 TGAAGTCCACACCC 17

RESULT 179
 LOCUS 164698 17 bp DNA linear PAT 07-OCT-1997
 DEFINITION Sequence 5 from patent US 5665588.
 ACCESSION 164698
 VERSION 164698.1 GI:2481592
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 UNCLASSIFIED.
 1 (bases 1 to 17)
 REFERENCE 1
 AUTHORS Kornbluth, J.
 TITL DNA encoding natural killer lytic associated protein

JOURNAL Patent: US 5665588-A 5 09-SEP-1997;
 FEATURES Location/Qualifiers
 1. .17
 /organism="unknown"

BASE COUNT 6 a 3 c 4 g 4 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.6e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1375 GAGATTACAGCTTC 1389
 |||
 16 GTGATTACAGCTTC 2

RESULT 180
 LOCUS 194270 17 bp DNA linear PAT 01-DEC-1998
 DEFINITION Sequence 433 from patent US 5731295.
 ACCESSION 194270
 VERSION 194270.1 GI:3938740
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 UNCLASSIFIED.
 1 (bases 1 to 17)
 REFERENCE 1
 AUTHORS Draper, K.G., Pavco, P., McSwiggen, J., Gustofson, J. and Stinchcomb, D.T.
 TITL Method of reducing stromelysin RNA via ribozymes
 JOURNAL Patent: US 5731295-A 433 24-MAR-1998;
 FEATURES Location/Qualifiers
 1. .17
 /organism="unknown"

BASE COUNT 4 a 8 c 3 g 2 t

Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.6e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1586 TGAAGTCCACACCC 1600
 |||
 3 TGAAGTCCACACCC 17

RESULT 181
 LOCUS AR119016 14 bp DNA linear PAT 16-MAY-2001
 DEFINITION Sequence 142 from patent US 6150092.
 ACCESSION AR119016
 VERSION AR119016.1 GI:14100926
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 UNCLASSIFIED.
 1 (bases 1 to 14)
 REFERENCE 1
 AUTHORS Uchida, K., Uchida, T., Tanaka, Y., Matsuda, Y. and Kondo, S.
 TITL Antisense nucleic acid compound targeted to VEGF
 JOURNAL Patent: US 6150092-A 142 21-NOV-2000;
 FEATURES Location/Qualifiers
 1. .14
 /organism="unknown"

BASE COUNT 4 a 3 c 6 g 1 t

Query Match 0.9%; Score 13; DB 1; Length 14;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1934 GCACACGAGTGG 1946
 |||
 2 GCACACGAGTGG 14

RESULT 182

AX328242/c
LOCUS AX328242 15 bp mRNA linear PAT 07-JAN-2002
DEFINITION Sequence 14 from Patent WO0183754.
ACCESSION AX328242
VERSION AX328242.1 GI:18098223
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE 1
AUTHORS Kruger, M., Welch, P.J. and Barber, J.R.
TITLE Cellular regulators of infectious agents and methods of use
JOURNAL Patent: WO 0183754-A 14 08-NOV-2001;
Immunol Incorporated (US)
FEATURES
source
1. .15
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT 4 a 4 c 5 g 2 t

Query Match 0.9%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1346 CAGTTCGCCAGC 1358
Db 14 CAGTTCGCCAGC 2

RESULT 183
AR030682/c
LOCUS AR030682 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 18 from patent US 5861294.
ACCESSION AR030682
VERSION AR030682.1 GI:5943896
KEYWORDS
SOURCE Unknown.
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Cowart, M. Daniel., Halbert, D.N., Kervin, J.F. Jr. and McNally, T.
TITLE Adenosine kinase polypeptides
JOURNAL Patent: US 5861294-A 18 19-JAN-1999;
FEATURES
source
1. .17
/organism="unknown"

BASE COUNT 4 a 2 c 2 g 4 t 5 others

Query Match 0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 1.8e+02;
Matches 10; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2400 GGAGGACTTTTAA 2414
Db 16 GAGGAAATTTTAA 2

RESULT 184
ARI96283
LOCUS ARI96283 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 748 from patent US 6350934.
ACCESSION ARI96283
VERSION ARI96283.1 GI:20245720
KEYWORDS
SOURCE Unknown.
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Zwick, M.G., Edington, B.E., McSwiggen, J.A., Merlo, P. Ann, Owens, G., Skokut, T.A., Young, S.A., Folkerts, O. and Merlo, D.J.
TITLE Nucleic acid encoding delta-9 desaturase

JOURNAL Patent: US 6350934-A 748 26-FEB-2002;
FEATURES
source
1. .17
/organism="unknown"
BASE COUNT 5 a 2 c 7 g 3 t

Query Match 0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1866 GGTCGACAGATG 1878
Db 4 GGTCGACAGATG 16

RESULT 185
AX216364/c
LOCUS AX216364 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 1806 from Patent WO0159103.
ACCESSION AX216364
VERSION AX216364.1 GI:15526425
KEYWORDS
SOURCE synthetic construct
ORGANISM
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowitra, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 1806 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowitra, Bharat M. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

BASE COUNT 3 a 2 c 9 g 3 t

Query Match 0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1573 TCCAGCTCTCCA 1585
Db 14 TCCAGCTCTCCA 2

RESULT 186
AX227661
LOCUS AX227661 17 bp mRNA linear PAT 10-SEP-2001
DEFINITION Sequence 1033 from Patent WO0157206.
ACCESSION AX227661
VERSION AX227661.1 GI:15556802
KEYWORDS
SOURCE synthetic construct
ORGANISM
REFERENCE 1
AUTHORS Fattaey, A.R., Jarvis, T., McSwiggen, J., Booher, R.N. and Holman, P.S.
TITLE Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme
JOURNAL Patent: WO 0157206-A 1033 09-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"

BASE COUNT 6 a 4 c 6 g 1 t

Query Match 0.9%; Score 13; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1730 CCTCGGAGAGG 1742
|||||
Db 5 CCTCGGAGAGG 17

RESULT 187

AX688031 17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 763 from Patent EP1281758.
ACCESSION AX688031
VERSION AX688031.1 GI:29410729
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 763 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 7 a 5 c 3 g 2 t

Query Match 0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2506 TCCGAGAGACCA 2518
|||||
Db 5 TCCGAGAGACCA 17

RESULT 188
AX688032 17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 764 from Patent EP1281758.
ACCESSION AX688032
VERSION AX688032.1 GI:29410730
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 764 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 7 a 5 c 4 g 1 t

Query Match 0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2506 TCCGAGAGACCA 2518
|||||
Db 4 TCCGAGAGACCA 16

RESULT 189

AX688033 17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 765 from Patent EP1281758.
ACCESSION AX688033
VERSION AX688033.1 GI:29410731
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 765 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 8 a 5 c 3 g 1 t

Query Match 0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2506 TCCGAGAGACCA 2518
|||||
Db 3 TCCGAGAGACCA 15

RESULT 190
AX688034 17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 766 from Patent EP1281758.
ACCESSION AX688034
VERSION AX688034.1 GI:29410732
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 766 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 7 a 5 c 4 g 1 t

Query Match 0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2506 TCCGAGAGACCA 2518
|||||
Db 2 TCCGAGAGACCA 14

RESULT 191

AX688035 17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 767 from Patent EP1281758.
ACCESSION AX688035
VERSION AX688035.1 GI:29410733

```

KEYWORDS      Homo sapiens (human)
SOURCE
ORGANISM      Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS       Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE         Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
               mdz12
JOURNAL       Patent: EP 1281758-A 767 05-FEB-2003;
               Aeomica, Inc. (US)
FEATURES
SOURCE        location/Qualifiers
               1..17
               /organism="Homo sapiens"
               /mol_type="genomic DNA"
               /db_xref="taxon:9606"
BASE COUNT    7 a 5 c 4 g 1 t
Query Match   0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2506 TCCGAGACCAA 2518
Db 1 TCCGAGACCAA 13

RESULT 192
LOCUS 137553 17 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 566 from patent US 5612215.
ACCESSION 137553
VERSION 137553.1 GI:2085513
KEYWORDS
SOURCE        Unknown.
ORGANISM      Unclassified.
REFERENCE     1 (bases 1 to 17)
AUTHORS       Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
               Stinchcomb,D.T.
TITLE         Stromelysin targeted ribozymes
JOURNAL       Patent: US 5612215-A 566 18-MAR-1997;
FEATURES
SOURCE        Location/Qualifiers
               1..17
               /organism="unknown"
BASE COUNT    2 a 6 c 3 g 6 t
Query Match   0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2416 CTGCTGAAGAG 2428
Db 15 CTGCTGAAGAG 3

RESULT 193
LOCUS 137554 17 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 567 from patent US 5612215.
ACCESSION 137554
VERSION 137554.1 GI:2085514
KEYWORDS
SOURCE        Unknown.
ORGANISM      Unclassified.
REFERENCE     1 (bases 1 to 17)
AUTHORS       Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
               Stinchcomb,D.T.
TITLE         Stromelysin targeted ribozymes
JOURNAL       Patent: US 5612215-A 567 18-MAR-1997;
FEATURES
SOURCE        Location/Qualifiers
               1..17

```

```

BASE COUNT    2 a 5 c 4 g 6 t
Query Match   0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2416 CTGCTGAAGAG 2428
Db 14 CTGCTGAAGAG 2

RESULT 194
LOCUS 194403 17 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 566 from patent US 5731295.
ACCESSION 194403
VERSION 194403.1 GI:3938873
KEYWORDS
SOURCE        Unknown.
ORGANISM      Unclassified.
REFERENCE     1 (bases 1 to 17)
AUTHORS       Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
               Stinchcomb,D.T.
TITLE         Method of reducing stromelysin RNA via ribozymes
JOURNAL       Patent: US 5731295-A 566 24-MAR-1998;
FEATURES
SOURCE        Location/Qualifiers
               1..17
               /organism="unknown"
BASE COUNT    2 a 6 c 3 g 6 t
Query Match   0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2416 CTGCTGAAGAG 2428
Db 15 CTGCTGAAGAG 3

RESULT 195
LOCUS 194404 17 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 567 from patent US 5731295.
ACCESSION 194404
VERSION 194404.1 GI:3938874
KEYWORDS
SOURCE        Unknown.
ORGANISM      Unclassified.
REFERENCE     1 (bases 1 to 17)
AUTHORS       Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
               Stinchcomb,D.T.
TITLE         Method of reducing stromelysin RNA via ribozymes
JOURNAL       Patent: US 5731295-A 567 24-MAR-1998;
FEATURES
SOURCE        Location/Qualifiers
               1..17
               /organism="unknown"
BASE COUNT    2 a 5 c 4 g 6 t
Query Match   0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2416 CTGCTGAAGAG 2428
Db 14 CTGCTGAAGAG 2

RESULT 196
LOCUS AX282045 16 bp DNA linear PAT 02-NOV-2001

```

DEFINITION Sequence 177 from Patent WO0177392.
ACCESSION AX282045
VERSION AX282045.1 GI:16609296
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Ashby, M.
TITLE Methods for the survey and genetic analysis of populations
JOURNAL Patent: WO 0177392-A 177 18-OCT-2001;
Ashby, Matthew (US)
FEATURES Location/Qualifiers
source 1..16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
/note="Uncultured Acidobacterium Sub.Div-1"
BASE COUNT 2 a 5 c 6 g 3 t
Query Match 0.9%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1511 CGCGTGTGCACAGCT 1526
Db 1 CGCGTGTGCCAGACT 16
RESULT 197
LOCUS AX284081 16 bp DNA linear PAT 20-NOV-2001
DEFINITION Sequence 46 from Patent WO0179487.
ACCESSION AX284081
VERSION AX284081.1 GI:17044791
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Degitz, K.K. and Besch, R.
TITLE Polydesoxyribonucleotides for inhibiting the expression of the
JOURNAL Patent: WO 0179487-A 46 25-OCT-2001;
Degitz, Klaus Karl (DE); Besch, Robert (DE)
FEATURES Location/Qualifiers
source 1..16
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kunstlichen
Sequenz: Polydesoxyribonukleotid"
BASE COUNT 10 a 0 c 6 g 0 t
Query Match 0.9%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2421 GAAGGAGGACACAGA 2436
Db 1 GAAGGAGGAAAAAGA 16
RESULT 198
LOCUS AX284082 16 bp DNA linear PAT 20-NOV-2001
DEFINITION Sequence 47 from Patent WO0179487.
ACCESSION AX284082
VERSION AX284082.1 GI:17044792
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Degitz, K.K. and Besch, R.
TITLE Polydesoxyribonucleotides for inhibiting the expression of the
JOURNAL Patent: WO 0179487-A 47 25-OCT-2001;
Degitz, Klaus Karl (DE); Besch, Robert (DE)
FEATURES Location/Qualifiers
source 1..16
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kunstlichen
Sequenz: Polydesoxyribonukleotid"
BASE COUNT 0 a 6 c 0 g 10 t
Query Match 0.9%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2421 GAAGGAGGACACAGA 2436
Db 1 GAAGGAGGAAAAAGA 16
RESULT 199
LOCUS A19468 17 bp DNA linear PAT 08-JUN-1994
DEFINITION oligonucleotide VI.
ACCESSION A19468
VERSION A19468.1 GI:583206
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 17)
AUTHORS
TITLE MODIFIED SEED STORAGE PROTEINS
JOURNAL Patent: WO 9104270-A 13 04-APR-1991;
FEATURES Location/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
BASE COUNT 4 a 0 c 6 g 7 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1881 GATGATGAGTGTGTT 1896
Db 2 GATGATGATGATGTT 17
RESULT 200
LOCUS AR024071 17 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 21 from Patent US 5795778.
ACCESSION AR024071
VERSION AR024071.1 GI:3977365
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper, K.G.
TITLE Method and reagent for inhibiting herpes simplex virus replication
JOURNAL Patent: US 5795778-A 21 18-AUG-1998;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 3 a 5 c 7 g 2 t

DEFINITION Sequence 177 from Patent WO0177392.
ACCESSION AX282045
VERSION AX282045.1 GI:16609296
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Ashby, M.
TITLE Methods for the survey and genetic analysis of populations
JOURNAL Patent: WO 0177392-A 177 18-OCT-2001;
Ashby, Matthew (US)
FEATURES Location/Qualifiers
source 1..16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
/note="Uncultured Acidobacterium Sub.Div-1"
BASE COUNT 2 a 5 c 6 g 3 t
Query Match 0.9%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1511 CGCGTGTGCACAGCT 1526
Db 1 CGCGTGTGCCAGACT 16
RESULT 197
LOCUS AX284081 16 bp DNA linear PAT 20-NOV-2001
DEFINITION Sequence 46 from Patent WO0179487.
ACCESSION AX284081
VERSION AX284081.1 GI:17044791
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Degitz, K.K. and Besch, R.
TITLE Polydesoxyribonucleotides for inhibiting the expression of the
JOURNAL Patent: WO 0179487-A 46 25-OCT-2001;
Degitz, Klaus Karl (DE); Besch, Robert (DE)
FEATURES Location/Qualifiers
source 1..16
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kunstlichen
Sequenz: Polydesoxyribonukleotid"
BASE COUNT 10 a 0 c 6 g 0 t
Query Match 0.9%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2421 GAAGGAGGACACAGA 2436
Db 1 GAAGGAGGAAAAAGA 16
RESULT 198
LOCUS AX284082 16 bp DNA linear PAT 20-NOV-2001
DEFINITION Sequence 47 from Patent WO0179487.
ACCESSION AX284082
VERSION AX284082.1 GI:17044792
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Degitz, K.K. and Besch, R.
TITLE Polydesoxyribonucleotides for inhibiting the expression of the
JOURNAL Patent: WO 0179487-A 47 25-OCT-2001;
Degitz, Klaus Karl (DE); Besch, Robert (DE)
FEATURES Location/Qualifiers
source 1..16
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kunstlichen
Sequenz: Polydesoxyribonukleotid"
BASE COUNT 0 a 6 c 0 g 10 t
Query Match 0.9%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2421 GAAGGAGGACACAGA 2436
Db 1 GAAGGAGGAAAAAGA 16
RESULT 199
LOCUS A19468 17 bp DNA linear PAT 08-JUN-1994
DEFINITION oligonucleotide VI.
ACCESSION A19468
VERSION A19468.1 GI:583206
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 17)
AUTHORS
TITLE MODIFIED SEED STORAGE PROTEINS
JOURNAL Patent: WO 9104270-A 13 04-APR-1991;
FEATURES Location/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
BASE COUNT 4 a 0 c 6 g 7 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1881 GATGATGAGTGTGTT 1896
Db 2 GATGATGATGATGTT 17
RESULT 200
LOCUS AR024071 17 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 21 from Patent US 5795778.
ACCESSION AR024071
VERSION AR024071.1 GI:3977365
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper, K.G.
TITLE Method and reagent for inhibiting herpes simplex virus replication
JOURNAL Patent: US 5795778-A 21 18-AUG-1998;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 3 a 5 c 7 g 2 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2279 GGATGGCTCCAGAAC 2294
 |||||||
 Db 2 GGTCGCTCCAGAAC 17

RESULT 201
 AR036431/c 17 bp DNA linear PAT 29-SEP-1999
 LOCUS AR036431
 DEFINITION Sequence 23 from patent US 5872214.
 ACCESSION AR036431
 VERSION AR036431.1 GI:5953099
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 17)
 AUTHORS Seizinger,B.R., Kley,N.A. and Bianchi,A.B.
 TITLE NF2 isoforms
 JOURNAL Patent: US 5872214-A 23 16-FEB-1999;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"

BASE COUNT 6 a 1 c 7 g 3 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1579 TCTTCATGAAGTCCA 1594
 |||||||
 Db 17 TTCTCATGATCTCCA 2

RESULT 202
 AR039275/c 17 bp DNA linear PAT 29-SEP-1999
 LOCUS AR039275
 DEFINITION Sequence 123 from patent US 5807743.
 ACCESSION AR039275
 VERSION AR039275.1 GI:5958638
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 17)
 AUTHORS Stinchcomb,D.T. and McSwigen,J.A.
 TITLE Interleukin-2 receptor gamma-chain ribozymes
 JOURNAL Patent: US 5807743-A 123 15-SEP-1998;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"

BASE COUNT 4 a 4 c 3 g 6 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2156 CAGCCAGAAATGTTT 2171
 |||||||
 Db 16 CAGCCAGAAATGATT 1

RESULT 203
 AR045623/c 17 bp DNA linear PAT 29-SEP-1999
 LOCUS AR045623
 DEFINITION Sequence 416 from patent US 5817796.
 ACCESSION AR045623
 VERSION AR045623.1 GI:5967088
 KEYWORDS
 SOURCE Unknown.

ORGANISM Unknown.
 Unclassified.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Stinchcomb,D.T., Draper,K., McSwigen,J. and Jarvis,T.
 TITLE C-myb ribozymes having 2'-5'-linked adenylate residues
 JOURNAL Patent: US 5817796-A 416 06-OCT-1998;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"

BASE COUNT 2 a 8 c 3 g 4 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1866 GGTCGAGAGTGAG 1881
 |||||||
 Db 16 GCTGCAGAGTGAG 1

RESULT 204
 AR045741/c 17 bp DNA linear PAT 29-SEP-1999
 LOCUS AR045741
 DEFINITION Sequence 534 from patent US 5817796.
 ACCESSION AR045741
 VERSION AR045741.1 GI:5967206
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 17)
 AUTHORS Stinchcomb,D.T., Draper,K., McSwigen,J. and Jarvis,T.
 TITLE C-myb ribozymes having 2'-5'-linked adenylate residues
 JOURNAL Patent: US 5817796-A 534 06-OCT-1998;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"

BASE COUNT 7 a 7 c 1 g 2 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1584 CATGAATCCACACC 1599
 |||||||
 Db 1 CAAGAACTCTACACC 16

RESULT 205
 AR046321/c 17 bp DNA linear PAT 29-SEP-1999
 LOCUS AR046321
 DEFINITION Sequence 1114 from patent US 5817796.
 ACCESSION AR046321
 VERSION AR046321.1 GI:5967786
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 17)
 AUTHORS Stinchcomb,D.T., Draper,K., McSwigen,J. and Jarvis,T.
 TITLE C-myb ribozymes having 2'-5'-linked adenylate residues
 JOURNAL Patent: US 5817796-A 1114 06-OCT-1998;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"

BASE COUNT 1 a 0 c 4 g 12 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2240 ATTACAAAAGACAC 2255
 |||||||

Db 17 ATACAAAAAACAC 2

RESULT 206

LOCUS AR046323/c 17 bp DNA linear PAT 29-SEP-1999

DEFINITION Sequence 1116 from patent US 5817796.

ACCESSION AR046323

VERSION AR046323.1 GI:5967788

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Stinchcomb,D.T., Draper,K., McSwigen,J. and Jarvis,T.

TITLE C-myb ribozymes having 2'-5'-linked adenylylate residues

JOURNAL Patent: US 5817796-A 1116 06-OCT-1998;

FEATURES

Source 1..17

Location/Qualifiers

BASE COUNT 1 a 0 c 4 g 12 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.9e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2240 ATTACAAAAGACAC 2255

Db 16 ATACAAAAAACAC 1

RESULT 207

LOCUS AR047630 17 bp DNA linear PAT 29-SEP-1999

DEFINITION Sequence 2423 from patent US 5817796.

ACCESSION AR047630

VERSION AR047630.1 GI:5969095

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Stinchcomb,D.T., Draper,K., McSwigen,J. and Jarvis,T.

TITLE C-myb ribozymes having 2'-5'-linked adenylylate residues

JOURNAL Patent: US 5817796-A 2423 06-OCT-1998;

FEATURES

Source 1..17

Location/Qualifiers

BASE COUNT 6 a 7 c 2 g 2 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.9e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1584 CATGAACCTCAACAC 1599

Db 1 CAAGACTCTACAC 16

RESULT 208

LOCUS AR048077 17 bp DNA linear PAT 29-SEP-1999

DEFINITION Sequence 18 from patent US 5821046.

ACCESSION AR048077

VERSION AR048077.1 GI:5970420

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Karn,J., Galt,M.John., Heaphy,S. and Dingwall,C.

TITLE RNA oligonucleotides that bind HIV tat protein

JOURNAL Patent: US 5821046-A 18 13-OCT-1998;

FEATURES

Source 1..17

Location/Qualifiers

BASE COUNT 5 a 4 c 5 g 2 t 1 others

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 1.9e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1490 AGCCAGACTTCAGCAGC 1506

Db 1 AGCCAGATTGAGCAGC 17

RESULT 209

LOCUS AR048078 17 bp DNA linear PAT 29-SEP-1999

DEFINITION Sequence 19 from patent US 5821046.

ACCESSION AR048078

VERSION AR048078.1 GI:5970421

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Karn,J., Galt,M.John., Heaphy,S. and Dingwall,C.

TITLE RNA oligonucleotides that bind HIV tat protein

JOURNAL Patent: US 5821046-A 19 13-OCT-1998;

FEATURES

Source 1..17

Location/Qualifiers

BASE COUNT 5 a 4 c 5 g 2 t 1 others

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 1.9e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1490 AGCCAGACTTCAGCAGC 1506

Db 1 AGCCAGATTGAGCAGC 17

RESULT 210

LOCUS AR048080 17 bp DNA linear PAT 29-SEP-1999

DEFINITION Sequence 21 from patent US 5821046.

ACCESSION AR048080

VERSION AR048080.1 GI:5970423

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Karn,J., Galt,M.John., Heaphy,S. and Dingwall,C.

TITLE RNA oligonucleotides that bind HIV tat protein

JOURNAL Patent: US 5821046-A 21 13-OCT-1998;

FEATURES

Source 1..17

Location/Qualifiers

BASE COUNT 5 a 4 c 5 g 2 t 1 others

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 1.9e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1490 AGCCAGACTTCAGCAGC 1506

Db 1 AGCCAGATTGAGCAGC 17

RESULT 211

LOCUS AR048081 17 bp DNA linear PAT 29-SEP-1999

DEFINITION Sequence 22 from patent US 5821046.
ACCESSION AR048081
VERSION AR048081.1 GI:5970424
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
TITLE Karn,J., Galt,M.J., Heaphy,S. and Dingwall,C.
JOURNAL RNA oligonucleotides that bind HIV tat protein
PATENT: US 5821046-A 22 13-OCT-1998;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 5 a 4 c 5 g 2 t 1 others
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred.No.1.9e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1490 AGCCAGACTTCAGCAGC 1506
Db 1 AGCCAGATTGAGCAGC 17
RESULT 212
LOCUS AR108980 17 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 18 from patent US 6114109.
ACCESSION AR108980
VERSION AR108980.1 GI:12825256
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
TITLE Karn,J., Galt,M.J., Heaphy,S. and Dingwall,C.
JOURNAL Viral (HIV) growth inhibition
PATENT: US 6114109-A 18 05-SEP-2000;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 5 a 4 c 5 g 2 t 1 others
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred.No.1.9e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1490 AGCCAGACTTCAGCAGC 1506
Db 1 AGCCAGATTGAGCAGC 17
RESULT 213
LOCUS AR108981 17 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 19 from patent US 6114109.
ACCESSION AR108981
VERSION AR108981.1 GI:12825257
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
TITLE Karn,J., Galt,M.J., Heaphy,S. and Dingwall,C.
JOURNAL Viral (HIV) growth inhibition
PATENT: US 6114109-A 19 05-SEP-2000;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 5 a 4 c 5 g 2 t 1 others
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred.No.1.9e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1490 AGCCAGACTTCAGCAGC 1506
Db 1 AGCCAGATTGAGCAGC 17

Best Local Similarity 82.4%; Pred.No.1.9e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1490 AGCCAGACTTCAGCAGC 1506
Db 1 AGCCAGATTGAGCAGC 17
RESULT 214
LOCUS AR108983 17 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 21 from patent US 6114109.
ACCESSION AR108983
VERSION AR108983.1 GI:12825259
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
TITLE Karn,J., Galt,M.J., Heaphy,S. and Dingwall,C.
JOURNAL Viral (HIV) growth inhibition
PATENT: US 6114109-A 21 05-SEP-2000;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 5 a 4 c 5 g 2 t 1 others
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred.No.1.9e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1490 AGCCAGACTTCAGCAGC 1506
Db 1 AGCCAGATTGAGCAGC 17
RESULT 215
LOCUS AR108984 17 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 22 from patent US 6114109.
ACCESSION AR108984
VERSION AR108984.1 GI:12825260
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
TITLE Karn,J., Galt,M.J., Heaphy,S. and Dingwall,C.
JOURNAL Viral (HIV) growth inhibition
PATENT: US 6114109-A 22 05-SEP-2000;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 5 a 4 c 5 g 2 t 1 others
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred.No.1.9e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1490 AGCCAGACTTCAGCAGC 1506
Db 1 AGCCAGATTGAGCAGC 17
RESULT 216
LOCUS AR186504/c 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 1992 from patent US 6346398.
ACCESSION AR186504
VERSION AR186504.1 GI:20232469
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

```

REFERENCE      Unclassified.
AUTHORS        1 (bases 1 to 17)
TITLE          Method and reagent for the treatment of diseases or conditions
               related to levels of vascular endothelial growth factor receptor
JOURNAL        Patent: US 6346398-A 1992 12-FEB-2002;
FEATURES       Location/Qualifiers
SOURCE         1..17
               /organism="unknown"
BASE COUNT     4 a 0 c 4 g 9 t

Query Match    0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1909 AATATCAATATCTTC 1924
Db 17 AAATACAAATCTTC 2

RESULT 217
LOCUS          AR186521 17 bp DNA linear PAT 20-APR-2002
DEFINITION     Sequence 2009 from patent US 6346398.
ACCESSION      AR186521
VERSION        AR186521.1 GI:20232486
KEYWORDS
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS        Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE          Method and reagent for the treatment of diseases or conditions
               related to levels of vascular endothelial growth factor receptor
JOURNAL        Patent: US 6346398-A 2009 12-FEB-2002;
FEATURES       Location/Qualifiers
SOURCE         1..17
               /organism="unknown"
BASE COUNT     3 a 5 c 5 g 4 t

Query Match    0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2279 GGATGCTCCGAGAC 2294
Db 1 GGATGCTCCGAGATC 16

RESULT 218
LOCUS          AR187273 17 bp DNA linear PAT 20-APR-2002
DEFINITION     Sequence 2761 from patent US 6346398.
ACCESSION      AR187273
VERSION        AR187273.1 GI:20233238
KEYWORDS
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS        Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE          Method and reagent for the treatment of diseases or conditions
               related to levels of vascular endothelial growth factor receptor
JOURNAL        Patent: US 6346398-A 2761 12-FEB-2002;
FEATURES       Location/Qualifiers
SOURCE         1..17
               /organism="unknown"
BASE COUNT     2 a 6 c 1 g 8 t

Query Match    0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Oy 2422 AAGAGAGACACAGAA 2437
Db 16 ATGAGAGAGACAGAA 1

RESULT 219
LOCUS          AR188652 17 bp DNA linear PAT 20-APR-2002
DEFINITION     Sequence 4140 from patent US 6346398.
ACCESSION      AR188652
VERSION        AR188652.1 GI:20234617
KEYWORDS
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS        Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE          Method and reagent for the treatment of diseases or conditions
               related to levels of vascular endothelial growth factor receptor
JOURNAL        Patent: US 6346398-A 4140 12-FEB-2002;
FEATURES       Location/Qualifiers
SOURCE         1..17
               /organism="unknown"
BASE COUNT     9 a 1 c 4 g 3 t

Query Match    0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1822 AAGATGTTGAAGATG 1837
Db 2 AAATGTTGAAGAG 17

RESULT 220
LOCUS          AR190328 17 bp DNA linear PAT 20-APR-2002
DEFINITION     Sequence 5816 from patent US 6346398.
ACCESSION      AR190328
VERSION        AR190328.1 GI:20236293
KEYWORDS
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS        Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE          Method and reagent for the treatment of diseases or conditions
               related to levels of vascular endothelial growth factor receptor
JOURNAL        Patent: US 6346398-A 5816 12-FEB-2002;
FEATURES       Location/Qualifiers
SOURCE         1..17
               /organism="unknown"
BASE COUNT     0 a 2 c 7 g 8 t

Query Match    0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2332 TGGTCTTCGGGGGT 2347
Db 2 TGGTCTTCGGGTGT 17

RESULT 221
LOCUS          AR192483 17 bp DNA linear PAT 20-APR-2002
DEFINITION     Sequence 7971 from patent US 6346398.
ACCESSION      AR192483
VERSION        AR192483.1 GI:20238448
KEYWORDS
SOURCE         Unknown.
ORGANISM       Unclassified.

```

```

REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7971 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"

BASE COUNT 4 a 2 c 5 g 6 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1843 ACAGAGAAAGCCTTT 1858
Db 16 ACAGAGAAAGCCTTT 1

RESULT 222
AR192618/c
LOCUS AR192618 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 8106 from patent US 6346398.
ACCESSION AR192618
VERSION AR192618.1 GI:20238583
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 8106 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"

BASE COUNT 3 a 5 c 2 g 7 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1775 TCGGAATTGACAAAGA 1790
Db 17 TCGGAATTGACAAAGA 2

RESULT 223
AR224290
LOCUS AR224290 17 bp DNA linear PAT 26-SEP-2002
DEFINITION Sequence 21 from patent US 6440719.
ACCESSION AR224290
VERSION AR224290.1 GI:23333067
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G.
TITLE Method and reagent for inhibiting herpes simplex virus replication
JOURNAL Patent: US 6440719-A 21 27-AUG-2002;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"

BASE COUNT 3 a 5 c 7 g 2 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2279 GGATGGCTCCAGAAC 2294
Db 11 GGATGGCTCCAGAAC 2

```

```

Db 2 GGTGGCTCCAGAAC 17

RESULT 224
AR275226/c
LOCUS AR275226 17 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 31 from patent US 6506893.
ACCESSION AR275226
VERSION AR275226.1 GI:29708227
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS El Solh,N. and Allignat,J.
TITLE Polynucleotides and their use for detecting resistance to
streptogramin A or to streptogramin B and related compounds
JOURNAL Patent: US 6506893-A 31 14-JAN-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"

BASE COUNT 6 a 5 c 4 g 2 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1741 GGTTCCTTTGGGCAAG 1756
Db 17 GGTTCCTTTGGGCAAG 2

RESULT 225
AR286411
LOCUS AR286411 17 bp RNA linear PAT 10-APR-2003
DEFINITION Sequence 783 from patent US 6528640.
ACCESSION AR286411
VERSION AR286411.1 GI:29724007
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A., Beaudry,A., Karpolsky,A.,
Matulic-Adamcic,J., Sweedler,D. and Zimen,S.
TITLE Synthetic ribonucleic acids with RNase activity
JOURNAL Patent: US 6528640-A 783 04-MAR-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"

BASE COUNT 4 a 4 c 5 g 4 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2317 CATCAGAGTATGTCT 2332
Db 2 CACCAAGATGATGTGT 17

RESULT 226
AX215401/c
LOCUS AX215401 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 843 from Patent.WO0159103.
ACCESSION AX215401
VERSION AX215401.1 GI:15525444
KEYWORDS
SOURCE Synthetic construct
ORGANISM Synthetic construct
REFERENCE 1
AUTHORS Blatt,L., McSwiggen,J. and Chowrira,B.M.

```

TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 843 16-AUG-2001; Blatt, Lawrence (US) ;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Chowitra, Bharat M. (US)
FEATURES
source Location/Qualifiers
1.17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
BASE COUNT 1 a 8 c 7 g 1 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1651 GTGCAGGGGTCTCCG 1666
17 CCGGCGAGGGGTCCCG 2
RESULT 227 17 bp mRNA linear PAT 07-SEP-2001
AX215403/c
LOCUS AX215403
DEFINITION Sequence 845 from Patent WO0159103.
ACCESSION AX215403
VERSION AX215403.1 GI:15525446
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowitra, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 845 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowitra, Bharat M. (US)
FEATURES
source Location/Qualifiers
1.17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
BASE COUNT 1 a 8 c 7 g 1 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1650 GCTGCAGGGGTCTCC 1665
16 GCCGCGAGGGGTCCCG 1
RESULT 228 17 bp mRNA linear PAT 07-SEP-2001
AX216650/c
LOCUS AX216650
DEFINITION Sequence 2092 from Patent WO0159103.
ACCESSION AX216650
VERSION AX216650.1 GI:15526711
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowitra, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 2092 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowitra, Bharat M. (US)

FEATURES
source Location/Qualifiers
1.17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
BASE COUNT 5 a 5 c 5 g 2 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1572 GTCCAGCTCTCCATG 1587
16 GTCCAGCTCTCCATG 1
RESULT 229 17 bp mRNA linear PAT 07-SEP-2001
AX216661/c
LOCUS AX216661
DEFINITION Sequence 2103 from Patent WO0159103.
ACCESSION AX216661
VERSION AX216661.1 GI:15526722
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowitra, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 2103 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowitra, Bharat M. (US)
FEATURES
source Location/Qualifiers
1.17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
BASE COUNT 1 a 10 c 5 g 1 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1653 GGCAGGGGTCTCCGAG 1668
17 GGCAGGGGTCTCCCGG 2
RESULT 230 17 bp mRNA linear PAT 07-SEP-2001
AX216899/c
LOCUS AX216899
DEFINITION Sequence 2341 from Patent WO0159103.
ACCESSION AX216899
VERSION AX216899.1 GI:15526960
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowitra, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 2341 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowitra, Bharat M. (US)
FEATURES
source Location/Qualifiers
1.17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"

BASE COUNT 5 a 5 c 5 g 2 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1572 GTCAGCTCCCTCATG 1587
DB 17 GTCAGGCTTCCTCATG 2

RESULT 231
LOCUS AX217484/c 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 2926 from Patent WO0159103.
ACCESSION AX217484
VERSION AX217484.1 GI:15527545
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
Patent: WO 0159103-A 2926 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

BASE COUNT 2 a 7 c 0 g 8 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1362 TGAAGAGAAAGAG 1377
DB 16 TGTAAAGAGAAAGAG 1

RESULT 232
LOCUS AX217829 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 3271 from Patent WO0159103.
ACCESSION AX217829
VERSION AX217829.1 GI:15527890
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Blatt, L., Mcswiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
Patent: WO 0159103-A 3271 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

BASE COUNT 6 a 4 c 4 g 3 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1703 CAAGAGTAAGCTGAC 1718
DB 1 CAAGAGACAGCTGAC 16

RESULT 233
LOCUS AX217853/c 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 3295 from Patent WO0159103.
ACCESSION AX217853
VERSION AX217853.1 GI:15527914
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
Patent: WO 0159103-A 3295 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

BASE COUNT 2 a 7 c 1 g 7 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1362 TGAAGAGAAAGAG 1377
DB 17 TGTAAAGAGAAAGAG 2

RESULT 234
LOCUS AX226704 17 bp mRNA linear PAT 10-SEP-2001
DEFINITION Sequence 76 from Patent WO0157206.
ACCESSION AX226704
VERSION AX226704.1 GI:15555845
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Fattaey, A.R., Jarvis, T., McSwiggen, J., Bocher, R.N. and Holman, P.S.
TITLE Method and reagent for the inhibition of checkpoint kinase-1 (chk
JOURNAL 1) enzyme
Patent: WO 0157206-A 76 09-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)
FEATURES
source location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"

BASE COUNT 6 a 4 c 2 g 5 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2194 AAAATGACAGACTTTG 2209
DB 2 AAAATTCAGACTTTG 17

```

RESULT 235
AX227307/c
LOCUS AX227307 17 bp mRNA linear PAT 10-SEP-2001
DEFINITION Sequence 679 from Patent WO0157206.
ACCESSION AX227307
VERSION AX227307.1 GI:15556448
KEYWORDS
SOURCE
ORGANISM synthetic construct
artificial sequences.
REFERENCE
1 Fatcaey,A.R., Jarvis,T., Moswiggen,J., Boohar,R.N. and Holman,P.S.
METHOD Method and reagent for the inhibition of checkpoint kinase-1 (chk
1) enzyme
PATENT Patent: WO 0157206-A 679 09-AUG-2001.
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US) ; Fatcaey, Ali R. (US)
FEATURES
source
LOCATION/Qualifiers
1..17
/mol_type="synthetic construct"
/db_xref="taxon:32630"
BASE COUNT 6 a 2 c 0 g 9 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2163 AAATGTTTGGTAAACA 2178
Db 17 AAATGTTTGGTAAACA 2

RESULT 236
AX227715
LOCUS AX227715 17 bp mRNA linear PAT 10-SEP-2001
DEFINITION Sequence 1087 from Patent WO0157206.
ACCESSION AX227715
VERSION AX227715.1 GI:15556856
KEYWORDS
SOURCE
ORGANISM synthetic construct
artificial sequences.
REFERENCE
1 Fatcaey,A.R., Jarvis,T., Moswiggen,J., Boohar,R.N. and Holman,P.S.
METHOD Method and reagent for the inhibition of checkpoint kinase-1 (chk
1) enzyme
PATENT Patent: WO 0157206-A 1087 09-AUG-2001.
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US) ; Fatcaey, Ali R. (US)
FEATURES
source
LOCATION/Qualifiers
1..17
/mol_type="synthetic construct"
/db_xref="taxon:32630"
BASE COUNT 5 a 4 c 3 g 5 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2195 AAATGACAGACTTGG 2210
Db 1 AAATGACAGACTTGG 16

RESULT 237
AX264368
LOCUS AX264368 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 1759 from Patent WO0173002.
ACCESSION AX264368
VERSION AX264368.1 GI:16513167
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

```

```

REFERENCE
1 Kmiec,E.B., Gamper,H.B. and Rice,M.C.
METHOD Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
PATENT Patent: WO 0173002-A 1759 04-OCT-2001.
JOURNAL UNIVERSITY OF DELAWARE (US)
FEATURES
source
LOCATION/Qualifiers
1..17
/mol_type="Homo sapiens"
/db_xref="taxon:9606"
BASE COUNT 6 a 1 c 5 g 5 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1880 AGATGATCAGATGAT 1895
Db 1 AGATGATCAGATGAT 16

RESULT 238
AX264369/c
LOCUS AX264369 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 1760 from Patent WO0173002.
ACCESSION AX264369
VERSION AX264369.1 GI:16513168
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE
1 Kmiec,E.B., Gamper,H.B. and Rice,M.C.
METHOD Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
PATENT Patent: WO 0173002-A 1760 04-OCT-2001.
JOURNAL UNIVERSITY OF DELAWARE (US)
FEATURES
source
LOCATION/Qualifiers
1..17
/mol_type="Homo sapiens"
/db_xref="taxon:9606"
BASE COUNT 5 a 5 c 1 g 6 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1880 AGATGATCAGATGAT 1895
Db 17 AGATGATCAGATGAT 2

RESULT 239
AX265923
LOCUS AX265923 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 3314 from Patent WO0173002.
ACCESSION AX265923
VERSION AX265923.1 GI:16514722
KEYWORDS
SOURCE Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE
1 Kmiec,E.B., Gamper,H.B. and Rice,M.C.
METHOD Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
PATENT Patent: WO 0173002-A 3314 04-OCT-2001.
JOURNAL

```

```

UNIVERSITY OF DELAWARE (US)
Location/Qualifiers
FEATURES
Source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT      3 a      3 c      4 g      7 t

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1686 CCCAAATGGAGTTT 1701
Db      1 CCCAAATGGAGTTT 16

RESULT 240
AX265924/c      17 bp      DNA      linear      PAT 26-OCT-2001
LOCUS
DEFINITION      Sequence 3315 from Patent WO0173002.
ACCESSION      AX265924
VERSION      AX265924.1 GI:16514723
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM      Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 Kniec, E.B., Gamper, H.B. and Rice, M.C.
Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
Patent: WO 0173002-A 3315 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
Location/Qualifiers
FEATURES
Source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT      7 a      4 c      3 g      3 t

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1686 CCCAAATGGAGTTT 1701
Db      17 CCCAAATGGAGTTT 2

RESULT 241
AX272714      17 bp      mRNA      linear      PAT 29-OCT-2001
LOCUS
DEFINITION      Sequence 283 from Patent WO0162911.
ACCESSION      AX272714
VERSION      AX272714.1 GI:16545451
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM      Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 Jarvis, T., von Carlwiltz, I., Mcswigen, J.A., Hamblin, P.A. and
Ellis, J.H.
Method and reagent for the inhibition of grid
Patent: WO 0162911-A 283 30-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
Location/Qualifiers
FEATURES
Source
1. .17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT      2 a      7 c      1 g      7 t

```

```

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1869 GTCAGAGTGAAGATG 1884
Db      17 GACAGAGTGAAGAG 2

RESULT 242
AX422198/c      17 bp      mRNA      linear      PAT 18-JUN-2002
LOCUS
DEFINITION      Sequence 534 from Patent WO0188124.
ACCESSION      AX422198
VERSION      AX422198.1 GI:21525580.
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM      Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 Jarvis, T., von Carlwiltz, I., Mcswigen, J.A., McLaughlin, P.G. and
Randi, A.M.
Method and reagent for the inhibition of erg
Patent: WO 0188124-A 534 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
Location/Qualifiers
FEATURES
Source
1. .17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT      4 a      3 c      5 g      5 t

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2094 CTACAGCTGGCCAGA 2109
Db      17 CTACAGCTGTTCCAGA 2

RESULT 243
AX422876      17 bp      mRNA      linear      PAT 18-JUN-2002
LOCUS
DEFINITION      Sequence 1212 from Patent WO0188124.
ACCESSION      AX422876
VERSION      AX422876.1 GI:21526258
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM      Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 Jarvis, T., von Carlwiltz, I., Mcswigen, J.A., McLaughlin, P.G. and
Randi, A.M.
Method and reagent for the inhibition of erg
Patent: WO 0188124-A 1212 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
Location/Qualifiers
FEATURES
Source
1. .17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT      6 a      2 c      6 g      3 t

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2464 GAAGTGAATGATGATGA 2479

```

Db 2 GAACGTGCAAGATGA 17

RESULT 244
AX423045/C 17 bp mRNA linear PAT 18-JUN-2002
LOCUS
DEFINITION Sequence 1381 from Patent WO0188124.
ACCESSION AX423045
VERSION AX423045.1 GI:21526427
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 Jarrys, T., von Carlowitz, I., Mcswigen, J.A., McLaughlin, F.G. and
Randl, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1381 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"

BASE COUNT 5 a 3 c 5 g 4 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2094 CTACCACTGCGCCGA 2109
Db 16 CTACCACTGTTTCA 1

RESULT 245
AX498837 17 bp DNA linear PAT 27-SEP-2002
LOCUS
DEFINITION Sequence 144 from Patent EP1229046.
ACCESSION AX498837
VERSION AX498837.1 GI:23381119
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 144 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 7 a 7 c 2 g 1 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1518 GCACAGCTGACCAA 1533
Db 2 GCCCAAGCTCACCAA 17

RESULT 246
AX498839 17 bp DNA linear PAT 27-SEP-2002
LOCUS
DEFINITION Sequence 146 from Patent EP1229046.
ACCESSION AX498839

VERSION AX498839.1 GI:23381121
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 146 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 6 a 9 c 1 g 1 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1519 CACAAGCTGACCAAC 1534
Db 1 CCAAGCTCACCAAC 16

RESULT 247
AX500368/C 17 bp DNA linear PAT 27-SEP-2002
LOCUS
DEFINITION Sequence 1675 from Patent EP1229046.
ACCESSION AX500368
VERSION AX500368.1 GI:23382661
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 1675 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 5 a 2 c 1 g 9 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2187 TGTGATGAAATGCA 2202
Db 17 TGTATATAAATGCA 2

RESULT 248
AX500370/C 17 bp DNA linear PAT 27-SEP-2002
LOCUS
DEFINITION Sequence 1677 from Patent EP1229046.
ACCESSION AX500370
VERSION AX500370.1 GI:23382663
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 Zhan, J.
TITLE Human testis expressed patched like protein

JOURNAL Patent: EP 1229046-A 1677 07-AUG-2002;
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 3 c 1 g 8 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2186 ATGTGATGAATAATGAC 2201
Db 16 ATGTTATATAAATAGC 1

RESULT 249
AX530612/c 17 bp DNA linear PAT 22-NOV-2002
LOCUS
DEFINITION Sequence 121 from Patent EP1239051.
ACCESSION AX530612
KEYWORDS AX530612.1 GI:25253031
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 121 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 4 c 5 g 3 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1565 CGGCTGAGTCCAGCTC 1580
Db 17 CTGCTGAGTCCAGCTC 2

RESULT 250
AX530615/c 17 bp DNA linear PAT 22-NOV-2002
LOCUS
DEFINITION Sequence 124 from Patent EP1239051.
ACCESSION AX530615
VERSION AX530615.1 GI:25253037
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 124 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 4 c 5 g 2 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1563 TTCGCTGAGTCCAGC 1578
Db 16 TTCGCTGAGTCCAGC 1

RESULT 251
AX615893/c 17 bp DNA linear PAT 20-FEB-2003
LOCUS
DEFINITION Sequence 700 from Patent EP1262488.
ACCESSION AX615893
VERSION AX615893.1 GI:28446939
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Gu,Y. and Nguyen,C.T.
TITLE Human lcc1-domain containing protein
JOURNAL Patent: EP 1262488-A 700 04-DEC-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 3 a 6 c 4 g 4 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2054 CTGAGGAGCAGATGAC 2069
Db 17 CTGAGGAGCAGCTGTC 2

RESULT 252
AX615894/c 17 bp DNA linear PAT 20-FEB-2003
LOCUS
DEFINITION Sequence 701 from Patent EP1262488.
ACCESSION AX615894
VERSION AX615894.1 GI:28446940
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Gu,Y. and Nguyen,C.T.
TITLE Human lcc1-domain containing protein
JOURNAL Patent: EP 1262488-A 701 04-DEC-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 3 a 7 c 4 g 3 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2054 CTGAGGAGCAGATGAC 2069
Db 16 CTGAGGAGCAGCTGTC 1

```

RESULT 253
AX648748/c      17 bp   DNA      linear      PAT 22-MAR-2003
LOCUS           Sequence 588 from Patent EP1273660.
DEFINITION      AX648748
ACCESSION       AX648748.1 GI:29151566
VERSION
KEYWORDS
SOURCE          Homo sapiens (human)
ORGANISM        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
1
AUTHORS         Gu.Y.
TITLE           Human sodium-hydrogen exchanger like protein 1
JOURNML         Patent: EP 1273660-A 588 08-JAN-2003;
                Aeomica, Inc. (US)
FEATURES
source          Location/Qualifiers
BASE COUNT      3 a 4 c 4 g 6 t
Query Match     0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1692 ATGGAGTTCCACAGA 1707
|||||
Db 17 ATGGCAGTTCCACAGA 2

RESULT 254
AX648749/c      17 bp   DNA      linear      PAT 22-MAR-2003
LOCUS           Sequence 589 from Patent EP1273660.
DEFINITION      AX648749
ACCESSION       AX648749.1 GI:29151567
VERSION
KEYWORDS
SOURCE          Homo sapiens (human)
ORGANISM        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
1
AUTHORS         Gu.Y.
TITLE           Human sodium-hydrogen exchanger like protein 1
JOURNML         Patent: EP 1273660-A 589 08-JAN-2003;
                Aeomica, Inc. (US)
FEATURES
source          Location/Qualifiers
BASE COUNT      3 a 5 c 4 g 5 t
Query Match     0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1692 ATGGAGTTCCACAGA 1707
|||||
Db 16 ATGGCAGTTCCACAGA 1

RESULT 255
AX672107        17 bp   DNA      linear      PAT 27-MAR-2003
LOCUS           Sequence 552 from Patent WO03004526.
DEFINITION      AX672107
ACCESSION       AX672107.1 GI:29330455
VERSION
KEYWORDS
SOURCE          Homo sapiens (human)
ORGANISM        Homo sapiens

```

```

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
1
AUTHORS         Telerman,A., Amson,R. and Tuijnder,M.
TITLE           Sequences involved in phenomena of tumour suppression, tumour
                reversion, apoptosis and/or resistance to viruses and their use as
                medicines
JOURNML         Patent: WO 03004526-A 552 16-JAN-2003;
                Molecular Engines Laboratories (FR)
FEATURES
source          Location/Qualifiers
BASE COUNT      6 a 3 c 4 g 4 t
Query Match     0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2643 TTCTTCAGAGATGAT 2658
|||||
Db 17 TTCTTCAGAGCTGAT 2

RESULT 256
AX672299/c      17 bp   DNA      linear      PAT 27-MAR-2003
LOCUS           Sequence 744 from Patent WO03004526.
DEFINITION      AX672299
ACCESSION       AX672299.1 GI:29330647
VERSION
KEYWORDS
SOURCE          Homo sapiens (human)
ORGANISM        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
1
AUTHORS         Telerman,A., Amson,R. and Tuijnder,M.
TITLE           Sequences involved in phenomena of tumour suppression, tumour
                reversion, apoptosis and/or resistance to viruses and their use as
                medicines
JOURNML         Patent: WO 03004526-A 744 16-JAN-2003;
                Molecular Engines Laboratories (FR)
FEATURES
source          Location/Qualifiers
BASE COUNT      4 a 6 c 1 g 6 t
Query Match     0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2055 TGAGGACAGATGACC 2070
|||||
Db 16 TGAGGAGAGATGATC 1

RESULT 257
AX672663/c      17 bp   DNA      linear      PAT 27-MAR-2003
LOCUS           Sequence 1108 from Patent WO03004526.
DEFINITION      AX672663
ACCESSION       AX672663.1 GI:29331011
VERSION
KEYWORDS
SOURCE          Homo sapiens (human)
ORGANISM        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
1
AUTHORS         Telerman,A., Amson,R. and Tuijnder,M.
TITLE           Sequences involved in phenomena of tumour suppression, tumour

```

reversion, apoptosis and/or resistance to viruses and their use as medicines
Patent: WO 03004526-A 1108 16-JAN-2003;
Molecular Engines Laboratories (PR)
Location/Qualifiers

FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT
5 a 4 c 4 g 4 t

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2267 TTCGAGTCAGTGAT 2282
Db 17 TTCGAGTCAGTGAT 2

RESULT 258
AX673076 17 bp DNA linear PAT 27-MAR-2003
LOCUS Sequence 1521 from Patent WO03004526.
ACCESSION AX673076
VERSION AX673076.1 GI:29331424
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines
JOURNAL Patent: WO 03004526-A 1521 16-JAN-2003;
FEATURES Molecular Engines Laboratories (PR)
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT
5 a 6 c 3 g 3 t

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2064 GATGACCTTCAAGAC 2079
Db 1 GATGACCTTCAAGAC 16

RESULT 259
AX673485 17 bp DNA linear PAT 27-MAR-2003
LOCUS Sequence 1930 from Patent WO03004526.
ACCESSION AX673485
VERSION AX673485.1 GI:29331833
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines
JOURNAL Patent: WO 03004526-A 1930 16-JAN-2003;
FEATURES Molecular Engines Laboratories (PR)
Location/Qualifiers

source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT
5 a 3 c 5 g 4 t

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1459 ATCCTGTGCCGAATGA 1474
Db 2 ATCCTGTGCCGAATGA 17

RESULT 260
AX674784 17 bp DNA linear PAT 27-MAR-2003
LOCUS Sequence 3229 from Patent WO03004526.
ACCESSION AX674784
VERSION AX674784.1 GI:2933132
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines
JOURNAL Patent: WO 03004526-A 3229 16-JAN-2003;
FEATURES Molecular Engines Laboratories (PR)
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT
4 a 4 c 3 g 6 t

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2404 GAACCTTTTAACTGC 2419
Db 1 GATCTTTCAAGCTGC 16

RESULT 261
AX687397 17 bp DNA linear PAT 31-MAR-2003
LOCUS Sequence 129 from Patent EPI281758.
ACCESSION AX687397
VERSION AX687397.1 GI:29410091
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 129 05-FEB-2003;
FEATURES Aemica, Inc. (US)
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT
7 a 2 c 4 g 4 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1820 TGAAGATGCTGAAGA 1835
|||||
2 TGAAGATGCTTAAGA 17

RESULT 262
AX687398 17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 130 from Patent EP1281758.
AX687398
VERSION AX687398.1 GI:29410092
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 130 05-FEB-2003;
Aeomica, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 7 a 1 c 5 g 4 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1820 TGAAGATGCTGAAGA 1835
|||||
1 TGAAGATGCTTAAGA 16

RESULT 263
AX687586 17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 318 from Patent EP1281758.
AX687586
VERSION AX687586.1 GI:29410282
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 318 05-FEB-2003;
Aeomica, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 2 a 5 c 7 g 3 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2283 GGCTCCAGAGCCCTG 2298
|||||
2 GGCTCCAGAGCTCTG 17

RESULT 264
AX687588 17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 320 from Patent EP1281758.
AX687588
VERSION AX687588.1 GI:29410284
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 320 05-FEB-2003;
Aeomica, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 2 a 6 c 5 g 4 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2284 GCTCCAGAGCCCTG 2299
|||||
1 GCTCCAGAGCTCTGT 16

RESULT 265
AX687609/c 17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 341 from Patent EP1281758.
AX687609
VERSION AX687609.1 GI:29410305
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 341 05-FEB-2003;
Aeomica, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 2 a 4 c 8 g 3 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2579 ACTTGACCTCAGCCA 2594
|||||
17 ACTGCGGCTCAGCCA 2

RESULT 266
AX687610/c 17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 342 from Patent EP1281758.
AX687610

VERSION AX687610.1 GI:29410306
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
JOURNAL Patent: EP 1281758-A 342 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 2 a 4 c 7 g 4 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2579 ACTGACCTCAGCCA 2594
Db 16 ACTGGGCTCAGCCA 1
RESULT 267
AX688397 17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 1129 from Patent EPI281758.
ACCESSION AX688397.1 GI:29411099
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
JOURNAL Patent: EP 1281758-A 1129 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 3 a 8 c 3 g 3 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2676 CCCCATGCTTACGAA 2691
Db 2 CCCCTGCTGACGAA 17
RESULT 268
AX688398 17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 1130 from Patent EPI281758.
ACCESSION AX688398
VERSION AX688398.1 GI:29411100
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1

AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
JOURNAL Patent: EP 1281758-A 1130 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 3 a 8 c 4 g 2 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2676 CCCCATGCTTACGAA 2691
Db 1 CCCCTGCTGACGAA 16
RESULT 269
AX692517 17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 5249 from Patent EPI281758.
ACCESSION AX692517
VERSION AX692517.1 GI:29415475
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
JOURNAL Patent: EP 1281758-A 5249 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 2 a 1 c 4 g 10 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2653 GATGATCTGTGTTTT 2668
Db 2 GAGGATCTGTTTTT 17
RESULT 270
AX692518 17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 5250 from Patent EPI281758.
ACCESSION AX692518
VERSION AX692518.1 GI:29415476
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
JOURNAL Patent: EP 1281758-A 5250 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source 1. .17
Location/Qualifiers

/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 2 a 1 c 3 g 11 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2653 GATGATTCCTGTTTTT 2668
Db 1 GAGGATTCCTTTTTT 16

RESULT 271
AX721055 17 bp RNA linear PAT 11-APR-2003
DEFINITION Sequence 355 from Patent EP1288296.
ACCESSION AX721055
VERSION AX721055.1 GI:29787436
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1. 17
/organism="Herpes simplex virus unknown type"
/mol_type="genomic RNA"
/db_xref="taxon:126283"

BASE COUNT 3 a 5 c 7 g 2 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2279 GGATGGCTCCAGAAC 2294
Db 2 GGATGGCTCCAGAAC 17

RESULT 272
AX722358 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 45 from Patent WO03025176.
ACCESSION AX722358
VERSION AX722358.1 GI:30422859
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
Molecular Engines Laboratories (PR)
FEATURES
source
1. 17
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"

BASE COUNT 5 a 3 c 6 g 3 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1459 ATCTGTGCGGAATGA 1474
Db 2 ATCTGTGCGGAAGA 17

RESULT 273
AX722882 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 569 from Patent WO03025176.
ACCESSION AX722882
VERSION AX722882.1 GI:30423383
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
Molecular Engines Laboratories (PR)
FEATURES
source
1. 17
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"

BASE COUNT 3 a 2 c 6 g 6 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2318 ATCAGAGTGATGCTG 2333
Db 2 ATCAGAGTGATGCTG 17

RESULT 274
AX723196 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 883 from Patent WO03025176.
ACCESSION AX723196
VERSION AX723196.1 GI:30423697
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
Molecular Engines Laboratories (PR)
FEATURES
source
1. 17
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"

BASE COUNT 6 a 1 c 5 g 5 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1849 AAAGACCTTCTGATC 1864
Db 1 AAAGACCTTCTGATC 1864

Db 16 ACATACCTTCTGATC 1

RESULT 275
LOCUS AX724155/c 17 bp DNA
DEFINITION Sequence 1842 from Patent WO03025176.
ACCESSION AX724155
VERSION AX724155.1 GI:30503498
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 1842 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1. .17
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"

BASE COUNT 2 a 4 c 6 g 5 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1929 AGCTGCACACAGAT 1944
Db 17 AGCCTGCACACAGAT 2

RESULT 276
LOCUS AX724673/c 17 bp DNA
DEFINITION Sequence 2360 from Patent WO03025176.
ACCESSION AX724673
VERSION AX724673.1 GI:30504016
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 2360 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1. .17
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"

BASE COUNT 4 a 6 c 4 g 3 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2289 AGAGCCCTGTTGAT 2304
Db 17 AGAGCCCTGTTGAT 2

RESULT 277
AX724703

LOCUS AX724703 17 bp DNA
DEFINITION Sequence 2390 from Patent WO03025176.
ACCESSION AX724703
VERSION AX724703.1 GI:30504046
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 2390 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1. .17
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"

BASE COUNT 2 a 3 c 4 g 8 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2358 GATCTTCACCTTAGG 2373
Db 1 GATCTTCCTTAGG 16

RESULT 278
LOCUS AX725084 17 bp DNA
DEFINITION Sequence 2771 from Patent WO03025176.
ACCESSION AX725084
VERSION AX725084.1 GI:30504427
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 2771 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1. .17
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"

BASE COUNT 5 a 3 c 4 g 5 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1459 ATCTGTGCCGATGA 1474
Db 2 ATCTGTGCCGATGA 17

RESULT 279
AX725777 17 bp DNA
LOCUS AX725777 17 bp DNA
DEFINITION Sequence 3464 from Patent WO03025176.
ACCESSION AX725777
VERSION AX725777.1 GI:30505120
KEYWORDS

SOURCE	ORGANISM	Mus musculus (house mouse)
REFERENCE	AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sclurognathi; Muridae; Murinae; Mus.
TITLE	1	Telesman, A., Amson, R. and Tuijinder, M.
JOURNAL		Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
FEATURES	source	Patent: WO 03025176-A 3464 27-MAR-2003; Molecular Engines Laboratories (FR)
BASE COUNT		Location/Qualifiers
		1..17
		/organism="Mus musculus"
		/mol_type="genomic DNA"
		/db_xref="taxon:10090"
Query Match	0.9%;	Score 12.8; DB 1;
Best Local Similarity	87.5%;	Pred. No. 1.9e+02;
Matches	14;	Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy	2414	AGCTGCTGAGGAGG 2429
Db	2	ATCTCTGATGAGG 17
RESULT 280		
LOCUS	AX725869	17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 3556 from Patent WO03025176.	
ACCESSION	AX725869	
VERSION	AX725869.1	GI:30505212
KEYWORDS		
SOURCE		
ORGANISM	Mus musculus (house mouse)	
REFERENCE		
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sclurognathi; Muridae; Murinae; Mus.	
TITLE	1	Telesman, A., Amson, R. and Tuijinder, M.
JOURNAL		Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
FEATURES	source	Patent: WO 03025176-A 3556 27-MAR-2003; Molecular Engines Laboratories (FR)
BASE COUNT		Location/Qualifiers
		1..17
		/organism="Mus musculus"
		/mol_type="genomic DNA"
		/db_xref="taxon:10090"
Query Match	0.9%;	Score 12.8; DB 1;
Best Local Similarity	87.5%;	Pred. No. 1.9e+02;
Matches	14;	Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy	2267	TTCCAGTCAAGTGAT 2282
Db	17	TTCTGCGCAAGTGAT 2
RESULT 281		
LOCUS	AX726992	17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 4679 from Patent WO03025176.	
ACCESSION	AX726992	
VERSION	AX726992.1	GI:30506335
KEYWORDS		
SOURCE		
ORGANISM	Mus musculus (house mouse)	
REFERENCE		
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sclurognathi; Muridae; Murinae; Mus.	
TITLE	1	Telesman, A., Amson, R. and Tuijinder, M.
JOURNAL		Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
FEATURES	source	Patent: WO 03025176-A 4679 27-MAR-2003; Molecular Engines Laboratories (FR)
BASE COUNT		Location/Qualifiers
		1..17
		/organism="Mus musculus"
		/mol_type="genomic DNA"
		/db_xref="taxon:10090"
Query Match	0.9%;	Score 12.8; DB 1;
Best Local Similarity	87.5%;	Pred. No. 1.9e+02;
Matches	14;	Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy	2267	TTCCAGTCAAGTGAT 2282
Db	17	TTCTGCGCAAGTGAT 2

AUTHORS	Teleman,A., Amson,R. and Tuijinder,M.									
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversal, apoptosis and/or virus resistance and their use as medicines									
JOURNAL	Patent: WO 03025176-A 4679 27-MAR-2003;									
FEATURES	Molecular Engines Laboratories (R)									
source	location/Qualifiers									
	1..17									
	/organism="Mus musculus"									
	/mol_type="genomic DNA"									
	/db_xref="taxon:10090"									
BASE COUNT	3 a 5 c 4 g 5 t									
Query Match	0.9%; Score 12.8; DB 1; Length 17;									
Best Local Similarity	87.5%; Pred. No. 1.9e+02;									
Matches 14; Conservative	0; Mismatches 2; Indels 0; Gaps 0;									
QY	1672 GAACCTCCAGAGCACC 1687									
Db	1 GATCTTCCAGAGTCC 16									
RESULT 282										
AX727138	17 bp DNA linear PAT 08-MAY-2003									
LOCUS	AX727138									
DEFINITION	Sequence 4825 from Patent WO03025176.									
ACCESSION	AX727138									
VERSION	AX727138.1 GI:30506481									
KEYWORDS										
SOURCE	Mus musculus (house mouse)									
ORGANISM	Mus musculus									
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.									
REFERENCE	1									
AUTHORS	Teleman,A., Amson,R. and Tuijinder,M.									
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversal, apoptosis and/or virus resistance and their use as medicines									
JOURNAL	Patent: WO 03025176-A 4825 27-MAR-2003;									
FEATURES	Molecular Engines Laboratories (R)									
source	location/Qualifiers									
	1..17									
	/organism="Mus musculus"									
	/mol_type="genomic DNA"									
	/db_xref="taxon:10090"									
BASE COUNT	6 a 3 c 4 g 4 t									
Query Match	0.9%; Score 12.8; DB 1; Length 17;									
Best Local Similarity	87.5%; Pred. No. 1.9e+02;									
Matches 14; Conservative	0; Mismatches 2; Indels 0; Gaps 0;									
QY	1861 GATCTGGTGCAGAGA 1876									
Db	1 GATCTAATGTCAGAGA 16									
RESULT 283										
AX727199	17 bp DNA linear PAT 08-MAY-2003									
LOCUS	AX727199									
DEFINITION	Sequence 4886 from Patent WO03025176.									
ACCESSION	AX727199									
VERSION	AX727199.1 GI:30506542									
KEYWORDS										
SOURCE	Mus musculus (house mouse)									
ORGANISM	Mus musculus									
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.									
REFERENCE	1									
AUTHORS	Teleman,A., Amson,R. and Tuijinder,M.									
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversal, apoptosis and/or virus resistance and their use as medicines									
JOURNAL	Patent: WO 03025176-A 4886 27-MAR-2003;									

FEATURES	Molecular Engines Laboratories (R)				
source	Location/Qualifiers				
	1..17				
	/organism="Mus musculus"				
	/mol_type="genomic DNA"				
	/db_xref="taxon:10090"				
BASE COUNT	8 a 3 c 2 g 4 t				
Query Match	0.9%; Score 12.8; DB 1; Length 17;				
Best Local Similarity	87.5%; Pred. No. 1.9e+02;				
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;				
QY	2224 ATCAACATATAGACT 2239				
Db	2 ATCCACATATAGAT 17				
RESULT 284					
AX727780					
LOCUS	AX727780 17 bp DNA linear PAT 08-MAY-2003				
DEFINITION	Sequence 5467 from Patent WO03025176.				
ACCESSION	AX727780				
VERSION	AX727780.1 GI:30507123				
KEYWORDS					
SOURCE	Mus musculus (house mouse)				
ORGANISM	Mus musculus				
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.				
REFERENCE	1				
AUTHORS	Telerman, A., Amson, R. and Tuijinder, M.				
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines				
JOURNAL	Patent: WO 03025176-A 5467 27-MAR-2003;				
FEATURES	Molecular Engines Laboratories (R)				
source	Location/Qualifiers				
	1..17				
	/organism="Mus musculus"				
	/mol_type="genomic DNA"				
	/db_xref="taxon:10090"				
BASE COUNT	4 a 3 c 6 g 4 t				
Query Match	0.9%; Score 12.8; DB 1; Length 17;				
Best Local Similarity	87.5%; Pred. No. 1.9e+02;				
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;				
QY	2016 ACCCGGATGGAGTAC 2031				
Db	2 ATCTGGATGGAGTAC 17				
RESULT 285					
AX728341/c					
LOCUS	AX728341 17 bp DNA linear PAT 08-MAY-2003				
DEFINITION	Sequence 6028 from Patent WO03025176.				
ACCESSION	AX728341				
VERSION	AX728341.1 GI:30507684				
KEYWORDS					
SOURCE	Mus musculus (house mouse)				
ORGANISM	Mus musculus				
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.				
REFERENCE	1				
AUTHORS	Telerman, A., Amson, R. and Tuijinder, M.				
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines				
JOURNAL	Patent: WO 03025176-A 6028 27-MAR-2003;				
FEATURES	Molecular Engines Laboratories (R)				
source	Location/Qualifiers				
	1..17				
	/organism="Mus musculus"				
	/mol_type="genomic DNA"				

/db_xref="taxon:10090"									
BASE COUNT	3 a	3 c	4 g	7 t					
Query Match					0.9%	Score 12.8;	DB 1;	Length 17;	
Beet Local Similarity					87.5%	Pred. No. 1.9e+02;			
Matches 14;					Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;	
QY	1470	AATGAGAACGACGACC	1485						
Db	16	AATGAGTACGATC	1						
RESULT 286									
AX728422									
LOCUS	AX728422				17 bp	DNA	linear	PAT 08-MAY-2003	
DEFINITION	Sequence 56 from Patent WO03025175.								
ACCESSION	AX728422								
VERSION	AX728422.1				GI:30507765				
KEYWORDS									
SOURCE									
ORGANISM	Homo sapiens (human)								
REFERENCE	Homo sapiens								
AUTHORS	Eukaryota; Metazoa; Chordata; Craniota; Vertebrata; Euteleostomi;								
TITLE	Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.								
JOURNAL	Telesman, A., Amson, R. and Tuijinder, M.								
FEATURES	Sequences involved in phenomena of tumour suppression, tumour								
source	reversion, apoptosis and/or virus resistance and their use as								
	medicines								
	Patent: WO 03025175-A 56 27-MAR-2003;								
	Molecular Engines Laboratories (FR)								
	location/Qualifiers								
	1..17								
	/organism="Homo sapiens"								
	/mol_type="genomic DNA"								
	/db_xref="taxon:9606"								
BASE COUNT	4 a	3 c	4 g	6 t					
Query Match					0.9%	Score 12.8;	DB 1;	Length 17;	
Beet Local Similarity					87.5%	Pred. No. 1.9e+02;			
Matches 14;					Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;	
QY	2358	GATCTTCACCTTAGGG	2373						
Db	1	GATCATTACTTTAGGG	16						
RESULT 287									
AX728590/c									
LOCUS	AX728590				17 bp	DNA	linear	PAT 08-MAY-2003	
DEFINITION	Sequence 224 from Patent WO03025175.								
ACCESSION	AX728590								
VERSION	AX728590.1				GI:30507933				
KEYWORDS									
SOURCE									
ORGANISM	Homo sapiens (human)								
REFERENCE	Homo sapiens								
AUTHORS	Eukaryota; Metazoa; Chordata; Craniota; Vertebrata; Euteleostomi;								
TITLE	Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.								
JOURNAL	Telesman, A., Amson, R. and Tuijinder, M.								
FEATURES	Sequences involved in phenomena of tumour suppression, tumour								
source	reversion, apoptosis and/or virus resistance and their use as								
	medicines								
	Patent: WO 03025175-A 224 27-MAR-2003;								
	Molecular Engines Laboratories (FR)								
	location/Qualifiers								
	1..17								
	/organism="Homo sapiens"								
	/mol_type="genomic DNA"								
	/db_xref="taxon:9606"								
BASE COUNT	4 a	5 c	4 g	4 t					
Query Match					0.9%	Score 12.8;	DB 1;	Length 17;	
Beet Local Similarity					87.5%	Pred. No. 1.9e+02;			

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1391 CAGACTACCTGGAGAT 1406
 DB 17 CAGATTACTGGGAT 2

RESULT 288
 AX728851/c
 LOCUS AX728851 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 485 from Patent WO03025175.
 ACCESSION AX728851
 VERSION AX728851.1 GI:30508194
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
 AUTHORS 1
 TITLE Telerman, A., Amson, R. and Tuijinder, M.
 JOURNAL Sequences involved in phenomena of tumour suppression, tumour
 reversal, apoptosis and/or virus resistance and their use as
 medicines
 PATENT: WO 03025175-A 485 27-MAR-2003;
 Molecular Engines Laboratories (FR)
 FEATURES
 SOURCE 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606" 4 a 3 c 4 g 6 t

BASE COUNT 4 a 3 c 4 g 6 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2177 CAGAAACAAATGTAT 2192
 DB 17 CAGATTACCTGGAT 2

RESULT 289
 AX729046/c
 LOCUS AX729046 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 680 from Patent WO03025175.
 ACCESSION AX729046
 VERSION AX729046.1 GI:30508389
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
 AUTHORS 1
 TITLE Telerman, A., Amson, R. and Tuijinder, M.
 JOURNAL Sequences involved in phenomena of tumour suppression, tumour
 reversal, apoptosis and/or virus resistance and their use as
 medicines
 PATENT: WO 03025175-A 680 27-MAR-2003;
 Molecular Engines Laboratories (FR)
 FEATURES
 SOURCE 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606" 2 a 6 c 2 g 7 t

BASE COUNT 2 a 6 c 2 g 7 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1364 GAAGAGAAAGGAGAT 1379
 DB 17 GAAGAGCAATGGAGAT 2

RESULT 290
 AX729296/c
 LOCUS AX729296 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 930 from Patent WO03025175.
 ACCESSION AX729296
 VERSION AX729296.1 GI:30508639
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
 AUTHORS 1
 TITLE Telerman, A., Amson, R. and Tuijinder, M.
 JOURNAL Sequences involved in phenomena of tumour suppression, tumour
 reversal, apoptosis and/or virus resistance and their use as
 medicines
 PATENT: WO 03025175-A 930 27-MAR-2003;
 Molecular Engines Laboratories (FR)
 FEATURES
 SOURCE 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606" 5 a 1 c 4 g 7 t

BASE COUNT 5 a 1 c 4 g 7 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1849 AAAGACCTTCTATC 1864
 DB 16 AAAAACCTTCAGATC 1

RESULT 291
 AX729326/c
 LOCUS AX729326 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 960 from Patent WO03025175.
 ACCESSION AX729326
 VERSION AX729326.1 GI:30508669
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
 AUTHORS 1
 TITLE Telerman, A., Amson, R. and Tuijinder, M.
 JOURNAL Sequences involved in phenomena of tumour suppression, tumour
 reversal, apoptosis and/or virus resistance and their use as
 medicines
 PATENT: WO 03025175-A 960 27-MAR-2003;
 Molecular Engines Laboratories (FR)
 FEATURES
 SOURCE 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606" 4 a 7 c 4 g 2 t

BASE COUNT 4 a 7 c 4 g 2 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2051 TTCCTGAGGAGAGAT 2066
 DB 17 TTCCTGGGGGAGAGAT 2

RESULT 292
 AX729354/c
 LOCUS AX729354 17 bp DNA linear PAT 08-MAY-2003

DEFINITION Sequence 988 from Patent WO03025175.
ACCESSION AX729354
VERSION AX729354.1 GI:30508697
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 988 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 3 c 4 g 4 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2640 TTGTTCTTCAGAGAT 2655
|||||
Db 17 TTGTTCTTCAGACAGAT 2
RESULT 293
AX729580 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 1214 from Patent WO03025175.
ACCESSION AX729580
VERSION AX729580.1 GI:30508923
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 1214 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 4 a 4 c 3 g 6 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2358 GATCTTCACCTTAGG 2373
|||||
Db 1 GATCATCCTTATG 16
RESULT 294
AX730392 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 2026 from Patent WO03025175.
ACCESSION AX730392
VERSION AX730392.1 GI:30509735
KEYWORDS
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 2026 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 1 c 5 g 6 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1849 AAAGACCTTCTGATC 1864
|||||
Db 16 AAACACTTCTGATC 1
RESULT 295
AX731487 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 3121 from Patent WO03025175.
ACCESSION AX731487
VERSION AX731487.1 GI:30510830
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 3121 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 7 a 1 c 5 g 4 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2525 AGCAGTTGCTGAAGA 2540
|||||
Db 2 ATCAGTTGTAAGA 17
RESULT 296
AX731824 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 3458 from Patent WO03025175.
ACCESSION AX731824
VERSION AX731824.1 GI:30511167
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.

TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025175-A 3458 27-MAR-2003;

FEATURES
source Location/Qualifiers

1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 6 a 4 c 2 g 5 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1695 GGAGTTTCCAGAGAT 1710
DB 17 GGATTTTCAAGAGAT 2

RESULT 297
AX732003/c 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 3637 from Patent WO03025175.
ACCESSION AX732003
VERSION AX732003.1 GI:30511346
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 3637 27-MAR-2003;
FEATURES
source Location/Qualifiers

1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 4 a 7 c 1 g 5 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2533 GTAGAGACTTGGATC 2548
DB 16 GTGGAGAGCTTGGATC 1

RESULT 298
AX732048 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 3682 from Patent WO03025175.
ACCESSION AX732048
VERSION AX732048.1 GI:30511391
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 3682 27-MAR-2003;
FEATURES
source Location/Qualifiers

FEATURES
source Location/Qualifiers

1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 5 a 7 c 3 g 2 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1377 GATTACAGCTTCCCCA 1392
DB 1 GATCAGAGCTGCCCA 16

RESULT 299
AX732049 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 3683 from Patent WO03025175.
ACCESSION AX732049
VERSION AX732049.1 GI:30511392
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 3683 27-MAR-2003;
FEATURES
source Location/Qualifiers

1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 6 a 1 c 6 g 4 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2318 ATCAGAGTGTGCTG 2333
DB 2 ATCAGAGTGAAGTATG 17

RESULT 300
AX733473/c 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 5107 from Patent WO03025175.
ACCESSION AX733473
VERSION AX733473.1 GI:30512816
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 5107 27-MAR-2003;
FEATURES
source Location/Qualifiers

1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 5 a 1 c 4 g 7 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2238 CTATTACAAAAGACC 2253
Db 16 CTTTACAAAAGATC 1

RESULT 301
AX733774/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5408 from Patent WO03025175.
ACCESSION AX733774
VERSION AX733774.1 GI:30513117
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
Telerman, A., Amson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
Patent: WO 03025175-A 5408 27-MAR-2003;
Molecular Engines Laboratories (FR)

JOURNAL
location/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 2 a 5 c 2 g 8 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1364 GAAGAGAAAGAGAT 1379
Db 17 GCAGAGAAATGAGAT 2

RESULT 302
AX733950/c 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX733950
DEFINITION Sequence 5584 from Patent WO03025175.
ACCESSION AX733950
VERSION AX733950.1 GI:30513293
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
Telerman, A., Amson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
Patent: WO 03025175-A 5584 27-MAR-2003;
Molecular Engines Laboratories (FR)

JOURNAL
location/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 4 a 5 c 4 g 4 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2051 TTCTGAGAGCAGAT 2066
Db 17 TTCTGAGAGCAGAT 2

RESULT 303
AX734767 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX734767
DEFINITION Sequence 357 from Patent WO03025177.
ACCESSION AX734767
VERSION AX734767.1 GI:30514044
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
Telerman, A., Amson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
Patent: WO 03025177-A 357 27-MAR-2003;
Molecular Engines Laboratories (FR)

JOURNAL
location/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 10 a 2 c 2 g 3 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 ATCAACAATATGACT 2239
Db 2 ATCAACAATATGACT 17

RESULT 304
AX734878 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX734878
DEFINITION Sequence 468 from Patent WO03025177.
ACCESSION AX734878
VERSION AX734878.1 GI:30514155
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
Telerman, A., Amson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
Patent: WO 03025177-A 468 27-MAR-2003;
Molecular Engines Laboratories (FR)

JOURNAL
location/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 4 a 5 c 3 g 5 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2545 GATCGAATTCCTACTC 2560
Db 1 GATCGAATTCCTACTC 16

```

RESULT 305
AX735178/c
LOCUS AX735178
DEFINITION Sequence 768 from Patent WO03025177.
ACCESSION AX735178
VERSION AX735178.1 GI:30514455
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
JOURNAL
TEJERMAN, A., AMSON, R. and TUIJNDER, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
Patent: WO 03025177-A 768 27-MAR-2003;
MOLECULAR ENGINEERING LABORATORIES (PR)
FEATURES
SOURCE Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 2 a 6 c 1 g 8 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1364 GAAGAGAAAGAGAT 1379
|||||
Db 17 GAAGAGAGAGAT 2

RESULT 306
AX737461
LOCUS AX737461
DEFINITION Sequence 3051 from Patent WO03025177.
ACCESSION AX737461
VERSION AX737461.1 GI:30516749
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
JOURNAL
TEJERMAN, A., AMSON, R. and TUIJNDER, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
Patent: WO 03025177-A 3051 27-MAR-2003;
MOLECULAR ENGINEERING LABORATORIES (PR)
FEATURES
SOURCE Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 3 c 5 g 4 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1459 ATCTGTGCGGATGA 1474
|||||
Db 2 ATCTGTGCGGATGA 17

RESULT 307
AX738552/c
LOCUS AX738552
DEFINITION Sequence 4142 from Patent WO03025177.

```

```

ACCESSION AX738552
VERSION AX738552.1 GI:30517840
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
JOURNAL
TEJERMAN, A., AMSON, R. and TUIJNDER, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
Patent: WO 03025177-A 4142 27-MAR-2003;
MOLECULAR ENGINEERING LABORATORIES (PR)
FEATURES
SOURCE Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 4 a 5 c 4 g 4 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1391 CAGACTACCTGGAGAT 1406
|||||
Db 17 CAGATTACTGGGAT 2

RESULT 308
AX738641/c
LOCUS AX738641
DEFINITION Sequence 4231 from Patent WO03025177.
ACCESSION AX738641
VERSION AX738641.1 GI:30517931
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
JOURNAL
TEJERMAN, A., AMSON, R. and TUIJNDER, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
Patent: WO 03025177-A 4231 27-MAR-2003;
MOLECULAR ENGINEERING LABORATORIES (PR)
FEATURES
SOURCE Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 7 a 4 c 4 g 2 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2267 TTCAGTCAGTGAT 2282
|||||
Db 17 TTCAGTCAGTGAT 2

RESULT 309
AX744527
LOCUS AX744527
DEFINITION Sequence 492 from Patent WO03031621.
ACCESSION AX744527
VERSION AX744527.1 GI:30723194
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)

```

REFERENCE	1	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS	Zhang, J.	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE	A human G protein coupled receptor	
JOURNAL	Patent: WO 03031621-A 492 17-APR-2003;	
FEATURES	Amersham Biosciences (SV) Corp. (US)	
source	location/Qualifiers	
	1..17	
	/organism="Homo sapiens"	
	/mol_type="genomic DNA"	
	/db_xref="taxon:9606"	
BASE COUNT	4 a 7 c 1 g 5 t	
Query Match	0.9%; Score 12.8; DB 1;	Length 17;
Best Local Similarity	87.5%; Pred. No. 1.9e+02;	
Matches 14; Conservative	0; Mismatches 2;	Indels 0; Gaps 0;
OY	2585 ACCTGAGCCACCTCT 2600	
Dn	1 2. ACTTCAGTCAACCTCT 17	
RESULT 310		
AX744529	17 bp DNA	PAT 14-MAY-2003
LOCUS	AX744529	
DEFINITION	Sequence 494 from Patent WO03031621.	
ACCESSION	AX744529	
VERSION	AX744529.1 GI:30723196	
KEYWORDS	.	
SOURCE	Homo sapiens (human)	
ORGANISM	Homo sapiens	
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
TITLE	Zhang, J.	
JOURNAL	A human G protein coupled receptor	
FEATURES	Patent: WO 03031621-A 494 17-APR-2003;	
source	Amersham Biosciences (SV) Corp. (US)	
	location/Qualifiers	
	1..17	
	/organism="Homo sapiens"	
	/mol_type="genomic DNA"	
	/db_xref="taxon:9606"	
BASE COUNT	3 a 8 c 1 g 5 t .	
Query Match	0.9%; Score 12.8; DB 1;	Length 17;
Best Local Similarity	87.5%; Pred. No. 1.9e+02;	
Matches 14; Conservative	0; Mismatches 2;	Indels 0; Gaps 0;
OY	2586 CCTGAGCCACCTCTC 2601	
Dn	1 1 CTTGAGTCAACCTCTC 16	
RESULT 311		
BD0001175	17 bp RNA	linear PAT 31-JAN-2002
LOCUS	BD0001175	
DEFINITION	Method and reagent for inhibiting viral replication.	
ACCESSION	BD0001175	
VERSION	BD0001175.1 GI:18625734	
KEYWORDS	JP 2000342285-A/335.	
SOURCE	synthetic construct	
ORGANISM	synthetic construct	
REFERENCE	artificial sequences.	
AUTHORS	1 (bases 1 to 17)	
TITLE	Draper,K.G., Dadykzt,L.W., Macswigen,J.A., Maysejak,D.G.,	
JOURNAL	Holesek,J.J., and Mamone,A.J.	
COMMENT	Method and reagent for inhibiting viral replication	
OS	Patent: JP 2000342285-A 335 12-DEC-2000;	
PN	RIBOZYME PHARMACEUTICALS INC	
	Artificial Sequence	
	JP 2000342285-A/335	

FEATURES	source	Location/Qualifiers
BASE COUNT	3 a 5 c 7 g 2 t	
Query Match	0.9%; Score 12.8; DB 1; Length 17;	
Best Local Similarity	87.5%; Pred. No. 1.9e+02;	
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
CY	2279 GGATGCTCCGAGAC 2294	
Db	2 GGGTGGCTCCGAGACC 17	
RESULT 312		
BD001604		
LOCUS	BD001604 17 bp RNA linear PAT 31-JAN-2002	
DEFINITION	Method and reagent for inhibiting viral replication.	
ACCESSION	BD001604	
VERSION	BD001604.1 GI:18626163	
KEYWORDS	JP 2000342286-A/335.	
SOURCE	JP 2000342286-A/335.	
ORGANISM	synthetic construct	
REFERENCE	synthetic construct	
AUTHORS	artificial sequences.	
TITLE	1 (bases 1 to 17)	
JOURNAL	Drafer, K.G., Dadyktz, L.W., Macswigen, J.A., Maysejak, D.G., Holesek, J.J. and Mamone, A.J. Method and reagent for inhibiting viral replication Patent: JP 2000342286-A 335 12-DEC-2000; RIBOZYME PHARMACEUTICALS INC	
COMMENT	OS Artificial Sequence PN JP 2000342286-A/335	
	PD 12-DEC-2000	
	PF 01-MAY-2000 JP 2000132651	
	PR 11-MAY-1992 US 07/882689, 14-MAY-1992 US 07/882712 PR	
	14-MAY-1992 US 07/882713, 14-MAY-1992 US 07/882714 PR	
	14-MAY-1992 US 07/882866, 14-MAY-1992 US 07/882868 PR	
	14-MAY-1992 US 07/882869, 14-MAY-1992 US 07/882921 PR	
	14-MAY-1992 US 07/882922, 14-MAY-1992 US 07/883823 PR	
	14-MAY-1992 US 07/883849, 14-MAY-1992 US 07/884073 PR	
	14-MAY-1992 US 07/884074, 14-MAY-1992 US 07/884433 PR	
	14-MAY-1992 US 07/884432, 14-MAY-1992 US 07/884431 PR	
	14-MAY-1992 US 07/884436, 14-MAY-1992 US 07/884521 PR	
	31-JUL-1992 US 07/923738, 26-AUG-1992 US 07/935854 PR	
	PI JAMES J HOLESEK, ANTHONY J MAMONE	
	PC C12N15/09, C12N5/10, C12N7/00, C12N9/22// (C12N5/10, C12R1:91), PC	
	C12N15/00, (C12N5/00, C12R1:91)	
	PC C12N5/00, (C12N5/00, C12R1:91)	
	CC	
	FH Key Location/Qualifiers	
	FT source 1..17	
	FT Location/Qualifiers	
	1..17	
	/organism="synthetic construct"	
	/mol_type="genomic RNA"	
	/db_xref="taxon:32630"	
	/db_xref="taxon:32630"	
	PI JAMES J HOLESEK, ANTHONY J MAMONE	
	PC C12N15/09, C12N5/10, C12N7/00, C12N9/22// (C12N5/10, C12R1:91), PC	
	C12N15/00, (C12N5/00, C12R1:91)	
	CC	
	FH Key Location/Qualifiers	
	FT source 1..17	
	FT Location/Qualifiers	
	1..17	
	/organism="Artificial Sequence".	
	PI JAMES J HOLESEK, ANTHONY J MAMONE	
	PC C12N15/09, C12N5/10, C12N7/00, C12N9/22// (C12N5/10, C12R1:91), PC	
	C12N15/00, (C12N5/00, C12R1:91)	
	CC	
	FH Key Location/Qualifiers	
	FT source 1..17	
	FT Location/Qualifiers	
	1..17	
	/organism="Artificial Sequence".	
	PI JAMES J HOLESEK, ANTHONY J MAMONE	
	PC C12N15/09, C12N5/10, C12N7/00, C12N9/22// (C12N5/10, C12R1:91), PC	
	C12N15/00, (C12N5/00, C12R1:91)	
	CC	
	FH Key Location/Qualifiers	
	FT source 1..17	
	FT Location/Qualifiers	
	1..17	
	/organism="Artificial Sequence".	
	PI JAMES J HOLESEK, ANTHONY J MAMONE	
	PC C12N15/09, C12N5/10, C12N7/00, C12N9/22// (C12N5/10, C12R1:91), PC	
	C12N15/00, (C12N5/00, C12R1:91)	
	CC	
	FH Key Location/Qualifiers	
	FT source 1..17	
	FT Location/Qualifiers	
	1..17	
	/organism="Artificial Sequence".	
	PI JAMES J HOLESEK, ANTHONY J MAMONE	
	PC C12N15/09, C12N5/10, C12N7/00, C12N9/22// (C12N5/10, C12R1:91), PC	
	C12N15/00, (C12N5/00, C12R1:91)	
	CC	
	FH Key Location/Qualifiers	
	FT source 1..17	
	FT Location/Qualifiers	
	1..17	
	/organism="Artificial Sequence".	
	PI JAMES J HOLESEK, ANTHONY J MAMONE	
	PC C12N15/09, C12N5/10, C12N7/00, C12N9/22// (C12N5/10, C12R1:91), PC	
	C12N15/00, (C12N5/00, C12R1:91)	
	CC	
	FH Key Location/Qualifiers	
	FT source 1..17	
	FT Location/Qualifiers	
	1..17	
	/organism="Artificial Sequence".	
	PI JAMES J HOLESEK, ANTHONY J MAMONE	
	PC C12N15/09, C12N5/10, C12N7/00, C12N9/22// (C12N5/10, C12R1:91), PC	
	C12N15/00, (C12N5/00, C12R1:91)	
	CC	
	FH Key Location/Qualifiers	
	FT source 1..17	
	FT Location/Qualifiers	
	1..17	
	/organism="Artificial Sequence".	
	PI JAMES J HOLESEK, ANTHONY J MAMONE	

26-AUG-1992 US 07/936086,18-SEP-1992 US 07/948359 PR
15-OCT-1992 US 07/963322,07-DEC-1992 US 07/987129 PR
07-DEC-1992 US 07/987130,07-DEC-1992 US 07/987133 PI
KENNETH G DRAPER, LEC W DADYKIZ, JAMES A MCSWIGEN, PI DENNIS G
MAYSEJAK,
PI JAMES J HOLESEK, ANTHONY J MAMONE
PC C12N15/09, C12N5/10, C12N7/00//A61K38/43, A61K39/125, A61K39/13,
PC A61K39/135,
PC A61K39/145, A61K39/21, A61K39/23, A61K39/245, A61K39/29, A61K48/00,
PC A61P1/16, A61P31/14, A61P31/16, A61P31/18, A61P31/22, A61P35/02, C12Q1/68, PC
C12N15/09, C12R1/93, C12N15/00, C12N5/00, A61K37/48, C12N15/00, PC
C12R1/93)
CC
FH .key Location/Qualifiers
FT source 1..17
FT /organism='Artificial Sequence'.
1..17
Location/Qualifiers
1..17
/organism='synthetic construct'
/mol_type='genomic RNA'
/db_xref='taxon:32630'
5 c 7 g 2 t
BASE COUNT 3 a 5 c 7 g 2 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
-Db 2279 GGATGCTCCAGAAC 2294
|||
2 GGGTGGCTCCAGAAC 17
RESULT 313
BD067344/c
LOCUS 17 bp RNA linear PAT 27-AUG-2002
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors.
ACCESSION BD067344
BD067344.1 GI:22612947
VERSION JP 2001511003-A/184.
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar, S., Fell, P. and Mcswiggen, J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 184 07-AUG-2001;
RIBOZYME PHARMACEUTICALS INC, ASTON UNIV
COMMENT OS Unidentified
PN JP 2001511003-A/184
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476, 04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR, PATRICIA FELL, JAMES A MCSWIGEN PC
C12N9/00, C07K14/71
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions CC
related to
CC levels of epidermal growth factor receptors
FH key Location/Qualifiers
FT source 1..17
FT /organism='Unidentified'.
1..17
Location/Qualifiers
1..17
/organism='unidentified'
/mol_type='genomic RNA'
/db_xref='taxon:32644'
4 c 3 g 9 t
BASE COUNT 1 a 4 c 3 g 9 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Features
source
1..17
Location/Qualifiers
1..17
/organism='unidentified'
/mol_type='genomic RNA'
/db_xref='taxon:32644'
4 c 3 g 9 t
BASE COUNT 1 a 4 c 3 g 9 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
-Db 1358 CGCCTCGAAGAGAAA 1373
|||
16 CGACTGCAGAGAGAAA 1
RESULT 314
BD067486
LOCUS 17 bp RNA linear PAT 27-AUG-2002
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors.
ACCESSION BD067486
BD067486.1 GI:22613089
VERSION JP 2001511003-A/326.
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar, S., Fell, P. and Mcswiggen, J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 326 07-AUG-2001;
RIBOZYME PHARMACEUTICALS INC, ASTON UNIV
COMMENT OS Unidentified
PN JP 2001511003-A/326
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476, 04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR, PATRICIA FELL, JAMES A MCSWIGEN PC
C12N9/00, C07K14/71
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions CC
related to
CC levels of epidermal growth factor receptors
FH key Location/Qualifiers
FT source 1..17
FT /organism='Unidentified'.
1..17
Location/Qualifiers
1..17
/organism='unidentified'
/mol_type='genomic RNA'
/db_xref='taxon:32644'
4 a 2 c 6 g 5 t
BASE COUNT 4 a 2 c 6 g 5 t
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
-Db 2233 AGTATGCTGCTGCT 2338
|||
1 AGTATGCTGCTGACT 16
RESULT 315
BD104906/c
LOCUS 17 bp DNA linear PAT 27-AUG-2002
DEFINITION Kit and method for determining HLA type.
ACCESSION BD104906
BD104906.1 GI:22650480
VERSION WO 0192572-A/1010.
KEYWORDS WO 0192572-A/1010.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 17)
AUTHORS Inoko, H., Kagiya, T., Ichihara, T., Matsumura, Y., Moriya, S. and
Nishida, M.
TITLE Kit and method for determining HLA type
JOURNAL Patent: WO 0192572-A 1010 06-DEC-2001;
NISHINO INDUSTRIES INC, SYSTEM RESEARCH INC, HIDEOTOSHI INOKO, TAEKO
KAGIYA, TATSUO ICHIHARA, YOSHIYUKI MATSUMURA, SHOGO MORIYA, MICHIO

COMMENT NISHIDA
OS Artificial Sequence
PN WO 0192572-A/1010
PD 06-DEC-2001
PF 01-JUN-2001 WO 2001JP004662
PR 01-JUN-2000 JP 00P 164798
PI HIDEOSHI INOKO, TAEKO KAGIYA, TATSUO ICHIHARA, YOSHIYUKI PI
MATSUDURA,
PI SHOJO MORIYA, MICHIO NISHIDA
PC C12Q1/68, C12M1/00, C12N15/09, G01N33/53
CC Description of Artificial Sequence: capture
FH Key
FT source 1. .17
/organism='Artificial Sequence'.
Location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

BASE COUNT 2 a 8 c 3 g 4 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2391 GATTCCTCGAGGAA 2406
Db 17 GGTAACCGTGAGGAA 2

RESULT 316
LOCUS 107297 17 bp DNA linear PAT 02-DEC-1994
DEFINITION Sequence 9 from Patent EP 0339009.
ACCESSION 107297
VERSION 107297.1 GI:589899
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Fuchs, R.L., Kishore, G.M. and MacIntosh, S.C.
TITLE Method for improving the efficacy of insect toxins
JOURNAL Patent: EP 0339009-A2 9 25-OCT-1989;
FEATURES
source 1. .17
Location/Qualifiers
/organism="unknown"

BASE COUNT 7 a 7 c 2 g 1 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1585 ATGAACCTCCACACCC 1600
Db 1 ATGAACCTCCACACCC 16

RESULT 317
LOCUS 129872 17 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 23 from patent US 5578462.
ACCESSION 129872
VERSION 129872.1 GI:1820663
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Seizinger, B.R., Kley, N.A. and Bianchi, A.B.
TITLE NF2 isoforms
JOURNAL Patent: US 5578462-A 23 26-NOV-1996;
FEATURES
Location/Qualifiers

source 1. .17
/organism="unknown"

BASE COUNT 6 a 1 c 7 g 3 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1579 TCCTCCATGAAGTCCA 1594
Db 17 TTCCTCATGTAAGTCCA 2

RESULT 318
LOCUS 137681 17 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 694 from patent US 5612215.
ACCESSION 137681
VERSION 137681.1 GI:2085641
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper, K.G., Pavco, P., McSwiggen, J., Gustofson, J. and
Stinchcomb, D.T.
TITLE Stromelysin targeted ribozymes
JOURNAL Patent: US 5612215-A 694 18-MAR-1997;
FEATURES
source 1. .17
Location/Qualifiers
/organism="unknown"

BASE COUNT 5 a 4 c 6 g 2 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1694 GGGAGTTTCCACAGCA 1709
Db 2 GGGAGTTTCCACAGCA 17

RESULT 319
LOCUS 137682 17 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 695 from patent US 5612215.
ACCESSION 137682
VERSION 137682.1 GI:2085642
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper, K.G., Pavco, P., McSwiggen, J., Gustofson, J. and
Stinchcomb, D.T.
TITLE Stromelysin targeted ribozymes
JOURNAL Patent: US 5612215-A 695 18-MAR-1997;
FEATURES
source 1. .17
Location/Qualifiers
/organism="unknown"

BASE COUNT 4 a 5 c 6 g 2 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1694 GGGAGTTTCCACAGCA 1709
Db 1 GGGAGTTTCCACAGCA 16

RESULT 320
LOCUS 152675 17 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 695 from patent US 5612215.
ACCESSION 152675
VERSION 152675.1 GI:2085642
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper, K.G., Pavco, P., McSwiggen, J., Gustofson, J. and
Stinchcomb, D.T.
TITLE Stromelysin targeted ribozymes
JOURNAL Patent: US 5612215-A 695 18-MAR-1997;
FEATURES
source 1. .17
Location/Qualifiers
/organism="unknown"

```

LOCUS      152675                      17 bp   DNA          linear   PAT 07-OCT-1997
DEFINITION Sequence 416 from patent US 5646042.
ACCESSION  152675
VERSION    152675.1  GI:2473876
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE     C-myb targeted ribozymes
JOURNAL   Patent: US 5646042-A 416 08-JUL-1997;
FEATURES   Location/Qualifiers
SOURCE     1..17
            /organism="unknown"

BASE COUNT      2 a      8 c      3 g      4 t

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1866  GGTGTCAAGATGGAG 1881
Db      16  GCTGCGAGAGATGGAG 1

RESULT 321
LOCUS      152793                      17 bp   DNA          linear   PAT 07-OCT-1997
DEFINITION Sequence 534 from patent US 5646042.
ACCESSION  152793
VERSION    152793.1  GI:2473994
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE     C-myb targeted ribozymes
JOURNAL   Patent: US 5646042-A 534 08-JUL-1997;
FEATURES   Location/Qualifiers
SOURCE     1..17
            /organism="unknown"

BASE COUNT      7 a      7 c      1 g      2 t

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1584  CATGAAGCTCCACAC 1599
Db      1  CAAGAACTCTCAAC 16

RESULT 322
LOCUS      153373                      17 bp   DNA          linear   PAT 07-OCT-1997
DEFINITION Sequence 1114 from patent US 5646042.
ACCESSION  153373
VERSION    153373.1  GI:2474576
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE     C-myb targeted ribozymes
JOURNAL   Patent: US 5646042-A 1114 08-JUL-1997;
FEATURES   Location/Qualifiers
SOURCE     1..17
            /organism="unknown"

BASE COUNT      1 a      0 c      4 g      12 t

```

```

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2240  ATTACAAAAGACAC 2255
Db      17  ATTAACAAAAGACAC 2

RESULT 323
LOCUS      153375                      17 bp   DNA          linear   PAT 07-OCT-1997
DEFINITION Sequence 1116 from patent US 5646042.
ACCESSION  153375
VERSION    153375.1  GI:2474578
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE     C-myb targeted ribozymes
JOURNAL   Patent: US 5646042-A 1116 08-JUL-1997;
FEATURES   Location/Qualifiers
SOURCE     1..17
            /organism="unknown"

BASE COUNT      1 a      0 c      4 g      12 t

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2240  ATTACAAAAGACAC 2255
Db      16  ATTAACAAAAGACAC 1

RESULT 324
LOCUS      154682                      17 bp   DNA          linear   PAT 07-OCT-1997
DEFINITION Sequence 2423 from patent US 5646042.
ACCESSION  154682
VERSION    154682.1  GI:2475885
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE     C-myb targeted ribozymes
JOURNAL   Patent: US 5646042-A 2423 08-JUL-1997;
FEATURES   Location/Qualifiers
SOURCE     1..17
            /organism="unknown"

BASE COUNT      6 a      7 c      2 g      2 t

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1584  CATGAAGCTCCACAC 1599
Db      1  CAAGAACTCTCAAC 16

RESULT 325
LOCUS      194531                      17 bp   DNA          linear   PAT 01-DEC-1998
DEFINITION Sequence 694 from patent US 5731295.
ACCESSION  194531
VERSION    194531.1  GI:3939001
KEYWORDS
SOURCE     Unknown.

```

```

ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
          Stinchcomb,D.T.
TITLE Method of reducing stromelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 694 24-MAR-1998;
FEATURES Location/Qualifiers
          source
            1..17
              /organism="unknown"
BASE COUNT 5 a 4 c 6 g 2 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1694 GGGAGTTTCCAAGACA 1709
Db 2 GGGAGCTTCCAAGACA 17

RESULT 326
LOCUS 194532 17 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 695 from patent US 5731295.
ACCESSION 194532
VERSION 194532.1 GI:3939002
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
          Stinchcomb,D.T.
TITLE Method of reducing stromelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 695 24-MAR-1998;
FEATURES Location/Qualifiers
          source
            1..17
              /organism="unknown"
BASE COUNT 4 a 5 c 6 g 2 t

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1694 GGGAGTTTCCAAGACA 1709
Db 1 GGGAGCTTCCAAGACA 16

RESULT 327
LOCUS ARI05805 14 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 75 from patent US 6103244.
ACCESSION ARI05805
VERSION ARI05805.1 GI:12819870
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 14)
AUTHORS Dörner,F., Schneiflinger,F., Falkner,F.,Günter, and Pfeleiderer,M.
TITLE Methods for generating immune responses employing modified vaccinia
          of fowlpox viruses
JOURNAL Patent: US 6103244-A 75 15-AUG-2000;
FEATURES Location/Qualifiers
          source
            1..14
              /organism="unknown"
BASE COUNT 3 a 4 c 5 g 2 t

Query Match 0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

OY 1811 CCGTGGCCGTGAAG 1824
Db 1 CCATGGCCGTGAAG 14

RESULT 328
LOCUS AR214947 14 bp RNA linear PAT 25-SEP-2002
DEFINITION Sequence 3 from patent US 6410241.
ACCESSION AR214947
VERSION AR214947.1 GI:23312902
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 14)
AUTHORS Sykes,K.F. and Johnston,S.A.
TITLE Methods of screening open reading frames to determine whether they
          encode polypeptides with an ability to generate an immune response
JOURNAL Patent: US 6410241-A 3 25-JUN-2002;
FEATURES Location/Qualifiers
          source
            1..14
              /organism="unknown"
BASE COUNT 5 a 0 c 4 g 5 t

Query Match 0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1882 ATGATGAAGATGAT 1895
Db 1 ATGATGATGATGAT 14

RESULT 329
LOCUS AR214949 14 bp RNA linear PAT 25-SEP-2002
DEFINITION Sequence 5 from patent US 6410241.
ACCESSION AR214949
VERSION AR214949.1 GI:23312904
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 14)
AUTHORS Sykes,K.F. and Johnston,S.A.
TITLE Methods of screening open reading frames to determine whether they
          encode polypeptides with an ability to generate an immune response
JOURNAL Patent: US 6410241-A 5 25-JUN-2002;
FEATURES Location/Qualifiers
          source
            1..14
              /organism="unknown"
BASE COUNT 5 a 4 c 0 g 5 t

Query Match 0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1882 ATGATGAAGATGAT 1895
Db 1 ATGATGATGATGAT 1

RESULT 330
LOCUS BD123479 14 bp DNA linear PAT 18-SEP-2002
DEFINITION Photoregulatory adenylate cyclase and DNA.
ACCESSION BD123479
VERSION BD123479.1 GI:23218424
KEYWORDS JP 2002017374-A/5.
SOURCE synthetic construct
ORGANISM synthetic construct

```

artificial sequences.
REFERENCE 1 (bases 1 to 14)
AUTHORS Iseki, M. and Watanabe, M.
TITLE Photoregulatory adenylate cyclase and DNA
JOURNAL Patent: JP 2002017374-A 5 22-JAN-2002;
MINEO ISEKI, MASAKATSU WATANABE
COMMENT OS Artificial Sequence
PN JP 2002017374-A/5
PD 22-JAN-2002
PF 03-JUL-2000 JP 2000240426
PI MINEO ISEKI, MASAKATSU WATANABE
PC C12N15/09, C12N9/88, C12R1:89, C12N15/00 CC
Designed oligonucleotide to act as a primer for reverse CC
transcription.
FH Key location/Qualifiers
FT source 1..14
Location/Qualifiers
1..14
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
BASE COUNT 3 a 1 c 6 g 4 t

Query Match 0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2345 TGTTAATGTGGAG 2358
Db 1 TGTCAATGTGGAG 14

RESULT 331
LOCUS A12791 15 bp DNA linear PAT 28-APR-1994
DEFINITION oligonucleotide from clone PHD 119.
ACCESSION A12791
VERSION A12791.1 GI:512655
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
FEATURES
REFERENCE 1 (bases 1 to 15)
AUTHORS
TITLE A DNA SEQUENCE
JOURNAL Patent: WO 8605804-A 22 09-OCT-1986;
FEATURES Location/Qualifiers
source 1..15
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
BASE COUNT 3 a 3 c 6 g 3 t

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1497 CTTGAGCAGCCAGC 1510
Db 15 CTTGAGCAGCCATC 2

RESULT 332
LOCUS A40008 15 bp DNA linear PAT 05-MAR-1997
DEFINITION Sequence 13 from Patent WO9423047.
ACCESSION A40008
VERSION A40008.1 GI:2296192
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
COMMENT unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Guest, P.J., Windass, J.D., Sumner, M. and Barley, F.G.
TITLE BIOLOGICAL CONTROL AGENTS CONTAINING MOLLUSC TOXINS
JOURNAL Patent: WO 9423047-A 13 13-OCT-1994;
ZENECA LTD (GB)
COMMENT Other publication AU 6432694 941024
Other publication GB 2276622 941005
Other publication BR 9406500 960102.
FEATURES Location/Qualifiers
source 1..15
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 3 a 3 c 3 g 6 t

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2166 TGTTCGTACAG 2179
Db 2 TGTTCGTACAG 15

RESULT 333
LOCUS A46520 15 bp DNA linear PAT 07-MAR-1997
DEFINITION Sequence 13 from Patent WO9526410.
ACCESSION A46520
VERSION A46520.1 GI:2300692
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
FEATURES
REFERENCE 1 (bases 1 to 15)
AUTHORS Windass, J.D.
TITLE BIOLOGICAL INSECT CONTROL AGENT
JOURNAL Patent: WO 9526410-A 13 05-OCT-1995;
ZENECA LTD (GB)
COMMENT Other publication AU 1957095 951017.
FEATURES Location/Qualifiers
source 1..15
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 3 a 3 c 3 g 6 t

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2166 TGTTCGTACAG 2179
Db 2 TGTTCGTACAG 15

RESULT 334
LOCUS A64369 15 bp DNA linear PAT 29-MAR-1999
DEFINITION Sequence 157 from Patent WO9727332.
ACCESSION A64369
VERSION A64369.1 GI:3717800
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
FEATURES
REFERENCE 1
AUTHORS Scuyver, L., Louwagie, J. and Rossau, R.
TITLE METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE
JOURNAL TRANSCRIPTASE GENE
PATENT: WO 9727332-A 157 31-JUL-1997;
INNOGENETICS NV (BE)
COMMENT Other publication AU 1444397 19970820.

```

FEATURES
  source
    location/Qualifiers
    1..15
    /organism="unidentified"
    /mol_type="genomic DNA"
    /db_xref="taxon:32644"
BASE COUNT      8 a      5 c      1 g      1 t

Query Match
  Best Local Similarity 92.9%; Score 12.4; DB 1; Length 15;
  Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1856 TTTCGATCTGCTG 1869
Db 14 TTTTGATCTGCTG 1

RESULT 335
AR028988/c 15 bp DNA linear PAT 29-SEP-1999
LOCUS
DEFINITION Sequence 27 from patent US 5858981.
ACCESSION AR028988
VERSION AR028988.1 GI:5940961
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 15)
  Schreiber,A.D. and Park,J.-G.
  TITLE
  Method of inhibiting phagocytosis
  JOURNAL
  Patent: US 5858981-A 27 12-JAN-1999;
  FEATURES
    location/Qualifiers
    1..15
    /organism="unknown"
BASE COUNT      0 a      3 c      3 g      9 t

Query Match
  Best Local Similarity 92.9%; Score 12.4; DB 1; Length 15;
  Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1783 GACAAAGACAAAGCC 1796
Db 15 GACAAAGACAAAGAC 2

RESULT 336
AR028992/c 15 bp DNA linear PAT 29-SEP-1999
LOCUS
DEFINITION Sequence 31 from patent US 5858981.
ACCESSION AR028992
VERSION AR028992.1 GI:5940965
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 15)
  Schreiber,A.D. and Park,J.-G.
  TITLE
  Method of inhibiting phagocytosis
  JOURNAL
  Patent: US 5858981-A 31 12-JAN-1999;
  FEATURES
    location/Qualifiers
    1..15
    /organism="unknown"
BASE COUNT      0 a      3 c      3 g      9 t

Query Match
  Best Local Similarity 92.9%; Score 12.4; DB 1; Length 15;
  Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1783 GACAAAGACAAAGCC 1796
Db 15 GACAAAGACAAAGAC 2

RESULT 337

```

```

AR102668/c 15 bp DNA linear PAT 14-FEB-2001
LOCUS
DEFINITION Sequence 157 from patent US 6087093.
ACCESSION AR102668
VERSION AR102668.1 GI:12814256
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 15)
  Lieven,S., Joost,L. and Rudi,R.
  TITLE
  Method for detection of drug-induced mutations in the reverse
  transcriptase gene
  JOURNAL
  Patent: US 6087093-A 157 11-JUL-2000;
  FEATURES
    location/Qualifiers
    1..15
    /organism="unknown"
BASE COUNT      8 a      5 c      1 g      1 t

Query Match
  Best Local Similarity 92.9%; Score 12.4; DB 1; Length 15;
  Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1856 TTTCGATCTGCTG 1869
Db 14 TTTTGATCTGCTG 1

RESULT 338
AR133690/c 15 bp DNA linear PAT 16-MAY-2001
LOCUS
DEFINITION Sequence 2115 from patent US 6194150.
ACCESSION AR133690
VERSION AR133690.1 GI:14122595
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 15)
  Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  TITLE
  Nucleic acid based inhibition of CD40
  JOURNAL
  Patent: US 6194150-A 2115 27-FEB-2001;
  FEATURES
    location/Qualifiers
    1..15
    /organism="unknown"
BASE COUNT      2 a      7 c      1 g      5 t

Query Match
  Best Local Similarity 92.9%; Score 12.4; DB 1; Length 15;
  Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1887 GAAGATGATGGGA 1900
Db 14 GAAGTATGATGGGA 1

RESULT 339
AR156870/c 15 bp DNA linear PAT 08-AUG-2001
LOCUS
DEFINITION Sequence 27 from patent US 6242427.
ACCESSION AR156870
VERSION AR156870.1 GI:15125574
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 15)
  Schreiber,A.D. and Park,J.-G.
  TITLE
  Methods of inhibiting phagocytosis
  JOURNAL
  Patent: US 6242427-A 27 05-JUN-2001;
  FEATURES
    location/Qualifiers
    1..15
    /organism="unknown"

```

```
BASE COUNT      0 a      3 c      3 g      9 t
Query Match      0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1783 GACAAAGCAGAGCC 1796
      |||||
      15 GACAAAGCAGAGAC 2

RESULT 340
LOCUS      AR156874      15 bp      DNA      linear      PAT 08-AUG-2001
DEFINITION      Sequence 31 from patent US 6242427.
ACCESSION      AR156874
VERSION      AR156874.1 GI:15125578
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 15)
AUTHORS      Schreiber,A.D. and Park,J.-G.
TITLE      Methods of inhibiting phagocytosis
JOURNAL      Patent: US 6242427-A 31 05-JUN-2001;
FEATURES
      source
      1..15
      /organism="unknown"

BASE COUNT      0 a      3 c      3 g      9 t
Query Match      0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1783 GACAAAGCAGAGCC 1796
      |||||
      15 GACAAAGCAGAGAC 2

Db

RESULT 341
LOCUS      AR192985      15 bp      DNA      linear      PAT 20-APR-2002
DEFINITION      Sequence 8473 from patent US 6346398.
ACCESSION      AR192985
VERSION      AR192985.1 GI:20238950
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 15)
AUTHORS      Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE      Method and reagent for the treatment of diseases or conditions
      related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6346398-A 8473 12-FEB-2002;
FEATURES
      source
      1..15
      /organism="unknown"

BASE COUNT      9 a      0 c      3 g      3 t
Query Match      0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1822 AAGATGTTGAAAGA 1835
      |||||
      1 AAAATGTTGAAAGA 14

Db

RESULT 342
LOCUS      AR262971      15 bp      DNA      linear      PAT 29-JAN-2003
DEFINITION      Sequence 157 from patent US 6331389.
ACCESSION      AR262971
```

```
VERSION      AR262971.1 GI:28074674
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 15)
AUTHORS      Lieven,S., Joost,L. and Rudi,R.
TITLE      Method for detection of drug-induced mutations in the reverse
      transcriptase gene
JOURNAL      Patent: US 6331389-A 157 18-DEC-2001;
FEATURES
      source
      1..15
      /organism="unknown"

BASE COUNT      8 a      5 c      1 g      1 t
Query Match      0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1856 TTTCGATCTGCTG 1869
      |||||
      14 TTTTGTATCTGCTG 1

Db

RESULT 343
LOCUS      AX598512      15 bp      DNA      linear      PAT 14-FEB-2003
DEFINITION      Sequence 786 from Patent WO0244994.
ACCESSION      AX598512
VERSION      AX598512.1 GI:28398690
KEYWORDS
SOURCE      synthetic construct
ORGANISM      synthetic construct
      artificial sequences.
REFERENCE      1
AUTHORS      Brower,A., Brow,M.A., Cracauer,R.F., Fors,L., Granske,R., de arruda
      Indig,M., Kurenky,D., Luedtke,C., Lukowiak,A.A., Lyamichev,V.,
      Neri,B.P., Reimer,N.D., Roeven,R.T., Skrzypczynski,Z., Ziarno,W.A.,
      Comerford,J., Stump,S. and Viegut,D.D.
      Systems and method for detection assay production and sale
      Patent: WO 0244994-A 786 06-JUN-2002;
      THIRD WAVE TECHNOLOGIES, INC. (US)
      Location/Qualifiers
      1..15
      /organism="synthetic construct"
      /mol_type="genomic DNA"
      /db_xref="taxon:32630"

BASE COUNT      3 a      4 c      5 g      3 t
Query Match      0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1397 ACCTGGAGATGACC 1410
      |||||
      15 ACCTGGATGATGCC 2

Db

RESULT 344
LOCUS      AX598514      15 bp      DNA      linear      PAT 14-FEB-2003
DEFINITION      Sequence 788 from Patent WO0244994.
ACCESSION      AX598514
VERSION      AX598514.1 GI:28398692
KEYWORDS
SOURCE      synthetic construct
ORGANISM      synthetic construct
      artificial sequences.
REFERENCE      1
AUTHORS      Brower,A., Brow,M.A., Cracauer,R.F., Fors,L., Granske,R., de arruda
      Indig,M., Kurenky,D., Luedtke,C., Lukowiak,A.A., Lyamichev,V.,
      Neri,B.P., Reimer,N.D., Roeven,R.T., Skrzypczynski,Z., Ziarno,W.A.,
      Comerford,J., Stump,S. and Viegut,D.D.
```



```
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2281 ATGGCTCAGAAC 2234
Db 15 ATGGCTCAGAAC 2

RESULT 348
LOCUS 177589 15 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 296 from patent US 5693532.
ACCESSION 177589
VERSION 177589.1 GI:3013743
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 15)
McSwiggen,J., Draper,K., Pavco,P. and Woolf,T.
TITLE Respiratory syncytial virus ribozymes
JOURNAL Patent: US 5693532-A 296 02-DEC-1997;
FEATURES
Source Location/Qualifiers
1..15
/organism="unknown"

BASE COUNT 8 a 3 c 1 g 3 t

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2237 ACTATTACAAAG 2250
Db 2 ACTATTACAAAG 15

RESULT 349
LOCUS AR054087 16 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 14 from patent US 5834440.
ACCESSION AR054087
VERSION AR054087.1 GI:5978949
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 16)
Goldenberg,T. and Tritz,R.
TITLE Ribozyme therapy for the inhibition of restenosis
JOURNAL Patent: US 5834440-A 14 10-NOV-1998;
FEATURES
Source Location/Qualifiers
1..16
/organism="unknown"

BASE COUNT 4 a 4 c 1 g 7 t

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2169 TTGTGTACAGAA 2182
Db 14 TTGTGTACAGAA 1

RESULT 350
LOCUS AX132931 16 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 4149 from Patent WO0130362.
ACCESSION AX132931
VERSION AX132931.1 GI:14139241
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2281 ATGGCTCAGAAC 2234
Db 15 ATGGCTCAGAAC 2

RESULT 348
LOCUS 177589 15 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 296 from patent US 5693532.
ACCESSION 177589
VERSION 177589.1 GI:3013743
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 15)
McSwiggen,J., Draper,K., Pavco,P. and Woolf,T.
TITLE Respiratory syncytial virus ribozymes
JOURNAL Patent: US 5693532-A 296 02-DEC-1997;
FEATURES
Source Location/Qualifiers
1..15
/organism="unknown"

BASE COUNT 8 a 3 c 1 g 3 t

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2237 ACTATTACAAAG 2250
Db 2 ACTATTACAAAG 15

RESULT 349
LOCUS AR054087 16 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 14 from patent US 5834440.
ACCESSION AR054087
VERSION AR054087.1 GI:5978949
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 16)
Goldenberg,T. and Tritz,R.
TITLE Ribozyme therapy for the inhibition of restenosis
JOURNAL Patent: US 5834440-A 14 10-NOV-1998;
FEATURES
Source Location/Qualifiers
1..16
/organism="unknown"

BASE COUNT 4 a 4 c 1 g 7 t

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2169 TTGTGTACAGAA 2182
Db 14 TTGTGTACAGAA 1

RESULT 352
LOCUS AX320908 16 bp DNA linear PAT 14-DEC-2001
DEFINITION Sequence 29 from Patent WO0179272.
ACCESSION AX320908
VERSION AX320908.1 GI:17902457
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1
Tian,H., Schultz,J. and Shan,B.
TITLE Site-specific ribozyme gene (ssg): compositions and methods
of use
```

JOURNAL Patent: WO 0179272-A 29 25-OCT-2001;

Tularik Inc. (US)

FEATURES

SOURCE

Location/Qualifiers
1. 16

/organism="Homo sapiens"
/mol_type="genomic DNA"

/db_xref="taxon:9606"

/note="5' splicing site for exon 6"

3 a 3 c 6 g 4 t

BASE COUNT

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1649 TGCTGGCAGGGGTC 1662

Db 1 TGCTGGCAGAGGTC 14

RESULT 353

AX708809/c

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

FEATURES

SOURCE

BASE COUNT

Query Match

Best Local Similarity

Matches

Matches

OY

Db

1979 AAGCAACTCCGA 1992

16 AAGCCACTCCGA 3

Search completed: December 1, 2003, 11:51:24

Job time : 6 secs

0.9%; Score 12.4; DB 1; Length 16;

92.9%; Pred. No. 2e+02;

0; Mismatches 1; Indels 0; Gaps 0;

1649 TGCTGGCAGGGGTC 1662

1 TGCTGGCAGAGGTC 14

AX708809

Sequence 25 from Patent WO2095071.

AX708809

AX708809.1 GI:29564536

synthetic construct

synthetic construct

artificial sequences.

1

Plasterk, R.H.

Means and methods for identifying genes and proteins involved in

the prevention and/or repair of a replication error

Patent: WO 02095071-A 25 28-NOV-2002;

Koninklijke Nederlandse Akademie van Wetenschappen (NL)

Location/Qualifiers

1. 16

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

/note="unc-93 (e1500) mutation in C. elegans msh-6"

1 a 4 c 7 g 4 t

Query Match

Best Local Similarity

Matches

Matches

OY

Db

1979 AAGCAACTCCGA 1992

16 AAGCCACTCCGA 3

Search completed: December 1, 2003, 11:51:24

Job time : 6 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model1

Run on: December 1, 2003, 11:54:59 ; Search time 6 Seconds
(without alignments)
3.781 Million cell updates/sec

Title: us-09-954-556-3

Perfect score: 1404
Sequence: 1 tgggatactccttcactctg.....cctcagratcacacataaa 1404

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 468 seqs, 8078 residues

Total number of hits satisfying chosen parameters: 936

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 468 summaries

Database : rng.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	ID	Description
1	25.8	1.8	30 1	AAQ13309
2	23.6	1.7	31 1	AAFS8623
3	22.4	1.6	28 1	AAV44045
4	21.4	1.5	25 1	AAV05314
5	21.4	1.5	27 1	AAQ52728
6	21	1.5	21 1	AAV63286
7	21	1.5	21 1	AAV05498
8	20	1.4	20 1	AAV34892
9	20	1.4	20 1	AAV00032
10	18.8	1.3	22 1	AAV84432
11	18.8	1.3	22 1	AAV80714
12	18.8	1.3	23 1	AAH23018
13	18.6	1.3	23 1	ABX90509
14	18.6	1.3	20 1	AAV95390
15	18.4	1.3	20 1	AAV60732
16	18.2	1.3	24 1	AAQ33179
17	18.2	1.3	24 1	AAV95598
18	18.2	1.3	24 1	AAV56500
19	18.2	1.3	24 1	AAV96613
20	18.2	1.3	24 1	AAV93502
21	18.2	1.3	24 1	AAV67171
22	17.8	1.3	21 1	AAV60725
23	17.8	1.3	21 1	AAZ18094
24	17.8	1.3	21 1	AAZ18102
25	17.8	1.3	21 1	AAZ18110
26	17.8	1.3	21 1	AAZ18118
27	17.8	1.3	21 1	AAZ18216
28	17.4	1.2	19 1	AAV82640
29	17.4	1.2	19 1	AAV82641
30	17.4	1.2	19 1	AAH57802
31	17.4	1.2	19 1	AAH57803
32	17.2	1.2	22 1	ABV78766
33	17	1.2	20 1	AAZ18107

34	17	1.2	20 1	AAZ18109	PTK 10 gene specif
35	17	1.2	20 1	AAZ18111	PTK 11 gene specif
36	17	1.2	20 1	AAZ18113	PTK 12 gene specif
37	17	1.2	20 1	AAZ18189	PTK 31 gene specif
38	17	1.2	20 1	AAZ18191	PTK 32 gene specif
39	17	1.2	20 1	AAZ18187	PTK 30 gene specif
40	17	1.2	20 1	AAZ29362	JNK3-specific prob
41	17	1.2	20 1	AAV62905	JNK antisense olig
42	17	1.2	22 1	AAV00049	PCR PCR sense pri
43	16.8	1.2	20 1	AAV34894	PCR primer used to
44	16.8	1.2	20 1	AAV95391	Rat FGFR coding se
45	16.8	1.2	20 1	AAAD41768	Human REC02 antis
46	16.8	1.2	21 1	AAV30118	PCR primer used fo
47	16.4	1.2	20 1	AAV92592	Human nucleolin ph
48	16.4	1.2	21 1	AAV59328	Human STR2 exon 7
49	16.2	1.2	21 1	AAV37791	Staphylococcus sp.
50	16	1.1	19 1	AAV52215	Neuroblastoma spec
51	15.8	1.1	19 1	AAV82642	cdk2 ribozyme bind
52	15.8	1.1	19 1	AAV57804	Cell-cycle depende
53	15.8	1.1	20 1	AAV07940	Mannose binding pr
54	15.8	1.1	20 1	AAV07637	HERG gene exon 7/i
55	15.8	1.1	20 1	AAV96638	Telomerase reverse
56	15.8	1.1	21 1	AAV97467	Human diazepam bin
57	15.8	1.1	21 1	AAV97555	Human epoxide hydr
58	15.8	1.1	21 1	AAV084277	Beta-actin Tagman
59	15.4	1.1	17 1	AAV74847	Mouse flt-1 VEGF r
60	15.4	1.1	17 1	AAV96481	Potato citrate syn
61	15.4	1.1	18 1	AAV081992	Kaposi's Sarcoma T
62	15.4	1.1	19 1	AAV60990	Tomato TDE11 gene
63	15.4	1.1	19 1	AAV71996	Human MTC16 gene,
64	15.4	1.1	20 1	AAV31581	3' PCR primer for
65	15.4	1.1	20 1	AAV69511	Intestinal bacteri
66	15.4	1.1	20 1	AAV20838	C. perfringens det
67	15.4	1.1	20 1	AAV97941	Murine Sact1 gene-s
68	15.2	1.1	20 1	AAV62462	HEK-2 receptor pri
69	15.2	1.1	20 1	AAV64159	Primer for amplify
70	15.2	1.1	20 1	AAV38287	Degenerate PCR pri
71	15.2	1.1	20 1	AAV01150	Homeobox 7 PCR pri
72	15.2	1.1	20 1	AAV01155	c-Kit protooncogen
73	15.2	1.1	20 1	AAV218093	PTK 2 gene specif
74	15.2	1.1	20 1	AAV218095	PTK 3 gene specif
75	15.2	1.1	20 1	AAV218097	PTK 4 gene specif
76	15.2	1.1	20 1	AAV218099	PTK 5 gene specif
77	15.2	1.1	20 1	AAV218101	PTK 6 gene specif
78	15.2	1.1	20 1	AAV218103	PTK 7 gene specif
79	15.2	1.1	20 1	AAV218105	PTK 8 gene specif
80	15.2	1.1	20 1	AAV218091	PTK 1 gene specif
81	15.2	1.1	20 1	AAV218185	PTK 28 gene specif
82	15.2	1.1	20 1	AAV218183	PTK 27 gene specif
83	15.2	1.1	20 1	AAV218181	PTK 26 gene specif
84	15.2	1.1	20 1	AAV95953	PCR primer used to
85	15.2	1.1	20 1	AAV622008	PCR primer used to
86	15.2	1.1	20 1	AAV08729	Human PD-ABC form
87	15.2	1.1	20 1	AAV088820	Human PD-ABC form
88	15.2	1.1	20 1	ABZ72168	Gene 216 SSCP dete
89	15.2	1.1	20 1	ABT06120	Human 11ght chain
90	15.2	1.1	20 1	ABK53119	HIV-1 protease gen
91	15.2	1.1	20 1	AAV34736	Human MEK3 CDNA t
92	15.2	1.1	20 1	AAV45481	HIV-1 pol gene pro
93	15.2	1.1	20 1	ABV75021	Human gene 216 pol
94	15	1.1	15 1	AAV65311	Mouse B7-2 hammerh
95	15	1.1	15 1	AAV66312	Mouse B7-2 hammerh
96	15	1.1	15 1	AAV66313	Mouse B7-2 hammerh
97	15	1.1	15 1	AAV52668	IGF-1 oligonucleot
98	15	1.1	15 1	AAV52669	IGF-1 oligonucleot
99	15	1.1	15 1	AAV52670	IGF-1 oligonucleot
100	15	1.1	20 1	AAV47315	Human RT-PCR rever
101	14.8	1.1	18 1	AAV60744	Primer #2 for huma
102	14.8	1.1	18 1	AAV48792	Human G-alpha-16 a
103	14.8	1.1	18 1	AAV75270	Human inducible NO
104	14.8	1.1	18 1	AAH25370	Antisense oligonuc
105	14.8	1.1	19 1	AAV85911	Cdc 25 hs ribozyme
106	14.8	1.1	19 1	AAV85912	Cdc 25 hs ribozyme

107	14.8	1.1	19	1	AAH61073	Cdc25 hs ribozyme
108	14.8	1.1	19	1	AAH61074	Cdc25 hs ribozyme
109	14.6	1.0	17	1	AAQ49761	Membrane serine/th
110	14.6	1.0	17	1	AAQ49762	Transforming growth
111	14.6	1.0	18	1	AAH40382	SNR specific lower
112	14.4	1.0	16	1	AAH6213	Antisense oligo ta
113	14.4	1.0	16	1	AAH90307	Oligonucleotide RT
114	14.4	1.0	16	1	AAH29601	Human fibroblast g
115	14.4	1.0	16	1	AAH61977	IL-1 beta hairpin/
116	14.4	1.0	17	1	AAH72965	Mouse flk-1 VEGF r
117	14.4	1.0	17	1	AAH18888	Human TIE-2 subscr
118	14.4	1.0	17	1	AAH08382	Human GDMLP-1 17-m
119	14.4	1.0	17	1	AAH08383	Human GDMLP-1 17-m
120	14.4	1.0	17	1	AAH09009	Human GDMLP-1 17-m
121	14.4	1.0	17	1	AAH09010	Human GDMLP-1 17-m
122	14.4	1.0	17	1	AAH261957	Human H-Ras DNAsym
123	14.4	1.0	18	1	AAH241119	Human G-alpha-11 p
124	14.4	1.0	18	1	AAH219490	Human G-alpha-11 p
125	14.4	1.0	18	1	AAH49070	Wild-type pRFP03.
126	14	1.0	15	1	AAH76258	Human IL6 receptor
127	14	1.0	15	1	AAH54048	Human IL-6 recepto
128	14	1.0	15	1	AAH19614	Human IL6 receptor
129	14	1.0	15	1	AAH33492	Low adenosine anti
130	14	1.0	15	1	AAH290843	Human NR8 gene pro
131	14	1.0	15	1	AAH52667	IGF-1 oligonucleot
132	14	1.0	15	1	AAH52671	IGF-1 oligonucleot
133	14	1.0	17	1	AAH95775	Human Chk1 ribozym
134	14	1.0	17	1	AAH95776	Human Chk1 ribozym
135	14	1.0	17	1	AAH95777	Human Chk1 ribozym
136	14	1.0	17	1	AAH06896	Human GDMLP-1 17-m
137	14	1.0	17	1	AAH06897	Human GDMLP-1 17-m
138	14	1.0	17	1	AAH06898	Human GDMLP-1 17-m
139	14	1.0	17	1	AAH06899	Human GDMLP-1 17-m
140	13.8	1.0	17	1	AAQ24060	Artificial HIV-1 T
141	13.8	1.0	17	1	AAH74934	Mouse flc-1 VEGF r
142	13.8	1.0	17	1	AAH74935	Mouse flc-1 VEGF r
143	13.8	1.0	17	1	AAH74936	Mouse flc-1 VEGF r
144	13.8	1.0	17	1	AAH74937	Mouse flc-1 VEGF r
145	13.8	1.0	17	1	AAH74924	Mouse flk-1 VEGF r
146	13.8	1.0	17	1	AAH73067	Mouse flk-1 VEGF r
147	13.8	1.0	17	1	AAH73029	Mouse flk-1 VEGF r
148	13.8	1.0	17	1	AAH73030	Mouse flk-1 VEGF r
149	13.8	1.0	17	1	AAH72964	Mouse flk-1 VEGF r
150	13.8	1.0	17	1	AAH71607	Human KDR VEGF rec
151	13.8	1.0	17	1	AAH71492	Human KDR VEGF rec
152	13.8	1.0	17	1	AAH71455	Human KDR VEGF rec
153	13.8	1.0	17	1	AAH71456	Human KDR VEGF rec
154	13.8	1.0	17	1	AAH1893	Human TIE-2 subscr
155	13.8	1.0	17	1	AAH200939	PCR primer moprac
156	13.8	1.0	17	1	AAH76853	PCR primer for clo
157	13.8	1.0	17	1	AAH91368	Human C-raif target
158	13.8	1.0	17	1	AAH91369	Human C-raif target
159	13.8	1.0	17	1	AAH04325	Hammerhead ribozym
160	13.8	1.0	17	1	AAH04773	Hammerhead ribozym
161	13.8	1.0	17	1	AAH07201	Hammerhead ribozym
162	13.8	1.0	17	1	AAH259070	HIV-1 TAR oligonuc
163	13.8	1.0	17	1	AAH95005	Human Chk1 ribozym
164	13.8	1.0	17	1	AAH00844	Human NCOG Inozyme
165	13.8	1.0	17	1	AAH03622	Human CD20 DNAsyme
166	13.8	1.0	17	1	AAH03757	Human CD20 DNAsyme
167	13.8	1.0	17	1	AAH78899	Human CD20 DNAsyme
168	13.8	1.0	17	1	AAH80430	Human HTPL scannin
169	13.8	1.0	17	1	AAH89409	Human HTPL scannin
170	13.8	1.0	17	1	AAH89410	Human POSHL1 scann
171	13.8	1.0	17	1	AAH06320	Human GDMLP-1 17-m
172	13.8	1.0	17	1	AAH07681	Human GDMLP-1 17-m
173	13.8	1.0	17	1	AAH09083	Human GDMLP-1 17-m
174	13.8	1.0	17	1	AAH26439	Waxy starch produc
175	13.8	1.0	17	1	AAH26440	Waxy starch produc
176	13.8	1.0	17	1	AAH35370	Tumour suppression
177	13.8	1.0	17	1	AAH39340	Tumour suppression
178	13.8	1.0	17	1	AAH09044	NR8 sub-unit modu
179	13.8	1.0	17	1	AAH264846	Human HER2 DNAsyme
180	13.8	1.0	17	1	AAH25209	Human HER2 DNAsyme
181	13.8	1.0	18	1	AAH04011	Multimeric (SBP) a
182	13.8	1.0	18	1	AAH05636	Primer F8-547S sen
183	13.8	1.0	18	1	AAH71737	Purification tag o
184	13.8	1.0	18	1	AAH48746	EBB-2 gene antisense
185	13.8	1.0	18	1	AAH27574	RT-PCR primer RT-N
186	13.8	1.0	18	1	AAH99371	cDNA encoding a pe
187	13.8	1.0	18	1	AAH52031	Antisense oligonuc
188	13.8	1.0	18	1	AAH46791	Human G-alpha-16 a
189	13.8	1.0	18	1	AAH23501	Clone vq1_1 hybrid
190	13.8	1.0	18	1	AAH25167	Hexa(his) oligonuc
191	13.8	1.0	18	1	AAH5168	Hexa(his) oligonuc
192	13.8	1.0	18	1	AAH59072	HIV-1 TAR oligonuc
193	13.8	1.0	18	1	AAH44139	Human EGR-1 DNA an
194	13.8	1.0	18	1	AAH36560	Probe hybridising
195	13.8	1.0	18	1	AAH74454	Human PRO2 gene-sp
196	13.8	1.0	18	1	AAH74457	Human PRO2 gene-sp
197	13.8	1.0	18	1	AAH56051	HIV DNA polymerase
198	13.8	1.0	18	1	AAH40986	Human PI3K p85 ant
199	13.8	1.0	18	1	AAH30659	Human HLA genotypi
200	13.8	1.0	18	1	AAH03503	Relaxin/IGF/Insuli
201	13.8	1.0	18	1	AAH23505	Primer for analysi
202	13.4	1.0	15	1	AAH31178	Tag sequence of a
203	13.4	1.0	15	1	AAH264164	Substrate for ham
204	13.4	1.0	15	1	AAH51572	IGF-1 oligonucleot
205	13.4	1.0	15	1	AAH51573	IGF-1 oligonucleot
206	13.4	1.0	15	1	AAH51574	IGF-1 oligonucleot
207	13.4	1.0	15	1	AAH52665	IGF-1 oligonucleot
208	13.4	1.0	15	1	AAH52666	IGF-1 oligonucleot
209	13.4	1.0	15	1	AAH01217	Hepatitis C virus
210	13.4	1.0	15	1	AAH32132	Human colon cancer
211	13.4	1.0	16	1	AAH46733	EBB-2 gene antisense
212	13.4	1.0	17	1	AAH63801	Rabbit stromelysin
213	13.4	1.0	17	1	AAH12596	Human Tx protease
214	13.4	1.0	17	1	AAH35236	Natural killer lylt
215	13.4	1.0	17	1	AAH71605	Human KDR VEGF rec
216	13.4	1.0	17	1	AAH71606	Human KDR VEGF rec
217	13.4	1.0	17	1	AAH21251	Integrin alpha 6 s
218	13.4	1.0	17	1	AAH04955	Hammerhead ribozym
219	13.4	1.0	17	1	AAH04956	Hammerhead ribozym
220	13.4	1.0	17	1	AAH02375	Human NCOG DNAsyme
221	13.4	1.0	17	1	AAH02376	Human NCOG DNAsyme
222	13.4	1.0	17	1	AAH08362	Human GDMLP-1 17-m
223	13.4	1.0	17	1	AAH08363	Human GDMLP-1 17-m
224	13.4	1.0	17	1	AAH08364	Human GDMLP-1 17-m
225	13.4	1.0	17	1	AAH08381	Human GDMLP-1 17-m
226	13.4	1.0	17	1	AAH08384	Human GDMLP-1 17-m
227	13.4	1.0	17	1	AAH08951	Human GDMLP-1 17-m
228	13.4	1.0	17	1	AAH08952	Human GDMLP-1 17-m
229	13.4	1.0	17	1	AAH08953	Human GDMLP-1 17-m
230	13.4	1.0	17	1	AAH09008	Human GDMLP-1 17-m
231	13.4	1.0	17	1	AAH09011	Human GDMLP-1 17-m
232	13.4	1.0	17	1	AAH34296	Oploid receptor D1
233	13.4	1.0	17	1	AAH38813	Tumour suppression
234	13.4	1.0	17	1	AAH38840	Tumour suppression
235	13.4	1.0	17	1	AAH15000	Human delta oploid
236	13.4	1.0	17	1	AAH261761	Human H-Ras DNAsym
237	13.4	1.0	17	1	AAH264832	Human HER2 DNAsyme
238	13.4	1.0	17	1	AAH265210	Human HER2 DNAsyme
239	13.4	1.0	17	1	AAH265221	Human HER2 DNAsyme
240	13	0.9	13	1	AAH46426	Oligonucleotide SE
241	13	0.9	13	1	AAH46427	Oligonucleotide SE
242	13	0.9	13	1	AAH49446	Oligonucleotide SE
243	13	0.9	13	1	AAH49447	Oligonucleotide SE
244	13	0.9	13	1	AAH06188	Oligonucleotide SE
245	13	0.9	13	1	AAH06189	Oligonucleotide SE
246	13	0.9	13	1	AAH51404	Oligonucleotide SE
247	13	0.9	13	1	AAH51405	Oligonucleotide SE
248	13	0.9	13	1	AAH51570	IGF-1 oligonucleot
249	13	0.9	15	1	AAH51571	IGF-1 oligonucleot
250	13	0.9	15	1	AAH52672	IGF-1 oligonucleot
251	13	0.9	15	1	AAH52953	IGF-1 oligonucleot
252	13	0.9	15	1	AAH52954	IGF-1 oligonucleot

C 253	13	0.9	15	1	AAFS2955	IGF-1 oligonucleot	C 326	12.8	0.9	17	1	ABK00843	Human NOGO Inozyme
C 254	13	0.9	15	1	AAH28575	Human interlentin-	C 327	12.8	0.9	17	1	ABK00845	Human NOGO Inozyme
C 255	13	0.9	15	1	ABK41344	Human eif2Bgamma r	C 328	12.8	0.9	17	1	ABK02092	Human NOGO DNAzyme
C 256	13	0.9	17	1	AAK63334	Rabbit stromelysin	C 329	12.8	0.9	17	1	ABK02103	Human NOGO DNAzyme
C 257	13	0.9	17	1	AAK63335	Rabbit stromelysin	C 330	12.8	0.9	17	1	ABK02341	Human NOGO Ambetzy
C 258	13	0.9	17	1	AAK62873	Delta-9 desaturase	C 331	12.8	0.9	17	1	ABK02926	Human CD20 Hammerh
C 259	13	0.9	17	1	AAK84687	Primer for KDR sig	C 332	12.8	0.9	17	1	ABK03271	Human CD20 Inozyme
C 260	13	0.9	17	1	AAK01105	PCR primer for rat	C 333	12.8	0.9	17	1	ABK03295	Human CD20 Inozyme
C 261	13	0.9	17	1	ABN86972	Hepatitis C virus	C 334	12.8	0.9	17	1	ABV78898	Human HTPL scanlin
C 262	13	0.9	17	1	AAH95774	Human Chk1 ribozym	C 335	12.8	0.9	17	1	ABV78900	Human HTPL scanlin
C 263	13	0.9	17	1	ABK01806	Human NOGO zinzyme	C 336	12.8	0.9	17	1	ABV80429	Human HTPL scanlin
C 264	13	0.9	17	1	ABN06895	Human GDMPL-1 17-m	C 337	12.8	0.9	17	1	ABV80431	Human HTPL scanlin
C 265	13	0.9	17	1	ABN06890	Human GDMPL-1 17-m	C 338	12.8	0.9	17	1	ABV89408	Human POSHL1 scan
C 266	13	0.9	17	1	ABN08954	Human GDMPL-1 17-m	C 339	12.8	0.9	17	1	ABV89411	Human POSHL1 scan
C 267	13	0.9	17	1	ABN08955	Human GDMPL-1 17-m	C 340	12.8	0.9	17	1	ABN83025	Human POSHL1 scan
C 268	13	0.9	17	1	ABN09038	Human GDMPL-1 17-m	C 341	12.8	0.9	17	1	ABN00661	Human GDMPL-1 17-m
C 269	13	0.9	17	1	ABN09039	Human GDMPL-1 17-m	C 342	12.8	0.9	17	1	ABN00662	Human GDMPL-1 17-m
C 270	13	0.9	17	1	ABN09040	Human GDMPL-1 17-m	C 343	12.8	0.9	17	1	ABN01115	Human GDMPL-1 17-m
C 271	13	0.9	17	1	ABN09041	Human GDMPL-1 17-m	C 344	12.8	0.9	17	1	ABN01116	Human GDMPL-1 17-m
C 272	13	0.9	17	1	ABN09042	Human GDMPL-1 17-m	C 345	12.8	0.9	17	1	ABN01120	Human GDMPL-1 17-m
C 273	12.8	0.9	16	1	ABT06463	HOXA5 gene methyla	C 346	12.8	0.9	17	1	ABN01121	Human GDMPL-1 17-m
C 274	12.8	0.9	16	1	ABH89557	Acidobacterium Tag	C 347	12.8	0.9	17	1	ABN01183	Human GDMPL-1 17-m
C 275	12.8	0.9	16	1	AAI68644	ICAM-1 triple heli	C 348	12.8	0.9	17	1	ABN01184	Human GDMPL-1 17-m
C 276	12.8	0.9	16	1	AAI68645	ICAM-1 triple heli	C 349	12.8	0.9	17	1	ABN01579	Human GDMPL-1 17-m
C 277	12.8	0.9	16	1	ABT34223	Dopamine-D2-recept	C 350	12.8	0.9	17	1	ABN01580	Human GDMPL-1 17-m
C 278	12.8	0.9	17	1	AAO52843	Probe A1 for Bacil	C 351	12.8	0.9	17	1	ABN06184	Human GDMPL-1 17-m
C 279	12.8	0.9	17	1	AAK64062	Herpes simplex vir	C 352	12.8	0.9	17	1	ABN06185	Human GDMPL-1 17-m
C 280	12.8	0.9	17	1	AAK64063	Rabbit stromelysin	C 353	12.8	0.9	17	1	ABN06319	Human GDMPL-1 17-m
C 281	12.8	0.9	17	1	AAK64063	Rabbit stromelysin	C 354	12.8	0.9	17	1	ABN06321	Human GDMPL-1 17-m
C 282	12.8	0.9	17	1	AAK64063	Rabbit stromelysin	C 355	12.8	0.9	17	1	ABN06539	Human GDMPL-1 17-m
C 283	12.8	0.9	17	1	AAK81587	Human c-myb hammer	C 356	12.8	0.9	17	1	ABN06540	Human GDMPL-1 17-m
C 284	12.8	0.9	17	1	AAK81588	Human c-myb hammer	C 357	12.8	0.9	17	1	ABN07353	Human GDMPL-1 17-m
C 285	12.8	0.9	17	1	AAK81188	Human c-myb hammer	C 358	12.8	0.9	17	1	ABN07354	Human GDMPL-1 17-m
C 286	12.8	0.9	17	1	AAK75356	Mouse flt-1 VEGF r	C 359	12.8	0.9	17	1	ABN07680	Human GDMPL-1 17-m
C 287	12.8	0.9	17	1	AAK75221	Mouse flt-1 VEGF r	C 360	12.8	0.9	17	1	ABN07682	Human GDMPL-1 17-m
C 288	12.8	0.9	17	1	AAK73066	Mouse flk-1 VEGF r	C 361	12.8	0.9	17	1	ABN09082	Human GDMPL-1 17-m
C 289	12.8	0.9	17	1	AAK73390	Human KDR VEGF rec	C 362	12.8	0.9	17	1	ABN09084	Human GDMPL-1 17-m
C 290	12.8	0.9	17	1	AAK70011	Human flt1 VEGF re	C 363	12.8	0.9	17	1	ABN10708	Human GDMPL-1 17-m
C 291	12.8	0.9	17	1	AAK69259	Human flt1 VEGF re	C 364	12.8	0.9	17	1	ABN10709	Human GDMPL-1 17-m
C 292	12.8	0.9	17	1	AAK69242	Human flt1 VEGF re	C 365	12.8	0.9	17	1	ABK17887	Human ERG hammerhe
C 293	12.8	0.9	17	1	AAK74828	PCR primer, 5m9, f	C 366	12.8	0.9	17	1	ABK18565	Human ERG G-Cleave
C 294	12.8	0.9	17	1	AAV97546	Human EGF-R target	C 367	12.8	0.9	17	1	ABK18734	Human ERG DNAzyme
C 295	12.8	0.9	17	1	AAV97404	Human EGF-R target	C 368	12.8	0.9	17	1	ABL31521	Human H1a genotypi
C 296	12.8	0.9	17	1	AAV94632	Human IL-2 recepto	C 369	12.8	0.9	17	1	ABL34419	Tumour suppression
C 297	12.8	0.9	17	1	AAV94682	Potato ciltatec syn	C 370	12.8	0.9	17	1	ABL34587	Tumour suppression
C 298	12.8	0.9	17	1	AAAI8720	Human TIR-2 subctr	C 371	12.8	0.9	17	1	ABL34848	Tumour suppression
C 299	12.8	0.9	17	1	AAAI8875	Human TIR-2 subctr	C 372	12.8	0.9	17	1	ABL35043	Tumour suppression
C 300	12.8	0.9	17	1	AAA20440	Integrin alpha 6 s	C 373	12.8	0.9	17	1	ABL35293	Tumour suppression
C 301	12.8	0.9	17	1	AAA20441	Integrin alpha 6 s	C 374	12.8	0.9	17	1	ABL35323	Tumour suppression
C 302	12.8	0.9	17	1	AAA20859	Integrin alpha 6 s	C 375	12.8	0.9	17	1	ABL35351	Tumour suppression
C 303	12.8	0.9	17	1	AAA21301	Integrin alpha 6 s	C 376	12.8	0.9	17	1	ABL35577	Tumour suppression
C 304	12.8	0.9	17	1	AAA21302	Integrin alpha 6 s	C 377	12.8	0.9	17	1	ABL36389	Tumour suppression
C 305	12.8	0.9	17	1	AAA23037	Integrin subunit b	C 378	12.8	0.9	17	1	ABL37484	Tumour suppression
C 306	12.8	0.9	17	1	AAK16147	Mouse neurofibroma	C 379	12.8	0.9	17	1	ABL37821	Tumour suppression
C 307	12.8	0.9	17	1	AAV93558	Human B-raf subctr	C 380	12.8	0.9	17	1	ABL38000	Tumour suppression
C 308	12.8	0.9	17	1	AAV93511	Human B-raf subctr	C 381	12.8	0.9	17	1	ABL38045	Tumour suppression
C 309	12.8	0.9	17	1	AAV90932	Human C-raf target	C 382	12.8	0.9	17	1	ABL38046	Tumour suppression
C 310	12.8	0.9	17	1	AAV90933	Human C-raf target	C 383	12.8	0.9	17	1	ABL39470	Tumour suppression
C 311	12.8	0.9	17	1	AAV91069	Human C-raf target	C 384	12.8	0.9	17	1	ABL39771	Tumour suppression
C 312	12.8	0.9	17	1	AAV91152	Human C-raf target	C 385	12.8	0.9	17	1	ABL39947	Tumour suppression
C 313	12.8	0.9	17	1	AAV91151	Human C-raf target	C 386	12.8	0.9	17	1	ACA06845	NFKB sub-unit modu
C 314	12.8	0.9	17	1	AAFO6118	Hammerhead ribozym	C 387	12.8	0.9	17	1	ACA07798	NFKB sub-unit modu
C 315	12.8	0.9	17	1	AAFO7173	Hammerhead ribozym	C 388	12.8	0.9	17	1	ABT23605	Stabilising reagen
C 316	12.8	0.9	17	1	AAA24827	Oestrogen receptor	C 389	12.8	0.9	17	1	ABZ60549	Human K-Ras DNAzym
C 317	12.8	0.9	17	1	AAA25517	Oestrogen receptor	C 390	12.8	0.9	17	1	ABZ60832	Human K-Ras DNAzym
C 318	12.8	0.9	17	1	AAA25518	Oestrogen receptor	C 391	12.8	0.9	17	1	ABZ61775	Human H-Ras DNAzym
C 319	12.8	0.9	17	1	ABA78913	APC mutation corre	C 392	12.8	0.9	17	1	ABZ62111	Human H-Ras DNAzym
C 320	12.8	0.9	17	1	ABA78914	APC mutation corre	C 393	12.8	0.9	17	1	ABZ65220	Human HER2 DNAzyme
C 321	12.8	0.9	17	1	ABA80468	MSH2 mutation cor	C 394	12.8	0.9	17	1	ABZ65478	Human HER2 DNAzyme
C 322	12.8	0.9	17	1	AAH80469	MSH2 mutation cor	C 395	12.6	0.9	13	1	ABC41010	Oligonucleotide SE
C 323	12.8	0.9	17	1	AAH94651	Human Chk1 ribozym	C 396	12.6	0.9	13	1	ABC41011	Oligonucleotide SE
C 324	12.8	0.9	17	1	AAH95254	Human Chk1 ribozym	C 397	12.6	0.9	13	1	ABC76782	Oligonucleotide SE
C 325	12.8	0.9	17	1	AAH95836	Human Chk1 ribozym	C 398	12.6	0.9	13	1	ABC76783	Oligonucleotide SE

C 399	12.6	0.9	13	1	ABC79816	Oligonucleotide SE
C 400	12.6	0.9	13	1	ABC79817	Oligonucleotide SE
C 401	12.6	0.9	13	1	ABF84730	Oligonucleotide SE
C 402	12.6	0.9	13	1	ABF84731	Oligonucleotide SE
C 403	12.6	0.9	13	1	ABH29758	Oligonucleotide SE
C 404	12.6	0.9	13	1	ABH29759	Oligonucleotide SE
C 405	12.6	0.9	13	1	ABH61844	Oligonucleotide SE
C 406	12.6	0.9	13	1	ABH61845	Oligonucleotide SE
C 407	12.6	0.9	15	1	ABK55502	Selectin L Lymphoc
C 408	12.6	0.9	15	1	ABD26040	Human apolipoprote
C 409	12.6	0.9	14	1	AAQ41008	Sequence around tr
C 410	12.4	0.9	14	1	AAV95609	Human c-fos target
C 411	12.4	0.9	14	1	AAV97202	Potato citrate syn
C 412	12.4	0.9	14	1	AAA19206	Human TIR-2 target
C 413	12.4	0.9	14	1	AAA09609	Primer SEQ ID 3 us
C 414	12.4	0.9	14	1	AAA09611	Primer SEQ ID 5 us
C 415	12.4	0.9	14	1	AAA89885	DNA sequence aroun
C 416	12.4	0.9	14	1	AAAS12903	Modified gp160MN p
C 417	12.4	0.9	14	1	ABL52817	Light-controlled a
C 418	12.4	0.9	15	1	AAH56846	RSV 1B hammerhead
C 419	12.4	0.9	15	1	AAH66621	Human CD40 Hammer
C 420	12.4	0.9	15	1	AAH49651	Human CERP HH ribo
C 421	12.4	0.9	15	1	AAH75723	Human flt-1 and KD
C 422	12.4	0.9	15	1	AAH99048	Probe 219m8 for dr
C 423	12.4	0.9	15	1	AAZ07078	Peptide nucleic ac
C 424	12.4	0.9	15	1	AAH57566	Antisense oligo #5
C 425	12.4	0.9	15	1	AAZ59271	Human NR8 gene pro
C 426	12.4	0.9	15	1	AAZ59273	Human NR8 gene pro
C 427	12.4	0.9	15	1	AAZ59278	Human NR8 gene pro
C 428	12.4	0.9	15	1	AAZ59282	Human NR8 gene pro
C 429	12.4	0.9	15	1	AAZ59300	Human NR8 gene pro
C 430	12.4	0.9	15	1	AAZ90836	Human NR8 gene pro
C 431	12.4	0.9	15	1	AAZ90837	Human NR8 gene pro
C 432	12.4	0.9	15	1	AAZ90846	Human NR8 gene pro
C 433	12.4	0.9	15	1	AAZ90861	Human NR8 gene pro
C 434	12.4	0.9	15	1	AAZ90870	Human NR8 gene pro
C 435	12.4	0.9	15	1	AAZ90883	Human NR8 gene pro
C 436	12.4	0.9	15	1	AAZ90895	Human NR8 gene pro
C 437	12.4	0.9	15	1	AAZ90902	Human NR8 gene pro
C 438	12.4	0.9	15	1	AAZ90906	Human NR8 gene pro
C 439	12.4	0.9	15	1	AAZ90908	Human NR8 gene pro
C 440	12.4	0.9	15	1	AAH26020	Stem-loop antisens
C 441	12.4	0.9	15	1	AAH05867	Human cholinergic
C 442	12.4	0.9	15	1	AAH18856	UCP3 polymorphism
C 443	12.4	0.9	15	1	AAH69549	Human IL4Ra1pha ge
C 444	12.4	0.9	15	1	AAH46143	IGFBP2 oligonucleo
C 445	12.4	0.9	15	1	AAH46144	IGFBP2 oligonucleo
C 446	12.4	0.9	15	1	AAH46266	IGFBP2 oligonucleo
C 447	12.4	0.9	15	1	AAH46267	IGFBP2 oligonucleo
C 448	12.4	0.9	15	1	AAH49086	IGF-I oligonucleot
C 449	12.4	0.9	15	1	AAH49087	IGF-I oligonucleot
C 450	12.4	0.9	15	1	AAH51575	IGF-I oligonucleot
C 451	12.4	0.9	15	1	AAH52664	IGF-I oligonucleot
C 452	12.4	0.9	15	1	AAH52781	IGF-I oligonucleot
C 453	12.4	0.9	15	1	AAH52782	IGF-I oligonucleot
C 454	12.4	0.9	15	1	AAH53986	IGF-I oligonucleot
C 455	12.4	0.9	15	1	AAH53987	IGF-I oligonucleot
C 456	12.4	0.9	15	1	AAH62187	Oligomer antiparal
C 457	12.4	0.9	15	1	ABX15428	Human Syk mRNA tar
C 458	12.4	0.9	15	1	AAH49046	MVP gene androgen
C 459	12.4	0.9	16	1	AAH60192	Synthetic PCNA rib
C 460	12.4	0.9	16	1	AAH86559	PCNA hairpin riboz
C 461	12.4	0.9	16	1	AAH86780	PCNA hammerhead ri
C 462	12.4	0.9	16	1	AAH61725	PCNA hairpin/hamme
C 463	12.4	0.9	16	1	AAH61946	PCNA hammerhead ri
C 464	12.4	0.9	16	1	AAH50533	Mycobacterium kans
C 465	12.4	0.9	16	1	AAH84079	FRI coliar sequenc
C 466	12.4	0.9	16	1	AAH22032	Human sitosterolae
C 467	12.4	0.9	16	1	ABT33749	Ribozyme substrate
C 468	12.4	0.9	16	1	AAH48398	Forward PCR primer

ALIGNMENTS

RESULT 1	
AAQ13309/c	
ID	AAQ13309 standard; DNA; 30 BP.
AC	AAQ13309;
XX	
XX	
DT	25-MAR-2003 (updated)
DT	28-OCT-1991 (first entry)
DE	Probe OAB984 for bFGF receptor DNA.
XX	
XX	
XX	Basic fibroblast growth factor; human; ss.
OS	Synthetic.
PN	MO911459-A.
XX	
PD	08-AUG-1991.
XX	
XX	
PF	21-JAN-1991; 91WO-EP00103.
XX	
PR	23-JAN-1990; 90GB-0001466.
XX	
PA	(FARM) FARMITALIA ERBA SRL CARLO.
XX	
PI	Bergonzoni L, Mazue G, Isacchi A, Roncucci R, Sarmientos P;
XX	WPI; 1991-252611/34.
XX	
PT	Extracellular form of human fibroblast growth factor receptor -
PT	used to treat tumours, abnormal angiogenesis e.g. diabetic
PT	retinopathy, rheumatoid arthritis and arteriosclerosis and as
PT	contraceptives.
XX	
PS	Example 1; Page 11; 29pp; English.
CC	
CC	The probe was used to screen a human placental lambda gt11 cDNA
CC	library for the gene encoding basic FGF receptor. It was designed
CC	from the partial cDNA clone published by Ruta et al, 1988.
CC	See also AAQ13308-01311.
CC	(Updated on 25-MAR-2003 to correct PA field.)
XX	
SQ	Sequence 30 BP; 5 A; 8 C; 11 G; 6 T; 0 other;
Query Match	1.8%; Score 25.8; DB 1; Length 30;
Best Local Similarity	93.1%; Pred. No. 4.5;
Matches	27; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy	2488 TGTGGCATGCGATGCCCTCCAGAGACC 2516
DB	30 TGCTGCATGCGATGCCCTCCAGAGACC 2
RESULT 2	
AAFS8623	
ID	AAFS8623 standard; cDNA; 31 BP.
AC	AAFS8623;
XX	
DT	27-APR-2001 (first entry)
XX	
DE	Murine c-kit exon 17 potential mutagenic oligonucleotide.
XX	
KW	Mouse; c-kit; drosophila recombination associated protein; DRAP;
KW	gene targeting; ss.
OS	Mus sp.
XX	
PN	WO200107627-A1.
XX	
PD	01-FEB-2001.

XX 21-JUL-2000; 2000WO-US19901.
 PF
 XX
 PR 21-JUL-1999; 99US-0144736.
 XX
 PA (YESH) UNIV YESHIVA EINSTEIN COLLEGE.
 XX
 PI Eisen A;
 XX
 DR WPI; 2001-168555/17.
 XX
 PT New nucleic acid encoding Drosophila Recombination-Associated Protein
 PT is useful for genomic cloning, gene isolation and gene mapping
 XX
 PS Example 8; Page 7; 63pp; English.
 XX
 CC The present sequence is given in a specification relating to an
 CC isolated nucleic acid encoding Drosophila Recombination-Associated
 CC Protein (DRAP). DRAP is useful for isolating genomic DNA, targeting
 CC mutagenesis of a defined segment of DNA, removing a segment of DNA,
 CC cloning a defined segment of DNA, mapping a defined segment of DNA,
 CC promoting gene disruptions of a defined segment of DNA, and
 CC experimental and therapeutic application of DRAP driven genetic
 CC modification of a gene responsible for a genetic disease.
 CC The DRAP gene is suitable for very efficient gene targeting.
 XX
 SQ Sequence 31 BP; 10 A; 5 C; 8 G; 8 T; 0 other;
 Query Match 1.7%; Score 23.6; DB 1; Length 31;
 Best Local Similarity 86.7%; Pred. No. 11;
 Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 Oy 2137 TGTATTCACAGAGATTGGCAGCAGGAAAT 2166
 Db 1 TGTATTCACAGAGATTGGCAGCAGGAAAT 30
 RESULT 3
 AAV44045/C
 ID AAV44045 standard; DNA; 28 BP.
 AC
 XX AAV44045;
 XX
 DT 25-MAR-2003 (updated)
 DT 01-OCT-1998 (first entry)
 XX
 DE Mouse bFGF receptor DNA PCR primer #3.
 XX
 KM Basic fibroblast growth factor receptor; bFGF; heparin binding; murine;
 KM antitumour agent; inhibitor; wound healing; PCR primer; ss.
 XX
 OS Synthetic.
 OS Mus sp.
 OS
 PN US5789182-A.
 PN
 PD 04-AUG-1998.
 PD
 PF 14-DEC-1993; 93US-0166717.
 PF
 PR 20-DEC-1990; 90US-0631717.
 PR 14-DEC-1993; 93US-0166717.
 PR
 PA (CHIL-) CHILDRENS MEDICAL CENT.
 PA (HARD) HARVARD COLLEGE.
 XX
 PI Flanagan JG, Klagesbrun M, Leder P, Ornitz DM, Yayon A;
 PI
 DR WPI; 1998-446074/38.
 DR
 XX Assays for high-affinity heparin-binding growth factor receptor
 PT ligands - using receptor-overexpressing cells or cell-free system
 XX

PS Example 1; Column 7; 38pp; English.
 XX
 CC AAV44043-V44045 are PCR primers used to amplify a murine basic
 CC fibroblast growth factor (bFGF) which is a member of the heparin-binding
 CC growth factor receptor family. This protein is used in a method which
 CC assays the ability of a substance to bind to a high-affinity
 CC heparin-binding growth factor (HBGF) receptor. The assay screens for
 CC potential antitumour agents that inhibit binding of HBGF to
 CC high-affinity receptors, or for potential wound healing agents that
 CC promote such binding.
 CC (Updated on 25-MAR-2003 to correct PF field.)
 XX
 SQ Sequence 28 BP; 6 A; 11 C; 1 G; 10 T; 0 other;
 Query Match 1.6%; Score 22.4; DB 1; Length 28;
 Best Local Similarity 95.8%; Pred. No. 15;
 Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 1873 GAGATGAGATGATGATGATGAT 1896
 Db 28 GAGATGAGATGATGATGATGAT 5
 RESULT 4
 AAV05314/C
 ID AAV05314 standard; DNA; 25 BP.
 AC
 XX AAV05314;
 XX
 DT 06-JUL-1998 (first entry)
 DT
 XX
 DE Kinase domain 3' PCR primer.
 XX
 KM Williams syndrome cognitive profile; WSCP; cognition; LIM-kinase 1;
 KM LIMK1 gene; supra-vascular aortic stenosis; protein kinase; human;
 KM PCR; primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 OS
 PN M09801740-A2.
 PN
 PD 15-JAN-1998.
 PD
 PF 07-JUL-1997; 92MO-US11687.
 PF
 PR 10-JUL-1996; 96US-0678039.
 PR
 PA (UTAH) UNIV UTAH RES FOUND.
 PA
 XX Keating MT, Morris CA;
 XX
 DT Keating MT, Morris CA;
 DT
 DR WPI; 1998-101185/09.
 DR
 XX
 PT Diagnosing Williams syndrome cognitive profile from hemizygosity of
 PT LIMK1 - gene on chromosome 7 encoding new kinase, allowing
 PT differentiation from classic Williams syndrome and supra-vascular
 PT aortic stenosis
 XX
 PS Example 3; Page 22; 62pp; English.
 PS
 XX This oligonucleotide was designed to amplify the region of
 CC homology in the kinase domains of PDGF receptor, HER2, HER3,
 CC FGF-FRG, FGF-BER, insulin receptor and IRR. It was used with
 CC another kinase homology domain-based primer (see AAV05313) in the
 CC amplification of human LIM-kinase 1 (LIMK1) sequences. The LIMK1
 CC gene is composed of 16 exons (see AAV05315 and AAT99599-T99629) and is
 CC located 15.4 kb 3' of elastin in chromosome 7. It encodes a
 CC novel protein kinase (see AAV46576). Williams syndrome cognitive
 CC profile (WSCP) is detected by determining zygosity of the LIMK1
 CC locus, with hemizygosity being indicative of impaired visuo-spatial
 CC constructive cognition. Chromosome 7 deletion analysis allows
 CC discrimination between WSCP, SVAS (supra-vascular aortic stenosis)

```

CC and Williams syndrome.
XX Sequence 25 BP; 4 A; 10 C; 6 G; 5 T; 0 other;
SQ
Query Match 1.5%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 18;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2269 CCAGTCAAGTGGATGGCTCCAGA 2291
DB 24 CCAGTCAAGTGGATGGCTCCGGA 2

RESULT 5
AAQ52728/c
ID AAQ52728 standard; DNA; 27 BP.
XX
AC AAQ52728;
XX
DT 29-JUN-1994 (first entry)
XX
DE Mouse fibroblast growth factor 3' DNA primer.
XX
KW Fibroblast growth factor; DNA primer; ss.
XX
OS Synthetic.
XX
PS US5270197-A.
XX
PD 14-DEC-1993.
XX
PP 20-DEC-1990; 90US-0631717.
XX
PR 20-DEC-1990; 90US-0631717.
XX
PA (CHIL-) CHILDRENS MEDICAL CENT.
XX
PA (HARD) HARVARD COLLEGE.
XX
P1 Klagsbrun M, Leder P, Ornitz DM, Yayon A;
XX
DR WPI; 1993-404932/50.
XX
PT Cells having high-affinity heparin-binding growth factor binding
PT sites - are used for screening substances for e.g. anti-tumour
PT agents or wound healing promoters
XX
PS Disclosure; Column 7; 37pp; English.
XX
CC This primer and its 5' partner (AAQ52727) correspond to regions highly
CC conserved among mouse BEK, human FLG and chicken fibroblast growth
CC factor cDNA.
XX
SQ Sequence 27 BP; 6 A; 10 C; 1 G; 10 T; 0 other;

Query Match 1.5%; Score 21.4; DB 1; Length 27;
Best Local Similarity 95.7%; Pred. No. 21;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1874 AGATGAGATGATGAGATGATT 1896
DB 27 AGATGAGATGATGAGATGATT 5

RESULT 6
AAT63286/c
ID AAT63286 standard; DNA; 21 BP.
XX
AC AAT63286;
XX
DT 21-MAY-1997 (first entry)
XX
DE FGF receptor gene downstream primer binds bases 110-130.
XX

```

```

KW Cornea; proliferation; in vivo; hepatocyte growth factor; injury; PCR;
KW keratinocyte growth factor; ocular surgery; epithelium; endothelium;
KW expression; receptor; polymerase chain reaction; amplification; primer;
KW healing; beta-actin; upstream; downstream; intron; ss.
XX
OS Synthetic.
XX
PS US5589451-A.
XX
PD 31-DEC-1996.
XX
PP 21-SEP-1992; 92US-0947683.
XX
PR 21-SEP-1992; 92US-0947683.
XX
PA (TEXA ) UNIV TEXAS SYSTEM.
XX
PI Wilson SE;
XX
DR WPI; 1997-076876/07.
XX
PT Promoting or suppressing corneal cell proliferation - using
PT hepatocyte growth factor or calcium ions resp., e.g. for treating
PT corneal injury or for preserving corneal tissue prior to
PT transplantation
XX
PS Example 1; Column 11-12; 25pp; English.
XX
CC The invention relates to methods for promoting corneal cell
CC proliferation in vivo by treating the cells with hepatocyte growth factor
CC (HGF) and optionally keratinocyte growth factor (KGF). Methods for
CC suppressing corneal cell growth include administering Ca ions to the
CC cells. The methods are used for the treatment of corneal tissue injury
CC following accidental injury, ocular surgery or due to corneal disorders
CC caused by abnormal healing processes of the corneal epithelium and
CC endothelium. The methods are based on the discovery that corneal tissue
CC can express mRNA for HGF, KGF and their respective receptors. The
CC discovery was shown by PCR amplification using the primers AAT63273-87.
CC Primers AAT63283 and AAT63286 were used to amplify a 205 fragment of the
CC fibroblast growth factor (FGF) receptor 2 cDNA. This primer is the
CC downstream amplification primer and corresponds to bases 110-130 of the
CC FGF receptor 2 gene. The amplified fragment was detected using probe
CC AAT63287.
XX
SQ Sequence 21 BP; 9 A; 3 C; 6 G; 3 T; 0 other;

Query Match 1.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1322 TATCCTTCACTGTCATGGT 1342
DB 21 TATCCTTCACTGTCATGGT 1

RESULT 7
AAV05498/c
ID AAV05498 standard; DNA; 21 BP.
XX
AC AAV05498;
XX
DT 01-MAY-1998 (first entry)
XX
DE Downstream primer for FGF receptor DNA.
XX
KW Inhibition; corneal epithelial cell; differentiation; treatment;
KW hepatocyte growth factor; HGF; keratinocyte growth factor; KGF;
KW dry eye; keratoconjunctivitis sicca; PCR primer; receptor;
KW fibroblast growth factor; FGF; ss.
XX
OS Synthetic.
XX
DE Homo sapiens.
XX

```

```

PN  US5703047-A.
XX
XX  30-DEC-1997.
XX
XX  09-MAR-1995; 95US-0400323.
XX
XX  09-MAR-1995; 95US-0400323.
XX
XX  21-SEP-1992; 92US-0947683.
XX
XX  (TEXA ) UNIV TEXAS SYSTEM.
XX
XX  Wilson SE;
XX
XX  WPI; 1998-076459/07.
XX
XX  Inhibition of corneal cell differentiation - by using hepatocyte
XX  growth factor and/or keratinocyte growth factor
XX
XX  Example 1; Columns 17-18; 36pp; English.
XX
XX  The present sequence was used in the development of a novel method
XX  for the inhibition of corneal epithelial cell differentiation. The
XX  method comprises contacting the cells with a hepatocyte growth
XX  factor (HGF) and/or keratinocyte growth factor (KGF). When HGF and
XX  KGF are both used, the cells can be contacted with them
XX  sequentially or simultaneously. The HGF and/or KGF is in a timed
XX  release delivery system, especially comprising biodegradable
XX  polymer microcapsules. The HGF and/or KGF are administered
XX  topically. The method is used for treating dry eye, especially
XX  keratoconjunctivitis sicca.
XX
XX  Sequence 21 BP; 9 A; 3 C; 6 G; 3 T; 0 other;
XX
XX  Query Match 1.5%; Score 21; DB 1; Length 21;
XX  Best Local Similarity 100.0%; Pred. No. 16;
XX  Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY  1322 TATCCTTCACTCGCATGGT 1342
DB  21 TATCCTTCACTCGCATGGT 1

```

RESULT 8
AA34892/C
ID AA34892 standard; DNA; 20 BP.
XX
XX AA34892;
XX
XX 28-JUN-1999 (first entry)
XX
XX PCR primer used to amplify FGFR2.
XX
XX Immortalized human hair papilla cell; HPC; screening; hair growth;
XX SV40 viral Large T-antigen gene; deleted replication initiation point;
XX hair growth stimulating agent; PCR primer; ss.
XX
XX Synthetic.
XX
XX JPI1089565-A.
XX
XX 06-APR-1999.
XX
XX 19-SEP-1997; 97JP-0271927.
XX
XX 19-SEP-1997; 97JP-0271927.
XX
XX (SHIS) SHISEIDO CO LTD.
XX
XX WPI; 1999-281045/24.
XX
XX Immortalized human hair papilla cells used for evaluation of hair
XX growth agent - are prepared by transformation of human hair papilla
XX cells with gene with deleted replication initiation point

```

XX
XX  Example 2; Page 7; 23pp; Japanese.
XX
XX  The specification describes the preparation of immortalized human
XX  hair papilla cells (HPC). The method comprises transformation of HPC
XX  with an SV40 viral Large T-antigen gene with deleted replication
XX  initiation point. The immortalized HPC can be used in a screening
XX  method for a hair growth agent, by culture of immortalized HPC in
XX  the presence of a substance to be tested and observation of the
XX  growth of the immortalized HPC. HPC is also used in development of
XX  hair growth stimulating agents. The present sequence represents a
XX  PCR primer, which is used in the course of the invention.
XX
XX  Sequence 20 BP; 1 A; 4 C; 4 G; 11 T; 0 other;
XX
XX  Query Match 1.4%; Score 20; DB 1; Length 20;
XX  Best Local Similarity 100.0%; Pred. No. 22;
XX  Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY  1470 AATGAGAACGACGACCAAGA 1489
DB  20 AATGAGAACGACGACCAAGA 1

```

RESULT 9
AA00032/C
ID AA00032 standard; DNA; 20 BP.
XX
XX AA00032;
XX
XX 16-MAR-1999 (first entry)
XX
XX FGFR-2 (bek) PCR antisense primer.
XX
XX Neuroepithelial stem cell; lineage restricted intermediate precursor;
XX oligodendrocyte; astrocyte; self-renewal; neuron; differentiation;
XX neural crest cell; fibroblast growth factor; GGF; receptor; CNS;
XX central nervous system; glial cell; PCR primer; amplification; ss.
XX
XX Synthetic.
XX
XX Homo sapiens.
XX
XX MO9850526-A1.
XX
XX 12-NOV-1998.
XX
XX 07-MAY-1998; 98WO-US09630.
XX
XX 06-MAY-1998; 98US-0073881.
XX
XX 07-MAY-1997; 97US-0852744.
XX
XX (UTAH) UNIV UTAH RES FOUND.
XX
XX Mayer-Proschel M., Mujtaba T, Rao MS;
XX
XX WPI; 1999-070093/06.
XX
XX Mammalian neuroepithelial stem cells and glial restricted precursor
XX - can self renew and differentiate into central nervous system
XX cells, used for generating various types of cells
XX
XX Example 26; Page 57; 78pp; English.
XX
XX The present invention describes an isolated, pure population of
XX mammalian neuroepithelial stem cells, which are capable of self-renewal
XX in adherent feeder-cell-independent (AFCI) culture medium and
XX differentiation to central nervous system (CNS) neuronal or glial cells
XX and to neuronal crest stem cells. Also described is an isolated
XX population of mammalian CNS glial-restricted precursor (GRP) cells which
XX can self-renew in the APCI culture medium and can differentiate to CNS
XX glial cells but not to CNS neuronal cells. The stem cells can be used to
XX generate a population of mammalian motor neurons by incubating the stem
XX cells in a medium promoting cell proliferation and neuronal

CC differentiation. The medium comprises laminin-coated plates and NRP
 CC medium lacking chick embryo extract. The stem cells can also produce
 CC neural crest stem cells by inducing the cells to differentiate in vitro.
 CC The inducing step comprises replating the cells on a laminin-coated
 CC substrate and preferably withdrawing a mitogen (preferably fibroblast
 CC growth factor; FGF) and chick embryo extract. Inducing can also comprise
 CC adding a demoralizing agent to the cells, preferably a bone morphogenetic
 CC protein (BMP) such as BMP-2, -4 or -7. The stem cells can be used to
 CC produce cells of the peripheral nervous system, by inducing the stem
 CC cells to differentiate in vitro to neural crest stem cells, and inducing
 CC these cells to differentiate. AAX00029 to AAX00054 represent PCR primers
 CC which are used in an example from the present invention to amplify
 CC different FGF and RGR genes.

XX SQ Sequence 20 BP; 7 A; 6 C; 4 G; 3 T; 0 other;

Query Match 1.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 22;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1335 TGCATGGTTGACAGTCTGC 1354

Db 20 TGCATGGTTGACAGTCTGC 1

RESULT 10
 AAT84432
 ID AAT84432 standard; DNA; 22 BP.

XX AAT84432;

XX 13-NOV-1997 (first entry)

XX KIT gene primer KITDEL1-FOR for pig coat colour determination.

XX KIT gene; pig; coat colour; pigmentation; primer; PCR;

XX polymerase chain reaction; ss.

XX Synthetic.

XX WO9705278-A1.

XX 13-FEB-1997.

XX 24-JUL-1996; 96WO-GB01794.

XX 12-DEC-1995; 95GB-0025364.

XX 27-JUL-1995; 95GB-0015385.

XX (DALG-) DALGETY PLC.

XX Andersson L, Moller MJ, Plastow GS, Siggens KW;

XX Wales R;

XX WPI; 1997-145712/13.

XX Determn. of coat colour genotype in pigs by analysis of the KIT gene
 PT - for duplication or deletions, or analysis of KIT protein, used to
 PT establish breeding programmes for pigs of selected colour

XX Claim 39; Page 43; 49pp; English.

XX Primer pairs KITDEL1-FOR (AAT84432) and KITDEL1-REV (AAT84433), and

XX KITDEL2-FOR (AAT84434) and KITDEL2-REV (AAT84435), can be used in a

XX claimed method for identifying the presence or absence of a

XX deletion of the KIT gene sequence in pig genomic DNA. Other

XX claimed primers (see AAT84420-27) are used to detect a duplication

XX of the KIT gene. The 3 alleles for coat colour (1, inhibition of

XX coat colour; 1(p), patch; and 1, development of colour) can be

XX differentiated on the basis of duplication/deletion in the KIT

XX gene. This allows breeding of pigs with the desired, usually

XX white, coat colour.

SQ Sequence 22 BP; 2 A; 4 C; 7 G; 9 T; 0 other;

Query Match 1.3%; Score 18.8; DB 1; Length 22;

Best Local Similarity 90.9%; Pred. No. 41;

Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2351 TGTGGAGATCTTCACCTTAGG 2372

Db 1 TGTGGAGATCTTCCTTAGG 22

RESULT 11

AAV80714

AAV80714 standard; DNA; 22 BP.

XX AAV80714;

XX 26-MAR-1999 (first entry)

XX KIT gene PCR forward primer KITDEL1-FOR.

XX Porcine; wild boar; welsh; piebald; large white; hampshire; duroc;

XX differentiation; breed origin; alpha-MSHR; coat colour; stock purity;

XX alpha melanocyte-stimulating hormone receptor; KIT; PCR primer; ss.

XX Synthetic.

XX WO9854360-A1.

XX 03-DEC-1998.

XX 27-MAY-1998; 98WO-GB01531.

XX 31-JAN-1998; 98GB-0001990.

XX 30-MAY-1997; 97GB-0011214.

XX (PIGT-) PIG IMPROVEMENT CO UK LTD.

XX Andersson L, Evans GJ, Giuffra E, Kijas J, Plastow GS;

XX Wales R;

XX WPI; 1999-070222/06.

XX Differentiating products from different animal breeds - by the

XX analysis of alleles of breed-determinant genes, at the nucleic acid

XX or protein level

XX Example 15; Page 56; 101pp; English.

XX A method has been developed for: (a) differentiating animals and animal

XX products according to breed origin; (b) determining or testing the breed

XX origin of a product; or (c) validating an animal product. The method

XX comprises analysing a sample of the product for the allele(s) of at

XX least one breed-determinant (BD) gene. The present invention also

XX describes: (i) methods for determining the coat colour genotype of a pig

XX by determining: (i) the allele(s) of the alpha melanocyte-stimulating

XX hormone receptor (alpha-MSHR) gene; (ii) the amino acid sequence of an

XX alpha-MSHR protein at positions associated with coat colour, or the size

XX of the protein; (iii) detecting which microsatellites (or other linked

XX marker alleles), linked to the alpha-MSHR gene, or particular alleles of

XX it, are present; and (iv) analysing nucleic acid to determine if the KIT

XX gene carries a polymorphism associated with the belt genotype. The

XX main method of the invention is applied to samples from fish, birds and

XX mammals, especially pigs. Particular applications are confirming stated

XX origin of meats; in quality control; for maintaining stock purity, and

XX in breeding programmes (to confirm particular crosses). The method

XX requires only very small samples and many samples can be screened

XX quickly and inexpensively. The process can be made quantitative. The

XX present sequence represents a KIT gene PCR primer from the present

XX invention.

XX Sequence 22 BP; 2 A; 4 C; 7 G; 9 T; 0 other;

XX

Query Match 1.3%; Score 18.8; DB 1; Length 22;
 Best Local Similarity 90.9%; Pred. No. 43;
 Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2351 TGTGGAGATCTTCACCTTAGG 2372

Db 1 TGTGGAGACTCTTCTCTTAGG 22

RESULT 12

AAH23018 AAH23018 standard; DNA; 23 BP.

AC AAH23018;

DT 17-SEP-2001 (first entry)

DE VEGFR-1 gene specific forward primer.

KM Vascular endothelial growth factor; VEGF; antisense; angiogenesis;

KM cell proliferation; Kaposi's sarcoma; cancer; melanoma; cytostatic;

KM antisense therapy; RT-PCR; primer; VEGFR-1; ss.

OS Synthetic.

OS Homo sapiens.

PN WO200152904-A2.

PD 26-JUL-2001.

PF 19-JAN-2001; 2001WO-US00019.

PR 19-JAN-2000; 2000US-0487023.

PA (GILL/) GILL P S.

PI Gill PS, Masood R;

DR WPI; 2001-451898/48.

PT Novel antisense oligonucleotides useful for inhibiting vascular

PT endothelial growth factor expression, angiogenesis and for treating

PT cancer, e.g., Kaposi's sarcoma, ovarian cancer and prostate cancer

XX Example 12; Page 56; 105pp; English.

XX The invention provides a composition comprising one or more antisense

XX oligonucleotides directed against vascular endothelial growth factor

XX (VEGF) where the antisense oligonucleotides inhibits proliferation of

XX cells exhibiting autocrine VEGF activity at an IC₅₀ concentration of

XX between 0.5-2.5 micro M. The antisense oligonucleotides may be directed

XX against VEGF for inhibiting cancer cell proliferation and angiogenesis.

XX Preferably the oligonucleotide AAH23032 (a modified version of AAH22984)

XX is used and may be utilized to treat Kaposi's sarcoma, ovarian cancer,

XX prostate cancer, pancreatic cancer or melanoma. Sequences AAH23012-023

XX represent gene-specific primers used in RT-PCR amplification of VEGF

XX receptors.

XX Sequence 23 BP; 6 A; 4 C; 9 G; 4 T; 0 other;

XX SQ

Query Match 1.3%; Score 18.8; DB 1; Length 23;

Best Local Similarity 90.9%; Pred. No. 43;

Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2098 CAGCTGGCCAGAGCGATGAGT 2119

Db 1 CAAGTGGCCAGAGCGATGAGT 22

RESULT 13

ABX90509 ABX90509 standard; DNA; 23 BP.

XX

AC ABX90509;

DT 01-MAY-2003 (first entry)

DE Human VEGFR-1 RT-PCR primer #1.

KM Antisense; ss; PCR; VEGF; vascular endothelial growth factor; human;

KM cancer; angiogenesis; neoplastic proliferation; cellular proliferation;

KM primer; RT-PCR; reverse transcriptase PCR.

OS Homo sapiens.

PN US2002165174-A1.

PD 07-NOV-2002.

PF 13-MAR-2001; 2001US-0805761.

PR 31-JAN-1997; 97US-037004P.

PR 19-JAN-2001; 2001WO-US00019.

PR 30-JAN-1998; 98US-0016541.

PR 19-JAN-2000; 2000US-0487023.

PA (GILL/) GILL P S.

PA (MASO/) MASOOD R.

PI Gill PS, Masood R;

DR WPI; 2003-246674/25.

PT New composition comprising an antisense oligonucleotide directed

PT against vascular endothelial growth factor, useful for preparing a

PT composition for treating cancer

XX Example 12; Page 19; 54pp; English.

XX The invention relates to a composition comprising an antisense

XX oligonucleotide directed against vascular endothelial growth factor

XX (VEGF). The antisense oligonucleotide is useful for preparing a

XX composition treating cancer, neoplastic proliferation, abnormal

XX cellular proliferation and preventing angiogenesis. The present sequence

XX is a reverse transcriptase (RT)-PCR primer for a VEGF or related

XX gene, used to clone the coding region for expression in tumour cell

XX lines. The cell lines were used to test prospective antisense

XX oligonucleotides.

XX Sequence 23 BP; 6 A; 4 C; 9 G; 4 T; 0 other;

XX SQ

Query Match 1.3%; Score 18.8; DB 1; Length 23;

Best Local Similarity 90.9%; Pred. No. 43;

Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2098 CAGCTGGCCAGAGCGATGAGT 2119

Db 1 CAAGTGGCCAGAGCGATGAGT 22

RESULT 14

AAA95390 AAA95390 standard; DNA; 20 BP.

AC AAA95390;

DT 12-FEB-2001 (first entry)

DE Rat FGFR coding sequence PCR primer #1.

KM Rat; Nurr1; tyrosine hydroxylase; catecholamine-related disease;

KM Parkinson's disease; manic depression; schizophrenia; PCR primer; ss.

OS Rattus norvegicus.

PN WO200058451-A1.

```

XX 05-OCT-2000.
PD 21-MAR-2000; 2000WO-US07544.
XX 26-MAR-1999; 99US-0277078.
XX (SALK ) SALK INST BIOLOGICAL STUDIES.
PA Sakurada K, Palmer T, Gage FH;
PI WPI; 2000-656165/63.
DR
XX Cell comprising exogenous nucleic acid inducing tyrosine hydroxylase
PT expression useful for treating catecholamine-related diseases such as
PT Parkinson's disease, manic depression and schizophrenia
XX
XX Example 1; Page 20; 68pp; English.
XX The present invention describes the rat Nurrl coding and protein
CC sequences. The Nurrl protein is involved in the induction of tyrosine
CC hydroxylase expression in adult rat-derived hippocampal progenitor cells.
CC The Nurrl gene and protein can be used in the treatment of
CC catecholamine-related diseases such as Parkinson's disease, manic
CC depression and schizophrenia. They can also be used to induce tyrosine
CC hydroxylase expression and identify tyrosine hydroxylase related
CC deficiencies, which are linked to the same diseases. The present sequence
CC is a PCR primer used in a method to differentiate adult neural progenitor
CC cells.
XX
SQ Sequence 20 BP; 6 A; 1 C; 7 G; 4 T; 2 other;

```

Query Match 1.3%; Score 18.6; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 38;
Matches 18; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

1870 TCAGAGTGGAGTGGTGA 1889
Db 1 TCNAGATGGAGRTGATGAA 20

```

RESULT 15
AAV60732/c
ID AAV60732 standard; DNA; 20 BP.
XX
AC AAV60732;
XX
DT 08-DEC-1998 (first entry)
XX
DE Primer #2 for human CDK2 codons 1-149.
XX
XX PCR primer; amplification; yeast; UAS; upstream activating sequence;
XX transcription terminator; cell cycle; Upstream Activation Sequence; UAS;
XX promoter; phosphorylation; cyclin; cyclin-dependent kinase; CDK; vector;
XX cyclin kinase inhibitor; CKI; growth; wound healing; cancer therapy; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX WO9816660-A1.
XX
XX 23-APR-1998.
XX
XX 16-OCT-1997; 97WO-US18608.
XX
XX 27-NOV-1996; 96US-0031968.
XX
XX 16-OCT-1996; 96US-0029127.
XX
XX (BITT-) BITTECH INC.
PA
PI Bitter GA;
XX
XX WPI; 1998-251302/22.

```

```

XX Screening for agents that effect cell cycle regulatory proteins -
PT using a cell line that expresses a reporter gene in response to
PT regulation through phosphorylation by a cyclin/CDK system
XX
XX Example 4; Page 70; 93pp; English.
XX
XX Primers AAV60731-V60732 were used to PCR amplify codons 1-149 of the
CC human cyclin-dependent kinase 2 (hCDK2) gene. The amplified product was
CC used to generate a fusion protein comprising part of the hCDK2 sequence
CC linked to codons 154-302 of the yeast PHO85 gene. The fusion protein is
CC used to screen for compounds that affect mammalian cell cycle regulatory
CC proteins. The method comprises administering a compound to a cell line,
CC which contains a reporter gene linked to an Upstream Activation Sequence
CC (UAS) and a promoter, where the UAS binds a transcription control factor
CC (rTF) which is regulated through cyclin/cyclin-dependent kinase (CDK)
CC phosphorylation. Also included in the construct is an effector gene
CC providing a gene product to permit normal cyclin/CDK regulation of the
CC TCF. Expression of the reporter gene is then analysed in the cell line,
CC thereby determining whether the compound affects the normal regulation.
CC The method can be used to identify inhibitors and activators of
CC mammalian cell cycle regulatory proteins, especially inhibitors and
CC activators of cyclins, CDKs, cyclin/CDK complexes, cyclin kinase
CC inhibitors (CKIs), and cyclin/CDK complexes. The identified agents
CC can be used for stimulating growth of cells (as in wound healing), or
CC regulating excessive cell growth and division (as in cancer therapy).
XX
XX
SQ Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 other;

```

Query Match 1.3%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 41;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

2201 CAGACTTGGACTGCGCAGA 2220
Db 20 CAGACTTGGACTGACGACAGA 1

```

RESULT 16
AAQ33179/c
ID AAQ33179 standard; DNA; 24 BP.
XX
AC AAQ33179;
XX
DT 25-MAR-2003 (updated)
DT 28-JAN-1993 (first entry)
XX
XX PCR primer #3 to identify subtle DP2.5 mutations.
XX
XX neoplasm; cancer; oncogene; tumour; growth; detection; diagnosis;
XX prognosis; treatment; sporadic colorectal carcinomas; ss.
XX
XX Synthetic.
OS
XX
XX WO9213103-A1.
XX
XX 06-AUG-1992.
XX
XX 16-JAN-1992; 92WO-US00376.
XX
XX 16-JAN-1991; 91GB-0000963.
XX
XX 08-AUG-1991; 91US-0741940.
XX
XX (CANC-) CANCER INST.
PA (ICIL ) IMPERIAL CHEM IND PLC.
PA (UYUO ) UNIV JOHNS HOPKINS.
PA (UTAH ) UNIV UTAH.
XX
XX Kinzler KW, Vogelstein B, Anand R, Hedge PJ, Markham AF,
PI Albertsen H, Carlson ML, Groden JL, Joslyn G, Thliveris A,
PI White RL, Nakamura Y;
XX
XX WPI; 1992-284685/34.

```

XX Detection of somatic and germ-line alterations of human APC gene
 PT - used to diagnose, treat and study familial adenomatous
 PT polypsis and sporadic colorectal cancer
 XX
 XX Example 8; Table 3; 132pp; English.
 CC This PCR primer was used to detect subtle mutations in the DP2.5
 CC gene. It was used with AAQ31180. To obtain DNA sequence adjacent to
 CC the exons of the gene, sequencing substrate was obtained by inverse
 CC PCR amplification of DNAs from two YACs 31008 and 183112 that span
 CC the deletions. Ligation at low concentration cyclized the
 CC restriction enzyme digested YAC DNAs. Oligonucleotides with
 CC sequencing tails designed in inverse orientation at intervals
 CC along the cDNAs primed PCR amplification from the cyclised
 CC templates. Comparison of these DNA sequences with the cDNA
 CC sequences placed exon boundaries at the divergence points.
 CC NOTE: The sequence as given in the specification is barely legible.
 CC See also AAQ31158-253.
 CC (Updated on 25-MAR-2003 to correct PI field.)
 CC (Updated on 25-MAR-2003 to correct PI field.)
 CC
 XX Sequence 24 BP; 10 A; 3 C; 4 G; 7 T; 0 other;
 SQ
 Query Match 1.3%; Score 18.2; DB 1; Length 24;
 Best Local Similarity 87.0%; Pred. No. 58;
 Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 2645 CTTGAGAGATGATTCGTGTTT 2667
 Db 23 CTTGAGAGATGATTCGTGTTT 1
 XX
 XX RESULT 17
 XX AAT95598/c
 XX ID AAT95598 standard; DNA; 24 BP.
 XX
 XX AAT95598;
 AC
 XX 25-MAR-2003 (updated)
 DT 11-MAR-1998 (first entry)
 DT
 XX
 XX DE Primer for SSCP analysis of DP2.5 (APC).
 XX
 XX Human; adenomatous Polyposis coli; APC; diagnosis; prognosis;
 KW neoplastic tissue; tumour tissue; tumour repressor; mutation;
 KW sporadic colorectal cancer; detection; PCR primer; DP2.5;
 KW SSCP; single stranded conformation polymorphism; ss.
 KW
 XX
 XX Synthetic.
 OS
 XX Homo sapiens.
 OS
 XX
 XX US5648212-A.
 PN
 XX 15-JUL-1997.
 PD
 XX 12-AUG-1994; 94US-0289548.
 PF
 XX 16-JAN-1991; 91GB-0000962.
 PR 16-JAN-1991; 91GB-0000963.
 PR 16-JAN-1991; 91GB-0000974.
 PR 16-JAN-1991; 91GB-0000975.
 PR 08-AUG-1991; 91US-0741940.
 PR
 XX
 XX (NICA-) JAPANESE FOUND CANCER RES.
 PA (UYJO) UNIV JOHNS HOPKINS.
 PA (UTAH) UNIV UTAH.
 PA (ZENE) ZENECA LTD.
 PA
 XX
 XX Albertsen H, Anand R, Carlson M, Groden J, Hedge PJ;
 PI Joselyn G, Kinzler K, Markham A, Nakamura Y, Thliveris A;
 PI Vogelstein B, White RL;
 XX

DR WPI; 1997-372053/34.
 XX
 XX Cancer diagnosis - by detecting mutation(s) in adenomatous polyposis
 PT coli gene
 PT
 XX
 XX Example 8; Columns 31-32; 140pp; English.
 XX
 CC The present sequence is a primer for the SSCP analysis of DP2.5
 CC (APC), which was used in the development of a novel method of
 CC diagnosing or prognosing a human adenomatous polyposis coli (APC)
 CC gene associated neoplastic tissue. The method comprises comparing
 CC APC gene coding sequences or mRNA in a tumour tissue, to APC gene
 CC coding sequences or mRNA in a non-neoplastic tissue, where a
 CC difference indicates an APC gene associated neoplasia of the tumour
 CC tissue. APC is a tumour repressor expressed in most normal tissues.
 CC APC mutations are found in familial adenomatous polyposis and
 CC sporadic colorectal cancer patients. The method enables mutations
 CC to be detected to provide an indication of predisposition to
 CC cancer.
 CC (Updated on 25-MAR-2003 to correct PR field.)
 CC
 XX Sequence 24 BP; 10 A; 3 C; 4 G; 7 T; 0 other;
 SQ
 Query Match 1.3%; Score 18.2; DB 1; Length 24;
 Best Local Similarity 87.0%; Pred. No. 58;
 Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 2645 CTTGAGAGATGATTCGTGTTT 2667
 Db 23 CTTGAGAGATGATTCGTGTTT 1
 XX
 XX RESULT 18
 XX AAV56500/c
 XX ID AAV56500 standard; DNA; 24 BP.
 XX
 XX AAV56500;
 AC
 XX 25-MAR-2003 (updated)
 DT 23-NOV-1998 (first entry)
 DT
 XX
 XX DE Human DP2.5 APC primer #23.
 XX
 XX Familial adenomatous polyposis coli; APC; tumour suppressor; therapy;
 KW chromosome 5q21; tumorigenesis; retinoblastoma; colorectal tumour;
 KW FAP; Gardner's Syndrome; GS; predisposition; primer; ss.
 KW
 XX
 XX Synthetic.
 OS
 XX Homo sapiens.
 OS
 XX
 XX US5783666-A.
 PN
 XX 21-JUL-1998.
 PD
 XX 25-MAY-1995; 95US-0452655.
 PF
 XX 16-JAN-1991; 91GB-0000962.
 PR 16-JAN-1991; 91GB-0000963.
 PR 16-JAN-1991; 91GB-0000974.
 PR 16-JAN-1991; 91GB-0000975.
 PR 08-AUG-1991; 91US-0741940.
 PR 12-AUG-1994; 94US-0289548.
 PR
 XX
 XX (CANC-) CANCER INST.
 PA (UYJO) UNIV JOHNS HOPKINS.
 PA (UTAH) UNIV UTAH.
 PA (ZENE) ZENECA PHARM.
 PA
 XX
 XX Albertsen H, Anand R, Carlson M, Groden J, Hedge PJ;
 PI Joselyn G, Kinzler K, Markham A, Nakamura Y, Thliveris A;
 PI Vogelstein B, White RL;
 XX
 XX WPI; 1998-427100/36.

```

XX Adenomatous polyposis coli protein - useful in the treatment of
PT cancers associated with mutation(s) on human chromosome 5q21
XX
XX Example 8; Column 31-32; 102pp; English.
XX
CC AA56477-V56581 are primers used in the isolation of a human familial
CC adenomatous polyposis coli (APC) protein from clone DP2.5. The gene
CC for the protein is present on human chromosome 5q21 and is also referred
CC to as adenomatous polyposis coli gene. It is a tumour suppressor gene,
CC and mutations in this gene have been associated with tumorigenesis in
CC retinoblastoma and colorectal tumours, and especially familial
CC adenomatous polyposis (FAP) and Gardner's Syndrome (GS). The protein can
CC be used in therapy to replace lack of native functional protein and the
CC nucleic acids can be used for gene therapy. The nucleic acids that
CC encode them can also be used as probes and primers in detection of the
CC cancers and predisposition to it.
CC (Updated on 25-MAR-2003 to correct PR field.)
CC
XX Sequence 24 BP; 10 A; 3 C; 4 G; 7 T; 0 other;
SQ
Query Match 1.3%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 58;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 2645 CTTGAGAGATGATTCGTGTTT 2667
Db 23 CTTGAGAGATGATTCGTGTTT 1

RESULT 19
AAT96213/c
ID AAT96213 standard; DNA; 24 BP.
XX
XX AAT96213;
AC
XX 25-MAR-2003 (updated)
DT 08-APR-1998 (first entry)
XX
XX Primer for SSCP analysis of DP2.5 (APC).
DE
XX Human; adenomatous Polyposis coli; APC; diagnosis; prognosis;
KW neoplastic tissue; tumour tissue; tumour repressor; mutation;
KW sporadic colorectal cancer; detection; PCR primer; DP2.5;
KW SSCP; single stranded conformation polymorphism; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX US691454-A.
FN
XX 25-NOV-1997.
PD
XX 25-MAY-1995; 95US-0452654.
PF
XX 16-JAN-1991; 91GB-0000962.
PR 16-JAN-1991; 91GB-0000963.
PR 16-JAN-1991; 91GB-0000974.
PR 16-JAN-1991; 91GB-0000975.
PR 08-AUG-1991; 91US-0741940.
PR 12-AUG-1994; 94US-0289548.
PR
XX (CANC-) CANCER INST.
PA (ICIL ) IMPERIAL CHEM IND PLC.
PA (UYJO ) UNIV JOHNS HOPKINS.
PA (UTAH ) UNIV UTAH.
XX
XX Albertsen H, Anand R, Carlson M, Groden J, Hedge PJ,
PI Joslyn G, Kinzler K, Markham AF, Nakamura Y, Thliveris A,
PI Vogelstein B, White RL,
XX WPI; 1998-017712/02.
XX

```

```

PT Antibodies to normal and mutant adenomatous polyposis coli proteins
PT - useful for detecting genetic predisposition to cancer
XX
XX Example 8; Columns 25-26; 107pp; English.
XX
CC The present sequence is a primer for the SSCP analysis of DP2.5
CC (APC), which was used in the development of a novel method of
CC diagnosing or prognosing a human adenomatous Polyposis coli (APC)
CC gene associated neoplastic tissue. The method comprises comparing
CC APC gene coding sequences or mRNA in a tumour tissue, to APC gene
CC coding sequences or mRNA in a non-neoplastic tissue, where a
CC difference indicates an APC gene associated neoplasia of the tumour
CC tissue. APC is a tumour repressor expressed in most normal tissues.
CC APC mutations are found in familial adenomatous polyposis and
CC sporadic colorectal cancer patients. The method enables mutations
CC to be detected to provide an indication of predisposition to
CC cancer.
CC (Updated on 25-MAR-2003 to correct PR field.)
CC
XX Sequence 24 BP; 10 A; 3 C; 4 G; 7 T; 0 other;
SQ
Query Match 1.3%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 58;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 2645 CTTGAGAGATGATTCGTGTTT 2667
Db 23 CTTGAGAGATGATTCGTGTTT 1

RESULT 20
AAA93502/c
ID AAA93502 standard; DNA; 24 BP.
XX
XX AAA93502;
AC
XX 16-JAN-2001 (first entry)
DT
XX Human APC (DP2.5) gene exon 2 PCR primer 1.
DE
XX APC gene; Adenomatous Polyposis Coli gene; human; chromosome 5q21;
KW familial adenomatous polyposis; FAP locus; Gardner's syndrome; GS;
KW sporadic tumour; adenoma; carcinoma; cancer; lung; breast; colon; rectum;
KW bladder; liver; sarcoma; stomach; prostate; leukemia; lymphoma;
KW tumour suppressor; anti-APC antibody; detection; diagnosis; prognosis;
KW genetic predisposition; drug screening; DP2.5; exon; PCR primer; ss.
XX
XX Homo sapiens.
OS
XX US6114124-A.
FN
XX 05-SEP-2000.
PD
XX 25-MAY-1995; 95US-0450582.
PF
XX 16-JAN-1991; 91GB-0000962.
PR 16-JAN-1991; 91GB-0000963.
PR 16-JAN-1991; 91GB-0000974.
PR 16-JAN-1991; 91GB-0000975.
PR 08-AUG-1991; 91US-0741940.
PR 12-AUG-1994; 94US-0289548.
PR
XX (ICIL ) IMPERIAL CHEM IND PLC.
PA (UYJO ) UNIV JOHNS HOPKINS.
PA (UTAH ) UNIV UTAH.
XX
XX (CANC-) CANCER INST.
XX
XX Carlson M, Groden J, Joslyn G, Kinzler K, Markham AF, Anand R,
PI Albertsen H, White RL, Thliveris A, Nakamura Y, Vogelstein B,
PI Hedge PJ,
XX WPI; 2000-565003/52.
XX

```

PT Detecting Adenomatous Polyposis Coli (APC) protein in a sample for
 PT diagnosing cancers, involves contacting the sample with antibodies that
 PT specifically bind to APC protein and detecting the complex formed -
 XX
 PS Example 8; Column 31; 125pp; English.

CC The invention relates to a novel method for detecting Adenomatous
 CC Polyposis Coli (APC) protein in a sample. The method involves
 CC contacting the sample with antibodies which specifically binds to the
 CC 2843 amino acid form of the human APC protein, or to a mutant APC
 CC protein, and detecting an APC-antibody complex. Mutations in the APC
 CC gene play a role in tumorigenesis, indicating that it is a tumour
 CC suppressor gene. It is located on chromosome 5q21, which corresponds to
 CC the FAP (familial adenomatous polyposis) locus. FAP is an autosomal
 CC dominant inherited disease in which affected individuals develop
 CC hundreds to thousands of adenomatous polyps in the colon and rectum,
 CC some of which progress to malignancy. The FAP locus is often found to
 CC be deleted in sporadic (i.e., non-familial) adenomas and carcinomas, and
 CC chromosome 5q deletions have also been observed in tumours of the lung,
 CC breast, colon, rectum, bladder, liver, sarcoma, stomach, and prostate,
 CC and in leukaemias and lymphomas. Although the FAP locus contains
 CC several other genes such as FFR, TBI, T52, and MCC, it is thought that
 CC mutations in the APC gene play a key role in the development of FAP and
 CC sporadic tumours. The method is useful for detecting APC protein and its
 CC mutant forms in foetal tissue, placental tissue, amniotic fluid, blood,
 CC serum or a tumour sample. The method is useful for diagnosing or
 CC prognosing neoplastic tissue, for detecting a genetic predisposition to
 CC cancer, for detecting germline and somatic alteration of wild-type APC
 CC genes, and for testing therapeutic agents for the ability to suppress
 CC tumours. Sequences AAA3500-A93577, AAA3582-A93585 and AAA3602-A93615
 CC represent PCR primers used in exemplifications of the invention to
 CC amplify exonic regions (or exon fragments) of the human APC gene (also
 CC referred to as the DP2.5 gene in the specification).

XX Sequence 24 BP; 10 A; 3 C; 4 G; 7 T; 0 other;

SO Query Match 1.3%; Score 18.2; DB 1; Length 24;
 Best Local Similarity 87.0%; Pred. No. 58;
 Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2645 CTTGAGAGATGATTCGTGTTT 2667
 DB 23 CTTCAAGACATGATTCGTATTT 1

RESULT 21
 ABS67171/C
 ID ABS67171 standard; DNA; 24 BP.
 XX
 AC ABS67171;
 XX
 DT 29-NOV-2002 (first entry)
 XX
 DE DP1, SRP19, DP25 gene SSCP primer #23.
 XX
 KW Adenomatous polyposis coli; APC; human; neoplastic tissue;
 KW mutation detection; tumour; cancer;
 KW single stranded conformational polymorphism; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN US6413727-B1.
 XX
 PD 02-JUL-2002.
 XX
 PF 25-MAY-1995; 95US-0449731.
 XX
 PR 16-JAN-1991; 91GB-0000962.
 PR 16-JAN-1991; 91GB-0000963.
 PR 16-JAN-1991; 91GB-0000974.
 PR 16-JAN-1991; 91GB-0000975.
 PR 08-AUG-1991; 91US-0741940.
 PR 12-AUG-1994; 94US-0289548.

XX
 XX (UYJO) UNIV JOHNS HOPKINS.
 PA (UTRAH) UNIV UTAH.
 PA (NICA-) JAPANESE FOUND CANCER RES.
 PA (ZENE) ZENECA LTD.
 XX
 PI Albertsen H, Aand R, Carlson M, Groden J, Hedge PJ, Joslyn G;
 PI Kinzler K, Marham AF, Nakamura Y, Thliveris A, Vogelstein B;
 PI White RL;
 DR WPI; 2002-641559/69.
 XX
 XX Method to aid in the diagnosis/prognosis of neoplastic tissues in
 PT humans, by detecting somatic alteration of wild-type APC protein in
 PT tumor tissue isolated from human, the alteration indicating neoplasia
 PT of the tissue -

XX Example 15; Column 31-32; 140pp; English.

CC This invention relates to a novel method to aid in the diagnosis or
 CC prognosis of a neoplastic tissue of a human. The method involves
 CC detecting somatic alteration of wild-type adenomatous polyposis coli)
 CC protein in a tumour tissue isolated from a human (the alteration
 CC indicating neoplasia of the tissue). The method of the invention
 CC is useful in diagnosis or prognosis of a neoplastic tissue of a human.
 CC The method is useful in detection of genetic predisposition to cancer.
 CC The present sequence represents a DNA sequence used in the method
 CC of the invention

XX Sequence 24 BP; 10 A; 3 C; 4 G; 7 T; 0 other;

SO Query Match 1.3%; Score 18.2; DB 1; Length 24;
 Best Local Similarity 87.0%; Pred. No. 58;
 Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2645 CTTGAGAGATGATTCGTGTTT 2667
 DB 23 CTTCAAGACATGATTCGTATTT 1

RESULT 22
 AAV60725/C
 ID AAV60725 standard; DNA; 21 BP.
 XX
 AC AAV60725;
 XX
 DT 08-DEC-1998 (first entry)
 XX
 DE Primer #2 for human CDK2 codons 1-151.
 XX
 KW PCR primer; amplification; yeast; UAS; upstream activating sequence;
 KW transcription terminator; cell cycle; Upstream Activation Sequence; UAS;
 KW promoter; phosphorylation; cyclin; cyclin-dependent kinase; CDK; vector;
 KW cyclin kinase inhibitor; CKI; growth; wound healing; cancer therapy; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9816660-A1.
 XX
 PD 23-APR-1998.
 XX
 PF 16-OCT-1997; 97WO-US18608.
 XX
 PR 27-NOV-1996; 96US-0031968.
 PR 16-OCT-1996; 96US-0029127.
 XX
 PA (BITT-) BITTECH INC.
 XX
 PI Bitter GA;
 XX
 DR WPI; 1998-251302/22.

PT Screening for agents that effect cell cycle regulatory proteins -
 PT using a cell line that expresses a reporter gene in response to
 PT regulation through phosphorylation by a cyclin/CDK system
 XX Example 4; Page 68; 93pp; English.

CC Primers AAV60724-V60725 were used to PCR amplify codons 1-151 of the
 CC human cyclin-dependent kinase 2 (hCDK2). The amplified product was used
 CC to generate a fusion protein comprising part of the hCDK2 sequence
 CC linked to codons 155-302 of the yeast PH085 gene. The fusion protein is
 CC used to screen for compounds that affect mammalian cell cycle regulatory
 CC proteins. The method comprises administering a compound to a cell line,
 CC which contains a reporter gene linked to an Upstream Activation Sequence
 CC (UAS) and a promoter, where the UAS binds a transcription control factor
 CC (TCF) which is regulated through cyclin/cyclin-dependent kinase (CDK)
 CC phosphorylation. Also included in the construct is an effector gene
 CC providing a gene product to permit normal cyclin/CDK regulation of the
 CC TCF. Expression of the reporter gene is then analysed in the cell line,
 CC thereby determining whether the compound affects the normal regulation.
 CC The method can be used to identify inhibitors and activators of
 CC mammalian cell cycle regulatory proteins, especially inhibitors and
 CC activators of cyclins, CDKs, cyclin/CDK complexes, cyclin kinase
 CC inhibitors (CKIs), and cyclin/CDK complexes. The identified agents
 CC can be used for stimulating growth of cells (as in wound healing), or
 CC regulating excessive cell growth and division (as in cancer therapy).

XX Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 other;
 SQ

Query Match 1.3%; Score 17.8; DB 1; Length 21;
 Best Local Similarity 90.5%; Pred. No. 55;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2203 GACTTTGACTCGCCAGAGAT 2223
 Db 21 GACTTTGACTCGCCAGAGAT 1

RESULT 23
 AA218094/C
 ID AA218094 standard; DNA; 21 BP.
 XX
 AC AA218094;
 XX
 XX 11-OCT-1999 (first entry)
 XX
 DE PTK 2 gene specific primer.
 XX
 KW Genetic proximity; gene expression; cell characterisation; homeobox gene;
 KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
 KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
 KW primer; ss.
 XX
 KM Synthetic.
 OS Homo sapiens.
 OS
 XX
 PN MO9934016-A2.
 XX
 PD 08-JUL-1999.
 XX
 PF 28-DEC-1998; 98WO-IL00625.
 XX
 PR 16-OCT-1998; 98IL-0126627.
 PR 29-DEC-1997; 97IL-0122793.
 XX
 PA (GENE-) GENENALTD.
 PI
 PI Vidar B;
 XX
 DR WPI; 1999-419113/35.
 DR P-PSDB; AAY14629.
 XX
 PT Identifying and characterizing cells by comparing the pattern of
 PT gene expression in a selected gene family

XX Claim 4; Page 42; 102pp; English.
 PS
 XX
 XX The invention provides a new method for identifying and characterizing
 CC cells. The method for determining the genetic proximity of a first cell
 CC and a second cell comprises: (a) obtaining the first cell and the second
 CC cell; (b) determining in the first cell and the second cell the pattern
 CC of expression of genes in a selected gene family; and (c) calculating a
 CC proximity index using a specified formula. The methods can be used for
 CC characterizing cells, e.g. for determining the origin of a cell, its
 CC genetic status, whether it carries a genetic defect, or whether it is
 CC transformed. They can be used for detecting a selected genetic defect in
 CC an individual, e.g. a fetus. They can also be used for determining the
 CC effect of a selected treatment on a test cell. They can also be used for
 CC obtaining cells capable of expressing an homeobox related desired
 CC property. The method uses reverse transcriptase polymerase chain
 CC reaction (RT-PCR) for determining the pattern of gene expression in a
 CC selected gene family. Sequences AA217803-218342 represent primers that
 CC can be used in the RT-PCR reactions to determine the pattern of gene
 CC expression. The gene family can be selected from a set of homeobox genes,
 CC kinase genes, protein phosphatase genes, P450 enzyme genes, steroid
 CC receptor superfamily genes or cadherin superfamily genes.

XX Sequence 21 BP; 7 A; 8 C; 3 G; 3 T; 0 other;
 SQ

Query Match 1.3%; Score 17.8; DB 1; Length 21;
 Best Local Similarity 90.5%; Pred. No. 55;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2233 AGTGATGTCGTGCTCCGCG 2343
 Db 21 AGTGATGTCGTGCTCTATGCG 1

RESULT 24
 AA218102/C
 ID AA218102 standard; DNA; 21 BP.
 XX
 AC AA218102;
 XX
 XX 11-OCT-1999 (first entry)
 XX
 DE PTK 6 gene specific primer.
 XX
 KW Genetic proximity; gene expression; cell characterisation; homeobox gene;
 KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
 KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
 KW primer; ss.
 XX
 KM Synthetic.
 OS Homo sapiens.
 OS
 XX
 PN MO9934016-A2.
 XX
 PD 08-JUL-1999.
 XX
 PF 28-DEC-1998; 98WO-IL00625.
 XX
 PR 16-OCT-1998; 98IL-0126627.
 PR 29-DEC-1997; 97IL-0122793.
 XX
 PA (GENE-) GENENALTD.
 PI
 PI Vidar B;
 XX
 DR WPI; 1999-419113/35.
 DR P-PSDB; AAY14637.
 XX
 PT Identifying and characterizing cells by comparing the pattern of
 PT gene expression in a selected gene family
 XX
 PS Claim 4; Page 42; 102pp; English.

CC The invention provides a new method for identifying and characterizing
 CC cells. The method for determining the genetic proximity of a first cell
 CC and a second cell comprises: (a) obtaining the first cell and the second
 CC cell; (b) determining in the first cell and the second cell the pattern
 CC of expression of genes in a selected gene family; and (c) calculating a
 CC proximity index using a specified formula. The methods can be used for
 CC characterizing cells, e.g. for determining the origin of a cell, its
 CC genetic status, whether it carries a genetic defect, or whether it is
 CC transformed. They can also be used for determining the effect of a
 CC selected treatment on a test cell. They can also be used for
 CC obtaining cells capable of expressing an homeobox related desired
 CC property. The method uses reverse transcriptase polymerase chain
 CC reaction (RT-PCR) for determining the pattern of gene expression in a
 CC selected gene family. Sequences AA217803-218342 represent primers that
 CC can be used in the RT-PCR reactions to determine the pattern of gene
 CC expression. The gene family can be selected from a set of homeobox genes,
 CC kinase genes, protein phosphatase genes, P450 enzyme genes, steroid
 CC receptor superfamily genes or cadherin superfamily genes.

XX Sequence 21 BP; 7 A; 8 C; 3 G; 3 T; 0 other;

Query Match 1.3%; Score 17.8; DB 1; Length 21;
 Best Local Similarity 90.5%; Pred. No. 55;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2323 AGTATGCTGCTGCTTGGG 2343

Db 21 AGTATGCTGCTGCTTGGG 1

RESULT 25

AA218110/c
 ID AA218110 standard; DNA; 21 BP.

AC AA218110;

DT 11-OCT-1999 (first entry)

DE PTK 10 gene specific primer.

XX Genetic proximity; gene expression; cell characterisation; homeobox gene;
 KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
 KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
 KW primer; ss.

XX Synthetic.

OS Homo sapiens.

XX WO9934016-A2.

PD 08-JUL-1999.

PF 28-DEC-1998; 98WO-IL00625.

PR 16-OCT-1998; 98IL-0126627.

PR 29-DEC-1997; 97IL-0122793.

PA (GENE-) GENENNA LTD.

PI Vider B;

DR WPI; 1999-419113/35.

DR P-PSDB; AAY14645.

PT Identifying and characterizing cells by comparing the pattern of
 PT gene expression in a selected gene family

XX Claim 4; Page 42; 102pp; English.

XX The invention provides a new method for identifying and characterizing
 CC cells. The method for determining the genetic proximity of a first cell
 CC and a second cell comprises: (a) obtaining the first cell and the second
 CC cell; (b) determining in the first cell and the second cell the pattern
 CC of expression of genes in a selected gene family; and (c) calculating a
 CC proximity index using a specified formula. The methods can be used for

CC cell; (b) determining in the first cell and the second cell the pattern
 CC of expression of genes in a selected gene family; and (c) calculating a
 CC proximity index using a specified formula. The methods can be used for
 CC characterizing cells, e.g. for determining the origin of a cell, its
 CC genetic status, whether it carries a genetic defect, or whether it is
 CC transformed. They can also be used for determining the effect of a
 CC selected treatment on a test cell. They can also be used for
 CC obtaining cells capable of expressing an homeobox related desired
 CC property. The method uses reverse transcriptase polymerase chain
 CC reaction (RT-PCR) for determining the pattern of gene expression in a
 CC selected gene family. Sequences AA217803-218342 represent primers that
 CC can be used in the RT-PCR reactions to determine the pattern of gene
 CC expression. The gene family can be selected from a set of homeobox genes,
 CC kinase genes, protein phosphatase genes, P450 enzyme genes, steroid
 CC receptor superfamily genes or cadherin superfamily genes.

SQ Sequence 21 BP; 7 A; 8 C; 3 G; 3 T; 0 other;

Query Match 1.3%; Score 17.8; DB 1; Length 21;
 Best Local Similarity 90.5%; Pred. No. 55;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2323 AGTATGCTGCTGCTTGGG 2343

Db 21 AGTATGCTGCTGCTTGGG 1

RESULT 26

AA218118/c
 ID AA218118 standard; DNA; 21 BP.

AC AA218118;

DT 11-OCT-1999 (first entry)

DE PTK 14 gene specific primer.

XX Genetic proximity; gene expression; cell characterisation; homeobox gene;
 KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
 KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
 KW primer; ss.

XX Synthetic.

OS Homo sapiens.

XX WO9934016-A2.

PD 08-JUL-1999.

PF 28-DEC-1998; 98WO-IL00625.

PR 16-OCT-1998; 98IL-0126627.

PR 29-DEC-1997; 97IL-0122793.

PA (GENE-) GENENNA LTD.

PI Vider B;

DR WPI; 1999-419113/35.

DR P-PSDB; AAY14653.

PT Identifying and characterizing cells by comparing the pattern of
 PT gene expression in a selected gene family

XX Claim 4; Page 43; 102pp; English.

XX The invention provides a new method for identifying and characterizing
 CC cells. The method for determining the genetic proximity of a first cell
 CC and a second cell comprises: (a) obtaining the first cell and the second
 CC cell; (b) determining in the first cell and the second cell the pattern
 CC of expression of genes in a selected gene family; and (c) calculating a
 CC proximity index using a specified formula. The methods can be used for

CC characterizing cells, e.g. for determining the origin of a cell, its
CC genetic status, whether it carries a genetic defect, or whether it is
CC transformed. They can be used for detecting a selected genetic defect in
CC an individual, e.g. a fetus. They can also be used for determining the
CC effect of a selected treatment on a test cell. They can also be used for
CC obtaining cells capable of expressing an homeobox related desired
CC property. The method uses reverse transcriptase polymerase chain
CC reaction (RT-PCR) for determining the pattern of gene expression in a
CC selected gene family. Sequences AA217803-218342 represent primers that
CC can be used in the RT-PCR reactions to determine the pattern of gene
CC expression. The gene family can be selected from a set of homeobox genes,
CC kinase genes, protein phosphatase genes, P450 enzyme genes, steroid
CC receptor superfamily genes or cadherin superfamily genes.

XX Sequence 21 BP; 7 A; 8 C; 3 G; 3 T; 0 other;

SO Query Match 1.3%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 55;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2323 AGTATGTCGTGCTCCTCGGG 2343
DB 21 AGTGATGTCGTGCTCCTATGG 1

RESULT 27
AA218216/c
ID AA218216 standard; DNA; 21 BP.
XX
AC AA218216;
XX
DT 11-OCT-1999 (first entry)
XX
DE Tyrosine kinase gene specific primer 409.
XX
KW Genetic proximity; gene expression; cell characterisation; homeobox gene;
KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
KW primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9934016-A2.
XX
PD 08-JUL-1999.
XX
PF 28-DEC-1998; 98WO-IL00625.
XX
PR 16-OCT-1998; 98IL-0126627.
PR 29-DEC-1997; 97IL-0122793.
XX
PA (GENE-) GENENNA LTD.
XX
PI Vider B;
XX
XX WPI; 1999-419113/35.
DR P-PSDB; AAY14750.
XX
PT Identifying and characterizing cells by comparing the pattern of
PT gene expression in a selected gene family

XX Claim 4; Page 48; 102pp; English.

XX The invention provides a new method for identifying and characterizing
XX cells. The method for determining the genetic proximity of a first cell
XX and a second cell comprises: (a) obtaining the first cell and the second
XX cell; (b) determining in the first cell and the second cell the pattern
XX of expression of genes in a selected gene family; and (c) calculating a
XX proximity index using a specified formula. The method can be used for
XX characterizing cells, e.g. for determining the origin of a cell, its
XX genetic status, whether it carries a genetic defect, or whether it is
XX transformed. They can be used for detecting a selected genetic defect in

CC an individual, e.g. a fetus. They can also be used for determining the
CC effect of a selected treatment on a test cell. They can also be used for
CC obtaining cells capable of expressing an homeobox related desired
CC property. The method uses reverse transcriptase polymerase chain
CC reaction (RT-PCR) for determining the pattern of gene expression in a
CC selected gene family. Sequences AA217803-218342 represent primers that
CC can be used in the RT-PCR reactions to determine the pattern of gene
CC expression. The gene family can be selected from a set of homeobox genes,
CC kinase genes, protein phosphatase genes, P450 enzyme genes, steroid
CC receptor superfamily genes or cadherin superfamily genes.

XX Sequence 21 BP; 6 A; 9 C; 4 G; 2 T; 0 other;

SO Query Match 1.3%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 55;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2323 AGTATGTCGTGCTCCTCGGG 2343
DB 21 AGCGATGTCGTGCTCCTCGGG 1

RESULT 28
AAA82640
ID AAA82640 standard; DNA; 19 BP.
XX
AC AAA82640;
XX
DT 04-DEC-2000 (first entry)
XX
DE cdk2 ribozyme binding site #77.
XX
KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic;
KW restenosis; ss.
XX
OS Mammalia.
XX
PN WO200032765-A2.
XX
PD 08-JUN-2000.
XX
PF 06-DEC-1999; 99WO-US28772.
XX
PR 04-DEC-1998; 98US-0110954.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Tritz R, Welch PJ, Barber JR, Robbins JW;
XX
XX WPI; 2000-412314/35.
DR
XX
PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1 -
XX
XX Disclosure; Page 49; 109pp; English.

XX The present invention relates to a hairpin or hammerhead ribozyme,
XX designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
XX other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
XX Representative examples of ribozyme recognition sites are given in
XX AA82415 to AA86787. The ribozyme of the invention is useful for
XX inhibiting restenosis by introduction of the ribozyme into cells.
XX The ribozyme is resistant to endonuclease activity and hence is
XX efficient in restenosis treatment.

XX Sequence 19 BP; 5 A; 4 C; 5 G; 5 T; 0 other;

SO Query Match 1.2%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 56;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2198 TAGCAGACTTTGACCTCGC 2216

Db 1 TAGCAGACTTTGAGCTAGC 19

RESULT 29
AAH57802
ID AAH57802 standard; DNA; 19 BP.

XX AAH57802;

DT 04-DEC-2000 (first entry)

DE cdk2 ribozyme binding site #78.

XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic;
KM reestenosis; ss.

XX Mammalia.

PN WO200032765-A2.

XX 08-JUN-2000.

PP 06-DEC-1999; 99WO-US28772.

PR 04-DEC-1998; 98US-0110954.

XX (IMMU-) IMMUSOL INC.

PI Tritz R, Welch PJ, Barber JR, Robbins JM;

DR WPI; 2000-412314/35.

PT New hairpin and hammerhead ribozyme for inhibiting reestenosis, cleaves
RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PCNA and Cyclin B1

XX Disclosure; Page 49; 109pp; English.

CC The present invention relates to a hairpin or hammerhead ribozyme,
designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.

CC Representative examples of ribozyme recognition sites are given in
CC AA82415 to AA86787. The ribozyme of the invention is useful for
inhibiting reestenosis by introduction of the ribozyme into cells.

CC The ribozyme is resistant to endonuclease activity and hence is
efficient in reestenosis treatment.

XX Sequence 19 BP; 5 A; 5 C; 5 G; 4 T; 0 other;

Query Match 1.2%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 56;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2199 AGCAGACTTTGAGCTGCC 2217
Db 1 AGCAGACTTTGAGCTAGC 19

RESULT 30
AAH57802
ID AAH57802 standard; DNA; 19 BP.

XX AAH57802;

DT 10-SEP-2001 (first entry)

DE Cell-cycle dependent kinase cdk2 ribozyme binding site SEQ ID NO:226.

XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KM recognition site; target; ribozyme binding site; eye disease; vulnery;
KM proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KM cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;

KM matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KM antiproliferative; dermatological; anti-seborrheic; antidiabetic; virucide;
KM antiscaling; ophthalmological; keratolytic; gene therapy; viral wart;
KM atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KM basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KM sickle cell retinopathy; ss.

XX Homo sapiens.
OS Synthetic.

PN WO200130362-A2.

XX 03-MAY-2001.

PP 26-OCT-2000; 2000WO-US29500.

PR 26-OCT-1999; 99US-0161532.

XX (IMMU-) IMMUSOL INC.

PI Robbins JM, Tritz R;

DR WPI; 2001-300427/31.

PT Treating proliferative skin or eye diseases and scarring, using
PT ribozymes that cleave RNA encoding cytokines involved in inflammation,
matrix metalloproteinases, growth factors and cell-cycle dependent
PT kinases

PS Example 1; Page 88; 408pp; English.

CC The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antiproliferative,
CC dermatological, cytostatic, anti-seborrheic, antidiabetic, antiscaling,
CC ophthalmological, vulnery, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative
CC skin diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH57099 represent sequences used in the
CC exemplification of the present invention.

XX Sequence 19 BP; 5 A; 4 C; 5 G; 5 T; 0 other;

Query Match 1.2%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 56;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2198 TAGCAGACTTTGAGCTGCC 2216
Db 1 TAGCAGACTTTGAGCTAGC 19

RESULT 31
AAH57803
ID AAH57803 standard; DNA; 19 BP.

XX AAH57803;

DT 10-SEP-2001 (first entry)

DE Cell-cycle dependent kinase cdk2 ribozyme binding site SEQ ID NO:227.

XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;

recognition site; target; ribozyme binding site; eye disease; vulnery; proliferative disease; skin disease; psoriasis; diabetic retinopathy; cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP; matrix metalloproteinase; growth factor; reductase; scarring; cytostatic; antiproliferic; dermatological; antiseborrheic; antidiabetic; virucide; anti-sclerotic; ophthalmological; keratolytic; gene therapy; viral wart; atopic dermatitis; actinic keratosis; squamous cell carcinoma; basal cell carcinoma; seboreic wart; vitreoretinopathy; scar; sickle cell retinopathy; ss.

Homo sapiens.
Synthetic.
WO200130362-A2.

03-MAY-2001.

26-OCT-2000; 2000WO-US29500.

26-OCT-1999; 99US-0161532.

(IMMU-) IMMUSOL INC.

Robbins JM, Tritz R;
WPI; 2001-300427/31.

Treating proliferative skin or eye diseases and scarring, using ribozymes that cleave RNA encoding cytokines involved in inflammation, matrix metalloproteinases, growth factors and cell-cycle dependent kinases -

Example 1; Page 88; 408pp; English.

The present invention describes a method for treating a proliferative skin or eye disease and scarring. The method involves administering a ribozyme (I) which cleaves RNA encoding a cytokine involved in inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle dependent kinase, growth factor or a reductase, or administering a nucleic acid molecule (II) comprising a promoter operably linked to a nucleic acid segment encoding (i). (i) can have antiproliferic, dermatological, cytostatic, antiseborrheic, antidiabetic, anti-sclerotic, ophthalmological, vulnery, keratolytic and virucide activities, and cleaves RNA encoding cytokine involved in inflammation. (I) can be used in gene therapy. (I) and (II) are useful for treating proliferative skin diseases such as psoriasis, atopic dermatitis, actinic keratosis, squamous or basal cell carcinoma and viral or seboreic wart. They can also be used for treating proliferative eye diseases such as diabetic retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of prematurity and retinal detachment, and for treating and preventing scarring such as keloid, adhesion and hypertrophic or hypertrophic burn scar. AAH57577 to AAH62099 represent sequences used in the exemplification of the present invention.

Sequence 19 BP; 5 A; 5 C; 5 G; 4 T; 0 other;

Query Match 1.2%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 56;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

2199 AGCAGACTTGGACTCGCC 2217
|||||
1 AGCAGACTTGGACTAGCC 19

RESULT 32
ABS78766
ID ABS78766 standard; DNA; 22 BP.
XX
AC ABS78766;
XX
DT 16-DEC-2002 (first entry)
XX

Human NOX forward primer Ag3477.

Human; NOX; human disease; NOX-associated disorder; cancer; addiction; Hodgkin disease; Von Hippel-Lindau syndrome; Alzheimer's disease; stroke; tubercous sclerosis; hypercalcaemia; Parkinson's disease; depression; Huntington's disease; cerebral palsy; epilepsy; Lesch-Nyhan syndrome; multiple sclerosis; ataxia-telangiectasia; leukodystrophy; anxiety; pain; obesity; Crohn's disease; osteoporosis; inflammatory bowel disease; infertility; inflammatory bowel disease; atherosclerosis; hypertension; scleroderma; haemophilia; diabetes; pancreatitis; autoimmune disease; asthma; arthritis; immunodeficiency; HIV; viral infection; neurogenesis; bacterial infection; parasitic infection; graft-versus-host disease; cell differentiation; cell proliferation; haematopoiesis; wound healing; angiogenesis; PCR; primer; ss.

Homo sapiens.
WO200272770-A2.

19-SEP-2002.

08-MAR-2002; 2002WO-US07283.

08-MAR-2001; 2001US-274281P.
09-MAR-2001; 2001US-274849P.
12-MAR-2001; 2001US-275235P.
13-MAR-2001; 2001US-275579P.
13-MAR-2001; 2001US-275601P.
14-MAR-2001; 2001US-276000P.
20-MAR-2001; 2001US-277233P.
20-MAR-2001; 2001US-277327P.
20-MAR-2001; 2001US-277338P.
21-MAR-2001; 2001US-277791P.
22-MAR-2001; 2001US-278333P.
23-MAR-2001; 2001US-278152P.
26-MAR-2001; 2001US-278894P.
27-MAR-2001; 2001US-279036P.
28-MAR-2001; 2001US-279344P.
30-MAR-2001; 2001US-280232P.
02-APR-2001; 2001US-280802P.
02-MAY-2001; 2001US-288148P.
31-MAY-2001; 2001US-294821P.
31-OCT-2001; 2001US-335302P.
04-DEC-2001; 2001US-338375P.
07-MAR-2002; 2002US-0094466.

(CURA-) CURAGEN CORP.

Spytek KA, Vernet CA, Tchernev VT, Malyanar UM, Gerlach VL, Li L, Zernusen BD, Paturajan M, Gusev VY, Kekuda R, Pena CEA, Zhong M, Gangoli EA, Taupier RJ;
WPI; 2002-713508/77.

New NOX polypeptides and polynucleotides, useful for preventing, diagnosing or treating NOX-associated disorders, e.g. diabetes, multiple sclerosis, atherosclerosis, cancer, infections, osteoporosis or Parkinson's disease -

Example C; Page 200; 266pp; English.

The present invention relates to a new polypeptide (NOX). The NOX polypeptide, nucleic acid and antibody are useful in the manufacture of a medicament for treating a syndrome associated with a human disease, preferably a NOX-associated disorder. The NOX nucleic acids, polypeptides and antibodies are useful for treating, preventing or diagnosing diseases such as cancer, Hodgkin disease, Von Hippel-Lindau syndrome, Alzheimer's disease, stroke, tubercous sclerosis, hypercalcaemia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, addiction, anxiety, depression, pain, obesity, Crohn's disease, osteoporosis, inflammatory bowel disease, infertility, inflammatory bowel disease, atherosclerosis, hypertension,

CC scleroderma, haemophilia, diabetes, pancreatitis, autoimmune disease,
 CC asthma, arthritis, immunodeficiencies, HIV, viral, bacterial or parasitic
 CC infections, or graft-versus-host disease. The nucleic acids and
 CC polypeptides may also be used as targets for the identification of small
 CC molecules that modulate or inhibit e.g. neurogenesis, wound healing and
 CC differentiation, cell proliferation, haematopoiesis, cell
 CC angiogenesis, in gene therapy, in generation of antibodies that bind
 CC immunospecifically to NOVX substances for use in therapeutic or
 CC diagnostic methods. The nucleic acids are further used as hybridisation
 CC probes, in chromosome mapping, tissue typing, preventive medicine, and
 CC pharmacogenomics. The present nucleic acid sequence represents a PCR
 CC primer that was used in the methods of the invention for amplification
 CC of human NOVX.

XX Sequence 22 BP; 10 A; 3 C; 4 G; 5 T; 0 other;

Query Match 1.2%; Score 17.2; DB 1; Length 22;
 Best Local Similarity 86.4%; Pred. No. 74;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1686 TGAAGATGATTCGGAACACAA 1907
 DB 1 TGAACATGTTGAAACACAA 22

RESULT 33

AAZ18107
 ID AAZ18107 standard; DNA; 20 BP.

XX AAZ18107;

XX 11-OCT-1999 (first entry)

XX PTK 9 gene specific primer.

XX Genetic proximity; gene expression; cell characterisation; homeobox gene;
 KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
 KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
 KW primer; ss.

XX Synthetic.

OS Homo sapiens.

XX MO9934016-A2.

XX 08-JUL-1999.

XX 28-DEC-1998; 98WO-IL00625.

XX 16-OCT-1998; 98IL-0126627.

XX 29-DEC-1997; 97IL-0122793.

XX (GENE-) GENENNA LTD.

XX Vidler B;

XX WPI; 1999-419113/35.

XX P-PSDB; AAY14642.

XX Identifying and characterizing cells by comparing the pattern of
 PT gene expression in a selected gene family

XX Claim 4; Page 42; 102pp; English.

XX The invention provides a new method for identifying and characterising
 CC cells. The method for determining the genetic proximity of a first cell
 CC and a second cell comprises: (a) obtaining the first cell and the second
 CC cell; (b) determining in the first cell and the second cell the pattern
 CC of expression of genes in a selected gene family; and (c) calculating a
 CC proximity index using a specified formula. The methods can be used for
 CC characterising cells, e.g. for determining the origin of a cell, its
 CC genetic status, whether it carries a genetic defect, or whether it is
 CC transformed. They can be used for detecting a selected genetic defect in

CC an individual, e.g. a fetus. They can also be used for determining the
 CC effect of a selected treatment on a test cell. They can also be used for
 CC obtaining cells capable of expressing an homeobox related desired
 CC property. The method uses reverse transcriptase polymerase chain
 CC reaction (RT-PCR) for determining the pattern of gene expression in a
 CC selected gene family. Sequences AAZ17803-218342 represent primers that
 CC can be used in the RT-PCR reactions to determine the pattern of gene
 CC expression. The gene family can be selected from a set of homeobox genes,
 CC kinase genes, protein phosphatase genes, P450 enzyme genes, steroid
 CC receptor superfamily genes or cadherin superfamily genes.

XX Sequence 20 BP; 7 A; 3 C; 4 G; 6 T; 0 other;

Query Match 1.2%; Score 17; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 69;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2194 AAAATAGCAGACTTTGG 2210
 DB 1 AAAATAGCAGACTTTGG 17

RESULT 34

AAZ18109
 ID AAZ18109 standard; DNA; 20 BP.

XX AAZ18109;

XX 11-OCT-1999 (first entry)

XX PTK 10 gene specific primer.

XX Genetic proximity; gene expression; cell characterisation; homeobox gene;
 KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
 KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
 KW primer; ss.

XX Synthetic.

OS Homo sapiens.

XX MO9934016-A2.

XX 08-JUL-1999.

XX 28-DEC-1998; 98WO-IL00625.

XX 16-OCT-1998; 98IL-0126627.

XX 29-DEC-1997; 97IL-0122793.

XX (GENE-) GENENNA LTD.

XX Vidler B;

XX WPI; 1999-419113/35.

XX P-PSDB; AAY14644.

XX Identifying and characterizing cells by comparing the pattern of
 PT gene expression in a selected gene family

XX Claim 4; Page 42; 102pp; English.

XX The invention provides a new method for identifying and characterising
 CC cells. The method for determining the genetic proximity of a first cell
 CC and a second cell comprises: (a) obtaining the first cell and the second
 CC cell; (b) determining in the first cell and the second cell the pattern
 CC of expression of genes in a selected gene family; and (c) calculating a
 CC proximity index using a specified formula. The methods can be used for
 CC characterising cells, e.g. for determining the origin of a cell, its
 CC genetic status, whether it carries a genetic defect, or whether it is
 CC transformed. They can be used for detecting a selected genetic defect in
 CC an individual, e.g. a fetus. They can also be used for determining the
 CC effect of a selected treatment on a test cell. They can also be used for
 CC obtaining cells capable of expressing an homeobox related desired

CC property. The method uses reverse transcriptase polymerase chain
 CC reaction (RT-PCR) for determining the pattern of gene expression in a
 CC selected gene family. Sequences AA217803-218342 represent primers that
 CC can be used in the RT-PCR reactions to determine the pattern of gene
 CC expression. The gene family can be selected from a set of homeobox genes,
 CC kinase genes, protein phosphatase genes, P450 enzyme genes, steroid
 CC receptor superfamily genes or cadherin superfamily genes.

XX Sequence 20 BP; 7 A; 3 C; 4 G; 6 T; 0 other;

Query Match 1.2%; Score 17; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 69;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 2194 AAATAGCAGACTTTGG 2210
 Db 1 AAATAGCAGACTTTGG 17

RESULT 35

AA218113
 ID AA218113 standard; DNA; 20 BP.

AC AA218113;

DT 11-OCT-1999 (first entry)

XX PTK 11 gene specific primer.

XX Genetic proximity; gene expression; cell characterisation; homeobox gene;

KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;

KM kinase gene; protein phosphatase; P450; steroid receptor; cadherin;

KM primer; ss.

XX Synthetic.

OS Homo sapiens.

XX MO9934016-A2.

XX 08-JUL-1999.

PF 28-DEC-1998; 98WO-IL00625.

XX 16-OCT-1998; 98IL-0126627.

PR 29-DEC-1997; 97IL-0122793.

XX (GENE-) GENENALTD.

PA Vidler B;

PI WPI; 1999-419113/35.

DR P-PSDB; AAY14646.

XX Claim 4; Page 42; 102pp; English.

XX The invention provides a new method for identifying and characterizing
 CC cells. The method for determining the genetic proximity of a first cell
 CC and a second cell comprises: (a) obtaining the first cell and the second
 CC cell; (b) determining in the first cell and the second cell the pattern
 CC of expression of genes in a selected gene family; and (c) calculating a
 CC proximity index using a specified formula. The methods can be used for
 CC characterizing cells, e.g. for determining the origin of a cell, its
 CC genetic status, whether it carries a genetic defect, or whether it is
 CC transformed. They can be used for detecting a selected genetic defect in
 CC an individual, e.g. a fetus. They can also be used for determining the
 CC effect of a selected treatment on a test cell. They can also be used for
 CC obtaining cells capable of expressing an homeobox related desired
 CC property. The method uses reverse transcriptase polymerase chain
 CC reaction (RT-PCR) for determining the pattern of gene expression in a
 CC selected gene family. Sequences AA217803-218342 represent primers that

CC can be used in the RT-PCR reactions to determine the pattern of gene
 CC expression. The gene family can be selected from a set of homeobox genes,
 CC kinase genes, protein phosphatase genes, P450 enzyme genes, steroid
 CC receptor superfamily genes or cadherin superfamily genes.

XX Sequence 20 BP; 7 A; 3 C; 4 G; 6 T; 0 other;

Query Match 1.2%; Score 17; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 69;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 2194 AAATAGCAGACTTTGG 2210
 Db 1 AAATAGCAGACTTTGG 17

RESULT 36

AA218113
 ID AA218113 standard; DNA; 20 BP.

AC AA218113;

DT 11-OCT-1999 (first entry)

XX PTK 12 gene specific primer.

XX Genetic proximity; gene expression; cell characterisation; homeobox gene;

KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;

KM kinase gene; protein phosphatase; P450; steroid receptor; cadherin;

KM primer; ss.

XX Synthetic.

OS Homo sapiens.

XX MO9934016-A2.

XX 08-JUL-1999.

PF 28-DEC-1998; 98WO-IL00625.

XX 16-OCT-1998; 98IL-0126627.

PR 29-DEC-1997; 97IL-0122793.

XX (GENE-) GENENALTD.

PA Vidler B;

PI WPI; 1999-419113/35.

DR P-PSDB; AAY14648.

XX Claim 4; Page 42; 102pp; English.

XX The invention provides a new method for identifying and characterizing
 CC cells. The method for determining the genetic proximity of a first cell
 CC and a second cell comprises: (a) obtaining the first cell and the second
 CC cell; (b) determining in the first cell and the second cell the pattern
 CC of expression of genes in a selected gene family; and (c) calculating a
 CC proximity index using a specified formula. The methods can be used for
 CC characterizing cells, e.g. for determining the origin of a cell, its
 CC genetic status, whether it carries a genetic defect, or whether it is
 CC transformed. They can be used for detecting a selected genetic defect in
 CC an individual, e.g. a fetus. They can also be used for determining the
 CC effect of a selected treatment on a test cell. They can also be used for
 CC obtaining cells capable of expressing an homeobox related desired
 CC property. The method uses reverse transcriptase polymerase chain
 CC reaction (RT-PCR) for determining the pattern of gene expression in a
 CC selected gene family. Sequences AA217803-218342 represent primers that
 CC can be used in the RT-PCR reactions to determine the pattern of gene
 CC expression. The gene family can be selected from a set of homeobox genes,
 CC kinase genes, protein phosphatase genes, P450 enzyme genes, steroid

CC receptor superfamily genes or cadherin superfamily genes.
 XX Sequence 20 BP; 7 A; 3 C; 4 G; 6 T; 0 other;

Query Match 1.2%; Score 17; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 69;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2194 AAATAGCAGACTTTGG 2210
 Db 1 AAATAGCAGACTTTGG 17

RESULT 37
 AA218189
 ID AA218189 standard; DNA; 20 BP.

AC AA218189;
 XX
 DT 11-OCT-1999 (first entry)
 XX
 DE PTK 31 gene specific primer.

XX Genetic proximity; gene expression; cell characterisation; homeobox gene;
 KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
 KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
 KW primer; ss.

XX Synthetic.
 OS Homo sapiens.

XX WO9934016-A2.

XX 08-JUL-1999.

XX 28-DEC-1998; 98WO-IL00625.

XX 16-OCT-1998; 98IL-0126627.

XX 29-DEC-1997; 97IL-0122793.

XX (GENE-) GENENVA LTD.

XX Vider B;

XX WPI; 1999-419113/35.

XX P-PSDB; AAY14724.

PT Identifying and characterizing cells by comparing the pattern of
 gene expression in a selected gene family

XX Claim 4; Page 47; 102pp; English.

CC The invention provides a new method for identifying and characterising
 CC cells. The method for determining the genetic proximity of a first cell
 CC and a second cell comprises: (a) obtaining the first cell and the second
 CC cell; (b) determining in the first cell and the second cell the pattern
 CC of expression of genes in a selected gene family; and (c) calculating a
 CC proximity index using a specified formula. The methods can be used for
 CC characterising cells, e.g. for determining the origin of a cell, its
 CC genetic status, whether it carries a genetic defect, or whether it is
 CC transformed. They can be used for detecting a selected genetic defect in
 CC an individual, e.g. a fetus. They can also be used for determining the
 CC effect of a selected treatment on a test cell. They can also be used for
 CC obtaining cells capable of expressing an homeobox related desired
 CC property. The method uses reverse transcriptase polymerase chain
 CC reaction (RT-PCR) for determining the pattern of gene expression in a
 CC selected gene family. Sequences AA217803-218342 represent primers that
 CC can be used in the RT-PCR reactions to determine the pattern of gene
 CC expression. The gene family can be selected from a set of homeobox genes,
 CC kinase genes, protein phosphatase genes, P450 enzyme genes, steroid
 CC receptor superfamily genes or cadherin superfamily genes.

XX Sequence 20 BP; 7 A; 3 C; 4 G; 6 T; 0 other;

Query Match 1.2%; Score 17; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 69;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2194 AAATAGCAGACTTTGG 2210
 Db 1 AAATAGCAGACTTTGG 17

RESULT 38
 AA218191
 ID AA218191 standard; DNA; 20 BP.

AC AA218191;
 XX
 DT 11-OCT-1999 (first entry)
 XX
 DE PTK 32 gene specific primer.

XX Genetic proximity; gene expression; cell characterisation; homeobox gene;
 KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
 KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
 KW primer; ss.

XX Synthetic.
 OS Homo sapiens.

XX WO9934016-A2.

XX 08-JUL-1999.

XX 28-DEC-1998; 98WO-IL00625.

XX 16-OCT-1998; 98IL-0126627.

XX 29-DEC-1997; 97IL-0122793.

XX (GENE-) GENENVA LTD.

XX Vider B;

XX WPI; 1999-419113/35.

XX P-PSDB; AAY14726.

PT Identifying and characterizing cells by comparing the pattern of
 gene expression in a selected gene family

XX Claim 4; Page 47; 102pp; English.

CC The invention provides a new method for identifying and characterising
 CC cells. The method for determining the genetic proximity of a first cell
 CC and a second cell comprises: (a) obtaining the first cell and the second
 CC cell; (b) determining in the first cell and the second cell the pattern
 CC of expression of genes in a selected gene family; and (c) calculating a
 CC proximity index using a specified formula. The methods can be used for
 CC characterising cells, e.g. for determining the origin of a cell, its
 CC genetic status, whether it carries a genetic defect, or whether it is
 CC transformed. They can be used for detecting a selected genetic defect in
 CC an individual, e.g. a fetus. They can also be used for determining the
 CC effect of a selected treatment on a test cell. They can also be used for
 CC obtaining cells capable of expressing an homeobox related desired
 CC property. The method uses reverse transcriptase polymerase chain
 CC reaction (RT-PCR) for determining the pattern of gene expression in a
 CC selected gene family. Sequences AA217803-218342 represent primers that
 CC can be used in the RT-PCR reactions to determine the pattern of gene
 CC expression. The gene family can be selected from a set of homeobox genes,
 CC kinase genes, protein phosphatase genes, P450 enzyme genes, steroid
 CC receptor superfamily genes or cadherin superfamily genes.

XX Sequence 20 BP; 7 A; 3 C; 4 G; 6 T; 0 other;

Query Match 1.2%; Score 17; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 69;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2194 AAAATAGCAGACTTTGG 2210

Db 1 AAAATAGCAGACTTTGG 17

RESULT 39

AAZ18187

ID AAZ18187 standard; DNA; 20 BP.

AC AAZ18187;

DT 11-OCT-1999 (first entry)

DE PTK 30 gene specific primer.

XX Genetic proximity; gene expression; cell characterisation; homeobox gene;

KM genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;

KM kinase gene; protein phosphatase; P450; steroid receptor; cadherin;

KM primer; ss.

XX Synthetic.

OS Homo sapiens.

XX MO9934016-A2.

XX 08-JUL-1999.

XX 28-DEC-1998; 98WO-IL00625.

XX 16-OCT-1998; 98IL-0126627.

XX 29-DEC-1997; 97IL-0122793.

XX (GENE-) GENENA LTD.

XX Vider B;

XX WPI; 1999-419113/35.

XX P-PSDB; AAY14722.

XX Identifying and characterizing cells by comparing the pattern of

PT gene expression in a selected gene family

XX Claim 4; Page 46; 102pp; English.

XX The invention provides a new method for identifying and characterizing

CC cells. The method for determining the genetic proximity of a first cell

CC and a second cell comprises: (a) obtaining the first cell and the second

CC cell; (b) determining in the first cell and the second cell the pattern

CC of expression of genes in a selected gene family; and (c) calculating a

CC proximity index using a specified formula. The methods can be used for

CC characterizing cells, e.g. for determining the origin of a cell, its

CC genetic status, whether it carries a genetic defect, or whether it is

CC transformed. They can be used for detecting a selected genetic defect in

CC an individual, e.g. a fetus. They can also be used for determining the

CC effect of a selected treatment on a test cell. They can also be used for

CC obtaining cells capable of expressing an homeobox related desired

CC property. The method uses reverse transcriptase polymerase chain

CC reaction (RT-PCR) for determining the pattern of gene expression in a

CC selected gene family. Sequences AAZ17803-Z18342 represent primers that

CC can be used in the RT-PCR reactions to determine the pattern of gene

CC expression. The gene family can be selected from a set of homeobox genes,

CC kinase genes, protein phosphatase genes, P450 enzyme genes, steroid

CC receptor superfamily genes or cadherin superfamily genes.

XX Sequence 20 BP; 7 A; 3 C; 4 G; 6 T; 0 other;

QY Query Match 1.2%; Score 17; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 69;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2194 AAAATAGCAGACTTTGG 2210

Db 1 AAAATAGCAGACTTTGG 17

RESULT 40

AAZ29362/c

ID AAZ29362 standard; DNA; 20 BP.

AC AAZ29362;

DT 10-JUN-1999 (first entry)

XX JNK3-specific probe ISIS No: 16709.

XX Antisense oligonucleotide; Jun N-terminal kinase; JNK; hybridise; JNK1;

KM JNK2; JNK3; cell cycle progression; phosphorylation; tumour; probe;

KM hyperproliferative disease; human; ss.

XX Synthetic.

OS Homo sapiens.

XX MO9909214-A1.

XX 25-FEB-1999.

XX 07-AUG-1998; 98WO-US16488.

XX 13-AUG-1997; 97US-0910629.

XX (ISIS-) ISIS PHARM INC.

XX Dean N, Gaarde WA, McKay R, Monia BP, Nero PS;

XX WPI; 1999-181060/15.

XX New antisense oligonucleotides that detect and modulate the

PT expression of Jun N-terminal kinase proteins - useful for treating

PT hyperproliferative diseases and inhibiting tumor growth in animals,

PT and for modulating protein phosphorylation by these proteins

XX Example 5; Page 102; 190pp; English.

XX The invention relates to antisense oligonucleotides that detect and

CC modulate the expression of Jun N-terminal kinase (JNK) proteins. The

CC oligonucleotides specifically hybridize to a nucleic acid encoding a

CC JNK1, JNK2 or JNK3 protein, and which modulate expression of these

CC proteins. The oligonucleotides are useful for modulating JNK protein

CC expression and cell cycle progression in cultured cells or animal cells.

CC The oligonucleotides are also useful for modulating the phosphorylation

CC of a protein that has been phosphorylated by a JNK protein, and the

CC expression of a cellular protein that promotes one or more metastatic

CC events. The oligonucleotides also form pharmaceutical compositions for

CC treating animals with a hyperproliferative disease, and for inhibiting

CC tumor growth in an animal.

XX Sequence 20 BP; 6 A; 6 C; 3 G; 5 T; 0 other;

QY Query Match 1.2%; Score 17; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 69;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2642 GTTCTTACGAGATGAT 2658

Db 17 GTTCTTACGAGATGAT 1

RESULT 41

AAZ62905/c

ID AAZ62905 standard; DNA; 20 BP.

XX AAZ62905;

XX 06-FEB-2001 (first entry)

XX UNK antisense oligonucleotide ISIS #16709.
 XX
 XX Antisense; gene therapy; JNK2 protein; apoptosis; cancer;
 XX cellular hyperproliferation; Alzheimer's; Parkinson's disease;
 XX amyotrophic lateral sclerosis; retinitis; pigmentosa; epilepsy;
 XX myocardial infarction; stroke; obstructive jaundice; polycystic kidney;
 XX diabetes; Jun N-terminal kinase; ss.
 XX
 XX Homo sapiens.
 XX
 XX WO200059549-A1.
 XX
 XX 12-OCT-2000.
 XX
 XX 04-APR-2000; 2000WO-US08880.
 XX
 XX 07-APR-1999; 99US-0287796.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX McKay R, Dean NM, Monia BP, Nero PS, Gaarde WA;
 XX
 XX WPI; 2000-638427/61.
 XX
 XX Novel methods for reducing apoptosis comprising contacting cells with
 XX antisense oligonucleotides, useful for treating apoptotic disorders,
 XX e.g. cancer -
 XX
 XX Example 5; Page 139; 160pp; English.
 XX
 XX The present invention relates to antisense oligonucleotides
 XX (AAC62844-C63000, AAA9693-A9609 and AAA07993) that hybridise
 XX specifically to a nucleotide encoding a Jun N-terminal kinase (JNK2)
 XX protein, resulting in decrease of JNK2 expression and leading to
 XX induction of apoptosis. The present sequence is one such antisense
 XX oligonucleotide. The oligonucleotides of the present invention are useful
 XX for treating diseases or conditions with reduced apoptosis, e.g. cancer
 XX and cellular hyperproliferation. The oligonucleotides may also be used to
 XX increase the stimulation of apoptotic proteins, e.g. for treating
 XX Alzheimer's or Parkinson's disease, amyotrophic lateral sclerosis,
 XX retinitis, pigmentosa, epilepsy, myocardial infarction, stroke,
 XX obstructive jaundice, polycystic kidney and diabetes. The present
 XX sequence may have a phosphorothioate backbone.
 XX
 XX Sequence 20 BP; 6 A; 6 C; 3 G; 5 T; 0 other;
 XX
 XX Query Match 1.2%; Score 17; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 69;
 XX Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 XX 2642 GTTCTTCGAGATGAT 2658
 XX |||||
 XX Db 17 GTTCTTCGAGATGAT 1
 XX
 XX RESULT 42
 XX AAX00049
 XX ID AAX00049 standard; DNA; 22 BP.
 XX
 XX AAX00049;
 XX
 XX 16-MAR-1999 (first entry)
 XX
 XX FGFR PCR sense primer.
 XX
 XX Neuroepithelial stem cell; lineage restricted intermediate precursor;
 XX oligodendrocyte; astrocyte; self-renewal; neuron; differentiation; CNS;
 XX neural crest cell; fibroblast growth factor; FGFR; receptor; CNS;
 XX central nervous system; glial cell; PCR primer; amplification; ss.
 XX
 XX Synthetic.
 XX
 XX Homo sapiens.
 XX

XX WO9850526-A1.
 XX
 XX 12-NOV-1998.
 XX
 XX 07-MAY-1998; 98WO-US09630.
 XX
 XX 06-MAY-1998; 98US-0073881.
 XX
 XX 07-MAY-1997; 97US-0852744.
 XX
 XX (UTAH) UNIV UTAH RES FOUND.
 XX
 XX Mayer-Proschel M, Mujtaba T, Rao MS;
 XX
 XX WPI; 1999-070093/06.
 XX
 XX Mammalian neuroepithelial stem cells and glial restricted precursor
 XX - can self renew and differentiate into central nervous system
 XX cells, used for generating various types of cells
 XX
 XX Example 26; Page 61; 78pp; English.
 XX
 XX The present invention describes an isolated, pure population of
 XX mammalian neuroepithelial stem cells, which are capable of self-renewal
 XX in adherent feeder-cell-independent (AFCI) culture medium and
 XX differentiation to central nervous system (CNS) neuronal or glial cells
 XX and to neuronal crest stem cells. Also described is an isolated
 XX population of mammalian CNS glial-restricted precursor (GRP) cells which
 XX can self-renew in the APCI culture medium and can differentiate to CNS
 XX glial cells but not to CNS neuronal cells. The stem cells can be used to
 XX generate a population of mammalian motor neurons by incubating the stem
 XX cells in a medium promoting cell proliferation and neuronal
 XX differentiation. The medium comprises laminin-coated plates and NEP
 XX medium lacking chick embryo extract. The stem cells can also produce
 XX neural crest stem cells by inducing the cells to differentiate in vitro.
 XX The inducing step comprises replating the cells on a laminin-coated
 XX substrate and preferably withdrawing a mitogen (preferably fibroblast
 XX growth factor; GGF) and chick embryo extract. Inducing can also comprise
 XX adding a dorsalizing agent to the cells, preferably a bone morphogenetic
 XX protein (BMP), such as BMP-2, -4 or -7. The stem cells can be used to
 XX produce cells of the peripheral nervous system, by inducing the stem
 XX cells to differentiate in vitro to neural crest stem cells, and inducing
 XX these cells to differentiate. AAX00029 to AAX00054 represent PCR primers
 XX which are used in an example from the present invention to amplify
 XX different FGFR and FGFR genes.
 XX
 XX Sequence 22 BP; 8 A; 1 C; 8 G; 5 T; 0 other;
 XX
 XX Query Match 1.2%; Score 17; DB 1; Length 22;
 XX Best Local Similarity 100.0%; Pred. No. 79;
 XX Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 XX 1873 GAGATGAGATGATGAA 1889
 XX |||||
 XX Db 6 GAGATGAGATGATGAA 22
 XX
 XX RESULT 43
 XX AAX34894/C
 XX ID AAX34894 standard; DNA; 20 BP.
 XX
 XX AAX34894;
 XX
 XX 28-JUN-1999 (first entry)
 XX
 XX PCR primer used to amplify FGFR3.
 XX
 XX Immortalized human hair papilla cell; HPC; screening; hair growth;
 XX SV40 viral large T-antigen gene; deleted replication initiation point;
 XX hair growth stimulating agent; PCR primer; ss.
 XX
 XX Synthetic.
 XX
 XX Homo sapiens.
 XX

```

FN      JP11089565-A.
PD      06-APR-1999.
XX
XX      19-SEP-1997;    97JP-0271927.
PF      19-SEP-1997;    97JP-0271927.
PR      19-SEP-1997;    97JP-0271927.
XX
PA      (SHIS ) SHISEIDO CO LTD.
DR      WPI; 1999-281045/24.
XX
XX      Immortalized human hair papilla cells used for evaluation of hair
PT      growth agent - are prepared by transformation of human hair papila
PT      cells with gene with deleted replication initiation point
XX
PS      Example 2; Page 7; 23pp; Japanese.
CC
CC      The specification describes the preparation of immortalized human
CC      hair papilla cells (HPC). The method comprises transformation of HPC
CC      with an SV40 viral Large T-antigen gene with deleted replication
CC      initiation point. The immortalized HPC can be used in a screening
CC      method for a hair growth agent, by culture of immortalized HPC in
CC      the presence of a substance to be tested and observation of the
CC      growth of the immortalized HPC. HPC is also used in development of
CC      hair growth stimulating agents. The present sequence represents a
CC      PCR primer, which is used in the course of the invention.
XX
SQ      Sequence 20 BP; 3 A; 6 C; 3 G; 8 T; 0 other;
        Query Match          1.2%; Score 16.8; DB 1; Length 20;
        Best Local Similarity 90.0%; Pred. No. 75;
        Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0.
OY      1822 AAGATGTTGAAGAAGCATGC 1841
DB      20 AAGATGCTGAAGACCATGC 1

RESULT 44
ID      AAA95391/c
AC      AAA95391;
DT      12-FEB-2001 (first entry)
DE      Rat FGFR coding sequence PCR primer #2.
XX
XX      Rat; Nurr1; tyrosine hydroxylase; catecholamine-related disease;
KM      Parkinson's disease; manic depression; schizophrenia; PCR primer; ss.
OS      Rattus norvegicus.
NN      WO200058451-A1.
ND      05-OCT-2000.
PE      21-MAR-2000; 2000WO-US07544.
PR      26-MAR-1999; 99US-0277078.
XX
PA      (SALK ) SALK INST BIOLOGICAL STUDIES.
PL      Sakurada K, Palmer T, Gage FH;
DR      WPI; 2000-656165/63.
XX
XX      Cell comprising exogenous nucleic acid inducing tyrosine hydroxylase
PT      expression useful for treating catecholamine-related diseases such as
PT      Parkinson's disease, manic depression and schizophrenia -
SS      Example 1; Page 20; 68pp; English.

```

XX	The present invention describes the rat Nurrl coding and protein
CC	sequences. The Nurrl protein is involved in the induction of tyrosine
CC	hydroxylase expression in adult rat-derived hippocampal progenitor cells.
CC	The Nurrl gene and protein can be used in the treatment of
CC	catecholamine-related diseases such as Parkinson's disease, manic
CC	depression and schizophrenia. They can also be used to induce tyrosine
CC	hydroxylase expression and identify tyrosine hydroxylase related
CC	deficiencies, which are linked to the same diseases. The present sequence
CC	is a PCR primer used in a method to differentiate adult neural progenitor
CC	cells.
XX	
SQ	Sequence 20 BP; 5 A; 6 C; 2 G; 5 T; 2 other;
Oy	Query Match 1.2%; Score 16.8; DB 1; Length 20; Best Local Similarity 85.0%; Pred. No. 75; Matches 17; Conservative 2; Mismatches 1; Indels 0; Gaps 0
Db	2191 ATGAATAATAGCAGACTTTGG 2210 ::: 20 ATGAAGATHGCDGACCTTGG 1
RESULT 45	
ID	AAD41768/C
XX	AAD41768 standard; DNA; 20 BP.
AC	AAD41768;
XX	
DT	30-OCT-2002 (first entry)
DE	Human REQL2 antisense oligonucleotide, ISIS #137549.
XX	
KW	Antisense; REQL2; Bloom's disorder; prophylaxis; infection; tumour;
KM	inflammation; therapy; human; phosphorothioate; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
FH	Key
FT	modified_base
FT	Location/Qualifiers
FT	1..20
FT	/tag= a
FT	/mod_base= OTHER
FT	/note= "Phosphorothioate backbone"
FT	1..5
FT	/tag= b
FT	/mod_base= OTHER
FT	/note= "2'-methoxyethyl nucleotides"
FT	16..20
FT	/tag= c
FT	/mod_base= OTHER
FT	/note= "2'-methoxyethyl nucleotides"
FT	3..5
FT	/tag= d
FT	/mod_base= m5c
FT	9
FT	/tag= e
FT	/mod_base= m5c
FT	12
FT	/tag= f
FT	/mod_base= m5c
FT	15
FT	/tag= g
FT	/mod_base= m5c
FT	18
FT	/tag= h
FT	/mod_base= m5c
XX	
PN	US6399378-B1.
XX	
PD	04-JUN-2002.
XX	
PF	01-MAR-2001; 2001US-0798096.

XX 01-MAR-2001; 2001US-0798096.
XX (ISIS-) ISIS PHARM INC.
XX
XX Ward DT, Walt AT;
XX WPI; 2002-535979/57.
XX
PT Antisense compounds targeted to nucleic acids encoding RECQL2
PT associated with Bloom's disorder, for modulating RECQL2 expression and
PT treating diseases e.g. tumors associated with expression of the RECQL2
PT in humans
XX
PS Claim 3; Column 45; 86pp; English.
XX
CC The invention relates to antisense compounds targeted to nucleic acid
CC encoding RECQL2 (gene associated with Bloom's disorder) to inhibit the
CC expression of RECQL2. Antisense compounds of the invention are useful
CC for treating diseases associated with expression of RECQL2, in humans.
CC They are useful for diagnostics, therapeutics and as research reagent,
CC e.g. prophylactically to prevent or delay infection, inflammation or
CC tumour formation. They are also useful in antisense therapy. The
CC present sequence is an antisense oligonucleotide targeted to human
CC RECQL2 DNA.
XX
SQ Sequence 20 BP; 5 A; 7 C; 1 G; 7 T; 0 other;
Query Match 1.2%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 75;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1882 ATGATGAAGATGATTGGAA 1901
DB 20 ATGATGATGATGACTGGAA 1
RESULT 46
ID AAA30118/c
ID AAA30118 standard; DNA; 21 BP.
XX
AC AAA30118;
XX
DT 10-AUG-2000 (first entry)
XX
DE PCR primer used for analysis of Ret expression.
XX
KW PCR primer; GFRalpha1; GPI-anchored GDNF family receptor alpha-1; GDNF;
KW glial cell line-derived neurotrophic factor; glycoposphatidyl-inositol;
KW GPI; auditory neuron protector; improve learning ability; treatment;
KW Parkinson's disease; epilepsy; neuronal disease; Ret; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200020867-A1.
PN
XX
PD 13-APR-2000.
XX
XX 01-OCT-1999; 99WO-IB01681.
PF
XX
XX 01-OCT-1998; 98US-0102647.
PR
XX
XX (TITL/) TITIVSKY A V.
PA (POTE/) POTERIAEV D.
PA (ARUM/) ARUMAE U.
PA (SAAR/) SAARMA M.
XX
PI Titievsky AV, Poteriaev D, Arumae U, Saarma M;
XX WPI; 2000-317748/27.
DR
XX
XX Methods for screening for agonists and antagonists of GPI-anchored
PT independent intracellular signalling particularly GFR alpha-dependent,

PT Ret-independent intracellular signalling, useful in methods for
PT treatment of neuronal diseases
XX
XX Examples; Page 22; 71pp; English.
XX
XX The present sequence represents a PCR primer used in the RT-PCR analysis
XX of receptor tyrosine kinase (Ret) expression. GDNF (glial cell
XX line-derived neurotrophic factor) is a transforming growth factor-beta
XX family related neurotrophic protein. GDNF action is thought to act
XX through GPI-anchored GDNF family receptor alpha-1 (GFRalpha1) and Ret.
XX The PCR primer represented by this sequence is used in an example of the
XX method of the invention. The method is used to identify compounds that
XX are agonists or antagonists of intracellular signalling effected by
XX glycoposphatidyl-inositol (GPI)-anchored receptors in cells of the
XX nervous system. Ret-independent signalling pathways may stimulate
XX neuronal survival, neurite extension, and the enhancement of
XX neurotransmitter synthesis. The compounds identified by the method of the
XX invention can be used for protecting auditory neurons, improving learning
XX ability, treating epilepsy and treating Parkinson's disease.
XX
SQ Sequence 21 BP; 7 A; 6 C; 4 G; 4 T; 0 other;
Query Match 1.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 80;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2319 TCAGATGATGTCTGCTCT 2338
DB 20 TCAGATGATGTGTGCTCT 1
RESULT 47
ID AAC92592/c
ID AAC92592 standard; DNA; 20 BP.
XX
AC AAC92592;
XX
DT 27-MAR-2001 (first entry)
XX
XX Human nucleolin phosphorothioate antisense oligonucleotide, SEQ ID NO:42.
DE
XX
KW Human nucleolin; P92; C23; phosphoprotein; ribosome biogenesis;
KW ribosome transport; cytokinesis; nucleogenesis; cell proliferation;
KW cell growth; transcriptional repression; replication;
KW signal transduction; chromatin decondensation; Ag-NOR family;
KW nucleolin antibody; systemic connective tissue disease; SLE;
KW systemic lupus erythematosus;
KW scleroderma-like chronic graft versus host disease;
KW expression inhibition; tumour formation; cancer; inflammation;
KW immune disorder; phosphorothioate; antisense oligonucleotide; ss.
XX
XX Homo sapiens.
OS
XX
XX US6165786-A.
PN
XX
XX 26-DEC-2000.
PD
XX
XX 03-NOV-1999; 99US-0433699.
PF
XX
XX 03-NOV-1999; 99US-0433699.
PR
XX
XX (ISIS-) ISIS PHARM INC.
PA
PI Bennett CF, Cowseart LM;
XX WPI; 2001-079848/09.
DR
XX
XX Novel antisense compound targeted to human nucleolin which specifically
PT hybridizes with and inhibits the expression of human nucleolin, useful
PT for modulating the expression of nucleolin in cells
XX
PS Claim 14; Column 41-42; 41pp; English.

CC Sequences AAC92560-C92639 represent antisense oligonucleotides
CC targeted to the human nucleolin gene, which inhibit its expression.
CC The antisense oligonucleotides were designed to target different
CC regions of the human nucleolin mRNA, and were analysed for their effect
CC on nucleolin mRNA levels by quantitative real-time PCR. Nucleolin (also
CC known as P92 or C23) is the most abundant nucleolar phosphoprotein in
CC actively growing cells. Nucleolin primarily participates in ribosome
CC biogenesis and transport of ribosomal components, being able to
CC transiently bind to pre-ribosomes in the nucleolus via a
CC ribonucleoprotein consensus sequence. However, it has also been shown to
CC be involved in cytokinesis, nucleogenesis, cell proliferation and
CC growth, transcriptional repression, replication, signal transduction,
CC and chromatin decondensation. Nucleolin is a member of the Ag-NOR
CC (active ribosomal gene located in the nucleolar organiser region) family
CC of proteins which are markers of active ribosomal genes, and whose
CC expression is associated with the prediction of tumour growth rate. The
CC presence of antibodies against nucleolin are associated with systemic
CC connective tissue diseases such as systemic lupus erythematosus (SLE)
CC and scleroderma-like chronic graft versus host disease. The
CC oligonucleotides of the invention are useful for diagnosis, prevention
CC and treatment of conditions associated with nucleolin expression, such as
CC tumour formation, immune disorders and inflammation.

XX
XX
SQ Sequence 20 BP; 4 A; 7 C; 1 G; 8 T; 0 other;

Query Match 1.2%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 86;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1878 GGAGTGTGTAAGATGAT 1895
| | | | | | | | | | | | | | | | | | | | | |
Db 19 GAAGTGTGTAAGATGAT 2

RESULT 48
AA59328/C
ID AA59328 standard; DNA; 21 BP.
XX
XX AA59328;
XX
XX
DT 05-APR-2000 (first entry)
XX
DE Human STP2 exon 7 polymorphism sequence 86.
XX
XX Single nucleotide polymorphism; SNP; STP2; phenol sulphotransferase;
XX KW probe; genotyping; human; drug metabolism; ss.
XX
XX Homo sapiens.
XX
XX
FH Key Location/Qualifiers
FT variation 11
FT /*tag= a
FT /note= "Site of polymorphism"
XX
XX
XX WO9964630-A1.
XX
XX 16-DEC-1999.
XX
XX 09-JUN-1999; 99WO-US13094.
XX
XX 10-JUN-1998; 98US-0088710.
XX
XX
XX (AMYS-) AMYS PHARM INC.
XX
XX Guida M, Kurth J;
XX
XX WPI; 2000-105892/09.
XX
XX Novel nucleic acid used for genotyping, e.g. to predict rate of drug
XX metabolism -
XX
XX Claim 2; Page 16; 46pp; English.

CC Sequences AA59305-Z59352 are fragments of the human STP2 gene. The
CC fragments are from the 8 exons, the promoter region, 3' and 5',
CC untranslated regions of the STP2 gene. Each sequence contains a newly
CC identified STP2 gene single nucleotide polymorphism (SNP). STP2 is a
CC phenol sulphotransferase. Substrates for STP2 include minoxidil,
CC acetaminophen, and paracetamol. Several of the nucleotide changes
CC identified at the polymorphism sites, give rise to an amino acid change.
CC Amino acid changes may result in altered enzyme activity. The sequences
CC can be used as probes for detecting STP2 polymorphisms. The polymorphic
CC probes are used in screening and genotyping, i.e. to predict the rate of
CC metabolism of STP2 substrates, potential drug-drug interactions and
CC adverse side effects. They can also be used to detect diseases resulting
CC from accidental or occupational exposure to toxins and to establish
CC animal, cell or in vitro models for drug metabolism.

XX
XX
SQ Sequence 21 BP; 8 A; 6 C; 4 G; 3 T; 0 other;

Query Match 1.2%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 92;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1419 CATAGGGGTCTTCTTAAT 1436
| | | | | | | | | | | | | | | | | | | | | |
Db 18 CATAGGGGTCTTCTTAAT 1

RESULT 49
AA37791/C
ID AA37791 standard; DNA; 21 BP.
XX
XX AA37791;
XX
XX
DT 09-JUL-1999 (first entry)
XX
XX
DE Staphylococcus sp. detecting oligonucleotide 26.
XX
XX
XX FemA; primer; identification; detection; therapy; infection; femB;
XX KW amplification; genotyping; gram-positive bacteria; vaccine; ss.
XX
XX Synthetic.
XX
XX Staphylococcus sp.
XX
XX
XX WO9916780-A2.
XX
XX 08-APR-1999.
XX
XX 28-SEP-1998; 98WO-BE00141.
XX
XX 26-SEP-1997; 97EP-0870146.
XX
XX
XX (BENA-) BELGIAN MIN NAT DEFENCE.
XX PA (UYLO-) UNIV CATHOLIQUE LOUVAIN.
XX
XX Gala J, Vannuffel P;
XX
XX
XX WPI; 1999-287521/24.
XX
XX
XX New Staphylococcus-specific oligonucleotides
XX
XX Example 1; Fig 1; 48pp; English.

CC This invention describes novel Staphylococcus-specific oligonucleotides
CC based on the consensus femA nucleotide sequence which are used to
CC develop products for the identification, detection and therapy of
CC infections. The oligonucleotides can be used for the genetic
CC amplification, the identification and/or quantification of various femA
CC sequences which are specific to known or unknown Staphylococci species.
CC Since the femA sequence is similar to the femB sequence, the
CC oligonucleotides can also be used for the molecular genotyping of femB
CC genes of different Staphylococci species or other gram-positive bacteria.
CC The femA nucleic acids can also be used in therapeutic applications.
CC They can also be used to identify inhibitors, e.g. antibodies or
CC antisense oligonucleotides, for blocking expression of the femA

CC nucleotide sequences. They can also be used for producing vaccines
 CC against *Staphylococci* infections.
 XX
 SQ Sequence 21 BP; 5 A; 8 C; 2 G; 6 T; 0 other;
 Query Match 1.2%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 99;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 1878 GCAGATGATGAAGATGTTGG 1898
 Db 21 GAAGATGCTGAAGATGTTGG 1
 RESULT 50
 ID AA052215 standard; RNA; 19 BP.
 XX AA052215;
 AC
 XX
 DT 25-MAR-2003 (updated)
 DT 26-MAY-1994 (first entry)
 XX
 DE Neuroblastoma specific mRNA ribozyme cleavable nucleotide (1441).
 XX
 KW Multiple drug resistance; mdr-1; ribozyme; membrane protein; liver;
 KW resistance; chemotherapeutic agent; colchicine; doxorubicin; colon;
 KW actinomycin D; vinblastine; small intestine; kidney; adrenal gland;
 KW adenocarcinoma; bowel; transformed phenotype; promyelocytic leukemia;
 KW human; chronic myelogenous leukemia; CML; follicular lymphoma;
 KW B-cell acute lymphocytic leukemia; breast cancer; colon carcinoma;
 KW neuroblastoma; lung cancer; genetic drift; mutation; hammerhead motif;
 KW hairpin; hepatitis delta virus; group I intron; RNaseP; leukemia; ss.
 XX
 OS Homo sapiens.
 XX
 PN W09323057-A1.
 XX
 PD 25-NOV-1993.
 XX
 PF 13-MAY-1993; 93WO-US04573.
 XX
 PR 14-MAY-1992; 92US-0882822.
 PR 14-MAY-1992; 92US-0882885.
 PR 26-AUG-1992; 92US-0936110.
 PR 26-AUG-1992; 92US-0936421.
 PR 26-AUG-1992; 92US-0936422.
 PR 26-AUG-1992; 92US-0936531.
 PR 26-AUG-1992; 92US-0936532.
 PR 07-DEC-1992; 92US-0987131.
 PR 19-JAN-1993; 93US-0006122.
 PR 19-JAN-1993; 93US-0008910.
 PA
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Draper KG, Thompson JD;
 XX
 DR WPI; 1993-386203/48.
 XX
 PT New enzymatic RNA molecules (ribozymes) - which cleave mRNA
 PT associated with tumors or mRNA expressed from gene encoding
 PT multiple drug resistance
 XX
 PS Claim 3; Fig 10; 69pp; English.
 XX
 CC The sequences given in AA051825-2266 represent areas of mRNAs which are
 CC associated with development or maintenance of chronic myelogenous
 CC leukemia (CML), promyelocytic leukemia, Burkitt's lymphoma, or
 CC acute lymphocytic leukemia, follicular lymphoma, B-cell acute
 CC lymphocytic leukemia, breast cancer, colon carcinoma, neuroblastoma
 CC and lung cancer. The full length mRNAs containing these target
 CC sequences, encode aberrant cellular proteins which are able to control
 CC cellular proliferation and are directly linked to a leukemic

CC phenotype. These target sequences are identified by the ribozyme of
 CC the invention. The ribozymes is formed in a hammerhead motif, but may
 CC also be formed in the motif of a hairpin, hepatitis delta virus, group
 CC I intron or RNaseP-like RNA. These ribozymes may be used to inhibit
 CC the development or expression of a transformed phenotype in man and
 CC other animals by modulating expression of the corresponding gene.
 CC Cleavage of target mRNAs expressed in pre-neoplastic and transformed
 CC cells elicits inhibition of the transformed state. Multiple drug
 CC resistance (mdr-1) mRNA specific ribozymes remove the mechanism of
 CC drug resistance used by transformed cells and thus enhances drug
 CC therapies for tumors. The ribozymes may also be used to study
 CC genetic drift and mutations within cells.
 CC (Updated on 25-MAR-2003 to correct FN field.)
 XX
 SQ Sequence 19 BP; 8 A; 1 C; 6 G; 4 U; 0 other;
 Query Match 1.1%; Score 16; DB 1; Length 19;
 Best Local Similarity 75.0%; Pred. No. 93;
 Matches 12; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 1880 AGATGATGAAGATGAT 1895
 Db 2 AGAUGAUGAAGAU 17
 RESULT 51
 ID AA082642 standard; DNA; 19 BP.
 XX AA082642;
 AC
 XX
 DT 04-DEC-2000 (first entry)
 DT
 XX
 DE cdk2 ribozyme binding site #79.
 XX
 KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic;
 KW restenosis; ss.
 XX
 OS Mammalia.
 XX
 PN W0300032765-A2.
 XX
 PD 08-JUN-2000.
 XX
 PF 06-DEC-1999; 99WO-US28772.
 XX
 PR 04-DEC-1998; 98US-0110954.
 XX
 PA (IMMU-) IMMUSOL INC.
 XX
 PI Tritz R, Welch PJ, Barber JR, Robbins JM;
 XX
 DR WPI; 2000-412314/35.
 XX
 PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
 PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
 PT PCNA and Cyclin B1
 XX
 PS Disclosure; Page 49; 109pp; English.
 XX
 CC The present invention relates to a hairpin or hammerhead ribozyme,
 CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
 CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
 CC Representative examples of ribozyme recognition sites are given in
 CC AA082415 to AA086787. The ribozyme of the invention is useful for
 CC inhibiting restenosis by introduction of the ribozyme into cells.
 CC The ribozyme is resistant to endonuclease activity and hence is
 CC efficient in restenosis treatment.
 XX
 SQ Sequence 19 BP; 4 A; 5 C; 5 G; 5 T; 0 other;
 Query Match 1.1%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2205 CTTGGACTCCCGAGAGT 2223
|||||
Db 1 CTTGGACTAGCCAGAGCT 19

RESULT 52
AAH57804
ID AAH57804 standard; DNA; 19 BP.
XX
XX AAH57804;
XX
XX 10-SEP-2001 (first entry)
XX
XX
XX Cell-cycle dependent kinase cdk2 ribozyme binding site SEQ ID NO:228.
XX
XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
XX recognition site; target; ribozyme binding site; eye disease; vulnery;
XX proliferative disease; skin disease; psoriasis; diabetic retinopathy;
XX cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
XX matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
XX antiproliferative; dermatological; antiherpetic; antiviral;
XX antisticking; ophthalmological; keratolytic; gene therapy; viral wart;
XX atopic dermatitis; actinic keratosis; squamous cell carcinoma;
XX basal cell carcinoma; sebaceous wart; vitreoretinopathy; scar;
XX sickle cell retinopathy; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO200130362-A2.
XX
XX 03-MAY-2001.
XX
XX 26-OCT-2000; 2000MO-US29500.
XX
XX 26-OCT-1999; 99US-0161532.
XX
XX (IMMU-) IMMUSOL INC.
XX
XX Robbins JM, Tritz R;
XX
XX WPI; 2001-300427/31.
XX
XX Treating proliferative skin or eye diseases and scarring, using
XX ribozymes that cleave RNA encoding cytokines involved in inflammation,
XX matrix metalloproteinases, growth factors and cell-cycle dependent
XX kinases -
XX
XX Example 1; Page 88; 409pp; English.
XX
XX The present invention describes a method for treating a proliferative
XX skin or eye disease and scarring. The method involves administering a
XX ribozyme (I) which cleaves RNA encoding a cytokine involved in
XX inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
XX dependent kinase, growth factor or a reductase, or administering a
XX nucleic acid molecule (II) comprising a promoter operably linked to a
XX nucleic acid segment encoding (I). (I) can have antiherpetic,
XX dermatological, cytostatic, antiherpetic, antidiabetic, antisticking,
XX ophthalmological, vulnery, keratolytic and antiviral activities, and
XX cleaves RNA encoding cytokine involved in inflammation. (I) can be used
XX in gene therapy. (I) and (II) are useful for treating proliferative
XX skin diseases such as psoriasis, atopic dermatitis, actinic keratosis,
XX squamous or basal cell carcinoma and viral or sebaceous wart. They can
XX also be used for treating proliferative eye diseases such as diabetic
XX retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
XX prematurity and retinal detachment, and for treating and preventing
XX scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
XX scar. AAH57577 to AAH62099 represent sequences used in the
XX exemplification of the present invention.
XX
XX Sequence 19 BP; 4 A; 5 C; 5 G; 5 T; 0 other;

Query Match 1.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2205 CTTGGACTCCCGAGAGT 2223
|||||
Db 1 CTTGGACTAGCCAGAGCT 19

RESULT 53
AAZ07940/c
ID AAZ07940 standard; DNA; 20 BP.
XX
XX AAZ07940;
XX
XX 20-DEC-1999 (first entry)
XX
XX
XX Mannose binding protein (MBP) cDNA fragment amplifying primer.
XX
XX Chimeric protein; IZEC-CIM; extracellular; CD23; asthma; gene therapy;
XX allergic disease; mannose binding protein; MBP; PCR primer; ss.
XX
XX Synthetic.
XX
XX US5965712-A.
XX
XX 12-OCT-1999.
XX
XX 19-JUN-1998; 98US-0100398.
XX
XX 19-JUN-1998; 98US-0100398.
XX
XX (UYVI-) UNIV VIRGINIA COMMONWEALTH.
XX
XX Conrad DH, Kelly AE;
XX
XX WPI; 1999-579942/49.
XX
XX Chimeric protein derived from the extracellular region of CD23, useful
XX for treating asthma and allergic diseases -
XX
XX Disclosure; Column 4; 18pp; English.
XX
XX The invention relates to a chimeric protein IZEC-CIM, derived from the
XX extracellular region of CD23, with an isoleucine zipper. IZEC-CIM is
XX useful for the treatment of asthma and in gene therapy for the treatment
XX of allergic diseases. IZEC-CIM blocks IGE binding to mast
XX cells/basophils, 10000 fold better than native soluble CD23, and has
XX comparable blocking and binding efficiency to antibodies, but without any
XX side effects. Sequences AAZ07939-946 represent PCR primers used in the
XX preparation of chimeric CD23 constructs.
XX
XX Sequence 20 BP; 4 A; 6 C; 0 G; 10 T; 0 other;

Query Match 1.1%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1819 GTGAAGTGTGAAGATG 1837
|||||
Db 19 GTGAAGTGTGAAGATG 1

RESULT 54
AAZ07637/c
ID AAZ07637 standard; DNA; 20 BP.
XX
XX AAZ07637;
XX
XX 19-JUN-2000 (first entry)
XX
XX HERG gene exon 7/intron 7 junction sequence.
XX

XX HERG; mutation; long QT syndrome; LQT syndrome; gene therapy;
KM human; ss.
XX Homo sapiens.
OS MO200006772-A1.
XX 10-FEB-2000.
XX 20-JUL-1999; 99WO-US16337.
XX 27-JUL-1998; 98US-0122847.
PR 06-JAN-1999; 99US-0226012.
XX (UTAH) UNIV UTAH RES FOUND.
PA Keating MT, Splawski I;
PI WPI; 2000-195319/17.
XX
XX New isolated mutant HERG nucleic acids, useful for developing products
PT for the diagnosis, prevention and treatment of long QT syndrome
PS Example 8; Page 71; 163pp; English.
XX
XX The invention relates to a HERG protein having a mutation compared to
CC wild-type HERG, and is useful for developing products for the diagnosis,
CC prevention and treatment of long QT (LQT) syndrome. The products and
CC methods can be used for the diagnosis of subjects with LQT syndrome.
CC This can also be used to screen for drugs for treating or preventing LQT
CC syndrome. The HERG nucleic acids can also be used for gene therapy and
CC HERG peptides can be used for peptide therapy. Sequences AAA07624-653
CC represent intron/exon junction sequences of the HERG gene.
XX
SQ Sequence 20 BP; 2 A; 4 C; 7 G; 7 T; 0 other;

Query Match 1.1%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2556 CACTCTCACACCAATGAG 2574
DB 19 CACTCTCACACCAATGAG 1

RESULT 55
AAS96638
ID AAS96638 standard; DNA; 20 BP.
XX AAS96638;
AC
XX 09-APR-2002 (first entry)
DT
XX
DE Telomerase reverse transcriptase, antisense oligonucleotide #48.
XX
XX Telomerase reverse transcriptase; TERT; cytosolic; apoptosis;
KM cell growth inhibitor; antisense oligonucleotide;
KM antisense technology; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX MO200188198-A1.
XX
XX 22-NOV-2001.
XX
XX 15-MAY-2001; 2001WO-US15774.
XX
XX 16-MAY-2000; 2000US-0572423.
PR 07-DEC-2000; 2000US-0733294.
XX
XX (ISIS-) ISIS PHARM INC.

XX
PI Monia BP, Gaarde WA, Freier SM, Manciewicz E;
XX WPI; 2002-075321/10.
DR
XX
XX New compound targeted to nucleic acid molecule encoding telomerase
PT transcriptase (TERT), which specifically hybridizes with and inhibits
PT expression of TERT, useful for modulating apoptosis and inhibiting cell
PI growth
XX
XX Claim 26; Page 91; 154pp; English.
XX
XX The invention describes a compound, 8-50 nucleobases in length targeted
CC to a nucleic acid molecule encoding human TERT (telomerase reverse
CC transcriptase), where the compound specifically hybridizes with and
CC inhibits the expression of TERT. A series of oligonucleotides were
CC designed to target different regions of the human TERT RNA. These were
CC 20 nucleotides in length and composed of a central gap region consisting
CC of ten 2'-deoxynucleotides, flanked on both sides (5' and 3' directions)
CC by five-nucleotide wings. The wings were composed of 2'-methoxyethyl
CC (2'-MOE) nucleotides. The compounds were analysed for their effect on
CC human TERT mRNA levels by reverse transcriptase (RT)-polymerase chain
CC reaction (PCR). The compound is useful for inhibiting the expression of
CC TERT in cells or tissues, for treating a human having disease or
CC condition associated with TERT, for modulating apoptosis, for inhibiting
CC cell growth (preferably, cancer cell growth), in antisense therapy and
CC for diagnostics and therapeutics. This sequence is an antisense
CC oligonucleotide used to modulate the activity of nucleic acid molecules
CC encoding TERT, described in the method of the invention.
XX
SQ Sequence 20 BP; 4 A; 3 C; 6 G; 7 T; 0 other;

Query Match 1.1%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2020 GGGATGGAGTCTCTATG 2038
DB 1 GGGATGGAGTCTCTATG 19

RESULT 56
ABS97467/C
ID ABS97467 standard; DNA; 21 BP.
XX ABS97467;
AC
XX 23-DEC-2002 (first entry)
DT
XX
DE Human diazepam binding inhibitor (DBI) gene polymorphic sequence #11.
XX
XX Human; ds; cytochrome P450 A1; CYP450A1; UGT2B4; MDR1;
KM cytochrome P450 A2; CYP450A2; cytochrome P450 02B; CYP45002B1; LTP;
KM adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MR3; NR1I2;
KM aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
KM cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
KM epoxide hydrolase 2; EPXH2; 5-lipoxygenase activating protein; FLAP;
KM glutathione-S-transferase 12; GSTI2; histamine-N-methyl transferase;
KM HMMT; kallikrein 2; KLR2; nicotinamide-N-methyl transferase; NMNT;
KM NADPH quinone oxidoreductase 2; NQO2; sulfoltransferase thermolabile;
KM STM; UDP-glucuronosyl transferase 284; UDP-glucuronosyl transferase 287;
KM UGT2B7; UDP-glucuronosyl transferase; UGT2B15; utoklinase receptor; UPA;
KM multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
KM acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
KM altered drug metabolism; cardiovascular function; colorectal tumour;
KM central nervous system; pulmonary; immunological; SNF;
KM single nucleotide polymorphism.
XX
XX Homo sapiens.
OS
XX
XX MO200257410-A2.

PD 25-JUL-2002.
XX
XX 28-NOV-2001, 2001WO-US44838.
XX
XX 28-NOV-2000; 2000US-0724389.
XX
PA (DNAS-) DNA SCI LAB INC.
XX
XX Guida M, Hall J;
XX
XX WPI; 2002-698522/75.
XX
XX Isolated nucleic acid molecules having polymorphisms in known human
PT genes e.g. cytochrome p450 and cathepsin S useful as genetic linkage
PT markers for locating, identifying and characterizing the genes
XX
XX responsible for disorder-related traits
XX
XX Example 9; Page 115; 714pp; English.
XX
XX This invention relates to the sequence of an isolated nucleic acid
CC molecule comprising at least one base variation from that of a known
CC human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2),
CC cytochrome P450 02B1 (CYP45002B1), adrenergic receptor beta1 (ADBR1),
CC aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
CC (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding
CC inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase
CC activating protein (FLAP), glutathione-S-transferase 12 (GST12),
CC histamine-N-methyl transferase (HNMT), (kallikrein 2) KXK2, nicotinamide
CC -N-methyl transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),
CC sulforanferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
CC (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
CC 1 (MDR1), lactotransferrin (LTF), multidrug resistance associated
CC protein 3 (MRP3), orphan nuclear receptor (NR112), or acetylcholine
CC muscarinic receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or
CC CHMR5) sequence. The polymorphisms in the human genes cited in the
CC invention are useful as genetic linkage markers for locating and
CC characterizing the genes that are responsible for specific traits within
CC the genome and eventually identifying the genes responsible for a
CC variety of disorder-related traits as a result of their e.g.,
CC overexpression, constitutive expression, mutation or underexpression,
CC which may be used in diagnosing and/or treating the disorders. The
CC nucleic acid molecules comprising the polymorphic sequences contained
CC in CYP450A1, CYP4501A2, CYP4502B1, ARNT, EPHX2, GST12, NNMT, NQO2,
CC NR112, STM, UGT2B4, UGT2B7, UGT2B15, AHR, MDR1 and/or MDR3 are useful
CC for screening individuals for altered drug metabolism. The polymorphic
CC sequences contained in CYP4501A1, CYP4501A2, AHR, MDR1 and/or MDR3 may
CC also be used to screen individuals for susceptibility to cancer.
CC Polymorphic sequences in ADRB1 or CHMR2 are used to screen for altered
CC cardiovascular function, in COX2 for altered susceptibility to
CC colorectal tumours, in DBI or CHMR1 for altered central nervous system
CC function, in FLAP and HNMT for altered pulmonary, immunological or
CC haematological function, in KXK2 for altered serine protease activity in
CC the prostate, in LTF for altered immunological or haematological
CC function, in CHMR3, CHMR4 or CHMR5 for altered central and peripheral
CC nervous system function. The present sequence represents a polymorphic
CC DNA sequence of the invention.
XX
XX Sequence 21 BP; 6 A; 5 C; 6 G; 4 T; 0 other;
XX
XX Query Match 1.1%; Score 15.8; DB 1; Length 21;
XX Best Local Similarity 89.5%; Pred. No. 1.1e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

AC ABS97555;
XX
XX 23-DEC-2002 (first entry)
XX
XX Human epoxide hydroxylase 2 polymorphic sequence #46.
XX
XX Human; dr; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1;
XX cytochrome P450 A2; CYP4501A2; cytochrome P450 02B; CYP45002B1; LTF;
XX adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR112;
XX aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
XX cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
XX epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
XX glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
XX HNMT; kallikrein 2; KXK2; nicotinamide-N-methyl transferase; NNMT;
XX NADPH quinone oxidoreductase 2; NQO2; sulforanferase thermolabile;
XX STM; UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
XX UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
XX multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
XX multidrug resistance associated protein 3; cancer; prostate;
XX acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
XX altered drug metabolism; cardiovascular function; colorectal tumour;
XX central nervous system; pulmonary; immunological; SNP;
XX single nucleotide polymorphism.
XX
XX Homo sapiens.
XX
XX WO200257410-A2.
XX
XX 25-JUL-2002.
XX
XX 28-NOV-2001; 2001WO-US44838.
XX
XX 28-NOV-2000; 2000US-0724389.
XX
XX (DNAS-) DNA SCI LAB INC.
XX
XX Guida M, Hall J;
XX
XX WPI; 2002-698522/75.
XX
XX Isolated nucleic acid molecules having polymorphisms in known human
PT genes e.g. cytochrome p450 and cathepsin S useful as genetic linkage
PT markers for locating, identifying and characterizing the genes
XX
XX responsible for disorder-related traits
XX
XX Example 10; Page 118; 714pp; English.
XX
XX This invention relates to the sequence of an isolated nucleic acid
CC molecule comprising at least one base variation from that of a known
CC human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2),
CC cytochrome P450 02B1 (CYP45002B1), adrenergic receptor beta1 (ADBR1),
CC aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
CC (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding
CC inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase
CC activating protein (FLAP), glutathione-S-transferase 12 (GST12),
CC histamine-N-methyl transferase (HNMT), (kallikrein 2) KXK2, nicotinamide
CC -N-methyl transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),
CC sulforanferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
CC (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
CC transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance
CC 1 (MDR1), lactotransferrin (LTF), multidrug resistance associated
CC protein 3 (MRP3), orphan nuclear receptor (NR112), or acetylcholine
CC muscarinic receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or
CC CHMR5) sequence. The polymorphisms in the human genes cited in the
CC invention are useful as genetic linkage markers for locating and
CC characterizing the genes that are responsible for specific traits within
CC the genome and eventually identifying the genes responsible for a
CC variety of disorder-related traits as a result of their e.g.,
CC overexpression, constitutive expression, mutation or underexpression,
CC which may be used in diagnosing and/or treating the disorders. The
CC nucleic acid molecules comprising the polymorphic sequences contained
CC in CYP4501A1, CYP4501A2, CYP4502B1, ARNT, EPHX2, GST12, NNMT, NQO2,
CC NR112, STM, UGT2B4, UGT2B7, UGT2B15, AHR, MDR1 and/or MDR3 are useful

for screening individuals for altered drug metabolism. The polymorphic sequences contained in CYP4501A1, CYP4501A2, AHR, MDR1 and/or MDR3 may also be used to screen individuals for susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are used to screen for altered cardiovascular function. In COX2 for altered susceptibility to colorectal tumours, in DBI or CHMR1 for altered central nervous system function, in FLAP and HMT for altered pulmonary, immunological or haematological function. In KKK2 for altered serine protease activity in the prostate, in LTR for altered immunological or haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and peripheral nervous system function. The present sequence represents a polymorphic DNA sequence of the invention.

Sequence 21 BP; 3 A; 3 C; 5 G; 10 T; 0 other;

Query Match 1.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2638 TCTGTCTTCAGGAGATG 2656
|||||
Db 3 TCTTCTCTTAGAGATG 21

RESULT 58

ABQ84277 ID ABQ84277 standard; DNA; 21 BP.

XX ABQ84277;

DT 20-FEB-2003 (first entry)

XX Beta-actin Tagman probe.

DE DP10; dipeptidyl peptidase; prolyl oligopeptidase; enzyme; asthma;
XX antiinflammatory; antiasthmatic; antipsoriatic; antiarthritic;
KW antirheumatic; vaccine; gene therapy; inflammatory disease;
KW inflammatory bowel disease; atopy; rheumatoid arthritis; psoriasis;
KW chromosome 2q14; probe; ss.

XX Homo sapiens.

OS Synthetic..

PN WO200286113-A2.

XX 31-OCT-2002.

PF 24-APR-2002; 2002WO-GB01887.

XX 24-APR-2001; 2001GB-0010044.

PR 24-APR-2001; 2001GB-0010046.

PR 12-OCT-2001; 2001GB-0024575.

PR 12-OCT-2001; 2001GB-0024594.

XX (ISIS-) ISIS INNOVATIONS LTD.

XX Cookson WOCM, Mofeat MF, Allen M, Lench N;

XX WPI; 2003-093132/08.

XX New nucleic acid sequence comprising DP10 mRNA, useful for the

PT manufacture of a medicament for regulating DP10 protein expression or

PT for preventing or treating inflammatory disease e.g., inflammatory

PT bowel disease

XX Example 2; Page 70; 321pp; English.

XX The present invention describes a new isolated nucleic acid sequence (I)

CC comprising a DP10 mRNA sequence. DP10 is a dipeptidyl peptidase (also

CC known as prolyl oligopeptidase). (I) has antiinflammatory, antiasthmatic,

CC antipsoriatic, antiarthritic and antirheumatic activities, and can be

CC used in vaccines and gene therapy. A composition comprising (I) can be

or for preventing or treating inflammatory disease e.g., inflammatory bowel disease, asthma, atopy, rheumatoid arthritis or psoriasis. (I) can also be used in an assay for detecting or measuring DP10 in a sample. A host cell comprising (I) can be used for producing recombinant DP10 gene products, or in drug screening systems to identify agents for diagnosis or treatment of individuals having or susceptible to inflammatory disease. Human DP10 is located on chromosome 2, more specifically chromosome 2p14. ABQ84254 to ABQ84612 and ABP55569 to ABP55629 represent sequences used in the exemplification of the present invention.

Sequence 21 BP; 2 A; 10 C; 4 G; 5 T; 0 other;

Query Match 1.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1565 CGGCTGAGTCCAGCTCCTC 1583
|||||
Db 3 CGGCTGCTTCAGCTCCTC 21

RESULT 59

AAK74847 ID AAK74847 standard; RNA; 17 BP.

XX AAK74847;

DT 28-JUL-1999 (first entry)

XX Mouse flt-1 VEGF receptor hammetthead ribozyme substrate #375.

XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
KW flk-1; KDR; hammetthead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.

XX Mus sp.

OS WO9715662-A2.

PN 01-MAY-1997.

XX 25-OCT-1996; 96WO-US17480.

PF 11-JAN-1996; 96US-0584040.

PR 26-OCT-1995; 95US-0005974.

XX (CHIR) CHIRON CORP.

PA (RIBO-) RIBOZYME PHARM INC.

XX Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;

XX WPI; 1997-259017/23.

XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or

PT mRNA stability - useful for treating e.g. tumour angiogenesis,

PT psoriasis, rheumatoid arthritis, etc., in a human patient

XX Claim 4; Page 166; 218pp; English.

XX The present invention describes nucleic acid molecules which modulate the synthesis, expression and/or stability of a mRNA encoding 1 or more receptors of vascular endothelial growth factor (VEGF). A patient (preferably human) having a condition associated with the level of the fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be treated by administering the nucleic acid molecule or the expression vector to the patient. AAK67275 to AAK75752 represent specific examples of nucleic acid molecules from the present invention.

SO Sequence 17 BP; 7 A; 0 C; 7 G; 3 U; 0 other;
Query Match 1.1%; Score 15.4; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 99;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
OY 1821 GAAGATGTTGAAGATG 1837
DB 1 GAAGATGTTGAAGATG 17
RESULT 60
AAV96481/c
ID AAV96481 standard; RNA; 17 BP.
XX
AC AAV96481;
XX
DT 01-MAR-1999 (first entry)
XX
DE Potato citrate synthase target sequence position 543.
XX
KM Solanidine; glucosyltransferase; potato; citrate synthase; target;
KM hammerhead ribozyme; hairpin ribozyme; alkaloid biosynthesis;
KM flower formation; cleavage; solanaceous plant; ss.
XX
OS Solanum tuberosum.
XX
PN W09832843-A2.
XX
PD 30-JUL-1998.
XX
PF 14-JAN-1998; 98WO-US00738.
XX
PR 24-NOV-1997; 97US-0979416.
PR 28-JAN-1997; 97US-0036545.
PR 28-JAN-1997; 97US-0036599.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI McSwigen JA, Zwick MG;
XX
DR WPI; 1998-427939/36.
XX
PT New enzymatic nucleic acid(s) - useful for, e.g. reducing alkaloid
PT biosynthesis or regulating flowering
XX
PS Claim 53; Page 53; 79pp; English.
XX
CC The present invention describes enzymatic nucleic acid molecules with
CC RNA-cleaving activity (e.g. ribozymes) which are capable of modulating
CC the expression of plant genes: (i) involved in biosynthesis of
CC alkaloids; or (ii) involved in flower formation. AAV95982 to AAV96334,
CC and AAV96335 to AAV96354 represent potato solanidine glucosyltransferase
CC hammerhead and hairpin ribozymes, respectively. AAV95629 to AAV95981,
CC and AAV96355 to AAV96734 represent potato solanidine glucosyltransferase
CC target sequences. AAV96773 to AAV97170, and AAV97171 to AAV97195
CC represent potato citrate synthase hammerhead and hairpin ribozymes,
CC respectively. AAV96735 to AAV96772, and AAV97196 to AAV97220 represent
CC potato citrate synthase target sequences. Ribozymes of the present
CC invention can be used to inhibit the synthesis of toxic alkaloids in
CC solanaceous plants, particularly potato but also tomato, pepper,
CC aubergine and datura or to inhibit flowering in potato, lettuce, spinach,
CC cabbage, brussel sprouts, arugula, kale, collards, chard, beet, turnip,
CC sweet potato and turf grass. Also the ribozymes can be used for RNA
CC manipulation in the same way that restriction endonucleases are for DNA,
CC as well as to examine genetic drift and mutations in plants and to
CC detect specific RNA. The ribozymes can be targeted to specific genes or
CC to consensus sequences within a family of related genes, and being
CC catalytic need to be present at only very low concentrations.
XX
SQ Sequence 17 BP; 4 A; 5 C; 2 G; 6 U; 0 other;
Query Match 1.1%; Score 15.4; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 99;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2470 TACATGATGATGACGGA 2486
DB 17 TACATGATGATGACGGA 1
RESULT 61
ABQ8192/c
ID ABQ8192 standard; DNA; 18 BP.
XX
AC ABQ8192;
XX
DT 19-NOV-2002 (first entry)
XX
DE Kaposi's Sarcoma TAG PCR primer SEQ ID NO:142.
XX
KM Human; Kaposi's sarcoma; tumour; angiogenesis; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN EP125233-A2.
XX
PD 24-JUL-2002.
XX
PF 23-JAN-2002; 2002EP-0075264.
XX
PR 23-JAN-2001; 2001EP-0200228.
PR 28-SEP-2001; 2001EP-0203703.
PR 28-SEP-2001; 2001US-325722P.
XX
PA (AMST-) AMSTERDAM SUPPORT DIAGNOSTICS BV.
XX
PI Van Der Kuyt AC, Cornelissen M;
XX
DR WPI; 2002-668396/72.
XX
PT Determining presence of a tumor cell or angiogenesis, and the
PT effectiveness of treatment, by detecting the presence of marker genes
PT is useful to detect and monitor treatment of Kaposi's Sarcoma
XX
PS Example 10; Page 24; 38pp; English.
XX
CC The present invention describes a method for determining if an individual
CC has a tumor cell or site of angiogenesis, or if a treatment is effective
CC in changing angiogenesis or changing a status of a set of target cells,
CC comprising determining if a sample of the subject has an expression
CC product of at least one marker gene. Also described is a compound capable
CC of altering the expression or activity of Keratin 14, TIE 1, Sialoadhesin
CC or Siglec in a cell. Peripheral blood mononuclear cell (PBMC)-expressed
CC Keratin 14, TIE 1, Sialoadhesin or Siglec, and kits containing them from
CC the present invention can be used in a diagnostic method, particularly as
CC an indicator of angiogenesis or to determine presence of a tumor cell.
CC The method of the invention is suitable to determine within a few days if
CC a certain treatment against Kaposi's Sarcoma is successful. ABQ81951 to
CC ABQ82006 represent nucleotide sequence used in the exemplification of the
CC present invention.
XX
SQ Sequence 18 BP; 2 A; 8 C; 3 G; 5 T; 0 other;
Query Match 1.1%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2413 AAGCTGCTGAAGGAGG 2429
DB 18 AAGCTGCTGAAGGAGG 2
RESULT 62
AAK60990/c
ID AAK60990 standard; cDNA to mRNA; 19 BP.

```

XX AAX60990;
AC 03-SEP-1999 (first entry)
XX
XX 03-SEP-1999 (first entry)
DT
XX Tomato TDE1 gene amplifying nested primer.
XX
XX Tomato; TDE1 (HP-2) gene; light hypersensitive phenotype; mutation;
XX carotenoid; chlorophyll; flavonoid; transgenic; TDE1 gene; anthocyanin;
XX agro-industrial; antioxidant; antitumoural; plant protection; variant;
XX ornamental; herbicide; fruit ripening; PCR primer; ss.
XX
XX Synthetic.
OS Lycopersicon sp.
XX
XX WO9929866-A1.
XX
XX 17-JUN-1999.
XX
XX 07-DEC-1998; 98WO-IT00350.
XX
XX 09-DEC-1997; 97IT-RM00760.
XX
XX (STAZ-) STAZIONE ZOOLOGICA DOHRN ANTON.
XX
XX Bowler C, Mastilli AC;
XX
XX WPI; 1999-385610/32.
XX
XX Nucleotide sequences of the tomato TDE1 (HP-2) gene, which if
XX modified, results in a light hypersensitive phenotype
XX
XX Disclosure; Page 15; 57pp; English.
XX
XX The invention describes a tomato TDE1 (HP-2) gene, which if modified,
XX result in a light hypersensitive phenotype. The gene, when altered, is
XX responsible for the light hypersensitive mutant phenotype in Solanum
XX lycopersicum (tomato) plants, the phenotype comprising a reduced growth
XX of the plant associated with high levels of carotenoids and/or
XX chlorophylls and/or flavonoids. Vectors comprising the sequence gene can
XX be used to produce transgenic plants, such as pepper, eggplant, soybean,
XX grape, melon, rice, carrot, spinach, citrus, pomaceae or ornamental
XX species, that contain a tomato TDE1 gene. The TDE1 mutants are useful
XX in the agro-industrial sector, for generating tomato fruits with high
XX carotenoid and/or flavonoid contents. Carotenoids and flavonoids have
XX antioxidant properties and in addition some flavonoids exhibit
XX antitumoural properties. They also exhibit a role in plant protection
XX against pathogenic agents and UV light irradiation. Manipulation of the
XX TDE1 gene expression can also be used to modify anthocyanin and
XX carotenoid content in ornamental species for the achievement of new
XX colour variants. Alteration of carotenoid content is useful for improving
XX resistance to Nothofluoron herbicides. Further it is possible to combine a
XX modified TDE1 activity with mutations such as rin, nor and Nr, which
XX interrupt the fruit ripening process.
XX
XX Sequence 19 BP; 4 A; 6 C; 3 G; 6 T; 0 other;
SQ
XX
XX Query Match 1.1%; Score 15.4; DB 1; Length 19;
XX Best Local Similarity 94.1%; Pred. No. 1.2e+02;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1816 GCCGTGAAGATGTGAA 1832
DB 19 GCCGTGAAGATGTGAA 3

```

```

XX Human MTG16 gene, PCR primer #31.
DE
XX
XX Human; MTG16; tumour suppressor gene; 5-aza-2'-deoxycytidine; skin;
XX cancer; DNA methylation; adenocarcinoma; leukaemia; lymphoma; melanoma;
XX myeloma; sarcoma; teratocarcinoma; breast; prostate; liver; ovary;
XX head and neck cancer; neuroectoderm; placenta; skeletal muscle; tonsil;
XX lymph tissue; kidney; colon; uterus; testis; stomach; adrenal gland;
XX bladder; bone; bone marrow; gall bladder; ganglia; salivary gland;
XX gastrointestinal tract; parathyroid; penis; salivary gland; spleen;
XX synovial membrane; thymus; thyroid gland; PCR; primer; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200218592-A1.
XX
XX 07-MAR-2002.
XX
XX 31-AUG-2001; 2001WO-AU01097.
XX
XX 01-SEP-2000; 2000AU-0009806.
XX
XX (BION-) BIONOMICS LTD.
XX
XX Callen DF, Whitmore SA, Kremmidiotis G, Kochetkova M, Crawford J;
XX
XX WPI; 2002-382966/41.
XX
XX Tumour suppressor gene which encodes polypeptide MTG16 active in
XX suppressing cellular function associated with cancer, useful for
XX manufacturing a medicament for treating cancer e.g. adenocarcinoma,
XX leukaemia
XX
XX Example 8; Page 67; 125pp; English.
XX
XX The invention relates to a novel tumour suppressor gene (I) MTG16a or
XX MTG16b and encoded polypeptide (II). (I) and (II) or a compound that
XX mimics MTG16 activity such as 5-aza-2'-deoxycytidine, are useful for
XX manufacturing a medicament for treating cancer, where it reverses DNA
XX methylation. The cancer is adenocarcinoma, leukaemia, lymphoma, melanoma,
XX myeloma, sarcoma, teratocarcinoma, and especially cancer of the breast,
XX prostate, liver, ovary, head and neck, neuroectoderm, placenta, skeletal
XX muscle, tonsil, lymph tissue, kidney, colon, uterus, testis, stomach,
XX adrenal gland, bladder, bone, bone marrow, gall bladder, ganglia,
XX gastrointestinal tract, parathyroid, penis, salivary glands, skin, spleen
XX synovial membrane, thymus and thyroid gland. (I) and (II) are useful for
XX diagnosis of a cancer, or predisposition to cancer, by establishing a
XX profile for normal expression of MTG16 in unaffected subjects using
XX primers derived from (I). MTG16 is further useful for identifying
XX interacting protein suitable as drug targets, where MTG16 is fused to a
XX DNA binding domain and used as the bait in a yeast two-hybrid system.
XX ABK71964-ABK72041 represent human MTG16 coding sequences and PCR
XX primers of the invention.
XX
XX Sequence 19 BP; 2 A; 6 C; 6 G; 5 T; 0 other;
SQ
XX
XX Query Match 1.1%; Score 15.4; DB 1; Length 19;
XX Best Local Similarity 94.1%; Pred. No. 1.2e+02;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1935 CACACAGATGGCCAC 1951
DB 17 CACACAGATGGCCAC 1

```

```

RESULT 63
ABK71996/C
ID ABK71996 standard; DNA; 19 BP.
XX
XX AC ABK71996;
XX
XX 30-JUL-2002 (first entry)
DT

```

```

RESULT 64
AAT31581/C
ID AAT31581 standard; DNA; 20 BP.
XX
XX AC AAT31581;
XX
XX 25-SEP-1996 (first entry)
DT
XX

```

DE 3' PCR primer for murine Ich-1 amplification.
 XX
 XX Ich-1; ICE-ced-3 homologue; programmed cell death; apoptosis;
 KW interleukin-1 beta converting enzyme; gene therapy; primer; PCR;
 KW polymerase chain reaction; ss.
 XX
 OS Synthetic.
 XX
 PN WO9620721-A1.
 XX
 PD 11-JUL-1996.
 XX
 PP 04-JAN-1996; 96WO-US00177.
 XX
 PR 04-JAN-1995; 95US-0368704.
 XX
 PA (GEHO) GEN HOSPITAL CORP.
 XX
 PI Miura M, Yuan J;
 XX
 DR WPI; 1996-333763/33.
 XX
 PT Preventing or promoting programmed cell death in vertebrate cells
 PT comprises inhibiting or increasing the activity of
 PT interleukin-1-beta converting enzyme, or altering expression of
 PT other related genes
 XX
 PS Example 5; Page 77; 127p; English.
 XX
 CC Quantitative PCR analysis was performed using primers (AA131580-81)
 CC to amplify mouse Ich-1, primers (AA131582-83) to amplify human
 CC Ich-1, primers (AA131584-85) to amplify human interleukin-1 beta
 CC converting enzyme (ICE), and control primers (AA131586-87) for
 CC mouse beta-actin. Ich-1 is a new member of the ICE/ced-3
 CC family of cell death genes. Ich-1L (see also AA131552) and Ich-1S
 CC (AA131553) were amplified simultaneously to produce DNA fragments
 CC of 234 and 235 bp, respectively. Expression of Ich-1S was detected
 CC in HeLa and Jurkat cells but not in THP.1 or U937 cells.
 CC Expression levels of Ich-1L increased in dying hybridoma D011.10
 CC cells.
 CC
 XX Sequence 20 BP; 4 A; 8 C; 1 G; 7 T; 0 other;
 SQ
 Query Match 1.1%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 1.2e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 1878 GGAGATGATGAAGATGA 1894
 Db 20 GGAGTTGATGAAGATGA 4
 RESULT 65
 AA169511/c
 ID AA169511 standard; DNA; 20 BP.
 XX
 AC AA169511;
 XX
 DT 11-DEC-2001 (first entry)
 XX
 DE Intestinal bacteria detection primer SEQ ID NO: 11.
 XX
 KW Intestinal bacteria detection; PCR primer; ss.
 XX
 OS Bacteria.
 XX
 PN JP2001112485-A.
 XX
 PD 24-APR-2001.
 XX
 PP 19-OCT-1999; 99JP-0296815.
 XX
 PR 19-OCT-1999; 99JP-0296815.
 PR

XX
 PA (HONS) YAKUIT HONGSHA KK.
 PA (YAKU-) 2H YAKULT BIOSCIENCE KENKYU ZAIDAN.
 XX
 DR WPI; 2001-372656/39.
 XX
 PT Primers for intestinal bacteria and a method for detection using the
 PT primers -
 XX
 PS Claim 1; Page 15; 17pp; Japanese.
 XX
 CC The present invention relates to the detection and identification of
 CC intestinal bacteria using the primers shown in AA169501-AA169547. The
 CC present sequence is one of these primers.
 XX
 SQ Sequence 20 BP; 7 A; 5 C; 3 G; 5 T; 0 other;
 XX
 Query Match 1.1%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 1.2e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 1827 GTTGAAAGATGATGCCA 1843
 Db 20 GTTGATGATGATGCCA 4
 RESULT 66
 AAH20838
 ID AAH20838 standard; DNA; 20 BP.
 XX
 AC AAH20838;
 XX
 DT 21-AUG-2001 (first entry)
 XX
 DE C. perfringens detecting probe Cloper.
 XX
 KW Detection; probe; identification; food; pathogen; tuberculosis; sepsis;
 KW bacterium; fungus; protozoa; multi-cellular parasite; infection;
 KW septic shock; necrotizing fasciitis; cystic fibrosis; meningitis;
 KW urogenital infection; fulminant endocarditis; ophthalmitis; ss.
 XX
 OS Clostridium perfringens.
 XX
 PN DE19955303-A1.
 XX
 PD 31-MAY-2001.
 XX
 PP 17-NOV-1999; 99DE-1055303.
 XX
 PR 17-NOV-1999; 99DE-1055303.
 XX
 PA (CREA-) CREATOGEN AG.
 XX
 PI Apfel H, Trebesius K, Autenrieth I, Heesemann J;
 XX
 DR WPI; 2001-336626/36.
 XX
 PT Direct and rapid identification of microorganisms, useful for
 PT determining pathogens that cause fulminant infections, based on
 PT hybridization with labeled immobilized probes -
 XX
 PS Claim 27; Page 29; 38pp; German.
 XX
 CC This invention describes a novel method for the direct identification of
 CC organisms (A) in a biological sample which comprises (i) dividing the
 CC sample into many parts (B); (ii) immobilizing (A) in (B); (iii)
 CC contacting (B) with at least one labeled hybridization probe (HP) and
 CC (iv) detecting bound label. Different HP (or combinations of them) are
 CC used for each (B) and HP comprise a hybridization region that is
 CC complementary to a target sequence, available for hybridization within
 CC the cell, in (A)-specific nucleic acid. The method is used to identify
 CC (A), i.e. bacteria, fungi, protozoa or multi-cellular parasites, (i) in
 CC foods (or pharmaceuticals), for process or quality control and (ii) in

recombinant techniques and is useful for preventing obesity, diabetes or

malicious 1/;	conservative 0/;	misinformation 3/;	insects 0/;	gaps 0/;
---------------	------------------	--------------------	-------------	----------

QY 2323 AGTGATGCTGCTCTTGG 2342
 |||||
 DB 20 AGTGATGCTGACCTATGG 1

RESULT 69
 ID AA064159 standard; DNA; 20 BP.
 XX AA064159;
 AC
 XX 25-MAR-2003 (updated)
 DT 03-FEB-1995 (first entry)
 XX
 XX Primer for amplifying tyrosine kinase receptor coding sequence.
 DE
 XX Tyrosine kinase; receptor; proto-oncogene; trk; detection;
 KW diagnosis; antibody; treatment; tumour; antisense; ss.
 XX
 XX Synthetic.
 OS
 XX DE4239817-A1.
 XX
 XX 01-JUN-1994.
 PD
 XX 26-NOV-1992; 92DE-4239817.
 PF
 XX 26-NOV-1992; 92DE-4239817.
 PR
 XX (CHEM-) CHEMOTHERAPEUTISCHES FORSCHUNG.
 PA
 XX Holtrich U, Ruebsamen-waismann H, Strebhardt K;
 P1 WPI; 1994-184380/23.
 DR
 XX
 XX New protein tyrosine kinase and related nucleic acid - vectors,
 PT transformed cells, etc., useful for diagnosis and treatment of
 PT tumours
 PS
 XX Example 1; Page 8; 39p; German.
 XX
 XX Three primers (AA064159-Q64161) were used to amplify regions of the
 CC protein tyrosine kinase receptor. The gene encoding the receptor is
 CC related to the trk proto-oncogene. Antibodies against the encoded
 CC polypeptide are useful for diagnosis and for the treatment of
 CC tumours. The antibodies may also be radiolabelled or coupled to a
 CC cytotoxin for destruction of cancer cells. Antisense nucleic acid
 CC can be used to inhibit gene expression.
 CC (Updated on 25-MAR-2003 to correct PN field.)
 CC
 XX
 SQ Sequence 20 BP; 6 A; 7 C; 3 G; 4 T; 0 other;

Query Match 1.1%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.3e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2323 AGTGATGCTGCTCTTGG 2342
 |||||
 DB 20 AGTGATGCTGACCTATGG 1

RESULT 70
 ID AA064159 standard; DNA; 20 BP.
 XX
 AC AA064159;
 XX
 XX 25-MAR-2003 (updated)
 DT 14-MAY-1997 (first entry)
 XX
 XX Degenerate PCR primer for protein kinase cDNA isolation.
 DE
 XX Protein kinase; treatment; disorder; cancer; human; primer; PCR;

KW foetal liver; degenerate; polymerase chain reaction; ss.
 XX
 XX Synthetic.
 OS
 XX WO9628554-A1.
 PN
 XX 19-SEP-1996.
 PD
 XX 15-MAR-1996; 96WO-JP00660.
 PF
 XX 16-MAR-1995; 95JP-0057104.
 PR
 XX (CHUS) CHUGAI SEIYAKU KK.
 PA
 XX Nezu J;
 P1
 XX WPI; 1996-433826/43.
 DR
 XX
 XX DNA encoding protein kinase - for potential treatment of protein
 PT kinase activity related disorders and cancer
 PT
 XX Example A-1; Page 23; 30p; Japanese.
 XX
 XX The present sequence is a degenerate PCR primer for protein kinase
 CC (PK) cDNA isolation. The PK may be used to treat disorders related
 CC to abnormal PK activity, and cancer. Human foetal liver polyA+ RNA
 CC was PCR amplified, and the products subcloned, sequenced and used
 CC to produce the plasmids pLKB1-1 and pLKB1-2. When the coding
 CC region of pLKB1-1 was isolated by restriction digest, and analysed
 CC by northern blotting against polyA+ RNA prepared from various
 CC human organs and cultured cells, weak expression was detected in
 CC almost all tissue and cell types.
 CC (Updated on 25-MAR-2003 to correct PA field.)
 CC
 XX
 SQ Sequence 20 BP; 5 A; 1 C; 4 G; 4 T; 6 other;

Query Match 1.1%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 70.0%; Pred. No. 1.3e+02;
 Matches 14; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1813 GTGGCCGTGAAGATGTGAA 1832
 |||||
 DB 1 GTGGCNGTMAARATGYTMA 20

RESULT 71
 ID AA01150 standard; DNA; 20 BP.
 XX
 AC AA01150;
 XX
 XX 23-MAR-1998 (first entry)
 DT
 XX Homeobox 7 PCR primer for universal mammalian STS's.
 DE
 XX PCR primer; polymerase chain reaction; amplification; UM-STS;
 KW universal mammalian sequence tagged site; genomic map; clone; ss.
 KW
 XX Synthetic.
 OS
 XX WO9731012-A1.
 PN
 XX 28-AUG-1997.
 PD
 XX 18-FEB-1997; 97WO-US02403.
 PF
 XX 22-FEB-1996; 96US-0012061.
 PR
 XX (UNMI) UNIV MICHIGAN.
 PA (UNMS) UNIV MICHIGAN STATE.
 PA
 XX Brewer GJ, Venta PJ, Yuzbasian-Gurkan V;
 P1

DR WPI; 1997-435083/40.
 XX
 PT New oligonucleotide primers amplifying gene regions conserved among
 PT mammals - useful for developing genomic maps, isolating clones and
 PT making cross-species comparisons
 XX
 PS Claim 1; Page 9; 26pp; English.
 XX
 CC The present sequence represents a specifically claimed oligonucleotide
 CC PCR primer. The oligonucleotide can be used for polymerase chain
 CC reaction (PCR) amplification of DNA, specifically regions of specific
 CC genes that are conserved among mammalian species, i.e. pairs of
 CC oligonucleotides from the present specification represent universal
 CC mammalian sequence-tagged site (UM-STS) primers. The primers are used
 CC to develop genomic maps, to isolate clones from libraries, to make
 CC cross-species comparisons and to develop additional genetic markers.
 CC UM-STS allow genomic comparisons to be made between more species.
 XX
 SO Sequence 20 BP; 3 A; 8 C; 2 G; 7 T; 0 other;
 Query Match 1.1%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.3e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Oy 1873 GAGATGAGATGATGATGAT 1892
 Db 20 GAGCTGAGAGACTGACAT 1
 RESULT 72
 AAV01155
 ID AAV01155 standard; DNA; 20 BP.
 AC AAV01155;
 XX
 DT 23-MAR-1998 (first entry)
 XX
 DE C-KIT protooncogene PCR primer for universal mammalian STS's.
 XX
 KW PCR primer; polymerase chain reaction; amplification; UM-STS;
 KW universal mammalian sequence tagged site; genomic map; clone; ss.
 XX
 OS Synthetic.
 OS
 PN WO9731012-A1.
 PD 28-AUG-1997.
 XX
 PF 18-FEB-1997; 97WO-US02403.
 XX
 PR 22-FEB-1996; 96US-0012061.
 XX
 PA (UNMI) UNIV MICHIGAN.
 PA (UNMS) UNIV MICHIGAN STATE.
 XX
 PI Brewer GJ, Venta PJ, Yuzbaslyan-Gurkan V;
 XX
 DR WPI; 1997-435083/40.
 XX
 PT New oligonucleotide primers amplifying gene regions conserved among
 PT mammals - useful for developing genomic maps, isolating clones and
 PT making cross-species comparisons
 XX
 PS Claim 1; Page 9; 26pp; English.
 XX
 CC The present sequence represents a specifically claimed oligonucleotide
 CC PCR primer. The oligonucleotide can be used for polymerase chain
 CC reaction (PCR) amplification of DNA, specifically regions of specific
 CC genes that are conserved among mammalian species, i.e. pairs of
 CC oligonucleotides from the present specification represent universal
 CC mammalian sequence-tagged site (UM-STS) primers. The primers are used
 CC to develop genomic maps, to isolate clones from libraries, to make
 CC cross-species comparisons and to develop additional genetic markers.

CC UM-STS allow genomic comparisons to be made between more species.
 XX
 SQ Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 other;
 Query Match 1.1%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.3e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Oy 2269 CCAGTCAGTGTGATGCTCC 2288
 Db 1 CCTGTGAGTGTGATGCTCAC 20
 RESULT 73
 AAZ18093
 ID AAZ18093 standard; DNA; 20 BP.
 AC AAZ18093;
 XX
 DT 11-OCT-1999 (first entry)
 XX
 DE PTK 2 gene specific primer.
 XX
 KW Genetic proximity; gene expression; cell characterisation; homeobox gene;
 KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
 KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
 KW primer; ss.
 XX
 OS Synthetic.
 OS
 PN Homo sapiens.
 PD WO9934016-A2.
 XX
 PD 08-JUL-1999.
 XX
 PF 28-DEC-1998; 98WO-IL00625.
 XX
 PR 16-OCT-1998; 98IL-0126627.
 PR 29-DEC-1997; 97IL-0122793.
 XX
 PA (GENE-) GENEVA LTD.
 XX
 PI Vidler B;
 XX
 DR WPI; 1999-419113/35.
 DR P-PSDB; AAY14628.
 XX
 PT Identifying and characterizing cells by comparing the pattern of
 PT gene expression in a selected gene family
 XX
 PS Claim 4; Page 42; 102pp; English.
 XX
 CC The invention provides a new method for identifying and characterizing
 CC cells. The method for determining the genetic proximity of a first cell
 CC and a second cell comprises: (a) obtaining the first cell and the second
 CC cell; (b) determining in the first cell and the second cell the pattern
 CC of expression of genes in a selected gene family; and (c) calculating a
 CC proximity index using a specified formula. The methods can be used for
 CC characterizing cells, e.g. for determining the origin of a cell, its
 CC genetic status, whether it carries a genetic defect, or whether it is
 CC transformed. They can be used for detecting a selected genetic defect in
 CC an individual, e.g. a fetus. They can also be used for determining the
 CC effect of a selected treatment on a test cell. They can also be used for
 CC obtaining cells capable of expressing an homeobox related desired
 CC property. The method uses reverse transcriptase polymerase chain
 CC reaction (RT-PCR) for determining the pattern of gene expression in a
 CC selected gene family. Sequences AAZ17803-Z18342 represent primers that
 CC can be used in the RT-PCR reactions to determine the pattern of gene
 CC expression. The gene family can be selected from a set of homeobox genes,
 CC kinase genes, protein phosphatase genes, P450 enzyme genes, steroid
 CC receptor superfamily genes or cadherin superfamily genes.
 XX
 SQ Sequence 20 BP; 8 A; 1 C; 5 G; 6 T; 0 other;

Db 1 AAAATTGACAGCTTTGGAAT 20

RESULT 76

AAZ18099 AAZ18099 standard; DNA; 20 BP.

AC AAZ18099;

DT 11-OCT-1999 (first entry)

DE PTK 5 gene specific primer.

XX Genetic proximity; gene expression; cell characterisation; homeobox gene;

KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;

KM kinase gene; protein phosphatase; P450; steroid receptor; cadherin;

KW primer; ss.

XX Synthetic.

OS Homo sapiens.

XX MO9934016-A2.

PD 08-JUL-1999.

XX 28-DEC-1998; 98WO-IL00625.

XX 16-OCT-1998; 98IL-0126627.

XX 29-DEC-1997; 97IL-0122793.

XX (GENE-) GENENA LTD.

XX Vidar B;

XX WPI; 1999-419113/35.

XX P-PSDB; AAY14634.

XX Identifying and characterizing cells by comparing the pattern of

PT gene expression in a selected gene family

XX Claim 4; Page 42; 102pp; English.

XX The invention provides a new method for identifying and characterizing

CC cells. The method for determining the genetic proximity of a first cell

CC and a second cell comprises: (a) obtaining the first cell and the second

CC cell; (b) determining in the first cell and the second cell the pattern

CC of expression of genes in a selected gene family; and (c) calculating a

CC proximity index using a specified formula. The method can be used for

CC characterizing cells, e.g. for determining the origin of a cell, its

CC genetic status, whether it carries a genetic defect, or whether it is

CC transformed. They can be used for detecting a selected genetic defect in

CC an individual, e.g. a fetus. They can also be used for determining the

CC effect of a selected treatment on a test cell. They can also be used for

CC obtaining cells capable of expressing an homeobox related desired

CC property. The method uses reverse transcriptase polymerase chain

CC reaction (RT-PCR) for determining the pattern of gene expression in a

CC selected gene family. Sequences AAZ17803-218342 represent primers that

CC can be used in the RT-PCR reactions to determine the pattern of gene

CC expression. The gene family can be selected from a set of homeobox genes,

CC kinase genes, protein phosphatase genes, P450 enzyme genes, steroid

CC receptor superfamily genes or cadherin superfamily genes.

XX Sequence 20 BP; 6 A; 3 C; 4 G; 7 T; 0 other;

SO Query Match 1.1%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.3e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2194 AAAATGACAGCTTTGGAAT 2213

Db 1 AAAATTGACAGCTTTGGAAT 20

RESULT 77
AAZ18101 AAZ18101 standard; DNA; 20 BP.

AC AAZ18101;

DT 11-OCT-1999 (first entry)

DE PTK 6 gene specific primer.

XX Genetic proximity; gene expression; cell characterisation; homeobox gene;

KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;

KM kinase gene; protein phosphatase; P450; steroid receptor; cadherin;

KW primer; ss.

XX Synthetic.

OS Homo sapiens.

XX MO9934016-A2.

PD 08-JUL-1999.

XX 28-DEC-1998; 98WO-IL00625.

XX 16-OCT-1998; 98IL-0126627.

XX 29-DEC-1997; 97IL-0122793.

XX (GENE-) GENENA LTD.

XX Vidar B;

XX WPI; 1999-419113/35.

XX P-PSDB; AAY14636.

XX Identifying and characterizing cells by comparing the pattern of

PT gene expression in a selected gene family

XX Claim 4; Page 42; 102pp; English.

XX The invention provides a new method for identifying and characterizing

CC cells. The method for determining the genetic proximity of a first cell

CC and a second cell comprises: (a) obtaining the first cell and the second

CC cell; (b) determining in the first cell and the second cell the pattern

CC of expression of genes in a selected gene family; and (c) calculating a

CC proximity index using a specified formula. The method can be used for

CC characterizing cells, e.g. for determining the origin of a cell, its

CC genetic status, whether it carries a genetic defect, or whether it is

CC transformed. They can be used for detecting a selected genetic defect in

CC an individual, e.g. a fetus. They can also be used for determining the

CC effect of a selected treatment on a test cell. They can also be used for

CC obtaining cells capable of expressing an homeobox related desired

CC property. The method uses reverse transcriptase polymerase chain

CC reaction (RT-PCR) for determining the pattern of gene expression in a

CC selected gene family. Sequences AAZ17803-218342 represent primers that

CC can be used in the RT-PCR reactions to determine the pattern of gene

CC expression. The gene family can be selected from a set of homeobox genes,

CC kinase genes, protein phosphatase genes, P450 enzyme genes, steroid

CC receptor superfamily genes or cadherin superfamily genes.

XX Sequence 20 BP; 6 A; 3 C; 4 G; 7 T; 0 other;

SO Query Match 1.1%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.3e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2194 AAAATGACAGCTTTGGAAT 2213

Db 1 AAAATTGACAGCTTTGGAAT 20

RESULT 78

AAZ18103

```

ID AA218103 standard; DNA; 20 BP.
XX
XX AA218103;
AC
XX
XX 11-OCT-1999 (first entry)
DT
XX PTK 7 gene specific primer.
DE
XX
XX Genetic proximity; gene expression; cell characterisation; homeobox gene;
KM genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
KM kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
KM primer; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX WO9934016-A2.
PN
XX
XX 08-JUL-1999.
PD
XX
XX 28-DEC-1998; 98WO-IL00625.
PF
XX
XX 16-OCT-1998; 98IL-0126627.
PR 16-OCT-1998; 98IL-0126627.
PR 29-DEC-1997; 97IL-0122793.
XX
XX (GENE-) GENENA LTD.
PA
XX
XX Vider B;
FI
XX
XX WPI; 1999-419113/35.
DR
XX P-PSDB; AAY14638.
DR
XX
XX Identifying and characterizing cells by comparing the pattern of
PT gene expression in a selected gene family
XX
XX Claim 4; Page 42; 102pp; English.
PS
XX
XX The invention provides a new method for identifying and characterizing
CC cells. The method for determining the genetic proximity of a first cell
CC and a second cell comprises: (a) obtaining the first cell and the second
CC cell; (b) determining in the first cell and the second cell the pattern
CC of expression of genes in a selected gene family; and (c) calculating a
CC proximity index using a specified formula. The methods can be used for
CC characterizing cells, e.g. for determining the origin of a cell, its
CC genetic status, whether it carries a genetic defect, or whether it is
CC transformed. They can be used for detecting a selected genetic defect in
CC an individual, e.g. a fetus. They can also be used for determining the
CC effect of a selected treatment on a test cell. They can also be used for
CC obtaining cells capable of expressing an homeobox related desired
CC property. The method uses reverse transcriptase polymerase chain
CC reaction (RT-PCR) for determining the pattern of gene expression in a
CC selected gene family. Sequences AA217803-Z18342 represent primers that
CC can be used in the RT-PCR reactions to determine the pattern of gene
CC expression. The gene family can be selected from a set of homeobox genes,
CC kinase genes, protein phosphatase genes, P450 enzyme genes, steroid
CC receptor superfamily genes or cadherin superfamily genes.
CC
XX
XX Sequence 20 BP; 6 A; 3 C; 4 G; 7 T; 0 other;
SQ
Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Oy 2194 AAAATGACAGCTTGACCT 2213
Db 1 AAAATGACAGCTTGACCT 20

```

```

XX
XX 11-OCT-1999 (first entry)
DT
XX
XX PTK 8 gene specific primer.
DE
XX
XX Genetic proximity; gene expression; cell characterisation; homeobox gene;
KM genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
KM kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
KM primer; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX WO9934016-A2.
PN
XX
XX 08-JUL-1999.
PD
XX
XX 28-DEC-1998; 98WO-IL00625.
PF
XX
XX 16-OCT-1998; 98IL-0126627.
PR 16-OCT-1998; 98IL-0126627.
PR 29-DEC-1997; 97IL-0122793.
XX
XX (GENE-) GENENA LTD.
PA
XX
XX Vider B;
PI
XX
XX WPI; 1999-419113/35.
DR
XX P-PSDB; AAY14640.
DR
XX
XX Identifying and characterizing cells by comparing the pattern of
PT gene expression in a selected gene family
XX
XX Claim 4; Page 42; 102pp; English.
PS
XX
XX The invention provides a new method for identifying and characterizing
CC cells. The method for determining the genetic proximity of a first cell
CC and a second cell comprises: (a) obtaining the first cell and the second
CC cell; (b) determining in the first cell and the second cell the pattern
CC of expression of genes in a selected gene family; and (c) calculating a
CC proximity index using a specified formula. The methods can be used for
CC characterizing cells, e.g. for determining the origin of a cell, its
CC genetic status, whether it carries a genetic defect, or whether it is
CC transformed. They can be used for detecting a selected genetic defect in
CC an individual, e.g. a fetus. They can also be used for determining the
CC effect of a selected treatment on a test cell. They can also be used for
CC obtaining cells capable of expressing an homeobox related desired
CC property. The method uses reverse transcriptase polymerase chain
CC reaction (RT-PCR) for determining the pattern of gene expression in a
CC selected gene family. Sequences AA217803-Z18342 represent primers that
CC can be used in the RT-PCR reactions to determine the pattern of gene
CC expression. The gene family can be selected from a set of homeobox genes,
CC kinase genes, protein phosphatase genes, P450 enzyme genes, steroid
CC receptor superfamily genes or cadherin superfamily genes.
CC
XX
XX Sequence 20 BP; 6 A; 3 C; 4 G; 7 T; 0 other;
SQ
Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Oy 2194 AAAATGACAGCTTGACCT 2213
Db 1 AAAATGACAGCTTGACCT 20

```

```

RESULT 79
AA218105
ID AA218105 standard; DNA; 20 BP.
XX
XX AA218105;
AC

```

```

RESULT 80
AA218091
ID AA218091 standard; DNA; 20 BP.
XX
XX AA218091;
AC
XX
XX 11-OCT-1999 (first entry)
DT
XX

```

DE PTK 1 gene specific primer.
 XX
 KW Genetic proximity; gene expression; cell characterisation; homeobox gene;
 KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
 KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
 KW primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9934016-A2.
 PD
 XX 08-JUL-1999.
 PF
 XX 28-DEC-1998; 98WO-IL00625.
 PR
 XX 16-OCT-1998; 98IL-0126627.
 PR 29-DEC-1997; 97IL-0122793.
 XX
 PA (GENE-) GENENNA LTD.
 XX
 PI Vidler B;
 DR WPI; 1999-419113/35.
 DR P-PSDB; AAY14626.
 XX
 PT Identifying and characterizing cells by comparing the pattern of
 PT gene expression in a selected gene family
 XX
 PS Claim 4; Page 42; 102pp; English.
 XX
 CC The invention provides a new method for identifying and characterizing
 CC cells. The method for determining the genetic proximity of a first cell
 CC and a second cell comprises: (a) obtaining the first cell and the second
 CC cell; (b) determining in the first cell and the second cell the pattern
 CC of expression of genes in a selected gene family; and (c) calculating a
 CC proximity index using a specified formula. The methods can be used for
 CC characterizing cells, e.g. for determining the origin of a cell, its
 CC genetic status, whether it carries a genetic defect, or whether it is
 CC transformed. They can be used for detecting a selected genetic defect in
 CC an individual, e.g. a fetus. They can also be used for determining the
 CC effect of a selected treatment on a test cell. They can also be used for
 CC obtaining cells capable of expressing an homeobox related desired
 CC property. The method uses reverse transcriptase polymerase chain
 CC reaction (RT-PCR) for determining the pattern of gene expression in a
 CC selected gene family. Sequences AA217803-218342 represent primers that
 CC can be used in the RT-PCR reactions to determine the pattern of gene
 CC expression. The gene family can be selected from a set of homeobox genes,
 CC kinase genes, protein phosphatase genes, P450 enzyme genes, steroid
 CC receptor superfamily genes or cadherin superfamily genes.
 XX
 SQ Sequence 20 BP; 8 A; 1 C; 5 G; 6 T; 0 other;
 Query Match 1.1%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.3e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Oy 2194 AAATAGCAGCTTGGACT 2213
 Db 1 AAATGGAGACTTGAAT 20
 RESULT 81
 AA218185
 ID AA218185 standard; DNA; 20 BP.
 AC AA218185;
 XX
 DT 11-OCT-1999 (first entry)
 XX
 DE PTK 28 gene specific primer.
 XX
 KW Genetic proximity; gene expression; cell characterisation; homeobox gene;

KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
 KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
 KW primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9934016-A2.
 PD
 XX 08-JUL-1999.
 PF
 XX 28-DEC-1998; 98WO-IL00625.
 PR
 XX 16-OCT-1998; 98IL-0126627.
 PR 29-DEC-1997; 97IL-0122793.
 XX
 PA (GENE-) GENENNA LTD.
 XX
 PI Vidler B;
 DR WPI; 1999-419113/35.
 DR P-PSDB; AAY14720.
 XX
 PT Identifying and characterizing cells by comparing the pattern of
 PT gene expression in a selected gene family
 XX
 PS Claim 4; Page 46; 102pp; English.
 XX
 CC The invention provides a new method for identifying and characterizing
 CC cells. The method for determining the genetic proximity of a first cell
 CC and a second cell comprises: (a) obtaining the first cell and the second
 CC cell; (b) determining in the first cell and the second cell the pattern
 CC of expression of genes in a selected gene family; and (c) calculating a
 CC proximity index using a specified formula. The methods can be used for
 CC characterizing cells, e.g. for determining the origin of a cell, its
 CC genetic status, whether it carries a genetic defect, or whether it is
 CC transformed. They can be used for detecting a selected genetic defect in
 CC an individual, e.g. a fetus. They can also be used for determining the
 CC effect of a selected treatment on a test cell. They can also be used for
 CC obtaining cells capable of expressing an homeobox related desired
 CC property. The method uses reverse transcriptase polymerase chain
 CC reaction (RT-PCR) for determining the pattern of gene expression in a
 CC selected gene family. Sequences AA217803-218342 represent primers that
 CC can be used in the RT-PCR reactions to determine the pattern of gene
 CC expression. The gene family can be selected from a set of homeobox genes,
 CC kinase genes, protein phosphatase genes, P450 enzyme genes, steroid
 CC receptor superfamily genes or cadherin superfamily genes.
 XX
 SQ Sequence 20 BP; 8 A; 1 C; 5 G; 6 T; 0 other;
 Query Match 1.1%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.3e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Oy 2194 AAATAGCAGCTTGGACT 2213
 Db 1 AAATGGAGACTTGAAT 20
 RESULT 82
 AA218183
 ID AA218183 standard; DNA; 20 BP.
 AC AA218183;
 XX
 DT 11-OCT-1999 (first entry)
 XX
 DE PTK 27 gene specific primer.
 XX
 KW Genetic proximity; gene expression; cell characterisation; homeobox gene;
 KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
 KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
 KW primer; ss.

XX OS Synthetic.
 XX OS Homo sapiens.
 XX PN M09934016-A2.
 XX XX 08-JUL-1999.
 XX PF 28-DEC-1998; 98MO-IL00625.
 XX PR 16-OCT-1998; 98IL-0126627.
 XX PR 29-DEC-1997; 97IL-0122793.
 XX PA (GENE-) GENENVA LTD.
 XX PI Vidler B;
 XX DR WPI; 1999-419113/35.
 XX DR P-PSDB; AAY14718.
 XX PS Claim 4; Page 46; 102pp; English.
 CC The invention provides a new method for identifying and characterising
 CC cells. The method for determining the genetic proximity of a first cell
 CC and a second cell comprises: (a) obtaining the first cell and the second
 CC cell; (b) determining in the first cell and the second cell the pattern
 CC of expression of genes in a selected gene family; and (c) calculating a
 CC proximity index using a specified formula. The method can be used for
 CC characterising cells, e.g. for determining the origin of a cell, its
 CC genetic status, whether it carries a genetic defect, or whether it is
 CC transformed. They can be used for detecting a selected genetic defect in
 CC an individual, e.g. a fetus. They can also be used for determining the
 CC effect of a selected treatment on a test cell. They can also be used for
 CC obtaining cells capable of expressing an homeobox related desired
 CC property. The method uses reverse transcriptase polymerase chain
 CC reaction (RT-PCR) for determining the pattern of gene expression in a
 CC selected gene family. Sequences AA217803-218342 represent primers that
 CC can be used in the RT-PCR reactions to determine the pattern of gene
 CC expression. The gene family can be selected from a set of homeobox genes,
 CC kinase genes, protein phosphatase genes, P450 enzyme genes, steroid
 CC receptor superfamily genes or cadherin superfamily genes.
 CC XX
 SQ Sequence 20 BP; 8 A; 1 C; 5 G; 6 T; 0 other;
 Query Match 1.1%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.3e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Oy 2194 AAAATGACAGACTTGGACT 2213
 Db 1 AAAATGACAGACTTGGAAAT 20
 RESULT 83
 ID AA218181 standard; DNA; 20 BP.
 AC AA218181;
 XX 11-OCT-1999 (first entry)
 DE PTK 26 gene specific primer.
 XX Genetic proximity; gene expression; cell characterisation; homeobox gene;
 KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
 KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
 KW primer; ss.
 XX OS Synthetic.
 OS Homo sapiens.

XX PN M09934016-A2.
 XX XX 08-JUL-1999.
 XX PF 28-DEC-1998; 98MO-IL00625.
 XX PR 16-OCT-1998; 98IL-0126627.
 XX PR 29-DEC-1997; 97IL-0122793.
 XX PA (GENE-) GENENVA LTD.
 XX PI Vidler B;
 XX DR WPI; 1999-419113/35.
 XX DR P-PSDB; AAY14716.
 XX PS Claim 4; Page 46; 102pp; English.
 CC The invention provides a new method for identifying and characterising
 CC cells. The method for determining the genetic proximity of a first cell
 CC and a second cell comprises: (a) obtaining the first cell and the second
 CC cell; (b) determining in the first cell and the second cell the pattern
 CC of expression of genes in a selected gene family; and (c) calculating a
 CC proximity index using a specified formula. The method can be used for
 CC characterising cells, e.g. for determining the origin of a cell, its
 CC genetic status, whether it carries a genetic defect, or whether it is
 CC transformed. They can be used for detecting a selected genetic defect in
 CC an individual, e.g. a fetus. They can also be used for determining the
 CC effect of a selected treatment on a test cell. They can also be used for
 CC obtaining cells capable of expressing an homeobox related desired
 CC property. The method uses reverse transcriptase polymerase chain
 CC reaction (RT-PCR) for determining the pattern of gene expression in a
 CC selected gene family. Sequences AA217803-218342 represent primers that
 CC can be used in the RT-PCR reactions to determine the pattern of gene
 CC expression. The gene family can be selected from a set of homeobox genes,
 CC kinase genes, protein phosphatase genes, P450 enzyme genes, steroid
 CC receptor superfamily genes or cadherin superfamily genes.
 CC XX
 SQ Sequence 20 BP; 8 A; 1 C; 5 G; 6 T; 0 other;
 Query Match 1.1%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.3e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Oy 2194 AAAATGACAGACTTGGACT 2213
 Db 1 AAAATGACAGACTTGGAAAT 20
 RESULT 84
 ID AAX95953 standard; DNA; 20 BP.
 AC AAX95953;
 XX 13-SEP-1999 (first entry)
 DE PCR primer used to amplify an ORF of Chlamydia pneumoniae.
 XX Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
 KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis;
 KW vaccine; neutralising epitope; PCR primer; ss.
 XX OS Synthetic.
 OS Chlamydia pneumoniae.
 XX M09927105-A2.
 XX PN 03-JUN-1999.

```
XX 20-NOV-1998; 98WO-IB01890.
PF 04-NOV-1998; 98US-0107078.
PR 21-NOV-1997; 97FR-0014673.
XX (GEST ) GENSET.
XX Grifffals R;
XX WPI; 1999-357842/30.
XX Genome sequence of Chlamydia pneumoniae
XX Page 1788; Disclosure; 1912pp; English.
XX AAY91991-X97517 represent PCR primers used to amplify open reading
XX frames and other nucleic acid sequences from the genome of
XX Chlamydia pneumoniae (see AAY91990). C. pneumoniae causes respiratory
XX disease such as pneumonia and bronchitis and is thought to be a
XX contributing factor in heart disease, sarcoidosis, sinusitis, purulent
XX otitis media, erythema nodosum or pharyngitis. The polypeptides encoded
XX by the open reading frames of the C. pneumoniae genome (see AAY94584-
XX AAY935879) can be used in immunogenic compositions as vaccines. Vectors
XX containing C. pneumoniae nucleotide sequences can also be used as
XX immunogenic compositions, especially where the vector directs the
XX expression of a neutralising epitope of C. pneumoniae.
XX Sequence 20 BP; 5 A; 5 C; 4 G; 6 T; 0 other;
SQ
Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2633 GAAGTCTGTGTTCTTCAGCA 2652
Db 1 GAAGTCTGTGTCATCAGCA 20
| | | | | | | | | |
| | | | | | | | | |
RESULT 85
AAC62208
ID AAC62208 standard; DNA; 20 BP.
XX
XX AAC62208;
AC
XX
XX 06-MAR-2001 (first entry)
DT
XX
XX PCR primer used to amplify cDNA encoding flt-4.
DE
XX
XX Antisense oligonucleotide; flt-4; receptor type tyrosine kinase;
KW lymphangiogenesis; prostate cancer; prostate cell; PCR primer; 88.
XX
XX Homo sapiens.
OS
XX
XX WO200062063-A1.
PN
XX
XX 19-OCT-2000.
PD
XX
XX 13-APR-1999; 99WO-US08079.
PF
XX
XX 13-APR-1999; 99WO-US08079.
PR
XX
XX (NMBI-) NORTHWEST BIOTHERAPEUTICS INC.
PA
XX
XX Su SL;
PI
XX
XX WPI; 2000-687067/67.
DR
XX
XX Detecting metastatic potential, diagnosing metastatic prostate cancer
XX or determining the prognosis of a subject with prostate cancer
XX comprising detecting the expression of flt-4 in a prostate cell
XX
XX Example; Page 50; 78pp; English.
PS
```

```
XX PCR primers AAC62208-09 were used to amplify cDNA encoding flt-4. Flt-4
XX is a receptor type tyrosine kinase with 7 ig-like domains similar to
XX other VEGF receptors. Flt-4 may play a role in lymphangiogenesis.
XX Antisense oligonucleotides can be used for detecting the metastatic
XX potential, diagnosing metastatic prostate cancer or determining the
XX prognosis of a subject with prostate cancer. The method comprises
XX identifying the prostate cell in a body fluid sample and detecting the
XX expression of flt-4 in the cell. Expression of flt-4 in a prostate cell
XX indicates that the cell is a cancerous prostate cell that has metastatic
XX potential or is a secondary tumour metastasis of a primary prostate
XX tumour.
XX Sequence 20 BP; 4 A; 3 C; 9 G; 4 T; 0 other;
SQ
Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2107 AGAGCGATGAGTCTTGGC 2126
Db 1 AGAGCGATGAGTCTTGGC 20
| | | | | | | | | |
| | | | | | | | | |
RESULT 86
AAS08729/C
ID AAS08729 standard; DNA; 20 BP.
XX
XX AAS08729;
AC
XX
XX 26-SEP-2001 (first entry)
DT
XX
XX Human PD-ABC form 1 DNA exon 6 5' splice site.
DE
XX
XX PD-ATP-binding cassette; PD-ABC; chromosome 19p13.3; spleen; thymus; ds;
KW peripheral blood leukocyte; bone marrow; lymph node; dyslipidaemia;
KW cardiovascular disorder; inflammatory disorder; abnormal calcium flux;
KW epilepsy; coronary artery disease; Tangier's disease; atherosclerosis;
KW familial high-density lipoprotein deficiency; fatty liver disease;
KW atherosclerosis; diabetes; insulin resistance; obesity; drug screening;
KW alcoholism; retinal degeneration; hypertension; vascular disease.
XX
XX Homo sapiens.
OS
XX
XX WO200153490-A1.
PN
XX
XX 26-JUL-2001.
PD
XX
XX 23-JAN-2001; 2001WO-US02191.
PF
XX
XX 24-JAN-2000; 2000US-0177889.
PR
XX
XX 30-JUN-2000; 2000US-0215405.
XX
XX (WARN ) WARNER LAMBERT CO.
PA
XX
XX Johns MA, Tafuri SR, Wang M;
PI
XX
XX WPI; 2001-442259/47.
DR
XX
XX New Human PD-ABC DNA molecules and proteins for diagnosis and treatment
XX of dyslipidaemia, epilepsy and diseases related to abnormal calcium flux
XX
XX Disclosure; Page 37; 77pp; English.
XX
XX The sequence represents a splice site within a DNA molecule encoding
XX human PD-ATP-binding cassette (PD-ABC) protein. PD-ABC maps to chromosome
XX 19p13.3 and is expressed in various tissues including spleen, thymus,
XX peripheral blood leukocytes, bone marrow and lymph nodes. The PD-ABC DNA
XX molecules and proteins are used to diagnose and treat cardiovascular
XX disorders, inflammatory disorders, dyslipidaemia, epilepsy, diseases
XX related to abnormal calcium flux, coronary artery disease, Tangier's
XX disease, familial high-density lipoprotein deficiency, atherosclerosis,
XX
```

CC diabetes, fatty liver disease, insulin resistance, obesity, alcoholism,
CC retinal degeneration, hypertension and vascular disease. The sequences
CC are also used in drug screening assays.

XX
XX
XX Sequence 20 BP; 3 A; 8 C; 3 G; 6 T; 0 other;

Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 2387 CAGGATTCCTCGGAGAA 2406
Db 20 CAGGATTCCTCGGAGAA 1

RESULT 87
AAS08820/c
ID AAS08820 standard; DNA; 20 BP.
XX
XX AAS08820;
AC
XX
XX 26-SEP-2001 (first entry)
DT
XX
XX Human PD-ABC form 2 DNA exon 6 5' splice site.

XX PD-ATP-binding cassette; PD-ABC; chromosome 19p13.3; spleen; thymus; ds;
XX peripheral blood leukocyte; bone marrow; lymph node; dyslipidaemia;
XX cardiovascular disorder; inflammatory disorder; abnormal calcium flux;
XX 'epilepsy; coronary artery disease; Tangier's disease; atherosclerosis;
XX familial high-density lipoprotein deficiency; fatty liver disease;
XX atherosclerosis; diabetes; insulin resistance; obesity; drug screening;
XX alcoholism; retinal degeneration; hypertension; vascular disease.

XX Homo sapiens.

XX WO200153490-A1.

XX 26-JUL-2001.

XX 23-JAN-2001; 2001WO-US02191.

XX 24-JAN-2000; 2000US-0177889.

XX 30-JUN-2000; 2000US-0215405.

XX (WARN) WARNER LAMBERT CO.

XX Johns MA., Tafuri SR., Wang M;

XX WPI; 2001-442259/47.

XX New Human PD-ABC DNA molecules and proteins for diagnosis and treatment
XX of dyslipidaemia, epilepsy and diseases related to abnormal calcium flux
XX
XX Disclosure; Page 39; 77pp; English.

XX The sequence represents a splice site within a DNA molecule encoding
XX human PD-ATP-binding cassette (PD-ABC) protein. PD-ABC maps to chromosome
XX 19p13.3 and is expressed in various tissues including spleen, thymus,
XX peripheral blood leukocytes, bone marrow and lymph nodes. The PD-ABC DNA
XX molecules and proteins are used to diagnose and treat cardiovascular
XX disorders, inflammatory disorders, dyslipidaemia, epilepsy, diseases
XX related to abnormal calcium flux, coronary artery disease, Tangier's
XX disease, familial high-density lipoprotein deficiency, atherosclerosis,
XX diabetes, fatty liver disease, insulin resistance, obesity, alcoholism,
XX retinal degeneration, hypertension and vascular disease. The sequences
XX are also used in drug screening assays.

XX Sequence 20 BP; 3 A; 8 C; 3 G; 6 T; 0 other;

Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 2387 CAGGATTCCTCGGAGAA 2406
Db 20 CAGGATTCCTCGGAGAA 1

RESULT 88
AB272168
ID AB272168 standard; DNA; 20 BP.
XX
XX
XX AB272168;
AC
XX
XX 03-APR-2003 (first entry)
DT

XX Gene 216 SSCP detection primer SEQ ID NO 140.
XX
XX Human; Gene 216; chromosome 20p13-p12; antiasthmatic; anorectic;
XX antiinflammatory; gastrointestinal; gene therapy; vaccine; asthma;
XX obesity; inflammatory bowel disease; primer; ss.

XX Synthetic.

XX WO200178894-A2.

XX 25-OCT-2001.

XX 13-APR-2001; 2001WO-US12245.

XX 13-APR-2000; 2000US-0548797.

XX (GENO-) GENOME THERAPEUTICS CORP.

XX Keith T;

XX WPI; 2001-639428/73.

XX Isolated genes (Gene 216) from human chromosome 20p13-p12 and the
XX proteins they encode, useful for the prevention, diagnosis and
XX treatment of asthma, obesity and inflammatory bowel disease -
XX
XX Example 10; Page 149; 520pp; English.

XX The invention relates to isolated genes (Gene 216) from human chromosome
XX 20p13-p12 and the proteins they encode. The nucleic acids and proteins
XX may be used in the prevention, diagnosis and treatment of diseases
XX associated with inappropriate Gene 216 expression. For example, the
XX nucleic acids (or vectors) and proteins may be used to treat disorders
XX associated with decreased expression by rectifying mutations or deletions
XX in a patient's genome that affect the activity of gene 216 by expressing
XX inactive proteins or to supplement the patient's own production of Gene
XX 216 proteins. Additionally, the nucleic acids may be used to produce the
XX secreted Gene 216 protein, by inserting the nucleic acids into a host
XX cell and culturing the cell to express the protein. The nucleic acids
XX and complementary sequences may also be used as DNA probes in diagnostic
XX assays to detect and quantitate the presence of similar nucleic acid
XX sequences in samples and therefore which patients may be in need of
XX restorative therapy. The Gene 216 protein may also be used as antigens in
XX the production of antibodies against Gene 216 and in assays to identify
XX modulators of Gene 216 expression and activity. The anti-Gene 216
XX antibodies and antagonists may also be used to down regulate expression
XX and activity. The anti-Gene 216 antibodies may also be used as diagnostic
XX agents for detecting the presence of Gene 216 proteins in samples (e.g.
XX by enzyme linked immunosorbant assay or ELISA). Disorders that may be
XX prevented, diagnosed and/or treated by the above methods include, for
XX example asthma, obesity and inflammatory bowel disease. The present
XX sequence is that of a Gene 216 related primer used in examples of the
XX invention. The primers are used in the physical mapping of the gene
XX (AB272067-AB272088), polymorphism identification using single strand
XX conformational polymorphism (SSCP) analysis (AB272091-AB272184),
XX sequencing (AB272185-AB272268) and genotyping (AB272317-AB272362).

XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 other;

```

Query Match          1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      2098 CAGCTGCCAGAGCATGCA 2117
          ||||| ||||| |||||
          1 CAGCTGACACAGTGTATGCA 20

RESULT 89
ABT06120
ID      ABT06120 standard; DNA; 20 BP.
XX
AC      ABT06120;
XX
DT      28-OCT-2002 (first entry)
XX
DE      Human light chain kappa gene related oligo SEQ ID No 134.
XX
KW      Single Primer Amplification; nested oligonucleotide extension reaction;
XX      hairpin; SPA; library; ds.
OS      Homo sapiens.
XX
FN      WO200248401-A2.
XX
PD      20-JUN-2002.
XX
PF      10-DEC-2001; 2001WO-US47727.
XX
PR      11-DEC-2000; 2000US-254669P.
XX      19-SEP-2001; 2001US-323400P.
XX
PA      (ALEX-) ALEXION PHARM INC.
XX
PI      Bowdish KS, Barbas-Frederickson S, Lin Y, McWhirter J, Maruyama T;
XX      WPI; 2002-500537/53.
XX
PT      Amplifying nucleic acid by synthesizing template nucleic acid
XX      containing a predetermined sequence and hairpin structure and using the
XX      template for target amplification by Single Primer Amplification -
XX      Example 5; Page 32; 54pp; English.
XX
PS      The invention relates to a method for amplifying a nucleic acid using
XX      Single Primer Amplification (SPA). The method comprises synthesizing a
XX      template nucleic acid containing a predetermined sequence and hairpin
XX      structure with the nested oligonucleotide extension reaction. The method
XX      is useful for amplifying a nucleic acid, preferably for amplifying a
XX      family of related nucleic acid sequences to build a complex library of
XX      polypeptides encoded by the sequences. The engineered nucleic acid strand
XX      is useful for amplifying a nucleic acid strand by providing a nucleic
XX      acid with a predetermined sequence engineered onto its first end, a
XX      sequence complementary to the predetermined sequence and a hairpin
XX      structure between them and connecting the engineered nucleic acid strand
XX      with a primer containing at least a portion of the predetermined
XX      sequence. This process is done in the presence of a polymerase and
XX      nucleotides under conditions suitable for polymerisation to produce a
XX      complementary nucleic acid strand. The method of the invention is useful
XX      for producing large amounts of a target nucleic acid sequence and for
XX      amplifying simultaneously more than one different target nucleic acid
XX      sequence located on the same or different nucleic acid molecules. This
XX      polynucleotide sequence represents an oligonucleotide relating to the
XX      invention.
XX
SQ      Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 other;

Query Match          1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      1858 TCTATCTCGTGTACAGAT 1877

```

```

DB      1 TCTGCCCTGTATCAGACAT 20

RESULT 90
ABK53119
ID      ABK53119 standard; DNA; 20 BP.
XX
AC      ABK53119;
XX
DT      12-AUG-2002 (first entry)
XX
DE      HIV-1 protease gene specific oligonucleotide primer #3.
XX
KW      HIV; human immunodeficiency virus; SE; primer; gag; pol;
XX      protease; reverse transcriptase; infection; PCR.
XX
OS      Human immunodeficiency virus type 1.
XX
FH      Key      Location/Qualifiers
FT      modified_base 1..2
FT      /*tag= a
FT      /mod_base= OTHER
FT      /note= "OTHER= 2'-O-methyladenosine"
FT      modified_base 3..4
FT      /*tag= b
FT      /mod_base= gm
FT      /note= "2'-O-methylguanosine"

US2002055095-A1.
09-MAY-2002.
31-AUG-2001; 2001US-0944036.
01-SEP-2000; 2000US-229790P.

PA      (YANG/) YANG Y Y.
PA      (BERN/) BRENTANO S T.
PA      (BABO/) BABOLA O.
PA      (TRAN/) TRAN N.
PA      (VERN/) VERNET G.
XX
PI      Yang YY, Brentano ST, Babola O, Tran N, Vernet G;
XX      WPI; 2002-462902/49.
XX
DR      New nucleic acid oligomers for amplifying a nucleotide sequence from
XX      HIV-1 and probes for detecting the amplified product are specific for
XX      gag and pol regions and are useful to detect different subtypes of
XX      HIV-1.
XX
PS      Claim 1; Page 17; 37pp; English.
XX
CC      This invention relates to a series of nucleic acid oligomers for
XX      amplifying and detecting a nucleotide sequence of human immunodeficiency
XX      virus type 1 (HIV-1). The invention also comprises a labeled
XX      oligonucleotide that specifically hybridises to an HIV-1 sequence
XX      derived from gag or pol sequences, having one of the sequences fully
XX      defined in the specification, and a method for detecting HIV-1 in a
XX      biological sample, comprising mixing the sample with two or more of the
XX      amplification oligomers that specifically amplify at least one HIV-1
XX      target sequence within gag and a pol sequence which is a protease or
XX      reverse transcriptase sequence, amplifying the target, and detecting the
XX      amplified product. The oligonucleotides of the invention may be used to
XX      diagnose HIV-1 infection. The presents sequence represents a PCR
XX      primer used to amplify the HIV-1 protease gene in the HIV detection
XX      method of the invention.
XX
SQ      Sequence 20 BP; 11 A; 3 C; 5 G; 1 T; 0 other;

Query Match          1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.3e+02;

```

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2422 AAGGAGGACACAGATGCA 2441
|||||
Db 1 AAGGAGGACACCAATGAA 20
|||||

RESULT 91
AAD34736
ID AAD34736 standard; DNA; 20 BP.
XX
AC AAD34736;
XX
DT 16-JUN-2002 (first entry)
XX
DE Human MEK3 CDNA targeted antisense oligonucleotide ISIS #122984.
XX
KW Human; MAP/ERK kinase kinase 3; MEK3; mitogen activated protein kinase;
KW MAP; ERK; extracellular signal regulated kinase; infection; cytostatic;
KW antisense therapy; tumour formation; phosphorothioate backbone;
KW inflammation; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "Methoxyethyl residues"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "Methoxyethyl residues"
FT modified_base 6
FT /tag= d
FT /mod_base= m5c
FT modified_base 9
FT /tag= e
FT /mod_base= m5c
FT modified_base 12
FT /tag= f
FT /mod_base= m5c
FT modified_base 13
FT /tag= g
FT /mod_base= m5c
FT modified_base 17
FT /tag= h
FT /mod_base= m5c
XX
PN WO200220550-A1.
XX
PD 14-MAR-2002.
XX
PF 07-SEP-2001; 2001WO-US28118.
XX
XX 08-SEP-2000; 2000US-0658688.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ward DT, Gaarde WA, Monia BP, Wyatt JR;
XX
DR WPI; 2002-329863/36.
XX
PT New antisense oligonucleotides targeted to nucleic acid encoding
PT MAP/ERK kinase kinase 3 (MEK3), useful for inhibiting the expression
PT of MEK3 and for treating a disease or condition associated with the
PT expression of MEK3
XX

PS Claim 3; Page 89; 116pp; English.
XX
CC The invention relates to antisense oligonucleotides targeted to nucleic
CC acids encoding mitogen activated protein kinase (MAP)/extracellular
CC signal regulated (ERK) kinase kinase 3 (MEK3) or a splice variant of
CC MEK3. MEK3 is an ubiquitously expressed serine-threonine kinase and
CC activates only the ERK and JNK/SAPK pathways. The antisense compound is
CC useful for inhibiting the expression of MEK3 and for treating a disease
CC or condition associated with the expression of MEK3. These may also be
CC used as research reagents and diagnostics, to distinguish between
CC functions of various members of a biological pathway, and in the
CC treatment of a disease or disorder, which can be treated by modulating
CC the expression of MEK3. The antisense compounds are further useful
CC prophylactically, e.g. to prevent or delay infection, inflammation or
CC tumour formation, and as probes or primers. The present sequence is
CC an antisense oligonucleotide targeted towards human MEK3 CDNA.
XX
SQ Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 other;
Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2258 ATGGGCGGCTTCAGTCAG 2277
|||||
Db 1 ATGGCAGCTTCAGACAG 20
|||||

RESULT 92
AAL45481
ID AAL45481 standard; DNA; 20 BP.
XX
AC AAL45481;
XX
DT 06-JUN-2002 (first entry)
XX
DE HIV-1 pol gene protease amplification oligomer SEQ ID NO: 19.
XX
KW HIV-1; gag gene; pol gene; PCR; primer; drug resistance; genetic subtype;
KW probe; ss.
XX
OS Human immunodeficiency virus type 1.
XX
FH Key Location/Qualifiers
FT modified_base 1..2
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methylthymidine"
FT modified_base 3..4
FT /tag= b
FT /mod_base= OTHER
FT /note= "designated gm in the specification"
XX
PN WO200220852-A1.
XX
PD 14-MAR-2002.
XX
PF 01-SEP-2000; 2000WO-US24117.
XX
XX 01-SEP-2000; 2000WO-US24117.
XX
PA (GENP-) GEN-PROBE INC.
PA (INMR) BIOMERIEUX SA.
XX
PI Yang YX, Brentano ST, Babola O, Tran N, Vernet G;
XX
DR WPI; 2002-292273/33.
XX
PT New nucleic acid oligomer, useful for detecting selected regions of gag
PT and pol genes of human immune deficiency virus, particularly for
PT assessing drug resistance
XX
PS Claim 1; Page 43; 82pp; English.

XX The present invention provides a number of nucleic acid oligomers which
CC can be used to amplify the gag and pol genes of human immunodeficiency
CC virus type 1 (HIV-1). These are used to detect regions of the gag and pol
CC genes, especially regions associated with drug resistance, and also for
CC identifying genetic subtypes of the virus. The present sequence is an
CC oligomer of the invention.

XX
SQ Sequence 20 BP; 11 A; 3 C; 5 G; 1 T; 0 other;

Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.3e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 2422 AAGGAGGACACAGATGGA 2441

Db 1 AAGGAGGACACCAATGAA 20

RESULT 93

ABX75021
ID ABX75021 standard; DNA; 20 BP.

XX
AC
XX ABX75021;

DT 25-MAR-2003 (first entry)

XX Human gene 216 polymorphism detection PCR primer #78.

XX Human; mouse; ss; primer; gene 216; antiasthmatic; antiinflammatory;

XX anorectic; chromosome 20p13-p12; single nucleotide polymorphism;

XX SNP; gene therapy; respiratory disease; asthma; obesity; PCR;

XX bronchial hyper-responsiveness; chronic obstructive pulmonary disease;

XX adult respiratory distress syndrome; inflammatory bowel syndrome.

XX Homo sapiens.

XX OS

XX WO200283077-A2.

XX PD 24-OCT-2002.

XX PF 15-APR-2002; 2002WO-US12063.

XX PR 13-APR-2001; 2001US-0834597.

XX PR 13-APR-2001; 2001WO-US12245.

XX PA (SCHE) SCHERING CORP.

XX PA (GENO-) GENOME THERAPEUTICS CORP.

XX PI Keith T, Little RD, Van Eerdewegh P, Dupuis J, Del Mastro RG;

XX PI Simon J, Allen K, Pandit S;

XX DR WPI; 2003-092960/08.

XX PT New isolated gene 216 nucleic acids, useful for diagnosing, preventing

XX PT or treating a disorder, such as asthma, bronchial hyper-responsiveness,

XX PT chronic obstructive pulmonary disease, obesity or inflammatory bowel

XX PT syndrome -

XX Example 10; Page 155; 650pp; English.

CG disorders mentioned. The nucleic acids can also be used as primers and
CC templates for the recombinant production of disorder-associated
CC peptides or polypeptides, for chromosome and gene mapping, or for
CC tissue distribution studies. The present sequence represents a gene
CC 216 specific PCR primer used in the scope of the invention.

XX
SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 other;

Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.3e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 2098 CAGCTGCCAGAGCATGGA 2117

Db 1 CAGCTGCCAGATGGA 20

RESULT 94

AAK66311
ID AAK66311 standard; RNA; 15 BP.

XX
AC
XX AAK66311;

DT 20-JUL-1999 (first entry)

XX Mouse B7-2 hammerhead ribozyme target SEQ ID NO:2943.

XX Arthritic condition; graft tolerance; immune response; target; cleavage;

XX hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;

XX stromelysin; synovial membrane; joint; arthritis; osteoarthritis;

XX rheumatoid arthritis; autoimmune disease; allergy; inflammation;

XX diagnosis; ss.

XX Mus sp.

XX OS

XX WO9618736-A2.

XX PD 20-JUN-1996.

XX PF 22-NOV-1995; 95WO-US15516.

XX PR 05-OCT-1995; 95US-0541365.

XX PR 13-DEC-1994; 94US-0354920.

XX PR 23-DEC-1994; 94US-0363253.

XX PR 23-DEC-1994; 94US-0363253.

XX PR 17-FEB-1995; 95US-0390850.

XX PR 20-APR-1995; 95US-0426124.

XX PR 02-MAY-1995; 95US-0432874.

XX PR 04-MAY-1995; 95US-0434509.

XX PR 07-JUL-1995; 95US-0000951.

XX PR 07-JUL-1995; 95US-0000974.

XX PR 07-AUG-1995; 95US-0512861.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Draper K, Gustafson J, McSwigen J, Pavco P, Stinchcomb DT;

XX PI Beigelman L, Karpelsky A, Modak A, Usman N, Burgin A;

XX PI Matulic-Adamic J, Jarvis T, Thompson JD, Wincott F;

XX DR WPI; 1996-300653/30.

XX PT Enzymatic nucleic acid molecules having a hammer-head motif - used

XX PT for the treatment of arthritis, induction of graft tolerance or

XX PT treatment of auto-immune diseases

XX Claim 10; Page 198; 307pp; English.

XX The present invention describes a novel enzymatic nucleic acid (ENA)

XX having a hammerhead motif (HM) comprising: (i) at least 5 ribose

XX residues; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii)

XX at least ten 2'-O-methyl modifications; and (iv) a 3'-end modification.

XX The ENA's can inhibit collagenase and stromelysin production in the

XX synovial membrane of joints for the treatment or prevention of arthritis,

XX Example 8; Page 84; 201pp; English.
PS
CC The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
SQ Sequence 15 BP; 0 A; 4 C; 6 G; 5 T; 0 other;
Query Match 1.1%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 97;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2330 TCTGTCCTTGGGG 2344
DB 1 TCTGTCCTTGGGG 15
RESULT 99
AAF52670
ID AAF52670 standard; DNA; 15 BP.
XX
AC AAF52670;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-1 oligonucleotide #3630.
XX
KM Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KM cycostatic; dermatological; cardiac; virucide; ophthalmological; keloid;
KM skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KM growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KM hyperneovascular condition; hyperplasia; kidney disease;
KM neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PE 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345.
XX
PA (MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
PS Example 8; Page 84; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects

CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
SQ Sequence 15 BP; 0 A; 4 C; 6 G; 5 T; 0 other;
Query Match 1.1%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 97;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2331 CTGTCCTTGGGGT 2345
DB 1 CTGTCCTTGGGGT 15
RESULT 100
AAD47315/C
ID AAD47315 standard; DNA; 20 BP.
XX
AC AAD47315;
XX
DT 24-FEB-2003 (first entry)
XX
DE Human RT-PCR reverse primer for synaptophysin DNA isolation.
XX
KM Human; insulin-secreting cell; neurogenin 3; ng3; precursor stem cell;
KM pancreatic exocrine cell; transplantation; RT-PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200274946-A2.
XX
PD 26-SEP-2002.
XX
PE 26-FEB-2002; 2002WO-DK00130.
XX
PR 26-FEB-2001; 2001US-271474P.
XX
PA (NOVO) NOVO NORDISK AS.
XX
PI Serup P, Heimberg H, Gradwohl G;
XX
DR WPI; 2003-018804/01.
XX
PT Generating insulin-secreting cells from precursor stem cells or adult
PT pancreatic exocrine cells, for generating glucose sensitive insulin
PT secreting beta cells for transplantation, comprises using neurogenin3
PT or NeuroD/beta2 -
XX
PS Example 5B; Page 36; 66pp; English.
XX
CC The invention relates to a method for generating insulin-secreting cells
CC from precursor stem cells or adult pancreatic exocrine cells. The method
CC comprises exposing the precursor cells or exocrine cells to a nucleic
CC acid molecule encoding neurogenin 3 (ngn3) or NeuroD/beta2; or an
CC activator of ngn3 or NeuroD/beta2 gene expression, under conditions
CC effective to generate the insulin-generating cells from the precursor or
CC exocrine cells. The invention is useful in generating insulin-secreting
CC cells from precursor stem cells or adult pancreatic exocrine cells, is
CC useful for generating glucose sensitive insulin secreting beta cells
CC suitable for transplantation, and for in situ development of insulin-
CC secreting cells in a patient. The method is also useful for preventing

CC premature differentiation of precursor stem cells into insulin-secreting
CC beta cells and for identifying compounds that prevent or activate beta
CC cell differentiation. The present sequence is human R1-PCR primer for
CC isolation of synaptophysin DNA.
XX
SQ Sequence 20 BP; 7 A; 6 C; 6 G; 1 T; 0 other;
Query Match 1.1%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1807 GTCACCGTGGCCGTG 1821
Db 16 GTCACCGTGGCCGTG 2
RESULT 101
AAV60744/C
ID AAV60744 standard; DNA; 18 BP.
XX
AC AAV60744;
XX
DT 08-DEC-1998 (first entry)
XX
DE Primer #2 for human CDK4 codons 1-163.
XX
PCB primer; amplification; yeast; UAS; upstream activating sequence;
KM transcription terminator; cell cycle; Upstream Activation Sequence; UAS;
KM promoter; phosphorylation; cyclin; cyclin-dependent kinase; CDK; vector;
KM cyclin kinase inhibitor; CKI; growth; wound healing; cancer therapy; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN MO9816660-A1.
XX
PD 23-APR-1998.
XX
PF 16-OCT-1997; 97WO-US18608.
XX
PR 27-NOV-1996; 96US-0031966.
PR 16-OCT-1996; 96US-0029127.
XX
PA (BITT-) BITTECH INC.
XX
PI Bitter GA;
XX
DR WPI; 1998-251302/22.
XX
PT Screening for agents that effect cell cycle regulatory proteins -
PT using a cell line that expresses a reporter gene in response to
PT regulation through phosphorylation by a cyclin/CDK system
XX
PS Example 4; Page 75; 93pp; English.
XX
CC Primers AAV60743-V60745 were used to PCR amplify codons 1-163 of the
CC human cyclin-dependent kinase 4 (hCDK4). The amplified product was used
CC to generate a fusion protein comprising part of the hCDK4 sequence
CC linked to codons 154-302 of the yeast PHO85 gene. The fusion protein is
CC used to screen for compounds that affect mammalian cell cycle regulatory
CC proteins. The method comprises administering a compound to a cell line,
CC which contains a reporter gene linked to an upstream Activation Sequence
CC (UAS) and a promoter, where the UAS binds a transcription control factor
CC (TCF) which is regulated through cyclin/cyclin-dependent kinase (CDK)
CC phosphorylation. Also included in the construct is an effector gene
CC providing a gene product to permit normal cyclin/CDK regulation of the
CC TCF. Expression of the reporter gene is then analysed in the cell line,
CC thereby determining whether the compound affects the normal regulation.
CC The method can be used to identify inhibitors and activators of
CC mammalian cell cycle regulatory proteins, especially cyclin kinase
CC activators (CKIs), and cyclin/CDK complexes. The identified agents
CC can be used for stimulating growth of cells (as in wound healing), or

CC regulating excessive cell growth and division (as in cancer therapy).
XX
SQ Sequence 18 BP; 4 A; 6 C; 5 G; 3 T; 0 other;
Query Match 1.1%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2203 GACTTTGACCTGGCCAGA 2220
Db 18 GACTTTGACCTGGCCAGA 1
RESULT 102
AAA48792/C
ID AAA48792 standard; DNA; 18 BP.
XX
AC AAA48792;
XX
DT 08-SEP-2000 (first entry)
XX
DE Human G-alpha-16 antisense oligonucleotide ISIS# 20849.
XX
KM Human; G-alpha-16; G protein; cytosolic; hyperproliferative disorder;
KM cancer; inflammation; infection; antisense inhibition; ss.
XX
OS Homo sapiens.
XX
PN WO200032817-A1.
XX
PD 08-JUN-2000.
XX
PF 25-AUG-1999; 99WO-US19613.
XX
PR 03-DEC-1998; 98US-0205143.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Cowsett LM;
XX
DR WPI; 2000-412354/35.
XX
PT A new antisense compound for inhibiting the expression of human
PT G-alpha-16 and treating, preventing or delaying infections,
PT inflammation or hyperproliferative disorders such as cancer -
XX
PS Example 15; Page 73; 100pp; English.
XX
CC The present sequence is an antisense oligonucleotide used to
CC modulate expression of G-alpha-16. G-alpha-16 is a human G protein which
CC interacts differentially with several receptor types including members
CC of the opioid and chemokine receptor families. A series of antisense
CC oligonucleotides have been designed to target different regions of the
CC human G-alpha-16 RNA. They may be used to inhibit the expression of
CC G-alpha-16 in human cells and tissues and thus to treat diseases
CC associated with G-alpha-16, such as hyperproliferative disorders,
CC especially cancer. Infections, inflammation or tumour formation can
CC be prevented or delayed. The compounds can be used in research and
CC diagnostics in sandwich and other assays.
CC Note: The sequence has a phosphorothioate backbone and may be
CC either an oligodeoxynucleotide or a chimeric oligonucleotide
CC containing 2'-methoxyethyl (2'-MOE) wings and a deoxy gap. The ISIS
CC number given above corresponds to the oligodeoxynucleotide sequence.
XX
SQ Sequence 18 BP; 2 A; 7 C; 4 G; 5 T; 0 other;
Query Match 1.1%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1354 CCAGCGCTGGAGAGAA 1371
Db 18 CCAGCGCTGGAGAGAA 1

```

RESULT 103
AAH75270/c
ID AAH75270 standard; DNA, 18 BP.
XX
AC AAH75270;
XX
DT 02-OCT-2001 (first entry)
XX
DE Human inducible NOS antisense oligonucleotide SEQ ID NO 114.
XX
KW Antisense oligonucleotide; inducible nitric oxide synthase; NOS;
KW modulate expression; immunomodulator; antidiabetic; cardiovascular;
KW cardiant; neuroprotective; vasotropic; ischaemia; reperfusion injury;
KW 2'-O-methoxyethyl; phosphorothioate; human; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..18
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone, 5' and 3' four
FT nucleotide 2'-MOE (2'-O-methoxyethyl) wings, all
FT cytidine residues are 5-methylcytidines and a
FT deoxy_gap"
XX
PN WO200152902-A1.
XX
PD 26-JUL-2001.
XX
PF 15-JAN-2001; 2001WO-US01381.
XX
PR 24-JAN-2000; 2000US-0490208.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Dean NM, Cowsett LM,
XX
DR WPI; 2001-465340/50.
XX
PT New antisense oligonucleotides for modulating the expression of
PT inducible nitric oxide synthase in cells or tissues, particularly
PT useful for treating e.g. immunological, cardiovascular or neurological
PT disorders, or ischaemia
XX
PS Example 15; Page 85; 144pp; English.
XX
CC The invention relates to antisense compounds, especially
CC oligonucleotides, which are targeted to a nucleic acid encoding inducible
CC nitric oxide synthase and which specifically hybridize to and modulate
CC expression of inducible nitric oxide synthase. The antisense compounds
CC have immunomodulator, antidiabetic, cardiovascular, cardiant,
CC neuroprotective, disorder and vasotropic activity. The antisense
CC oligonucleotides are useful for inhibiting the expression of inducible
CC nitric oxide synthase in cells or tissues. In particular, the antisense
CC oligonucleotides are useful for treating diseases or disorders associated
CC with inducible nitric oxide synthase, e.g. diabetes, immunological
CC disorder, cardiovascular disorder, neurological disorder or
CC ischaemia/reperfusion injury. The antisense oligonucleotides are also
CC useful for research and diagnostics. The present sequence is that of an
CC antisense 2'-O-methoxyethyl gapmer oligonucleotide with a
CC phosphorothioate backbone, a central "gap" region of ten nucleotides
CC flanked by four nucleotide 2'-MOE (2'-methoxyethyl) wings and
CC 5-methylcytidine residues throughout the oligonucleotide. The antisense
CC oligonucleotide is targeted to human inducible nitric oxide synthase (NOS)
CC mRNA (AAH7973).
XX
SQ Sequence 18 BP; 4 A; 7 C; 0 G; 7 T; 0 other;
XX
Query Match 1.1%; Score 14.8; DB 1; Length 18;
Beet Local Similarity 88.9%; Pred. No. 1.3e+02;

```

```

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1884 GATGAGATGATTGGGA 1901
Db 18 GATGAGAGGATTGGAA 1
XX
RESULT 104
AAH25370/c
ID AAH25370 standard; DNA, 18 BP.
XX
AC AAH25370;
XX
DT 22-AUG-2001 (first entry)
XX
DE Antisense oligonucleotide targeted to human Her-4 coding region.
XX
KW Antisense oligonucleotide; Her-4; receptor kinase; tyrosine kinase;
KW infection; inflammation; tumour; phosphorothioate; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..4
FT /*tag= a
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 1..18
FT /*tag= b
FT /note= "all cytidine residues are 5-methylcytidines"
FT modified_base 1..18
FT /*tag= c
FT /note= "all internucleoside linkages are
FT phosphorothioate linkages"
FT modified_base 5..14
FT /*tag= d
FT /note= "2'-deoxynucleotides"
FT modified_base 15..18
FT /*tag= e
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN US6255111-B1.
XX
PD 03-JUL-2001.
XX
PF 31-JUL-2000; 2000US-0632580.
XX
PR 31-JUL-2000; 2000US-0632580.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Cowsett LM,
XX
DR WPI; 2001-388929/41.
XX
PT Compound for inhibiting the expression of Her-4 (a receptor/tyrosine
PT kinase) e.g. in preventing tumour formation, comprises an antisense
PT oligonucleotide that hybridizes to a nucleic acid encoding Her-4 -
XX
PS Example 15; Column 45-46; 44pp; English.
XX
CC The specification describes antisense oligonucleotides which are
CC targeted to a nucleic acid encoding Her-4 (a receptor/tyrosine kinase).
CC The antisense oligonucleotides are used to inhibit the expression of
CC Her-4 in cells or tissues in vitro. They can be used in diagnostics,
CC therapeutics, prophylaxis and as a probe in research reagents. The
CC antisense oligonucleotides can be used to prevent or delay infection,
CC inflammation or tumour formation. AAH25315-AAH25398 represent antisense
CC oligonucleotides which are targeted to different regions of the human
CC Her-4 gene.
XX
SQ Sequence 18 BP; 4 A; 7 C; 0 G; 7 T; 0 other;
XX
Query Match 1.1%; Score 14.8; DB 1; Length 18;

```

Best Local Similarity 88.9%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1884 GATGAGATGATGGGAA 1901
Db 18 GATGAGAGGATTTGGAA 1

RESULT 105

AAA85911
ID AAA85911 standard; DNA; 19 BP.

XX
AC AAA85911;

XX
DT 04-DEC-2000 (first entry)

XX
DE Cdc 25 hs ribozyme binding site #19.

XX
KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic;

XX
KM restenosis; ss.

XX
OS Mammalia.

XX
PN WO200032765-A2.

XX
PD 08-JUN-2000.

XX
PF 06-DEC-1999; 99WO-US28772.

XX
PR 04-DEC-1998; 98US-0110954.

XX
PA (IMMU-) IMMUSOL INC.

XX
PI Tritz R, Welch PJ, Barber JR, Robbins JM;

XX
DR WPI; 2000-412314/35.

XX
PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1

XX
PS Disclosure; Page 99; 109pp; English.

XX
CC The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.

XX
CC Representative examples of ribozyme recognition sites are given in
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells.

XX
CC The ribozyme is resistant to endonuclease activity and hence is
CC efficient in restenosis treatment.

XX
CC

XX
SQ Sequence 19 BP; 3 A; 5 C; 2 G; 9 T; 0 other;

XX
Query March 1.1%; Score 14.8; DB 1; Length 19;

XX
Best Local Similarity 88.9%; Pred. No. 1.4e+02;

XX
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1320 GATATCCTTTCATCTGTC 1337
Db 2 GATTTCCCTTTCATCTGTC 19

RESULT 106
AAA85912
ID AAA85912 standard; DNA; 19 BP.

XX
AC AAA85912;

XX
DT 04-DEC-2000 (first entry)

XX
DE Cdc 25 hs ribozyme binding site #20.

XX

KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic;
KW restenosis; ss.

XX
OS Mammalia.

XX
PN WO200032765-A2.

XX
PD 08-JUN-2000.

XX
PF 06-DEC-1999; 99WO-US28772.

XX
PR 04-DEC-1998; 98US-0110954.

XX
PA (IMMU-) IMMUSOL INC.

XX
PI Tritz R, Welch PJ, Barber JR, Robbins JM;

XX
DR WPI; 2000-412314/35.

XX
PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1

XX
PS Disclosure; Page 99; 109pp; English.

XX
CC The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.

XX
CC Representative examples of ribozyme recognition sites are given in
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells.

XX
CC The ribozyme is resistant to endonuclease activity and hence is
CC efficient in restenosis treatment.

XX
CC

XX
SQ Sequence 19 BP; 2 A; 5 C; 2 G; 10 T; 0 other;

XX
Query March 1.1%; Score 14.8; DB 1; Length 19;

XX
Best Local Similarity 88.9%; Pred. No. 1.4e+02;

XX
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1320 GATATCCTTTCATCTGTC 1337
Db 1 GATTTCCCTTTCATCTGTC 18

RESULT 107

AAH61073
ID AAH61073 standard; DNA; 19 BP.

XX
AC AAH61073;

XX
DT 10-SEP-2001 (first entry)

XX
DE Cdc25 hs ribozyme binding site SEQ ID NO:3497.

XX
KW Human, ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnary;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;

XX
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antiproliferative; dermatological; antiseborrheic; antidiabetic; virucide;
KW antisticking; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seboreic wart; vitreoretinopathy; scar;

XX
KW sickle cell retinopathy; ss.

XX
KW

XX
OS Homo sapiens.

XX
OS Synthetic.

XX
PN WO200130362-A2.

XX
PD 03-MAY-2001.

XX

XX


```

PF 15-MAR-1993; 93WO-US02387.
XX
XX 18-MAR-1992; 92US-0853396.
PR 11-MAR-1993; 93US-0028673.
XX
XX (GEHO ) GEN HOSPITAL CORP.
PA
PI Donahoe PK, Gustafson M, He MW;
XX WPI; 1993-320743/40.
XX
XX New receptors of the transforming growth factor-beta receptor
PT family - comprising Mullerian Inhibitory Substance Receptors and
PT inhibin receptors
XX
XX Disclosure; Page 23; 59pp; English.
XX
XX The primers given in AA049761 and AA049762 were used in the isolation
CC of four novel membrane serine/threonine kinase receptor cDNAs.
CC Mislrl (AA049763) is believed to encode an isoform of the rat
CC Mlsr receptor. Mlsr2A/misr2B (AA049764), misr3 (AA049765) and misr4
CC (AA049766) are believed to encode monomeric isoforms of the rat
CC inhibin receptor and/or BMP receptor.
CC (Updated on 25-MAR-2003 to correct PF field.)
SQ
SQ Sequence 17 BP; 3 A; 2 C; 4 G; 5 T; 3 other;

Query Match 1.0%; Score 14.6; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 1.3e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 1813 GTGGCCGTGAAGATGTT 1829
DB 1 GTGGCCGTGAAGATGTT 17

RESULT 110
AA036072
ID AA036072 standard; cDNA, 17 BP.
XX
XX AA036072;
XX
XX 25-MAR-2003 (updated)
DT 30-OCT-1996 (first entry)
XX
XX Transforming growth factor beta receptor superfamily PCR primer.
DE
XX Mullerian inhibiting substance receptor; Mlsr; TGF-beta receptor;
KM transforming growth factor beta type I receptor; gene therapy;
KM wound healing; tumour treatment; rat inhibin;
KM polymerase chain reaction; ss.
XX
XX Synthetic.
OS
XX US5538892-A.
XX
XX 23-JUL-1996.
XX
XX 04-NOV-1993; 93US-0149105.
XX
XX 04-NOV-1993; 93US-0149105.
XX
XX 04-NOV-1993; 93US-0149105.
XX
XX 18-MAR-1992; 92US-0853396.
PR 11-MAR-1993; 93US-0028673.
XX
XX (GEHO ) GEN HOSPITAL CORP.
PA (UYDU-) UNIV DUKE.
XX
XX Donahoe PK, Gustafson M, He W, Wang X;
XX WPI; 1996-353830/35.
XX
XX New isolated TGF-beta type I receptor DNA - used to develop prods
PT for diagnosis and therapy, e.g. for treating tumours or promoting

```

```

PT wound healing
XX
XX Disclosure; Column 14; 44pp; English.
XX
XX Degenerate PCR primers were designed based on two highly conserved
CC regions within the cDNA encoding a murine activin receptor, human
CC and porcine TGF-beta type II receptor and the daf-1 receptor of
CC C.elegans. The primers (see AAT36072 and AAT36073) were used for
CC amplifying clones present in a 14.5 day foetal rat urogenital ridge
CC cDNA COS cell expression library. Four clones encoding portions of
CC four novel polypeptides (all putative serine/threonine kinases)
CC were obtained and designated pGEM7-Mislrl, 2, 3 and 4. The inserts
CC from these clones were used as probes to isolate full-length cDNA
CC sequences for each of the four TGF-beta type I receptors. Mislrl is
CC believed to encode an isoform of the rat Mullerian Inhibiting
CC Substance (MIS) receptor, while misr2A/misr2B, misr3 and misr4 are
CC believed to encode monomeric isoforms of the rat inhibin receptor
CC and/or BMP receptor.
CC (Updated on 25-MAR-2003 to correct PF field.)
SQ
SQ Sequence 17 BP; 3 A; 2 C; 4 G; 5 T; 3 other;

Query Match 1.0%; Score 14.6; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 1.3e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 1813 GTGGCCGTGAAGATGTT 1829
DB 1 GTGGCCGTGAAGATGTT 17

RESULT 111
AAH40382/C
ID AAH40382 standard; DNA; 18 BP.
XX
XX AAH40382;
XX
XX 14-AUG-2001 (first entry)
DT
XX
XX SNP specific lower PCR primer SEQ ID 3178.
DE
XX
XX Single nucleotide polymorphism; SNP; single nucleotide primer extension;
KM SNPE; genotyping; agammaglobulinemia; diabetes insipidus; cancer;
KM Leech-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;
KM polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;
KM acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;
KM inflammation; forensic investigation; paternity analysis; PCR primer; ss.
XX
XX Homo sapiens.
OS
XX WO200129262-A2.
XX
XX 26-APR-2001.
XX
XX 13-OCT-2000; 2000WO-US28436.
XX
XX 15-OCT-1999; 99US-0160096.
XX
XX (ORCH-) ORCHID BIOSCIENCES INC.
XX
XX Picoult-Newburg L, Pohl M;
XX
XX WPI; 2001-290930/30.
XX
XX New genotyping oligonucleotide, useful for detecting the presence,
PT absence or identity of single polynucleotide polymorphism in a nucleic
PT acid sample
XX
XX Claim 1; Page 66; 83pp; English.
XX
XX Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide
CC primer extension (SNPE) primers, and the sequences of regions flanking
CC sites of single nucleotide polymorphisms SNPs. The present invention

```



```

Db      16 CAGAACCCAGCGGCT 1
      ||| ||||| |||||
RESULT 114
AAA29601/c
ID      AAA29601 standard; DNA; 16 BP.
XX
AC      AAA29601;
XX
DT      10-AUG-2000 (first entry)
XX
DE      Human fibroblast growth factor antisense PCR primer.
XX
KW      Hormone dependent cancer; hormone independent cancer; hormonal drug;
KW      prostate cancer; breast cancer; cervical cancer; ovarian cancer;
KW      PCR primer; ss.
XX
OS      Homo sapiens.
XX
PN      WO200020034-A1.
XX
PD      13-APR-2000.
XX
PF      07-OCT-1999; 99WO-JP05533.
XX
PR      08-OCT-1998; 98JP-0286793.
XX
PA      (TAKE ) TAKEDA CHEM IND LTD.
XX
PI      Matsutani E, Naito K;
XX
DR      WPI; 2000-303644/26.
XX
PT      Hormonal drug-containing agents for retarding conversion of
PT      hormone-dependent cancers into hormone-independent cancers, useful e.g.
PT      for treating prostate and breast cancers -
XX
PS      Example 1; Page 19; 31pp; Japanese.
XX
CC      The present invention describes a hormonal drug-containing agent (I) for
CC      retarding the conversion of a hormone-dependent cancer into a hormone-
CC      independent cancer. The agents can be used to treat prostate, breast,
CC      cervical and ovarian cancers and to make hormonal drugs for retarding
CC      the conversion of a hormone-dependent cancer into a hormone-independent
CC      cancer. The drug can retard the change of hormone-dependent cancers
CC      into hormone-independent cancers effectively. The present sequence
CC      represents a PCR primer which is used in an example from the present
CC      invention.
XX
SQ      Sequence 16 BP; 4 A; 5 C; 1 G; 2 T; 4 other;
XX
Query Match      1.0%; Score 14.4; DB 1; Length 16;
Best Local Similarity 75.0%; Pred. No. 1.3e+02;
Matches 12; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY      2323 AGTGATGCTGCTCT 2338
      |||:|||||:|
Db      16 AGYGAGTGTGCTCT 1
XX
RESULT 115
AAH61977
ID      AAH61977 standard; DNA; 16 BP.
XX
AC      AAH61977;
XX
DT      10-SEP-2001 (first entry)
XX
DE      IL-1 beta hairpin/hammerhead ribozyme recognition site SEQ ID NO:4401.
XX
KW      Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW      recognition site; target; ribozyme binding site; eye disease; vulnery;

```

```

KW      Proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW      cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW      matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW      antiproliferative; dermatological; antiseborrheic; antidiabetic; vituicide;
KW      antischlicking; ophthalmological; keratolytic; gene therapy; viral wart;
KW      atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW      basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW      sickle cell retinopathy; ss.
XX
OS      Homo sapiens.
XX
PN      Synthetic.
XX
PD      WO200130362-A2.
XX
PF      03-MAY-2001.
XX
PR      26-OCT-2000; 2000WO-US29500.
XX
PA      (IMMU-) IMMUSOL INC.
XX
PI      Robbins JM, Triltz R;
XX
DR      WPI; 2001-300427/31.
XX
PT      Treating proliferative skin or eye diseases and scarring, using
PT      ribozymes that cleave RNA encoding cytokines involved in inflammation,
PT      matrix metalloproteinases, growth factors and cell-cycle dependent
PT      kinases -
XX
PS      Example 1; Page 20; 408pp; English.
XX
CC      The present invention describes a method for treating a proliferative
CC      skin or eye disease and scarring. The method involves administering a
CC      ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC      inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC      dependent kinase, growth factor or a reductase, or administering a
CC      nucleic acid molecule (II) comprising a promoter operably linked to a
CC      nucleic acid segment encoding (I). (I) can have antiproliferative,
CC      dermatological, cytostatic, antiseborrheic, antidiabetic, antischlicking,
CC      ophthalmological, vulnery, keratolytic and vituicide activities, and
CC      cleaves RNA encoding cytokine involved in inflammation. (II) can be used
CC      in gene therapy. (I) and (II) are useful for treating proliferative
CC      skin diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC      squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC      also be used for treating proliferative eye diseases such as diabetic
CC      retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC      prematurity and retinal detachment, and for treating and preventing
CC      scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC      scar. AAH57577 to AAH62099 represent sequences used in the
CC      exemplification of the present invention.
XX
SQ      Sequence 16 BP; 2 A; 3 C; 5 G; 6 T; 0 other;
XX
Query Match      1.0%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY      2324 GTGATGCTGCTCT 2339
      |||:|||||:|
Db      1 GTGATGCTGCTCAT 16
XX
RESULT 116
AAK72965
ID      AAK72965 standard; RNA; 17 BP.
XX
AC      AAK72965;
XX
DT      28-JUL-1999 (first entry)
XX
DE      Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #398.

```

XX Vascular endothelial growth factor receptor; VEGF receptor; flk-1;
 KW flk-1; KDR; hammetthead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX
 OS Mus sp.
 XX
 PN MO9715662-A2.
 XX
 PD 01-MAY-1997.
 XX
 PF 25-OCT-1996; 96WO-US17480.
 XX
 PR 11-JAN-1996; 96US-0584040.
 PR 26-OCT-1995; 95US-0005974.
 XX
 PA (CHIR) CHIRON CORP.
 PA (RIBO-) RIBOZYME PHARM INC.
 PI Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;
 DR WPI; 1997-259017/23.
 XX
 PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or
 PT mRNA stability - useful for treating e.g. tumour angiogenesis,
 PT psoriasis, rheumatoid arthritis, etc., in a human patient
 XX
 PS Claim 4; Page 135; 218pp; English.
 XX
 CC The present invention describes nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
 CC be treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AA67275 to AA75752 represent specific examples
 CC of nucleic acid molecules from the present invention.
 XX
 SQ Sequence 17 BP; 8 A; 1 C; 5 G; 3 U; 0 other;
 Query Match 1.0%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 1.4e+02;
 Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
 Oy 1822 AAGATGTTGAAGATG 1837
 Db 2 AAGAGUGUGAAGGAG 17
 XX
 RESULT 117
 AAA18888
 ID AAA18888 standard; RNA; 17 BP.
 XX
 AC AAA18888;
 XX
 DT 19-JUN-2000 (first entry)
 XX
 DE Human TIE-2 substrate sequence SEQ ID NO:2114.
 KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammetthead ribozyme; angiogenic factor; cytoskeletal; antidiabetic;
 KW opthalmitis; antiinflammatory; antirheumatic; antipsoriatic; ARMD;
 KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; inflammation; neovascular glaucoma;
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 KW tuberculous scleritis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenauay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 KW
 XX

OS Homo sapiens.
 XX
 XX MO9950403-A2.
 XX
 PD 07-OCT-1999.
 XX
 PF 24-MAR-1999; 99WO-US06507.
 XX
 PR 27-MAR-1998; 98US-0079678.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PI Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
 DR WPI; 1999-591315/50.
 XX
 PT Novel ribozymes for modulating the synthesis, expression and/or
 PT stability of an mRNA encoding an angiogenic factors -
 XX
 PS Claim 56; Page 123; 305pp; English.
 XX
 CC The present invention describes enzymatic nucleic acid molecules with
 CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AA16775 to
 CC AA17167 and AA17561 to AA17622 represent ribozyme sequences for ARNT,
 CC and AA17168 to AA17560 and AA17623 to AA17684 represent their
 CC corresponding target sequences; AA17685 to AA18385 and AA19087 to
 CC AA19154 represent ribozyme sequences for Tie-2, and AA18386 to AA19086
 CC and AA19155 to AA19222 represent their corresponding target sequences;
 CC AA19223 to AA20361 and AA21501 to AA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AA20362 to AA21500 and
 CC AA21596 to AA21688 represent their corresponding target sequences;
 CC AA21689 to AA22475 and AA23263 to AA23342 represent ribozyme sequence
 CC for integrin subunit beta 3, and AA22476 to AA23262, AA23343 to
 CC AA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiofibroma of tuberculous scleritis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenauay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3.
 XX
 SQ Sequence 17 BP; 4 A; 2 C; 5 G; 6 U; 0 other;
 Query Match 1.0%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 56.2%; Pred. No. 1.4e+02;
 Matches 9; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
 Oy 2323 AGTGATGCTGCTCT 2338
 Db 1 AGUGAUGUAGGUCU 16
 XX
 RESULT 118
 AEN08382/C
 ID AEN08382 standard; DNA; 17 BP.
 XX
 AC AEN08382;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMTP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8374.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMTP-1; hGDMTP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 KW
 OS Homo sapiens.

XX WO200192524-A2.
 XX 06-DEC-2001.
 XX 25-MAY-2001; 2001WO-US16981.
 XX 26-MAY-2000; 2000US-207456P.
 PR 21-SEP-2000; 2000US-234687P.
 PR 27-SEP-2000; 2000US-236359P.
 PR 04-OCT-2000; 2000GB-0024263.
 PR 30-JAN-2001; 2001WO-US00661.
 PR 30-JAN-2001; 2001WO-US00662.
 PR 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00666.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 05-FEB-2001; 2001US-266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMLP-1 -
 XX Disclosure; SEQ ID 8374; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
 CC hGDMLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.
 XX Sequence 17 BP; 4 A; 5 C; 6 G; 2 T; 0 other;
 XX Query Match 1.0%; Score 14.4; DB 1; Length 17;
 XX Best Local Similarity 93.8%; Pred. No. 1.4e+02;
 XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1506 CCAGCCGGCTGTGCAC 1521
 Db 17 CCAGCTGCTGTGCAC 2

ID ABN08383 standard; DNA; 17 BP.
 XX ABN08383;
 AC 29-MAY-2002 (first entry)
 DT Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8375.
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8375.
 XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KM skeletal; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KM skeletal muscle disorder; amplicon; screening; ss.
 OS Homo sapiens.
 XX WO200192524-A2.
 XX 06-DEC-2001.
 XX 25-MAY-2001; 2001WO-US16981.
 XX 26-MAY-2000; 2000US-207456P.
 PR 21-SEP-2000; 2000US-234687P.
 PR 27-SEP-2000; 2000US-236359P.
 PR 04-OCT-2000; 2000GB-0024263.
 PR 30-JAN-2001; 2001WO-US00661.
 PR 30-JAN-2001; 2001WO-US00662.
 PR 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00666.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 30-JAN-2001; 2001WO-US00670.
 PR 05-FEB-2001; 2001US-266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMLP-1 -
 XX Disclosure; SEQ ID 8375; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
 CC hGDMLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.

SQL Sequence 17 BP; 4 A; 5 C; 6 G; 2 T; 0 other;

Query Match 1.0%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1506 CCAGCCGCGCTGTGCAC 1521
|||
16 CCAGCTGCTGTGCAC 1

RESULT 120
ABN09009
ID ABN09009 standard; DNA; 17 BP.

AC ABN09009;
XX
DT 29-MAY-2002 (first entry)
XX

DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9001.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.

OS Homo sapiens.
XX
XX MO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
XX 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 05-FEB-2001; 2001US-266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
XX
PS Disclosure; SEQ ID 9001; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
XX hGDMLP-1 can be used in gene therapy and vaccine production. The
XX hGDMLP-1 nucleic acids can be used as probes to detect, characterise
XX and quantify hGDMLP-1 nucleic acids in samples, as amplification
XX substrates, to provide initial substrates for the recombinant engineering
XX of hGDMLP-1 protein variants having desired phenotypic improvements, and
XX for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
XX be used as immunogens to raise antibodies that specifically recognise
XX hGDMLP-1 proteins, as standards in assays used to determine the
XX concentration and/or amount specifically of hGDMLP proteins, as specific

CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX

SQL Sequence 17 BP; 2 A; 6 C; 8 G; 1 T; 0 other;

Query Match 1.0%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1505 GCCAGCCGCGCTGTGCA 1520
|||
2 GCCAGCCGCGCTGCA 17

RESULT 121
ABN09010
ID ABN09010 standard; DNA; 17 BP.

AC ABN09010;
XX
DT 29-MAY-2002 (first entry)
XX
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9002.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.

OS Homo sapiens.
XX
XX MO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
XX 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 05-FEB-2001; 2001US-266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX

PS Disclosure; SEQ ID 9002; 214bp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMRP-1). The protein and polynucleotide sequences of
CC hGDMRP-1 can be used in gene therapy and vaccine production. The
CC hGDMRP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMRP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMRP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMRP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMRP-1 protein, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMRP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMRP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMRP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMRP-1, in
CC particular heart and skeletal muscle disorders. hGDMRP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMRP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 2 A; 6 C; 7 G; 2 T; 0 other;
Query Match 1.0%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1505 GCCAGCCGCGCTGTGCA 1520
Db 1 GCCAGCCGCGCGTGTGCA 16
|||||
RESULT 122
AB261957/c
ID AB261957 standard; RNA; 17 BP.
XX
AC AB261957;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human H-Ras DNAzyme target #748.
XX
KM Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KM enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;
KM anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US16840.
XX
PR 29-MAY-2001; 2001US-294140P.
PR 06-JUN-2001; 2001US-296249P.
PR 10-SEP-2001; 2001US-318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcawigsen J;
XX
DR WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX

PS Claim 58; Page 125; 1855pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytosstatic, anti-HIV, and
CC anti-rheumatic activity. The nucleic acid molecules are useful for
CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
CC acids are also useful for treating breast, ovarian, colorectal, lung,
CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
CC The sequences shown in AB259889 - AB262216, AB264544 - AB265531,
CC AB265520 - AB265524, AB265530 - AB265585 represent substrate/target
CC sequences for the human ribozymes of the invention.
XX
SQ Sequence 17 BP; 2 A; 6 C; 5 G; 4 U; 0 other;
Query Match 1.0%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1722 GGGCAAGCCCTGTGCA 1737
Db 16 GGGCAAGCCCTGTGCA 1
|||||
RESULT 123
AA241119
ID AA241119 standard; DNA; 18 BP.
XX
AC AA241119;
XX
DT 26-JAN-2000 (first entry)
XX
DE Human G-alpha-11 phosphorochloate antisense oligonucleotide #23.
XX
KM Identification; genetic target; gene modulation; human; probe;
KM antisense oligonucleotide; phosphorochloate; PCR primer;
KM nucleotide sequence-based technology; antisense drug discovery;
KM target validation; ss.
XX
OS Synthetic.
XX
PN Homo sapiens.
XX
PD WO9953101-A1.
XX
PF 21-OCT-1999.
XX
PR 13-APR-1999; 99WO-US08268.
XX
PR 13-APR-1998; 98US-0081483.
PR 28-APR-1998; 98US-0067638.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Cowseert LM, Baker BF, McNeil J, Freiler SM, Sasemor HM, Brooks DG;
PI Ohasi C, Wyatt JR, Borchers AH, Vickers TA;
XX
DR WPI; 1999-620446/53.
XX
PT Identifying compounds which modulate expression of nucleic acids, used
PT to provide compounds having defined physical, chemical or bioactive
PT properties, e.g. antisense activity -
XX
PS Example 27; Page 108; 264pp; English.
XX
CC A method has been developed of defining a set of compounds that modulate
CC the expression of a target nucleic acid (tNA) sequence via binding of
CC the compounds with the tNA sequence. The method comprises generating a
CC library of virtual compounds in silico according to defined criteria,
CC and evaluating in silico the binding of the virtual compounds with the
CC tNA according to defined criteria. Also described are: (1) a method of
CC defining a set of oligonucleotides (ONs) that modulate the expression of

CC a tNA sequence via binding of the ONs with the tNA sequence comprising
 CC generating a library of virtual compounds in silico according to defined
 CC criteria, and evaluating in silico the binding of the virtual ONs with
 CC the tNA according to defined criteria; and (2) a method of defining a
 CC set of compounds that modulate the expression of a tNA sequence via
 CC binding of the compounds with the tNA. The methods can be used for the
 CC generation and identification of synthetic compounds having defined
 CC physical, chemical or bioactive properties. Information gathered from
 CC assays of such compounds is used to identify nucleic acid sequences that
 CC are tractable to a variety of nucleotide sequence-based technologies,
 CC e.g., antisense drug discovery and target validation. AA40852 to
 CC AA4120, and AA452701 to AA452706, represent sequences used in the
 CC exemplification of the present invention.

XX Sequence 18 BP; 3 A; 2 C; 7 G; 6 T; 0 other;
 SQ

Query Match 1.0%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1814 TGGCGGTGAAGATGTT 1829
 |||||
 1 TGGCGGTGAAGATGTT 16

Db

RESULT 124
 AA219490
 ID AA219490 standard; DNA; 18 BP.
 XX
 AC AA219490;
 XX
 DT 15-NOV-1999 (first entry)
 XX
 DE Human G-alpha-11 phosphorothioate antisense oligonucleotide SEQ ID NO:30.
 XX
 DE Human: G-alpha-11; antisense oligonucleotide; inhibition; expression;
 KW phosphorothioate; ss.
 XX
 KW Synthetic.
 OS Homo sapiens.
 OS
 PN US5951455-A.
 XX
 PD 14-SEP-1999.
 XX
 PF 04-DEC-1998; 98US-0205922.
 XX
 PR 04-DEC-1998; 98US-0205922.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Cowsext LM;
 XX
 DR WPI; 1999-539140/45.
 XX
 PT Inhibitory antisense compounds useful for the treatment of diseases
 PT associated with G-alpha-11
 XX
 PS Example 15; Column 40; 38pp; English.
 XX
 CC The present invention describes inhibitory antisense compounds of 8-30
 CC nucleotides, targeted to a nucleic acid molecule encoding human
 CC G-alpha-11. AA219468 to AA219547 represent human G-alpha-11
 CC phosphorothioate antisense oligonucleotides given in the present
 CC invention. The oligonucleotides may be useful for the treatment of
 CC diseases associated with G-alpha-11.
 CC
 XX Sequence 18 BP; 3 A; 2 C; 7 G; 6 T; 0 other;
 SQ

Query Match 1.0%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1814 TGGCGGTGAAGATGTT 1829
 |||||
 1 TGGCGGTGAAGATGTT 16

Db

RESULT 125
 ABK49070
 ID ABK49070 standard; DNA; 18 BP.
 XX
 AC ABK49070;
 XX
 DT 02-JUN-2002 (first entry)
 XX
 DE Wild-type pATP003.xb restriction site #2, used in cassette mutagenesis.
 XX
 KW 2,5-diketo-D-gluconic acid reductase A enzyme; cofactor specificity site;
 KW cofactor dependency; metabolically engineered organism; enzyme;
 KW 2-keto-L-gluconic acid; glucose; single fermentation step;
 KW cassette mutagenesis; restriction site; pATP003.xb; ds.
 XX
 OS Synthetic.
 OS
 FH Key Location/Qualifiers
 FT 1..18
 FT CDS /tag= a
 FT /partial
 FT /product= "Wild-type pATP003.xb restriction site
 FT peptide #2"
 FT /note= "This sequence lacks both a start and stop codon"

XX
 PN WO200222537-A2.
 XX
 PD 21-MAR-2002.
 XX
 PF 11-SEP-2001; 2001WO-US28366.
 XX
 PR 11-SEP-2000; 2000US-0658645.
 XX
 PA (RUTP) UNIV RUTGERS STATE NEW JERSEY.
 XX
 PI Anderson S, Banta S;
 XX
 PN WPI; 2002-351864/38.
 XX
 DR P-PSDB; AAU79911.
 XX
 PT Making mutant 2,5-diketo-D-gluconic acid reductase enzymes with altered
 PT cofactor dependency, for producing 2-keto-L-gluconic acid from glucose
 PT in one fermentation step, comprises mutating a cofactor specificity
 PT site amino acid -
 XX
 XX Example 1; Page 34; 45pp; English.
 PS
 CC The present invention relates to a new method of producing mutant
 CC 2,5-diketo-D-gluconic acid reductase enzymes with altered cofactor
 CC dependency. The method of the invention involves identifying a cofactor
 CC specificity site in a wild type 2,5-diketo-D-gluconic acid reductase
 CC enzyme and mutating an amino acid in the identified cofactor specificity
 CC site so that cofactor dependency of reactions catalysed by the enzyme is
 CC altered. The method is useful for producing mutant 2,5-diketo-D-gluconic
 CC acid reductase enzymes with altered cofactor dependency and as such is
 CC useful in metabolically engineered organisms to produce 2-keto-L-gluconic
 CC acid from glucose in a single fermentation step. The mutant 2,5-diketo-D-
 CC gluconic acid reductase enzyme produces 2-keto-L-gluconic acid from
 CC glucose in a single fermentation step in metabolically engineered
 CC organisms. Flexibility in catalysing the enzymatic reaction by the enzyme
 CC with NADH or nonspecifically with NADH (reduced nicotinamide adenine
 CC dinucleotide) or NADPH provides advantages. Since the cost of NADPH is an
 CC order of magnitude greater than that of NADH, use of the enzyme of the
 CC invention in any in vitro system where cofactor must be purchased and
 CC provided for the enzymes provides a significant cost saving advantage.
 CC The mutant 2,5-diketo-D-gluconic acid reductase enzyme exhibits increased
 CC levels of apparent expression which leads to an increased rate of
 CC production of 2-keto-L-gluconic acid. The present nucleic acid sequence

CC represent the wild-type PATP003.xb restriction site #2 that encodes the
CC wild-type PATP003.xb restriction site peptide #2. This sequence was used
CC in the methods of the invention for cassette mutagenesis.

SO Sequence 18 BP; 6 A; 5 C; 6 G; 1 T; 0 other;

Query Match 1.0%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1356 AGCGCTCGAAGAGAA 1371
DB 2 AGCGCTCGAAGAGAA 17

RESULT 126
AAT76258/C
ID AAT76258 standard; DNA; 15 BP.

XX AAT76258;

XX 15-SEP-1997 (first entry)

XX Human IL6 receptor antisense oligonucleotide.

XX Asthma; airway epithelium; adenosine free; cystic fibrosis;

XX chronic obstructive pulmonary disease; bronchitis; interleukin; ss.

XX Synthetic.

XX MO9640162-A1.

XX 19-DEC-1996.

XX 06-JUN-1996; 96WO-US093306.

XX 07-JUN-1995; 95US-0474497.

XX (UYEC-) UNIV EAST CAROLINA.

XX Metzger WJ, Nyce JW;

XX WPI; 1997-051871/05.

XX Treatment of airway diseases such as asthma - by topically applying
XX adenosine-free antisense oligo:nucleotide to airway epithelium of
XX subject

XX Example 5; Page 32; 71pp; English.

XX A method for treating airway disease in a subject has been produced,
XX which involves the topical administration of an essentially adenosine
XX free antisense oligonucleotide (ON) to the airway epithelium of the
XX subject. The present sequence is an antisense oligonucleotide
XX specific for the human IL6 receptor. The method can be used to
XX treat airway diseases such as cystic fibrosis, asthma, chronic
XX obstructive pulmonary disease, bronchitis and other airway diseases
XX characterised by an inflammatory response. By eliminating adenosine from
XX the antisense ON, its liberation upon antisense degradation is
XX prevented, thereby preventing adenosine-induced bronchoconstriction in
XX patients with hyper-reactive airways.

SO Sequence 15 BP; 0 A; 7 C; 5 G; 3 T; 0 other;

Query Match 1.0%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2003 GAGCCCGAGGCCA 2016
DB 14 GAGCCCGAGGCCA 1

RESULT 127
AA554048/C
ID AA554048 standard; DNA; 15 BP.

XX AA554048;

XX 05-JUL-1999 (first entry)

XX Human IL-6 receptor antisense oligonucleotide fragment.

XX Antisense oligonucleotide; multiple target; antisense treatment;

XX impaired respiration; inflammation; lung disease;

XX pulmonary vasoconstriction; inflammation; allergic rhinitis;

XX acute asthma; allergy; asthma; impeded respiration;

XX respiratory distress syndrome; pain; cystic fibrosis;

XX chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;

XX colon cancer; breast cancer; lung cancer; pancreatic cancer;

XX hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;

XX prostate cancer; ss.

XX Synthetic.

XX MO9913886-A1.

XX 25-MAR-1999.

XX 17-SEP-1998; 98WO-US19419.

XX 09-JUN-1998; 98US-0093972.

XX 17-SEP-1997; 97US-0059160.

XX (UYEC-) UNIV EAST CAROLINA.

XX Nyce JW;

XX WPI; 1999-229400/19.

XX New antisense oligonucleotides used in treatment of, e.g. pulmonary
XX vasoconstriction

XX Disclosure; Page 50; 120pp; English.

XX The specification describes antisense oligonucleotides (AA52869-X55271)
XX directed against at least 2 mRNAs selected from target genes, coding and
XX non-coding regions of RNAs corresponding to target genes, gene
XX initiation codons, genomic flanking regions, intron-exon borders, the
XX 5'-end, the 3'-end and the junction-section between coding and non-coding
XX regions and all segments of RNAs encoding proteins associated with one
XX or more diseases, conditions or mixtures. The antisense oligonucleotides
XX may be derived from sequences AA55272-74. These multiple target
XX oligonucleotides (specifically AA55180-271) can be used for the
XX antisense treatment of diseases and conditions. Typical diseases and
XX conditions are those associated with impaired respiration and
XX inflammation, including lung diseases, pulmonary vasoconstriction,
XX inflammation, allergic rhinitis, acute asthma, allergies, asthma, impeded
XX respiration, respiratory distress syndrome, pain, cystic fibrosis,
XX pulmonary hypertension, pulmonary vasoconstriction, emphysema, chronic
XX obstructive pulmonary disease (COPD), and cancers such as leukemias,
XX lymphomas, carcinomas e.g. colon cancer, breast cancer, lung cancer,
XX pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma,
XX hepatic metastases, as well as all types of cancers which may metastasize
XX or have metastasized to the lungs, including breast and prostate cancer.

SO Sequence 15 BP; 0 A; 7 C; 5 G; 3 T; 0 other;

Query Match 1.0%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2003 GAGCCCGAGGCCA 2016
DB 14 GAGCCCGAGGCCA 1

RESULT 128
AAFI9614/C
ID AAFI9614 standard; DNA; 15 BP.
XX
AC AAFI9614;
XX
DT 14-MAR-2001 (first entry)
XX
DE Human IL6 receptor polynucleotide fragment #1181.
XX
KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KW human; airway disorder; bronchoconstriction; lung inflammation;
KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KW immunosuppressive; antialasthmatic; analgesic; hypotensive; cytostatic;
KW respiratory obstruction; pulmonary obstruction; impeded respiration;
KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KW cancer; ss.
XX
OS Homo sapiens.
XX
PN WO200062736-A2.
XX
PD 26-OCT-2000.
XX
PF 24-MAR-2000; 2000WO-US08020.
XX
PR 06-APR-1999; 99US-0127958.
XX
PA (UYEC-) UNIV EAST CAROLINA.
PA (NYCE/) NYCE J W.
PI Nyce JW;
XX
DR WPI; 2000-679539/66.
XX
PT Low adenosine (A) content antisense oligonucleotides which do not
PT trigger adenosine receptors during metabolism, useful e.g. for treating
PT cancers and respiratory obstructions -
XX
PS Claim 14; Page 209; 1592pp; English.
XX
CC The present invention describes low adenosine (A) content antisense
CC oligonucleotides and compositions (I) comprising them. In the antisense
CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC immunosuppressive, antialasthmatic, hypotensive and cytostatic activities.
CC The antisense oligonucleotides and (I) can be used to down-regulate the
CC expression and or activity of target polypeptides associated with
CC lung/respiratory disorders and malignancies, such as stimulating and
CC activating peptide factors and transmitters, transcription factors,
CC immunoglobulins and antibodies, antibody receptors, cytokines and
CC chemokines, endogenously produced specific and non-specific enzymes,
CC binding proteins, adhesion molecules and their receptors, cytokine and
CC chemokine receptors, adenosine receptors, bradykinin receptors, central
CC nervous system (CNS) and peripheral nervous and non-nervous system
CC receptors, CNS and peripheral nervous and non-nervous system peptide
CC transmitters, defensins, growth factors, vasoactive peptides and
CC receptors, binding proteins and malignancy associated proteins. The
CC antisense oligonucleotides may be used in this way to treat disorders
CC including respiratory obstruction (especially pulmonary obstruction
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
CC and/or surfactant hypoproduction which are associated with a disease or
CC condition selected from pulmonary vasoconstriction, inflammation,
CC allergies, asthma, impeded respiration, respiratory distress syndrome
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC hyperension, emphysema, chronic obstructive pulmonary disease (COPD),
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC and/or cancer. AAFI8434 to AAFI21543 represent human polynucleotide

CC fragments and antisense oligonucleotides used in the exemplification of
CC the present invention.
CC
SQ Sequence 15 BP; 0 A; 7 C; 5 G; 3 T; 0 other;
XX
Query Match 1.0%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
DY 2003 GAGCCCGAGGCCA 2016
DB 14 GAGCCCGAGGCCA 1
XX
RESULT 129
AAA33492/C
ID AAA33492 standard; DNA; 15 BP.
XX
AC AAA33492;
XX
DT 28-JUL-2000 (first entry)
XX
DE Low adenosine antisense oligonucleotide SEQ ID NO:1181.
XX
KW Human; adenosine receptor; low adenosine antisense oligonucleotide;
KW phosphorothioate; impaired respiration; inflammation; allergy;
KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
KW antiallergic; antialasthmatic; cytostatic; analgesic; impaired airway;
KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
KW cancer; leukemia; lymphoma; carcinoma; metastasis; ss.
XX
OS Homo sapiens.
XX
PN WO200009525-A2.
XX
PD 24-FEB-2000.
XX
PF 03-AUG-1999; 99WO-US17712.
XX
PR 03-AUG-1998; 98US-0095212.
XX
PA (UYEC-) UNIV EAST CAROLINA.
PA Nyce JW;
PI
XX
PS WPI; 2000-205971/18.
XX
DR
XX
PT New antisense oligonucleotides useful for treating e.g. pulmonary
PT vasoconstriction, inflammation, allergies, asthma, hypertension,
PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT cancers -
XX
PS Claim 18; Page 412; 1343pp; English.
XX
CC The present invention describes a new composition comprising an
CC antisense oligonucleotide (ON) with low adenosine (up to 15%), which
CC targets nucleic acids involved in bronchoconstriction, allergies, and/or
CC inflammation. The ON can have antiinflammatory, antiallergic,
CC antialasthmatic, cytostatic and analgesic activities. The compositions are
CC useful for the treatment of diseases associated with inflammation,
CC impaired airways, including lung disease and diseases whose secondary
CC effects afflict the lungs of a subject. They can be used for treating
CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies,
CC asthma, impeded respiration, respiratory distress syndrome, pain, cystic
CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
CC pulmonary disease (COPD), and cancers such as leukemias, lymphomas,
CC carcinomas, and cancers which may metastasize to the lungs, including
CC breast and prostate cancer. The reduction of the adenosine content of
CC the ONs reduces side effects. The A-containing ONs break down with the
CC release of deoxyadenosine which activates adenosine receptors causing
CC bronchoconstriction and inflammation. AAA33313 to AAA35312 represent the

CC nucleotide sequences given in the sequence listing from the present
CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
CC differ from the previously named sequences. SEQ ID NO:11 to 1680
CC (AAA32323 to AAA33922) are specifically claimed ONS from the present
CC invention. N.B. Sequences given in the disclosure of the present
CC invention do not match up with their corresponding SEQ ID NO: sequences
CC given in the sequence listing.

XX
XX
XX Sequence 15 BP; 0 A, 7 C, 5 G, 3 T, 0 other;

Sequence 15 BP; 0 A; 7 C; 5 G; 3 T; 0 other;

Query Match	1.0%	Score	14	DB	1	Length	15
Best Local Similarity	100.0%	Pred.	No.	1.4e+02			
Matches	14	Conservative	0	Mismatches	0	Indels	0
						Gaps	0

Qy	2003	GAGCCCGAGGCCA	2016
Db	14	GAGCCCGAGGCCA	1

RESULT 130
AAZ90843/C
ID AAZ90843 standard; DNA; 15 BP

AC AAZ90843;

DT 24-MAY-2000 (first entry)

DE Human NR8 gene probe #71.

KM Haemopoietin receptor family; NR8; antibody; diagnosis;
KM blood formation disorder; fusion protein; probe; ss.

OS Homo sapiens.

PN WO9967290-A1.

PD 29-DEC-1999

PF 23-JUN-1999; 99WO-JP03351.

PR 24-JUN-1998; 98JP-0214720.

PR 19-OCT-1998; 98JP-0297409.

PA (CHUG-) CHUGAI RES INST MOLECULAR MEDICINE INC.

PI Nomura H, Maeda M;

DR WPI; 2000-116933/10.

PT Hemopoietin receptor protein family NR8 used for diagnosis of blood
PT formation disorders -

PS Example 1; Page 41; 176pp; Japanese.

CC The invention relates to the isolation of sequences encoding human
CC hemopoietin receptor protein family NRS genes. The NRS family
CC sequences were initially searched for comparison on a nucleic acid
CC database with the nucleic acid probe sequence TGGAGVNNNGAGAT encoding
CC the amino acid sequence Trp-Ser-Xaa-Trp-Ser. The sequences
CC AA259358-753300 and AA298816-730953 represent specific examples of probe
CC sequences used in the search. Antibodies to the NRS family proteins are
CC used for the diagnosis of blood formation disorders. Compounds identified
CC as binding to the proteins are used for the treatment of such disorders.

Sequence 15 BP; 3 A; 1 C; 6 G; 5 T; 0 other;

Query Match	1.0%	Score 14;	DB 1;	Length 15;
Best Local Similarity	100.0%	Pred. No. 1.4e+02;		
Matches 14;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

QY 1581 CTCGATGAACTCCA 1594

Db 14 CTCGATGACTCCA 1

RESULT 131

ID AAF52667 standard; DNA; 15 BP.

AC AAF52667;

DT 30-MAR-2001 (first entry)

DE IGF-I oligonucleotide #3627.

KM Antisense therapy; antiproliferative; antinflammatory; antipapillary;
 KM cytostatic; dermatological; cardiac; virucide; ophthalmological; keloid
 KM skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pterygiae;
 KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilars;
 KM growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba
 KM keratosis; neoplasia; sclerodema; wart; skin cancer; sclerotic disease;
 KM hyperneovascular condition; hyperplasia; kidney disease;
 KM neovascular condition of the retina; ss.

05 Homo sapiens.

PN WO200078341-A1

PD 28-DEC-2000

PF 21-JUN-2000; 2000WO-AU00693.

PR 21-JUN-1999; 99US-0140345.

PA (MURD-) MURDOCH CHILDRENS RES INST

PI Wraight CJ, Werther GA, Edmondson SR;

DR WPI; 2001-041421/05

PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisenesc
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -

PS Example 8; Page 84; 201pp; English

The present invention relates to a method for ameliorating the effects of skin disorders. The method comprises contacting the skin with an antisenese oligonucleotide, (for Insulin-like Growth Factor [IGF]-1 receptor, IGF binding protein (IGBP)-2 or IGFBP-3), which is capable of inhibiting or reducing growth factor mediated cell proliferation, inflammation and/or other disorders. The present sequence is an oligonucleotide which can be used to design the antisenese oligonucleotides of the present invention (see AAR45151 and AAR45153-F45161). The method is useful for ameliorating the effects of psoriasis, ichthyosis, pityriasis, tinea, pilaris, seborrheoa, keloids, keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the skin, a hyperneovascular condition such as a neovascular condition of the retina, brain or skin, growth factor-mediated malignancies, other sclerotic disease, kidney disease, hyperproliferation of the inside of blood vessels or any other hyperplasia.

Sequence 15 BP; 0 A; 5 C; 5 G; 5 T; 0 other;

Query Match	1.0%	Score 14;	DB 1;	Length 15;
Best Local Similarity	100.0%	Pred. No. 1.4e+02;		
Matches 14; Conservative	0;	Mismatches 0;	Indels 0;	Gaps 0;

```

QY      2329 GTCTGGTCTTCGG 2342
          |||||
Db       2   GTCTGGTCTTCGG 15

```

RESULT 132

AAFS2671
ID AAFS2671 standard; DNA; 15 BP.
AC AAFS2671;
XX
XX
DT 30-MAR-2001 (first entry)
XX
XX IGF-1 oligonucleotide #3631.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KM cytosolic; dermatological; cardiac; virucide; ophthalmological; keloid;
KM skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KM growth factor mediated cell proliferation; ichthyosis; seborrhoea; rubra;
KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KM hyperneovascular condition; hyperplasia; kidney disease;
KM neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX MO200078341-A1.
PN
XX 28-DEC-2000.
PD
XX 21-JUN-2000; 2000WO-AU00693.
PE
XX 21-JUN-1999; 99US-0140345.
PR
XX (MURD-) MURDOCH CHILDRENS RES INST.
PA
XX
XX Wright CJ, Werther GA, Edmondson SR;
PI
XX WPI; 2001-041421/05.
DR
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
XX Example 8; Page 84; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, rubra, pilaris, seborrhoea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
XX Sequence 15 BP; 0 A; 4 C; 6 G; 5 T; 0 other;
SQ

Query Match 1.0%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2332 TGGTCTTCGGGGT 2345
|||
1 TGGTCTTCGGGGT 14

Db 1 TGGTCTTCGGGGT 14

RESULT 133
AAH95775
ID AAH95775 standard; RNA; 17 BP.
XX
XX AAH95775;

XX
DT 09-OCT-2001 (first entry)
XX
XX Human Chk1 ribozyme substrate SEQ ID NO: 1200.
DE
XX Human; checkpoint kinase-1; Chk1; antisense; ribozyme; gene therapy;
KM RNA cleavage; cancer; ss.
XX
XX Homo sapiens.
OS
XX MO200157206-A2.
PN
XX 09-AUG-2001.
PD
XX 02-FEB-2001; 2001WO-US03504.
PE
XX 03-FEB-2000; 2000US-0179983.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (PAT/) FATTNEY A R.
XX
XX Fattaey AR, Jarvis T, McSwiggen J, Booher RN, Holman PS;
PI
XX WPI; 2001-496922/54.
DR
XX
XX Novel nucleic acid molecule e.g., ribozymes or antisense nucleic acid
PT molecules, which downregulates expression of a checkpoint kinase-1
PT gene, useful for treating colorectal, lung, breast or prostate cancers
PT -
XX
XX Claim 4; Page 88; 115pp; English.
PS
XX
XX The present invention provides nucleic acid molecules capable of
CC downregulating the expression of the human checkpoint kinase-1 (Chk1)
CC gene. These may be antisense or ribozyme sequences, and are useful in the
CC treatment of diseases associated with conditions affected by Chk1 levels,
CC including cancer. The present sequence is an oligonucleotide described in
CC the exemplification of the invention.
XX
XX Sequence 17 BP; 6 A; 3 C; 6 G; 2 U; 0 other;
SQ

Query Match 1.0%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 1.6e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1730 CCCTGGAGGAAGT 1743
|||
4 CCCTGGAGGAAGT 17

Db 4 CCCTGGAGGAAGT 17

RESULT 134
AAH95776
ID AAH95776 standard; RNA; 17 BP.
XX
XX AAH95776;
AC
XX 09-OCT-2001 (first entry)
DT
XX Human Chk1 ribozyme substrate SEQ ID NO: 1201.
DE
XX Human; checkpoint kinase-1; Chk1; antisense; ribozyme; gene therapy;
KM RNA cleavage; cancer; ss.
XX
XX Homo sapiens.
OS
XX MO200157206-A2.
PN
XX 09-AUG-2001.
PD
XX 02-FEB-2001; 2001WO-US03504.
PE
XX 03-FEB-2000; 2000US-0179983.
PR
XX

PA (RIBO-) RIBOZYME PHARM INC.
PA (FAT/) FATTALEY A R.
PI Fattaey AR, Jarvis T, McSwiggen J, Booher RN, Holman PS;
XX WPI; 2001-496922/54.
XX
XX Novel nucleic acid molecule e.g., ribozymes or antisense nucleic acid
PT molecules, which downregulate expression of a checkpoint kinase-1
PT gene, useful for treating colorectal, lung, breast or prostate cancers
PT
PS Claim 4; Page 88; 115pp; English.
XX
XX The present invention provides nucleic acid molecules capable of
CC downregulating the expression of the human checkpoint kinase-1 (Chk1)
CC gene. These may be antisense or ribozyme sequences, and are useful in the
CC treatment of diseases associated with conditions affected by Chk1 levels,
CC including cancer. The present sequence is an oligonucleotide described in
CC the exemplification of the invention.
XX
XX Sequence 17 BP; 5 A; 3 C; 7 G; 2 U; 0 other;
SQ
Query Match 1.0%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 1.6e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
OY 1730 CCTGGGAGAAAGT 1743
||:|||||:
||:|||||:
3 CCCUGGAGAAAGU 16
Db
RESULT 135
AAH95777
ID AAH95777 standard; RNA; 17 BP.
XX
XX AAH95777;
AC
XX 09-OCT-2001 (first entry)
DT
XX Human Chk1 ribozyme substrate SEQ ID NO: 1202.
DE
XX Human Chk1 ribozyme substrate SEQ ID NO: 1202.
KM Human; checkpoint kinase-1; Chk1; antisense; ribozyme; gene therapy;
KW RNA cleavage; cancer; ss.
XX
XX Homo sapiens.
OS
XX WO200157206-A2.
PN
XX 09-AUG-2001.
PD
XX
XX 02-FEB-2001; 2001WO-US03504.
PF
XX
XX 03-FEB-2000; 2000US-0179983.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (FAT/) FATTALEY A R.
XX
XX Fattaey AR, Jarvis T, McSwiggen J, Booher RN, Holman PS;
PI WPI; 2001-496922/54.
DR
XX
XX Novel nucleic acid molecule e.g., ribozymes or antisense nucleic acid
PT molecules, which downregulate expression of a checkpoint kinase-1
PT gene, useful for treating colorectal, lung, breast or prostate cancers
PT
PS Claim 4; Page 88; 115pp; English.
XX
XX The present invention provides nucleic acid molecules capable of
CC downregulating the expression of the human checkpoint kinase-1 (Chk1)
CC gene. These may be antisense or ribozyme sequences, and are useful in the
CC treatment of diseases associated with conditions affected by Chk1 levels,

CC including cancer. The present sequence is an oligonucleotide described in
CC the exemplification of the invention.
CC
XX
XX Sequence 17 BP; 3 A; 5 C; 7 G; 2 U; 0 other;
SQ
Query Match 1.0%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 1.6e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
OY 1730 CCTGGGAGAAAGT 1743
||:|||||:
||:|||||:
1 CCCUGGAGAAAGU 14
Db
RESULT 136
ABN06896/c
ID ABN06896 standard; DNA; 17 BP.
XX
XX ABN06896;
AC
XX 29-MAY-2002 (first entry)
DT
XX
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6888.
DE
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
OS
XX WO200192524-A2.
PN
XX
XX 06-DEC-2001.
PD
XX
XX 25-MAY-2001; 2001WO-US16981.
PF
XX
XX 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX
XX (AEOM-) AEOMICA INC.
PA
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI WPI; 2002-179446/23.
DR
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
PT
XX
XX Disclosure; SEQ ID 6888; 214pp; English.
PS
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may

CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
CC
SQ Sequence 17 BP; 1 A; 6 C; 4 G; 6 T; 0 other;

Query Match 1.0%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1358 CGCCTGAGAGAGAA 1371
Db 17 CGCCTGAGAGAGAA 4

RESULT 137
ABN06897/c
ID ABN06897 standard; DNA; 17 BP.
XX
AC ABN06897;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6889.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
PR 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for

PT surface-enhanced laser desorption ionization, comprises human
PT myosin-like protein hGDMLP-1 -
PS Disclosure; SEQ ID 6889; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
CC
SQ Sequence 17 BP; 1 A; 6 C; 5 G; 5 T; 0 other;

Query Match 1.0%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1358 CGCCTGAGAGAGAA 1371
Db 16 CGCCTGAGAGAGAA 3

RESULT 138
ABN06898/c
ID ABN06898 standard; DNA; 17 BP.
XX
AC ABN06898;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6890.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
PR 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.


```

XX DE Artificial HIV-1 TAR sequence containing U-rich bubble.
XX KW human immunodeficiency virus; tat protein; AIDS; hairpin loop;
XX KW trans-activation responsive region; ss.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT misc_structure 5..12
XX FT /*tag= a
FT /note= "U-rich bubble. Base pairs to nucleotides
FT 6-10 of AAQ24061"
XX PN WO9202228-A.
XX PD 20-FEB-1992.
XX PF 02-AUG-1991; 91WO-GB01321.
XX PR 02-AUG-1990; 90GB-0016973.
XX PA (MED1-) MED RES COUNCIL.
XX PI Karn J, Galt MJ, Heaphy S, Dingwall C;
XX WPI; 1992-079785/10.
XX DR
XX PT New HIV growth inhibiting oligo:nucleotide(s) - comprising RNA
XX PT binding sequences capable of binding to tat protein within cells,
XX PT and in assays to identify cpds. with tat binding
XX PS Disclosure; Fig 18c; 89pp; English.
XX CC The HIV-1 TAR stem-loop sequence (see AAQ21425) was compared to that
XX CC from HIV-2 (see AAQ21426). The only regions common to the two TAR
XX CC structures are in the loop region and the U-rich bubble in the upper
XX CC stem. This 17-mer was synthesised and can hybridise to a 14-mer
XX CC (see AAQ24061) to mimic the known HIV-1 tat recognition sequence but
XX CC without the apical loop. In an assay, the 17-mer plus 14-mer
XX CC structure competed satisfactorily with full-length (59-mer) TAR
XX CC for binding to tat. See AAQ21427-Q21435 for TAR mutants.
XX SQ Sequence 17 BP; 5 A; 4 C; 5 G; 3 U; 0 other;
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.8e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 1490 AGCCAGACTTCAGCAGC 1506
DB 1 AGCCAGAUUUGAGCAGC 17
RESULT 141
AAx74934
ID AAx74934 standard; RNA; 17 BP.
AC AAx74934;
XX
XX 28-JUL-1999 (first entry)
XX
XX Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #462.
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
XX flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
XX tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
XX fms-like tyrosine kinase 1; kinase insert domain containing receptor;
XX foetal liver kinase 1; ss.
XX
XX Mus sp.
XX
XX WO9715662-A2.
XX

```

```

XX PD 01-MAY-1997.
XX PF 25-OCT-1996; 96WO-US17480.
XX PR 11-JAN-1996; 96US-0584040.
XX PR 26-OCT-1995; 95US-0005974.
XX PA (CHIR ) CHIRON CORP.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;
XX WPI; 1997-259017/23.
XX DR
XX PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or
XX PT mRNA stability - useful for treating e.g. tumour angiogenesis,
XX PT psoriasis, rheumatoid arthritis, etc., in a human patient
XX PS Claim 4; Page 169; 218pp; English.
XX CC The present invention describes nucleic acid molecules which modulate
XX CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
XX CC receptors of vascular endothelial growth factor (VEGF). A patient
XX CC (preferably human) having a condition associated with the level of the
XX CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
XX CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
XX CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
XX CC be treated by administering the nucleic acid molecule or the expression
XX CC vector to the patient. AAx67275 to AAx7572 represent specific examples
XX CC of nucleic acid molecules from the present invention.
XX SQ Sequence 17 BP; 2 A; 4 C; 4 G; 7 U; 0 other;
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 1.8e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
QY 2353 TGGGAGATCTTCAGCTTT 2369
DB 1 UGGGAGAUUUGUCCUCCU 17
RESULT 142
AAx74935
ID AAx74935 standard; RNA; 17 BP.
AC AAx74935;
XX
XX 28-JUL-1999 (first entry)
XX
XX Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #463.
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
XX flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
XX tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
XX fms-like tyrosine kinase 1; kinase insert domain containing receptor;
XX foetal liver kinase 1; ss.
XX
XX Mus sp.
XX
XX WO9715662-A2.
XX
XX 01-MAY-1997.
XX
XX 25-OCT-1996; 96WO-US17480.
XX PR 11-JAN-1996; 96US-0584040.
XX PR 26-OCT-1995; 95US-0005974.
XX PA (CHIR ) CHIRON CORP.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX

```

PI Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;
XX WPI; 1997-259017/23.
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
PT mRNA stability - useful for treating e.g. tumour angiogenesis,
PT psoriasis, rheumatoid arthritis, etc., in a human patient
XX
PS Claim 4; Page 169; 218pp; English.
XX
XX The present invention describes nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (Flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
CC be treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention.
CC
SQ Sequence 17 BP; 3 A; 4 C; 4 G; 6 U; 0 other;
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.8e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
OY 2355 GGAGATCTTCACTTAG 2371
DB 1 GGAGATCTTCACTTAG 17
RESULT 143
AAX74936
ID AAX74936 standard; RNA; 17 BP.
AC AAX74936;
XX
XX 28-JUL-1999 (first entry)
DT
XX
XX Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #464.
DE
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
KM flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KM tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KM fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KM foetal liver kinase 1; ss.
XX
OS Mus sp.
XX
XX W09715662-A2.
PN
XX
PD 01-MAY-1997.
PD
XX
PF 25-OCT-1996; 96WO-US17480.
PF
XX
PR 11-JAN-1996; 96US-0584040.
PR
XX 26-OCT-1995; 95US-0005974.
XX
PA (CHIR) CHIRON CORP.
PA (RIBO-) RIBOZYME PHARM INC.
XX
XX Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;
PI WPI; 1997-259017/23.
DR
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
PT mRNA stability - useful for treating e.g. tumour angiogenesis,
PT psoriasis, rheumatoid arthritis, etc., in a human patient
XX
PS Claim 4; Page 169; 218pp; English.
XX
XX The present invention describes nucleic acid molecules which modulate

CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (Flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
CC be treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention.
CC
SQ Sequence 17 BP; 3 A; 4 C; 4 G; 6 U; 0 other;
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.8e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
OY 2356 GGAGATCTTCACTTAGG 2372
DB 1 GGAGATCTTCACTTAGG 17
RESULT 144
AAX74937
ID AAX74937 standard; RNA; 17 BP.
AC AAX74937;
XX
XX 28-JUL-1999 (first entry)
DT
XX
XX Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #465.
DE
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
KM flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KM tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KM fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KM foetal liver kinase 1; ss.
XX
OS Mus sp.
XX
XX W09715662-A2.
PN
XX
PD 01-MAY-1997.
PD
XX
PF 25-OCT-1996; 96WO-US17480.
PF
XX
PR 11-JAN-1996; 96US-0584040.
PR
XX 26-OCT-1995; 95US-0005974.
XX
PA (CHIR) CHIRON CORP.
PA (RIBO-) RIBOZYME PHARM INC.
XX
XX Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;
PI WPI; 1997-259017/23.
DR
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
PT mRNA stability - useful for treating e.g. tumour angiogenesis,
PT psoriasis, rheumatoid arthritis, etc., in a human patient
XX
PS Claim 4; Page 169; 218pp; English.
XX
XX The present invention describes nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (Flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
CC be treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention.
CC
SQ Sequence 17 BP; 2 A; 4 C; 5 G; 6 U; 0 other;

KM tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KM fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KM foetal liver kinase 1; ss.
 XX
 OS Mus sp.
 XX
 PN W09715662-A2.
 XX
 PD 01-MAY-1997.
 XX
 PF 25-OCT-1996; 96WO-US17480.
 XX
 PR 11-JAN-1996; 96US-0584040.
 PR 26-OCT-1995; 95US-0005974.
 XX
 PA (CHIR) CHIRON CORP.
 PA (RIBO-) RIBOZYME PHARM INC.
 PI Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;
 PI WPI; 1997-259017/23.
 DR
 PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or
 PT mRNA stability - useful for treating e.g. tumour angiogenesis,
 PT psoriasis, rheumatoid arthritis, etc., in a human patient
 XX
 PS Claim 4; Page 137; 218pp; English.
 XX
 CC The present invention describes nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular disease, psoriasis and rheumatoid arthritis) can
 CC be treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention.
 CC
 SQ Sequence 17 BP; 3 A; 3 C; 5 G; 6 U; 0 other;
 QY Query Match 1.0%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 58.8%; Pred. No. 1.8e+02;
 Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
 QY 2112 CATGAGTACTTGCGCTT 2128
 ||:||||:|:||||:|:
 1 CAUGGAGUUCUUGGCAU 17
 DB
 RESULT 148
 AAX73030
 ID AAX73030 standard; RNA; 17 BP.
 XX
 AC AAX73030;
 XX
 DT 28-JUL-1999 (first entry)
 XX
 DE Mouse flk-1 VEGF receptor hammetthead ribozyme substrate #463.
 XX
 KM Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
 KM flk-1; KDR; hammetthead ribozyme; hairpin ribozyme; cleavage;
 KM tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KM fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KM foetal liver kinase 1; ss.
 XX
 OS Mus sp.
 XX
 PN W09715662-A2.
 XX
 PD 01-MAY-1997.
 XX
 PF 25-OCT-1996; 96WO-US17480.

XX
 PR 11-JAN-1996; 96US-0584040.
 PR 26-OCT-1995; 95US-0005974.
 XX
 PA (CHIR) CHIRON CORP.
 PA (RIBO-) RIBOZYME PHARM INC.
 PI Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;
 PI WPI; 1997-259017/23.
 DR
 PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or
 PT mRNA stability - useful for treating e.g. tumour angiogenesis,
 PT psoriasis, rheumatoid arthritis, etc., in a human patient
 XX
 PS Claim 4; Page 137; 218pp; English.
 XX
 CC The present invention describes nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular disease, psoriasis and rheumatoid arthritis) can
 CC be treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention.
 CC
 SQ Sequence 17 BP; 3 A; 3 C; 5 G; 6 U; 0 other;
 QY Query Match 1.0%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 58.8%; Pred. No. 1.8e+02;
 Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
 QY 2113 ATGAGTACTTGCGCTT 2129
 ||:||||:|:||||:|:
 1 AUGGAGUUCUUGGCAU 17
 DB
 RESULT 149
 AAX72964
 ID AAX72964 standard; RNA; 17 BP.
 XX
 AC AAX72964;
 XX
 DT 28-JUL-1999 (first entry)
 XX
 DE Mouse flk-1 VEGF receptor hammetthead ribozyme substrate #397.
 XX
 KM Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
 KM flk-1; KDR; hammetthead ribozyme; hairpin ribozyme; cleavage;
 KM tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KM fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KM foetal liver kinase 1; ss.
 XX
 OS Mus sp.
 XX
 PN W09715662-A2.
 XX
 PD 01-MAY-1997.
 XX
 PF 25-OCT-1996; 96WO-US17480.
 XX
 PR 11-JAN-1996; 96US-0584040.
 PR 26-OCT-1995; 95US-0005974.
 XX
 PA (CHIR) CHIRON CORP.
 PA (RIBO-) RIBOZYME PHARM INC.
 PI Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;
 PI WPI; 1997-259017/23.
 DR

PT	Nucleic acid molecule modulating VEGF receptor(s) gene expression or
CC	mRNA stability - useful for treating e.g. tumour angiogenesis,
PT	psoriasis, rheumatoid arthritis, etc., in a human patient
XX	
PS	Claim 4; Page 135; 218pp; English.
XX	
CC	The present invention describes nucleic acid molecules which modulate
CC	the synthesis, expression and/or stability of a mRNA encoding 1 or more
CC	receptors of vascular endothelial growth factor (VEGF). A patient
CC	(preferably human) having a condition associated with the level of the
CC	fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC	receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC	angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
CC	be treated by administering the nucleic acid molecule or the expression
CC	vector to the patient. AAX67275 to AAX75752 represent specific examples
CC	of nucleic acid molecules from the present invention.
SQ	
Sequence	17 BP; 4 A; 3 C; 5 G; 5 U; 0 other;
Oy	
Query Match	1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity	58.8%; Pred. No. 1.8e+02;
Matches	10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
Dn	
1	GTGCGCCGTGAAGATGTT 1829
:	: ::
1	GUAGCCGUCAGAUGUU 17
RESULT 150	
AAX71607	
ID	AAX71607 standard; RNA; 17 BP.
AC	
AA	AAX71607;
XX	
DT	28-JUL-1999 (first entry)
XX	
DE	Human KDR VEGF receptor hammerhead ribozyme substrate #619.
XX	
KW	Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
RW	flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW	tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW	fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW	foetal liver kinase 1; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO9715662-A2.
PD	
BD	01-MAY-1997.
XX	
Pf	25-OCT-1996; 96WO-US17480.
XX	
PR	11-JAN-1996; 96US-0584040.
PR	26-OCT-1995; 95US-0005974.
XX	
PA	(CHIR) CHIRON CORP.
PA	(RIBO-) RIBOZYME PHARM INC.
XX	
PI	Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;
XX	
DR	WPI; 1997-259017/23.
PT	
PT	Nucleic acid molecule modulating VEGF receptor(s) gene expression or
PT	mRNA stability - useful for treating e.g. tumour angiogenesis,
PT	psoriasis, rheumatoid arthritis, etc., in a human patient
XX	
PS	Claim 4; Page 115; 218pp; English.
XX	
CC	The present invention describes nucleic acid molecules which modulate
CC	the synthesis, expression and/or stability of a mRNA encoding 1 or more
CC	receptors of vascular endothelial growth factor (VEGF). A patient
CC	(preferably human) having a condition associated with the level of the
CC	fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC	

```

CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
CC be treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention.
CC
XX
SQ Sequence 17 BP; 6 A; 2 C; 3 G; 6 U; 0 other;
XX
XX
Query March 1.0*; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 1.8e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
OY 2404 GAACTTTTAAGTCGCT 2420
||||:|||||:|
1 GAACUUUUAAGCUGAU 17
RESULT 151
AAX71492
ID AAX71492 standard; RNA; 17 BP.
XX
XX AC AAX71492;
XX
XX DT 28-JUL-1999 (first entry)
XX
DE Human KDR VEGF receptor hammerhead ribozyme substrate #504.
KW
KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
KW flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
KW
XX
OS Homo sapiens.
XX
XX PN W09715662-A2.
XX
XX PD 01-MAY-1997.
XX
XX PF 25-OCT-1996; 96WO-US17480.
XX
XX PR 11-JAN-1996; 96US-0584040.
XX
XX PR 26-OCT-1995; 95US-0005974.
XX
XX PA (CHIR ) CHIRON CORP.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;
XX
XX DR WPI; 1997-259017/23.
XX
XX PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or
XX PT mRNA stability - useful for treating e.g. tumour angiogenesis,
XX PT psoriasis, rheumatoid arthritis, etc., in a human patient
XX
XX Claim 4; Page 112; 218pp; English.
XX
XX
The present invention describes nucleic acid molecules which modulate
the synthesis, expression and/or stability of a mRNA encoding 1 or more
receptors of vascular endothelial growth factor (VEGF). A patient
(preferably human) having a condition associated with the level of the
fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
be treated by administering the nucleic acid molecule or the expression
vector to the patient. AAX67275 to AAX75752 represent specific examples
of nucleic acid molecules from the present invention.
XX
XX
Sequence 17 BP; 2 A; 3 C; 5 G; 7 U; 0 other;
XX
XX
Query March 1.0*; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 1.8e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

```

Oy	2323	AGTGAATCTGTCCTT	2339
	:: :	:: :	::
Dd	1	AGUGACGUCUGUCUUU	17
RESULT 152			
ID	AAW71456		
XX	AAW71456 standard; RNA; 17 BP.		
AC			
XX	AAW71456;		
DT	28-JUL-1999 (first entry)		
XX			
DE	Human KDR VEGF receptor hammerhead ribozyme substrate #468.		
XX			
KM	Vascular endothelial growth factor receptor: VEGF receptor; flt-1;		
KM	flt-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;		
KM	tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;		
KM	fms-like tyrosine kinase 1; kinase insert domain containing receptor;		
XX	foetal liver kinase 1; ss.		
XX			
OS	Homo sapiens.		
XX			
PN	WO9715662-A2.		
PD	01-MAY-1997.		
PF	25-OCT-1996; 96WO-US17480.		
XX			
PR	11-JAN-1996; 96US-0584040.		
PR	26-OCT-1995; 95US-0005974.		
PA	(CHIR) CHIRON CORP.		
PA	(RIBO-) RIBOZYME PHARM INC.		
P1	Escobedo J, McSwiggan J, Pavco P, Stinchcomb D;		
XX			
DR	WPI; 1997-259017/23.		
XX			
PT	Nucleic acid molecule modulating VEGF receptor(s) gene expression or		
PT	mRNA stability - useful for treating e.g. tumour angiogenesis,		
PS	psoriasis, rheumatoid arthritis, etc., in a human patient		
XX			
PS	Claim 4; Page 111; 218pp; English.		
CC	The present invention describes nucleic acid molecules which modulate		
CC	the synthesis, expression and/or stability of a mRNA encoding 1 or more		
CC	receptors of vascular endothelial growth factor (VEGF). A patient		
CC	(preferably human) having a condition associated with the level of the		
CC	fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing		
CC	receptor (KDR) and/or foetal liver kinase 1 (flt-1) (e.g. tumour		
CC	angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can		
CC	be treated by administering the nucleic acid molecule or the expression		
CC	vector to the patient. AA67275 to AA67572 represent specific examples		
CC	of nucleic acid molecules from the present invention.		
XX			
SQ	Sequence 17 BP; 3 A; 3 C; 5 G; 6 U; 0 other;		
Query Match	1.0%; Score 13.8; DB 1; Length 17;		
Best Local Similarity	58.8%; Pred. No. 1.8e+02;		
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;			
Oy	2113	ATGGAGTACTTGCTTC	2129
	:: :	:: :	:
Dd	1	AUGGAGUUCUGGCACUC	17
RESULT 153			
ID	AAW71455		
XX	AAW71455 standard; RNA; 17 BP.		
XC	AAW71455;		

28-JUL-1999 (first entry)

Human KDR VEGF receptor hammerhead ribozyme substrate #467.

Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage; tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease; fms-like tyrosine kinase 1; kinase insert domain containing receptor; foetal liver kinase 1; ss.

Homo sapiens.

MO9715662-A2.

01-MAY-1997.

25-OCT-1996; 96WO-US17480.

11-JAN-1996; 96US-0584040.

26-OCT-1995; 95US-0005974.

(CHIR) CHIRON CORP.

(RIBO-) RIBOZYME PHARM INC.

Escobedo J, McSwiggen J, Pavco P, Stinchcomb D; WPI, 1997-259017/23.

Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA stability - useful for treating e.g. tumour angiogenesis, psoriasis, rheumatoid arthritis, etc., in a human patient

Claim 4; Page 11; 218pp; English.

The present invention describes nucleic acid molecules which modulate the synthesis, expression and/or stability of a mRNA encoding 1 or more receptors of vascular endothelial growth factor (VEGF). A patient (preferably human) having a condition associated with the level of the fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be treated by administering the nucleic acid molecule or the expression vector to the patient. AAX67275 to AAX75752 represent specific examples of nucleic acid molecules from the present invention.

Sequence 17 BP, 3 A; 3 C; 5 G; 6 U; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.8e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

2112 CATGAGTACTTGCTT 2128
||:||||:|:||||:
1 CAUGAGUUCUGGCAU 17

RESULT 154
AAAI8893
ID AAAI893 standard; RNA, 17 BP.
XX
XX AAAI8893;
XX
XX 19-JUN-2000 (first entry)
XX
XX Human TIF-2 substrate sequence SEQ ID NO:2119.
XX
XX
XX Human; aryl hydrocarbon nuclear transport; ARNT; TIF-2; angiogenesis; integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme; hammerhead ribozyme; angiogenic factor; cytoskeletal; antidiabetic; ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD; dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis; age related macular degeneration; inflammation; neovascular glaucoma;

KW myopic degeneration; psoriasis; verruca vulgaris; angioidfibroma;
 KW tubercous scleriosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trennauay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX
 OS Homo sapiens.
 XX
 PN MO9950403-A2.
 XX
 PD 07-OCT-1999.
 XX
 PF 24-MAR-1999; 99WO-US06507.
 XX
 PR 27-MAR-1998; 98US-0079678.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
 XX WPI; 1999-591315/50.
 DR
 PT Novel ribozymes for modulating the synthesis, expression and/or
 PT stability of an mRNA encoding an angiogenic factors -
 XX
 PS Claim 56; Page 123; 305pp; English.
 XX
 CC The present invention describes enzymatic nucleic acid molecules with
 CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AA16775 to
 CC AA117167 and AA117561 to AA117622 represent ribozyme sequences for ARNT,
 CC and AA117168 to AA117560 and AA117623 to AA117684 represent their
 CC corresponding target sequences. AA117685 to AA118385 and AA119087 to
 CC AA119154 represent ribozyme sequences for Tie-2, and AA118386 to AA119086
 CC and AA119155 to AA119222 represent their corresponding target sequences;
 CC AA119223 to AA120361 and AA121501 to AA121595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AA120362 to AA121500 and
 CC AA121596 to AA121688 represent their corresponding target sequences;
 CC AA121689 to AA122475 and AA123263 to AA123342 represent ribozyme sequence
 CC for integrin subunit beta 3, and AA122476 to AA123262, AA123343 to
 CC AA123422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angioidfibroma of tuberosus sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trennauay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3.
 CC
 XX
 SQ Sequence 17 BP; 4 A; 1 C; 6 G; 6 U; 0 other;
 XX
 QY Query Match 1.0%; Score 13.8; DB 1; Length 17;
 Db Best Local Similarity 52.9%; Pred. No. 1.8e+02;
 Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 2344 GTGTTAATGTGGAGAT 2360
 Db 1 GUGUUCACUAGGAGAU 17
 XX
 RESULT 155
 AA200939/C
 ID AA200939 standard; DNA; 17 BP.
 XX
 AC AA200939;
 XX
 DT 27-SEP-1999 (first entry)
 XX
 DE PCR primer MOGracesR444 for PGI gene.
 XX
 KW PGI gene; biallelic marker; PCR primer; PGI-related biallelic marker;

KW Cancer; prostate cancer; diagnosis; therapy; prostate specific antigen;
 KW PSA; mouse; ss.
 XX
 OS Synthetic.
 OS Mus musculus.
 XX
 PN MO9932644-A2.
 XX
 PD 01-JUL-1999.
 XX
 PF 22-DEC-1998; 98WO-IB02133.
 XX
 PR 09-SEP-1998; 98US-0099658.
 PR 22-DEC-1997; 97US-0996306.
 XX
 PA (GEST) GENSET.
 XX
 PI Blumenfeld M, Bougueleret L, Chumakov I, Cohen D;
 XX WPI; 1999-405178/34.
 DR
 PT Use of a prostate cancer associated gene and biallelic markers
 PT derived from it
 XX
 PS Example 22; Page 104; 385pp; English.
 XX
 CC The invention relates to a mammalian PGI gene and protein, and a set of
 CC PGI biallelic markers. The PGI polynucleotide and biallelic markers are
 CC used in a hybridisation assay, a sequencing assay, or in an
 CC allele-specific amplification assay for determining the identity of a
 CC nucleotide at a PGI-related biallelic marker. The methods can be used to
 CC detect and to assess the risk of developing cancer or prostate cancer.
 CC Early-stage diagnosis of prostate cancer relies on prostate specific
 CC antigen (PSA) dosage. However, the effectiveness of this is limited due
 CC to its inability to discriminate between malignant and non-malignant
 CC affections of the organ. A need exists for both a reliable diagnostic
 CC procedure which would enable early-stage diagnosis, and for preventative
 CC and curative treatments of the disease. The PGI gene can be used for
 CC detection of prostate cancer, and the risk of developing it in the
 CC future, and can also be used to determine therapies for the disease.
 CC
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 other;
 XX
 QY Query Match 1.0%; Score 13.8; DB 1; Length 17;
 Db Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 2092 ACCTACGACGTGGCCAG 2108
 Db 17 ACCTACCTGCTGGCCTG 1
 XX
 RESULT 156
 AAX76853/C
 ID AAX76853 standard; DNA; 17 BP.
 XX
 AC AAX76853;
 XX
 DT 05-AUG-1999 (first entry)
 XX
 DE PCR primer for cloning of T66Bk gene.
 XX
 KW Transcription unit; MARK2 kinase; rsk3 kinase; regulatory region; T66Bk;
 KW contraceptive; Responder/Distorter signalling cascade; t-Responder;
 KW PCR primer; ss.
 XX
 OS Synthetic.
 OS Mus sp.
 XX
 PN MO9925815-A2.
 XX
 PD 27-MAY-1999.
 XX

PF 18-NOV-1998; 98WO-EP07395.
 XX
 XX 02-MAR-1998; 98EP-0103596.
 PR 18-NOV-1997; 97EP-0120190.
 XX
 PA (PLAC) MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN.
 XX
 PI Herrmann B, Kispert A, Koschorz B;
 XX WPI; 1999-347466/29.
 DR
 XX
 PT Nucleic acids involved in the Responder phenotype in mice
 PS
 XX Example 7; Page 59; 117pp; English.
 XX
 CC This sequence is a PCR primer used in the cloning of the T66Bk gene.
 CC The invention related to a nucleic acid molecule (I) comprising a
 CC transcrption unit encoding in its 5' portion a kinase having a homology
 CC to MARK2 kinase and the 3' portion of the nucleotide sequence has a high
 CC homology to rak3 kinase. Sperm produced by transgenic creatures
 CC containing (I) are useful for production of offspring. T66Bk, its
 CC regulatory region, recombinant DNA, vectors, host cells, antibodies,
 CC etc., are useful for the isolation of receptors on the surface of sperm
 CC recognising attractants of the egg cell for the development and/or
 CC production of contraceptives. They can also be used to identify chemicals
 CC or biological compounds able to trigger the (premature) activation or
 CC inhibition of the Responder/Distorter signalling cascade, or to identify
 CC and isolate receptors and other members of the cascade that bind the
 CC expression products. The methods for detecting the sperm of the
 CC transgenic animal, and selecting against (I) also provide a means for
 CC distorting the transmission ratio of genetic traits by altering genes of
 CC the Responder/Distorter signal cascade other than the t-Responder. They
 CC also allow distortion, to a non-Mendelian ratio, of the transmission of a
 CC genetic trait, i.e. determination of sex, from male mammals to their
 CC offspring by expressing during spermatogenesis/spermiogenesis a gene
 CC involved in sperm motility and/or fertilisation. The genes and proteins
 CC involved in the responder phenotype and Responder/Distorter signalling
 CC cascade, as well as the inventive methods are advantageous in breeding
 CC strategies by allowing for specific selection of genetic traits and in
 CC particular, of sex.
 CC
 SQ Sequence 17 BP; 3 A; 7 C; 3 G; 4 T; 0 other;
 XX
 OY Query Match 1.0%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 2272 GTCAAGTGGATGGCTCC 2288
 ||||||||||||
 17 GTGAAGTGGATGGCAC 1
 RESULT 157
 AAV91368/c
 ID AAV91368 standard; RNA; 17 BP.
 XX
 AC AAV91368;
 XX
 DT 18-FEB-1999 (first entry)
 XX
 DE Human C-raf target site nucleotide position 2752.
 XX
 KM Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
 KM target; substrate; catalytic; modulation; expression; Raf gene;
 KM delivery; screening; identification; synthesis; deprotection;
 KM purification; cancer; inflammation; psoriasis; non-hepatic ascites;
 KM infection; genetic drift; restenosis; rheumatoid arthritis; ss.
 XX
 OS Homo sapiens.
 XX
 PN MO9850530-A2.
 XX
 PD 12-NOV-1998.

XX
 PF 05-MAY-1998; 98WO-US09249.
 XX
 PR 19-DEC-1997; 97US-0068212.
 PR 09-MAY-1997; 97US-0046059.
 PR 09-JUN-1997; 97US-0049002.
 PR 03-JUL-1997; 97US-0051718.
 PR 22-AUG-1997; 97US-0056808.
 PR 02-OCT-1997; 97US-0061321.
 PR 02-OCT-1997; 97US-0061324.
 PR 05-NOV-1997; 97US-0064866.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Beaudry A, Beigelman L, Belton L, Burgin A, Jarvis T;
 PI Kapelsky A, Kisch K, Matulic-Adamic J, McSwigen JA;
 PI Parry T, Reynolds M, Sweedler D, Thompson J, Workman CT;
 XX WPI; 1999-009494/01.
 DR
 XX
 PT Identifying new catalytic nucleic acid that modulates selected
 PT processes - especially ribozymes that cleave Raf RNA for treating
 PT cancer, restenosis, and also new ribozymes and modified nucleoside
 PT triphosphates used as antiviral agents and synthons
 XX
 PS Claim 177; Page 153; 259pp; English.
 XX
 CC A method has been developed for the identification of a nucleic acid
 CC capable of modulating a process in a biological system. The method
 CC comprises: (a) introducing into the system a random library of nucleic
 CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising
 CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC
 CC in systems where modulation has occurred and/or determining the sequence
 CC of at least part of the SBDs in such systems. Nucleic acid molecules
 CC with endonuclease activity and catalytic activity, from the present
 CC invention, are used to modulate gene expression in plant and mammalian
 CC cells and to cleave target nucleic acid, particularly for treating
 CC systemic diseases caused by specific RNA, e.g. cancer, inflammation,
 CC psoriasis, non-hepatic ascites and infection. They may also be used to
 CC detect genetic drift and mutations in diseased cells and to determine
 CC c-raf RNA. Specifically NACs with RNA-cleaving activity that modulate
 CC expression of the Raf gene, are used to treat cancer, restenosis,
 CC psoriasis or rheumatoid arthritis, or generally any condition associated
 CC with the level of c-raf. Introduction of sugar/phosphate modifications
 CC increases stability against nuclease and activity. AAV90922 to AAV93877
 CC represent NACs that can be used in the method, specifically for
 CC modulating the expression of a Raf gene.
 CC
 SQ Sequence 17 BP; 2 A; 4 C; 4 G; 7 U; 0 other;
 XX
 OY Query Match 1.0%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 1357 GCGCGTGGAGAGCAAAA 1373
 ||||||||||||
 17 GCTCCTGGAGACAAA 1
 Db
 RESULT 158
 AAV91369/c
 ID AAV91369 standard; RNA; 17 BP.
 XX
 AC AAV91369;
 XX
 DT 18-FEB-1999 (first entry)
 XX
 DE Human C-raf target site nucleotide position 2753.
 XX
 KM Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
 KM target; substrate; catalytic; modulation; expression; Raf gene;
 KM delivery; screening; identification; synthesis; deprotection;
 KM purification; cancer; inflammation; psoriasis; non-hepatic ascites;

KW infection; genetic drift; restenosis; rheumatoid arthritis; ss.
 XX
 XX Homo sapiens.
 OS
 KW MO9850530-A2.
 XX
 PD 12-NOV-1998.
 XX
 PF 05-MAY-1998; 98WO-US09249.
 XX
 PR 19-DEC-1997; 97US-0068212.
 PR 09-MAY-1997; 97US-0046059.
 PR 09-JUN-1997; 97US-0049003.
 PR 03-JUL-1997; 97US-0051718.
 PR 22-AUG-1997; 97US-0056808.
 PR 02-OCT-1997; 97US-0061321.
 PR 02-OCT-1997; 97US-0061324.
 PR 05-NOV-1997; 97US-0064866.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Beaudry A, Beigelman L, Bellon L, Burgin A, Jarvis T;
 PI Kapelsky A, Kisich K, Matulic-Adamic J, McSwiggen JA;
 PI Parry T, Reynolds M, Sweedler D, Thompson J, Workman CT;
 XX
 DR WPI; 1999-009494/01.
 XX
 PT Identifying new catalytic nucleic acid that modulates selected
 PT processes - especially ribozymes that cleave Raf RNA for treating
 PT cancer, restenosis, and also new ribozymes and modified nucleoside
 PT triphosphates used as antiviral agents and synthons
 XX
 PS Claim 177; Page 153; 259pp; English.
 XX
 CC A method has been developed for the identification of a nucleic acid
 CC capable of modulating a process in a biological system. The method
 CC comprises: (a) introducing into the system a random library of nucleic
 CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising
 CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC
 CC in systems where modulation has occurred and/or determining the sequence
 CC of at least part of the SBDs in such systems. Nucleic acid molecules
 CC with endonuclease activity and catalytic activity, from the present
 CC invention, are used to modulate gene expression in plant and mammalian
 CC cells and to cleave target nucleic acid, particularly for treating
 CC systemic diseases caused by specific RNA, e.g. cancer, inflammation,
 CC psoriasis, non-hepatic ascites and infection. They may also be used to
 CC detect genetic drift and mutations in diseased cells and to determine
 CC c-raf RNA. Specifically NACs with RNA-cleaving activity that modulate
 CC expression of the Raf gene, are used to treat cancer, restenosis,
 CC psoriasis or rheumatoid arthritis, or generally any condition associated
 CC with the level of C-raf. Introduction of sugar/phosphate modifications
 CC increases stability against nuclease and activity. AAV90922 to AAV93877
 CC represent NACs that can be used in the method, specifically for
 CC modulating the expression of a Raf gene.
 XX
 SQ Sequence 17 BP; 2 A; 4 C; 4 G; 7 U; 0 other;
 QY Query Match 1.0%; Score 13.8; DB 1; Length 17;
 Db Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1356 AGCGCTGGAGAGAAA 1372
 Db 17 AGCTCTGGAGAGACAAA 1
 RESULT 159
 ID AAF04325/c
 AC AAF04325; standard; DNA; 17 BP.
 XX
 XX AAF04325;
 DT 16-FEB-2001 (first entry)

XX
 DE Hammerhead ribozyme substrate #1841.
 XX
 KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 KW interferon alpha; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200061729-A2.
 XX
 PD 19-OCT-2000.
 XX
 PR 11-APR-2000; 2000WO-US09721.
 XX
 PR 12-APR-1999; 99US-0129390.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Zwick M, Pavco P, McSwiggen J;
 XX
 DR WPI; 2000-647423/62.
 XX
 PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor
 PT protein, interferon alpha and erythropoietin -
 XX
 PS Claim 4; Page 98; 164pp; English.
 XX
 CC The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the Tr2 Orphan receptor, EAR3/COUP-TF-1, the GATA
 CC transcription factor gene, IRF-2 and/or the C/EBP Displacement
 CC protein (CDP). Inhibition of the repressors removes prevents
 CC inhibition (and consequently increases expression of) genes involved in
 CC the production of erythropoietin, granulocyte colony stimulating factor
 CC protein and interferon alpha.
 XX
 SQ Sequence 17 BP; 7 A; 2 C; 4 G; 4 T; 0 other;
 QY Query Match 1.0%; Score 13.8; DB 1; Length 17;
 Db Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2659 TCTGTTTTTCTCCAGA 2675
 Db 17 TCAGTTTTTACTCCAGA 1
 RESULT 160
 ID AAF04773/c
 AC AAF04773; standard; DNA; 17 BP.
 XX
 XX AAF04773;
 DT 16-FEB-2001 (first entry)
 DE Hammerhead ribozyme substrate #2289.
 KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 KW interferon alpha; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200061729-A2.
 XX
 PD 19-OCT-2000.
 XX
 PR 11-APR-2000; 2000WO-US09721.
 XX
 PR 12-APR-1999; 99US-0129390.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX

PI Blact L, Zwick M, Pavco P, McSwiggen J;
XX
DR WPI; 2000-647423/62.
XX
PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
XX useful for producing e.g. granulocyte colony stimulating factor
PT protein, interferon alpha and erythropoietin -
XX
PS Claim 4; Page 108; 164pp; English.
XX
CC The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA
CC transcription factor gene, IRF-2 and/or the CATT Displacement
CC protein (CDP). Inhibition of the repressors removes prevents
CC inhibition (and consequently increases expression of) genes involved in
CC the production of erythropoietin, granulocyte colony stimulating factor
CC protein and interferon alpha.
XX
SQ Sequence 17 BP; 7 A; 2 C; 4 G; 4 T; 0 other;
XX
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2659 TCTGTTTCTCCAGA 2675
DB 17 TCAGTTTACTCCAGA 1
XX
RESULT 161
AAFO7201
ID AAFO7201 standard; DNA; 17 BP.
XX
AC AAFO7201;
XX
DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #3458.
XX
XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.
XX
OS Homo sapiens.
XX
XX MO200061729-A2.
XX
PD 19-OCT-2000.
XX
PF 11-APR-2000; 2000MO-US09721.
XX
XX 12-APR-1999; 99US-0129390.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blact L, Zwick M, Pavco P, McSwiggen J;
XX
DR WPI; 2000-647423/62.
XX
PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor
PT protein, interferon alpha and erythropoietin -
XX
PS Claim 54; Page 135; 164pp; English.
XX
CC The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA
CC transcription factor gene, IRF-2 and/or the CATT Displacement
CC protein (CDP). Inhibition of the repressors removes prevents
CC inhibition (and consequently increases expression of) genes involved in
CC the production of erythropoietin, granulocyte colony stimulating factor
CC protein and interferon alpha.

XX
SQ Sequence 17 BP; 5 A; 5 C; 4 G; 3 T; 0 other;
XX
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1507 CAGCCGCTGACCAA 1523
DB 1 CAGCCGATTGTGACAA 17
XX
RESULT 162
AA259070
ID AA259070 standard; RNA; 17 BP.
XX
AC AA259070;
XX
DT 11-APR-2000 (first entry)
XX
DE HIV-1 TAR oligonucleotide target sequence #1.
XX
DE Antiviral; antibacterial; antifungal; anticancer; detection; TAR; RRE;
KW fluorescence resonance energy transfer; tat; HIV-1; Rev response element;
KW autoimmune disease; trans-activation regulatory region; ss.
XX
OS Human immunodeficiency virus type 1.
XX
PN MO9964625-A2.
XX
PD 16-DEC-1999.
XX
PF 04-JUN-1999; 99MO-GB01761.
XX
PR 05-JUN-1998; 98GB-0012196.
XX
PR 02-MAR-1999; 99GB-0004790.
XX
PA (RIBO-) RIBOTARGETS LTD.
XX
PI Karn J, Prescott CD;
XX
DR WPI; 2000-097545/08.
XX
PT Identifying compounds that bind to target RNA, potentially useful for
PT treating infections, tumors and autoimmune diseases -
XX
PS Examples; Page 31; 82pp; English.
XX
CC The invention relates to a method of determining if a compound binds to
CC a target RNA by treating a test compound with a reporter (R) labelled
CC with a donor or acceptor group and labelled target RNA, labelled with
CC the complementary donor or acceptor group, and measuring the
CC fluorescence from fluorescent groups associated with a compound:target
CC RNA complex in presence of the test compound and comparing the result
CC with a standard. The oligonucleotides AA259070-259071 anneal to form a
CC double stranded oligonucleotide containing the HIV-1 tat protein binds. The complex
CC is labelled with 6-carboxyfluorescein and is used as a target for the
CC binding of a labelled ADP-1 protein. Detection of the complex is by
CC fluorescence resonance energy transfer (FRET). The method is used to
CC identify compounds that interfere with interaction between the target RNA
CC and ligands or proteins. Compounds that are identified are potentially
CC useful for treating infections (viral, bacterial or fungal), cancer
CC and autoimmune diseases. The compounds are preferably directed to the
CC TAR and RRE regions of human immunodeficiency virus RNA and inhibit
CC viral replication.
XX
SQ Sequence 17 BP; 5 A; 4 C; 5 G; 3 U; 0 other;
XX
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.8e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Oy 1490 AGCCAGACTGACGAGC 1506
Db 1 AGCCAGAUUUGAGCAGC 17

RESULT 163
AAH95005
ID AAH95005 standard; RNA; 17 BP.
XX
AC AAH95005;
XX
DT 09-OCT-2001 (first entry)
XX
DE Human Chk1 ribozyme substrate SEQ ID NO: 430.
XX
KW Human; checkpoint kinase-1; Chk1; antisense; ribozyme; gene therapy;
KW RNA cleavage; cancer; ss.
XX
OS Homo sapiens.
XX
PM WO200157206-A2.
XX
PD 09-AUG-2001.
XX
PF 02-FEB-2001; 2001WO-US03504.
XX
PR 03-FEB-2000; 2000US-0179983.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (FATT/) FATTAET A R.
XX
PI Fattaey AR, Jarvis T, McSwiggen J, Booher RN, Holman PS;
XX
DR WPI; 2001-496922/54.
XX
PT Novel nucleic acid molecule e.g., ribozymes or antisense nucleic acid
PT molecules, which downregulate expression of a checkpoint kinase-1
PT gene, useful for treating colorectal, lung, breast or prostate cancers
PT
XX
PS Claim 4; Page 61; 115pp; English.
XX
CC The present invention provides nucleic acid molecules capable of
CC downregulating the expression of the human checkpoint kinase-1 (Chk1)
CC gene. These may be antisense or ribozyme sequences, and are useful in the
CC treatment of diseases associated with conditions affected by Chk1 levels,
CC including cancer. The present sequence is an oligonucleotide described in
CC the exemplification of the invention.
XX
SO Sequence 17 BP; 6 A; 3 C; 3 G; 5 U; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Oy 2194 AAAATAGCAGACTTTGG 2210
Db 1 AAAAUCCAGACUUDGG 17

RESULT 164
ABK00844/C
ID ABK00844 standard; RNA; 17 BP.
XX
AC ABK00844;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Inozyme #114.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;

KW DNAzyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
XX
OS Synthetic.
XX
PM WO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US04273.
XX
PR 11-FEB-2000; 2000US-181797P.
PR 28-FEB-2000; 2000US-185516P.
PR 06-MAR-2000; 2000US-187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, McSwiggen J, Chowrira BM;
XX
DR WPI; 2001-607195/69.
XX
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia,
PT and central nervous system injury -
XX
PS Claim 88; Page 79; 200pp; English.

XX The invention relates to a nucleic acid molecule which down regulates
XX expression of a CD20 gene and a nucleic acid molecule which down
XX regulates expression of a neurite growth inhibitor gene (NOGO).
XX The nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
XX DNAzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
XX possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN
XX motif) or an amberzyme (cleaving RNA with an NGN triplet), a zinczyme
XX (cleaving RNA with a YGY motif). The CD20-targeting nucleic acid is used
XX to cleave RNA of CD20 in the presence of a divalent cation that is
XX preferably Mg²⁺. Furthermore, it may be contacted with a cell to reduce
XX CD20 activity of the cell and treat a patient having a condition
XX associated with the level of CD20. The treatment may further comprise the
XX use of one or more therapies. In particular, the CD20 targeting
XX nucleic acid may be used to treat lymphoma, leukemia, B-cell
XX lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky
XX low-grade or follicular NHL, lymphocytic leukaemia, HIV (human
XX immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL),
XX immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune
XX thrombocytopenia, and inflammatory arthropathy. The NOGO-targeting
XX nucleic acid is used to cleave RNA of the NOGO gene in the presence of a
XX divalent cation that is preferably Mg²⁺. Furthermore, the nucleic acid
XX may be contacted with a cell to reduce NOGO activity of the cell and
XX treat a patient having a condition associated with the level of NOGO. The
XX treatment may further comprise the use of one or more therapies.
XX In particular, the NOGO-targeting nucleic acid may be used to treat
XX central nervous system (CNS) injury and cerebrovascular accident (CVA,
XX stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
XX chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
XX Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
XX disease, muscular dystrophy, and/or other neurodegenerative disease
XX states which respond to the modulation of NOGO expression. The
XX present sequence is an inozyme of the invention.

SO Sequence 17 BP; 1 A; 8 C; 7 G; 1 U; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 89.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1650 GCTGGCAGGGGTCTCCG 1666
Db 17 GCCGCGACGGGTCCCG 1

RESULT 165
ABK03622
ID ABK03622 standard; RNA; 17 BP.
XX
XX ABK03622;
AC
XX
XX 12-MAR-2002 (first entry)
DT
XX
XX Human CD20 DNazyme #76.
DE
XX

Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KM cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
KM muscular; CD20; neurite growth inhibitor gene; NOGO; hammetthead ribozyme;
KM DNazyme; inozyme; G-cleaver; amberzyme; zincyme; lymphoma; leukaemia;
KM B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KM human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KM MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KM inflammatory arthropathy; central nervous system injury;
KM cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KM chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KM Parkinson's disease; ataxia; Huntington's disease;
KM Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
XX Homo sapiens.
OS Synthetic.
OS
XX WO200159103-A2.
XX
XX 16-AUG-2001.
XX
XX 09-FEB-2001; 2001WO-US04273.
XX
XX 11-FEB-2000; 2000US-181797P.
XX 28-FEB-2000; 2000US-185516P.
XX 06-MAR-2000; 2000US-187128P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (CHOW/) CHOWRIRA B M.
XX
XX Blatt L, McSwiggen J, Chowrira BM;
XX
XX WPI; 2001-607195/69.
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
XX constructs, which down regulate expression of a CD20 gene or neurite
XX growth inhibitor gene useful for treating, e.g., lymphoma, leukemia,
XX and central nervous system injury -
XX
XX
XX Claim 30; Page 160; 200pp; English.

The invention relates to a nucleic acid molecule which down regulates
XX expression of a CD20 gene and a nucleic acid molecule which down
XX regulates expression of a neurite growth inhibitor gene (NOGO).
XX The nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
XX DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
XX possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN
XX motif) or an amberzyme (cleaving RNA with an NGN triplet), a zincyme
XX (cleaving RNA with a YG motif). The CD20-targeting nucleic acid is used
XX to cleave RNA of CD20 in the presence of a divalent cation that is
XX preferably Mg²⁺. Furthermore, it may be contacted with a cell to reduce
XX CD20 activity of the cell and treat a patient having a condition

CC associated with the level of CD20. The treatment may further comprise the
CC use of one or more therapies. In particular, the CD20 targeting
CC nucleic acid may be used to treat lymphoma, leukaemia, B-cell
CC lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky
CC low-grade or follicular NHL, lymphocytic leukaemia, HIV (human
CC immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL),
CC immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune
CC thrombocytopaenia, and inflammatory arthropathy. The NOGO-targeting
CC nucleic acid is used to cleave RNA of the NOGO gene in the presence of a
CC divalent cation that is preferably Mg²⁺. Furthermore, the nucleic acid
CC may be contacted with a cell to reduce NOGO activity of the cell and
CC treat a patient having a condition associated with the level of NOGO. The
CC treatment may further comprise the use of one or more therapies.
CC In particular, the NOGO-targeting nucleic acid may be used to treat
CC central nervous system (CNS) injury and cerebrovascular accident (CVA,
CC stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The
CC present sequence is a DNazyme molecule of the invention.

XX
XX Sequence 17 BP; 6 A; 4 C; 4 G; 3 U; 0 other;
XX
XX

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.8e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1701 TCCAAGAGTAAGCTGA 1717
Db 1 UCCAAGAGACUUGUGA 17

RESULT 166
ABK03757
ID ABK03757 standard; RNA; 17 BP.
XX
XX
XX ABK03757;
AC
XX
XX 12-MAR-2002 (first entry)
DT
XX
XX Human CD20 Amberzyme #106.
XX
XX

Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KM cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
KM muscular; CD20; neurite growth inhibitor gene; NOGO; hammetthead ribozyme;
KM DNazyme; inozyme; G-cleaver; amberzyme; zincyme; lymphoma; leukaemia;
KM B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KM human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KM MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KM inflammatory arthropathy; central nervous system injury;
KM cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KM chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KM Parkinson's disease; ataxia; Huntington's disease;
KM Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
XX Homo sapiens.
OS Synthetic.
OS
XX WO200159103-A2.
XX
XX 16-AUG-2001.
XX
XX 09-FEB-2001; 2001WO-US04273.
XX
XX 11-FEB-2000; 2000US-181797P.
XX 28-FEB-2000; 2000US-185516P.
XX 06-MAR-2000; 2000US-187128P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (CHOW/) CHOWRIRA B M.

XX Blact L, McSwiggen J, Chowrira BM;
 XX WPI; 2001-607195/69.
 DR Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 XX constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia,
 PT and central nervous system injury -
 XX
 XX Claim 30; Page 168; 200BP; English.
 PS
 XX The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOSO).
 CC The nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NVN
 CC motif) pr an amberzyme (cleaving RNA with an NGN triplet), a zinczyme
 CC (cleaving RNA with a YGY motif). The CD20-targeting nucleic acid is used
 CC to cleave RNA of CD20 in the presence of a divalent cation that is
 CC preferably Mg²⁺. Furthermore, it may be contacted with a cell to reduce
 CC CD20 activity of the cell and treat a patient having a condition
 CC associated with the level of CD20. The treatment may further comprise the
 CC use of one or more therapies. In particular, the CD20 targeting
 CC nucleic acid may be used to treat lymphoma, leukaemia, B-cell
 CC lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky
 CC low-grade or follicular NHL, lymphocytic leukaemia, HIV (human
 CC immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL),
 CC immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune
 CC thrombocytopenia, and inflammatory arthropathy. The NOSO-targeting
 CC nucleic acid is used to cleave RNA of the NOSO gene in the presence of a
 CC divalent cation that is preferably Mg²⁺. Furthermore, the nucleic acid
 CC may be contacted with a cell to reduce NOSO activity of the cell and
 CC treat a patient having a condition associated with the level of NOSO. The
 CC treatment may further comprise the use of one or more therapies.
 CC In particular, the NOSO-targeting nucleic acid may be used to treat
 CC central nervous system (CNS) injury and cerebrovascular accident (CVA,
 CC stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOSO expression. The
 CC present sequence is an amberzyme molecule of the invention.
 CC
 XX Sequence 17 BP; 5 A; 4 C; 4 G; 4 U; 0 other;
 SQ
 XX
 XX Query Match 1.0%; Score 13.8; DB 1; Length 17;
 XX Best Local Similarity 70.6%; Pred. No. 1.8e+02;
 XX Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
 QY 1700 TTCACAGAGATGACTG 1716
 Db 1 UCCCAAGACACUUCUG 17
 XX
 XX RESULT 167
 XX ABV78899
 XX ID ABV78899 standard; DNA; 17 BP.
 XX AC ABV78899;
 XX
 XX 03-JAN-2003 (first entry)
 XX
 XX Human HTPL scanning oligonucleotide SEQ ID 145.
 XX
 XX Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
 XX human testis expressed; Patched like protein; testis; adrenal; liver;
 XX male germ cell development; bone marrow; brain; kidney; lung; placenta;
 XX prostate; skeletal muscle; colon; male infertility; cancer; ss.
 XX
 XX Homo sapiens.
 XX

PN EP1223046-A2.
 XX
 XX 07-AUG-2002.
 XX
 XX 28-JAN-2002; 2002EP-0001167.
 PF
 XX 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 23-MAY-2001; 2001US-0864761.
 PR 09-OCT-2001; 2001US-0327898.
 XX
 XX (AEOMICA INC.
 PA
 XX Zhan J;
 PI
 XX WPI; 2002-676582/73.
 XX
 XX Novel isolated human testis expressed Patched like protein (HTPL),
 PT useful for identifying agonist and antagonist and specific binding
 PT partners, and for treating subjects having defects in HTPL -
 XX
 XX Example 2; Page 82; 718BP; English.
 PS
 XX The present invention relates to human testis expressed Patched like
 XX protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
 XX has two isoforms, with a few single base pair differences between the
 XX two. One of the single base pair changes introduces a premature stop
 XX codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
 XX shares an overall structure organisation with the Patched protein. The
 XX shared structural features strongly imply that HTPL plays a role similar
 XX to that of Patched, and is a potential tumour suppressor. HTPL is
 XX important in regulating male germ cell development, and the HTPL gene was
 XX mapped to human chromosome 10p12.1. HTPL and its coding sequence are
 XX useful for diagnosing a disorder caused by mutation in HTPL, and in
 XX therapy and manufacture of a medicament for treatment or prevention of
 XX such disorder associated with decreased expression or activity of human
 XX HTPL. Such disorders include disorders of testis, or adrenal, adult and
 XX foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
 XX skeletal muscle or colon function. HTPL proteins and nucleic acids are
 XX clinically useful diagnostic markers and potential therapeutic agents for
 XX male infertility and cancer. The present oligonucleotide was used in an
 XX example from the invention.
 XX
 XX Sequence 17 BP; 6 A; 8 C; 2 G; 1 T; 0 other;
 SQ
 XX
 XX Query Match 1.0%; Score 13.8; DB 1; Length 17;
 XX Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1518 GCACAGCTGACCAAC 1534
 Db 1 GCCCAGCTCACCAAC 17
 XX
 XX RESULT 168
 XX ABV80430/C
 XX ID ABV80430 standard; DNA; 17 BP.
 XX AC ABV80430;
 XX
 XX 03-JAN-2003 (first entry)
 XX
 XX Human HTPL scanning oligonucleotide SEQ ID 1676.
 XX
 XX Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
 XX human testis expressed; Patched like protein; testis; adrenal; liver;
 XX male germ cell development; bone marrow; brain; kidney; lung; placenta;
 XX prostate; skeletal muscle; colon; male infertility; cancer; ss.
 XX
 XX Homo sapiens.
 XX

```

OS Homo sapiens.
XX
XX EPI229046-A2.
XX
XX 07-AUG-2002.
XX
XX 28-JAN-2002; 2002EP-0001167.
XX
XX 30-JAN-2001; 2001WO-US00663.
XX 30-JAN-2001; 2001WO-US00664.
XX 30-JAN-2001; 2001WO-US00665.
XX 30-JAN-2001; 2001WO-US00667.
XX 30-JAN-2001; 2001WO-US00668.
XX 30-JAN-2001; 2001WO-US00669.
XX 23-MAY-2001; 2001US-0864761.
XX 09-OCT-2001; 2001US-0327898.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Zhan J;
XX
XX WPI, 2002-676582/73.
XX
XX Novel isolated human testis expressed Patched like protein (HTPL),
XX useful for identifying agonist and antagonist and specific binding
XX partners, and for treating subjects having defects in HTPL -
XX
XX Example 2; Page 283; 718pp; English.
XX
XX The present invention relates to human testis expressed Patched like
XX protein (HTPL, see ABV78759 to ABV78762 and AB898519 to AB898520). HTPL
XX has two isoforms, with a few single base pair differences between the
XX two. One of the single base pair changes introduces a premature stop
XX codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
XX shares an overall structure organisation with the Patched protein. The
XX shared structural features strongly imply that HTPL plays a role similar
XX to that of Patched, and is a potential tumour suppressor. HTPL is
XX important in regulating male germ cell development, and the HTPL gene was
XX mapped to human chromosome 10p12.1. HTPL and its coding sequence are
XX useful for diagnosing a disorder caused by mutation in HTPL, and in
XX therapy and manufacture of a medicament for treatment or prevention of
XX such disorder associated with decreased expression or activity of human
XX HTPL. Such disorders include disorders of testis, or adrenal, adult and
XX foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
XX skeletal muscle or colon function. HTPL proteins and nucleic acids are
XX clinically useful diagnostic markers and potential therapeutic agents for
XX male infertility and cancer. The present oligonucleotide was used in an
XX example from the invention.
XX
XX Sequence 17 BP; 5 A; 2 C; 1 G; 9 T; 0 other;
SQ
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 2186 ATGTGATGAATAAGCA 2202
Db 17 ATGTTATTAATAATGCA 1

```

```

XX
XX Homo sapiens.
XX
XX EPI239051-A2.
XX
XX 11-SEP-2002.
XX
XX 28-JAN-2002; 2002EP-0001165.
XX
XX 30-JAN-2001; 2001WO-US00663.
XX 30-JAN-2001; 2001WO-US00664.
XX 30-JAN-2001; 2001WO-US00665.
XX 30-JAN-2001; 2001WO-US00666.
XX 30-JAN-2001; 2001WO-US00667.
XX 30-JAN-2001; 2001WO-US00668.
XX 30-JAN-2001; 2001WO-US00669.
XX 30-JAN-2001; 2001WO-US00670.
XX 23-MAY-2001; 2001US-0864761.
XX 10-OCT-2001; 2001US-0328205.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Shannon M;
XX
XX WPI, 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
XX POSHL-1, useful for treating disorders associated with decreased
XX expression or activity of human POSHL1 -
XX
XX Example 2; SEQ ID NO 122; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
XX protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
XX acids (S1, AB883999), a sequence having 65% sequence identity to (S1),
XX (S1) having 95% deviations, especially conservative substitutions or a
XX fragment of the sequences comprising at least 8 contiguous amino acids.
XX Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
XX adaptor protein that interacts with Rho family small GTPases as well as
XX downstream components of the signal transduction pathway. (I) is useful
XX for identifying a specific binding partner. (I) and nucleic acids (II)
XX encoding (I) are useful for diagnosing, monitoring disease and treating
XX caused by altered expression of human POSHL1 including diagnosing and
XX treating cancer, they useful in the development of vaccines and (II) is
XX useful in gene therapy. (II) is useful for constructing microarrays which
XX are useful for measuring and for surveying gene expression and creating
XX transgenic non-human animals capable of producing the proteins. The
XX present sequence is that of a scanning oligonucleotide useful in examples
XX of the invention.
XX
XX Note: The present sequence did not form part of the printed
XX specification, but is based on sequence information supplied to Derwent
XX by the European Patent Office.
XX
XX Sequence 17 BP; 6 A; 4 C; 5 G; 2 T; 0 other;
SQ
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1564 TCGGCTGAGTCACGCTC 1580
Db 17 TCTGCTGAGTCACGCTC 1

```

XX Human, POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
 KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
 KW gene therapy; transgenic; ss.
 XX Homo sapiens.
 XX EPI239051-A2.
 XX 11-SEP-2002.
 XX PD
 XX 28-JAN-2002; 2002EP-0001165.
 XX PR
 XX 30-JAN-2001; 2001WO-US00663.
 XX PR 30-JAN-2001; 2001WO-US00664.
 XX PR 30-JAN-2001; 2001WO-US00665.
 XX PR 30-JAN-2001; 2001WO-US00666.
 XX PR 30-JAN-2001; 2001WO-US00667.
 XX PR 30-JAN-2001; 2001WO-US00668.
 XX PR 30-JAN-2001; 2001WO-US00669.
 XX PR 30-JAN-2001; 2001WO-US00670.
 XX PR 23-MAY-2001; 2001US-0864761.
 XX PR 10-OCT-2001; 2001US-0328205.
 XX PA (AEOM-) AEOMICA INC.
 XX P1 Shannon M;
 XX DR WPI; 2002-684061/74.
 XX PT Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
 PT POSHL-1, useful for treating disorders associated with decreased
 PT expression or activity of human POSHL1 -
 XX PS
 XX Example 2; SEQ ID NO 123; 60pp + Sequence listing; English.
 XX CC The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (SI, AB88399), a sequence having 65% sequence identity to (SI),
 CC (SI) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with Rho family small GTPases as well as
 CC downstream components of the signal transduction pathway. (I) is useful
 CC for identifying a specific binding partner. (II) and nucleic acids (II)
 CC encoding (I) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention.
 CC Note: The present sequence did not form part of the printed
 CC specification, but is based on sequence information supplied to Derwent
 CC by the European Patent Office.
 XX CC
 XX Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 other;
 SQ
 Query Match 1.0%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1563 TTCCGCTGAGTCAGCT 1579
 DB |||||
 17 TTCTGCTGAGTCAGCT 1

XX 29-MAY-2002 (first entry)
 DT
 XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6312.
 XX DE
 XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 XX Homo sapiens.
 XX OS
 XX WO200192524-A2.
 XX PN
 XX 06-DEC-2001.
 XX PD
 XX 25-MAY-2001; 2001WO-US16981.
 XX PF
 XX 26-MAY-2000; 2000US-207456P.
 XX PR 21-SEP-2000; 2000US-234687P.
 XX PR 27-SEP-2000; 2000US-236359P.
 XX PR 04-OCT-2000; 2000GB-0024263.
 XX PR 30-JAN-2001; 2001WO-US00661.
 XX PR 30-JAN-2001; 2001WO-US00662.
 XX PR 30-JAN-2001; 2001WO-US00663.
 XX PR 30-JAN-2001; 2001WO-US00664.
 XX PR 30-JAN-2001; 2001WO-US00665.
 XX PR 30-JAN-2001; 2001WO-US00666.
 XX PR 30-JAN-2001; 2001WO-US00667.
 XX PR 30-JAN-2001; 2001WO-US00668.
 XX PR 30-JAN-2001; 2001WO-US00669.
 XX PR 30-JAN-2001; 2001WO-US00670.
 XX PR 05-FEB-2001; 2001US-266860P.
 XX PA (AEOM-) AEOMICA INC.
 XX P1 Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;
 XX DR WPI; 2002-179446/23.
 XX PT New polypeptide, for raising antibodies that recognize hGDMLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMLP-1 -
 XX PS
 XX Disclosure; SEQ ID 6312; 214pp; English.
 XX CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
 CC hGDMLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.
 XX CC
 XX Sequence 17 BP; 3 A; 9 C; 4 G; 1 T; 0 other;
 SQ
 Query Match 1.0%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2050 GCACCTACCAGCTGACC 2106
DB 1 GCACCTCCAGCAGGCC 17
RESULT 172
ABN07681/C
ID ABN07681 standard; DNA, 17 BP.
AC ABN07681;
XX
XX 29-MAY-2002 (first entry)
DT
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7673.
DE
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
OS
XX WO200192524-A2.
PN
XX 06-DEC-2001.
PD
XX 25-MAY-2001; 2001WO-US16981.
PF
XX 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX
XX (ABOM-) AEOMICA INC.
PA
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
XX Disclosure; SEQ ID 7673; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement

CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
XX Sequence 17 BP; 8 A; 2 C; 6 G; 1 T; 0 other;
SQ
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2658 TTCTGTTTCTTCAG 2674
DB 17 TTCTGTTTCTTCAG 1
RESULT 173
ABN09083
ID ABN09083 standard; DNA, 17 BP.
XX
XX ABN09083;
AC
XX 29-MAY-2002 (first entry)
DT
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9075.
DE
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
OS
XX WO200192524-A2.
PN
XX 06-DEC-2001.
PD
XX 25-MAY-2001; 2001WO-US16981.
PF
XX 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX
XX (ABOM-) AEOMICA INC.
PA
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
XX Disclosure; SEQ ID 9075; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like

protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-1 can be used in gene therapy and vaccine production. The hGDMLP-1 nucleic acids can be used as probes to detect, characterise and quantify hGDMLP-1 nucleic acids in samples, as amplification substrates, to provide initial substrates for the recombinant engineering of hGDMLP-1 protein variants having desired phenotypic improvements, and for expressing the proteins. The hGDMLP-1 proteins or polypeptides may be used as immunogens to raise antibodies that specifically recognise hGDMLP-1 proteins, as standards in assays used to determine the concentration and/or amount specifically of hGDMLP proteins, as specific biomolecule capture probes for surface-enhanced laser desorption/ionisation, as therapeutic supplement in patients having specific deficiency in hGDMLP-1 production, and in vaccines or for replacement therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a disorder associated with the expression of hGDMLP-1, in particular heart and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22. The present sequence represents an oligomer used in the screening of the hGDMLP-1 sequence in the exemplification of the present invention.

N.B. The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequence.

Sequence 17 BP; 5 A; 5 C; 3 G; 4 T; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1397 ACCTGAGATGACCAT 1413
Db 1 ACCTGAGATGACCAT 17

RESULT 174

ABK26439

ID ABK26439 standard; DNA; 17 BP.

XX AC ABK26439;

DT 09-APR-2002 (first entry)

DE Waxy starch production genome altering oligonucleotide #95.

XX Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
KW o-methyl modification; LNA modification; phosphorothioate linkage;
KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
KW abiotic stress tolerance; improved nutritional value; hygromycin; primer;
KW amino acid over production; herbicide resistance; glyphosate resistance;
KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
KW porphyrin herbicide resistance; triazine resistance; disease resistance;
KW modified oil production; modified starch production; waxy starch;
KW altered floral morphology; male-sterile plant; albino mutant;
KW modified fatty acid content; reduced palmitate production; albino plant;
KW increased stearate production; reduced linolenic acid production;
KW photosynthetic process.

XX Solanum tuberosum.

OS Synthetic.

XX WO200192512-A2.

XX 06-DEC-2001.

PF 01-JUN-2001; 2001WO-US17672.

XX 01-JUN-2000; 2000US-208538P.

PR 30-OCT-2000; 2000US-244989P.

XX 27-MAR-2001; 2001US-0818875.

PA (UYDE) UNIV DELAWARE.
PI Kmiec EB, Gamper HB, Rice MC, Kim J;

XX WPI; 2002-106307/14.

DR New oligonucleotides with modified nuclease-resistant termini, useful
XX for creating plants with desired phenotypes, e.g. stress tolerance,
PT improved nutritional value, herbicide or disease resistance, or
PT modified oil production -

XX Claim 7; Page 151; 220pp; English.

XX The invention relates to an oligonucleotide for targeted alteration of a
CC genetic sequence, which comprises a single-stranded oligonucleotide
CC having a DNA domain. The DNA domain has at least one mismatch with
CC respect to the genetic sequence to be altered and further comprises
CC chemical modifications of the oligonucleotide. The chemical modifications
CC consist of o-methyl modification, an LNA modification, two or more
CC phosphorothioate linkages on a terminus, or a combination of any two or
CC more of these modifications. The oligonucleotides are useful for
CC directing repair or alteration of plant genetic information. The
CC oligonucleotides are particularly useful for creating plants with desired
CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
CC nutritional value (e.g. altering amino acid content of plants or
CC conferring amino acid over production), herbicide resistance (e.g.
CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
CC resistance, porphyrin herbicide resistance or triazine resistance),
CC disease resistance, modified oil production, modified starch production
CC (e.g. increased starch or production of waxy starch), altered floral
CC morphology (e.g. male-sterile plants) or modified fatty acid content
CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
CC The oligonucleotides are also useful for producing albino mutants for the
CC analysis of photosynthetic processes. This sequence represents a genome
CC altering oligonucleotide of the invention.

XX Sequence 17 BP; 8 A; 4 C; 2 G; 3 T; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1485 CAAAGAGCCAGACTTCA 1501

Db 1 CAAAGAGCTAACTTCA 17

RESULT 175

ID ABK26440 standard; DNA; 17 BP.

XX AC ABK26440;

DT 09-APR-2002 (first entry)

DE Waxy starch production genome altering oligonucleotide #96.

XX Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
KW o-methyl modification; LNA modification; phosphorothioate linkage;
KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
KW abiotic stress tolerance; improved nutritional value; hygromycin; primer;
KW amino acid over production; herbicide resistance; glyphosate resistance;
KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
KW porphyrin herbicide resistance; triazine resistance; disease resistance;
KW modified oil production; modified starch production; waxy starch;
KW altered floral morphology; male-sterile plant; albino mutant;
KW modified fatty acid content; reduced palmitate production; albino plant;
KW increased stearate production; reduced linolenic acid production;
KW photosynthetic process.

XX Solanum tuberosum.

OS Synthetic.

XX WO200192512-A2.

XX 06-DEC-2001.

PF 17-SEP-2002; 2002MO-IB04208.
 XX
 PR 17-SEP-2001; 2001FR-0011978.
 XX
 XX (MOLE-) MOLECULAR ENGINES LAB.
 PA
 XX
 PI Telerman A, Amson R, Tuijnder M;
 DR WPI; 2003-313353/30.
 XX
 XX New isolated nucleic acid, useful for treating viral diseases
 PT associated with tumors and cell degeneration, also related
 PT polypeptides, antibodies and transfected cells -
 XX
 PS Disclosure; Page 615; 720pp; French.
 XX
 XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15
 CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
 CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
 CC sequence that hybridizes to them under highly stringent conditions, or
 CC the complement of any of them, or the corresponding RNA. The novel
 CC isolated nucleic acids of the invention are useful as probes and primers
 CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
 CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
 CC and for production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human funkutin oligonucleotide of the invention.
 CC
 XX Sequence 17 BP; 2 A; 4 C; 3 G; 8 T; 0 other;
 SQ
 Query Match 1.0%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1898 GGAACACACAGAGATATC 1914
 DB 17 GGAATCACAGAGAGATC 1
 RESULT 178
 ID ACA09044 standard; RNA; 17 BP.
 XX
 AC ACA09044;
 XX
 DT 03-JUN-2003 (first entry)
 XX
 XX NFKB sub-unit modulating amberzyme substrate #207.
 KW Enzymatic nucleic acid, nuclear factor kappa B, NFKB, inozyme; zincyme;
 KW G-cleaver; amberzyme; cancer; RBL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; RBL-A-specific inhibitor;
 KW chemotherap; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection;

KW 88.
 XX
 OS Homo sapiens.
 XX
 XX US2002177568-A1.
 PN
 XX
 PD 28-NOV-2002.
 PF
 XX 23-MAY-2001; 2001US-0864785.
 XX
 XX 15-AUG-1994; 94US-0291932.
 PR 07-DEC-1992; 92US-0987132.
 PR 18-MAY-1994; 94US-0245466.
 PR 23-DEC-1996; 96US-0777916.
 XX
 PA (STIN/) STINCHOMB D T.
 PA (MCSW/) MCSWIGEN J.
 PA (DRAP/) DRAPER K G.
 XX
 PI Stinchcomb DT, Mcswigen J, Draper KG;
 DR WPI; 2003-340953/32.
 XX
 XX Novel enzymatic nucleic acid molecules which down regulates expression
 PT of a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases -
 XX
 PS Claim 3; Page 55; 72pp; English.
 XX
 XX The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFKB), where (I) is an inozyme, zincyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating RBL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of RBL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of RBL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, RBL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel
 CC enzymatic nucleic acid molecule.
 CC
 XX Sequence 17 BP; 3 A; 9 C; 5 G; 0 U; 0 other;
 SQ
 Query Match 1.0%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2004 AGCCCGAGGCGCCCG 2020
 DB 1 AGCCCGAGGCGCCCG 17
 RESULT 179
 ID ABZ64846 standard; RNA; 17 BP.
 XX
 AC ABZ64846;
 XX
 DT 21-MAR-2003 (first entry)
 XX

```
DE Human HER2 DNAzyme substrate #303.
XX
XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KM enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;
XX anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
XX WO200297114-A2.
XX
XX 05-DEC-2002.
XX
XX 29-MAY-2002; 2002WO-US16840.
XX
XX 29-MAY-2001; 2001US-294140P.
XX 06-JUN-2001; 2001US-296249P.
XX 10-SEP-2001; 2001US-318471P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcawiggen J;
XX
XX WPI; 2003-140484/13.
XX
XX Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX
XX Claim 4; Page 138; 185pp; English.
XX
XX The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytosolic, anti-HIV, and
CC anti-rheumatic activity. The nucleic acid molecules are useful for
CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
CC acids are also useful for treating breast, ovarian, colorectal, lung,
CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
CC The sequences shown in AB259889 - AB262216, AB264544 - AB265531,
CC AB266520 - AB266524, AB266530 - AB266585 represent substrate/target
CC sequences for the human ribozymes of the invention.
XX
SQ Sequence 17 BP; 5 A; 3 C; 6 G; 3 U; 0 other;
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1920 TCTTCTTGAGCGCTGCA 1936
DB 17 TCTTCTTGAGCGCTGCA 1
RESULT 180
AB265209
ID AB265209 standard; RNA; 17 BP.
XX
XX AB265209;
XX
XX 21-MAR-2003 (first entry)
XX
XX Human HER2 DNAzyme substrate #666.
XX
XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KM enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;
XX anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
XX WO200297114-A2.
XX
XX 05-DEC-2002.
XX
XX
```

```
XX
XX 29-MAY-2002; 2002WO-US16840.
XX
XX 29-MAY-2001; 2001US-294140P.
XX 06-JUN-2001; 2001US-296249P.
XX 10-SEP-2001; 2001US-318471P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcawiggen J;
XX
XX WPI; 2003-140484/13.
XX
XX Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX
XX Claim 4; Page 145; 185pp; English.
XX
XX The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytosolic, anti-HIV, and
CC anti-rheumatic activity. The nucleic acid molecules are useful for
CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
CC acids are also useful for treating breast, ovarian, colorectal, lung,
CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
CC The sequences shown in AB259889 - AB262216, AB264544 - AB265531,
CC AB266520 - AB266524, AB266530 - AB266585 represent substrate/target
CC sequences for the human ribozymes of the invention.
XX
SQ Sequence 17 BP; 4 A; 5 C; 5 G; 3 U; 0 other;
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.8e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 2269 CCACTCAAGTGCATGCGC 2285
DB 1 CCACTCAAGTGCATGCGC 17
RESULT 181
AAQ49011
ID AAQ49011 standard; DNA; 18 BP.
XX
XX AAQ49011;
XX
XX 25-MAR-2003 (updated)
XX 22-APR-1994 (first entry)
XX
XX Multimeric (SBP) antibody chain primer.
XX
XX SBP; specific binding pair members; antibody; RGDp;
KM replicable genetic display package; recombination; PCR;
XX polymerase chain reaction; ss.
XX
OS Synthetic.
XX
XX WO9319172-A1.
XX
XX 30-SEP-1993.
XX
XX 24-MAR-1993; 93WO-GB00605.
XX
XX 24-MAR-1992; 92GB-0006318.
XX 15-MAY-1992; 92WO-GB00883.
XX
XX (CAMP-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX (MEDI-) MEDICAL RES COUNCIL.
XX
XX Griffiths AD, Johnson KS, Smith AJH, Waterhouse P;
XX
```

PI Winter GP;
XX WPI; 1993-320739/40.
XX
XX Prod. of specific binding pair members, e.g. antibody chains -
PT by display on surface of replicable genetic display packages
XX
XX Disclosure; Page 58; 81pp; English.
XX
XX The primers (AAQ48987-Q49045) are used in the amplification of Kappa
CC and lambda-chain genes of various antibodies. These genes are then
CC recombined into the same replicon, resulting in very diverse libraries
CC of antibody chains, e.g. from unimmunised donors. It is also useful
CC for chain shuffling, mutagenesis, humanising and CDR imprinting.
CC (Updated on 25-MAR-2003 to correct FN field.)
CC
XX Sequence 18 BP; 7 A; 6 C; 3 G; 2 T; 0 other;
SQ

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1673 AACTTCGAGAGACCA 1689
Db 1 AACATCCAGATGACCA 17

RESULT 182
AAT05636
ID AAT05636 standard; DNA; 18 BP.
XX
XX AAT05636;
XX
XX 06-JUN-1996 (first entry)
XX
XX Primer F8-547S sense to bases 547-565 of factor VIII CDNA.
XX
XX Primer; amplify; polymerase chain reaction; PCR; diagnosis; intron 10;
KW substitution; factor V; activated protein C; APC; cleavage site;
KW resistance; thrombo-embolic disease; coagulation cascade; ss.
XX
XX Synthetic.
XX
XX W09529259-A1.
XX
XX 02-NOV-1995.
XX
XX 21-APR-1995; 95WO-NL00149.
XX
XX 22-APR-1994; 94EP-0201116.
XX
XX (BLOE-) STICHTING CENT LAB VAN DE BLOEDTRANSFUSI.
XX
XX Mertens K, Van Mourik JA, Voorberg JF;
XX
XX WPI; 1995-383004/49.
XX
XX Activated protein C resistant mutant factors V or VIII - useful for
PT detecting and treating disorders in the blood coagulation cascade
XX
XX Example 6; Page 23; 48pp; English.
XX
XX The sequences given in AAT05636-39 are primers which were used in the
CC construction of a mutated factor VIII molecule. The amplified CDNA
CC encodes a molecule in which Arg 562 is substituted for Ile. This
CC mutation occurs in the cleavage site for activated protein C (APC) which
CC confers resistance to APC cleavage. The novel factor VIII based protein
CC can be used for the treatment of disorders in the blood coagulation
CC cascade.
XX
XX Sequence 18 BP; 7 A; 2 C; 4 G; 5 T; 0 other;
SQ

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2531 TGGTAGAGACTTGAT 2547
Db 2 TGGTMAAAGACTTGAT 18

RESULT 183
AAT71737/c
ID AAT71737 standard; CDNA; 18 BP.
XX
XX AAT71737;
XX
XX 26-AUG-1997 (first entry)
XX
XX Purification tag of a TGF-beta fusion protein encoding CDNA.
XX
XX Transforming growth factor-beta fusion protein; wound healing;
KW artificial skin; surgery recovery time; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FT mat_peptide 1..18
FT /*tag= a
FT /function= Purification_tag
XX
XX W09639430-A1.
XX
XX 12-DEC-1996.
XX
XX 05-JUN-1996; 96WO-US08973.
XX
XX 06-JUN-1995; 95US-0470837.
XX
XX (CHEU/) CHEUNG D T.
XX (HALL/) HALL F L.
XX (NIMMI/) NIMMI M B.
XX (TUAN/) TUAN T.
XX (WU/) WU L.
XX
XX Cheung DT, Hall FL, Nimmi ME, Tuan T, Wu L;
XX
XX WPI; 1997-043065/04.
XX
XX P-PSDB; AAM18225.
XX
XX Prep. of transforming growth factor-beta fusion protein - useful to
PT reduce surgery recovery time and to prepare artificial skin
XX
XX Disclosure; Page 40; 59pp; English.
XX
XX A novel transforming growth factor-beta (TGF-beta) fusion protein
CC comprises a purification tag and a TGF active fragment. The present
CC sequence encodes a specifically claimed purification tag.
CC Additionally, the fusion protein may comprise proteinase-sensitive
CC linker sites and binding domain so the protein sequence may contain
CC some or all of the following elements: purification tag; proteinase
CC site; ECM binding site; proteinase site; TGF-beta. TGF-beta promotes
CC wound healing, and the fusion protein can be used to reduce surgery
CC recovery time and in the preparation of artificial skin. The inclusion
CC of a purification tag facilitates purification of the fusion protein.
CC The proteinase site is included to permit cleavage and release of the
CC purification tag after purification if desired. The extracellular
CC matrix binding site facilitates delivery of the fusion protein to the
CC desired site of action. Delivery of the TGF-beta to the site to be
CC treated reduces the amount of TGF-beta required to be administered to
CC be effective and reduces the concentration of circulating TGF-beta
CC which may result in undesirable effects.
XX
XX Sequence 18 BP; 6 A; 7 C; 0 G; 5 T; 0 other;
SQ

Query Match 1.0%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1879 GAGATGATGAAGATGAT 1895
 |||||
 DB 18 GTGATGATGATGATGAT 2

RESULT 184
 AAV48746/C
 ID AAV48746 standard; DNA; 18 BP.
 AC AAV48746;
 XX
 XX
 DT 15-OCT-1998 (first entry)
 XX
 XX
 DE Erbb-2 gene antisense oligonucleotide Erbb-2-38.
 XX
 XX
 KW Erbb-2; antisense oligonucleotide; modulate; gene expression; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 XX
 PN EP856579-A1.
 XX
 XX
 PD 05-AUG-1998.
 XX
 XX
 PF 31-JAN-1997; 97EP-0101531.
 XX
 XX
 PR 31-JAN-1997; 97EP-0101531.
 XX
 XX
 PA (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
 XX
 P1 Brysch W, Schlingensiepen K;
 XX
 DR WPI; 1998-400910/35.
 XX
 XX
 PT Preparation of antisense oligonucleotide(s) which lack long runs of
 PT consecutive guanosine or inosine - and have specific ratio of
 PT residues able to form two or three hydrogen bonds, have greater
 PT activity and reduced toxicity, used therapeutically or to modulate
 PT growth of cells in culture
 XX
 PS Claim 10; Fig 6a; 286pp; English.
 XX
 XX
 CC AAV48709-886 represent antisense oligonucleotides directed against the
 CC Erbb-2 gene. Of these, only oligonucleotides AAV48709-91 resulted
 CC in significant reduction in Erbb-2 protein expression, while
 CC oligonucleotides AAV48792-886 had little effect. The oligonucleotides
 CC exemplify the invention. The specification describes oligonucleotides
 CC that contain 8-30 nucleotides, which contain at most 8 nucleotides that
 CC can each form three hydrogen bonds to cytosine; do not contain four
 CC consecutive nucleotides able to form three H-bonds each to four
 CC consecutive cytosines; do not contain two sequences of three consecutive
 CC nucleotides each able to form three H-bonds to three consecutive
 CC cytosines, and the ratio between residues able to form two H-bonds each
 CC (2R) or three such bonds (3R) is given by 2R/3R = 0.33-0.72. The
 CC oligonucleotides are used to modulate expression of genes, particularly
 CC the genes for p53, Erbb-2, junb, junD, TGF-beta 1 or beta 2 to control
 CC proliferation of primary cell cultures (e.g. bone marrow stem, liver or
 CC kidney cells, osteoclasts, osteoblasts and/or keratinocytes). The
 CC oligonucleotides can also be used to analyse function of proteins (by
 CC altering their expression or activity) and therapeutically, e.g. in
 CC cases of cancer or (targeting TGF) for stimulating the immune system.
 CC
 XX
 XX
 SQ Sequence 18 BP; 4 A; 6 C; 4 G; 4 T; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2317 CATCAGAGTGTGTCTG 2333

DB 17 CACCAGAGTGTGTGTG 1
 |||||
 |||||

RESULT 185
 AAX27574
 ID AAX27574 standard; DNA; 18 BP.
 XX
 XX
 AC AAX27574;
 XX
 XX
 DT 27-MAY-1999 (first entry)
 XX
 XX
 DE RT-PCR primer RT-NTRNA7.
 XX
 XX
 KW Influenza antigen; fusion product; extracellular; membrane protein;
 KW M2 protein; vaccine; human; animal; pig; horse; RT-PCR; primer; ss.
 XX
 OS Synthetic.
 XX
 XX
 PN WO9907839-A2.
 XX
 XX
 PD 18-FEB-1999.
 XX
 XX
 PF 05-AUG-1998; 98WO-EP05106.
 XX
 XX
 PR 05-AUG-1997; 97EP-0202434.
 XX
 XX
 PA (VIAA-) VIAAMS INTERUNIVERSITAIR INST BIOTECHNOG.
 XX
 PI Fiers W, Min Jou W, Neirynck S;
 XX
 XX
 DR WPI; 1999-167416/14.
 XX
 XX
 PT New influenza antigens for use in vaccines - comprising a fusion
 PT product of the extracellular part of a conserved influenza
 PT protein and a presenting carrier
 XX
 XX
 PS Disclosure; Fig 29; 100pp; English.
 XX
 XX
 CC The invention relates to new influenza antigens that comprise a fusion
 CC product of at least the extracellular part of a conserved influenza
 CC membrane protein (or a functional fragment) and a presenting carrier.
 CC The membrane protein consists of the extracellular part of the influenza
 CC M2 protein. The influenza antigens can be used in the preparation of a
 CC vaccine against influenza for humans and animals, e.g. pigs and horses.
 CC The vaccines can be direct vaccines, e.g. vaccines containing the fusion
 CC products or indirect, DNA vaccines.
 CC
 XX
 XX
 SQ Sequence 18 BP; 7 A; 0 C; 6 G; 5 T; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1821 GAGATGTTGAAGATG 1837
 |||||
 DB 2 GTGATGATTTGAAGATG 18

RESULT 186
 AAV99371/C
 ID AAV99371 standard; cDNA; 18 BP.
 XX
 XX
 AC AAV99371;
 XX
 XX
 DT 25-MAR-1999 (first entry)
 XX
 XX
 DE cDNA encoding a peptide comprising a purification tag.
 XX
 XX
 KW Proteinase site; bone morphogenetic fusion protein; bone binding site;
 KW bone morphogenetic protein; transforming growth factor beta;
 KW active fragment; wound healing; bone growth; purification tag; ss.
 XX

OS Synthetic.
XX Key Location/Qualifiers
FH CDS 1..18
FT /*tag= a
FT /note= "encodes a purification tag"
XX
XX MO9855137-A1.
XX
XX 10-DEC-1998.
XX
XX 02-JUN-1998; 98WO-US11189.
XX
XX 03-JUN-1997; 97US-0868452.
XX
XX (HALL/) HALL F L.
XX (HANE/) HAN B.
XX (NIMN/) NIMNI M E.
XX (SHOR/) SHORS E C.
XX (WUL/) WU L.
XX
XX Hall FL, Han B, Nimni ME, Shors EC, Wu L;
XX
XX WPI: 1999-059875/05.
XX P-PSDB; AAM84203.
XX
XX New bone morphogenetic fusion proteins - comprising a purification
XX tag and a bone morphogenetic active fragment, used for enhancing
XX wound healing or bone growth
XX
XX
XX Disclosure; Page 37; 64pp; English.
XX
XX The present sequence encodes a peptide comprising a purification tag
XX that was used in the creation of the bone morphogenetic fusion proteins
XX of the invention. The bone morphogenetic fusion protein may contain some
XX or all of the following elements: a purification tag, a proteinase site,
XX an ECM/bone binding site, a second proteinase site, and a bone
XX morphogenetic protein active fragment. The fusion proteins of the
XX invention also includes proteins that have transforming growth factor
XX beta active fragments instead of bone morphogenetic protein active
XX fragments. The bone morphogenetic fusion proteins can be used for
XX enhancing wound healing or bone growth.
XX
XX Sequence 18 BP; 6 A; 7 C; 0 G; 5 T; 0 other;
SQ
Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1879 GAGATGATGAGATGAT 1895
Db 18 GTGATGATGATGATGAT 2
RESULT 187
ID AAA52031 standard; cDNA; 18 BP.
XX
XX AAA52031;
XX
XX 19-DEC-2000 (first entry)
XX
XX Antisense oligonucleotide directed against PI3K p85 subunit.
XX
XX Phosphatidylinositol 3-kinase; PI3K; p85; p110; heterodimer;
XX hormone; growth factor; receptor; antisense; inhibition;
XX expression; diagnosis; modulation;
XX growth factor mediated cell transformation; mitogenesis;
XX protein trafficking; cell survival; cell proliferation;
XX DNA synthesis; apoptosis; neurite outgrowth; insulin-stimulated
XX glucose transport; ss.
XX
XX Synthetic.
OS

XX
XX US6100090-A.
XX
XX 08-AUG-2000.
XX
XX 25-JUN-1999; 99US-0344521.
XX
XX 25-JUN-1999; 99US-0344521.
XX
XX 25-JUN-1999; 99US-0344521.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Cowsett LM;
XX
XX WPI: 2000-542426/49.
XX
XX
XX Antisense compounds targeted to the coding region of human
XX phosphatidylinositol 3-kinase (PI3K) p85 and inhibiting PI3K p85
XX expression, useful for treating disorders associated with PI3K p85
XX expression
XX
XX Example 15; Column 39; 32pp; English.
XX
XX The phosphatidylinositol 3-kinases (PI3Ks) represent a ubiquitous
XX family of heterodimeric lipid kinases that are found in association
XX with the cytoplasmic domain of hormone and growth factor receptors
XX and oncogene products. PI3Ks act as downstream effectors of these
XX receptors, are recruited upon receptor stimulation and mediate the
XX activation of second messenger signaling pathways. The PI3 Kinase
XX enzyme consists of a 110kD catalytic subunit (p110) associated with
XX an 85kD regulatory subunit (p85) and it is through the SH2 domains
XX of the p85 subunit that the enzyme associates with the membrane
XX bound receptors. PI3Ks have been implicated in many cellular
XX activities including growth factor mediated cell transformation,
XX mitogenesis, protein trafficking, cell survival and proliferation,
XX DNA synthesis, apoptosis, neurite outgrowth and insulin-stimulated
XX glucose transport. Antisense compounds directed against PI3K p85 and
XX which inhibit its expression are useful as diagnostics and research
XX reagents, and as a component of kits, which can be used for detecting
XX the level of PI3K p85 in a sample. The compounds may be administered to
XX an animal or human suspected of having a disease or disorder which can
XX be treated by modulating the expression of PI3K p85. The compounds may
XX further be useful prophylactically, e.g., to prevent or delay
XX infection, inflammation or tumour formation. The target site of
XX this antisense molecule is nucleotide 1674 of the coding region of
XX the PI3K p85 subunit (See GENSEQ record AAA52007).
XX
XX Sequence 18 BP; 4 A; 5 C; 1 G; 8 T; 0 other;
SQ
Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2530 TTGCTAGAGACTTGCA 2546
Db 17 TTGCTAGAGACTTGCA 1
RESULT 188
ID AAA48791 standard; DNA; 18 BP.
XX
XX AAA48791;
XX
XX 08-SEP-2000 (first entry)
XX
XX Human G-alpha-16 antisense oligonucleotide ISIS# 20848.
XX
XX Human; G-alpha-16; G protein; cytosolic; hyperproliferative disorder;
XX cancer; inflammation; infection; antisense inhibition; ss.
XX
XX Homo sapiens.
XX
XX
XX WO200032817-A1.
FN

XX 08-JUN-2000.
PD 25-AUG-1999; 99WO-US19613.
XX 03-DEC-1998; 98US-0205143.
XX (ISIS-) ISIS PHARM INC.
XX Cowert LM;
PI WPI; 2000-412354/35.
DR A new antisense compound for inhibiting the expression of human
PT G-alpha-16 and treating, preventing or delaying infections,
PT inflammation or hyperproliferative disorders such as cancer -
XX Claim 3; Page 73; 100pp; English.
XX The present sequence is an antisense oligonucleotide used to
CC modulate expression of G-alpha-16. G-alpha-16 is a human G protein which
CC interacts differentially with several receptor types including members
CC of the oploid and chemokine receptor families. A series of antisense
CC oligonucleotides have been designed to target different regions of the
CC human G-alpha-16 RNA. They may be used to inhibit the expression of
CC G-alpha-16 in human cells and tissues and thus to treat diseases
CC associated with G-alpha-16, such as hyperproliferative disorders,
CC especially cancer. Infections, inflammation or tumour formation can
CC be prevented or delayed. The compounds can be used in research and
CC diagnostics in sandwich and other assays.
CC Note: The sequence has a phosphorothioate backbone and may be
CC either an oligodeoxynucleotide or a chimeric oligonucleotide
CC containing 2'-methoxyethyl (2'-MOE) wings and a deoxy gap. The ISIS
CC number given above corresponds to the oligodeoxynucleotide sequence.
XX Sequence 18 BP; 2 A; 7 C; 4 G; 5 T; 0 other;
SQ
Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1354 CCAGCGCTCGAAGAGA 1370
DB 17 CCAAGTGCCTGGAGAGA 1
RESULT 189
AAA23501
ID AAA23501 standard; DNA; 18 BP.
XX AAA23501;
AC 19-JUN-2000 (first entry)
XX
DT Clone vql_1 hybridisation probe, SEQ ID NO:119.
DE
XX Human; secreted protein; cancer; tumour; cardiovascular disorder;
KM blood disorder; haemophilia; autoimmune disease; diabetes; inflammation;
KM infection; fungal; bacterial; viral; HIV; allergy; arthritis;
KM neurodegenerative disease; asthma; contraceptive; hybridisation probe;
KM ss.
XX Homo sapiens.
OS
XX WO200011015-A1.
PN
XX 02-MAR-2000.
PD
XX 24-AUG-1999; 99WO-US19351.
PF
XX 24-AUG-1998; 98US-0097638.
PR 24-AUG-1998; 98US-0097659.
PR 09-SEP-1998; 98US-0099618.
PR

PR 28-SEP-1998; 98US-0102092.
PR 25-NOV-1998; 98US-0109978.
PR 23-DEC-1998; 98US-0113645.
PR 23-DEC-1998; 98US-0113646.
PR 23-AUG-1999; 99US-0379246.
XX (ALPH-) ALPHAGENE INC.
XX Valenzuela D, Yuan O, Hoffman H, Hall J, Rapiejko P;
PI WPI; 2000-224657/19.
DR
XX New secreted or transmembrane proteins and polynucleotides encoding
PT them, useful for treating neurodegenerative disorders, autoimmune
PT diseases and cancer -
XX Disclosure; Page 345; 357pp; English.
XX The invention relates to 40 human secreted proteins (AAV94981-Y95020),
CC and cDNA sequences encoding them (AAA23423-A23462). The secreted
CC proteins of the invention include those that are thought to be only
CC partially secreted, i.e., transmembrane proteins. The proteins of the
CC invention may exhibit one or more activities selected from the following:
CC cytokine activity; cell proliferation; differentiation; immune
CC modulation; haematopoiesis regulation; tissue growth activity;
CC activin/inhibin activity; chemotactic/chemokinetic activity; haemostatic
CC and thrombolytic activity; anti-inflammatory activity; and tumour
CC inhibition activity. The proteins may be administered to patients as
CC vaccines, and the nucleotides may be used as part of a gene therapy
CC regime. Diseases or conditions that may be treated using the proteins or
CC nucleotides of the invention include autoimmune diseases; genetic
CC disorders; haemophilia; cardiovascular diseases; cancer; bacterial,
CC fungal and viral infections, especially HIV; multiple sclerosis;
CC rheumatoid arthritis; pulmonary inflammation; Guillain-Barre syndrome;
CC insulin dependent diabetes mellitus; and allergic reactions such as
CC asthma and anaemia. They may also be used for treating wounds, burns,
CC ulcers, osteoporosis, osteoarthritis, periodontal diseases, Alzheimer's
CC disease, Parkinson's disease, Huntington's disease and ankyrotrophic
CC lateral sclerosis (ALS). Proteins with activin/inhibin activity may
CC additionally be useful as contraceptives. Nucleic acid sequences of the
CC invention may be used in chromosome mapping, and as a source of
CC diagnostic primers and probes. Sequences AAA23463-A23502 represent
CC hybridisation probes which may be used to isolate the cDNA clones of the
CC invention.
XX Sequence 18 BP; 6 A; 5 C; 6 G; 1 T; 0 other;
SQ
Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1493 CAGACTTCAGCAGCCAG 1509
DB 1 CAGACATGACGACGCCAG 17
RESULT 190
AAZ59167/C
ID AAZ59167 standard; DNA; 18 BP.
XX AAZ59167;
AC 20-APR-2000 (first entry)
XX
DT Hexa(his) oligonucleotide for MWPep-MWPmp10-(His)6-linker-Met-Proins.
DE
XX Fusion protein; Bacillus; cell wall protein; promoter; cleavage site;
KM TEV protease; PCR primer; ss.
XX Synthetic.
OS
XX JPL1341991-A.
PN
XX

PD 14-DEC-1999.
XX
XX 30-MAR-1999; 99JP-0089488.
XX
XX 31-MAR-1998; 98JP-0087339.
PR
XX (ITOH-) ITOHAM FOODS INC.
PA (UDAK/) UDAKA S.
XX
XX Sato S, Higashikuni N, Kudo T, Kondo M;
PI WPI; 2000-101697/09.
XX
XX A DNA coding a new fused protein and preparation of a useful peptide
PT through its expression -
XX
XX Example 1; Page 8; 43pp; Japanese.
XX
XX The invention relates to a DNA construct encoding a fusion protein
CC comprising a Bacillus species cell wall protein fused to a cleavage
CC peptide and a heterologous protein. The fusion construct is placed
CC downstream of a Bacillus species promoter sequence. This sequence
CC represents an oligonucleotide coding for the (His)6 part of the
CC construct MMPsp-MPmp10-(His)6-Linker-Met-Proinsulin. This construct
CC comprises the Bacillus brevis middle wall protein mp10 linked to the
CC proinsulin protein via a cleavable linker sequence.
CC
SQ Sequence 18 BP; 6 A; 7 C; 0 G; 5 T; 0 other;
XX
XX
XX Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1879 GAGATGATGAGATGAT 1895
DB 18 GTGATGATGATGATCAT 2
XX
XX
XX RESULT 191
AAZ59168
XX ID AAZ59168 standard; DNA; 18 BP.
XX
XX AC AAZ59168;
XX
XX 20-APR-2000 (first entry)
DT
XX Hexa (His) oligonucleotide for MMPsp-MPmp10-(His)6-Linker-Met-Proins.
DE Fusion protein; Bacillus; cell wall protein; promoter; cleavage site;
KW TEV protease; PCR primer; ss.
XX
XX Synthetic.
OS
XX JP1341991-A.
XX
XX 14-DEC-1999.
PD
XX 30-MAR-1999; 99JP-0089488.
PF
XX 31-MAR-1998; 98JP-0087339.
PR
XX (ITOH-) ITOHAM FOODS INC.
PA (UDAK/) UDAKA S.
XX
XX Sato S, Higashikuni N, Kudo T, Kondo M;
PI WPI; 2000-101697/09.
XX
XX A DNA coding a new fused protein and preparation of a useful peptide
PT through its expression -
XX
XX Example 1; Page 8; 43pp; Japanese.
XX

CC The invention relates to a DNA construct encoding a fusion protein
CC comprising a Bacillus species cell wall protein fused to a cleavage
CC peptide and a heterologous protein. The fusion construct is placed
CC downstream of a Bacillus species promoter sequence. This sequence
CC represents a reverse oligonucleotide coding for the (His)6 part of the
CC construct MMPsp-MPmp10-(His)6-Linker-Met-Proinsulin. This construct
CC comprises the Bacillus brevis middle wall protein mp10 linked to the
CC proinsulin protein via a cleavable linker sequence.
CC
SQ Sequence 18 BP; 5 A; 0 C; 7 G; 6 T; 0 other;
XX
XX
XX Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1879 GAGATGATGAGATGAT 1895
DB 1 GTGATGATGATGATCAT 17
XX
XX
XX RESULT 192
AAZ59072
XX ID AAZ59072 standard; RNA; 18 BP.
XX
XX AC AAZ59072;
XX
XX 11-APR-2000 (first entry)
DT
XX HIV-1 TAR oligonucleotide target sequence #3.
DE
XX Antiviral; antibacterial; antifungal; anticancer; detection; TAR; RRE;
KW fluorescence resonance energy transfer; tar; HIV-1; Rev response element;
KW autoimmune disease; trans-activation regulatory region; ss.
XX
XX Human immunodeficiency virus type 1.
OS
XX WO9964625-A2.
XX
XX 16-DEC-1999.
PD
XX 04-JUN-1999; 99WO-GB01761.
PF
XX 05-JUN-1998; 98GB-0012196.
PR 02-MAR-1999; 99GB-0004790.
XX
XX (RIBO-) RIBOTARGETS LTD.
PA
XX Karn J, Prescott CD;
PI WPI; 2000-097545/08.
XX
XX Identifying compounds that bind to target RNA, potentially useful for
PT treating infections, tumors and autoimmune diseases -
XX
XX Examples; Page 31; 82pp; English.
XX
XX The invention relates to a method of determining if a compound binds to
CC a target RNA by treating a test compound with a reporter (R) labelled
CC with a donor or acceptor group and labelled target RNA, labelled with
CC the complementary donor or acceptor group, and measuring the
CC fluorescence from fluorescent groups associated with a compound; target
CC RNA complex in presence of the test compound and comparing the result
CC with a standard. The oligonucleotides AAZ59070-259071 anneal to form a
CC double stranded oligonucleotide containing the HIV-1 tat protein binds.
CC The complex is labelled with 6-carboxyfluorescein and is used as a target for the
CC binding of a labelled ADP-1 protein. Detection of the complex is by
CC fluorescence resonance energy transfer (FRET). The method is used to
CC identify compounds that interfere with interaction between the target RNA
CC and ligands or proteins. Compounds that are identified are potentially
CC useful for treating infections (viral, bacterial or fungal), cancer
CC and autoimmune diseases. The compounds are preferably directed to the
CC TAR and RRE regions of human immunodeficiency virus RNA and inhibit

```

CC      viral replication.
XX
SQ      Sequence 18 BP; 5 A; 4 C; 6 G; 3 U; 0 other;

Query Match      1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 1.9e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY      1490 AGCCAGACTTCAGCAGC 1506
DB      1 AGCCAGAUUUGACGAGC 17

RESULT 193
AAZ44139/C
ID      AAZ44139 standard; DNA; 18 BP.
XX
AC      AAZ44139;
XX
DT      24-MAR-2000 (first entry)
XX
DE      Human EGR-1 DNA antisense primer #24161.
XX
KW      EGR-1; early growth response 1; antisense; inhibition; human; primer;
KW      anti-inflammatory; cytostatic; antiviral; detection; diagnosis;
KW      viral infection; inflammation; tumor; ss.
XX
OS      Homo sapiens.
XX
PN      US6008048-A.
XX
PD      28-DEC-1999.
XX
PF      04-DEC-1998; 98US-0205921.
XX
PR      04-DEC-1998; 98US-0205921.
XX
PA      (ISIS-) ISIS PHARM INC.
XX
PI      Monia BP, Cowsett LM;
XX
DR      WPI; 2000-096375/08.
XX
PT      Antisense oligonucleotides that inhibit expression of human early
PT      growth response-1, useful for diagnosis, treatment and prevention of
PT      tumors, inflammation and infection -
XX
PS      Example 15; Column 37-38; 31pp; English.
XX
CC      This invention describes novel antisense oligonucleotides (I) capable of
CC      inhibiting expression of human EGR-1 (early growth response-1). The
CC      products of the invention have anti-inflammatory, cytostatic and
CC      antiviral activity. (I) was tested for its effects on EGR-1 mRNA levels
CC      by real-time polymerase chain reaction (PCR), results indicated that 60%
CC      inhibition was achieved. When (I) was modified by 2'-O-methoxyethyl
CC      substitution of the first 4 and last 4 residues, and by replacing any C
CC      in these flanking regions with 5-methyl-C, the degree of inhibition was
CC      increased to 71%. (I) is used to inhibit expression of EGR-1 in cells
CC      and tissues in vitro, for research or diagnosis, e.g. detecting EGR-1
CC      encoding nucleic acid. (II) may also be used to treat or prevent
CC      EGR-1-associated diseases, particularly viral infections, inflammation
CC      and tumors. AAZ44124-Z44165 represent antisense primers used to inhibit
CC      the human EGR-1 protein.
XX
SQ      Sequence 18 BP; 2 A; 4 C; 9 G; 3 T; 0 other;

Query Match      1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1924 CTTGAGGCTGCACACA 1940
DB      17 CTTGAGGCTGCACCCA 1

```

```

RESULT 194
AAZ36560
ID      AAZ36560 standard; DNA; 18 BP.
XX
AC      AAZ36560;
XX
DT      22-FEB-2000 (first entry)
XX
DE      Probe hybridising to nucleotides of exon 28 of the MLL-1 gene.
XX
KW      Major breakpoint region; mbr; MLL-1 gene; chromosome aberration;
KW      acute lymphoblastic leukaemia-1; ALL-1; probe; peptide nucleic acid;
KW      haemopoietic malignancy; cancer; inborn constitutl disease;
KW      herbicide resistance gene; ss.
XX
OS      Synthetic.
XX
PN      Homo sapiens.
XX
PD      WO9957309-A1.
XX
PF      11-NOV-1999.
XX
PR      04-MAY-1999; 99WO-DK00245.
XX
PA      04-MAY-1998; 98DK-0000615.
XX
PI      (DAKO-) DAKO AS.
XX
DR      Pluzek K, Nielsen KV, Adelhorst K;
XX
PT      WPI; 2000-038821/03.
XX
PT      Detection of chromosome aberrations, used for detecting diseases and
PT      disorders, infections, and plant alterations related to e.g. herbicide
PT      resistance -
XX
PS      Disclosure; Page 40; 63pp; English.
XX
CC      AAZ36520-41 (set 1) and AAZ36542-61 (set 2) represent two sets of probes
CC      which flank each site of the major breakpoint region (mbr) of the MLL-1
CC      gene. The MLL gene is associated with acute lymphoblastic leukaemia-1
CC      (ALL-1). The probes are selected from the lower strand of the MLL-1
CC      gene, and so hybridise to the upper strand. The probes are used to
CC      demonstrate the method of the invention. The specification describes a
CC      method for the detection of chromosome aberrations in eukaryotic samples
CC      uses sets of peptide nucleic acid (PNA) probes in hybridisation
CC      reactions. The method comprises using at least 2 sets of hybridisation
CC      probes, where at least one set comprises one or more PNA probes capable
CC      of hybridising to specific nucleic acid sequences related to a potential
CC      aberration in a chromosome. The methods can be used for the detection of
CC      chromosome aberrations. They can be used for the diagnosis of disorders
CC      and diseases related to chromosomal aberrations or abnormalities such as
CC      e.g. haemopoietic malignancies, cancers and inborn constitutl diseases.
CC      The method may be used for detecting viral sequences and their
CC      localization in the chromosome. In plant biology, the methods can be
CC      used for monitoring the efficiency of transferring herbicide resistance
CC      genes to a plant.
XX
SQ      Sequence 18 BP; 3 A; 2 C; 7 G; 6 T; 0 other;

Query Match      1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2351 TGTGGAGATCTTCACCT 2367
DB      2 TGTGGAGATGTTGACT 18

RESULT 195
AAE74454

```

ID	AAAF74454 standard; DNA; 18 BP.
XX	AAAF74454 standard; DNA; 18 BP.
XX	AAAF74454;
AC	AAAF74454;
DT	09-MAY-2001 (first entry)
XX	09-MAY-2001 (first entry)
DE	Human PRO2 gene-specific sequencing primer SEQ ID NO:40.
XX	Human, PRO; PROX; cytostatic; immunomodulatory; reproduction;
KW	gene therapy; cell proliferation; differentiation disorder; cancer;
KW	immune associated disorder; gestational disease; pre-clampsia;
KW	PCR primer; sequencing primer; ss.
XX	PCR primer; sequencing primer; ss.
OS	Homo sapiens.
PN	WO200110902-A2.
PD	15-FEB-2001.
XX	15-FEB-2001.
PF	11-AUG-2000; 2000WO-US21857.
XX	11-AUG-2000; 2000WO-US21857.
PR	11-AUG-1999; 99US-0148433.
PR	10-AUG-2000; 2000US-0148433.
PA	(CURA-) CURAGEN CORP.
XX	(CURA-) CURAGEN CORP.
P1	Shimkets RA, Fernandes E;
DR	WPI, 2001-147509/15.
XX	WPI, 2001-147509/15.
PT	Nucleic acids encoding secreted polypeptides, designated PROX
PT	polypeptides, useful for treating a syndrome associated with a
XX	PROX-associated disorder, e.g. cancer -
PS	Example 2; Page 119; 166pp; English.
XX	Example 2; Page 119; 166pp; English.
CC	The present invention describes isolated nucleic acids encoding secreted
CC	polypeptides, designated PROX polypeptides (i.e. a PRO polypeptide where
CC	X is an integer from 1 to 17). PROX polypeptides have cytostatic,
CC	immunomodulatory and reproduction activities, and can be used in gene
CC	therapy, and as PROX antagonists and PROX agonists. PROX polypeptides,
CC	nucleic acids and antibodies are useful in the manufacture of a
CC	medicament for treating a syndrome associated with a PROX-associated
CC	disorder, e.g. a cell proliferation and/or differentiation disorder
CC	(e.g. cancer or immune associated disorders) and a gestational disease
CC	(e.g. pre-clampsia). They are also used for screening for a modulator of
CC	activity or of latency or predisposition to a PROX-associated disorder.
CC	AAAF74452 to AAFF7448 encode the specifically claimed human PROX
CC	polypeptides PRO1 to PRO17 given in AAB70531 to AAB70547. The present
CC	sequence represents a primer used in an example from the present
CC	invention.
XX	invention.
SQ	Sequence 18 BP; 6 A; 8 C; 3 G; 1 T; 0 other;
QY	Sequence 18 BP; 6 A; 8 C; 3 G; 1 T; 0 other;
Db	2 CTACCAAGAGCCAGCC 18
QY	1481 CGACCAAGAGCCAGAC 1497
Db	2 CTACCAAGAGCCAGCC 18
RESULT 196	Query Match 1.0%; Score 13.8; DB 1; Length 18;
AAAF74457/C	Best Local Similarity 88.2%; Pred. No. 1.9e+02;
AAAF74457 standard; DNA; 18 BP.	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
AAAF74457;	
09-MAY-2001 (first entry)	
Human PRO2 gene-specific sequencing primer SEQ ID NO:43.	

KW	Human; PRO; PROX; cytostatic; immunomodulatory; reproduction;
KV	gene therapy; cell proliferation; differentiation disorder; cancer;
KM	immune associated disorder; gestational disease; pre-clampsia;
KX	PCR primer; sequencing primer; ss.
OS	Homo sapiens.
PN	WO200110902-A2.
PD	15-FEB-2001.
PF	11-AUG-2000; 2000WO-US21857.
PR	11-AUG-1999; 99US-0148433.
PR	10-AUG-2000; 2000US-0148433.
PA	(CURA-) CURAGEN CORP.
PI	Shimkets RA, Fernandes E;
DR	WPI; 2001-147509/15.
PT	Nucleic acids encoding secreted polypeptides, designated PROX
PT	polypeptides, useful for treating a syndrome associated with a
PT	PROX-associated disorder, e.g. cancer -
PS	Example 2; Page 119; 16pp; English.
XX	The present invention describes isolated nucleic acids encoding secreted
CC	polypeptides, designated PROX polypeptides (i.e. a PRO polypeptide where
CC	X is an integer from 1 to 17). PROX polypeptides have cytostatic,
CC	immunomodulatory and reproduction activities, and can be used in gene
CC	therapy, and as PROX antagonists and PROX agonists. PROX polypeptides,
CC	nucleic acids and antibodies are useful in the manufacture of a
CC	medicament for treating a syndrome associated with a PROX-associated
CC	disorder, e.g. a cell proliferation and/or differentiation disorder
CC	(e.g. cancer or immune associated disorders) and a gestational disease
CC	(e.g. pre-clampsia). They are also used for screening for a modulator of
CC	activity or of latency or predisposition to a PROX-associated disorder.
CC	AAAF74432 to AAFF74448 encode the specifically claimed human PROX
CC	polypeptides PRO1 to PRO17 given in AAB70531 to AAB70547. The present
CC	sequence represents a primer used in an example from the present
CC	invention.
XX	
SQ	Sequence 18 BP; 1 A; 3 C; 8 G; 6 T; 0 other;
	Query Match 1.0%; Score 13.8; DB 1; Length 18;
	Best Local Similarity 88.2%; Pred. No. 1.9e+02;
	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	1481 CGACCAAGAGCCGAGAC 1497
DB	17 CTACCAAGAACCGAGCC 1
	RESULT 197
ID	AAFS6051
AC	AAFS6051 standard; DNA; 18 BP.
XX	AAFS6051;
XX	
DT	18-APR-2001 (first entry)
XX	
DE	HBV DNA polymerase gene MS52V/I mutation probe HBPR463.
XX	
XX	HBV; hepatitis B virus; DNA polymerase gene; anti-HBV drug resistance;
KM	mutation detection; probe; ss.
XX	
OS	Hepatitis B virus.
XX	
PN	WO200104358-A2.
XX	
PD	18-JAN-2001.

```

XX 05-JUL-2000; 2000WO-EP06306.
XX
XX 08-JUL-1999; 99EP-0870148.
XX 13-JUL-1999; 99US-0143546.
XX
XX (INNO-) INNOGENETICS NV.
XX
XX Stuyver L, Maertens G, Van Geyt C;
XX WPI; 2001-138370/14.
XX
XX Monitoring anti-HBV drug resistance by genetic detection of mutations
XX in DNA polymerase of HBV in patient's sample, involves hybridizing the
XX polynucleic acids of the sample with a probe and detecting the hybrid
XX
XX Claim 2; Page 10; 64pp; English.
XX
XX The present sequence is a probe used in a method for monitoring
XX anti-hepatitis B virus (HBV) drug resistance in a patient by genetic
XX detection of any one of mutations L528M, M552V/I and/or V/L/M551I in
XX HBV DNA polymerase in a biological sample from the patient. The
XX method is useful in the field of genetic detection of anti-HBV drug
XX resistance during HBV therapy. The method is rapid, reliable and
XX precise.
XX
XX Sequence 18 BP; 4 A; 2 C; 5 G; 7 T; 0 other;
SQ
Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2267 TTCCAGTCAGTGATG 2283
DB 1 TTTCAGTCATGTGATG 17
RESULT 198
AAB40986/C
ID AAD40986 standard; DNA; 18 BP.
AC AAD40986;
XX
XX 30-OCT-2002 (first entry)
XX
XX Human PI3K p85 antisense oligonucleotide ISIS #28034.
XX
XX Human; antisense; PI3K p85; obesity; type 2 diabetes; cancer; tumour;
XX prophylaxis; hyperproliferative condition; infection; inflammation;
XX therapy; phosphorothioate; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..18
XX /*tag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate backbone"
XX modified_base 1..4
XX /*tag= b
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl nucleotides"
XX modified_base 3
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl nucleotides"
XX modified_base 15
XX /*tag= d
XX /mod_base= m5c
XX modified_base 15
XX /*tag= e

```

```

FT /mod_base= m5c
XX
XX WO200240637-A2.
XX
XX 23-MAY-2002.
XX
XX 19-NOV-2001; 2001WO-US45006.
XX
XX 20-NOV-2000; 2000US-0715983.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Cowsett LM, Murray SF, Butler MM, Dean NM;
XX WPI; 2002-519374/55.
XX
XX Antisense compounds targeted against polynucleotides encoding PI3K p85
XX useful for treating e.g. cancer, Type 2 diabetes, obesity -
XX
XX Example 16; Page 79; 121pp; English.
XX
XX The invention relates to antisense compounds targeted to a nucleic
XX acid molecule encoding PI3K p85 to inhibit its expression. Antisense
XX compounds of the invention are used for treating obesity, Type 2
XX diabetes and hyperproliferative condition e.g. cancer. They may also
XX be useful prophylactically, e.g. to prevent or delay infection,
XX inflammation or tumour formation. Antisense compounds either alone or
XX in combination with other antisense compounds or therapeutics can be
XX used as tools in differential and/or combinatorial analyses to elucidate
XX expression patterns of a portion or the entire complement of genes
XX expressed within cells and tissues. They are commonly used as research
XX reagents and diagnostics. The present sequence is an antisense
XX oligonucleotide targeted to human PI3K p85 DNA.
XX
XX Sequence 18 BP; 4 A; 5 C; 1 G; 8 T; 0 other;
SQ
Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2530 TTGGTAGAGAGACTTGA 2546
DB 17 TTGGAAGAGAGACTTGA 1
RESULT 199
ABL30659/C
ID ABL30659 standard; DNA; 18 BP.
AC ABL30659;
XX
XX 21-MAR-2002 (first entry)
XX
XX Human HLA genotyping oligonucleotide SEQ ID NO 148.
XX
XX Human; human leukocyte antigen; HLA; genotype; polymorphism;
XX immunogenetic; transplantation; genetic disease; ss.
XX
XX Homo sapiens.
XX
XX WO200192572-A1.
XX
XX 06-DEC-2001.
XX
XX 01-JUN-2001; 2001WO-JP04662.
XX
XX 01-JUN-2000; 2000JP-0164798.
XX
XX (NISN ) NISSHINBO IND INC.
XX (SYST-) SYSTEM RES INC.
XX
XX Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
XX

```

DR WPI; 2002-122074/16.
XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
PT of individuals e.g. by determining immunogenetic differences when
XX transplanting between them -
PS Claim 10; Page 121; 345pp; Japanese.
XX
XX The invention relates to a typing kit for judging human leukocyte antigen
CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
CC oligonucleotides (ABJ30512-ABJ31809) originating in the sequences of
CC genes e.g. belonging to HLA class I antigens on human genome and
CC containing gene polymorphisms as alloantigens have been immobilised as
CC primers for amplification of cleaved nucleic acids relating to gene
CC polymorphisms. The method is useful for judging HLA genotypes of
CC individuals by determining immunogenetic differences before transplanting
CC between them, providing genetic information to decide compatibility of
CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
CC diagnosis of genetic diseases and identifying individuals.
CC
SQ Sequence 18 BP; 3 A; 3 C; 6 G; 6 T; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2619 TTACCCTGACACAGAA 2635
DB 18 TTACCCTGCCACAGCA 2

RESULT 200
ABA03503
ID ABA03503 standard; DNA; 18 BP.
XX
AC ABA03503;
XX
DT 20-FEB-2002 (first entry)
XX
DE Relaxin/IGF/insulin family proteins related PCR primer SEQ ID NO: 13.
XX
KM Relaxin; IGF; insulin; antidiabetic; vasoactive; antifertility;
KM antiarteriosclerotic; immunosuppressive; cytostatic; fibroblasts;
KM metabolic regulation; metabolic disorder; reproductive function;
KM neurological disorder; immune disorder; scleroderma; angiogenesis;
KM PCR primer; ss.
XX
OS Unidentified.
XX
XX WO200181562-A1.
XX
PD 01-NOV-2001.
XX
XX 20-APR-2001; 2001WO-JP03399.
XX
PF 20-APR-2001; 2000JP-0126340.
XX
PR 03-JUL-2000; 2000JP-0205587.
PR 10-AUG-2000; 2000JP-0247962.
PR 22-DEC-2000; 2000JP-0395050.
XX
PA (TAKE) TAKEDA CHEM IND LTD.
XX
XX Itoh Y, Suzuki N, Nishi K, Kizawa H, Harada M, Ogi K,
PI WPI; 2002-049275/06.
DR
XX WPI; 2002-049275/06.
XX Relaxin family polypeptides and antibodies recognizing them for
PT treatment and diagnosis of metabolic disorders such as diabetes -
XX Example 3; Page 151; 185pp; Japanese.
PS
XX The present invention relates to polypeptides belonging to the

CC relaxin/IGF/insulin family and their amides, esters and salts. These play
CC a key role in metabolic regulation, especially of usage of energy sources
CC such as sugars and lipids. The sequences can be used to prevent, treat
CC and diagnose metabolic disorders, including disorders of the growth,
CC proliferation and differentiation of tissues, functional lowering of
CC reproductive functions, abnormalities of the formation of connective
CC tissue, fibrodosis of lung, kidney or other organs, obstruction of blood
CC circulation and internal secretions, abnormalities of body fluid balance,
CC neurological disorders, immune disorders, scleroderma and suppression of
CC angiogenesis. The present sequence is a PCR primer described in the
CC exemplification of the invention.
XX
SQ Sequence 18 BP; 1 A; 3 C; 9 G; 5 T; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1653 GGCAGGGGTCTCCGAGT 1669
DB 2 GGCAGGGGTCTCTGTGT 18

RESULT 201
ABZ23505/C
ID ABZ23505 standard; DNA; 18 BP.
XX
AC ABZ23505;
XX
DT 07-APR-2003 (first entry)
XX
DE Primer for analysing microsatellite repeat instability in msh-6 worms.
XX
XX Replication error; drug development; microsatellite instability; msh-6;
KM PCR; primer; ss.
XX
XX Caenorhabditis elegans.
XX
PN WO200295071-A2.
XX
PD 28-NOV-2002.
XX
PF 22-MAY-2002; 2002WO-NL00322.
XX
PR 22-MAY-2001; 2001EP-0201936.
XX
PA (NEWM-) KONINK NEDERLANDSE AKAD VAN WETENSCHAPPE.
PA (TJUS/) TJUSTERMAN M.
XX
PI Plasterk RHA;
XX
XX WPI; 2003-129440/12.
DR
XX
XX Determining whether a product of a gene is involved in preventing a
PT replication error in a cell comprises providing a specific inhibitor
PT for the product and determining the level of expression of a marker
PT gene -
XX
XX Example 1; Page 19; 47pp; English.
XX
XX The specification describes a method for determining whether a product
CC of a gene is involved in preventing a replication error in a cell. The
CC method comprises providing the cell with a specific inhibitor for the
CC product and determining the level of functional expression of a marker
CC gene in the cell, where the level of expression of the marker gene is
CC dependent on the occurrence of the replication error. The method is
CC used for determining whether a product of a gene is involved in
CC preventing a replication error in a cell. The identified genes are
CC useful for developing diagnostic tools, or as targets for drug
CC development to manipulate cells on the basis of the presence or absence
CC of function of the gene. Primers ABZ23504-15 were used for PCR and
CC sequencing to analyse microsatellite instability in msh-6 worms, in the
CC course of the invention.

XX Sequence 18 BP; 4 A; 3 C; 8 G; 3 T; 0 other;
 SQ Query Match 1.0%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1987 CTCGAGATACCTCCG 2003
 DB 18 CTCGCTGAAACCTCCG 2

RESULT 202
 AAX31178/c
 ID AAX31178 standard; DNA; 15 BP.
 AC AAX31178;
 XX
 DT 21-MAY-1999 (first entry)
 XX Tag sequence of a transcript increased in colorectal cancer.
 DE Tag sequence; colorectal cancer; pancreatic cancer; colon cancer;
 KM diagnosis; prognosis; treatment; ss.
 XX Homo sapiens.
 OS
 XX MO9853319-A2.
 PN
 XX 26-NOV-1998.
 PD
 XX 20-MAY-1998; 98WO-US10277.
 PF
 XX 21-MAY-1997; 97US-0047352.
 PR
 XX (UUYO) UNIV JOHNS HOPKINS.
 PA
 XX Kinzler KW, Vogelstein B;
 PI
 XX WPI; 1999-070161/06.
 DR
 XX Use of isolated gene transcripts - useful for developing products
 PT for the diagnosis, prognosis and treatment of cancers, particularly
 PT colon and pancreatic cancer
 PS Claim 2; Page 34; 120pp; English.
 XX AAX30947-11815 represent tag sequences of transcripts that are
 CC differentially expressed in colorectal cancer, in pancreatic
 CC cancer, or in both. The tag sequences can be used to identify
 CC genes by matching the tag to a gen data base member, or by using
 CC the tag sequences as probes to isolate unidentified genes from
 CC cDNA libraries. The tag sequences can also be used in a method
 CC for diagnosis colon or pancreatic cancer in a sample suspected
 CC of being neoplastic. The method comprises comparing the level of
 CC at least one transcript in a first sample of a tissue to a second
 CC sample, where the first sample is a colonic tissue suspected of
 CC being neoplastic and the second sample is a normal human colonic
 CC tissue. The transcript is identified by a tag selected from
 CC AAX30947-11815. The methods of the invention can be used in the
 CC diagnosis, prognosis and treatment of cancer.
 CC
 XX Sequence 15 BP; 4 A; 3 C; 6 G; 2 T; 0 other;
 SQ Query Match 1.0%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.7e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1573 TCCAGCTCTCCATG 1587
 DB 15 TCCAGCTCTCCATG 1

RESULT 203
 AA64164/c
 ID AA64164 standard; RNA; 15 BP.
 XX
 AC AA64164;
 XX
 DT 28-MAR-2000 (first entry)
 XX Substrate for hammerhead ribozyme which cleaves HCV RNA at nt. 5677.
 DE
 XX Enzymatic nucleic acid; hammerhead ribozyme; virus replication; cleavage;
 KM cirrhosis; liver failure; hepatocellular carcinoma; interferon; cancer;
 KW autoimmune disease; ss.
 XX
 OS Hepatitis C virus.
 XX
 PN WO9955847-A2.
 XX
 PD 04-NOV-1999.
 XX
 PF 26-APR-1999; 99WO-US09027.
 XX
 PR 27-APR-1998; 98US-0083217.
 PR 18-SEP-1998; 98US-0100842.
 PR 25-FEB-1999; 99US-0257608.
 PR 23-MAR-1999; 99US-0274553.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, McSwiggen JA, Roberts E, Pavco PA, Macejak D;
 XX WPI; 2000-062023/05.
 DR
 XX Novel ribozymes for the treatment of diseases and conditions related to
 PT hepatitis C infection -
 PT
 XX Claim 1; Page 83; 123pp; English.
 PS
 XX The present sequence represents the preferred target sequence of an
 CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
 CC the Hepatitis C virus (HCV) RNA sequence at the base position given
 CC in the descriptor line.
 CC The HCV sequence was screened for optimal ribozyme target sites using
 CC a computer folding algorithm and regions of the mRNA which did not form
 CC secondary folding structures and contained potential ribozyme cleavage
 CC sites were identified. Ribozymes were synthesised to target these sites
 CC and their activities optimised by either varying the length of the
 CC binding arms or by modification to prevent degradation by nucleases.
 CC The ribozymes of the invention inhibit gene expression and/or viral
 CC replication, and are used to treat diseases associated with Hepatitis C
 CC virus (HCV) infection, e.g. cirrhosis, liver failure and hepatocellular
 CC carcinoma. The ribozymes may be used in combination with interferon to
 CC treat HCV infection, other infectious diseases, autoimmune diseases, and
 CC cancer.
 XX
 SQ Sequence 15 BP; 2 A; 5 C; 3 G; 5 U; 0 other;
 SQ Query Match 1.0%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.7e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2433 CAGATGATTAAGCC 2447
 DB 15 CAGATGATTAAGCC 1

RESULT 204
 AAF51572
 ID AAF51572 standard; DNA; 15 BP.
 XX
 AC AAF51572;
 XX
 DT 30-MAR-2001 (first entry)

XX IGF-I oligonucleotide #2532.
 DE
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytoskeletal; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 KM
 XX Homo sapiens.
 OS
 XX WO200078341-A1.
 PN
 XX 28-DEC-2000.
 PD
 XX 21-JUN-2000; 2000WO-AU00693.
 PF
 XX 21-JUN-1999; 99US-0140345.
 PR
 XX (MURDOCH CHILDRENS RES INST.
 PA
 XX Wright CJ, Werther GA, Edmondson SR;
 PI
 XX WPI; 2001-041421/05.
 DR
 XX
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by
 PT administering UV (ultra-violet) treatment (optional) and an antisense
 PT nucleic acid that inhibits or reduces growth factor mediated cell
 PT proliferation and/or inflammation -
 PT
 XX
 XX Example 8; Page 77; 201pp; English.
 PS
 XX The present invention relates to a method for ameliorating the effects
 CC of skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and
 CC AAF45153-445161). The method is useful for ameliorating the effects of
 CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids,
 CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
 CC skin, a hyperneovascular condition such as a neovascular condition of the
 CC retina, brain or skin, growth factor-mediated malignancies, other
 CC sclerotic disease, kidney disease, hyperproliferation of the inside of
 CC blood vessels or any other hyperplasia.
 CC
 XX
 XX Sequence 15 BP; 6 A; 2 C; 5 G; 2 T; 0 other;
 SQ
 QY Query Match 1.0%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.7e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 DB 2057 AGGACGATGACCT 2071
 1 AGGACGATGACAT 15
 RESULT 205
 AAF51573
 ID AAF51573 standard; DNA; 15 BP.
 AC AAF51573;
 XX
 XX 30-MAR-2001 (first entry)
 DT
 XX IGF-I oligonucleotide #2532.
 DE
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;

KW cytoskeletal; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 KM
 XX Homo sapiens.
 OS
 XX WO200078341-A1.
 PN
 XX 28-DEC-2000.
 PD
 XX 21-JUN-2000; 2000WO-AU00693.
 PF
 XX 21-JUN-1999; 99US-0140345.
 PR
 XX (MURDOCH CHILDRENS RES INST.
 PA
 XX Wright CJ, Werther GA, Edmondson SR;
 PI
 XX WPI; 2001-041421/05.
 DR
 XX
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by
 PT administering UV (ultra-violet) treatment (optional) and an antisense
 PT nucleic acid that inhibits or reduces growth factor mediated cell
 PT proliferation and/or inflammation -
 PT
 XX
 XX Example 8; Page 77; 201pp; English.
 PS
 XX The present invention relates to a method for ameliorating the effects
 CC of skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and
 CC AAF45153-445161). The method is useful for ameliorating the effects of
 CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids,
 CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
 CC skin, a hyperneovascular condition such as a neovascular condition of the
 CC retina, brain or skin, growth factor-mediated malignancies, other
 CC sclerotic disease, kidney disease, hyperproliferation of the inside of
 CC blood vessels or any other hyperplasia.
 CC
 XX
 XX Sequence 15 BP; 5 A; 2 C; 5 G; 3 T; 0 other;
 SQ
 QY Query Match 1.0%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.7e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 DB 2058 GGACGATGACCTT 2072
 1 GGACGATGACATT 15
 RESULT 206
 AAF51574
 ID AAF51574 standard; DNA; 15 BP.
 AC AAF51574;
 XX
 XX 30-MAR-2001 (first entry)
 DT
 XX IGF-I oligonucleotide #2534.
 DE
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytoskeletal; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;

KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 OS Homo sapiens.
 XX
 XX WO200078341-A1.
 XX
 XX
 XX 28-DEC-2000.
 XX
 XX PD 21-JUN-2000; 2000WO-AU00693.
 XX
 XX PF 21-JUN-1999; 99US-0140345.
 XX
 XX PR 21-JUN-1999; 99US-0140345.
 XX
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 XX PA Wraight CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 XX
 XX DR WPI; 2001-041421/05.
 XX
 XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by
 XX administering UV (ultra-violet) treatment (optional) and an antisense
 XX nucleic acid that inhibits or reduces growth factor mediated cell
 XX proliferation and/or inflammation -
 XX
 XX PS Example 8; Page 77; 201pp; English.
 XX
 XX CC The present invention relates to a method for ameliorating the effects
 XX of skin disorders. The method comprises contacting the skin with an
 XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 XX inhibiting or reducing growth factor mediated cell proliferation,
 XX inflammation and/or other disorders. The present sequence is an
 XX oligonucleotide which can be used to design the antisense
 XX oligonucleotides of the present invention (see AAF45151 and
 XX AAF45153-PA5161). The method is useful for ameliorating the effects of
 XX psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids,
 XX keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
 XX skin, a hyperneovascular condition such as a neovascular condition of the
 XX retina, brain or skin, growth factor-mediated malignancies, other
 XX sclerotic disease, kidney disease, hyperproliferation of the inside of
 XX blood vessels or any other hyperplasia.
 XX
 XX SQ Sequence 15 BP; 5 A; 3 C; 4 G; 3 T; 0 other;
 XX
 XX
 XX Query Match 1.0%; Score 13.4; DB 1; Length 15;
 XX Best Local Similarity 93.3%; Pred. No. 1.7e+02;
 XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 XX QY 2059 GAGCAGATGACCTTC 2073
 XX Db 1 GAGCAGATGACCTTC 15
 XX
 XX
 XX RESULT 207
 XX AAF52665
 XX ID AAF52665 standard; DNA; 15 BP.
 XX
 XX AC AAF52665;
 XX
 XX 30-MAR-2001 (first entry)
 XX
 XX XX IGF-I oligonucleotide #3625.
 XX
 XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytoskeletal; dermatological; cardiant; virulide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX

OS Homo sapiens.
 XX
 XX WO200078341-A1.
 XX
 XX PD 28-DEC-2000.
 XX
 XX PF 21-JUN-2000; 2000WO-AU00693.
 XX
 XX PR 21-JUN-1999; 99US-0140345.
 XX
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 XX PA Wraight CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 XX
 XX DR WPI; 2001-041421/05.
 XX
 XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by
 XX administering UV (ultra-violet) treatment (optional) and an antisense
 XX nucleic acid that inhibits or reduces growth factor mediated cell
 XX proliferation and/or inflammation -
 XX
 XX PS Example 8; Page 84; 201pp; English.
 XX
 XX CC The present invention relates to a method for ameliorating the effects
 XX of skin disorders. The method comprises contacting the skin with an
 XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 XX inhibiting or reducing growth factor mediated cell proliferation,
 XX inflammation and/or other disorders. The present sequence is an
 XX oligonucleotide which can be used to design the antisense
 XX oligonucleotides of the present invention (see AAF45151 and
 XX AAF45153-PA5161). The method is useful for ameliorating the effects of
 XX psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids,
 XX keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
 XX skin, a hyperneovascular condition such as a neovascular condition of the
 XX retina, brain or skin, growth factor-mediated malignancies, other
 XX sclerotic disease, kidney disease, hyperproliferation of the inside of
 XX blood vessels or any other hyperplasia.
 XX
 XX SQ Sequence 15 BP; 1 A; 5 C; 4 G; 5 T; 0 other;
 XX
 XX
 XX Query Match 1.0%; Score 13.4; DB 1; Length 15;
 XX Best Local Similarity 93.3%; Pred. No. 1.7e+02;
 XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 XX QY 2326 GATGCTGCTGCTTC 2340
 XX Db 1 GATGCTGCTGCTTC 15
 XX
 XX
 XX RESULT 208
 XX AAF52666
 XX ID AAF52666 standard; DNA; 15 BP.
 XX
 XX AC AAF52666;
 XX
 XX 30-MAR-2001 (first entry)
 XX
 XX XX IGF-I oligonucleotide #3626.
 XX
 XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytoskeletal; dermatological; cardiant; virulide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 XX OS Homo sapiens.
 XX
 XX XX WO200078341-A1.
 XX

```

PD 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU00693.
XX
XX 21-JUN-1999; 99US-0140345.
XX
XX (MURDOCH CHILDRENS RES INST.
XX
XX Wright CJ, Werther GA, Edmondson SR;
XX
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by
XX administering UV (ultra-violet) treatment (optional) and an antisense
XX nucleic acid that inhibits or reduces growth factor mediated cell
XX proliferation and/or inflammation -
XX
XX Example 8; Page 84; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects
XX of skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AA45151 and
XX AA45153-445161). The method is useful for ameliorating the effects of
XX psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids,
XX keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
XX skin, a hyperneovascular condition such as a neovascular condition of the
XX retina, brain or skin, growth factor-mediated malignancies, other
XX sclerotic diseases, kidney disease, hyperproliferation of the inside of
XX blood vessels or any other hyperplasia.
XX
XX Sequence 15 BP; 1 A; 5 C; 4 G; 5 T; 0 other;
XX
XX Query Match 1.0%; Score 13.4; DB 1; Length 15;
XX Best Local Similarity 93.3%; Pred. No. 1.7e+02;
XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 2327 ATGCTGTGCTCG 2341
XX | | | | |
XX 1 ACGTCTGCTCTTCG 15
XX
XX RESULT 209
XX ABX01217/C
XX ID ABX01217 standard; RNA; 15 BP.
XX
XX AC ABX01217;
XX
XX DT 23-DEC-2002 (first entry)
XX
XX DE Hepatitis C virus substrate #999 for HCV hammerhead ribozyme #999.
XX
XX KW Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;
XX HCV ribozyme; HCV expression; HCV replication; cirrhosis; virulence;
XX liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
XX type I interferon; interferon alpha; interferon beta; cytosolic;
XX interferon gamma; consensus interferon; hepatotropic; antiinflammatory;
XX substrate; hammerhead ribozyme; HH ribozyme; ss.
XX
XX OS Hepatitis C virus.
XX
XX PD US2002082225-A1.
XX
XX 27-JUN-2002.
XX
XX 23-MAR-1999; 99US-0274553.
XX
XX 23-MAR-1999; 99US-0274553.
XX

```

```

PA (BLATT/) BLATT L.
PA (MCSWIGEN J A.
PA (ROBERTS B.
PA (PAVCO/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
XX Blatt L, McSwiggen JA, Roberts B, Pavco PA, Macejack D;
XX
XX WPI; 2002-617759/66.
XX
XX New ribozymes targeting RNA derived from hepatitis C virus inhibit
XX viral replication and are useful to treat hepatitis C virus infections
XX and cirrhosis, liver failure or hepatocellular carcinoma -
XX
XX Claim 1; Page 50; 80pp; English.
XX
XX The present invention relates to enzymatic nucleic acids which
XX specifically cleave RNA derived from Hepatitis C virus (HCV). The
XX enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or
XX hairpin (HP) motif where the binding arms comprise sequences
XX complementary to one of the substrate sequences defined in the
XX specification. The HCV ribozymes are useful for modulating the
XX expression and/or replication of HCV. They can be used to treat
XX cirrhosis, liver failure and/or hepatocellular carcinoma. The HCV
XX ribozymes are also useful for treating a condition associated with
XX HCV infection in conjunction with one or more other drug therapies,
XX particularly type I interferon, especially interferon alpha, beta or
XX gamma or consensus interferon. The present sequence represents a
XX substrate for a HCV hammerhead (HH) ribozyme.
XX Note: Some of the sequence data for this patent did not form part of
XX the printed specification. The complete sequence data for this patent
XX was obtained in electronic format directly from the USPTO web site
XX at seqdata.uspto.gov/patseq/identity.html.
XX
XX Sequence 15 BP; 2 A; 5 C; 3 G; 5 U; 0 other;
XX
XX Query Match 1.0%; Score 13.4; DB 1; Length 15;
XX Best Local Similarity 93.3%; Pred. No. 1.7e+02;
XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 2433 CAGAGTGATAGCC 2447
XX | | | | |
XX 15 CAGAGTGATAGCC 1
XX
XX RESULT 210
XX ABK32132/C
XX ID ABK32132 standard; DNA; 15 BP.
XX
XX AC ABK32132;
XX
XX DT 23-APR-2002 (first entry)
XX
XX DE Human colon cancer SAGE tag #233.
XX
XX KW Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;
XX serial analysis of gene expression; diagnostic; prognostic; probe;
XX cancer marker; ss.
XX
XX OS Homo sapiens.
XX
XX PN US6333152-B1.
XX
XX PD 25-DEC-2001.
XX
XX PF 20-MAY-1998; 98US-0081646.
XX
XX 20-MAY-1998; 98US-0081646.
XX
XX (UYUO ) UNIV JOHNS HOPKINS.
XX
XX Vogelstein B, Kinzler KW, Zhang L, Zhou W;
XX

```

DR WPI, 2002-153821/20.
XX New human nucleic acid containing specific SAGE tags, useful as
PT diagnostic markers for cancer, also derived probes
XX
XX Disclosure; Column 29; 161pp; English.
XX
XX The invention relates to an isolated, purified human nucleic acid (I)
CC that has the same sequence as a mRNA found in humans and is a SAGE
CC (serial analysis of gene expression) tag comprising a single stranded
CC probe containing at least 10 consecutive nucleotides. SAGE tags, are
CC diagnostic and prognostic markers of cancer, especially of the colon and
CC pancreas. ABK31900-ABK3770 represent human colon and pancreatic cancer
CC SAGE tags of the invention.
XX
SQ Sequence 15 BP; 4 A; 3 C; 6 G; 2 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1573 TCCAGCTCCTCATG 1587
DB 15 TCCAGCTCCTCATG 1
RESULT 211
AAV48733/C
ID AAV48733 standard; DNA; 16 BP.
XX
AC AAV48733;
XX
DT 15-OCT-1998 (first entry)
XX
DE ErbB-2 gene antisense oligonucleotide ErbB-2-25.
XX
KW ErbB-2; antisense oligonucleotide; modulate; gene expression; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN EP856579-A1.
XX
PD 05-AUG-1998.
XX
PF 31-JAN-1997; 97EP-0101531.
XX
PR 31-JAN-1997; 97EP-0101531.
XX
PA (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
PI Brysch W, Schlingensiepen K;
XX
PT WPI; 1998-400910/35.
XX
PT Preparation of antisense oligo:nucleotide(s) which lack long runs of
PT consecutive guanosine or inosine - and have specific ratio of
PT residues able to form two or three hydrogen bonds, have greater
PT activity and reduced toxicity, used therapeutically or to modulate
PT growth of cells in culture
XX
PS Claim 10; Fig 6a; 286pp; English.
XX
XX AAV48709-886 represent antisense oligonucleotides directed against the
CC ErbB-2 gene. Of these, only oligonucleotides AAV48709-91 resulted
CC in significant reduction in ErbB-2 protein expression, while
CC oligonucleotides AAV48792-886 had little effect. The oligonucleotides
CC exemplify the invention. The specification describes oligonucleotides
CC that contain 8-30 nucleotides, which contain at most 8 nucleotides that
CC can each form three hydrogen bonds to cytosine; do not contain four
CC consecutive nucleotides able to form three H-bonds each to four
CC consecutive cytosines; do not contain two sequences of three consecutive
CC nucleotides each able to form three H-bonds to three consecutive

CC cytosines, and the ratio between residues able to form two H-bonds each
CC (2R) or three such bonds (3R) is given by 2R/3R = 0.33-0.72. The
CC oligonucleotides are used to modulate expression of genes, particularly
CC the genes for p53, Erb-2, junB, junD, TGF-beta 1 or beta 2 to control
CC proliferation of primary cell cultures (e.g., bone marrow stem, liver or
CC kidney cells, osteoclasts, osteoblasts and/or keratinocytes). The
CC oligonucleotides can also be used to analyse function of proteins (by
CC altering their expression or activity) and therapeutically, e.g. in
CC cases of cancer or (targeting TGF) for stimulating the immune system.
XX
SQ Sequence 16 BP; 4 A; 7 C; 2 G; 3 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2320 CAGAGTGATGTGTGG 2334
DB 15 CAGAGTGATGTGTGG 1
RESULT 212
AAK63801
ID AAK63801 standard; RNA; 17 BP.
XX
AC AAK63801;
XX
DT 20-JUN-1999 (first entry)
XX
DE Rabbit stromelysin hammerhead target SEQ ID NO:433.
XX
KW Arthritic condition; graft tolerance; immune response; target; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
KW diagnosis; ss.
XX
OS Oryctolagus cuniculus.
XX
PN WO9618736-A2.
XX
PD 20-JUN-1996.
XX
PF 22-NOV-1995; 95WO-US15516.
XX
PR 05-OCT-1995; 95US-0541365.
PR 13-DEC-1994; 94US-0354920.
PR 23-DEC-1994; 94US-0363253.
PR 23-DEC-1994; 94US-0363254.
PR 17-FEB-1995; 95US-0390850.
PR 20-APR-1995; 95US-0426124.
PR 02-MAY-1995; 95US-0432874.
PR 04-MAY-1995; 95US-0434509.
PR 07-JUL-1995; 95US-0000951.
PR 07-JUL-1995; 95US-0000974.
PR 07-AUG-1995; 95US-0512861.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Draper K, Gustofson J, McSwiggen J, Pavco P, Stinchcomb DT;
PI Beigelman L, Karpelsky A, Modak A, Usman N, Burgin A;
PI Maculic-Adamic J, Jarvis T, Thompson JD, Wincott F;
XX
XX WPI; 1996-300653/30.
XX
XX Enzymatic nucleic acid molecules having a hammer-head motif - used
PT for the treatment of arthritis, induction of graft tolerance or
PT treatment of auto-immune diseases
XX
XX Example 1; Page 153; 307pp; English.
XX
XX The present invention describes a novel enzymatic nucleic acid (ENA)
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose

CC residues; (iii) a 2'-C-allyl modification at position 4 of the ENA; (iii)
CC at least ten 2'-O-methyl modifications; and (iv) a 3'-end modification.
CC The ENA's can inhibit collagenase and stromelysin production in the
CC synovial membrane of joints for the treatment or prevention of arthritis,
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
CC be used to treat antigen presenting cells of a donor to induce tolerance
CC in a recipient to an alloantigen of a donor. They can also be used for
CC enhancing graft tolerance or for treating autoimmune disease, and for
CC treating allergies and other inflammatory conditions. The ENA's can also
CC be used in diagnosis. Ribozyme therapy impacts on the expression of
CC stromelysin without introducing the non-specific effects upon gene
CC expression which accompany treatment with retinoids and dexamethasone.
CC The concentration of ribozyme required to affect a therapeutic treatment
CC is lower than that required of antisense molecules, and is highly
CC specific. The present sequence is used in the exemplification of the
CC present invention.
XX
XX Sequence 17 BP; 4 A; 8 C; 3 G; 2 U; 0 other;
SQ
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 12; Conservative 2; Mismatches 1;
Gy 1586 TGAAGTCCACACCC 1600
Db 3 UGACUCCACACCC 17
RESULT 213
AAT12596
ID AAT12596 standard; DNA; 17 BP.
XX
XX AAT12596;
XX
XX 31-DEC-1996 (first entry)
XX
XX Human Tx protease cDNA primer Txa.
XX
XX Interleukin-1 beta converting enzyme; ICE; protease; apoptosis;
XX induction; inflammation; autoimmune disease; neurodegeneration;
XX cancer; infection; treatment; Tx protein; anchored PCR;
XX polymerase chain reaction; amplification primer; ss.
XX
XX Synthetic.
XX
XX WO9604387-A1.
XX
XX 15-FEB-1996.
XX
XX 01-AUG-1995; 95WO-FR01035.
XX
XX 02-AUG-1994; 94FR-0009567.
XX
XX (ROUS) ROUSSEL-UCIAP.
XX
XX Diu A, Faucheu C, Herceud T, Lalanne JL, Livingston DJ, Su MS;
XX WPI; 1996-129403/13.
XX
XX New DNA encoding human protease(s) that induce apoptosis - and cause
XX maturation of interleukin converting enzyme, useful e.g. in treating
XX autoimmune diseases
XX
XX Example 1; Page 17; 88pp; French.
XX
XX The present sequence is that of a PCR primer used for isolating the
XX 3'-end of a cDNA sequence coding for the human protease designated Tx
XX which is related to the interleukin-1 beta converting enzyme (ICE)
XX and which induces apoptosis. First, a 600 bp fragment of the coding
XX sequence was isolated from human monocyte cDNA using primers based
XX on the sequence of a human genomic fragment which was 92% identical to
XX the exon 6 sequence of the human ICE gene. Then, the 5'- and 3'-ends
XX were amplified using the Rapid Amplification of cDNA Ends (RACE)

CC technique. The Tx protease converts the p30 precursor of ICE into
CC 20 kD and 10 kD fragments and can be used for treating diseases which
CC respond to ICE, e.g. inflammation. The ability to induce apoptosis is
CC useful for treating cancer.
XX
XX Sequence 17 BP; 6 A; 2 C; 5 G; 4 T; 0 other;
SQ
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1;
Gy 2465 AACTGTACATGATCA 2479
Db 1 AACTGTACATGATCA 15
RESULT 214
AAT35236/C
ID AAT35236 standard; DNA; 17 BP.
XX
XX AAT35236;
XX
XX 05-DEC-1996 (first entry)
XX
XX Natural killer lytic associated protein gene primer 194.
XX
XX Natural killer lytic associated protein; NKLAIP;
XX cytotoxic T-lymphocyte; CTL; natural killer cell; primer;
XX ds.
XX
XX Synthetic.
XX
XX WO9626744-A1.
XX
XX 06-SEP-1996.
XX
XX 01-MAR-1996; 96WO-US02736.
XX
XX 02-MAR-1995; 95US-0398008.
XX
XX (UYAR-) UNIV ARKANSAS.
XX
XX Kornbluth J;
XX
XX WPI; 1996-412588/41.
XX
XX New human natural killer lytic associated protein - useful for
XX treating cancer, viral infections, graft vs. host or autoimmune
XX diseases.
XX
XX Example 1; Page 13; 65pp; English.
XX
XX A series of primers (AAT35236-49) were used to sequence natural
XX killer lytic associated protein clones (see also AAT35233) in
XX plasmid. Confirmation of the sequence of the 5' G-C rich
XX region of the NKLAIP gene was performed subsequent to subcloning
XX of the clones into M13 phage. A single open reading frame
XX coding for a 587-amino acid protein (AAR9256) was revealed.
XX
XX Sequence 17 BP; 6 A; 3 C; 4 G; 4 T; 0 other;
SQ
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1;
Gy 1375 GAGATTACAGCTCC 1389
Db 16 GTGATTACAGCTTC 2
RESULT 215
AAX71605
ID AAX71605 standard; RNA; 17 BP.

```

XX AAX71605;
AC
XX 28-JUL-1999 (first entry)
DT
XX
XX Human KDR VEGF receptor hammerhead ribozyme substrate #617.
DE
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
KW flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
XX Homo sapiens.
OS
XX WO9715662-A2.
PN
XX 01-MAY-1997.
PD
XX
XX 25-OCT-1996; 96WO-US17480.
PF
XX
XX 11-JAN-1996; 96US-0584040.
PR 26-OCT-1995; 95US-0005974.
XX
XX (CHIR ) CHIRON CORP.
PA (RIBO-) RIBOZYME PHARM INC.
XX
XX Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;
PI
XX WPI, 1997-259017/23.
DR
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
PT mRNA stability - useful for treating e.g. tumour angiogenesis,
PS psoriasis, rheumatoid arthritis, etc., in a human patient
XX
XX Claim 4; Page 115; 218pp; English.
XX
XX The present invention describes nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
CC be treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention.
XX
XX Sequence 17 BP; 6 A; 3 C; 3 G; 5 U; 0 other;
SQ
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 2e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
Cy 2404 GAACCTTTTAAGCTG 2418
Db 3 GAACCUUUAAGCUG 17

```

```

KW foetal liver kinase 1; ss.
XX
XX Homo sapiens.
OS
XX WO9715662-A2.
PN
XX 01-MAY-1997.
PD
XX
XX 25-OCT-1996; 96WO-US17480.
PF
XX
XX 11-JAN-1996; 96US-0584040.
PR 26-OCT-1995; 95US-0005974.
XX
XX (CHIR ) CHIRON CORP.
PA (RIBO-) RIBOZYME PHARM INC.
XX
XX Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;
PI
XX WPI, 1997-259017/23.
DR
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
PT mRNA stability - useful for treating e.g. tumour angiogenesis,
PS psoriasis, rheumatoid arthritis, etc., in a human patient
XX
XX Claim 4; Page 115; 218pp; English.
XX
XX The present invention describes nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
CC be treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention.
XX
XX Sequence 17 BP; 7 A; 2 C; 3 G; 5 U; 0 other;
SQ
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 2e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
Cy 2404 GAACCTTTTAAGCTG 2418
Db 2 GAACCUUUAAGCUG 16

```

```

RESULT 216
AAX71606
ID AAX71606 standard; RNA; 17 BP.
XX
XX AAX71606;
AC
XX
XX 28-JUL-1999 (first entry)
DT
XX
XX Human KDR VEGF receptor hammerhead ribozyme substrate #618.
DE
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
KW flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;

```

```

RESULT 217
AAA21251/c
ID AAA21251 standard; RNA; 17 BP.
XX
XX AAA21251;
AC
XX
XX 19-JUN-2000 (first entry)
DT
XX
XX Integrin alpha 6 subunit substrate sequence SEQ ID NO:4477.
DE
XX
XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytoskeletal; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW tubercous sclerosis; poc-wine stain; Sturge Weber syndrome;
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
XX Homo sapiens.
OS
XX WO9950403-A2.
PN
XX
XX 07-OCT-1999.
PD

```

XX 24-MAR-1999; 99WO-US06507.
 XX 27-MAR-1998; 98US-0079678.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
 DR WPI; 1999-591315/50.
 XX Novel ribozymes for modulating the synthesis, expression and/or
 PT stability of an mRNA encoding an angiogenic factors -
 XX Claim 55; Page 196; 305pp; English.
 PS The present invention describes enzymatic nucleic acid molecules with
 CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17467 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequences
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (AMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiodioma of tuberous sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3.
 XX Sequence 17 BP; 8 A; 5 C; 1 G; 3 U; 0 other;
 SO

Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2166 TGTTTTGGTACAGA 2180
 DB 17 TGTTTTGGTACAGA 3

RESULT 218
 AAF04955
 ID AAF04955 standard; DNA; 17 BP.
 AC AAF04955;
 XX 16-FEB-2001 (first entry)
 DT Hammerhead ribozyme substrate #2471.
 DE Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 KW interferon alpha; ss.
 XX Homo sapiens.
 OS WO200061729-A2.
 PN 19-OCT-2000.
 PD 11-APR-2000; 2000WO-US09721.
 PF

XX 12-APR-1999; 99US-0129390.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Blatt L, Zwick M, Pavco P, McSwiggen J;
 DR WPI; 2000-647423/62.
 XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor
 PT protein, interferon alpha and erythropoietin -
 XX Claim 4; Page 112; 164pp; English.
 PS The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor. EAR3/COUP-TF-1, the GATA
 CC transcription factor gene, IRF-2 and/or the C/EBP Displacement
 CC protein (CDP). Inhibition of the repressors removes prevents
 CC inhibition (and consequently increases expression of) genes involved in
 CC the production of erythropoietin, granulocyte colony stimulating factor
 CC protein and interferon alpha.
 XX Sequence 17 BP; 2 A; 6 C; 4 G; 5 T; 0 other;
 SO

Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1945 GGGCTCTCTATGTC 1959
 DB 3 GGGCTCTCTATGTC 17

RESULT 219
 AAF04956
 ID AAF04956 standard; DNA; 17 BP.
 AC AAF04956;
 XX 16-FEB-2001 (first entry)
 DT Hammerhead ribozyme substrate #2472.
 DE Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 KW interferon alpha; ss.
 XX Homo sapiens.
 OS WO200061729-A2.
 PN 19-OCT-2000.
 PD 11-APR-2000; 2000WO-US09721.
 PF 12-APR-1999; 99US-0129390.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Blatt L, Zwick M, Pavco P, McSwiggen J;
 DR WPI; 2000-647423/62.
 XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor
 PT protein, interferon alpha and erythropoietin -
 XX Claim 4; Page 112; 164pp; English.
 PS The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA

CC transcription factor gene, IRF-2 and/or the CAAAT Displacement
CC Protein (CDP). Inhibition of the repressors removes prevents
CC inhibition (and consequently increases expression of) genes involved in
CC the production of erythropoietin, granulocyte colony stimulating factor
CC protein and interferon alpha.
XX
SQ Sequence 17 BP; 1 A; 8 C; 3 G; 5 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 1945 GGGCTCTCTATGTC 1959
Db 1 GGGCTCTCTATCTC 15
RESULT 220
ABK02375/c
ID ABK02375 standard; RNA; 17 BP.
AC ABK02375;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Amberzyme #47.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN MO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US04273.
XX
PR 11-FEB-2000; 2000US-181797P.
PR 28-FEB-2000; 2000US-18516P.
PR 06-MAR-2000; 2000US-187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGEN J.
PA (CHOW/) CHOWRIRA B W.
XX
PI Blact L, MCSWigen J, Chowrira BM;
XX
DR WPI; 2001-607195/69.
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
FT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia,
PT and central nervous system injury
XX
PS Claim 88; Page 131; 200PP; English.
XX
CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO).
CC The nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a

CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NVN
CC motif) pr an amberzyme (cleaving RNA with an NNN triplet), a zinczyme
CC (cleaving RNA with a YGY motif). The CD20-targeting nucleic acid is used
CC to cleave RNA of CD20 in the presence of a divalent cation that is
CC preferably Mg²⁺. Furthermore, it may be contacted with a cell to reduce
CC CD20 activity of the cell and treat a patient having a condition
CC associated with the level of CD20. The treatment may further comprise the
CC use of one or more therapies. In particular, the CD20 targeting
CC nucleic acid may be used to treat lymphoma, leukaemia, B-cell
CC lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky
CC low-grade or follicular NHL, lymphocytic leukaemia, HIV (human
CC immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL),
CC immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune
CC thrombocytopenia, and inflammatory arthropathy. The NOGO-targeting
CC nucleic acid is used to cleave RNA of the NOGO gene in the presence of a
CC divalent cation that is preferably Mg²⁺. Furthermore, the nucleic acid
CC may be contacted with a cell to reduce NOGO activity of the cell and
CC treat a patient having a condition associated with the level of NOGO. The
CC treatment may further comprise the use of one or more therapies.
CC In particular, the NOGO-targeting nucleic acid may be used to treat
CC central nervous system (CNS) injury and cerebrovascular accident (CVA,
CC stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The
CC present sequence is an amberzyme molecule of the invention.
XX
SQ Sequence 17 BP; 4 A; 3 C; 8 G; 2 U; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 1573 TCCAGCTCTCCATG 1587
Db 17 TCCAGCTCTCCAGG 3
RESULT 221
ABK02376/c
ID ABK02376 standard; RNA; 17 BP.
AC ABK02376;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Amberzyme #48.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN MO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US04273.
XX
PR 11-FEB-2000; 2000US-181797P.

28-FEB-2000; 2000US-185516P.
06-MAR-2000; 2000US-187128P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
XX Blatt L, McSwigen J, Chowrira BM;
XX WPI; 2001-607195/69.
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
XX constructs, which down regulate expression of a CD20 gene or neurite
XX growth inhibitor gene useful for treating, e.g., lymphoma, leukemia,
XX and central nervous system injury
XX
XX Claim 88; Page 131; 200pp; English.
XX
XX The invention relates to a nucleic acid molecule which down regulates
XX expression of a CD20 gene and a nucleic acid molecule which down
XX regulates expression of a neurite growth inhibitor gene (NOCO).
XX The nucleic acids may be enzymatic nucleic acids (e.g., a ribozyme or a
XX DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
XX possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN
XX motif) or an amberzyme (cleaving RNA with an NGN triplet), a zinczyme
XX (cleaving RNA with a YG motif). The CD20-targeting nucleic acid is used
XX to cleave RNA of CD20 in the presence of a divalent cation that is
XX preferably Mg²⁺. Furthermore, it may be contacted with a cell to reduce
XX CD20 activity of the cell and treat a patient having a condition
XX associated with the level of CD20. The treatment may further comprise the
XX use of one or more therapies. In particular, the CD20-targeting
XX nucleic acid may be used to treat lymphoma, leukaemia, B-cell
XX lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky
XX low-grade or follicular NHL, lymphocytic leukaemia, HIV (human
XX immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL),
XX immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune
XX thrombocytopenia, and inflammatory arthropathy. The NOCO-targeting
XX nucleic acid is used to cleave RNA of the NOCO gene in the presence of a
XX divalent cation that is preferably Mg²⁺. Furthermore, the nucleic acid
XX may be contacted with a cell to reduce NOCO activity of the cell and
XX treat a patient having a condition associated with the level of NOCO. The
XX treatment may further comprise the use of one or more therapies.
XX In particular, the NOCO-targeting nucleic acid may be used to treat
XX central nervous system (CNS) injury and cerebrovascular accident (CVA,
XX stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
XX chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
XX Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
XX disease, muscular dystrophy, and/or other neurodegenerative disease
XX states which respond to the modulation of NOCO expression. The
XX present sequence is an amberzyme molecule of the invention.
XX
XX Sequence 17 BP; 4 A; 3 C; 8 G; 2 U; 0 other;
SQ
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1;
Oy 1573 TCCAGCTCTCCATG 1587
Db 16 TCCAGCTCTCTCAGG 2
RESULT 222
ABN08362/c
ID ABN08362 standard; DNA; 17 BP.
XX
XX ABN08362;
AC
XX 29-MAY-2002 (first entry)
XX DT
XX Human GDMMP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8354.
XX DE

Human; genome-derived myosin-like protein 1; hGDMMP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US16981.
XX
XX
XX 26-MAY-2000; 2000US-207456P.
XX 21-SEP-2000; 2000US-234687P.
XX 27-SEP-2000; 2000US-236359P.
XX 04-OCT-2000; 2000GB-0024263.
XX 30-JAN-2001; 2001WO-US00661.
XX 30-JAN-2001; 2001WO-US00662.
XX 30-JAN-2001; 2001WO-US00663.
XX 30-JAN-2001; 2001WO-US00664.
XX 30-JAN-2001; 2001WO-US00665.
XX 30-JAN-2001; 2001WO-US00666.
XX 30-JAN-2001; 2001WO-US00667.
XX 30-JAN-2001; 2001WO-US00668.
XX 30-JAN-2001; 2001WO-US00669.
XX 30-JAN-2001; 2001WO-US00670.
XX 05-FEB-2001; 2001US-266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMMP-1
XX proteins, or as specific biomolecule capture probes for
XX surface-enhanced laser desorption/ionization, comprises human
XX myosin-like protein hGDMMP-1 -
XX
XX Disclosure; SEQ ID 8354/ 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMMP-1). The protein and polynucleotide sequences of
XX hGDMMP-1 can be used in gene therapy and vaccine production. The
XX hGDMMP-1 nucleic acids can be used as probes to detect, characterise
XX and quantify hGDMMP-1 nucleic acids in samples, as amplification
XX substrates, to provide initial substrates for the recombinant engineering
XX of hGDMMP-1 protein variants having desired phenotypic improvements, and
XX for expressing the proteins. The hGDMMP-1 proteins or polypeptides may
XX be used as immunogens to raise antibodies that specifically recognise
XX hGDMMP-1 proteins, as standards in assays used to determine the
XX concentration and/or amount specifically of hGDMMP proteins, as specific
XX biomolecule capture probes for surface-enhanced laser desorption
XX ionisation, as therapeutic supplement in patients having specific
XX deficiency in hGDMMP-1 production, and in vaccines or for replacement
XX therapy. The polynucleotide sequences encoding hGDMMP-1 may be used for
XX diagnosing a disorder associated with the expression of hGDMMP-1, in
XX particular heart and skeletal muscle disorders. hGDMMP-1 is localised to
XX chromosome 22. The present sequence represents an oligomer used in the
XX screening of the hGDMMP-1 sequence in the exemplification of the present
XX invention.
XX N.B. The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence.
XX
XX Sequence 17 BP; 6 A; 2 C; 8 G; 1 T; 0 other;
SQ
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1;
Oy 1573 TCCAGCTCTCCATG 1587
XXXXXXXXXXXXXXXXXX

Db 17 TCAGCTCCTCTTG 3

RESULT 223
ABN08363/c
ID ABN08363 standard; DNA, 17 BP.
XX
AC ABN08363;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8355.
XX
KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KM skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
PR 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 05-FEB-2001; 2001US-266860P.
XX
XX (AEOM-) AEOMICA INC.
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
PS Disclosure; SEQ ID 8355; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
XX hGDMLP-1 can be used in gene therapy and vaccine production. The
XX hGDMLP-1 nucleic acids can be used as probes to detect, characterise
XX and quantify hGDMLP-1 nucleic acids in samples, as amplification
XX substrates, to provide initial substrates for the recombinant engineering
XX of hGDMLP-1 protein variants having desired phenotypic improvements, and
XX for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
XX be used as immunogens to raise antibodies that specifically recognise
XX hGDMLP-1 proteins, as standards in assays used to determine the
XX concentration and/or amount specifically of hGDMLP proteins, as specific
XX biomolecule capture probes for surface-enhanced laser desorption/
XX ionisation, as therapeutic supplement in patients having specific
XX deficiency in hGDMLP-1 production, and in vaccines or for replacement
XX therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
XX diagnosing a disorder associated with the expression of hGDMLP-1, in
XX particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
XX chromosome 22. The present sequence represents an oligomer used in the
XX screening of the hGDMLP-1 sequence in the exemplification of the present

CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
CC
XX
SQ Sequence 17 BP; 5 A; 2 C; 9 G; 1 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1;
QY 1573 TCAGCTCCTCTTGATG 1587
DB 16 TCAGCTCCTCTTG 2
RESULT 224
ABN08364/c
ID ABN08364 standard; DNA, 17 BP.
XX
AC ABN08364;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8356.
XX
KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KM skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
PR 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 05-FEB-2001; 2001US-266860P.
XX
XX (AEOM-) AEOMICA INC.
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
PS Disclosure; SEQ ID 8356; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
XX hGDMLP-1 can be used in gene therapy and vaccine production. The
XX hGDMLP-1 nucleic acids can be used as probes to detect, characterise
XX and quantify hGDMLP-1 nucleic acids in samples, as amplification
XX substrates, to provide initial substrates for the recombinant engineering

CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
CC
CC
SQ Sequence 17 BP; 6 A; 2 C; 8 G; 1 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1573 TCCAGCTCTCCATG 1587
Db 15 TCCAGCTCTCTCTG 1

RESULT 225
ABN08381/c
ID ABN08381 standard; DNA; 17 BP.
XX
AC ABN08381;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8373.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
PR 26-MAY-2000; 2000US-207456P.
XX
PR 21-SEP-2000; 2000US-234687P.
XX
PR 27-SEP-2000; 2000US-236359P.
XX
PR 04-OCT-2000; 2000GB-0024263.
XX
PR 30-JAN-2001; 2001WO-US00661.
XX
PR 30-JAN-2001; 2001WO-US00662.
XX
PR 30-JAN-2001; 2001WO-US00663.
XX
PR 30-JAN-2001; 2001WO-US00664.
XX
PR 30-JAN-2001; 2001WO-US00665.
XX
PR 30-JAN-2001; 2001WO-US00666.
XX
PR 30-JAN-2001; 2001WO-US00667.
XX
PR 30-JAN-2001; 2001WO-US00668.
XX
PR 30-JAN-2001; 2001WO-US00669.
XX
PR 30-JAN-2001; 2001WO-US00670.
XX
PR 05-FEB-2001; 2001US-266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX

PT New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
XX Disclosure; SEQ ID 8373; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
CC
CC
SQ Sequence 17 BP; 5 A; 5 C; 5 G; 2 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1507 CAGCGGCTGTGCAC 1521
Db 17 CAGCTGGCTGTGCAC 3

RESULT 226
ABN08384/c
ID ABN08384 standard; DNA; 17 BP.
XX
AC ABN08384;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8376.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
PR 26-MAY-2000; 2000US-207456P.
XX
PR 21-SEP-2000; 2000US-234687P.
XX
PR 27-SEP-2000; 2000US-236359P.
XX
PR 04-OCT-2000; 2000GB-0024263.
XX
PR 30-JAN-2001; 2001WO-US00661.
XX
PR 30-JAN-2001; 2001WO-US00662.
XX
PR 30-JAN-2001; 2001WO-US00663.
XX
PR 30-JAN-2001; 2001WO-US00664.
XX
PR 30-JAN-2001; 2001WO-US00665.
XX

PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX
XX (AEOM-) AEOMICA INC.
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
PS Disclosure; SEQ ID 8376; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP-1 proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 4 A; 5 C; 6 G; 2 T; 0 other;
XX
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1506 CCAGCGGCTGTGCA 1520
DB 15 CCAGCTGGCTGTGCA 1
XX
RESULT 227
ABN08951
ID ABN08951 standard; DNA; 17 BP.
XX
AC ABN08951;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8943.
XX
XX Human; genome-derived myosin-like protein 1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200192524-A2.
XX
XX

PD 06-DEC-2001.
XX
XX
XX 25-MAY-2001; 2001WO-US16981.
XX
XX 26-MAY-2000; 2000US-207456P.
XX 21-SEP-2000; 2000US-234687P.
XX 27-SEP-2000; 2000US-26359P.
XX 04-OCT-2000; 2000GB-0024263.
XX 30-JAN-2001; 2001WO-US00661.
XX 30-JAN-2001; 2001WO-US00662.
XX 30-JAN-2001; 2001WO-US00663.
XX 30-JAN-2001; 2001WO-US00664.
XX 30-JAN-2001; 2001WO-US00665.
XX 30-JAN-2001; 2001WO-US00666.
XX 30-JAN-2001; 2001WO-US00667.
XX 30-JAN-2001; 2001WO-US00668.
XX 30-JAN-2001; 2001WO-US00669.
XX 30-JAN-2001; 2001WO-US00670.
XX 05-FEB-2001; 2001US-266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
XX proteins, or as specific biomolecule capture probes for
XX surface-enhanced laser desorption/ionization, comprises human
XX myosin-like protein hGDMLP-1 -
XX
PS Disclosure; SEQ ID 8943; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
XX hGDMLP-1 can be used in gene therapy and vaccine production. The
XX hGDMLP-1 nucleic acids can be used as probes to detect, characterise
XX and quantify hGDMLP-1 nucleic acids in samples, as amplification
XX substrates, to provide initial substrates for the recombinant engineering
XX of hGDMLP-1 protein variants having desired phenotypic improvements, and
XX for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
XX be used as immunogens to raise antibodies that specifically recognise
XX hGDMLP-1 proteins, as standards in assays used to determine the
XX concentration and/or amount specifically of hGDMLP-1 proteins, as specific
XX biomolecule capture probes for surface-enhanced laser desorption
XX ionisation, as therapeutic supplement in patients having specific
XX deficiency in hGDMLP-1 production, and in vaccines or for replacement
XX therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
XX diagnosing a disorder associated with the expression of hGDMLP-1, in
XX particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
XX chromosome 22. The present sequence represents an oligomer used in the
XX screening of the hGDMLP-1 sequence in the exemplification of the present
XX invention.
XX N.B. The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 4 A; 4 C; 8 G; 1 T; 0 other;
XX
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1355 CAGCGGCTGTGAAGAG 1369
DB 3 CAGCGGCTGTGAAGAG 17
XX
RESULT 228
ABN08952
ID ABN08952 standard; DNA; 17 BP.
XX
AC ABN08952;
XX

XX 29-MAY-2002 (first entry)
DT
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8944.
DE
XX Human; genome-derived myosin-like protein 1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX Homo sapiens.
OS
XX WO200192524-A2..
PN
XX 06-DEC-2001.
PD
XX 25-MAY-2001; 2001WO-US16981.
PF
XX 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX (AEOM-1) AEOMICA INC.
PA
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI WPI; 2002-179446/23.
DR
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
PT
XX Disclosure; SEQ ID 8944; 214pp; English.
PS
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
CC
XX Sequence 17 BP; 3 A; 5 C; 8 G; 1 T; 0 other;
SQ
Query Match 1.0%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1355 CAGCGCTCGAAGAG 1369
Db 2 CGCGCCTCGAAGAG 16
RESULT 229
ABN08953
ID ABN08953 standard; DNA; 17 BP.
XX
AC ABN08953;
XX
DT 29-MAY-2002 (first entry)
DE
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8945.
DE
XX Human; genome-derived myosin-like protein 1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX Homo sapiens.
OS
XX WO200192524-A2..
PN
XX 06-DEC-2001.
PD
XX 25-MAY-2001; 2001WO-US16981.
PF
XX 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX (AEOM-1) AEOMICA INC.
PA
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI WPI; 2002-179446/23.
DR
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
PT
XX Disclosure; SEQ ID 8945; 214pp; English.
PS
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement

CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 3 A; 5 C; 7 G; 2 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1355 CAGCGCCTGGAAG 1369
1 CGCGCGCTGGAAG 15
Db
RESULT 230
ABN09008
ID ABN09008 standard; DNA; 17 BP.
XX
AC ABN09008;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9000.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
XX 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
PS Disclosure; SEQ ID 9000; 214P; English.
XX
XX The present invention describes a human genome-derived myosin-like

CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 2 A; 6 C; 8 G; 1 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1505 GCCAGCGCGCTGTGC 1519
3 GCCAGCGCGCGCTGC 17
Db
RESULT 231
ABN09011
ID ABN09011 standard; DNA; 17 BP.
XX
AC ABN09011;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9003.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
XX 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
PA (AEOM-) AEOMICA INC.
XX
XX

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMLP-1 -
 XX
 PS Disclosure; SEQ ID 9003; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
 CC hGDMLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 7 G; 2 T; 0 other;
 Qy
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Db 1506 CCAGCCGCGGTGCA 1520
 1 CCAGCCGCGGTGCA 15
 XX
 RESULT 232
 ABR34296/C
 ID ABR34296 standard; DNA; 17 BP.
 XX
 AC ABR34296;
 XX
 DT 12-JUN-2003 (first entry)
 XX
 DE Opioid receptor D1 probe SEQ ID No 82.
 XX
 KW Eating disorder; polymorphism; dataset; allele; HGBASE identification;
 KW serotonin receptor 1D; delta-opioid receptor; dopamine receptor D2;
 KW anorexia nervosa; bulimia nervosa; probe; ss.
 XX
 OS Unidentified.
 XX
 PN MO2003012143-A1.
 XX
 PD 13-FEB-2003.
 XX
 PF 16-JUL-2002; 2002WO-US22555.
 XX
 PR 16-JUL-2001; 2001US-305153P.
 PR 20-JUL-2001; 2001US-306440P.
 PR 13-NOV-2001; 2001US-331285P.
 PR 19-DEC-2001; 2001US-340843P.

PR 19-DEC-2001; 2001US-340844P.
 XX
 PA (PRIC-) PRICE FOUND LTD.
 XX
 PI Bergen AW, Yeager M;
 XX
 DR WPI; 2003-268122/26.
 XX
 PT New nucleic acid molecule having polymorphisms in the serotonin
 PT receptor 1D, delta-opioid receptor, or dopamine receptor D2, useful in
 PT diagnostic and prognostic assays for eating disorders, such as anorexia
 PT and bulimia nervosa -
 XX
 PS Example 3; Page 60; 149pp; English.
 XX
 CC The invention relates to a novel isolated nucleic acid molecule
 CC comprising a variant gene associated with an eating disorder and selected
 CC from any of 119 polymorphisms with their corresponding genotyping in
 CC dataset, alleles and HGBASE identification, given in the specification.
 CC The novel nucleic acid molecule has polymorphisms in the serotonin
 CC receptor 1D, delta-opioid receptor, or dopamine receptor D2, which is
 CC useful in diagnostic and prognostic assays for eating disorders, in
 CC particular anorexia nervosa and bulimia nervosa. This polynucleotide
 CC sequence represents a opioid receptor 1D probe of the invention.
 XX
 SQ Sequence 17 BP; 1 A; 4 C; 5 G; 7 T; 0 other;
 Qy
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Db 1831 AAAGATGATGCCACA 1845
 15 AAAGATGATGCCACA 1
 XX
 RESULT 233
 ABR38813/C
 ID ABR38813 standard; DNA; 17 BP.
 XX
 AC ABR38813;
 XX
 DT 12-JUN-2003 (first entry)
 XX
 DE Tumour suppression related human fukutin oligo SEQ ID No 4450.
 XX
 KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.
 XX
 OS Homo sapiens.
 XX
 PN MO2003025175-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB04208.
 XX
 PR 17-SEP-2001; 2001FR-0011978.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-31353/30.
 XX
 PF New isolated nucleic acid, useful for treating viral diseases
 PF associated with tumors and cell degeneration, also related
 PF polypeptides, antibodies and transfected cells -
 XX
 PS Disclosure; Page 554; 720pp; French.
 XX

XX New isolated nucleic acid molecule encoding a delta opioid receptor
PT variant associated with an eating or energy homeostasis disorder,
PT useful for diagnosing a genetic predisposition to such disorder, e.g.
PT anorexia nervosa -
XX
PS Example; Page 19; 39pp; English.
XX
CC The invention relates to an isolated nucleic acid molecule encoding a
CC delta opioid receptor variant associated with an eating or energy
CC homeostasis disorder. Also included are a delta opioid receptor variant
CC encoded by the nucleic acid, an isolated antibody that specifically
CC recognises the delta opioid receptor variant, a vector comprising the
CC nucleic acid, a host cell transformed to contain the vector, producing
CC the polypeptide by culturing the host cell, identifying an agent which
CC modulates the expression of the nucleic acid, diagnosing a genetic
CC predisposition to an eating or energy homeostasis disorder by detecting
CC the presence or absence of the variant nucleic acid in a patient sample,
CC an allele specific primer that detects a polymorphism in the gene
CC encoding a delta opioid receptor associated with an eating or energy
CC homeostasis disorder and a non-human transgenic animal modified to
CC contain the variant nucleic acids. The variants are named OPRD1-1
CC to OPRD1-8. The human opioid receptor gene is located on chromosome 1.
CC The nucleic acid molecules and delta opioid receptor variant are
CC useful for diagnosing a genetic predisposition to an eating or energy
CC homeostasis disorder, such as anorexia nervosa. The allele specific
CC primer is useful for detecting polymorphism in the gene encoding a
CC delta opioid receptor associated with the disorder cited.
CC The present sequence is a genotyping PCR probe for detecting the
CC presence of a particular SNP (single nucleotide polymorphism) in a
CC sample.
XX
SQ Sequence 17 BP; 1 A; 4 C; 5 G; 7 T; 0 other;
QY 1831 AAAGATGATGCCACA 1845
Db 15 AAAGATGAGCCACA 1
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
RESULT 236
ABZ61761/C
ID ABZ61761 standard; RNA; 17 BP.
XX
AC ABZ61761;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human H-Ras DNAzyme target #552.
XX
KM Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KM enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;
KM anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US16840.
XX
PR 29-MAY-2001; 2001US-294140P.
PR 06-JUN-2001; 2001US-296249P.
PR 10-SEP-2001; 2001US-318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcawiggen J;
XX

DR WPI; 2003-140484/13.
XX
XX Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX
PS Claim 58; Page 121; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytosstatic, anti-HIV, and
CC anti-rheumatic activity. The nucleic acid molecules are useful for
CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
CC acids are also useful for treating breast, ovarian, colorectal, lung,
CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
CC ABZ65520 - ABZ65524, ABZ65530 - ABZ65585 represent substrate/target
CC sequences for the human ribozymes of the invention.
XX
SQ Sequence 17 BP; 3 A; 4 C; 8 G; 2 U; 0 other;
QY 2283 GGCTCCAGAACCCCT 2297
Db 17 GGCTCCAGAGCCCT 3
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
RESULT 237
ABZ64832
ID ABZ64832 standard; RNA; 17 BP.
XX
AC ABZ64832;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human HER2 DNAzyme substrate #289.
XX
KM Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KM enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;
KM anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US16840.
XX
PR 29-MAY-2001; 2001US-294140P.
PR 06-JUN-2001; 2001US-296249P.
PR 10-SEP-2001; 2001US-318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcawiggen J;
XX
DR WPI; 2003-140484/13.
XX
XX Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX
PS Claim 4; Page 138; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,

CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic acid molecule of the invention has cytosstatic, anti-HIV, and anti-rheumatic activity. The nucleic acid molecules are useful for reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are also useful for treating breast, ovarian, colorectal, lung, prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences shown in AB259889 - AB262216, AB264544 - AB265531, CC AB26520 - AB26524, AB26530 - AB26585 represent substrate/target sequences for the human ribozymes of the invention.

CC Sequence 17 BP; 3 A; 4 C; 7 G; 3 U; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;

Best Local Similarity 73.3%; Pred. No. 2e+02; Mismatches 1; Indels 0; Gaps 0;

Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

DB 2110 GGCATGAGTCTTG 2124
1 GGCAGGAGACACUG 15

RESULT 238

AB265210 standard; RNA; 17 BP.

AB265210;

21-MAR-2003 (first entry)

Human HER2 DNAzyme substrate #667.

Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;

enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;

anti-rheumatic; cancer; AIDS; ss.

Homo sapiens.

WO200297114-A2.

29-MAY-2002; 2002WO-US16840.

29-MAY-2001; 2001US-294140P.

06-JUN-2001; 2001US-296249P.

10-SEP-2001; 2001US-318471P.

(RIBO-) RIBOZYME PHARM INC.

Mcswiggen J;

WPI; 2003-140484/13.

Novel short interfering RNA and enzymatic nucleic acid useful for treating cancer, modulates the expression of a nucleic acid encoding HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences

Claim 4; Page 145; 185pp; English.

The invention relates to a novel short interfering RNA (siRNA) nucleic acid molecule or an enzymatic nucleic acid molecule, that modulates

expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras, human immunodeficiency virus (HIV) or a component of HIV. The nucleic

acid molecule of the invention has cytosstatic, anti-HIV, and anti-rheumatic activity. The nucleic acid molecules are useful for

reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are also useful for treating breast, ovarian, colorectal, lung,

prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences shown in AB259889 - AB262216, AB264544 - AB265531,

AB26520 - AB26524, AB26530 - AB26585 represent substrate/target sequences for the human ribozymes of the invention.

Sequence 17 BP; 3 A; 3 C; 7 G; 4 U; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 2e+02; Mismatches 1; Indels 0; Gaps 0;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

DB 2273 TCAAGTGGATGCTC 2287
1 UCAAGUGAUGGCCG 15

RESULT 239

AB265221 standard; RNA; 17 BP.

AB265221;

21-MAR-2003 (first entry)

Human HER2 DNAzyme substrate #678.

Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;

enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;

anti-rheumatic; cancer; AIDS; ss.

Homo sapiens.

WO200297114-A2.

29-MAY-2002; 2002WO-US16840.

29-MAY-2001; 2001US-294140P.

06-JUN-2001; 2001US-296249P.

10-SEP-2001; 2001US-318471P.

(RIBO-) RIBOZYME PHARM INC.

Mcswiggen J;

WPI; 2003-140484/13.

Novel short interfering RNA and enzymatic nucleic acid useful for treating cancer, modulates the expression of a nucleic acid encoding HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences

Claim 4; Page 146; 185pp; English.

The invention relates to a novel short interfering RNA (siRNA) nucleic acid molecule or an enzymatic nucleic acid molecule, that modulates

expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras, human immunodeficiency virus (HIV) or a component of HIV. The nucleic

acid molecule of the invention has cytosstatic, anti-HIV, and anti-rheumatic activity. The nucleic acid molecules are useful for

reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are also useful for treating breast, ovarian, colorectal, lung,

prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences shown in AB259889 - AB262216, AB264544 - AB265531,

AB26520 - AB26524, AB26530 - AB26585 represent substrate/target sequences for the human ribozymes of the invention.

Sequence 17 BP; 4 A; 2 C; 7 G; 4 U; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;

Best Local Similarity 66.7%; Pred. No. 2e+02; Mismatches 1; Indels 0; Gaps 0;

Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

DB 2320 CAGAGTATGCTCG 2334
2 CAGAGUAGUUGUG 16

RESULT 240

ABF46426
ID ABR46426 standard; DNA; 13 BP.
XX
AC ABR46426;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 146423 for detecting SNP TSC0036912.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 146423; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and
CC AB100010-AB12073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 5 A; 0 C; 6 G; 2 T; 0 other;
XX
Query Match 0.9%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1872 AGAGATGAGATG 1884
DB 1 AGAGATGAGATG 13
|||||
RESULT 241
ABF46427/C
ID ABR46427 standard; DNA; 13 BP.
XX
AC ABR46427;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 146424 for detecting SNP TSC0036912.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PN 18-OCT-2001.
XX
PD 06-APR-2001; 2001WO-IB00713.
XX
PF 07-APR-2000; 2000DE-1019173.
XX
PR (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 146424; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation.
XX ABC00010-ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and
XX AB100010-AB12073 represent the oligomers described in the invention.
XX NOTE: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 2 A; 6 C; 0 G; 5 T; 0 other;
XX
Query Match 0.9%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1872 AGAGATGAGATG 1884
DB 13 AGAGATGAGATG 1
|||||
RESULT 242
ABF49446
ID ABR49446 standard; DNA; 13 BP.
XX
AC ABR49446;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 149443 for detecting SNP TSC0037724.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX

XX WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -
 XX
 PS Claim 1; SEQ ID 149443; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
 CC AB100010-AB182073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 CC
 XX Sequence 13 BP; 4 A; 0 C; 4 G; 5 T; 0 other;
 SQ
 Query Match 0.9%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2161 AGAAATGTTTGG 2173
 DB 1 AGAAATGTTTGG 13
 XX
 RESULT 243
 ABF49447/C
 ID ABF49447 standard; DNA; 13 BP.
 XX
 AC ABF49447;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 149444 for detecting SNP TSC0037724.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 OS
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB00713.
 XX
 PR 07-APR-2000; 2000DE-1019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -
 XX
 PS Claim 1; SEQ ID 149444; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
 CC AB100010-AB182073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 CC
 XX Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 other;
 SQ
 Query Match 0.9%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2161 AGAAATGTTTGG 2173
 DB 13 AGAAATGTTTGG 1
 XX
 RESULT 244
 ABH06188
 ID ABH06188 standard; DNA; 13 BP.
 XX
 AC ABH06188;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 206165 for detecting SNP TSC0050500.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 OS
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB00713.
 XX
 PR 07-APR-2000; 2000DE-1019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -
 XX
 PS Claim 1; SEQ ID 206165; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
 CC AB100010-AB182073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 CC
 XX Sequence 13 BP; 6 A; 0 C; 4 G; 3 T; 0 other;
 SQ
 Query Match 0.9%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;

```
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1821 GAAGATGTTGAA 1833
    |||||
    1 GAAGATGTTGAA 13
Db

RESULT 245
ABH06189/c
ID ABH06189 standard; DNA; 13 BP.
XX
XX ABH06189;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 206166 for detecting SNP TSC0050500.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB00713.
PF
XX
XX 07-APR-2000; 2000DE-1019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
PT
XX
XX Claim 1; SEQ ID 206166; 29bp + Sequence Listing; German.
PS
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB12073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pcr_sequences.
CC
XX
XX Sequence 13 BP; 3 A; 4 C; 0 G; 6 T; 0 other;
SQ

Query Match 0.9%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1821 GAAGATGTTGAA 1833
    |||||
    13 GAAGATGTTGAA 1
Db

RESULT 246
ABH51404/c
ID ABH51404 standard; DNA; 13 BP.
XX
XX ABH51404;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 251381 for detecting SNP TSC0061353.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB00713.
PF
XX
XX 07-APR-2000; 2000DE-1019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
PT
XX
XX Claim 1; SEQ ID 251381; 29bp + Sequence Listing; German.
PS
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB12073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pcr_sequences.
CC
XX
XX Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 other;
SQ

Query Match 0.9%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2707 TATCCACACATTA 2719
    |||||
    13 TATCCACACATTA 1
Db

RESULT 247
ABH51405
ID ABH51405 standard; DNA; 13 BP.
XX
XX ABH51405;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 251382 for detecting SNP TSC0061353.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
```

XX 06-APR-2001; 2001WO-IB00713.
XX
XX 07-APR-2000; 2000DE-1019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
XX Claim 1; SEQ ID 251382; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB102073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 other;

Query Match 0.9%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2707 TATCCACACATTA 2719
Db 1 TATCCACACATTA 13

RESULT 248
AAFS1570
ID AAFS1570 standard; DNA; 15 BP.
XX
AC AAFS1570;
XX
XX 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #2530.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytosatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborthoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
XX WO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU00693.
XX
XX 21-JUN-1999; 99US-0140345.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
PI

XX
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
XX Example 8; Page 77; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAFS151 and
CC AAFS153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborthoea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 6 A; 2 C; 6 G; 1 T; 0 other;

Query Match 0.9%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2057 AGGAGCAGATGAC 2069
Db 3 AGGAGCAGATGAC 15

RESULT 249
AAFS1571
ID AAFS1571 standard; DNA; 15 BP.
XX
AC AAFS1571;
XX
XX 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #2531.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytosatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborthoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
XX WO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU00693.
XX
XX 21-JUN-1999; 99US-0140345.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by
PT

PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
XX Example 8; Page 77; 201pp; English.
CC The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
SQ Sequence 15 BP; 7 A; 2 C; 5 G; 1 T; 0 other;
QY Query Match 0.9%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Db 2057 AGGAGCAGATGAC 2069
2 AGGAGCAGATGAC 14
RESULT 250
AAF52672
ID AAF52672 standard; DNA; 15 BP.
XX
AC AAF52672;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #3632.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
KM Homo sapiens.
XX
OS
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345.
XX
PA (MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX

PS Example 8; Page 84; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
SQ Sequence 15 BP; 0 A; 4 C; 7 G; 4 T; 0 other;
QY Query Match 0.9%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Db 2333 GGTCCTCGGGGT 2345
1 GGTCCTCGGGGT 13
RESULT 251
AAF52953/C
ID AAF52953 standard; DNA; 15 BP.
XX
AC AAF52953;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #3913.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
KM Homo sapiens.
XX
OS
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345.
XX
PA (MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
XX Example 8; Page 86; 201pp; English.
XX
PS The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an

CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-745161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrheoa, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.

CC Sequence 15 BP; 3 A; 4 C; 7 G; 1 T; 0 other;

Query Match 0.9%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1572 GTCCAGCTCTCTCC 1584
DB 15 GTCCAGCTCTCTCC 3

RESULT 252
AAF52954/C
ID AAF52954 standard; DNA; 15 BP.
XX AAF52954;
AC
XX 30-MAR-2001 (first entry)
DT
XX IGF-I oligonucleotide #3914.
DE
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cyostatic; dermatological; cardiant; vitruclide; ophthalmological; keloid;
XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; seborrheoa; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.

OS Homo sapiens.
XX
XX MO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU00693.
XX
XX 21-JUN-1999; 99US-0140345.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX

PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
PT
XX Example 8; Page 86; 201pp; English.

XX The present invention relates to a method for ameliorating the effects
XX of skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an

CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-745161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrheoa, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.

CC Sequence 15 BP; 3 A; 4 C; 7 G; 1 T; 0 other;

Query Match 0.9%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1572 GTCCAGCTCTCTCC 1584
DB 14 GTCCAGCTCTCTCC 2

RESULT 253
AAF52955/C
ID AAF52955 standard; DNA; 15 BP.
XX AAF52955;
AC
XX 30-MAR-2001 (first entry)
DT
XX IGF-I oligonucleotide #3915.
DE
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cyostatic; dermatological; cardiant; vitruclide; ophthalmological; keloid;
XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; seborrheoa; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.

OS Homo sapiens.
XX
XX MO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU00693.
XX
XX 21-JUN-1999; 99US-0140345.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX

PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
PT
XX Example 8; Page 86; 201pp; English.

XX The present invention relates to a method for ameliorating the effects
XX of skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and
XX AAF45153-745161). The method is useful for ameliorating the effects of
XX psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrheoa, keloids,

CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
 CC skin, a hyperneovascular condition such as a neovascular condition of the
 CC retina, brain or skin, growth factor-mediated malignancies, other
 CC sclerotic disease, kidney disease, hyperproliferation of the inside of
 CC blood vessels or any other hyperplasia.

XX
 SO Sequence 15 BP; 3 A; 3 C; 7 G; 2 T; 0 other;

Query Match 0.9%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2e+02;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1572 GTCGAGCTCTCC 1584

DB 13 GTCGAGCTCTCC 1

RESULT 254

AAH28575/C

ID AAH28575 standard; DNA; 15 BP.

AC AAH28575;

DT 17-JUL-2001 (first entry)

DE Human interleukin-13 allele specific oligonucleotide #61.

KW Human; interleukin-13; IL13; single nucleotide polymorphism; SNP;

KW cancer; inflammation; immune disorder; cytokine; asthma; chromosome 5q31;

KW fibrosis; forensic; disease susceptibility; drug screening; probe; ss.

OS Homo sapiens.

PN MO200123410-A2.

PD 05-APR-2001.

PF 27-SEP-2000; 2000WO-US26556.

PR 28-SEP-1999; 99US-0156489.

PA (GENA-) GENA1SSANCE PHARM INC.

PI Chew A, Denton RR, Nandabalan K, Stephens JC;

DR WPI; 2001-343160/36.

XX Novel polynucleotide comprising single nucleotide polymorphisms in

PT human interleukin-13 gene is useful for studying expression and

PT function of interleukin-13, as well as diagnosing and treating cancer,

PT inflammatory, and immune disorders

PS Claim 15; Page 20; 85pp; English.

XX The present invention provides the protein, cDNA and genomic sequences of

CC human interleukin-13 (IL13), and describes the single nucleotide

CC polymorphisms (SNPs) found within the gene, which is found on chromosome

CC 5q31. IL13 is a pro-inflammatory cytokine thought to be involved in the

CC pathogenesis of asthma and other immune and inflammatory diseases. The

CC IL13 sequences and the SNPs identified can be used in drug screening, to

CC determine an individual's susceptibility to disease, in forensic and

CC paternity testing, and to identify treatments for cancer, immune and

CC inflammatory diseases, including asthma and diseases characterised by

CC fibrosis. The present sequence is an IL13 allele-specific

CC oligonucleotide.

SO Sequence 15 BP; 4 A; 8 C; 2 G; 1 T; 0 other;

Query Match 0.9%; Score 13; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 2e+02;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1649 TGCTGGAGGGGT 1661

DB 15 TGCTGGAGGGGT 3

RESULT 255

ABK41344/C

ID ABK41344 standard; RNA; 15 BP.

AC ABK41344;

DT 21-MAY-2002 (first entry)

DE Human eIF2Bgamma ribozyme sequence tag #9.

KW Human; ss; translation initiation factor 2B gamma subunit;

KW eIF2Bgamma; ribozyme; ribozyme sequence tag; RST; TST;

KW target sequence tag; HCV; hepatitis C virus infection; virucide;

KW hepatotropic; antiinflammatory; proteasome alpha subunit; PMSA1.

OS Homo sapiens.

PN MO200183754-A2.

PD 08-NOV-2001.

PF 02-MAY-2001; 2001WO-US14337.

PR 02-MAY-2000; 2000US-0563794.

PA (IMMU-) IMMUSOL INC.

PI Kruger M, Welch PJ, Barber JR;

DR WPI; 2002-034514/04.

XX Identifying cellular regulators essential in pathogenesis of infectious

XX agents, useful for treatment of infectious diseases preferably viral

XX diseases especially hepatitis C virus (HCV)

PS Claim 16; Fig.4D; 74pp; English.

XX The invention relates to a randomised ribozyme gene vector library

CC which is introduced into a population of cells expressing negative

CC selection marker gene operatively linked to viral nucleic acid acted on

CC by cellular regulator of virus replication or expression (e.g. the

CC human translation initiation factor 2B gamma subunit, eIF2Bgamma,

CC and proteasome alpha subunit 1, PMSA1, acting on Hepatitis C virus, HCV,

CC sequences) and a target recognition sequence of recovered ribozymes are

CC sequenced to identify the cellular regulator. Also included are target

CC sequence tags, RST, derived from eIF2Bgamma and PMSA1, the ribozyme

CC in the specification), methods of identifying the ribozyme sequences

CC and other compounds having a positive or negative effect on viral

CC replication via interaction with the cellular regulator

CC The methods are useful for identifying a cellular regulator of virus

CC replication or expression, for identifying a compound that

CC modulates the activity of a viral cellular regulator, identifying

CC a ribozyme reactive with a cellular regulator of virus replication or

CC expression, and for treating an HCV infection by inhibiting the activity

CC of a cellular regulator involved in HCV replication. The ribozymes

CC and inhibitory compounds identified by the above screening methods are

CC used to reduce the severity of such an infection. The methods allow rapid

CC and efficient identification of cellular genes involved in the

CC propagation or pathogenesis of infectious agents. The present

CC sequence is a ribozyme sequence tag, RST, of the invention.

SO Sequence 15 BP; 4 A; 4 C; 5 G; 2 U; 0 other;

Query Match 0.9%; Score 13; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 2e+02;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1346 CAGTTCTGCAGC 1358
 XX |||||
 DB 14 CAGTTCTGCAGC 2

RESULT 256
 AAX63934/c
 ID AAX63934 standard; RNA; 17 BP.
 XX AAX63934;
 AC
 XX 20-JUL-1999 (first entry)
 DT
 XX
 DE Rabbit stromelysin hammerhead target SEQ ID NO:566.
 XX
 KW Arthritic condition; graft tolerance; immune response; target; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.

OS Oryctolagus cuniculus.
 XX
 XX MO9618736-A2.
 PN 20-JUN-1996.
 PD
 XX
 XX 22-NOV-1995; 95WO-US15516.
 PF
 XX 05-OCT-1995; 95US-0541365.
 PR 13-DEC-1994; 94US-0354920.
 PR 23-DEC-1994; 94US-0363253.
 PR 23-DEC-1994; 94US-0363254.
 PR 17-FEB-1995; 95US-0390850.
 PR 20-APR-1995; 95US-0426124.
 PR 02-MAY-1995; 95US-0432874.
 PR 04-MAY-1995; 95US-0434509.
 PR 07-JUL-1995; 95US-0000951.
 PR 07-JUL-1995; 95US-0000974.
 PR 07-AUG-1995; 95US-0512861.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 PI Draper K, Gustofson J, McSwigen J, Pavco P, Stinchcomb DT;
 PI Beigelman L, Karpelsky A, Modak A, Usman N, Burgin A;
 PI Matulic-Adamic J, Jarvis T, Thompson JD, Wincott F;
 XX
 DR WPI; 1996-300653/30.
 XX
 PT Enzymatic nucleic acid molecules having a hammer-head motif - used
 PT for the treatment of arthritis, induction of graft tolerance or
 PT treatment of auto-immune diseases
 PT
 XX
 PS Example 1; Page 154; 307pp; English.
 XX
 CC The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose
 CC residues; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii)
 CC at least ten 2'-O-methyl modifications; and (iv) a 3'-end modification.
 CC The ENA's can inhibit collagenase and stromelysin production in the
 CC synovial membrane of joints for the treatment or prevention of arthritis,
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention.

QY 2416 CTGCTGAAGGAG 2428
 XX |||||
 DB 15 CTGCTGAAGGAG 3

Query Match 0.9%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 257
 AAX63935/c
 ID AAX63935 standard; RNA; 17 BP.
 XX AAX63935;
 AC
 XX 20-JUL-1999 (first entry)
 DT
 XX
 DE Rabbit stromelysin hammerhead target SEQ ID NO:567.
 XX
 KW Arthritic condition; graft tolerance; immune response; target; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.

OS Oryctolagus cuniculus.
 XX
 XX MO9618736-A2.
 PN 20-JUN-1996.
 PD
 XX
 XX 22-NOV-1995; 95WO-US15516.
 PF
 XX 05-OCT-1995; 95US-0541365.
 PR 13-DEC-1994; 94US-0354920.
 PR 23-DEC-1994; 94US-0363253.
 PR 23-DEC-1994; 94US-0363254.
 PR 17-FEB-1995; 95US-0390850.
 PR 20-APR-1995; 95US-0426124.
 PR 02-MAY-1995; 95US-0432874.
 PR 04-MAY-1995; 95US-0434509.
 PR 07-JUL-1995; 95US-0000951.
 PR 07-JUL-1995; 95US-0000974.
 PR 07-AUG-1995; 95US-0512861.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 PI Draper K, Gustofson J, McSwigen J, Pavco P, Stinchcomb DT;
 PI Beigelman L, Karpelsky A, Modak A, Usman N, Burgin A;
 PI Matulic-Adamic J, Jarvis T, Thompson JD, Wincott F;
 XX
 DR WPI; 1996-300653/30.
 XX
 PT Enzymatic nucleic acid molecules having a hammer-head motif - used
 PT for the treatment of arthritis, induction of graft tolerance or
 PT treatment of auto-immune diseases
 PT
 XX
 PS Example 1; Page 154; 307pp; English.
 XX
 CC The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose
 CC residues; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii)
 CC at least ten 2'-O-methyl modifications; and (iv) a 3'-end modification.
 CC The ENA's can inhibit collagenase and stromelysin production in the
 CC synovial membrane of joints for the treatment or prevention of arthritis,
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also

Sequence 17 BP; 5 A; 2 C; 7 G; 3 U; 0 other;

ID AAX01105 standard; DNA; 17 BP.

AC AAX01105;
 XX 23-MAR-1999 (first entry)
 XX
 DE PCR primer for rat adenosine kinase coding sequence.
 XX
 KM Adenosine kinase; cytotoxic nucleoside resistance; anticancer; antiviral;
 KM liver tumor; gout; acquired immune deficiency syndrome; tissue injury;
 KM adenosine concentration; cytoprotection; rat; PCR primer; ss.
 OS
 OS Synthetic.
 OS Rattus sp.
 XX
 PN US5861294-A.
 XX
 PD 19-JAN-1999.
 XX
 PP 07-JUN-1995; 95US-0479614.
 XX
 PR 07-JUN-1995; 95US-0479614.
 XX
 PA (ABBO) ABBOTT LAB.
 XX
 PI Cowart MD, Halbert DN, Kerwin JF, McNally T;
 XX
 DR WPI; 1999-130392/11.
 XX
 PT New nucleic acid encoding adenosine kinases and related
 PT oligo-nucleotides - expression vectors and transformed cells, used
 PT to modulate adenosine levels and to screen for specific modulators
 XX
 PS Disclosure; Column 43; 39pp; English.
 XX
 CC This sequence is a PCR primer for DNA encoding the rat brain adenosine
 CC kinase (AK) of the invention. Cells transformed with the DNA are used to
 CC produce recombinant AK. The AK is used: (i) to screen for specific
 CC agonists and antagonists; (ii) to raise antibodies; and
 CC (iii) therapeutically (reduced levels of AK are associated with
 CC resistance to nucleoside analogues with cytotoxic, anticancer and
 CC antiviral properties, with liver tumors, gout and acquired immune
 CC deficiency syndrome). Fragments of the DNA sequence are used as primers
 CC and probes to screen DNA libraries and for identifying AK-encoding
 CC nucleic acid. Also as antisense therapeutics (particularly to increase
 CC local adenosine concentrations at the site of tissue injury, increasing
 CC the level of cytoprotection).
 CC
 XX
 SQ Sequence 17 BP; 4 A; 2 C; 2 G; 4 T; 5 other;
 XX
 QY Query Match 0.9%; Score 13; DB 1; Length 17;
 Best Local Similarity 66.7%; Pred. No. 2.3e+02;
 Matches 10; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
 XX
 DB 2400 GGAGCACTTTTAA 2414
 16 GRAGAAVTTTTRA 2
 XX
 RESULT 261
 ABN86972/C
 ID ABN86972 standard; RNA; 17 BP.
 XX
 AC ABN86972;
 XX
 DT 29-JUN-2002 (first entry)
 XX
 DE Hepatitis C virus NS5B+ RNA oligonucleotide SEQ ID NO:10.
 XX
 KM Producing ribozyme; ribozyme; SV40; HCV; hepatitis C virus; target;
 KM Simian virus 40; NS5B; viral infection; antiviral; cytosolic; HBV;
 KM anticancer; immunosuppressive; gene therapy; AIDS; hepatitis B virus;
 KM cancer; leukemia; genetic defect; allergy; autoimmune disease;
 KM familial genetic disease; primary genetic disease; ss.
 XX

OS Hepatitis C virus.
 XX
 PN WO200014252-A1.
 XX
 PD 16-MAR-2000.
 XX
 PF 02-SEP-1999; 99WO-JP04767.
 XX
 PR 03-SEP-1998; 98JP-0249900.
 XX
 PA (SUMU) SUMITOMO PHARM CO LTD.
 XX
 PI Tondoh N, Yamamoto H, Sudo Y;
 XX
 DR WPI; 2000-256397/22.
 XX
 PT Novel ribozyme prodng without RNA-cleaving activity, for use e.g. in
 PT gene therapy to treat viral infections, cancers and diseases due to
 PT defective genes
 XX
 PS Example 1; Page 81; 116pp; Japanese.
 XX
 CC The present invention describes a gene (I) encoding a ribozyme prodng
 CC comprising an intervening sequence removable by splicing, and/or lacking
 CC RNA-cleaving activity. Also described are: (i) an expression vector
 CC comprising (i) and preferably further comprising a tissue-specific
 CC promoter; (ii) a ribozyme prodng comprising an intervening sequence in
 CC the ribozyme sequence removable by splicing, and lacking RNA-cleaving
 CC activity; (iii) a drug composition comprising (i); and (iv) the in vivo
 CC production of mature ribozyme with RNA-cleaving activity by introducing
 CC (i) into a eukaryote. (I) has antiviral, cytosolic, anti-allergic and
 CC immunosuppressive activities, and can be used in ribozyme and gene
 CC therapy. The ribozyme prodng is useful e.g. in gene therapy,
 CC particularly for treating viral infections such as AIDS and those due to
 CC hepatitis B virus (HBV) and hepatitis C virus (HCV), cancers including
 CC those of the liver, pancreas and colon, and leukemia, and diseases
 CC caused by genetic defects such as allergy, autoimmune diseases, familial
 CC genetic diseases and primary genetic diseases. The ribozyme prodng,
 CC without RNA-cleaving activity, is encoded by a gene with an intervening
 CC sequence in the ribozyme sequence which can be spliced off in cytoplasm
 CC to give a functional ribozyme. The present sequence is used in the
 CC exemplification of the present invention.
 CC
 XX
 SQ Sequence 17 BP; 6 A; 5 C; 2 G; 4 U; 0 other;
 XX
 QY Query Match 0.9%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 DB 2469 GTACATGATGATG 2481
 15 GTACATGATGATG 3
 XX
 RESULT 262
 AAH95774
 ID AAH95774 standard; RNA; 17 BP.
 XX
 AC AAH95774;
 XX
 DT 09-OCT-2001 (first entry)
 XX
 DE Human Chk1 ribozyme substrate SEQ ID NO: 1199.
 XX
 KM Human; checkpoint kinase-1; Chk1; antisense; ribozyme; gene therapy;
 KM RNA cleavage; cancer; ss.
 XX
 OS Homo sapiens.
 OS
 PN WO200157206-A2.
 XX
 PD 09-AUG-2001.
 XX

PF 02-FEB-2001; 2001WO-US03504.
XX 03-FEB-2000; 2000US-0179983.
PR (RIBO-) RIBOZYME PHARM INC.
PA (FATT/) FATTAEY A R.
XX
PI Fattaey AR, Jarvis T, McSwiggen J, Booher RN, Holman PS;
XX WPI; 2001-496922/54.
DR
XX Novel nucleic acid molecule e.g., ribozymes or antisense nucleic acid
PT molecules, which downregulate expression of a checkpoint kinase-1
PT gene, useful for treating colorectal, lung, breast or prostate cancers
PT
XX
PS Claim 4; Page 88; 115pp; English.
XX
CC The present invention provides nucleic acid molecules capable of
CC downregulating the expression of the human checkpoint kinase-1 (Chk1)
CC gene. These may be antisense or ribozyme sequences, and are useful in the
CC treatment of diseases associated with conditions affected by Chk1 levels,
CC including cancer. The present sequence is an oligonucleotide described in
CC the exemplification of the invention.
XX
SO Sequence 17 BP; 6 A; 4 C; 6 G; 1 U; 0 other;
XX
Query Match 0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
OY 1730 CCCTGGGGAAGG 1742
DB 5 CCCUGGAGGAAGG 17
XX
RESULT 263
ABK01806/C
ID ABK01806 standard; RNA; 17 BP.
XX
AC ABK01806;
XX
DT 12-MAR-2002 (first entry)
DE
XX Human NOGO Zinzyne #128.
DE
XX Human; ss; antisense therapy; cytosolic; antiinflammatory; haemostatic;
KW cerebroprotective; neurotrophic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinzyne; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapeutic-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
WO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US04273.
XX
PR 11-FEB-2000; 2000US-181797P.
PR 28-FEB-2000; 2000US-185516P.
PR 06-MAR-2000; 2000US-187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.

PA (BLAT)/ BLATT L.
 PA (MCSW)/ MCSWIGEN J.
 PA (CHOW)/ CHOWIRIRA B M.
 P1 Blatt L, MCSwigen J, Chowirira BM,
 DR WPI; 2001-607195/69.
 XX
 XX
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia,
 PT and central nervous system injury -
 XX
 XX
 XX Claim 88; Page 98; 200pp; English.
 XX
 XX
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO).
 CC The nucleic acids may be enzymatic nucleic acids (e.g., a ribozyme or a
 CC DNAzyme), an inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN
 CC motif) or an amberzyme (cleaving RNA with an NGN triplet), a zynzyme
 CC (cleaving RNA with a YGY motif). The CD20-targeting nucleic acid is used
 CC to cleave RNA of CD20 in the presence of a divalent cation that is
 CC preferably Mg²⁺. Furthermore, it may be contacted with a cell to reduce
 CC CD20 activity of the cell and treat a patient having a condition
 CC associated with the level of CD20. The treatment may further comprise the
 CC use of one or more therapies. In particular, the CD20 targeting
 CC nucleic acid may be used to treat lymphoma, leukaemia, B-cell
 CC lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky
 CC low-grade or follicular NHL, lymphocytic leukaemia, HIV (human
 CC immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL),
 CC immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune
 CC thrombocytopenia, and inflammatory arthropathy. The NOGO-targeting
 CC nucleic acid is used to cleave RNA of the NOGO gene in the presence of a
 CC divalent cation that is preferably Mg²⁺. Furthermore, the nucleic acid
 CC may be contacted with a cell to reduce NOGO activity of the cell and
 CC treat a patient having a condition associated with the level of NOGO. The
 CC treatment may further comprise the use of one or more therapies.
 CC In particular, the NOGO-targeting nucleic acid may be used to treat
 CC central nervous system (CNS) injury and cerebrovascular accident (CVA,
 CC stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The
 CC present sequence is a zynzyme molecule of the invention.
 XX
 XX
 SQ Sequence 17 BP; 3 A; 2 C; 9 G; 3 U; 0 other;
 Query Match 0.9%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1573 TCCAGCTCTCTCCA 1585
 ID 14 TCCAGCTCTCTCCA 2
 ABNO6895/C
 ID ABNO6895 standard; DNA; 17 BP.
 XX
 XX
 AC ABNO6895;
 XX
 XX
 DT 29-MAY-2002 (first entry)
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6887.
 XX
 XX
 KM Human; genome-derived myosin-like protein 1; GDMLP-1; heart;
 KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KM skeletal muscle disorder; amplicon; screening; 88.
 XX

OS Homo sapiens.
 XX
 XX WO200192524-A2.
 XX
 XX 06-DEC-2001.
 XX
 XX 25-MAY-2001; 2001WO-US16981.
 XX
 XX 26-MAY-2000; 2000US-207456P.
 PR 21-SEP-2000; 2000US-234687P.
 PR 27-SEP-2000; 2000US-236359P.
 PR 04-OCT-2000; 2000GB-0024263.
 PR 30-JAN-2001; 2001WO-US00661.
 PR 30-JAN-2001; 2001WO-US00662.
 PR 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00666.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 30-JAN-2001; 2001WO-US00670.
 PR 05-FEB-2001; 2001US-266860P.
 XX
 XX (AEOM-1) AEOMICA INC.
 XX
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMLP-1 -
 XX
 XX Disclosure; SEQ ID 6887; 214P; English.
 XX
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
 CC hGDMLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.
 XX
 XX Sequence 17 BP; 2 A; 6 C; 3 G; 6 T; 0 other;
 SQ

Query Match 0.9%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1359 GCCTGGAAGAGAA 1371
 DB 17 GCCTGGAAGAGAA 5

ABN06900/C
 ID ABN06900 standard; DNA; 17 BP.
 XX
 XX AC ABN06900;
 XX
 XX 29-MAY-2002 (first entry)
 XX
 XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6892.
 DE
 XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 XX skeletal muscle disorder; amplicon; screening; ss.
 OS
 XX Homo sapiens.
 XX
 XX WO200192524-A2.
 XX
 XX 06-DEC-2001.
 XX
 XX 25-MAY-2001; 2001WO-US16981.
 XX
 XX 26-MAY-2000; 2000US-207456P.
 PR 21-SEP-2000; 2000US-234687P.
 PR 27-SEP-2000; 2000US-236359P.
 PR 04-OCT-2000; 2000GB-0024263.
 PR 30-JAN-2001; 2001WO-US00661.
 PR 30-JAN-2001; 2001WO-US00662.
 PR 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00666.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 30-JAN-2001; 2001WO-US00670.
 PR 05-FEB-2001; 2001US-266860P.
 XX
 XX (AEOM-1) AEOMICA INC.
 XX
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMLP-1 -
 XX
 XX Disclosure; SEQ ID 6892; 214P; English.
 XX
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
 CC hGDMLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.

XX SQ Sequence 17 BP; 1 A; 6 C; 4 G; 6 T; 0 other;
Query Match 0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1358 CGCCTGGAAGAGA 1370
13 CGCCTGGAAGAGA 1
Db
RESULT 266
ABN08954
ID ABN08954 standard; DNA; 17 BP.
XX AC ABN08954;
XX DT 29-MAY-2002 (first entry)
XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8946.
XX KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.
XX WO200192524-A2.
XX PD 06-DEC-2001.
XX DT 25-MAY-2001; 2001WO-US16981.
XX PR 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX PA (AEOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX DR
XX PT New polypeptide, for raising antibodies that recognize hGDMLP-1
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
XX PS Disclosure; SEQ ID 8946; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the

CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
XX SQ Sequence 17 BP; 3 A; 4 C; 8 G; 2 T; 0 other;
Query Match 0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1357 GCGCCTGGAAGAG 1369
2 GCGCCTGGAAGAG 14
Db
RESULT 267
ABN08955
ID ABN08955 standard; DNA; 17 BP.
XX AC ABN08955;
XX DT 29-MAY-2002 (first entry)
XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8947.
XX KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.
XX WO200192524-A2.
XX PD 06-DEC-2001.
XX DT 25-MAY-2001; 2001WO-US16981.
XX PR 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX PA (AEOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX DR
XX PT New polypeptide, for raising antibodies that recognize hGDMLP-1
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX

XX 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 05-FEB-2001; 2001US-266860P.
XX
PA (AEOMICA INC.
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMRP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMRP-1 -
XX
XX Disclosure; SEQ ID 9031; 214p; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMRP-1). The protein and polynucleotide sequences of
CC hGDMRP-1 can be used in gene therapy and vaccine production. The
CC hGDMRP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMRP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMRP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMRP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMRP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMRP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMRP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMRP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMRP-1, in
CC particular heart and skeletal muscle disorders. hGDMRP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMRP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 4 A; 2 C; 7 G; 4 T; 0 other;
OY Query Match 0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
DB 2397 CGTGAGGAGACTT 2409
4 CGTGAGGAGACTT 16
RESULT 270
ABN09040
ID ABN09040 standard; DNA; 17 BP.
XX
XX ABN09040;
AC
XX
XX 29-MAY-2002 (first entry)
DT
XX
DE Human GDMRP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9032.

XX Human; genome-derived myosin-like protein 1; GDMRP-1; hGDMRP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX Homo sapiens.
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US16981.
XX
XX 26-MAY-2000; 2000US-207456P.
XX 21-SEP-2000; 2000US-234687P.
XX 27-SEP-2000; 2000US-236359P.
XX 04-OCT-2000; 2000GB-0024263.
XX 30-JAN-2001; 2001WO-US00661.
XX 30-JAN-2001; 2001WO-US00662.
XX 30-JAN-2001; 2001WO-US00663.
XX 30-JAN-2001; 2001WO-US00664.
XX 30-JAN-2001; 2001WO-US00665.
XX 30-JAN-2001; 2001WO-US00666.
XX 30-JAN-2001; 2001WO-US00667.
XX 30-JAN-2001; 2001WO-US00668.
XX 30-JAN-2001; 2001WO-US00669.
XX 30-JAN-2001; 2001WO-US00670.
XX 05-FEB-2001; 2001US-266860P.
XX
XX (AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMRP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMRP-1 -
XX
XX Disclosure; SEQ ID 9032; 214p; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMRP-1). The protein and polynucleotide sequences of
CC hGDMRP-1 can be used in gene therapy and vaccine production. The
CC hGDMRP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMRP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMRP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMRP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMRP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMRP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMRP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMRP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMRP-1, in
CC particular heart and skeletal muscle disorders. hGDMRP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMRP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 4 A; 3 C; 6 G; 4 T; 0 other;
OY Query Match 0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 2397 CGTGAGGAGACTT 2409

DB 3 CGTGAGGACTT 15
|||||
RESULT 271
ID ABN09041 standard; DNA; 17 BP.
XX
AC ABN09041;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9033.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
PR 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX
PA (ABOM-) ABOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
PS Disclosure; SEQ ID 9033; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the

CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 5 A; 3 C; 6 G; 3 T; 0 other;
Query Match 0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2397 CGTGAGGACTT 2409
DB 2 CGTGAGGACTT 14
|||||
RESULT 272
ID ABN09042 standard; DNA; 17 BP.
XX
AC ABN09042;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9034.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
PR 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX
PA (ABOM-) ABOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
PS Disclosure; SEQ ID 9034; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification

Query Match 0.9%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2421 GAAGAGACACAGA 2436
 DB 16 GAAGAGAGAAAAAGA 1

RESULT 277
 ABT34223/c
 ID ABT34223 standard; DNA; 16 BP.

AC ABT34223;
 XX
 XX 12-JUN-2003 (first entry)
 XX
 XX Dopamine-D2-receptor PCR primer SEQ ID No 9.

XX Eating disorder; polymorphism; dataset; allele; HGBAB identification;
 KW serotonin receptor 1D; delta-opioid receptor; dopamine receptor D2;
 KW anorexia nervosa; bulimia nervosa; PCR; primer; ss.

XX Unidentified.
 OS
 XX WO2003012143-A1.

PD 13-FEB-2003.

XX 16-JUL-2002; 2002WO-US22555.

XX 16-JUL-2001; 2001US-305153P.

PR 20-JUL-2001; 2001US-306440P.

PR 13-NOV-2001; 2001US-331285P.

PR 19-DEC-2001; 2001US-340843P.

XX 19-DEC-2001; 2001US-340844P.

XX (PRIC-) PRICE FOUND LTD.

XX Bergen AW, Yeager M;

XX WPI; 2003-268122/26.

XX New nucleic acid molecule having polymorphisms in the serotonin
 PT receptor 1D, delta-opioid receptor, or dopamine receptor D2, useful in
 PT diagnostic and prognostic assays for eating disorders, such as anorexia
 XX and bulimia nervosa

XX Example 2; Page 41; 149PP; English.

XX The invention relates to a novel isolated nucleic acid molecule
 CC comprising a variant gene associated with an eating disorder and selected
 CC from any of 119 polymorphisms with their corresponding genotyping in
 CC dataset, alleles and HGBAB identification, given in the specification.

CC The novel nucleic acid molecule has polymorphisms in the serotonin
 CC receptor 1D, delta-opioid receptor, or dopamine receptor D2, which is
 CC useful in diagnostic and prognostic assays for eating disorders, in
 CC particular anorexia nervosa and bulimia nervosa. This polynucleotide
 CC sequence represents a dopamine D2 receptor PCR primer of the invention.

XX Sequence 16 BP; 0 A; 2 C; 7 G; 7 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1785 CAAGACACGCCCAAG 1800
 DB 16 CAAGACACGCCCAAG 1

RESULT 278

AAN91716
 ID AAN91716 standard; DNA; 17 BP.

XX AAN91716;

XX 25-MAR-2003 (updated)

DT 14-MAR-1990 (first entry)

XX Probe A1 for Bacillus thuringiensis tenebrionis.

XX Probe A1; Bacillus thuringiensis tenebrionis.

XX Bacillus thuringiensis tenebrionis.

XX EP339009-A.

XX 25-OCT-1989.

XX 14-APR-1989; 89EP-0870047.

XX 11-APR-1988; 88US-0179709.

XX (MONS) MONSANTO CO.

XX Fuchs RL, Kishore GM, Macintosh SC;

XX WPI; 1989-311431/43.

XX Toxin protein of Bacillus thuringiensis bacteria - improved in efficacy
 PT using a potentiating amt. of a trypsin inhibitor.

XX Disclosure; page 13; 56PP; English.

XX Probe A1 is based on amino acids 1-6 of the B.t.t. toxin gene.

XX (Updated on 25-MAR-2003 to correct PF field.)

XX Sequence 17 BP; 7 A; 7 C; 2 G; 1 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1585 ATGAACCTCCAAACCC 1600
 DB 1 ATGAACCTCCAAACCC 16

RESULT 279

AAQ52943
 ID AAQ52943 standard; RNA; 17 BP.

XX AAQ52943;

XX 25-MAR-2003 (updated)

DT 26-MAY-1994 (first entry)

XX Herpes simplex virus target sequence 21.

XX RNA; enzyme; enzymatic RNA molecule; ERN; cleave; RNA; mRNA; HnRNA;

XX picornavirus; HIV; immunodeficiency virus; hepatitis B virus; HBV;

XX Papilloma virus; HPV; Epstein-Barr virus; EBV; TCV;

XX T-cell leukaemia virus; hepatitis C virus; HCV; cytomegalovirus;

XX influenza virus; HSV; herpes simplex virus; vector; immune response;

XX antibody; ribozyme; viral RNA; treatment; ss.

XX Synthetic.

XX WO9323569-A1.

XX 25-NOV-1993.

XX 29-APR-1993; 93WO-US04020.

PR 11-MAY-1992; 92US-0882689.
 PR 14-MAY-1992; 92US-0882712.
 PR 14-MAY-1992; 92US-0882713.
 PR 14-MAY-1992; 92US-0882714.
 PR 14-MAY-1992; 92US-0882823.
 PR 14-MAY-1992; 92US-0882824.
 PR 14-MAY-1992; 92US-0882886.
 PR 14-MAY-1992; 92US-0882888.
 PR 14-MAY-1992; 92US-0882889.
 PR 14-MAY-1992; 92US-0882921.
 PR 14-MAY-1992; 92US-0882922.
 PR 14-MAY-1992; 92US-0883823.
 PR 14-MAY-1992; 92US-0883849.
 PR 14-MAY-1992; 92US-0884073.
 PR 14-MAY-1992; 92US-0884074.
 PR 14-MAY-1992; 92US-0884333.
 PR 14-MAY-1992; 92US-0884422.
 PR 14-MAY-1992; 92US-0884431.
 PR 14-MAY-1992; 92US-0884436.
 PR 14-MAY-1992; 92US-0884521.
 PR 31-JUL-1992; 92US-0923738.
 PR 26-AUG-1992; 92US-0938854.
 PR 26-AUG-1992; 92US-0936086.
 PR 18-SEP-1992; 92US-0948359.
 PR 15-OCT-1992; 92US-0963322.
 PR 07-DEC-1992; 92US-0987129.
 PR 07-DEC-1992; 92US-0987130.
 PR 07-DEC-1992; 92US-0987133.
 PA (RIBO-) RIBOZYME PHARM INC.
 PI Draper KG, Dudycz LW, Mcswiggen JA, Macejak DG, Holecsek JI;
 PI Mamone JA;
 DR WPI; 1993-386599/48.
 XX Enzymatic RNA molecules - used to inhibit viral replication,
 PT infection and gene expression
 PS Claim 5; Fig 15; 287pp; English.
 XX The sequences (AAQ52923-Q53037) are pref. herpes simplex virus target
 CC sequences for enzymatic RNA molecules. The RNA molecules are
 CC complementary to a substrate binding region in the specified gene
 CC target. They also have enzymatic activity, in that they specifically
 CC cleave RNA in the target. The ERMs interfere with viral replication and
 CC therefore have anti-viral properties. They can be used to attenuate
 CC viruses to be used in vaccines.
 CC (Updated on 25-MAR-2003 to correct PN field.)
 CC (Updated on 25-MAR-2003 to correct PR field.)
 CC (Updated on 25-MAR-2003 to correct PI field.)
 XX SQ Sequence 17 BP; 3 A; 5 C; 7 G; 2 U; 0 other;
 QY Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Db Best Local Similarity 75.0%; Pred. No. 2.5e+02;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
 2279 GGATGCTCTCAGAGC 2294
 ||:|||||
 2 GGGUGGCUCCAGAAC 17
 RESULT 280
 AAX64062
 ID AAX64062 standard; RNA; 17 BP.
 XX AAX64062;
 AC
 XX 20-JUL-1999 (first entry)
 DT
 XX Rabbit stromelysin hammerhead target SEQ ID NO:694.
 DE
 XX

KW Arthritic condition; graft tolerance; immune response; target; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.
 XX Oryctolagus cuniculus.
 XX WO9618736-A2.
 XX PD 20-JUN-1996.
 XX PF 22-NOV-1995; 95WO-US15516.
 XX 05-OCT-1995; 95US-0541365.
 PR 13-DEC-1994; 94US-0354920.
 PR 23-DEC-1994; 94US-0363253.
 PR 23-DEC-1994; 94US-0363254.
 PR 17-FEB-1995; 95US-0390850.
 PR 20-APR-1995; 95US-0426124.
 PR 02-MAY-1995; 95US-0432874.
 PR 04-MAY-1995; 95US-0434509.
 PR 07-JUL-1995; 95US-0000951.
 PR 07-JUL-1995; 95US-0000974.
 PR 07-AUG-1995; 95US-0512861.
 PA (RIBO-) RIBOZYME PHARM INC.
 XX Draper K, Gustofson J, Mcswiggen J, Pavco P, Stinchcomb DT;
 PI Belgelman L, Karpetsky A, Modak A, Ueman N, Burgin A;
 PI Maculic-Adamic J, Jarvis T, Thompson JD, Wincott F;
 DR WPI; 1996-300653/30.
 XX Enzymatic nucleic acid molecules having a hammer-head motif - used
 PT for the treatment of arthritis, induction of graft tolerance or
 PT treatment of auto-immune diseases
 PS Example 1; Page 156; 307pp; English.
 XX The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose
 CC residues; (ii) a 2'-C-all-yl modification at position 4 of the ENA; (iii)
 CC at least ten 2'-O-methyl modifications; and (iv) a 3'-end modification.
 CC The ENA's can inhibit collagenase and stromelysin production in the
 CC synovial membrane of joints for the treatment or prevention of arthritis,
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention.
 XX SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 U; 0 other;
 QY Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Db Best Local Similarity 75.0%; Pred. No. 2.5e+02;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
 1694 GGGAGTTTCCAGAGA 1709
 |||||:|||||
 2 GGGAGCUCCACGAGA 17
 RESULT 281
 AAX64063
 ID AAX64063 standard; RNA; 17 BP.
 XX

XX	AA64063;
AC	
XX	
DT	20-JUN-1999 (first entry)
XX	
DE	Rabbit stromelysin hammerhead target SEQ ID NO:695.
XX	
KW	Arthritic condition; graft tolerance; immune response; target; cleavage;
KW	hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW	stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW	rheumatoid arthritis; autoimmune disease; allergy; inflammation;
XX	diagnosis; ss.
OS	Oryctolagus cuniculus.
XX	
PN	WO9618736-A2.
XX	
PD	20-JUN-1996.
XX	
PF	22-NOV-1995; 95WO-US15516.
XX	
PR	05-OCT-1995; 95US-0541365.
PR	13-DEC-1994; 94US-0354920.
PR	23-DEC-1994; 94US-0363253.
PR	23-DEC-1994; 94US-0363254.
PR	17-FEB-1995; 95US-0390850.
PR	20-APR-1995; 95US-0426124.
PR	02-MAY-1995; 95US-0432874.
PR	04-MAY-1995; 95US-0434509.
PR	07-JUL-1995; 95US-0000951.
PR	07-JUL-1995; 95US-0000974.
PR	07-AUG-1995; 95US-0512861.
PA	(RIBO-) RIBOZYME PHARM INC.
PI	Draper K, Gustafson J, McSwiggan J, Pavco P, Stinchcomb DT;
PI	Belgeman L, Karpelsky A, Modak A, Uzman N, Burgin A;
PI	Matulis-Adamic J, Jarvis T, Thompson JD, Wincott F;
DR	WPI, 1996-300653/30.
PT	Enzymatic nucleic acid molecules having a hammer-head motif - used
PT	for the treatment of arthritis; induction of graft tolerance or
PT	treatment of auto-immune diseases
XX	
PS	Example 1; Page 156; 307BP; English.
XX	
CC	The present invention describes a novel enzymatic nucleic acid (ENA)
CC	having a hammerhead motif (HM) comprising: (i) at least 5 ribose
CC	residues; (ii) a 2',-C-allyl modification at position 4 of the ENA; (iii)
CC	at least ten 2',-O-methyl modifications; and (iv) a 3'-end modification.
CC	The ENA's can inhibit collagenase and stromelysin production in the
CC	synovial membrane of joints for the treatment or prevention of arthritis,
CC	particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
CC	be used to treat antigen presenting cells of a donor to induce tolerance
CC	in a recipient to an alloantigen of a donor. They can also be used for
CC	enhancing graft tolerance or for treating autoimmune disease, and for
CC	treating allergies and other inflammatory conditions. The ENA's can also
CC	be used in diagnosis. Ribozyme therapy impacts on the expression of
CC	stromelysin without introducing the non-specific effects upon gene
CC	expression which accompany treatment with retinoids and dexamethasone.
CC	The concentration of ribozyme required to affect a therapeutic treatment
CC	is lower than that required of antisense molecules, and is highly
CC	specific. The present sequence is used in the exemplification of the
CC	present invention.
XX	
SQ	Sequence 17 BP; 4 A; 5 C; 6 G; 2 U; 0 other;
XX	
Query Match	0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity	75.0%; Pred. No.2.5e-02;
Matches	12; Conservative 2; Mismatches 2; Indels 0; Gaps 0
QY	1694 GGGAGTTCCAGAGA 1709

```

Db      1 GGGAGCTUCCACGAGA 16
||||| :||| |||
RESULT 282
AAAT81587/c
ID      AAAT81587 standard; RNA; 17 BP.
XX
XX      AAAT81587;
XX
XX      21-DEC-1997 (first entry)
DE      Human c-myb hammerhead ribozyme target sequence (nt. position 2971).
XX
XX      Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
XX      smooth muscle cell; hyperproliferation; restenosis; cancer;
XX      c-myb; coronary angioplasty; ss.
OS      Homo sapiens.
XX
XX      MO9531541-A2.
XX
XX      23-NOV-1995.
XX
XX      18-MAY-1995; 95MO-US06368.
XX
XX      13-JAN-1995; 95US-0373124.
XX      18-MAY-1994; 94US-0245466.
XX
XX      (RIBO-) RIBOZYME PHARM INC.
PA
PI      Draper K, Jarvis T, McSwigen J, Stinchcomb DT;
PI      WPI; 1996-010927/01.
XX
XX      New enzymatic nucleic acid molecules - which cleave RNA produced by
XX      e.g. c-myb, for treating restenosis or cancer
XX
XX      Claim 1; Page 79; 128pp; English.
XX
XX      The present sequence represents the preferred target sequence for an
XX      enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
XX      the human c-myb sequence at the base position indicated in the
XX      descriptor line. The c-myb sequence was screened for optimal ribozyme
XX      target sites using a computer folding algorithm, and regions of the mRNA
XX      which did not form secondary folding structures and contained potential
XX      ribozyme cleavage sites were identified. Ribozymes were synthesised and
XX      their activities optimised by either varying the length of the binding
XX      arms or by modification to prevent degradation by nucleases.
XX      The ribozymes cleave the c-myb sequence and can be used to prevent
XX      smooth muscle cell hyperproliferation in restenosis, especially after
XX      coronary angioplasty, and in cancers.
XX
XX      Sequence 17 BP; 1 A; 0 C; 4 G; 12 U; 0 other;
SQ
Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      2240 ATTACAAAAGACCAC 2255
      |||||||
Db      17 ATAACAAAACACAC 2

```

```

XX Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW smooth muscle cell; hyperproliferation; restenosis; cancer;
KM c-myb; coronary angioplasty; ss.
XX
XX Homo sapiens.
XX
XX WO9531541-A2.
XX
XX 23-NOV-1995.
XX
XX 18-MAY-1995; 95WO-US06368.
XX
XX 13-JAN-1995; 95US-0373124.
XX
XX 18-MAY-1994; 94US-0245466.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Draper K, Jarvis T, McSwiggen J, Stinchcomb DT;
XX
XX WPI; 1996-010927/01.
XX
XX New enzymatic nucleic acid molecules - which cleave RNA produced by
XX e.g. c-myb, for treating restenosis or cancer
XX
XX Claim 1; Page 79; 128pp; English.
XX
XX The present sequence represents the preferred target sequence for an
XX enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
XX the human c-myb sequence at the base position indicated in the
XX descriptor line. The c-myb sequence was screened for optimal ribozyme
XX target sites using a computer folding algorithm, and regions of the mRNA
XX which did not form secondary folding structures and contained potential
XX ribozyme cleavage sites were identified. Ribozymes were synthesised and
XX their activities optimised by either varying the length of the binding
XX arms or by modification to prevent degradation by nucleases.
XX The ribozymes cleave the c-myb sequence and can be used to prevent
XX smooth muscle cell hyperproliferation in restenosis, especially after
XX coronary angioplasty, and in cancers.
XX
XX Sequence 17 BP; 1 A; 0 C; 4 G; 12 U; 0 other;
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.5e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 2240 ATTACAAAAGACCAC 2255
XX |||||
XX 16 ATACAAAAAACCCAC 1
XX
XX RESULT 284
XX AAT81253
XX ID AAT81253 standard; RNA; 17 BP.
XX
XX AAT81253;
XX
XX 05-OCT-1997 (first entry)
XX
XX Human c-myb hammerhead ribozyme target sequence (nt. position 1587).
XX
XX Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW smooth muscle cell; hyperproliferation; restenosis; cancer;
KM c-myb; coronary angioplasty; ss.
XX
XX Homo sapiens.
XX
XX WO9531541-A2.
XX
XX 23-NOV-1995.
XX
XX 18-MAY-1995; 95WO-US06368.
XX

```

```

PR 13-JAN-1995; 95US-0373124.
PR 18-MAY-1994; 94US-0245466.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Draper K, Jarvis T, McSwiggen J, Stinchcomb DT;
XX
XX WPI; 1996-010927/01.
XX
XX New enzymatic nucleic acid molecules - which cleave RNA produced by
XX e.g. c-myb, for treating restenosis or cancer
XX
XX Claim 1; Page 70; 128pp; English.
XX
XX The present sequence represents the preferred target sequence for an
XX enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
XX the human c-myb sequence at the base position indicated in the
XX descriptor line. The c-myb sequence was screened for optimal ribozyme
XX target sites using a computer folding algorithm, and regions of the mRNA
XX which did not form secondary folding structures and contained potential
XX ribozyme cleavage sites were identified. Ribozymes were synthesised and
XX their activities optimised by either varying the length of the binding
XX arms or by modification to prevent degradation by nucleases.
XX The ribozymes cleave the c-myb sequence and can be used to prevent
XX smooth muscle cell hyperproliferation in restenosis, especially after
XX coronary angioplasty, and in cancers.
XX
XX Sequence 17 BP; 7 A; 7 C; 1 G; 2 U; 0 other;
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 81.2%; Pred. No. 2.5e+02;
XX Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
XX
XX 1584 CATGAAGCTCAACACC 1599
XX |||||
XX 1 CAAGACATCCCAACACC 16
XX
XX Db
XX
XX RESULT 285
XX AAT81188/c
XX ID AAT81188 standard; RNA; 17 BP.
XX
XX AAT81188;
XX
XX 29-SEP-1997 (first entry)
XX
XX Human c-myb hammerhead ribozyme target sequence (nt. position 1257).
XX
XX Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW smooth muscle cell; hyperproliferation; restenosis; cancer;
KM c-myb; coronary angioplasty; ss.
XX
XX Homo sapiens.
XX
XX WO9531541-A2.
XX
XX 23-NOV-1995.
XX
XX 18-MAY-1995; 95WO-US06368.
XX
XX 13-JAN-1995; 95US-0373124.
XX
XX 18-MAY-1994; 94US-0245466.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Draper K, Jarvis T, McSwiggen J, Stinchcomb DT;
XX
XX WPI; 1996-010927/01.
XX
XX New enzymatic nucleic acid molecules - which cleave RNA produced by
XX e.g. c-myb, for treating restenosis or cancer
XX
XX Claim 1; Page 68; 128pp; English.
XX

```

XX The present sequence represents the preferred target sequence for an
CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC the human c-myc sequence at the base position indicated in the
CC descriptor line. The c-myc sequence was screened for optimal ribozyme
CC target sites using a computer folding algorithm, and regions of the mRNA
CC which did not form secondary folding structures and contained potential
CC ribozyme cleavage sites were identified. Ribozymes were synthesised and
CC their activities optimised by either varying the length of the binding
CC arms or by modification to prevent degradation by nucleases.
CC The ribozymes cleave the c-myc sequence and can be used to prevent
CC smooth muscle cell hyperproliferation in restenosis, especially after
CC coronary angioplasty, and in cancers.

XX SQ Sequence 17 BP; 2 A; 8 C; 3 G; 4 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1866 GGTGTGAGATGAG 1881
16 GCTGGCAGAGATGAG 1

RESULT 286
AAK75356/C
ID AAK75356 standard; RNA; 17 BP.
AC AAK75356;
XX
XX 28-JUL-1999 (first entry)
DT
XX Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #884.
DE
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
KW flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
XX Mus sp.
OS
XX WO9715662-A2.
PI
XX 01-MAY-1997.
PD
XX 25-OCT-1996; 96WO-US17480.
PF
XX 11-JAN-1996; 96US-0584040.
PR 26-OCT-1995; 95US-0005974.
XX
XX (CHIR) CHIRON CORP.
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;
XX
XX WPI; 1997-259017/23.
DR
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
PT mRNA stability - useful for treating e.g. tumour angiogenesis,
PT psoriasis, rheumatoid arthritis, etc., in a human patient
XX
XX Claim 4; Page 181; 218bp; English.

XX The present invention describes nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
CC be treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAK7275 to AAK7572 represent specific examples
CC of nucleic acid molecules from the present invention.

CC vector to the patient. AAK67275 to AAK7572 represent specific examples
CC of nucleic acid molecules from the present invention.

XX SQ Sequence 17 BP; 3 A; 5 C; 2 G; 7 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1775 TGGGAATTGACAAAGA 1790
17 TGGCAATGACAAAGA 2

RESULT 287
AAK75221/C
ID AAK75221 standard; RNA; 17 BP.
AC AAK75221;
XX
XX 28-JUL-1999 (first entry)
DT
XX Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #749.
DE
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
KW flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
XX Mus sp.
OS
XX WO9715662-A2.
PI
XX 01-MAY-1997.
PD
XX 25-OCT-1996; 96WO-US17480.
PF
XX 11-JAN-1996; 96US-0584040.
PR 26-OCT-1995; 95US-0005974.
XX
XX (CHIR) CHIRON CORP.
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;
XX
XX WPI; 1997-259017/23.
DR
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
PT mRNA stability - useful for treating e.g. tumour angiogenesis,
PT psoriasis, rheumatoid arthritis, etc., in a human patient
XX
XX Claim 4; Page 177; 218bp; English.

XX The present invention describes nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
CC be treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAK67275 to AAK7572 represent specific examples
CC of nucleic acid molecules from the present invention.

XX SQ Sequence 17 BP; 4 A; 2 C; 5 G; 6 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1843 ACAGGAAGACCTTT 1858
|||||


```

XX 01-MAY-1997.
PD 25-OCT-1996; 96WO-US17480.
XX
XX 11-JAN-1996; 96US-0584040.
PR 26-OCT-1995; 95US-0005974.
XX
XX (CHIR ) CHIRON CORP.
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;
XX WPI; 1997-259017/23.
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
PT mRNA stability - useful for treating e.g. tumour angiogenesis,
PT psoriasis, rheumatoid arthritis, etc., in a human patient
XX
PS Claim 4; Page 86; 218pp; English.
XX
XX The present invention describes nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
CC be treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX7275 to AAX7572 represent specific examples
CC of nucleic acid molecules from the present invention.
XX
SQ Sequence 17 BP; 2 A; 6 C; 1 G; 8 U; 0 other;
XX
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2422 AAGGAGGACACAGAA 2437
DB 16 ATGGAGGACACAGAA 1
XX
RESULT 291
AAX69259
ID AAX69259 standard; RNA; 17 BP.
XX
XX AAX69259;
AC
XX 28-JUL-1999 (first entry)
XX
XX Human flt1 VEGF receptor hammerhead ribozyme substrate #554.
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
KW flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
XX Homo sapiens.
OS
XX WO9715662-A2.
XX
XX 01-MAY-1997.
XX
XX 25-OCT-1996; 96WO-US17480.
XX
XX 11-JAN-1996; 96US-0584040.
PR 26-OCT-1995; 95US-0005974.
XX
XX (CHIR ) CHIRON CORP.
PA (RIBO-) RIBOZYME PHARM INC.
XX

```

```

PI Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;
XX WPI; 1997-259017/23.
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
PT mRNA stability - useful for treating e.g. tumour angiogenesis,
PT psoriasis, rheumatoid arthritis, etc., in a human patient
XX
PS Claim 4; Page 63; 218pp; English.
XX
XX The present invention describes nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
CC be treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX7275 to AAX7572 represent specific examples
CC of nucleic acid molecules from the present invention.
XX
SQ Sequence 17 BP; 3 A; 5 C; 5 G; 4 U; 0 other;
XX
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 2279 GGATGGCTCCGAGAGC 2294
DB 1 GGAUGGCTCCGAGAGC 16
XX
RESULT 292
AAX69242/C
ID AAX69242 standard; RNA; 17 BP.
XX
XX AAX69242;
AC
XX 28-JUL-1999 (first entry)
XX
XX Human flt1 VEGF receptor hammerhead ribozyme substrate #537.
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
KW flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
XX Homo sapiens.
OS
XX WO9715662-A2.
XX
XX 01-MAY-1997.
XX
XX 25-OCT-1996; 96WO-US17480.
XX
XX 11-JAN-1996; 96US-0584040.
PR 26-OCT-1995; 95US-0005974.
XX
XX (CHIR ) CHIRON CORP.
PA (RIBO-) RIBOZYME PHARM INC.
XX
XX Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;
XX WPI; 1997-259017/23.
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
PT mRNA stability - useful for treating e.g. tumour angiogenesis,
PT psoriasis, rheumatoid arthritis, etc., in a human patient
XX
PS Claim 4; Page 62; 218pp; English.
XX
XX The present invention describes nucleic acid molecules which modulate
CC

```

CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (Flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
 CC be treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention.

SO Sequence 17 BP; 4 A; 0 C; 4 G; 9 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1579 TCCATCATTAATCTTC 1924
 DB 17 AATATCACAATCTTC 2

RESULT 293
 AAT47828/C
 ID AAT47828 standard; cDNA; 17 BP.

AC AAT47828;

DT 14-MAY-1997 (first entry)

DE PCR primer, 5m9, for murine tumour-derived NF2 gene.

XX NF2; neurofibromatosis type 2; multiple tumours; nervous system;
 KW bilateral vestibular schwannoma; acoustic neuroma; cranial nerve;
 KW meningioma; lens opacity; chromosome region 22q12; tumour suppressor;
 KW merlin; moesin-erzin-radin like protein; alternative splicing;
 KW diagnosis; cancer; neoplasia; autosomal; dominant; hereditary;
 KW PCR; polymerase chain reaction; ss.

XX Synthetic.

OS US5578462-A.

PN 26-NOV-1996.

PD 10-JAN-1994; 94US-0179738.

PP 10-JAN-1994; 94US-0179738.

PR 10-JAN-1994; 94US-0179738.

PA (BRIM) BRISTOL-MYERS SQUIBB CO.

PI Bianchi AB, Kley NA, Seizinger BR;

DR WPI; 1997-020406/02.

XX New isolated mouse and human NF2 transcript isoforms - used to
 PT develop prods. for the diagnosis and treatment of neurofibromatosis
 PT type 2 diseases.

XX Disclosure; Column 14; 46pp; English.

XX AAT47828-T47830 are PCR primers used for the isolation of the NF2
 CC (neurofibromatosis type 2) gene from various murine tumours. NF2 is an
 CC autosomal, dominantly inherited disorder characterised by multiple
 CC tumours of the central nervous system, predominantly bilateral
 CC vestibular schwannomas (acoustic neuromas) of the eighth cranial nerve.
 CC Other symptoms of NF2 include cranial meningiomas, spinal nerve root
 CC schwannomas and presenile lens opacities. The NF2 gene, mapped to
 CC chromosome region 22q12 between the loci D2S1 and D2S28, acts a
 CC tumour suppressor. The NF2 gene is alternatively spliced resulting in
 CC three different isoforms encoding three different proteins, merlin
 CC isoforms I-III, which are likely to have differing functions. Merlin
 CC stands for moesin-erzin-radin like protein, so called due to
 CC substantial homology with these three proteins. The NF2 gene isoforms

CC and proteins encoded by them, are useful in diagnosing NF2 disease.
 CC Merlin protein products act as tumour suppressors and can be used to
 CC suppress tumour growth, as can the cDNA sequence in gene therapy
 CC applications. Antibodies raised against merlin proteins are useful as
 CC tumour targeting agents.

SO Sequence 17 BP; 6 A; 1 C; 7 G; 3 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1579 TCCATCATTAATCTTC 1594
 DB 17 TTCTCATGTACTCCA 2

RESULT 294
 AAV97546
 ID AAV97546 standard; RNA; 17 BP.

AC AAV97546;

DT 17-MAR-1999 (first entry)

DE Human EGF-R target sequence nucleotide position 2877.

XX Human; epidermal growth factor receptor; EGF-R; target sequence;
 KW hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
 KW cancer; genetic drift; detection; mutation; ss.

OS Homo sapiens.

PN WO9833893-A2.

PD 06-AUG-1998.

PP 14-JAN-1998; 98WO-US00730.

PR 04-DEC-1997; 97US-0985162.

PR 31-JAN-1997; 97US-0036476.

PA (RIBO-) RIBOZYME PHARM INC.

PI Akhtar S, Fell P, McSwiggen JA;

DR WPI; 1998-437449/37.

XX Enzymatic nucleic acids - which cleave RNA derived from an epidermal
 PT growth factor receptor, useful for inhibiting cell proliferation and
 PT for treating cancers

PS Claim 5; Page 74; 109pp; English.

XX The present invention describes enzymatic nucleic acid molecules (NAMS)
 CC which specifically cleave RNA derived from an epidermal growth factor
 CC receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
 CC represent specifically claimed target sequence from human EGF-R. AAV98044
 CC hairpin ribozymes respectively to V9878 represent hammerhead ribozymes and
 CC cleaving EGF-R RNA in the treatment of a condition associated with EGF-R
 CC expression levels e.g. to inhibit cell proliferation in the prevention or
 CC treatment of cancers. The NAMS can also be used as diagnostic tools to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of EGF-R RNA in a cell.

SO Sequence 17 BP; 4 A; 2 C; 6 G; 5 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 56.2%; Pred. No. 2.5e+02;
 Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2323 AGTATGTCGTCTCCT 2338
 DB 1 AGUGAUGUCUGAGACU 16

RESULT 295
 ID AAV97404/C
 AAV97404; standard; RNA; 17 BP.

AAV97404;
 AC
 XX
 XX
 DT 17-MAR-1999 (first entry)

DE Human EGF-R target sequence nucleotide position 1500.
 KW Human; epidermal growth factor receptor; EGFR; EGF-R; target sequence;
 KW hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
 KW cancer; genetic drift; detection; mutation; ss.

XX
 OS Homo sapiens.
 XX
 XX
 PN MO9833893-A2.
 PD 06-AUG-1998.
 PF 14-JAN-1998; 98WO-US00730.
 PR 04-DEC-1997; 97US-0985162.
 PR 31-JAN-1997; 97US-0036476.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (UTAS-) UNIV ASTON.
 PI Akhtar S, Fell P, McSwiggen JA;
 PI WPI; 1998-437449/37.

XX
 DR Enzymatic nucleic acids - which cleave RNA derived from an epidermal
 PT growth factor receptor, useful for inhibiting cell proliferation and
 PT for treating cancers

XX
 PS Claim 5; Page 71; 109pp; English.

XX
 CC The present invention describes enzymatic nucleic acid molecules (NAMS)
 CC which specifically cleave RNA derived from an epidermal growth factor
 CC receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
 CC represent specifically claimed target sequence from human EGF-R. AAV98044
 CC to AAV98866 and AAV98867 to V9878 represent hammerhead ribozymes and
 CC hairpin ribozymes respectively for human EGF-R. The NAMS are useful for
 CC cleaving EGF-R RNA in the treatment of a condition associated with EGFR
 CC expression levels e.g. to inhibit cell proliferation in the prevention or
 CC treatment of cancers. The NAMS can also be used as diagnostic tools to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of EGF-R RNA in a cell.

XX
 SQ Sequence 17 BP; 1 A; 4 C; 3 G; 9 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1358 CGCCTGGAAGAGAAAA 1373
 DB 16 CGACTGCAAGAGAAAA 1

RESULT 296
 ID AAV94632/C
 AAV94632; standard; RNA; 17 BP.

XX
 AC AAV94632;
 XX
 DT 24-FEB-1999 (first entry)

XX
 DE Human IL-2 receptor g-chain substrate position 351.
 XX
 KW Human; IL-2 receptor g-chain; interleukin 2 receptor gamma chain;
 KW hammerhead ribozyme; hairpin ribozyme; substrate; expression; cancer;
 KW autoimmune disease; psoriasis; allergy; inflammatory disease;
 KW graft rejection; ss.

XX
 OS Homo sapiens.
 XX
 XX
 PN MO9824913-A2.
 PD 11-JUN-1998.
 PF 02-DEC-1997; 97WO-US21748.
 PR 03-DEC-1996; 96US-0758306.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA McSwiggen JA, Stinchcomb DT;
 PI WPI; 1998-333332/29.

XX
 DR Ribozymes targeted to interleukin 2 - useful for treating e.g.
 PT cancer, autoimmune disease and allergies

XX
 PS Claim 4; Page 34; 61pp; English.

XX
 CC The present sequence invention describes ribozymes targeted to modulate
 CC the synthesis and/or expression of interleukin (IL)-2R gamma encoded
 CC RNA. AAV93888 to AAV94574 represent specifically claimed ribozymes, and
 CC AAV94575 to AAV95260 represent specifically claimed substrate sequences
 CC from the present invention. The ribozymes can be used for the treatment
 CC of, e.g. graft rejection, autoimmune disease, cancer, psoriasis,
 CC allergy and other inflammatory conditions. The ribozymes are also used
 CC to induce tolerance in a recipient to alloantigen from a donor.

XX
 SQ Sequence 17 BP; 4 A; 4 C; 3 G; 6 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2156 CAGCCAGAAATGTTT 2171
 DB 16 CAGCCAGAAAGATTT 1

RESULT 297
 ID AAV96482/C
 AAV96482; standard; RNA; 17 BP.

XX
 AC AAV96482;
 XX
 DT 01-MAR-1999 (first entry)

DE Potato citrate synthase target sequence position 546.
 KW Solanidine; glucosyltransferase; potato; citrate synthase; target;
 KW hammerhead ribozyme; hairpin ribozyme; alkalioid biosynthesis;
 KW flower formation; cleavage; solanaceous plant; ss.

XX
 OS Solanum tuberosum.
 XX
 PN MO9832843-A2.
 PD 30-JUL-1998.
 PF 14-JAN-1998; 98WO-US00738.
 PR 24-NOV-1997; 97US-0979416.
 PR 28-JAN-1997; 97US-0036545.

PR 28-JAN-1997; 97US-0036599.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 PI McSwiggen JA, Zwick MG;
 XX
 DR WPI; 1998-427939/36.
 XX
 PT New enzymatic nucleic acid(s) - useful for, e.g. reducing alkaloid
 PT biosynthesis or regulating flowering
 PS
 XX Claim 53; Page 53; 79pp; English.
 CC The present invention describes enzymatic nucleic acid molecules with
 CC RNA-cleaving activity (e.g. ribozymes) which are capable of modulating
 CC the expression of plant genes: (i) involved in biosynthesis of
 CC alkaloids; or (ii) involved in flower formation. AAV95982 to AAV96334,
 CC and AAV96335 to AAV96354 represent potato solanidine glucosyltransferase
 CC hammerhead and hairpin ribozymes, respectively. AAV95629 to AAV95981,
 CC and AAV96355 to AAV96734 represent potato solanidine glucosyltransferase
 CC target sequences. AAV96773 to AAV97170, and AAV97171 to AAV97195
 CC represent potato citrate synthase hammerhead and hairpin ribozymes,
 CC respectively. AAV96735 to AAV96772, and AAV97196 to AAV97220 represent
 CC potato citrate synthase target sequences. Ribozymes of the present
 CC invention can be used to inhibit the synthesis of toxic alkaloids in
 CC solanaceous plants, particularly potato but also tomato, pepper,
 CC aubergine and datura or to inhibit flowering in potato, lettuce, spinach,
 CC cabbage, brussel sprouts, arugula, kale, collards, chard, beet, turnip,
 CC sweet potato and turf grass. Also the ribozymes can be used for RNA
 CC manipulation in the same way that restriction endonucleases are for DNA,
 CC as well as to examine genetic drift and mutations in plants and to
 CC detect specific RNA. The ribozymes can be targeted to specific genes or
 CC to consensus sequences within a family of related genes, and being
 CC catalytic need to be present at only very low concentrations.
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 2 G; 6 U; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2468 TGTACATGATGATGAG 2483
 Db 16 TATACATGATGATGAG 1
 RESULT 298
 ID AAA18720/c
 ID AAA18720 standard; RNA; 17 BP.
 XX
 AC AAA18720;
 XX
 XX 19-JUN-2000 (first entry)
 DT
 XX
 DE Human TIE-2 substrate sequence SEQ ID NO:1946.
 XX
 XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 XX integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 XX hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
 XX optthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 XX dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 XX age related macular degeneration; inflammation; neovascular glaucoma;
 XX myopic degeneration; psoriasis; verruca vulgaris; angiodiroma;
 XX tubercous scleriosis; pot-wine stain; Sturge Weber syndrome;
 XX Kippel-Trenauay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO950403-A2.
 XX
 PD 07-OCT-1999.
 XX
 PF 24-MAR-1999; 99WO-US06507.

XX
 PR 27-MAR-1998; 98US-0079678.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 PI Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
 XX
 DR WPI; 1999-591315/50.
 XX
 PT Novel ribozymes for modulating the synthesis, expression and/or
 PT stability of an mRNA encoding an angiogenic factors
 PS
 XX Claim 56; Page 112; 305pp; English.
 CC The present invention describes enzymatic nucleic acid molecules with
 CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences. AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT.
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiodiroma of tubercous scleriosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenauay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3.
 XX
 SQ Sequence 17 BP; 7 A; 4 C; 1 G; 5 U; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2348 TAATGTGGAGATCTT 2363
 Db 17 TAATGTGGAAATCTT 2
 RESULT 299
 ID AAA18875
 ID AAA18875 standard; RNA; 17 BP.
 XX
 AC AAA18875;
 XX
 XX 19-JUN-2000 (first entry)
 DT
 XX
 DE Human TIE-2 substrate sequence SEQ ID NO:2101.
 XX
 XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 XX integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 XX hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
 XX optthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 XX dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 XX age related macular degeneration; inflammation; neovascular glaucoma;
 XX myopic degeneration; psoriasis; verruca vulgaris; angiodiroma;
 XX tubercous scleriosis; pot-wine stain; Sturge Weber syndrome;
 XX Kippel-Trenauay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX
 OS Homo sapiens.
 XX

```

PN      MO9950403-A2.
XX
XX      07-OCT-1999.
XX
XX      24-MAR-1999; 99WO-US06507.
XX
XX      27-MAR-1998; 98US-0079678.
XX
XX      (RIBO-) RIBOZYME PHARM INC.
XX
XX      Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
XX      WPI; 1999-591315/50.
XX
XX      Novel ribozymes for modulating the synthesis, expression and/or
XX      stability of an mRNA encoding an angiogenic factors
XX
XX      Claim 56; Page 122; 305pp; English.
XX
XX      The present invention describes enzymatic nucleic acid molecules with
XX      RNA cleaving activity, which specifically cleave RNA encoded by an aryl
XX      hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
XX      gene, an integrin alpha-6 subunit gene, or a Tie-2 gene. AAA16775 to
XX      AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
XX      and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
XX      corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
XX      AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
XX      and AAA19155 to AAA19222 represent their corresponding target sequences;
XX      AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
XX      sequences for integrin alpha 6 subunit, and AAA21500 and
XX      AAA21596 to AAA21688 represent their corresponding target sequences;
XX      AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
XX      for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
XX      AAA23422 represent their corresponding target sequences. The ribozymes of
XX      the invention are used for modulating the synthesis, expression and/or
XX      stability of an mRNA encoding angiogenic factor, especially ARNT,
XX      integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
XX      especially used to treat cancer, diabetic retinopathy, age related
XX      macular degeneration (ARMD), inflammation, and arthritis, as well as
XX      neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
XX      angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
XX      syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
XX      and other syndromes and diseases related to the levels of ARNT, Tie-2,
XX      integrin subunit alpha-6, or integrin subunit beta-3.
XX
XX      Sequence 17 BP; 4 A; 1 C; 5 G; 7 U; 0 other;
XX
XX      Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX      Best Local Similarity 56.2%; Pred. No. 2.5e+02;
XX      Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
XX
Qy      2198 TAGCAGACTTGGACT 2213
Db      :|||||:|||||:
      1 UAGCAGAUUUUGAUU 16

```

```

KW      tubercous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW      Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
XX      Homo sapiens.
XX
XX      MO9950403-A2.
XX
XX      07-OCT-1999.
XX
XX      24-MAR-1999; 99WO-US06507.
XX
XX      27-MAR-1998; 98US-0079678.
XX
XX      (RIBO-) RIBOZYME PHARM INC.
XX
XX      Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
XX      WPI; 1999-591315/50.
XX
XX      Novel ribozymes for modulating the synthesis, expression and/or
XX      stability of an mRNA encoding an angiogenic factors
XX
XX      Claim 55; Page 145; 305pp; English.
XX
XX      The present invention describes enzymatic nucleic acid molecules with
XX      RNA cleaving activity, which specifically cleave RNA encoded by an aryl
XX      hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
XX      gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
XX      AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
XX      and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
XX      corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
XX      AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
XX      and AAA19155 to AAA19222 represent their corresponding target sequences;
XX      AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
XX      sequences for integrin alpha 6 subunit, and AAA21500 and
XX      AAA21596 to AAA21688 represent their corresponding target sequences;
XX      AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
XX      for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
XX      AAA23422 represent their corresponding target sequences. The ribozymes of
XX      the invention are used for modulating the synthesis, expression and/or
XX      stability of an mRNA encoding angiogenic factor, especially ARNT,
XX      integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
XX      especially used to treat cancer, diabetic retinopathy, age related
XX      macular degeneration (ARMD), inflammation, and arthritis, as well as
XX      neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
XX      angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
XX      syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
XX      and other syndromes and diseases related to the levels of ARNT, Tie-2,
XX      integrin subunit alpha-6, or integrin subunit beta-3.
XX
XX      Sequence 17 BP; 5 A; 3 C; 1 G; 8 U; 0 other;
XX
XX      Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX      Best Local Similarity 87.5%; Pred. No. 2.5e+02;
XX      Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
Qy      2183 ACAATGATGAATAAT 2198
Db      :|||||:|||||:
      16 ACAATGTAATCAAGT 1

```

KN hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
 KN ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KN dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KN age related macular degeneration; inflammation; neovascular glaucoma;
 KN myopic degeneration; psoriasis; verruca vulgaris; angiodiroma;
 KN tuberos scleriosis; pot-wine stain; Sturge Weber syndrome;
 KN Kippel-Trenauay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 OS Homo sapiens.
 FN WO950403-A2.
 PD 07-OCT-1999.
 XX 24-MAR-1999; 99WO-US06507.
 XX 27-MAR-1998; 98US-0079678.
 PA (RIBO-) RIBOZYME PHARM INC.
 PI Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
 DR WPI; 1999-591315/50.
 PT Novel ribozymes for modulating the synthesis, expression and/or
 PT stability of an mRNA encoding an angiogenic factors -
 PS Claim 55; Page 146; 305pp; English.
 XX The present invention describes enzymatic nucleic acid molecules with
 CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiodiroma of tuberos scleriosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenauay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3.
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 1 G; 9 U; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2181 AACCAATGTGATGAAA 2196
 Db 17 ATACATGTATATGAAA 2
 RESULT 302
 AAA20859
 ID AAA20859 standard; RNA, 17 BP.
 XX AAA20859;
 AC
 XX 19-UN-2000 (first entry)

XX Integrin alpha 6 subunit substrate sequence SEQ ID NO:4085.
 DE Human; aryl hydrocarbon nuclear transporter; ARNT; Tie-2; angiogenesis;
 XX integrin alpha 6 subunit; integrin subunit beta 3; hairy cell ribozyme;
 KN hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
 KN ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KN dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KN age related macular degeneration; inflammation; neovascular glaucoma;
 KN myopic degeneration; psoriasis; verruca vulgaris; angiodiroma;
 KN tuberos scleriosis; pot-wine stain; Sturge Weber syndrome;
 KN Kippel-Trenauay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 OS Homo sapiens.
 FN WO950403-A2.
 PD 07-OCT-1999.
 XX 24-MAR-1999; 99WO-US06507.
 XX 27-MAR-1998; 98US-0079678.
 PA (RIBO-) RIBOZYME PHARM INC.
 PI Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
 DR WPI; 1999-591315/50.
 PT Novel ribozymes for modulating the synthesis, expression and/or
 PT stability of an mRNA encoding an angiogenic factors -
 PS Claim 55; Page 172; 305pp; English.
 XX The present invention describes enzymatic nucleic acid molecules with
 CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiodiroma of tuberos scleriosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenauay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3.
 XX
 SQ Sequence 17 BP; 9 A; 4 C; 2 G; 2 U; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 2.5e+02;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
 QY 2191 ATGAAAATTCAGACT 2206
 Db 1 AAGAAAATTCAGACU 16
 RESULT 303
 AAA21301

ID AAA21301 standard; RNA; 17 BP.
AC AAA21301;
DT 19-JUN-2000 (first entry)
DE Integrin alpha 6 subunit substrate sequence SEQ ID NO:4527.
XX
XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
XX Integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
XX hammerhead ribozyme; angiogenic factor; cytoskeletal; antidiabetic;
XX opthalmologic; antiinflammatory; antirheumatic; antipsoriatic; AMD;
XX dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
XX age related macular degeneration; inflammation; neovascular glaucoma;
XX myopic degeneration; psoriasis; verruca vulgaris; angioblastoma;
XX tuberculous scleritis; pot-wine stain; Sturge Weber syndrome;
XX Kippel-Trenauay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
OS Homo sapiens.
XX MO9950403-A2.
PD 07-OCT-1999.
XX 24-MAR-1999; 99WO-US06507.
XX 27-MAR-1998; 98US-0079678.
XX (RIBO-) RIBOZYME PHARM INC.
XX Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
XX WPI; 1999-591315/50.
XX Novel ribozymes for modulating the synthesis, expression and/or
PT stability of an mRNA encoding an angiogenic factors -
XX
XX Claim 55; Page 199; 305pp; English.
XX The present invention describes enzymatic nucleic acid molecules with
CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC and AAA17168 to AAA17560 and AAA17623 to AAA18385 and AAA19087 to
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19086
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC and AAA19155 to AAA19222 represent their corresponding target sequences;
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC AAA21596 to AAA21688 represent their corresponding target sequences;
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC AAA23422 represent their corresponding target sequences. The ribozymes of
CC the invention are used for modulating the synthesis, expression and/or
CC stability of an mRNA encoding angiogenic factor, especially ARNT,
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC especially used to treat cancer, diabetic retinopathy, age related
CC macular degeneration (ARMD), inflammation, and arthritis, as well as
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC angioblastoma of tuberculous scleritis, pot-wine stains, Sturge Weber
CC syndrome, Kippel-Trenauay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC integrin subunit alpha-6, or integrin subunit beta-3.
XX
SQ Sequence 17 BP; 7 A; 4 C; 2 G; 4 U; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.5e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
Gy 2309 TATACATCATCAGAG 2324
:::|||||::|

DB 2 UAUAUAUUAACAAGAG 17
RESULT 304
ID AAA21302 standard; RNA; 17 BP.
AC AAA21302;
DT 19-JUN-2000 (first entry)
DE Integrin alpha 6 subunit substrate sequence SEQ ID NO:4528.
XX
XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
XX Integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
XX hammerhead ribozyme; angiogenic factor; cytoskeletal; antidiabetic;
XX opthalmologic; antiinflammatory; antirheumatic; antipsoriatic; AMD;
XX dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
XX age related macular degeneration; inflammation; neovascular glaucoma;
XX myopic degeneration; psoriasis; verruca vulgaris; angioblastoma;
XX tuberculous scleritis; pot-wine stain; Sturge Weber syndrome;
XX Kippel-Trenauay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
OS Homo sapiens.
XX MO9950403-A2.
PD 07-OCT-1999.
XX 24-MAR-1999; 99WO-US06507.
XX 27-MAR-1998; 98US-0079678.
XX (RIBO-) RIBOZYME PHARM INC.
XX Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
XX WPI; 1999-591315/50.
XX Novel ribozymes for modulating the synthesis, expression and/or
PT stability of an mRNA encoding an angiogenic factors -
XX
XX Claim 55; Page 199; 305pp; English.
XX The present invention describes enzymatic nucleic acid molecules with
CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC and AAA17168 to AAA17560 and AAA17623 to AAA18385 and AAA19087 to
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19086
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC and AAA19155 to AAA19222 represent their corresponding target sequences;
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC AAA21596 to AAA21688 represent their corresponding target sequences;
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC AAA23422 represent their corresponding target sequences. The ribozymes of
CC the invention are used for modulating the synthesis, expression and/or
CC stability of an mRNA encoding angiogenic factor, especially ARNT,
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC especially used to treat cancer, diabetic retinopathy, age related
CC macular degeneration (ARMD), inflammation, and arthritis, as well as
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC angioblastoma of tuberculous scleritis, pot-wine stains, Sturge Weber
CC syndrome, Kippel-Trenauay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC integrin subunit alpha-6, or integrin subunit beta-3.
XX
SQ Sequence 17 BP; 8 A; 3 C; 2 G; 4 U; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Gy 2309 TATACATCATCAGAG 2324
:::|||||::|

Best Local Similarity 68.8%; Pred. No. 2.5e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 2309 TATACATCATCAGG 2324
Db 1 UAUACAUCACACAG 16
RESULT 305
AAA23037/c
ID AAA23037 standard; RNA; 17 BP.
XX AAA23037;
XX 19-JUN-2000 (first entry)
DE Integrin subunit beta 3 substrate sequence SEQ ID NO:6263.
XX Human; aryl hydrocarbon nuclear transport; ARNT; Tie-2; angiogenesis;
KW Integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiodiroma;
KW tuberculous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW Kippel-Trenauay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX Kippel-Trenauay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX Homo sapiens.
OS
XX MO9950403-A2.
XX 07-OCT-1999.
XX 24-MAR-1999; 99WO-US06507.
XX 27-MAR-1998; 98US-0079678.
XX (RIBO-) RIBOZYME PHARM INC.
XX Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
PI WPI; 1999-591315/50.
XX Novel ribozymes for modulating the synthesis, expression and/or
PT stability of an mRNA encoding an angiogenic factors -
XX Claim 54; Page 258; 305pp; English.
XX The present invention describes enzymatic nucleic acid molecules with
CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC and AAA19155 to AAA19222 represent their corresponding target sequences;
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC AAA21596 to AAA21688 represent their corresponding target sequences;
CC AAA21689 to AAA24475 and AAA23263 to AAA23342 represent ribozyme sequence
CC for integrin subunit beta 3, and AAA24476 to AAA23262, AAA23343 to
CC AAA23422 represent their corresponding target sequences. The ribozymes of
CC the invention are used for modulating the synthesis, expression and/or
CC stability of an mRNA encoding angiogenic factor, especially ARNT,
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC especially used to treat cancer, diabetic retinopathy, age related
CC macular degeneration (ARMD), inflammation, and arthritis, as well as
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC angiodiroma of tuberculous sclerosis, pot-wine stains, Sturge Weber
CC syndrome, Kippel-Trenauay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,

CC integrin subunit alpha-6, or integrin subunit beta-3.
XX Sequence 17 BP; 6 A; 1 C; 7 G; 3 U; 0 other;
SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2586 CCTCAGCCACCTCTC 2601
Db 17 CCTCAGTCATCTCTC 2
RESULT 306
AAK16147/c
ID AAK16147 standard; DNA; 17 BP.
XX AAK16147;
XX 16-APR-1999 (first entry)
DE Mouse neurofibromatosis type 2 PCR primer 5m9.
XX Human; neurofibromatosis type 2; NF2; tumour suppressor; cancer;
KW diagnosis; gene therapy; PCR primer; ss.
XX Synthetic.
OS Mus sp.
XX US5872214-A.
XX 16-FEB-1999.
XX 04-APR-1996; 96US-0628145.
XX 10-JAN-1994; 94US-0179738.
XX 04-APR-1996; 96US-0628145.
XX (BRIM) BRISTOL-MYERS SQUIBB CO.
XX Bianchi AB, Kley NA, Seizinger BR;
PI WPI; 1999-166715/14.
XX Proteins from neurofibromatosis type 2 transcript isoforms - used
PT for diagnosis or inhibition of tumours, and generation of antibodies
XX Example; Column 14; 45pp; English.
XX The present invention describes neurofibromatosis type 2 (NF2)
CC transcript isoforms. NF2 polynucleotides can be used for diagnosing
CC NF2 diseases, for inhibiting growth of tumours associated with NF2
CC mutations (including expression from cDNA introduced in gene therapy
CC vectors) and to raise antibodies (useful as tumour targeting agents,
CC since specific isoforms are often tumour-specific) and as immunoassay
CC reagents for detecting NF2-expression products. NF2 is a tumour
CC suppressor protein, and so has anticancer activity. The present
CC sequence represents a PCR primer for mouse NF2, from an example of
CC the present invention.
XX Sequence 17 BP; 6 A; 1 C; 7 G; 3 T; 0 other;
SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1579 TCCATCATGAACTCCA 1594
Db 17 TCCATCATGAACTCCA 2
RESULT 307
AAV93558/c

ID AAV93558 standard; RNA; 17 BP.
XX AAV93558;
AC
XX 18-FEB-1999 (first entry)
XX
XX
DE Human B-raf substrate nucleotide position 1679.
XX
XX Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
XX target; substrate; catalytic; modulation; expression; Raf gene;
XX delivery; screening; identification; synthesis; deprotection;
XX purification; cancer; inflammation; psoriasis; non-hepatic ascites;
XX infection; genetic drift; restenosis; rheumatoid arthritis; ss.
XX
XX Homo sapiens.
XX
XX WO9850530-A2.
XX
XX 12-NOV-1998.
XX
XX 05-MAY-1998; 98WO-US09249.
XX
XX 19-DEC-1997; 97US-0068212.
XX 09-MAY-1997; 97US-0046059.
XX 09-JUN-1997; 97US-0049002.
XX 03-JUL-1997; 97US-0051718.
XX 22-AUG-1997; 97US-0056808.
XX 02-OCT-1997; 97US-0061321.
XX 02-OCT-1997; 97US-0061324.
XX 05-NOV-1997; 97US-0064866.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Beaudry A, Beigelman L, Bellon L, Burgin A, Jarvis T;
XX Karpelesky A, Kleich K, Matulic-Adamic J, McSwigen JA;
XX Parry T, Reynolds M, Sweedler D, Thompson J, Workman CT;
XX
XX WPI; 1999-009494/01.
XX
XX Identifying new catalytic nucleic acid that modulates selected
XX processes - especially ribozymes that cleave Raf RNA for treating
XX cancer, restenosis, and also new ribozymes and modified nucleoside
XX triphosphates used as antiviral agents and synthons
XX
XX
XX Claim 177; Page 170; 259pp; English.
XX
XX A method has been developed for the identification of a nucleic acid
XX capable of modulating a process in a biological system. The method
XX comprises: (a) introducing into the system a random library of nucleic
XX acid catalysts (NAC) having a substrate binding domain (SBD), comprising
XX a random sequence, and a catalytic domain (CD); and (b) identifying NAC
XX in systems where modulation has occurred and/or determining the sequence
XX of at least part of the SBDs in such systems. Nucleic acid molecules
XX with endonuclease activity and catalytic activity, from the present
XX invention, are used to modulate gene expression in plant and mammalian
XX cells and to cleave target nucleic acid, particularly for treating
XX systemic diseases caused by specific RNA, e.g. cancer, inflammation,
XX psoriasis, non-hepatic ascites and infection. They may also be used to
XX detect genetic drift and mutations in diseased cells and to determine
XX c-raf RNA. Specifically NACs with RNA-cleaving activity that modulate
XX expression of the Raf gene, are used to treat cancer, restenosis,
XX psoriasis or rheumatoid arthritis, or generally any condition associated
XX with the level of c-raf. Introduction of sugar/phosphate modifications
XX increases stability against nuclease and activity. AAV90922 to AAV93877
XX represent NACs that can be used in the method, specifically for
XX modulating the expression of a Raf gene.
XX
XX Sequence 17 BP; 5 A; 7 C; 0 G; 5 U; 0 other;
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.5e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 1873 GAGATGAGATGATGA 1888
Db |||||||
17 GATATGAGATGCTGA 2
RESULT 308
AAV93511/c
ID AAV93511 standard; RNA; 17 BP.
XX
XX AAV93511;
XX
XX 18-FEB-1999 (first entry)
XX
XX
XX Human B-raf substrate nucleotide position 1346.
XX
XX Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
XX target; substrate; catalytic; modulation; expression; Raf gene;
XX delivery; screening; identification; synthesis; deprotection;
XX purification; cancer; inflammation; psoriasis; non-hepatic ascites;
XX infection; genetic drift; restenosis; rheumatoid arthritis; ss.
XX
XX Homo sapiens.
XX
XX WO9850530-A2.
XX
XX 12-NOV-1998.
XX
XX 05-MAY-1998; 98WO-US09249.
XX
XX 19-DEC-1997; 97US-0068212.
XX 09-MAY-1997; 97US-0046059.
XX 09-JUN-1997; 97US-0049002.
XX 03-JUL-1997; 97US-0051718.
XX 22-AUG-1997; 97US-0056808.
XX 02-OCT-1997; 97US-0061321.
XX 02-OCT-1997; 97US-0061324.
XX 05-NOV-1997; 97US-0064866.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Beaudry A, Beigelman L, Bellon L, Burgin A, Jarvis T;
XX Karpelesky A, Kleich K, Matulic-Adamic J, McSwigen JA;
XX Parry T, Reynolds M, Sweedler D, Thompson J, Workman CT;
XX
XX WPI; 1999-009494/01.
XX
XX Identifying new catalytic nucleic acid that modulates selected
XX processes - especially ribozymes that cleave Raf RNA for treating
XX cancer, restenosis, and also new ribozymes and modified nucleoside
XX triphosphates used as antiviral agents and synthons
XX
XX
XX Claim 177; Page 169; 259pp; English.
XX
XX A method has been developed for the identification of a nucleic acid
XX capable of modulating a process in a biological system. The method
XX comprises: (a) introducing into the system a random library of nucleic
XX acid catalysts (NAC) having a substrate binding domain (SBD), comprising
XX a random sequence, and a catalytic domain (CD); and (b) identifying NAC
XX in systems where modulation has occurred and/or determining the sequence
XX of at least part of the SBDs in such systems. Nucleic acid molecules
XX with endonuclease activity and catalytic activity, from the present
XX invention, are used to modulate gene expression in plant and mammalian
XX cells and to cleave target nucleic acid, particularly for treating
XX systemic diseases caused by specific RNA, e.g. cancer, inflammation,
XX psoriasis, non-hepatic ascites and infection. They may also be used to
XX detect genetic drift and mutations in diseased cells and to determine
XX c-raf RNA. Specifically NACs with RNA-cleaving activity that modulate
XX expression of the Raf gene, are used to treat cancer, restenosis,
XX psoriasis or rheumatoid arthritis, or generally any condition associated
XX with the level of c-raf. Introduction of sugar/phosphate modifications
XX increases stability against nuclease and activity. AAV90922 to AAV93877
XX represent NACs that can be used in the method, specifically for
XX modulating the expression of a Raf gene.

XX Sequence 17 BP; 4 A; 6 C; 1 G; 6 U; 0 other;
SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY .1881 GATGATGAAGATGATT 1896
Db 16 GAGGATGAAGATGACT 1
RESULT 309
AAV90932
ID AAV90932 standard; RNA; 17 BP.
AC AAV90932;
XX 18-FEB-1999 (first entry)
DT
XX Human C-raf target site nucleotide position 117.
DE
XX Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
KW target; substrate; catalyst; modulation; expression; Raf gene;
KW delivery; screening; identification; synthesis; deprotection;
KW purification; cancer; inflammation; psoriasis; non-hepatic ascites;
KW infection; genetic drift; restenosis; rheumatoid arthritis; ss.
XX
XX Homo sapiens.
OS
XX MO9850530-A2.
PN
XX 12-NOV-1998.
PD
XX 05-MAY-1998; 98WO-US09249.
PF
XX 19-DEC-1997; 97US-0068212.
PR 09-MAY-1997; 97US-0046052.
PR 09-JUN-1997; 97US-0049002.
PR 03-JUL-1997; 97US-0051718.
PR 22-AUG-1997; 97US-0056808.
PR 02-OCT-1997; 97US-0061321.
PR 02-OCT-1997; 97US-0061324.
PR 05-NOV-1997; 97US-0064866.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Beaudry A, Beigelman L, Bellon L, Burgin A, Jarvis T;
PI Karpelsky A, Kisch K, Matulic-Adamic J, McSwigen JA;
PI Parry T, Reynolds M, Sweedler D, Thompson J, Workman CT;
XX WPI; 1999-009494/01.
DR
XX Identifying new catalytic nucleic acid that modulates selected
PT processes - especially ribozymes that cleave Raf RNA for treating
PT cancer, restenosis, and also new ribozymes and modified nucleoside
PT triphosphates used as antiviral agents and synthons
XX
XX Claim 177; Page 146; 259pp; English.
XX
XX A method has been developed for the identification of a nucleic acid
CC capable of modulating a process in a biological system. The method
CC comprises: (a) introducing into the system a random library of nucleic
CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising
CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC
CC in systems where modulation has occurred and/or determining the sequence
CC of at least part of the SBDs in such systems. Nucleic acid molecules
CC with endonuclease activity and catalytic activity, from the present
CC invention, are used to modulate gene expression in plant and mammalian
CC cells and to cleave target nucleic acid, particularly for treating
CC systemic diseases caused by specific RNA, e.g. cancer, inflammation,
CC psoriasis, non-hepatic ascites and infection. They may also be used to
CC detect genetic drift and mutations in diseased cells and to determine

CC c-raf RNA. Specifically NACs with RNA-cleaving activity that modulate
CC expression of the Raf gene, are used to treat cancer, restenosis,
CC psoriasis or rheumatoid arthritis, or generally any condition associated
CC with the level of c-raf. Introduction of sugar/phosphate modifications
CC increases stability against nuclease and activity. AAV90922 to AAV93877
CC represent NACs that can be used in the method, specifically for
CC modulating the expression of a Raf gene.
XX
XX Sequence 17 BP; 5 A; 2 C; 4 G; 6 U; 0 other;
SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 2.5e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
QY 2404 GAACCTTTAAGCTGC 2419
Db 2 GAATUGUUAAGCTGC 17
RESULT 310
AAV90933
ID AAV90933 standard; RNA; 17 BP.
AC AAV90933;
XX 18-FEB-1999 (first entry)
DT
XX Human C-raf target site nucleotide position 118.
DE
XX Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
KW target; substrate; catalyst; modulation; expression; Raf gene;
KW delivery; screening; identification; synthesis; deprotection;
KW purification; cancer; inflammation; psoriasis; non-hepatic ascites;
KW infection; genetic drift; restenosis; rheumatoid arthritis; ss.
XX
XX Homo sapiens.
OS
XX MO9850530-A2.
PN
XX 12-NOV-1998.
PD
XX 05-MAY-1998; 98WO-US09249.
PF
XX 19-DEC-1997; 97US-0068212.
PR 09-MAY-1997; 97US-0046052.
PR 09-JUN-1997; 97US-0049002.
PR 03-JUL-1997; 97US-0051718.
PR 22-AUG-1997; 97US-0056808.
PR 02-OCT-1997; 97US-0061321.
PR 02-OCT-1997; 97US-0061324.
PR 05-NOV-1997; 97US-0064866.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Beaudry A, Beigelman L, Bellon L, Burgin A, Jarvis T;
PI Karpelsky A, Kisch K, Matulic-Adamic J, McSwigen JA;
PI Parry T, Reynolds M, Sweedler D, Thompson J, Workman CT;
XX WPI; 1999-009494/01.
DR
XX Identifying new catalytic nucleic acid that modulates selected
PT processes - especially ribozymes that cleave Raf RNA for treating
PT cancer, restenosis, and also new ribozymes and modified nucleoside
PT triphosphates used as antiviral agents and synthons
XX
XX Claim 177; Page 146; 259pp; English.
XX
XX A method has been developed for the identification of a nucleic acid
CC capable of modulating a process in a biological system. The method
CC comprises: (a) introducing into the system a random library of nucleic
CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising
CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC
CC in systems where modulation has occurred and/or determining the sequence

CC of at least part of the SBDs in such systems. Nucleic acid molecules
 CC with endonuclease activity and catalytic activity, from the present
 CC invention, are used to modulate gene expression in plant and mammalian
 CC cells and to cleave target nucleic acid, particularly for treating
 CC systemic diseases caused by specific RNA, e.g. cancer, inflammation,
 CC psoriasis, non-hepatic ascites and infection. They may also be used to
 CC detect genetic drift and mutations in diseased cells and to determine
 CC c-raf RNA. Specifically NACs with RNA-cleaving activity that modulate
 CC expression of the Raf gene, are used to treat cancer, restenosis,
 CC psoriasis or rheumatoid arthritis, or generally any condition associated
 CC with the level of c-raf. Introduction of sugar/phosphate modifications
 CC increases stability against nuclease and activity. AAV90922 to AAV93877
 CC represent NACs that can be used in the method, specifically for
 CC modulating the expression of a Raf gene.

CC
 CC
 CC Sequence 17 BP; 5 A; 2 C; 4 G; 6 U; 0 other;
 CC
 CC Query Match 0.9%; Score 12.8; DB 1; Length 17;
 CC Best Local Similarity 56.2%; Pred. No. 2.5e+02;
 CC Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2404 GAACCTTTTAAGCTGC 2419
 |||:|||||:
 1 GAUUGUUUAGGCTGC 16

Db
 RESULT 311
 AAV91069/C
 ID AAV91069 standard; RNA; 17 BP.
 XX
 AC AAV91069;
 DT 18-FEB-1999 (first entry)
 XX
 DE Human C-raf target site nucleotide position 862.
 XX
 KW Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
 KW target; substrate; catalyst; modulation; expression; Raf gene;
 KW delivery; screening; identification; synthesis; deprotection;
 KW purification; cancer; inflammation; psoriasis; non-hepatic ascites;
 KW infection; genetic drift; restenosis; rheumatoid arthritis; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9850530-A2.
 PD 12-NOV-1998.
 XX
 PF 05-MAY-1998; 98WO-US09249.
 XX
 PR 19-DEC-1997; 97US-0068212.
 PR 09-MAY-1997; 97US-0046059.
 PR 03-JUN-1997; 97US-0051718.
 PR 22-AUG-1997; 97US-0056808.
 PR 02-OCT-1997; 97US-0061321.
 PR 02-OCT-1997; 97US-0061324.
 PR 05-NOV-1997; 97US-0064866.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Beaudry A, Beigelman L, Bellon L, Burgin A, Jarvis T,
 PI Karpelsky A, Kisch K, Matulic-Adamic J, McSwiggan JA,
 PI Parry T, Reynolds M, Sweedler D, Thompson J, Workman CT;
 XX
 DR WPI, 1999-009494/01.
 XX
 PT Identifying new catalytic nucleic acid that modulates selected
 PT processes - especially ribozymes that cleave Raf RNA for treating
 PT cancer, restenosis, and also new ribozymes and modified nucleoside
 PT triphosphates used as antiviral agents and synthons
 XX
 PS Claim 177; Page 148; 259pp; English.

CC A method has been developed for the identification of a nucleic acid
 CC capable of modulating a process in a biological system. The method
 CC comprises: (a) introducing into the system a random library of nucleic
 CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising
 CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC
 CC in systems where modulation has occurred and/or determining the sequence
 CC of at least part of the SBDs in such systems. Nucleic acid molecules
 CC with endonuclease activity and catalytic activity, from the present
 CC invention, are used to modulate gene expression in plant and mammalian
 CC cells and to cleave target nucleic acid, particularly for treating
 CC systemic diseases caused by specific RNA, e.g. cancer, inflammation,
 CC psoriasis, non-hepatic ascites and infection. They may also be used to
 CC detect genetic drift and mutations in diseased cells and to determine
 CC c-raf RNA. Specifically NACs with RNA-cleaving activity that modulate
 CC expression of the Raf gene, are used to treat cancer, restenosis,
 CC psoriasis or rheumatoid arthritis, or generally any condition associated
 CC with the level of c-raf. Introduction of sugar/phosphate modifications
 CC increases stability against nuclease and activity. AAV90922 to AAV93877
 CC represent NACs that can be used in the method, specifically for
 CC modulating the expression of a Raf gene.

CC
 CC
 CC Sequence 17 BP; 2 A; 9 C; 1 G; 5 U; 0 other;
 CC
 CC Query Match 0.9%; Score 12.8; DB 1; Length 17;
 CC Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 CC Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2478 GATGAGGACTGTTCG 2493
 |||||:
 16 GATGAGGACTGTTCG 1

Db
 RESULT 312
 AAV91152
 ID AAV91152 standard; RNA; 17 BP.
 XX
 AC AAV91152;
 DT 18-FEB-1999 (first entry)
 XX
 DE Human C-raf target site nucleotide position 1505.
 XX
 KW Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
 KW target; substrate; catalyst; modulation; expression; Raf gene;
 KW delivery; screening; identification; synthesis; deprotection;
 KW purification; cancer; inflammation; psoriasis; non-hepatic ascites;
 KW infection; genetic drift; restenosis; rheumatoid arthritis; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9850530-A2.
 PD 12-NOV-1998.
 XX
 PF 05-MAY-1998; 98WO-US09249.
 XX
 PR 19-DEC-1997; 97US-0068212.
 PR 09-MAY-1997; 97US-0046059.
 PR 03-JUN-1997; 97US-0051718.
 PR 22-AUG-1997; 97US-0056808.
 PR 02-OCT-1997; 97US-0061321.
 PR 02-OCT-1997; 97US-0061324.
 PR 05-NOV-1997; 97US-0064866.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Beaudry A, Beigelman L, Bellon L, Burgin A, Jarvis T,
 PI Karpelsky A, Kisch K, Matulic-Adamic J, McSwiggan JA,
 PI Parry T, Reynolds M, Sweedler D, Thompson J, Workman CT;
 XX
 DR WPI, 1999-009494/01.

```

XX Identifying new catalytic nucleic acid that modulates selected
PT processes - especially ribozymes that cleave Raf RNA for treating
PT cancer, restenosis, and also new ribozymes and modified nucleoside
PT triphosphates used as antiviral agents and synthons
XX
XX Claim 177; Page 149; 259pp; English.
XX
CC A method has been developed for the identification of a nucleic acid
CC capable of modulating a process in a biological system. The method
CC comprises: (a) introducing into the system a random library of nucleic
CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising
CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC
CC in systems where modulation has occurred and/or determining the sequence
CC of at least part of the SBDs in such systems. Nucleic acid molecules
CC with endonuclease activity and catalytic activity, from the present
CC invention, are used to modulate gene expression in plant and mammalian
CC cells and to cleave target nucleic acid, particularly for treating
CC systemic diseases caused by specific RNA, e.g. cancer, inflammation,
CC psoriasis, non-hepatic ascites and infection. They may also be used to
CC detect genetic drift and mutations in diseased cells and to determine
CC c-raf RNA. Specifically NACs with RNA-cleaving activity that modulate
CC expression of the Raf gene, are used to treat cancer, restenosis,
CC psoriasis or rheumatoid arthritis, or generally any condition associated
CC with the level of c-raf. Introduction of sugar/phosphate modifications
CC increases stability against nuclease and activity. AAV90922 to AAV93877
CC represent NACs that can be used in the method, specifically for
CC modulating the expression of a Raf gene.
CC
SQ Sequence 17 BP; 5 A; 3 C; 4 G; 5 U; 0 other;
XX
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 62.5%; Pred. No. 2.5e+02;
XX Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2484 GGACTGTTGGCATGCA 2499
DB 1 GGACUAAUUGCAUGCA 16
||||:||||:||||
AAV91151
RESULT 313
ID AAV91151 standard; RNA; 17 BP.
XX
XX AAV91151;
XX
XX 18-FEB-1999 (first entry)
XX
DE Human C-raf target site nucleotide position 1504.
XX
XX Human; c-raf; A-raf; B-raf; hamsterhead ribozyme; hairpin ribozyme;
XX target; substrate; catalytic; modulation; expression; Raf gene;
XX delivery; screening; identification; synthesis; deprotection;
XX purification; cancer; inflammation; psoriasis; non-hepatic ascites;
XX infection; genetic drift; restenosis; rheumatoid arthritis; ss.
XX
OS Homo sapiens.
XX
XX MO3850530-A2.
XX
PD 12-NOV-1998.
XX
XX 05-MAY-1998; 98WO-US09249.
XX
XX 19-DEC-1997; 97US-0068212.
XX 09-MAY-1997; 97US-0046059.
XX 03-JUN-1997; 97US-0049002.
XX 22-AUG-1997; 97US-0051718.
XX 02-OCT-1997; 97US-0056808.
XX 02-OCT-1997; 97US-0061321.
XX 05-NOV-1997; 97US-0061324.
XX
XX 97US-0064866.

```

```

PA (RIBO-) RIBOZYME PHARM INC.
XX
XX Beaudry A, Beigelman L, Bellon L, Burgin A, Jarvis T;
PI Karpetsky A, Kisch K, Matulic-Adamic J, McSwiggen JA;
PI Parry T, Reynolds M, Sweedler D, Thompson J, Workman CT;
XX
XX WPI: 1999-009494/01.
XX
DR
XX
XX Identifying new catalytic nucleic acid that modulates selected
PT processes - especially ribozymes that cleave Raf RNA for treating
PT cancer, restenosis, and also new ribozymes and modified nucleoside
PT triphosphates used as antiviral agents and synthons
XX
XX Claim 177; Page 149; 259pp; English.
XX
XX
XX A method has been developed for the identification of a nucleic acid
XX capable of modulating a process in a biological system. The method
XX comprises: (a) introducing into the system a random library of nucleic
XX acid catalysts (NAC) having a substrate binding domain (SBD), comprising
XX a random sequence, and a catalytic domain (CD); and (b) identifying NAC
XX in systems where modulation has occurred and/or determining the sequence
XX of at least part of the SBDs in such systems. Nucleic acid molecules
XX with endonuclease activity and catalytic activity, from the present
XX invention, are used to modulate gene expression in plant and mammalian
XX cells and to cleave target nucleic acid, particularly for treating
XX systemic diseases caused by specific RNA, e.g. cancer, inflammation,
XX psoriasis, non-hepatic ascites and infection. They may also be used to
XX detect genetic drift and mutations in diseased cells and to determine
XX c-raf RNA. Specifically NACs with RNA-cleaving activity that modulate
XX expression of the Raf gene, are used to treat cancer, restenosis,
XX psoriasis or rheumatoid arthritis, or generally any condition associated
XX with the level of c-raf. Introduction of sugar/phosphate modifications
XX increases stability against nuclease and activity. AAV90922 to AAV93877
XX represent NACs that can be used in the method, specifically for
XX modulating the expression of a Raf gene.
XX
SQ Sequence 17 BP; 4 A; 3 C; 4 G; 6 U; 0 other;
XX
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 62.5%; Pred. No. 2.5e+02;
XX Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2484 GGACTGTTGGCATGCA 2499
DB 2 GGACUAAUUGCAUGCA 17
||||:||||:||||
AAV91151
RESULT 314
ID AAV91151 standard; DNA; 17 BP.
XX
XX AAV91151;
XX
XX 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #2915.
XX
XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
XX interferon alpha; ss.
XX
OS Homo sapiens.
XX
XX MO300061729-A2.
XX
XX 19-OCT-2000.
XX
XX 11-APR-2000; 2000WO-US09721.
XX
XX 12-APR-1999; 99US-0129390.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Zwick M, Pavco P, McSwiggen J;

```

XX WPI; 2000-647423/62.
XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor
PT protein, interferon alpha and erythropoietin -
XX
XX Claim 42; Page 123; 164pp; English.
XX
XX The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA
CC transcription factor gene, IRF-2 and/or the C/EBP Displacement
CC protein (CDP). Inhibition of the repressors removes prevents
CC inhibition (and consequently increases expression of) genes involved in
CC the production of erythropoietin, granulocyte colony stimulating factor
CC protein and interferon alpha.
XX
XX Sequence 17 BP; 2 A; 8 C; 1 G; 6 U; 0 other;
SQ
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1758 GGTCTATGCGGAGACA 1773
DB 16 GGTCTATGAGGAGAGAA 1
RESULT 315
AAFO7173
ID AAFO7173 standard; DNA; 17 BP.
XX
XX AAFO7173;
AC
XX 16-FEB-2001 (first entry)
DT
XX Hammerhead ribozyme substrate #3430.
DE
XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
XX interferon alpha; ss.
KW
XX Homo sapiens.
OS
XX WO200061729-A2.
PN
XX 19-OCT-2000.
PD
XX 11-APR-2000; 2000WO-US09721.
PF
XX 12-APR-1999; 99US-0129390.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Blatt L, Zwick M, Pavco P, McSwiggen J;
PI
XX WPI; 2000-647423/62.
XX
XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor
PT protein, interferon alpha and erythropoietin -
XX
XX Claim 54; Page 135; 164pp; English.
XX
XX The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA
CC transcription factor gene, IRF-2 and/or the C/EBP Displacement
CC protein (CDP). Inhibition of the repressors removes prevents
CC inhibition (and consequently increases expression of) genes involved in
CC the production of erythropoietin, granulocyte colony stimulating factor
CC protein and interferon alpha.
XX

SQ Sequence 17 BP; 1 A; 9 C; 3 G; 4 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2696 GCCCTCCTCAGTATCC 2711
DB 1 GCCCTCCTCCGATCC 16
RESULT 316
AAA24827
ID AAA24827 standard; DNA; 17 BP.
XX
XX AAA24827;
AC
XX 19-JUL-2000 (first entry)
DT
XX
XX Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1325.
DE
XX
XX Oestrogen receptor; c-ras; k-ras; bcl-2; ribozyme; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KW gene expression modification; cancer; phosphorothioate; endonuclease;
KW anticancer; breast cancer; endometrium cancer; ss.
XX
XX Homo sapiens.
OS
XX WO954459-A2.
PN
XX 28-OCT-1999.
PD
XX 19-APR-1999; 99WO-US08547.
PF
XX 20-APR-1998; 98US-0082404.
PR
XX 23-JUN-1998; 98US-0103636.
PX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Thompson JD, Beigelman L, McSwiggen JA, Karpelsky A, Bellon L;
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haeblerl P;
PI Matulic-Adamic J;
XX
XX WPI; 2000-013248/01.
DR
XX
XX New nucleic acids that interact, and optionally cleave, target
PT sequences, used to treat cancer -
PT
XX
XX Claim 77; Page 59; 148pp; English.
XX
XX The present invention describes nucleic acids (A) that interact stably
CC with a target sequence and contain at least one phosphorodithioate
CC link, having endonuclease activity. (A), and more generally any
CC catalytic nucleic acid (A') that modulates expression of the oestrogen
CC receptor gene, are used to treat cancer (particularly of breast or
CC endometrium), in vivo or by transforming cells ex vivo and implanting
CC treated cells, or for other conditions associated with levels of
CC oestrogen receptor. Because of the high selectivity for targeted RNA, (A)
CC can also be used to correlate inhibition of gene expression with
CC alterations in phenotype, particularly for identification of therapeutic
CC targets, and as research reagents (for RNA, in the same way that
CC restriction endonucleases are used with DNA). The combination of
CC modifications in (A) improves resistance to nucleases, binding affinity
CC and/or activity. AAA23503 to AAA24747 represent oestrogen receptor
CC hammerhead ribozyme sequences, and AAA24748 to AAA25992 represent their
CC corresponding target sequences. AAA25993 to AAA26105 represent oestrogen
CC receptor hairpin ribozyme sequences, and AAA26107 to AAA26218 represent
CC their corresponding target sequences. AAA26219 to AAA26271 represent
CC other ribozyme sequences and antisense oligonucleotides used in the
CC exemplification of the present invention.
XX
XX Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 other;
SQ

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1390 CCAGACTACCTGGAGA 1405
 |||||
 2 CCTACTACTGCTGAGA 17

RESULT 317

AAA25517/C
 ID AAA25517 standard; DNA; 17 BP.

AC AAA25517;

DT 19-JUL-2000 (first entry)

XX Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:2015.

XX Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;

KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;

KM gene expression modification; cancer; phosphorothioate; endonuclease;

XX anticancer; breast cancer; endometrium cancer; ss.

OS Homo sapiens.

PN MO9954459-A2.

PD 28-OCT-1999.

PF 19-APR-1999; 99WO-US08547.

PR 20-APR-1998; 98US-0082404.

XX 23-JUN-1998; 98US-0103636.

PA (RIBO-) RIBOZYME PHARM INC.

XX Thompson JD, Beigelman L, McSwiggen JA, Karpelesky A, Bellon L;

PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haeblerli P;

XX Matulic-Adamic J;

DR WPI; 2000-013248/01.

XX New nucleic acids that interact, and optionally cleave, target

PT sequences, used to treat cancer

PS Claim 77; Page 81; 148pp; English.

XX The present invention describes nucleic acids (A) that interact stably

CC with a target sequence and contain at least one phosphorodithioate

CC link, having endonuclease activity. (A), and more generally any

CC catalytic nucleic acid (A') that modulates expression of the oestrogen

CC receptor gene, are used to treat cancer (particularly of breast or

CC endometrium), in vivo or by transforming cells ex vivo and implanting

CC treated cells, or for other conditions associated with levels of

CC oestrogen receptor. Because of the high selectivity for targeted RNA, (A)

CC can also be used to correlate inhibition of gene expression with

CC alterations in phenotype, particularly for identification of therapeutic

CC targets, and as research reagents (for RNA, in the same way that

CC restriction endonucleases are used with DNA). The combination of

CC modifications in (A) improves resistance to nucleases, binding affinity

CC and/or activity. AAA23503 to AAA24747 represent oestrogen receptor

CC hammerhead ribozyme sequences, and AAA24748 to AAA25992 represent their

CC corresponding target sequences. AAA25993 to AAA26105 represent oestrogen

CC receptor hairpin ribozyme sequences, and AAA26107 to AAA26218 represent

CC their corresponding target sequences. AAA26219 to AAA26271 represent

CC other ribozyme sequences and antisense oligonucleotides used in the

CC exemplification of the present invention.

XX Sequence 17 BP; 5 A; 3 C; 1 G; 8 T; 0 other;

XX Query Match 0.9%; Score 12.8; DB 1; Length 17;

XX Best Local Similarity 87.5%; Pred. No. 2.5e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2168 TTTTGCTACGAGAAA 2183
 |||||
 17 TTTTGTTAAAGCAA 2

RESULT 318

AAA25518/C
 ID AAA25518 standard; DNA; 17 BP.

AC AAA25518;

DT 19-JUL-2000 (first entry)

XX Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:2016.

XX Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;

KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;

KM gene expression modification; cancer; phosphorothioate; endonuclease;

XX anticancer; breast cancer; endometrium cancer; ss.

OS Homo sapiens.

PN MO9954459-A2.

PD 28-OCT-1999.

PF 19-APR-1999; 99WO-US08547.

PR 20-APR-1998; 98US-0082404.

XX 23-JUN-1998; 98US-0103636.

PA (RIBO-) RIBOZYME PHARM INC.

XX Thompson JD, Beigelman L, McSwiggen JA, Karpelesky A, Bellon L;

PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haeblerli P;

XX Matulic-Adamic J;

DR WPI; 2000-013248/01.

XX New nucleic acids that interact, and optionally cleave, target

PT sequences, used to treat cancer

PS Claim 77; Page 81; 148pp; English.

XX The present invention describes nucleic acids (A) that interact stably

CC with a target sequence and contain at least one phosphorodithioate

CC link, having endonuclease activity. (A), and more generally any

CC catalytic nucleic acid (A') that modulates expression of the oestrogen

CC receptor gene, are used to treat cancer (particularly of breast or

CC endometrium), in vivo or by transforming cells ex vivo and implanting

CC treated cells, or for other conditions associated with levels of

CC oestrogen receptor. Because of the high selectivity for targeted RNA, (A)

CC can also be used to correlate inhibition of gene expression with

CC alterations in phenotype, particularly for identification of therapeutic

CC targets, and as research reagents (for RNA, in the same way that

CC restriction endonucleases are used with DNA). The combination of

CC modifications in (A) improves resistance to nucleases, binding affinity

CC and/or activity. AAA23503 to AAA24747 represent oestrogen receptor

CC hammerhead ribozyme sequences, and AAA24748 to AAA25992 represent their

CC corresponding target sequences. AAA25993 to AAA26105 represent oestrogen

CC receptor hairpin ribozyme sequences, and AAA26107 to AAA26218 represent

CC their corresponding target sequences. AAA26219 to AAA26271 represent

CC other ribozyme sequences and antisense oligonucleotides used in the

CC exemplification of the present invention.

XX Sequence 17 BP; 5 A; 3 C; 1 G; 8 T; 0 other;

XX Query Match 0.9%; Score 12.8; DB 1; Length 17;

XX Best Local Similarity 87.5%; Pred. No. 2.5e+02;

XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2168 TTTTGTACAGAAA 2183
DB 16 TTTGTAAAGCAA 1

RESULT 319
ABA78913
ID ABA78913 standard; DNA, 17 BP.
AC ABA78913;
XX
XX 24-JAN-2002 (first entry)
XX
XX APC mutation correcting oligonucleotide SEQ ID NO: 1759.
DE
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CPT1; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presentin-1;
KW Alzheimer's disease; cytoskeletal; antisticking; antinaemic; haemostatic;
KW antileptic; ss.
XX
XX Homo sapiens.
OS
XX WO200173002-A2.
PN
XX 04-OCT-2001.
PD
XX 27-MAR-2001; 2001WO-US09761.
PE
XX 27-MAR-2000; 2000US-192176P.
PR 27-MAR-2000; 2000US-192179P.
PR 01-JUN-2000; 2000US-208538P.
PR 30-OCT-2000; 2000US-244989P.
XX
XX (UYDE) UNIV DELAWARE.
PA
XX Kmiec EB, Gamper HB, Rice MC;
PI
XX WPI; 2001-639230/73.
DR
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification -
XX
XX Claim 7; Page 147; 294pp; English.
PS
XX
XX The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CPT1, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presentin-1 (PSEN1) and
CC presentin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention.
XX
XX
SQ Sequence 17 BP; 6 A; 1 C; 5 G; 5 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1880 AGATGATCAGATGAT 1895
DB 1 AGATGATCAGATGAT 16

RESULT 320
ABA78914/C
ID ABA78914 standard; DNA, 17 BP.
AC ABA78914;
XX
XX 24-JAN-2002 (first entry)
XX
XX APC mutation correcting oligonucleotide SEQ ID NO: 1760.
DE
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CPT1; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presentin-1;
KW Alzheimer's disease; cytoskeletal; antisticking; antinaemic; haemostatic;
KW antileptic; ss.
XX
XX Homo sapiens.
OS
XX WO200173002-A2.
PN
XX 04-OCT-2001.
PD
XX 27-MAR-2001; 2001WO-US09761.
PE
XX 27-MAR-2000; 2000US-192176P.
PR 27-MAR-2000; 2000US-192179P.
PR 01-JUN-2000; 2000US-208538P.
PR 30-OCT-2000; 2000US-244989P.
XX
XX (UYDE) UNIV DELAWARE.
PA
XX Kmiec EB, Gamper HB, Rice MC;
PI
XX WPI; 2001-639230/73.
DR
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification -
XX
XX Claim 7; Page 147; 294pp; English.
PS
XX
XX The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CPT1, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presentin-1 (PSEN1) and
CC presentin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention.
XX
XX
SQ Sequence 17 BP; 5 A; 5 C; 1 G; 6 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1880 AGATGATGAAGTGCAT 1895
| | | | | | | | | |
Db 17 AGATGATTCAGATGAT 2

RESULT 321
ABA80468
ID ABA80468 standard; DNA; 17 BP.
XX
XX ABA80468;
AC
XX
XX 24-JAN-2002 (first entry)
DT
XX
XX MSH2 mutation correcting oligonucleotide SEQ ID NO: 3314.
DE

Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CPTA; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytosolic; antisticking; antianaemic; haemostatic;
KW antileptic; ss.
XX
XX
XX Homo sapiens.
OS
XX
XX WO200173002-A2.
PN
XX
XX 04-OCT-2001.
PD
XX
XX 27-MAR-2001; 2001WO-US09761.
PF
XX
XX 27-MAR-2000; 2000US-192176P.
PR
XX 01-JUN-2000; 2000US-192179P.
PR 01-JUN-2000; 2000US-208538P.
PR 30-OCT-2000; 2000US-244989P.
XX
XX (UYDE) UNIV DELAWARE.
PA
XX
XX Kmiec EB, Gampier HB, Rice MC;
PI
XX WPI; 2001-639230/73.
DR

Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification -
XX
XX
XX Claim 7; Page 226; 294pp; English.
PS

The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CPTA, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention.
XX
XX Sequence 17 BP; 3 A; 3 C; 4 G; 7 T; 0 other;
SQ

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.5e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1686 CCCAAATGGAGCTTT 1701
| | | | | | | | | |
Db 1 CCCAAATGGAGCTTT 16

RESULT 322
ABA80469/C
ID ABA80469 standard; DNA; 17 BP.
XX
XX ABA80469;
AC
XX
XX 24-JAN-2002 (first entry)
DT
XX
XX MSH2 mutation correcting oligonucleotide SEQ ID NO: 3315.
DE

Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CPTA; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytosolic; antisticking; antianaemic; haemostatic;
KW antileptic; ss.
XX
XX
XX Homo sapiens.
OS
XX
XX WO200173002-A2.
PN
XX
XX 04-OCT-2001.
PD
XX
XX 27-MAR-2001; 2001WO-US09761.
PF
XX
XX 27-MAR-2000; 2000US-192176P.
PR
XX 01-JUN-2000; 2000US-192179P.
PR 01-JUN-2000; 2000US-208538P.
PR 30-OCT-2000; 2000US-244989P.
XX
XX (UYDE) UNIV DELAWARE.
PA
XX
XX Kmiec EB, Gampier HB, Rice MC;
PI
XX WPI; 2001-639230/73.
DR

Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification -
XX
XX
XX Claim 7; Page 226; 294pp; English.
PS

The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CPTA, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention.
XX
XX Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 other;
SQ

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 1686 CCAAAATGGAGTTT 1701
 |||||
 17 CCAAAATGGAGTTT 2

RESULT 323

AAH94651
 ID AAH94651 standard; RNA; 17 BP.

AC AAH94651;

DT 09-OCT-2001 (first entry)

DE Human Chk1 ribozyme substrate SEQ ID NO: 76.

XX Human; checkpoint kinase-1; Chk1; antisense; ribozyme; gene therapy;

KM RNA cleavage; cancer; ss.

OS Homo sapiens.

PN WO200157206-A2.

PD 09-AUG-2001.

PF 02-FEB-2001; 2001WO-US03504.

PR 03-FEB-2000; 2000US-0179983.

PA (RIBO-) RIBOZYME PHARM INC.

PA (FATT//) FATTAEY A R.

PI Fattaey AR, Jarvis T, McSwiggen J, Booher RN, Holman PS;

DR WPI; 2001-496922/54.

PT Novel nucleic acid molecule e.g., ribozymes or antisense nucleic acid

PT molecules, which downregulates expression of a checkpoint kinase-1

PT gene, useful for treating colorectal, lung, breast or prostate cancers

PS Claim 4; Page 53; 115pp; English.

CC The present invention provides nucleic acid molecules capable of

CC downregulating the expression of the human checkpoint kinase-1 (Chk1)

CC gene. These may be antisense or ribozyme sequences, and are useful in the

CC treatment of diseases associated with conditions affected by Chk1 levels,

CC including cancer. The present sequence is an oligonucleotide described in

CC the exemplification of the invention.

XX Sequence 17 BP; 6 A; 4 C; 2 G; 5 U; 0 other;

SQ

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 62.5%; Pred. No. 2.5e+02;

Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

OY 2194 AAAATAGCAGACTTGG 2209

DB 2 AAAAUCGACUUG 17

RESULT 324

AAH95254/C
 ID AAH95254 standard; RNA; 17 BP.

AC AAH95254;

DT 09-OCT-2001 (first entry)

DE Human Chk1 ribozyme substrate SEQ ID NO: 679.

XX Human; checkpoint kinase-1; Chk1; antisense; ribozyme; gene therapy;
 KM RNA cleavage; cancer; ss.
 XX Homo sapiens.
 PN WO200157206-A2.
 PD 09-AUG-2001.
 PF 02-FEB-2001; 2001WO-US03504.
 PR 03-FEB-2000; 2000US-0179983.
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (FATT//) FATTAEY A R.
 PI Fattaey AR, Jarvis T, McSwiggen J, Booher RN, Holman PS;

RESULT 325

AAH95836
 ID AAH95836 standard; RNA; 17 BP.

AC AAH95836;

DT 09-OCT-2001 (first entry)

DE Human Chk1 ribozyme substrate SEQ ID NO: 1261.

XX Human; checkpoint kinase-1; Chk1; antisense; ribozyme; gene therapy;

KM RNA cleavage; cancer; ss.

OS Homo sapiens.

PN WO200157206-A2.

PD 09-AUG-2001.

PF 02-FEB-2001; 2001WO-US03504.

PR 03-FEB-2000; 2000US-0179983.

PA (RIBO-) RIBOZYME PHARM INC.

PA (FATT//) FATTAEY A R.

PI Fattaey AR, Jarvis T, McSwiggen J, Booher RN, Holman PS;

DR WPI; 2001-496922/54.

PT Novel nucleic acid molecule e.g., ribozymes or antisense nucleic acid

PT molecules, which downregulates expression of a checkpoint kinase-1

PT gene, useful for treating colorectal, lung, breast or prostate cancers

PS Claim 4; Page 66; 115pp; English.

CC The present invention provides nucleic acid molecules capable of

CC downregulating the expression of the human checkpoint kinase-1 (Chk1)

CC gene. These may be antisense or ribozyme sequences, and are useful in the

CC treatment of diseases associated with conditions affected by Chk1 levels,

CC including cancer. The present sequence is an oligonucleotide described in

CC the exemplification of the invention.

XX Sequence 17 BP; 6 A; 2 C; 0 G; 9 U; 0 other;

SQ

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.5e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2163 AAATGTTTGGTACA 2178

DB 17 AAATGTTTGTATPAAA 2

XX WPI; 2001-496922/54.
DR Novel nucleic acid molecule e.g., ribozymes or antisense nucleic acid
XX molecules, which downregulate expression of a checkpoint kinase-1
PT gene, useful for treating colorectal, lung, breast or prostate cancers
PT -
XX
XX
PS Claim 4; Page 90; 115pp; English.
XX
CC The present invention provides nucleic acid molecules capable of
CC downregulating the expression of the human checkpoint kinase-1 (Chk1)
CC gene. These may be antisense or ribozyme sequences, and are useful in the
CC treatment of diseases associated with conditions affected by Chk1 levels,
CC including cancer. The present sequence is an oligonucleotide described in
CC the exemplification of the invention.
XX
SQ Sequence 17 BP; 5 A; 4 C; 3 G; 5 U; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 2.5e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
Qy 2195 AAATAGCAGACTTGG 2210
|||:|||||:|
Db 1 AAATUCGACGACUUCG 16
RESULT 326
ABK00843/c
ID ABK00843 standard; RNA; 17 BP.
XX
AC ABK00843;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Inozyme #13.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
OS Homo sapiens.
OS Synthetic.
XX
XX WO200159103-A2.
XX
XX 16-AUG-2001.
XX
XX 09-FEB-2001; 2001WO-US04273.
XX
XX 11-FEB-2000; 2000US-181797P.
XX 28-FEB-2000; 2000US-185516P.
XX 06-MAR-2000; 2000US-187128P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGEN J.
XX (CHOW/) CHOWIRIRA B M.
XX Blatt L, McSwigen J, Chowirira BM;
XX WPI; 2001-607195/69.
XX

PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia,
PT and central nervous system injury -
XX
XX
PS Claim 88; Page 79; 200pp; English.
XX
CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO).
CC The nucleic acids may be enzymatic nucleic acids (e.g., a ribozyme or a
CC DNAzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN
CC motif) or an amberzyme (cleaving RNA with an NGN triplet), a zinczyme
CC (cleaving RNA with a YGY motif). The CD20-targeting nucleic acid is used
CC to cleave RNA of CD20 in the presence of a divalent cation that is
CC preferably Mg²⁺. Furthermore, it may be contacted with a cell to reduce
CC CD20 activity of the cell and treat a patient having a condition
CC associated with the level of CD20. The treatment may further comprise the
CC use of one or more therapies. In particular, the CD20 targeting
CC nucleic acid may be used to treat lymphoma, leukaemia, B-cell
CC lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky
CC low-grade or follicular NHL, lymphocytic leukaemia, HIV (human
CC immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL),
CC immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune
CC thrombocytopenia, and inflammatory arthropathy. The NOGO-targeting
CC nucleic acid is used to cleave RNA of the NOGO gene in the presence of a
CC divalent cation that is preferably Mg²⁺. Furthermore, the nucleic acid
CC may be contacted with a cell to reduce NOGO activity of the cell and
CC treat a patient having a condition associated with the level of NOGO. The
CC treatment may further comprise the use of one or more therapies.
CC In particular, the NOGO-targeting nucleic acid may be used to treat
CC central nervous system (CNS) injury and cerebrovascular accident (CVA,
CC stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The
CC present sequence is an inozyme of the invention.
XX
SQ Sequence 17 BP; 1 A; 8 C; 7 G; 1 U; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1651 CTGGCAGGGGCTCCG 1666
|||:|||||:|
Db 17 CCGGACGGGGTCCCCG 2
RESULT 327
ABK00845/c
ID ABK00845 standard; RNA; 17 BP.
XX
AC ABK00845;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Inozyme #115.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
KW

XX Homo sapiens.
 OS Synthetic.
 XX MO200159103-A2.
 XX 16-AUG-2001.
 XX 09-FEB-2001; 2001WO-US04273.
 XX 11-FEB-2000; 2000US-181797P.
 PR 28-FEB-2000; 2000US-185516P.
 PR 06-MAR-2000; 2000US-187128P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX Blatt L, McSwigen J, Chowrira BM;
 PI WPI; 2001-607195/69.
 XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia,
 PT and central nervous system injury -
 XX Claim 88; Page 79; 200P; English.
 XX The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOCO).
 CC The nucleic acids may be enzymatic nucleic acids (e.g., a ribozyme or a
 CC DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN
 CC motif) or an amberzyme (cleaving RNA with an NGN triplet), a zinzyme
 CC (cleaving RNA with a YXY motif). The CD20-targeting nucleic acid is used
 CC to cleave RNA of CD20 in the presence of a divalent cation that is
 CC preferably Mg²⁺. Furthermore, it may be contacted with a cell to reduce
 CC CD20 activity of the cell and treat a patient having a condition
 CC associated with the level of CD20. The treatment may further comprise the
 CC use of one or more therapies. In particular, the CD20 targeting
 CC nucleic acid may be used to treat lymphoma, leukaemia, B-cell
 CC lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky
 CC low-grade or follicular NHL, lymphocytic leukaemia, HIV (human
 CC immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL),
 CC immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune
 CC thrombocytopenia, and inflammatory arthropathy. The NOCO-targeting
 CC nucleic acid is used to cleave RNA of the NOGO gene in the presence of a
 CC divalent cation that is preferably Mg²⁺. Furthermore, the nucleic acid
 CC may be contacted with a cell to reduce NOGO activity of the cell and
 CC treat a patient having a condition associated with the level of NOGO. The
 CC treatment may further comprise the use of one or more therapies.
 CC In particular, the NOGO-targeting nucleic acid may be used to treat
 CC central nervous system (CNS) injury and cerebrovascular accident (CVA,
 CC stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The
 CC present sequence is an inozyme of the invention.
 XX Sequence 17 BP; 1 A; 8 C; 7 G; 1 U; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 328
 ABK02092/C
 ID ABK02092 standard; RNA; 17 BP.
 XX
 XX
 AC ABK02092;
 XX
 XX 12-MAR-2002 (first entry)
 DT
 XX
 XX Human NOGO DNazyme #4.
 DE
 XX Human, ss; antisense therapy; cyostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX MO200159103-A2.
 XX 16-AUG-2001.
 XX 09-FEB-2001; 2001WO-US04273.
 XX 11-FEB-2000; 2000US-181797P.
 PR 28-FEB-2000; 2000US-185516P.
 PR 06-MAR-2000; 2000US-187128P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX Blatt L, McSwigen J, Chowrira BM;
 PI WPI; 2001-607195/69.
 XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia,
 PT and central nervous system injury -
 XX Claim 88; Page 112; 200P; English.
 XX The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOCO).
 CC The nucleic acids may be enzymatic nucleic acids (e.g., a ribozyme or a
 CC DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN
 CC motif) or an amberzyme (cleaving RNA with an NGN triplet), a zinzyme
 CC (cleaving RNA with a YXY motif). The CD20-targeting nucleic acid is used
 CC to cleave RNA of CD20 in the presence of a divalent cation that is
 CC preferably Mg²⁺. Furthermore, it may be contacted with a cell to reduce
 CC CD20 activity of the cell and treat a patient having a condition
 CC associated with the level of CD20. The treatment may further comprise the
 CC use of one or more therapies. In particular, the CD20 targeting
 CC nucleic acid may be used to treat lymphoma, leukaemia, B-cell
 CC lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky
 CC low-grade or follicular NHL, lymphocytic leukaemia, HIV (human
 CC immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL),
 CC immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune
 CC thrombocytopenia, and inflammatory arthropathy. The NOCO-targeting
 CC nucleic acid is used to cleave RNA of the NOGO gene in the presence of a

CC divalent cation that is preferably Mg^{2+} . Furthermore, the nucleic acid
 CC may be contacted with a cell to reduce NOGO activity of the cell and
 CC treat a patient having a condition associated with the level of NOGO. The
 CC treatment may further comprise the use of one or more therapies.
 CC In particular, the NOGO-targeting nucleic acid may be used to treat
 CC central nervous system (CNS) injury and cerebrovascular accident (CVA,
 CC stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The
 CC present sequence is a DNAzyme molecule of the invention.

CC Sequence 17 BP; 5 A; 5 C; 5 G; 2 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1572 GTCCAGGCTCCGAG 1587
 Db 16 GTCCAGGCTCCGAG 1

RESULT 329
 ID ABR02103/C
 XX ABR02103 standard; RNA; 17 BP.

AC ABR02103;
 XX
 DT 12-MAR-2002 (first entry)

DE Human NOGO DNAzyme #15.

XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotrophic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNAzyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

XX Homo sapiens.
 OS Synthetic.

XX WO200159103-A2.

XX 16-AUG-2001.

XX 09-FEB-2001; 2001WO-US04273.

XX 11-FEB-2000; 2000US-181797P.

XX 28-FEB-2000; 2000US-18516P.

XX 06-MAR-2000; 2000US-187128P.

XX (RIBO-) RIBOZYME PHARM INC.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGGEN J.

XX (CHOW/) CHOWRIRA B M.

XX Blact L, McSwiggen J, Chowrira BM;

XX WPI; 2001-607195/69.

XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia,
 PT and central nervous system injury -

XX Claim 88; Page 113; 200pp; English.

XX The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO).
 CC The nucleic acid may be enzymatic nucleic acids (e.g., a ribozyme or a
 CC DNAzyme) an inozyme (an endolytic nucleic acid cleaving a RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NUN
 CC motif) or an amberzyme (cleaving RNA with an NCH triplet), a zinczyme
 CC (cleaving RNA with a YGG motif). The CD20-targeting nucleic acid is used
 CC to cleave RNA of CD20 in the presence of a divalent cation that is
 CC preferably Mg^{2+} . Furthermore, it may be contacted with a cell to reduce
 CC CD20 activity of the cell and treat a patient having a condition
 CC associated with the level of CD20. The treatment may further comprise the
 CC use of one or more therapies. In particular, the CD20-targeting
 CC nucleic acid may be used to treat lymphoma, leukaemia, B-cell
 CC lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky
 CC low-grade or follicular NHL, lymphocytic leukaemia, HIV (human
 CC immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL),
 CC immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune
 CC thrombocytopenia, and inflammatory arthropathy. The NOGO-targeting
 CC nucleic acid is used to cleave RNA of the NOGO gene in the presence of a
 CC divalent cation that is preferably Mg^{2+} . Furthermore, the nucleic acid
 CC may be contacted with a cell to reduce NOGO activity of the cell and
 CC treat a patient having a condition associated with the level of NOGO. The
 CC treatment may further comprise the use of one or more therapies.
 CC In particular, the NOGO-targeting nucleic acid may be used to treat
 CC central nervous system (CNS) injury and cerebrovascular accident (CVA,
 CC stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The
 CC present sequence is a DNAzyme molecule of the invention.

XX Sequence 17 BP; 1 A; 10 C; 5 G; 1 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1653 GGCGAGGCTCCGAG 1668
 Db 17 GGCGAGGCTCCGAG 2

RESULT 330
 ID ABR02341/C
 XX ABR02341 standard; RNA; 17 BP.

XX ABR02341;

XX 12-MAR-2002 (first entry)

XX Human NOGO Amberzyme #13.

XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotrophic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNAzyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

XX Homo sapiens.

XX Synthetic.

PN WO200159103-A2.
 XX
 XX 16-AUG-2001.
 PD
 XX
 XX 09-FEB-2001; 2001WO-US04273.
 XX
 XX 11-FEB-2000; 2000US-181797P.
 PR 28-FEB-2000; 2000US-185516P.
 PR 06-MAR-2000; 2000US-187128P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 PI Blatt L, McSwigen J, Chowrira BM;
 XX WPI; 2001-607195/69.
 XX
 XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia,
 PT and central nervous system injury -
 XX
 XX Claim 88; Page 130; 200pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOCO).
 CC The nucleic acid may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN
 CC motif) pr an amberzyme (cleaving RNA with an NGN triplet), a zinzyme
 CC (cleaving RNA with a YGY motif). The CD20-targeting nucleic acid is used
 CC to cleave RNA of CD20 in the presence of a divalent cation that is
 CC preferably Mg²⁺. Furthermore, it may be contacted with a cell to reduce
 CC CD20 activity of the cell and treat a patient having a condition
 CC associated with the level of CD20. The treatment may further comprise the
 CC use of one or more therapies. In particular, the CD20 targeting
 CC nucleic acid may be used to treat lymphoma, leukaemia, B-cell
 CC lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky
 CC low-grade or follicular NHL, lymphocytic leukaemia, HIV (human
 CC immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL),
 CC immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune
 CC thrombocytopaenia, and inflammatory arthropathy. The NOGO-targeting
 CC nucleic acid is used to cleave RNA of the NOGO gene in the presence of a
 CC divalent cation that is preferably Mg²⁺. Furthermore, the nucleic acid
 CC may be contacted with a cell to reduce NOGO activity of the cell and
 CC treat a patient having a condition associated with the level of NOGO. The
 CC treatment may further comprise the use of one or more therapies.
 CC In particular, the NOGO-targeting nucleic acid may be used to treat
 CC central nervous system (CNS) injury and cerebrovascular accident (CVA,
 CC stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The
 CC present sequence is an amberzyme molecule of the invention.
 XX
 SQ Sequence 17 BP; 5 A; 5 C; 5 G; 2 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1572 GTCCAGGCTCCGATG 1587
 DB 17 GTCCAGGCTTCATG 2

RESULT 331
 ABK02926/C
 ID ABK02926 standard; RNA; 17 BP.

XX
 AC ABK02926;
 DT 12-MAR-2002 (first entry)
 DT
 XX
 DE Human CD20 Hammerhead ribozyme #225.
 XX
 XX Human, ss; antisense therapy; cytosstatic; antiinflammatory; haemostatic;
 KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX WO200159103-A2.
 XX
 XX 16-AUG-2001.
 PD
 XX
 XX 09-FEB-2001; 2001WO-US04273.
 XX
 XX 11-FEB-2000; 2000US-181797P.
 PR 28-FEB-2000; 2000US-185516P.
 PR 06-MAR-2000; 2000US-187128P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 PI Blatt L, McSwigen J, Chowrira BM;
 XX WPI; 2001-607195/69.
 XX
 CC Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia,
 PT and central nervous system injury -
 XX
 XX Claim 30; Page 143; 200pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOCO).
 CC The nucleic acid may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN
 CC motif) pr an amberzyme (cleaving RNA with an NGN triplet), a zinzyme
 CC (cleaving RNA with a YGY motif). The CD20-targeting nucleic acid is used
 CC to cleave RNA of CD20 in the presence of a divalent cation that is
 CC preferably Mg²⁺. Furthermore, it may be contacted with a cell to reduce
 CC CD20 activity of the cell and treat a patient having a condition
 CC associated with the level of CD20. The treatment may further comprise the
 CC use of one or more therapies. In particular, the CD20 targeting
 CC nucleic acid may be used to treat lymphoma, leukaemia, B-cell
 CC lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky
 CC low-grade or follicular NHL, lymphocytic leukaemia, HIV (human
 CC immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL),
 CC immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune
 CC thrombocytopaenia, and inflammatory arthropathy. The NOGO-targeting
 CC nucleic acid is used to cleave RNA of the NOGO gene in the presence of a
 CC divalent cation that is preferably Mg²⁺. Furthermore, the nucleic acid
 CC may be contacted with a cell to reduce NOGO activity of the cell and
 CC treat a patient having a condition associated with the level of NOGO. The
 CC treatment may further comprise the use of one or more therapies.

CC In particular, the NOGO-targeting nucleic acid may be used to treat
CC central nervous system (CNS) injury and cerebrovascular accident (CVA,
CC stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The
CC present sequence is a hammerhead ribozyme of the invention.
XX
SQ Sequence 17 BP; 2 A; 7 C; 0 G; 8 U; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1362 TGGAGAGAGAGAGAG 1377
Db 16 TGTAGAGAGAGAGAG 1
RESULT 332
ABK03271
ID ABK03271 standard; RNA; 17 BP.
XX
AC ABK03271;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human CD20 inozyme #222.
XX
XX Human; ss; antisense therapy; cytosolic; antiinflammatory; haemostatic;
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNazyme; inozyme; G-cleaver; amberzyme; zincyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX WO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US04273.
XX
XX 11-FEB-2000; 2000US-181797P.
PR 28-FEB-2000; 2000US-185516P.
PR 06-MAR-2000; 2000US-187128P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blact L, McSwiggen J, Chowrira BM;
XX WPI; 2001-607195/69.
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia,
PT and central nervous system injury -
XX
PS Claim 30; Page 149; 200pp; English.
XX
XX The invention relates to a nucleic acid molecule which down regulates

CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO).
CC The nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNazyme) an inozyme (an endolytic nucleic acid cleaving a RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NNN
CC motif) or an amberzyme (cleaving RNA with an NNN triplet), a zincyme
CC (cleaving RNA with a YGY motif). The CD20-targeting nucleic acid is used
CC to cleave RNA of CD20 in the presence of a divalent cation that is
CC preferably Mg²⁺. Furthermore, it may be contacted with a cell to reduce
CC CD20 activity of the cell and treat a patient having a condition
CC associated with the level of CD20. The treatment may further comprise the
CC use of one or more therapies. In particular, the CD20 targeting
CC nucleic acid may be used to treat lymphoma, leukaemia, B-cell
CC lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky
CC low-grade or follicular NHL, lymphocytic leukaemia, HIV (human
CC immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL),
CC immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune
CC thrombocytopenia, and inflammatory arthropathy. The NOGO-targeting
CC nucleic acid is used to cleave RNA of the NOGO gene in the presence of a
CC divalent cation that is preferably Mg²⁺. Furthermore, the nucleic acid
CC may be contacted with a cell to reduce NOGO activity of the cell and
CC treat a patient having a condition associated with the level of NOGO. The
CC treatment may further comprise the use of one or more therapies.
CC In particular, the NOGO-targeting nucleic acid may be used to treat
CC central nervous system (CNS) injury and cerebrovascular accident (CVA,
CC stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The
CC present sequence is an inozyme of the invention.
XX
SQ Sequence 17 BP; 6 A; 4 C; 4 G; 3 U; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2.5e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy 1703 CAGAGATTAAGCTGAC 1718
Db 1 CAAGAGACATCUCGAC 16
RESULT 333
ABK03295/C
ID ABK03295 standard; RNA; 17 BP.
XX
AC ABK03295;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human CD20 inozyme #246.
XX
XX Human; ss; antisense therapy; cytosolic; antiinflammatory; haemostatic;
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNazyme; inozyme; G-cleaver; amberzyme; zincyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX WO200159103-A2.
XX
PD 16-AUG-2001.
XX
XX The invention relates to a nucleic acid molecule which down regulates

PF 09-FEB-2001; 2001WO-US04273.
XX
XX 11-FEB-2000; 2000US-181797P.
PR 28-FEB-2000; 2000US-185516P.
PR 06-MAR-2000; 2000US-187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, McSwiggen J, Chowrira BM;
DR WPI; 2001-607195/69.
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia,
PT and central nervous system injury -
XX
PS Claim 30; Page 149; 200pp; English.
XX
XX The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOCO).
CC The nucleic acids may be enzymatic nucleic acids (e.g., a ribozyme or a
CC DNAzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NVN
CC motif) or an amberzyme (cleaving RNA with an NGN triplet), a zinczyme
CC (cleaving RNA with a YGY motif). The CD20-targeting nucleic acid is used
CC to cleave RNA of CD20 in the presence of a divalent cation that is
CC preferably Mg²⁺. Furthermore, it may be contacted with a cell to reduce
CC CD20 activity of the cell and treat a patient having a condition
CC associated with the level of CD20. The treatment may further comprise the
CC use of one or more therapies. In particular, the CD20 targeting
CC nucleic acid may be used to treat lymphoma, leukemia, B-cell
CC lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky
CC low-grade or follicular NHL, lymphocytic leukaemia, HIV (human
CC immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL),
CC immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune
CC thrombocytopenia, and inflammatory arthropathy. The NOCO-targeting
CC nucleic acid is used to cleave RNA of the NOCO gene in the presence of a
CC divalent cation that is preferably Mg²⁺. Furthermore, the nucleic acid
CC may be contacted with a cell to reduce NOCO activity of the cell and
CC treat a patient having a condition associated with the level of NOCO. The
CC treatment may further comprise the use of one or more therapies.
CC In particular, the NOCO-targeting nucleic acid may be used to treat
CC central nervous system (CNS) injury and cerebrovascular accident (CVA,
CC stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOCO expression. The
CC present sequence is an inozyme of the invention.
XX
XX Sequence 17 BP; 2 A; 7 C; 1 G; 7 U; 0 other;
SQ

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1362 TGAAGAGAAAAGGAG 1377
DB 17 TGTAAAGAGAAAGAG 2

RESULT 334
ABV7898
ID ABV7898 standard; DNA; 17 BP.
XX
XX ABV789898;
XX
DT 03-JAN-2003 (first entry)

XX
DE Human HTPL scanning oligonucleotide SEQ ID 144.
XX
XX Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
XX Homo sapiens.
XX
XX EPI23046-A2.
XX
XX 07-AUG-2002.
XX
XX 28-JAN-2002; 2002EP-0001167.
XX
XX 30-JAN-2001; 2001WO-US00663.
XX 30-JAN-2001; 2001WO-US00664.
XX 30-JAN-2001; 2001WO-US00665.
XX 30-JAN-2001; 2001WO-US00667.
XX 30-JAN-2001; 2001WO-US00668.
XX 30-JAN-2001; 2001WO-US00669.
XX 23-MAY-2001; 2001US-0864761.
XX 09-OCT-2001; 2001US-0327898.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Zhan J;
XX
XX WPI; 2002-676582/73.
XX
XX Novel isolated human testis expressed Patched like protein (HTPL),
PT useful for identifying agonist and antagonist and specific binding
PT partners, and for treating subjects having defects in HTPL -
XX
XX Example 2; Page 82; 718pp; English.
XX
XX The present invention relates to human testis expressed Patched like
XX protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
XX has two isoforms, with a few single base pair differences between the
XX two. One of the single base pair changes introduces a premature stop
XX codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
XX shares an overall structure organisation with the Patched protein. The
XX shared structural features strongly imply that HTPL plays a role similar
XX to that of Patched, and is a potential tumour suppressor. HTPL is
XX important in regulating male germ cell development, and the HTPL gene was
XX mapped to human chromosome 10p12.1. HTPL and its coding sequence are
XX useful for diagnosing a disorder caused by mutation in HTPL, and in
XX therapy and manufacture of a medicament for treatment or prevention of
XX such disorder associated with decreased expression or activity of human
XX HTPL. Such disorders include disorders of testis, or adrenal, adult and
XX foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
XX skeletal muscle or colon function. HTPL proteins and nucleic acids are
XX clinically useful diagnostic markers and potential therapeutic agents for
XX male infertility and cancer. The present oligonucleotide was used in an
XX example from the invention.
XX
XX Sequence 17 BP; 7 A; 7 C; 2 G; 1 T; 0 other;
SQ

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1518 GCACAGCTGACCAA 1533
DB 2 GCCCAAGCTCACCAA 17

RESULT 335
ABV78900
ID ABV78900 standard; DNA; 17 BP.
XX
XX ABV78900;
XX
AC

```
XX 03-JAN-2003 (first entry)
DT Human HTPL scanning oligonucleotide SEQ ID 146.
DE
XX Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
XX human testis expressed Patched like protein; testis; adrenal; liver;
XX male germ cell development; bone marrow; brain; kidney; lung; placenta;
XX prostate; skeletal muscle; colon; male infertility; cancer; ss.
OS Homo sapiens.
XX EPI229046-A2.
XX
XX 07-AUG-2002.
XX
XX 28-JAN-2002; 2002EP-0001167.
XX
XX 30-JAN-2001; 2001WO-US00663.
XX 30-JAN-2001; 2001WO-US00664.
XX 30-JAN-2001; 2001WO-US00665.
XX 30-JAN-2001; 2001WO-US00666.
XX 30-JAN-2001; 2001WO-US00667.
XX 30-JAN-2001; 2001WO-US00668.
XX 30-JAN-2001; 2001WO-US00669.
XX 23-MAY-2001; 2001US-0864761.
XX 09-OCT-2001; 2001US-0327898.
XX (AEOM-) AEOMICA INC.
XX
XX Zhan J;
XX
XX WPI; 2002-676582/73.
XX
XX Novel isolated human testis expressed Patched like protein (HTPL),
XX useful for identifying agonist and antagonist and specific binding
XX partners, and for treating subjects having defects in HTPL.
XX
XX Example 2; Page 82; 718pp; English.
XX
XX The present invention relates to human testis expressed Patched like
XX protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
XX has two isoforms, with a few single base pair differences between the
XX two. One of the single base pair changes introduces a premature stop
XX codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
XX shares an overall structure organisation with the Patched protein. The
XX shared structural features strongly imply that HTPL plays a role similar
XX to that of Patched, and is a potential tumour suppressor. HTPL is
XX important in regulating male germ cell development, and the HTPL gene was
XX mapped to human chromosome 10p12.1. HTPL and its coding sequence are
XX useful for diagnosing a disorder caused by mutation in HTPL, and in
XX therapy and manufacture of a medicament for treatment or prevention of
XX such disorder associated with decreased expression or activity of human
XX HTPL. Such disorders include disorders of testis, or adrenal, adult and
XX foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
XX skeletal muscle or colon function. HTPL proteins and nucleic acids are
XX clinically useful diagnostic markers and potential therapeutic agents for
XX male infertility and cancer. The present oligonucleotide was used in an
XX example from the invention.
XX
XX Sequence 17 BP; 6 A; 9 C; 1 G; 1 T; 0 other;
SQ
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.5e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1519 CACAAGCTGACCAAC 1534
XX | | | | | | | | | |
XX 1 CCCAAGCTCACCAC 16
DB
XX
XX RESULT 336
XX ABV80429/C
XX ID ABV80429 standard; DNA; 17 BP.
```

```
XX ABV80429;
AC 03-JAN-2003 (first entry)
XX
XX Human HTPL scanning oligonucleotide SEQ ID 1675.
DE
XX Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
XX human testis expressed Patched like protein; testis; adrenal; liver;
XX male germ cell development; bone marrow; brain; kidney; lung; placenta;
XX prostate; skeletal muscle; colon; male infertility; cancer; ss.
OS Homo sapiens.
XX EPI229046-A2.
XX
XX 07-AUG-2002.
XX
XX 28-JAN-2002; 2002EP-0001167.
XX
XX 30-JAN-2001; 2001WO-US00663.
XX 30-JAN-2001; 2001WO-US00664.
XX 30-JAN-2001; 2001WO-US00665.
XX 30-JAN-2001; 2001WO-US00666.
XX 30-JAN-2001; 2001WO-US00667.
XX 30-JAN-2001; 2001WO-US00668.
XX 30-JAN-2001; 2001WO-US00669.
XX 23-MAY-2001; 2001US-0864761.
XX 09-OCT-2001; 2001US-0327898.
XX (AEOM-) AEOMICA INC.
XX
XX Zhan J;
XX
XX WPI; 2002-676582/73.
XX
XX Novel isolated human testis expressed Patched like protein (HTPL),
XX useful for identifying agonist and antagonist and specific binding
XX partners, and for treating subjects having defects in HTPL.
XX
XX Example 2; Page 283; 718pp; English.
XX
XX The present invention relates to human testis expressed Patched like
XX protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
XX has two isoforms, with a few single base pair differences between the
XX two. One of the single base pair changes introduces a premature stop
XX codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
XX shares an overall structure organisation with the Patched protein. The
XX shared structural features strongly imply that HTPL plays a role similar
XX to that of Patched, and is a potential tumour suppressor. HTPL is
XX important in regulating male germ cell development, and the HTPL gene was
XX mapped to human chromosome 10p12.1. HTPL and its coding sequence are
XX useful for diagnosing a disorder caused by mutation in HTPL, and in
XX therapy and manufacture of a medicament for treatment or prevention of
XX such disorder associated with decreased expression or activity of human
XX HTPL. Such disorders include disorders of testis, or adrenal, adult and
XX foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
XX skeletal muscle or colon function. HTPL proteins and nucleic acids are
XX clinically useful diagnostic markers and potential therapeutic agents for
XX male infertility and cancer. The present oligonucleotide was used in an
XX example from the invention.
XX
XX Sequence 17 BP; 5 A; 2 C; 1 G; 9 T; 0 other;
SQ
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.5e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2187 TGTGATGAATACGA 2202
XX | | | | | | | | | |
XX 17 TGTATATAAATACGA 2
DB
XX
XX RESULT 337
```

ABV80431/c
ID ABV80431 standard; DNA, 17 BP.
XX
AC ABV80431;
XX
DT 03-JAN-2003 (first entry)
XX
DE Human HTPL scanning oligonucleotide SEQ ID 1677.
XX
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS Homo sapiens.
XX
PN EP1229046-A2.
XX
PD 07-AUG-2002.
XX
PF 28-JAN-2002; 2002EP-0001167.
XX
PR 30-JAN-2001; 2001WO-US00663.
XX
PR 30-JAN-2001; 2001WO-US00664.
XX
PR 30-JAN-2001; 2001WO-US00665.
XX
PR 30-JAN-2001; 2001WO-US00667.
XX
PR 30-JAN-2001; 2001WO-US00668.
XX
PR 30-JAN-2001; 2001WO-US00669.
XX
PR 23-MAY-2001; 2001US-0864761.
XX
PR 09-OCT-2001; 2001US-0327898.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhan J;
XX
DR WPI; 2002-676582/73.
XX
PT Novel isolated human testis expressed Patched like protein (HTPL),
PT useful for identifying agonist and antagonist and specific binding
PT partners, and for treating subjects having defects in HTPL -
XX
PS Example 2; Page 283; 718bp; English.
XX
CC The present invention relates to human testis expressed Patched like
CC protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
CC has two isoforms, with a few single base pair differences between the
CC two. One of the single base pair changes introduces a premature stop
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC shares an overall structure organisation with the Patched protein. The
CC shared structural features strongly imply that HTPL plays a role similar
CC to that of Patched, and is a potential tumour suppressor. HTPL is
CC important in regulating male germ cell development, and the HTPL gene was
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potential therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention.
XX
SQ Sequence 17 BP; 5 A; 3 C; 1 G; 8 T; 0 other;
XX
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 338
ABV89408/c
ID ABV89408 standard; DNA, 17 BP.
XX
AC ABV89408;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 121.
XX
KW Human; POSHL 1; SH3 domain; POSHL-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
PN EP1239051-A2.
XX
PD 11-SEP-2002.
XX
PF 28-JAN-2002; 2002EP-0001165.
XX
PR 30-JAN-2001; 2001WO-US00663.
XX
PR 30-JAN-2001; 2001WO-US00664.
XX
PR 30-JAN-2001; 2001WO-US00665.
XX
PR 30-JAN-2001; 2001WO-US00666.
XX
PR 30-JAN-2001; 2001WO-US00667.
XX
PR 30-JAN-2001; 2001WO-US00668.
XX
PR 30-JAN-2001; 2001WO-US00669.
XX
PR 30-JAN-2001; 2001WO-US00670.
XX
PR 23-MAY-2001; 2001US-0864761.
XX
PR 10-OCT-2001; 2001US-0328205.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M;
XX
DR WPI; 2002-684061/74.
XX
PT Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
PT POSHL-1, useful for treating disorders associated with decreased
PT expression or activity of human POSHL1 -
XX
PS Example 2; SEQ ID NO 121; 60pp + Sequence Listing; English.
XX
CC The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (SI, ABB83999), a sequence having 65% sequence identity to (SI),
CC (SI1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention.
CC Note: The present sequence did not form part of the printed
CC specification, but is based on sequence information supplied to Derwent
CC by the European Patent Office.
XX
SQ Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 other;
XX
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1565 CGGCTAGTCCAGCTC 1580
| | | | | | | | | |
DB 17 CTGCTGAGTTCAAGCTC 2

RESULT 339
ABV89411/c
ID ABV89411 standard; DNA; 17 BP.
AC ABV89411;
XX
DT 23-DEC-2002 (first entry)
XX
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 124.
DE
XX Human, POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
FN EPI239051-A2.
XX
PD 11-SEP-2002.
XX
PE 28-JAN-2002; 2002EP-0001165.
XX
PF 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 23-MAY-2001; 2001US-0864761.
PR 10-OCT-2001; 2001US-0328205.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Shannon M;
XX
XX WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide.
PT POSHL-1, useful for treating disorders associated with decreased
PT expression or activity of human POSHL1 -
XX
XX Example 2; SEQ ID NO 124; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
XX protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
XX acids (SI, ABB83999), a sequence having 65% sequence identity to (SI),
XX (SI) having 95% deviations, especially conservative substitutions or a
XX fragment of the sequences comprising at least 8 contiguous amino acids.
XX Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
XX adaptor protein that interacts with Rho family small GTPases as well as
XX downstream components of the signal transduction pathway. (I) is useful
XX for identifying a specific binding partner. (II) and nucleic acids (II)
XX encoding (I) are useful for diagnosing, monitoring disease and treating
XX caused by altered expression of human POSHL1 including diagnosing and
XX treating cancer, they useful in the development of vaccines and (II) is
XX useful in gene therapy. (II) is useful for constructing microarrays which
XX are useful for measuring and for surveying gene expression and creating
XX transgenic non-human animals capable of producing the proteins. The
XX present sequence is that of a scanning oligonucleotide useful in examples
XX of the invention.
XX Note: The present sequence did not form part of the printed
XX specification, but is based on sequence information supplied to Derwent
XX by the European Patent Office.
XX
XX Sequence 17 BP; 6 A; 4 C; 5 G; 2 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1563 TTCGCTGAGTCCAGC 1578
| | | | | | | | | |
DB 16 TTCTGCTGAGTTCAAGC 1

RESULT 340
ABN83025
ID ABN83025 standard; DNA; 17 BP.
XX
XX
AC ABN83025;
XX
DT 16-AUG-2002 (first entry)
XX
XX Ataxia telangiectasia locus 56594896-SNeg-t capture probe.
DE
XX Ataxia telangiectasia; probe; biochip; array; capture; ss.
XX
XX Homo sapiens.
XX
OS
XX
FN WO200180155-A2.
XX
PD 25-OCT-2001.
XX
PF 18-APR-2001; 2001WO-US12750.
XX
PR 18-APR-2000; 2000US-198045P.
PR 22-NOV-2000; 2000US-252880P.
XX
XX (COMB-) COMBIMATRIX CORP.
XX
PI Anderson BP, Quarles PA, Ghazvini S;
XX
XX WPI; 2002-017664/02.
XX
XX Automated process for custom-designed biochip design, comprises
PT obtaining desired target sequences from customer, creating sequence
PT content motif for an array and applying the motif to a surface suitable
PT for later detection -
XX
XX Example 5; Page 21; 47pp; English.
XX
XX The invention relates to a novel process for a manufacturer to obtain
XX customer orders for custom-designed biochips in an automated process. The
XX invention also includes an automated system and process for providing a
XX fully automated process for the design, manufacture and analysis of data
XX for biological array devices. The sequence represents a capture probe
XX designed in the invention for the "sample ataxia" set of targets, as an
XX example of an array that may be designed using the method of the
XX invention.
XX
XX Sequence 17 BP; 4 A; 3 C; 8 G; 2 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2104 GCCAGAGGCATGAGT 2119
| | | | | | | | | |
DB 1 GCCAGAGGCATGAGT 16

RESULT 341
ABN00661/c
ID ABN00661 standard; DNA; 17 BP.
XX
XX
AC ABN00661;
XX
XX
DT 29-MAY-2002 (first entry)
XX

DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:653.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
FN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
PR 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
F1 Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
XX Disclosure; SEQ ID 653; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
XX hGDMLP-1 can be used in gene therapy and vaccine production. The
XX hGDMLP-1 nucleic acids can be used as probes to detect, characterise
XX and quantify hGDMLP-1 nucleic acids in samples, as amplification
XX substrates, to provide initial substrates for the recombinant engineering
XX of hGDMLP-1, protein variants having desired phenotypic improvements, and
XX for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
XX be used as immunogens to raise antibodies that specifically recognise
XX hGDMLP-1 proteins, as standards in assays used to determine the
XX concentration and/or amount specifically of hGDMLP proteins, as specific
XX biomolecule capture probes for surface-enhanced laser desorption
XX ionisation, as therapeutic supplement in patients having specific
XX deficiency in hGDMLP-1 production, and in vaccines or for replacement
XX therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
XX diagnosing a disorder associated with the expression of hGDMLP-1, in
XX particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
XX chromosome 22. The present sequence represents an oligomer used in the
XX screening of the hGDMLP-1 sequence in the exemplification of the present
XX invention.
XX N.B. The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 3 A; 7 C; 5 G; 2 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1566 GGCTGAGTCCAGCTCC 1581
DB 17 GGCTGAGTCCAGCTCC 2
RESULT 342
ABN00662/C
ID ABN00662 standard; DNA; 17 BP.
AC
XX ABN00662;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:654.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
FN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
PR 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
F1 Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
XX Disclosure; SEQ ID 654; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
XX hGDMLP-1 can be used in gene therapy and vaccine production. The
XX hGDMLP-1 nucleic acids can be used as probes to detect, characterise
XX and quantify hGDMLP-1 nucleic acids in samples, as amplification
XX substrates, to provide initial substrates for the recombinant engineering
XX of hGDMLP-1, protein variants having desired phenotypic improvements, and
XX for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
XX be used as immunogens to raise antibodies that specifically recognise
XX hGDMLP-1 proteins, as standards in assays used to determine the
XX concentration and/or amount specifically of hGDMLP proteins, as specific
XX biomolecule capture probes for surface-enhanced laser desorption
XX ionisation, as therapeutic supplement in patients having specific
XX deficiency in hGDMLP-1 production, and in vaccines or for replacement
XX therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
XX diagnosing a disorder associated with the expression of hGDMLP-1, in
XX particular heart and skeletal muscle disorders. hGDMLP-1 is localised to

CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
CC
SQ Sequence 17 BP; 4 A; 7 C; 5 G; 1 T; 0 other;
XX
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1566 GAGTGTGTCAGCTCC 1581
DB 16 GGCTGAGTCCGGCTC 1
RESULT 343
ABN01115
ID ABN01115 standard; DNA; 17 BP.
AC ABN01115;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1107.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
FN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
PR 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 05-FEB-2001; 2001US-266860P.
XX
PA (AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
PS Disclosure; SEQ ID 1107; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise

CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
CC
SQ Sequence 17 BP; 6 A; 5 C; 4 G; 2 T; 0 other;
XX
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1725 CAGCCCTCGGAGAA 1740
DB 2 CAATCCCTCGGAGAA 17
RESULT 344
ABN01116
ID ABN01116 standard; DNA; 17 BP.
AC ABN01116;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1108.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
FN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
PR 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 05-FEB-2001; 2001US-266860P.
XX
PA (AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX

DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
PS Disclosure; SEQ ID 1108; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1725 CAAGCCCTGGAGAGA 1740
DB 1 CAATCCTGGAGAGA 16
RESULT 345
ABN01120
ID ABN01120 standard; DNA; 17 BP.
XX
AC ABN01120;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1112.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
PR 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.

PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognise hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
PS Disclosure; SEQ ID 1112; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 4 A; 3 C; 7 G; 3 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1730 CCCTGGAGAGAGTTG 1745
DB 2 CCCTGGAGAGAGTTG 17
RESULT 346
ABN01121
ID ABN01121 standard; DNA; 17 BP.
XX
AC ABN01121;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1113.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX

PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US16981.
 XX
 PR 26-MAY-2000; 2000US-207456P.
 PR 21-SEP-2000; 2000US-234687P.
 PR 27-SEP-2000; 2000US-236359P.
 PR 04-OCT-2000; 2000GB-0024263.
 PR 30-JAN-2001; 2001WO-US00661.
 PR 30-JAN-2001; 2001WO-US00662.
 PR 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00666.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 30-JAN-2001; 2001WO-US00670.
 PR 05-FEB-2001; 2001US-266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMLP-1 -
 XX
 PS Disclosure; SEQ ID 1113; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
 CC hGDMLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.
 CC
 XX Sequence 17 BP; 4 A; 3 C; 8 G; 2 T; 0 other;
 SQ
 Query March 0.9%; Score 12.8; DB 1; Length 17;
 Beec Local Similarity 87.5%; Fred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1730 CCTGTGAGAGGTTG 1745
 Db 1 CCTGTGAGAGGTTG 16
 RESULT 347
 ABN01183
 ID ABN01183 standard; DNA; 17 BP.

XX
 AC ABN01183;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1175.
 XX
 KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KM skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US16981.
 XX
 PR 26-MAY-2000; 2000US-207456P.
 PR 21-SEP-2000; 2000US-234687P.
 PR 27-SEP-2000; 2000US-236359P.
 PR 04-OCT-2000; 2000GB-0024263.
 PR 30-JAN-2001; 2001WO-US00661.
 PR 30-JAN-2001; 2001WO-US00662.
 PR 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00666.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 30-JAN-2001; 2001WO-US00670.
 PR 05-FEB-2001; 2001US-266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMLP-1 -
 XX
 PS Disclosure; SEQ ID 1175; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
 CC hGDMLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.
 CC
 XX Sequence 17 BP; 9 A; 1 C; 7 G; 0 U; 0 other;
 SQ

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

2425 GAAGGACACAGATGG 2440
Db 2 GAAGGACACAGAGCG 17
|||||

RESULT 348
ABN01184
ID ABN01184 standard; DNA; 17 BP.
AC ABN01184;
XX
DT 29-MAY-2002 (first entry)
XX

Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1176.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
XX MO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
XX 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX
XX (AEOMICA INC.
PA
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
PS Disclosure; SEQ ID 1176; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption

ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 8 A; 1 C; 8 G; 0 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

2425 GAAGGACACAGATGG 2440
Db 1 GAAGGACACAGAGCG 16
|||||

RESULT 349
ABN01579
ID ABN01579 standard; DNA; 17 BP.
AC ABN01579;
XX
DT 29-MAY-2002 (first entry)
XX

Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1571.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
XX MO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
XX 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX
XX (AEOMICA INC.
PA
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
PS Disclosure; SEQ ID 1571; 214pp; English.

PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
XX proteins, or as specific biomolecule capture probes for
XX surface-enhanced laser desorption/ionization, comprises human
XX myosin-like protein hGDMLP-1 -
XX
XX Disclosure; SEQ ID 6176; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
XX hGDMLP-1 can be used in gene therapy and vaccine production. The
XX hGDMLP-1 nucleic acids can be used as probes to detect, characterise
XX and quantify hGDMLP-1 nucleic acids in samples, as amplification
XX substrates, to provide initial substrates for the recombinant engineering
XX of hGDMLP-1 protein variants having desired phenotypic improvements, and
XX for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
XX be used as immunogens to raise antibodies that specifically recognise
XX hGDMLP-1 proteins, as standards in assays used to determine the
XX concentration and/or amount specifically of hGDMLP proteins, as specific
XX biomolecule capture probes for surface-enhanced laser desorption
XX ionisation, as therapeutic supplement in patients having specific
XX deficiency in hGDMLP-1 production, and in vaccines or for replacement
XX therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
XX diagnosing a disorder associated with the expression of hGDMLP-1, in
XX particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
XX chromosome 22. The present sequence represents an oligomer used in the
XX screening of the hGDMLP-1 sequence in the exemplification of the present
XX invention.
XX N.B. The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence.
XX
XX Sequence 17 BP; 7 A; 7 C; 3 G; 0 U; 0 other;
SQ
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1784 ACAAGACCAAGCCCA 1799
Db 2 ACAGAGCCCAAGCCCA 17
RESULT 352
ABN06185
ID ABN06185 standard; DNA; 17 BP.
XX
XX ABN06185;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6177.
XX
XX Human, genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW

KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
OS
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US16981.
XX
XX 26-MAY-2000; 2000US-207456P.
XX 21-SEP-2000; 2000US-234687P.
XX 27-SEP-2000; 2000US-236359P.
XX 04-OCT-2000; 2000GB-0024263.
XX 30-JAN-2001; 2001WO-US00661.
XX 30-JAN-2001; 2001WO-US00662.
XX 30-JAN-2001; 2001WO-US00663.
XX 30-JAN-2001; 2001WO-US00664.
XX 30-JAN-2001; 2001WO-US00665.
XX 30-JAN-2001; 2001WO-US00666.
XX 30-JAN-2001; 2001WO-US00667.
XX 30-JAN-2001; 2001WO-US00668.
XX 30-JAN-2001; 2001WO-US00669.
XX 30-JAN-2001; 2001WO-US00670.
XX 05-FEB-2001; 2001US-266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
XX proteins, or as specific biomolecule capture probes for
XX surface-enhanced laser desorption/ionization, comprises human
XX myosin-like protein hGDMLP-1 -
XX
XX Disclosure; SEQ ID 6177; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
XX hGDMLP-1 can be used in gene therapy and vaccine production. The
XX hGDMLP-1 nucleic acids can be used as probes to detect, characterise
XX and quantify hGDMLP-1 nucleic acids in samples, as amplification
XX substrates, to provide initial substrates for the recombinant engineering
XX of hGDMLP-1 protein variants having desired phenotypic improvements, and
XX for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
XX be used as immunogens to raise antibodies that specifically recognise
XX hGDMLP-1 proteins, as standards in assays used to determine the
XX concentration and/or amount specifically of hGDMLP proteins, as specific
XX biomolecule capture probes for surface-enhanced laser desorption
XX ionisation, as therapeutic supplement in patients having specific
XX deficiency in hGDMLP-1 production, and in vaccines or for replacement
XX therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
XX diagnosing a disorder associated with the expression of hGDMLP-1, in
XX particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
XX chromosome 22. The present sequence represents an oligomer used in the
XX screening of the hGDMLP-1 sequence in the exemplification of the present
XX invention.
XX N.B. The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence.
XX
XX Sequence 17 BP; 7 A; 7 C; 3 G; 0 U; 0 other;
SQ
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1784 ACAAGACCAAGCCCA 1799
Db 1 ACAGAGCCCAAGCCCA 16

CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
CC
SQ Sequence 17 BP; 3 A; 10 C; 3 G; 1 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2091 CACCTACCAAGCTGACC 2106
Db 1 CACCTCCAGCAGGCC 16

RESULT 355
ABN06539
ID ABN06539 standard; DNA; 17 BP.
AC ABN06539;
XX
XX 29-MAY-2002 (first entry)
DT
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6531.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
FN WO200192524-A2.
PD
XX
XX 06-DEC-2001.
PD
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
XX 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX
XX (AEOMICA INC.
PA
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
PT

PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
XX Disclosure; SEQ ID 6531; 214P; English.
PS
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
CC
SQ Sequence 17 BP; 6 A; 3 C; 6 G; 2 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1359 GCCTGGAAGGAAAG 1374
Db 2 GCCTGTAGAGACAAG 17

RESULT 356
ABN06540
ID ABN06540 standard; DNA; 17 BP.
AC ABN06540;
XX
XX 29-MAY-2002 (first entry)
DT
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6532.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
FN WO200192524-A2.
PD
XX
XX 06-DEC-2001.
PD
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
XX 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX
XX (AEOMICA INC.
PA
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
PT

PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
XX proteins, or as specific biomolecule capture probes for
XX surface-enhanced laser desorption/ionization, comprises human
XX myosin-like protein hGDMLP-1 -
XX
XX Disclosure; SEQ ID 6532; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
XX hGDMLP-1 can be used in gene therapy and vaccine production. The
XX hGDMLP-1 nucleic acids can be used as probes to detect, characterise
XX and quantify hGDMLP-1 nucleic acids in samples, as amplification
XX substrates, to provide initial substrates for the recombinant engineering
XX of hGDMLP-1 protein variants having desired phenotypic improvements, and
XX for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
XX be used as immunogens to raise antibodies that specifically recognise
XX hGDMLP-1 proteins, as standards in assays used to determine the
XX concentration and/or amount specifically of hGDMLP proteins, as specific
XX biomolecule capture probes for surface-enhanced laser desorption
XX ionisation, as therapeutic supplement in patients having specific
XX deficiency in hGDMLP-1 production, and in vaccines or for replacement
XX therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
XX diagnosing a disorder associated with the expression of hGDMLP-1, in
XX particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
XX chromosome 22. The present sequence represents an oligomer used in the
XX screening of the hGDMLP-1 sequence in the exemplification of the present
XX invention.
XX N.B. The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence.
XX
XX Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 other;
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.5e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 1359 GCCTGGAAGAGAAAG 1374
XX 1 GCCTGTAGAGACAAG 16
XX
XX RESULT 357
XX ID ABB07353 standard; DNA; 17 BP.
XX
XX ABB07353;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7345.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.

XX
XX 25-MAY-2001; 2001WO-US19981.
XX
XX 26-MAY-2000; 2000US-207456P.
XX
XX 21-SEP-2000; 2000US-234687P.
XX
XX 27-SEP-2000; 2000US-23639P.
XX
XX 04-OCT-2000; 2000GB-0024263.
XX
XX 30-JAN-2001; 2001WO-US00661.
XX
XX 30-JAN-2001; 2001WO-US00662.
XX
XX 30-JAN-2001; 2001WO-US00663.
XX
XX 30-JAN-2001; 2001WO-US00664.
XX
XX 30-JAN-2001; 2001WO-US00665.
XX
XX 30-JAN-2001; 2001WO-US00666.
XX
XX 30-JAN-2001; 2001WO-US00667.
XX
XX 30-JAN-2001; 2001WO-US00668.
XX
XX 30-JAN-2001; 2001WO-US00669.
XX
XX 05-FEB-2001; 2001US-266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
XX proteins, or as specific biomolecule capture probes for
XX surface-enhanced laser desorption/ionization, comprises human
XX myosin-like protein hGDMLP-1 -
XX
XX Disclosure; SEQ ID 7345; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
XX hGDMLP-1 can be used in gene therapy and vaccine production. The
XX hGDMLP-1 nucleic acids can be used as probes to detect, characterise
XX and quantify hGDMLP-1 nucleic acids in samples, as amplification
XX substrates, to provide initial substrates for the recombinant engineering
XX of hGDMLP-1 protein variants having desired phenotypic improvements, and
XX for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
XX be used as immunogens to raise antibodies that specifically recognise
XX hGDMLP-1 proteins, as standards in assays used to determine the
XX concentration and/or amount specifically of hGDMLP proteins, as specific
XX biomolecule capture probes for surface-enhanced laser desorption
XX ionisation, as therapeutic supplement in patients having specific
XX deficiency in hGDMLP-1 production, and in vaccines or for replacement
XX therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
XX diagnosing a disorder associated with the expression of hGDMLP-1, in
XX particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
XX chromosome 22. The present sequence represents an oligomer used in the
XX screening of the hGDMLP-1 sequence in the exemplification of the present
XX invention.
XX N.B. The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence.
XX
XX Sequence 17 BP; 8 A; 1 C; 5 G; 3 T; 0 other;
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.5e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 2524 AAGCAGTTGTAGAG 2539
XX 2 AAACAGTTGGAAGAG 17
XX
XX RESULT 358
XX ID ABB07354 standard; DNA; 17 BP.
XX
XX ABB07354;
XX
XX 06-DEC-2001.

Matches	14	Conservative	0	Mismatches	2	Indels	0	Gaps	0
Qy	2524	AAGCAGTTGTAGAAG	2539						
Db	1	AAACAGTTGGAGAAG	16						
RESULT 359									
ABN07680/c									
ID	ABN07680	standard; DNA, 17 BP.							
XX	AC	ABN07680;							
XX	DT	29-MAY-2002 (first entry)							
XX	DE	Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7672.							
XX	KM	Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;							
XX	KW	muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;							
XX	OS	skeletal muscle disorder; amplicon; screening; ss.							
XX	PF	Homo sapiens.							
XX	PN	WO200192524-A2.							
XX	PD	06-DEC-2001.							
XX	PF	25-MAY-2001; 2001WO-US16981.							
PR	PR	26-MAY-2000; 2000US-207456P.							
PR	PR	21-SEP-2000; 2000US-234687P.							
PR	PR	27-SEP-2000; 2000US-236359P.							
PR	PR	04-OCT-2000; 2000GB-0024263.							
PR	PR	30-JAN-2001; 2001WO-US00661.							
PR	PR	30-JAN-2001; 2001WO-US00662.							
PR	PR	30-JAN-2001; 2001WO-US00663.							
PR	PR	30-JAN-2001; 2001WO-US00664.							
PR	PR	30-JAN-2001; 2001WO-US00665.							
PR	PR	30-JAN-2001; 2001WO-US00666.							
PR	PR	30-JAN-2001; 2001WO-US00667.							
PR	PR	30-JAN-2001; 2001WO-US00668.							
PR	PR	30-JAN-2001; 2001WO-US00669.							
PR	PR	30-JAN-2001; 2001WO-US00670.							
PR	PR	05-FEB-2001; 2001US-266860P.							
PA		(ABOM-) AEOMICA INC.							
XX	XX								
XX	XX	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;							
XX	XX	WPI; 2002-179446/23.							
PT	PT	New polypeptide, for raising antibodies that recognize hGDMLP-1							
PT	PT	proteins, or as specific biomolecule capture probes for							
PT	PT	surface-enhanced laser desorption/ionization, comprises human							
PT	PT	myosin-like protein hGDMLP-1 -							
PS		Disclosure; SEQ ID 7672; 214pp; English.							
XX									
CC	CC	The present invention describes a human genome-derived myosin-like							
CC	CC	protein 1 (hGDMLP-1). The protein and polynucleotide sequences of							
CC	CC	hGDMLP-1 can be used in gene therapy and vaccine production. The							
CC	CC	hGDMLP-1 nucleic acids can be used as probes to detect, characterise							
CC	CC	and quantify hGDMLP-1 nucleic acids in samples, as amplification							
CC	CC	substrates, to provide initial substrates for the recombinant engineering							
CC	CC	of hGDMLP-1 protein variants having desired phenotypic improvements, and							
CC	CC	for expressing the proteins. The hGDMLP-1 proteins or polypeptides may							
CC	CC	be used as immunogens to raise antibodies that specifically recognise							
CC	CC	hGDMLP-1 proteins, as standards in assays used to determine the							
CC	CC	concentration and/or amount specifically of hGDMLP proteins, as specific							

CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
CC
XX Sequence 17 BP; 7 A; 2 C; 7 G; 1 T; 0 other;
SQ
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2659 TCTGTTTTTCTCCAG 2674
DB 17 TCTGCTCTCTCCAG 2
RESULT 360
ABN07682/C
ID ABN07682 standard; DNA; 17 BP.
XX
AC ABN07682;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7674.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
XX 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
XX Disclosure; SEQ ID 7674; 214pp; English.
PS
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of

CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
CC
XX Sequence 17 BP; 8 A; 1 C; 7 G; 1 T; 0 other;
SQ
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2658 TTCTGTTTTTCTCCA 2673
DB 16 TTCTGCTCTCTCTCCA 1
RESULT 361
ABN09082
ID ABN09082 standard; DNA; 17 BP.
XX
AC ABN09082;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9074.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
XX 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX

PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
XX Disclosure; SEQ ID 9074; 214bp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 5 A; 5 C; 4 G; 3 T; 0 other;
XX
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1397 ACCTGAGATGCCAT 1412
Db ||||||| |||||
2 ACCTGAGACATCCAT 17
XX
RESULT 362
ABN09084
ID ABN09084 standard; DNA; 17 BP.
XX
AC ABN09084;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9076.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
FN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PE 25-MAY-2001; 2001WO-US16981.
XX
PR 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-002426T.
PR 30-JAN-2001; 2001WO-US00661.

PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX
XX Disclosure; SEQ ID 9076; 214bp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 4 A; 6 C; 3 G; 4 T; 0 other;
XX
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1398 CCTGAGATGCCATT 1413
Db ||||||| |||||
1 CCTGAGACATCCATT 16
XX
RESULT 363
ABN10708
ID ABN10708 standard; DNA; 17 BP.
XX
AC ABN10708;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10700.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX

OS Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US16981.
XX
XX 26-MAY-2000; 2000US-207456P.
XX 21-SEP-2000; 2000US-234687P.
XX 27-SEP-2000; 2000US-236359P.
XX 04-OCT-2000; 2000GB-0024263.
XX 30-JAN-2001; 2001WO-US00661.
XX 30-JAN-2001; 2001WO-US00662.
XX 30-JAN-2001; 2001WO-US00663.
XX 30-JAN-2001; 2001WO-US00664.
XX 30-JAN-2001; 2001WO-US00665.
XX 30-JAN-2001; 2001WO-US00666.
XX 30-JAN-2001; 2001WO-US00667.
XX 30-JAN-2001; 2001WO-US00668.
XX 30-JAN-2001; 2001WO-US00669.
XX 30-JAN-2001; 2001WO-US00670.
XX 05-FEB-2001; 2001US-266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
XX proteins, or as specific biomolecule capture probes for
XX surface-enhanced laser desorption/ionization, comprises human
XX myosin-like protein hGDMLP-1 -
XX
XX Disclosure; SEQ ID 10700; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
XX hGDMLP-1 can be used in gene therapy and vaccine production. The
XX hGDMLP-1 nucleic acids can be used as probes to detect, characterise
XX and quantify hGDMLP-1 nucleic acids in samples, as amplification
XX substrates, to provide initial substrates for the recombinant engineering
XX of hGDMLP-1 protein variants having desired phenotypic improvements, and
XX for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
XX be used as immunogens to raise antibodies that specifically recognise
XX hGDMLP-1 proteins, as standards in assays used to determine the
XX concentration and/or amount specifically of hGDMLP proteins, as specific
XX biomolecule capture probes for surface-enhanced laser desorption
XX ionisation, as therapeutic supplement in patients having specific
XX deficiency in hGDMLP-1 production, and in vaccines or for replacement
XX therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
XX diagnosing a disorder associated with the expression of hGDMLP-1, in
XX particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
XX chromosome 22. The present sequence represents an oligomer used in the
XX screening of the hGDMLP-1 sequence in the exemplification of the present
XX invention.
XX N.B. The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence.
XX
XX Sequence 17 BP; 6 A; 4 C; 6 G; 1 T; 0 other;
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.5e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 1833 AGATGATCCACACAGG 1848
XX |||||
XX 2 AGATGATCCACACAGG 17
XX
XX RESULT 364

ABN10709
XX ID ABN10709 standard; DNA; 17 BP.
XX
XX AC ABN10709;
XX
XX DT 29-MAY-2002 (first entry)
XX
XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10701.
XX
XX KW Human; genome-derived myosin-like protein 1; GDMLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200192524-A2.
XX
XX PD 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US16981.
XX
XX 26-MAY-2000; 2000US-207456P.
XX 21-SEP-2000; 2000US-234687P.
XX 27-SEP-2000; 2000US-236359P.
XX 04-OCT-2000; 2000GB-0024263.
XX 30-JAN-2001; 2001WO-US00661.
XX 30-JAN-2001; 2001WO-US00662.
XX 30-JAN-2001; 2001WO-US00663.
XX 30-JAN-2001; 2001WO-US00664.
XX 30-JAN-2001; 2001WO-US00665.
XX 30-JAN-2001; 2001WO-US00666.
XX 30-JAN-2001; 2001WO-US00667.
XX 30-JAN-2001; 2001WO-US00668.
XX 30-JAN-2001; 2001WO-US00669.
XX 30-JAN-2001; 2001WO-US00670.
XX 05-FEB-2001; 2001US-266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
XX proteins, or as specific biomolecule capture probes for
XX surface-enhanced laser desorption/ionization, comprises human
XX myosin-like protein hGDMLP-1 -
XX
XX Disclosure; SEQ ID 10701; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
XX hGDMLP-1 can be used in gene therapy and vaccine production. The
XX hGDMLP-1 nucleic acids can be used as probes to detect, characterise
XX and quantify hGDMLP-1 nucleic acids in samples, as amplification
XX substrates, to provide initial substrates for the recombinant engineering
XX of hGDMLP-1 protein variants having desired phenotypic improvements, and
XX for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
XX be used as immunogens to raise antibodies that specifically recognise
XX hGDMLP-1 proteins, as standards in assays used to determine the
XX concentration and/or amount specifically of hGDMLP proteins, as specific
XX biomolecule capture probes for surface-enhanced laser desorption
XX ionisation, as therapeutic supplement in patients having specific
XX deficiency in hGDMLP-1 production, and in vaccines or for replacement
XX therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
XX diagnosing a disorder associated with the expression of hGDMLP-1, in
XX particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
XX chromosome 22. The present sequence represents an oligomer used in the
XX screening of the hGDMLP-1 sequence in the exemplification of the present
XX invention.
XX N.B. The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence.

XX Sequence 17 BP; 6 A; 4 C; 6 G; 1 T; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred.No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Oy 1833 AGATGATGCCACAG 1848
 Db 1 AGATGATGCCACAG 16
 RESULT 365
 ABK17887/C
 ID ABK17887 standard; RNA; 17 BP.
 XX ABK17887;
 AC
 XX
 DT 09-APR-2002 (first entry)
 XX
 DE Human ERG hammerhead ribozyme target sequence, Seq ID No 534.
 XX
 KW Human; hammerhead ribozyme; cytosolic; antitumour; antidiabetic;
 KW ophthalmological; antiarthritic; antipsoriatic; vitruide; osteopathic;
 KW vulnereary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
 KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KW angiofibroma of tuberos sclerosi; port-wine stain; wound healing;
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KW Osler-Weber-rendu syndrome; leukaemia; osteoporosis; DNAzyme; inozyme;
 KW amberzyme.
 XX
 OS Homo sapiens.
 XX
 PN WO200188124-A2.
 XX
 PD 22-NOV-2001.
 XX
 PF 16-MAY-2001; 2001WO-US15866.
 XX
 PR 16-MAY-2000; 2000US-0572021.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (GLAX) GLAXO GROUP LTD.
 XX
 PI Jarvis T, Von Carlowitz I, McSwigen JA, McLaughlin F, Randi AM;
 XX WPI; 2002-082995/11.
 XX
 DR Novel polynucleotide which down regulates expression of Ets-related
 PT gene, useful for treating cancer, diabetic retinopathy, macular
 PT degeneration, arthritis, psoriasis, verruca vulgaris and Sturge Weber
 PT syndrome -
 XX
 PS Claim 4; Page 68; 149pp; English.
 XX
 CC The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 CC vulgaris, angiofibroma of tuberos sclerosi, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC by contacting cells of the patient with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent

CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17554-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention.
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 5 G; 5 U; 0 other;
 Oy Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred.No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Db 2094 CTACACGCTGCGCAGA 2109
 17 CTACACGCTGTTTCTAGA 2
 RESULT 366
 ABK18565
 ID ABK18565 standard; RNA; 17 BP.
 XX
 AC ABK18565;
 XX
 DT 09-APR-2002 (first entry)
 XX
 DE Human ERG G-cleaver ribozyme target sequence Seq ID No 1212.
 XX
 KW Human; hammerhead ribozyme; cytosolic; antitumour; antidiabetic;
 KW ophthalmological; antiarthritic; antipsoriatic; vitruide; osteopathic;
 KW vulnereary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
 KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KW angiofibroma of tuberos sclerosi; port-wine stain; wound healing;
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KW Osler-Weber-rendu syndrome; leukaemia; osteoporosis; DNAzyme; inozyme;
 KW amberzyme.
 XX
 OS Homo sapiens.
 XX
 PN WO200188124-A2.
 XX
 PD 22-NOV-2001.
 XX
 PF 16-MAY-2001; 2001WO-US15866.
 XX
 PR 16-MAY-2000; 2000US-0572021.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (GLAX) GLAXO GROUP LTD.
 XX
 PI Jarvis T, Von Carlowitz I, McSwigen JA, McLaughlin F, Randi AM;
 XX WPI; 2002-082995/11.
 XX
 DR Novel polynucleotide which down regulates expression of Ets-related
 PT gene, useful for treating cancer, diabetic retinopathy, macular
 PT degeneration, arthritis, psoriasis, verruca vulgaris and Sturge Weber
 PT syndrome -
 XX
 PS Claim 4; Page 81; 149pp; English.
 XX
 CC The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 CC vulgaris, angiofibroma of tuberos sclerosi, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,

CC by contacting cells of the patient with (I) under conditions suitable for
CC the treatment. The method comprises the use of one or more therapies
CC under conditions suitable for the treatment. Leukaemia or tumour
CC angiogenesis is treated by administering (I) to the patient in
CC conjunction with one or more of other therapies such as radiation or
CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
CC diseases related to the expression of ERG, and as diagnostic tool to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of ERG RNA in a cell. (I) is useful for specifically
CC targeting genes that share homology with ERG gene or ERG fusion genes.
CC ABK17354-ABK22719 represent nucleic acids, including antisense and
CC enzymatic nucleic acid molecules which regulate expression of ERG, and
CC related PCR primers of the invention.

XX
SQ Sequence 17 BP; 6 A; 2 C; 6 G; 3 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.5e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2464 GAACGTGATGATGCA 2479
2 GAACGUGCAGCAUGCA 17
||||:|||||
ID ABK18734 standard; RNA; 17 BP.

XX
AC ABK18734;

DT 09-APR-2002 (first entry)

XX
DE Human ERG DNAzyme target sequence Seq ID No 1381.

XX
KW Human; hammerhead ribozyme; cytosstatic; antitumour; antidiabetic;
KW ophthalmological; antidiabetic; antiposrotatic; virucide; osteopathic;
KW vulnary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
KW Sturge Weber syndrome; Kipfel-Trenauay-Weber syndrome; leukaemia; ss;
KW Osler-Weber-tendu syndrome; leukaemia; osteoporosis; DNAzyme; inozyme;
KW amberyze.

XX
OS Homo sapiens.

XX
PN WO200188124-A2.

XX
PD 22-NOV-2001.

XX
PF 16-MAY-2001; 2001WO-US15866.

XX
PR 16-MAY-2000; 2000US-0572021.

XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.

XX
PI Jarvis T, Von Carlowitz I, McSwigen JA, McLaughlin F, Randi AM;
XX WPI; 2002-082995/11.

XX
PT Novel polynucleotide which down regulates expression of Ets-related
PT gene, useful for treating cancer; diabetic retinopathy, macular
PT degeneration, arthritis, psoriasis, verruca vulgaris and Sturge Weber
PT syndrome -

XX
PS Claim 4; Page 90; 149pp; English.

XX
CC The invention relates to a nucleic acid molecule (I) which down regulates

CC expression of an Ets-related gene (ERG). (I) is useful for treating
CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
CC Weber syndrome, Kipfel-Trenauay-Weber syndrome, Osler-Weber-tendu
CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
CC treating a patient having a condition associated with the level of ERG,
CC by contacting cells of the patient with (I) under conditions suitable for
CC the treatment. The method comprises the use of one or more therapies
CC under conditions suitable for the treatment. Leukaemia or tumour
CC angiogenesis is treated by administering (I) to the patient in
CC conjunction with one or more of other therapies such as radiation or
CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
CC diseases related to the expression of ERG, and as diagnostic tool to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of ERG RNA in a cell. (I) is useful for specifically
CC targeting genes that share homology with ERG gene or ERG fusion genes.
CC ABK17354-ABK22719 represent nucleic acids, including antisense and
CC enzymatic nucleic acid molecules which regulate expression of ERG, and
CC related PCR primers of the invention.

XX
SQ Sequence 17 BP; 5 A; 3 C; 5 G; 4 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2094 CTACGAGCTGGCCAGA 2109
16 CTACGAGCTGTTCAGA 1
|||||
ID ABL31521/c

XX
AC ABL31521 standard; DNA; 17 BP.

XX
AC ABL31521;

DT 21-MAR-2002 (first entry)

XX
DE Human HLA genotyping oligonucleotide SEQ ID NO 1010.

XX
KW Human; human leukocyte antigen; HLA; genotype; polymorphism;
KW immunogenetic; transplantation; genetic disease; ss.

XX
OS Homo sapiens.

XX
PN WO200192572-A1.

XX
PD 06-DEC-2001.

XX
PF 01-JUN-2001; 2001WO-JP04662.

XX
PR 01-JUN-2000; 2000JP-0164798.

XX
PA (NISON) NISSHINO IND INC.
PA (SYST-) SYSTEM RES INC.

XX
PI Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
XX WPI; 2002-122074/16.

XX
PT Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
PT of individuals e.g. by determining immunogenetic differences when
PT transplanting between them -

XX
PS Claim 10; Page 284; 345pp; Japanese.

XX
CC The invention relates to a typing kit for judging human leukocyte antigen

(H1A) genotype of a sample by hybridising a substrate on which 10-24 base oligonucleotides (AB130512-AB131809) originating in the sequences of CC genes e.g. belonging to H1A class I antigens on human genome and CC containing gene polymorphisms as alloantigens have been immobilised as CC primers for amplification of cleaved nucleic acids relating to gene CC polymorphisms. The method is useful for judging H1A genotypes of CC individuals by determining immunogenetic differences before transplanting CC between them, providing genetic information to decide compatibility of CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver, CC pancreas, Langerhans islet in pancreas and cornea, susceptibility CC diagnosis of genetic diseases and identifying individuals.

XX Sequence 17 BP; 2 A; 8 C; 3 G; 4 T; 0 other;

SO Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2391 GATCCCGCTGGAGGA 2406
DB 17 GGTACCCGTGGAGGA 2

RESULT 369
ABT34419
ID ABT34419 standard; DNA; 17 BP.
XX
XX ABT34419;
XX
XX 12-JUN-2003 (first entry)
XX
XX Tumour suppression related human fukutin oligo SEQ ID No 56.
XX
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
XX schizophrenia; protein chip; gene therapy; tumour suppression;
XX human fukutin; ds.
XX
XX Homo sapiens.
XX
XX MO2003025175-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB04208.
XX
XX 17-SEP-2001; 2001FR-0011978.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313353/30.
XX
XX New isolated nucleic acid, useful for treating viral diseases
XX associated with tumors and cell degeneration, also related
XX polypeptides, antibodies and transfected cells -
XX
XX Disclosure; Page 40; 720pp; French.

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
XX given in the specification, a sequence containing at least 15
XX consecutive nucleotides from the 17 mer sequence, a sequence with, after
XX optimal alignment, at least 80 % identity to the 17 mer sequence, a
XX sequence that hybridizes to them under highly stringent conditions, or
XX the complement of any of them, or the corresponding RNA. The novel
XX isolated nucleic acids of the invention are useful as probes and primers
XX for detecting, identifying, quantifying and/or amplifying a nucleic acid,
XX e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
XX and for production of recombinant polypeptides. Any of the nucleic acids,
XX polypeptides, vectors containing the nucleic acids, cells containing the
XX vector or antibodies directed against the polypeptides are useful for
XX preparation of pharmaceuticals for prevention and/or treatment of viral

CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention.

XX Sequence 17 BP; 4 A; 3 C; 4 G; 6 T; 0 other;

SO Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2358 GATCTGACTTTAGG 2373
DB 1 GATCATTACTTTAGG 16

RESULT 370
ABT34587/C
ID ABT34587 standard; DNA; 17 BP.
XX
XX AC ABT34587;
XX
XX 12-JUN-2003 (first entry)
XX
XX Tumour suppression related human fukutin oligo SEQ ID No 224.
XX
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
XX schizophrenia; protein chip; gene therapy; tumour suppression;
XX human fukutin; ds.
XX
XX Homo sapiens.
XX
XX MO2003025175-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB04208.
XX
XX 17-SEP-2001; 2001FR-0011978.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313353/30.
XX
XX New isolated nucleic acid, useful for treating viral diseases
XX associated with tumors and cell degeneration, also related
XX polypeptides, antibodies and transfected cells -
XX
XX Disclosure; Page 60; 720pp; French.

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
XX given in the specification, a sequence containing at least 15
XX consecutive nucleotides from the 17 mer sequence, a sequence with, after
XX optimal alignment, at least 80 % identity to the 17 mer sequence, a
XX sequence that hybridizes to them under highly stringent conditions, or
XX the complement of any of them, or the corresponding RNA. The novel
XX isolated nucleic acids of the invention are useful as probes and primers
XX for detecting, identifying, quantifying and/or amplifying a nucleic acid,
XX e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
XX and for production of recombinant polypeptides. Any of the nucleic acids,
XX polypeptides, vectors containing the nucleic acids, cells containing the
XX vector or antibodies directed against the polypeptides are useful for
XX preparation of pharmaceuticals for prevention and/or treatment of viral
XX diseases that are characterised by development of tumours or cell
XX degeneration, specifically cancer but also Alzheimer's disease and

CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention.
XX
SQ Sequence 17 BP; 4 A; 5 C; 4 G; 4 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1391 CAGACTACCTGGAGAT 1406
Db 17 CAGATTACCTGGGAT 2
RESULT 371
ABT34848/C
ID ABT34848 standard; DNA; 17 BP.
XX
AC ABT34848;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 485.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; de.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB04208.
XX
PR 17-SEP-2001; 2001FR-0011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases
PT associated with tumors and cell degeneration, also related
PT polypeptides, antibodies and transfected cells -
XX
PS Disclosure; Page 90; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15
CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
CC sequence that hybridizes to them under highly stringent conditions, or
CC the complement of any of them, or the corresponding RNA. The novel
CC isolated nucleic acids of the invention are useful as probes and primers
CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
CC and for production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these

CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention.
XX
SQ Sequence 17 BP; 4 A; 3 C; 4 G; 6 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2177 CAGAAACACATGTGAT 2192
Db 17 CAGATACACTGTGAT 2
RESULT 372
ABT35043/C
ID ABT35043 standard; DNA; 17 BP.
XX
AC ABT35043;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 680.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; da.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB04208.
XX
PR 17-SEP-2001; 2001FR-0011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases
PT associated with tumors and cell degeneration, also related
PT polypeptides, antibodies and transfected cells -
XX
PS Disclosure; Page 113; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15
CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
CC sequence that hybridizes to them under highly stringent conditions, or
CC the complement of any of them, or the corresponding RNA. The novel
CC isolated nucleic acids of the invention are useful as probes and primers
CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
CC and for production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein

Sequence 17 BP; 4 A; 7 C; 4 G; 2 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
2051 TTCTGAGGAGCAGAT 2066
17 TTCTGGGGGCGCAGAT 2

Db 17 TTCTGGGGGCGCAGAT 2

RESULT 375
ABT35351/C
ID ABT35351 standard; DNA; 17 BP.
XX
XX ABT35351;
AC
XX 12-JUN-2003 (first entry)
DT
XX
XX Tumour suppression related human fukutin oligo SEQ ID No 988.
DE
XX
XX Cytostatic; viroinucle; neuroprotective; nootropic; neuroleptic; gene chip;
KM antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KM schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
XX Homo sapiens.
OS
XX WO2003025175-A2.
PN
XX 27-MAR-2003.
PD
XX 17-SEP-2002; 2002MO-IB04208.
PE
XX 17-SEP-2001; 2001FR-0011978.
PR
XX (MOLE-) MOLECULAR ENGINES LAB.
PA
XX Tejerman A, Amson R, Tuijnder M;
PI
XX WPI; 2003-313353/30.
DR
XX
XX New isolated nucleic acid, useful for treating viral diseases
PT associated with tumors and cell degeneration, also related
PT polypeptides, antibodies and transfected cells -
PS
XX Disclosure; Page 148; 720pp; French.
PS
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15
CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
CC sequence that hybridizes to them under highly stringent conditions, or
CC the complement of any of them, or the corresponding RNA. The novel
CC isolated nucleic acids of the invention are useful as probes and primers
CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
CC and for production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention.
XX
XX Sequence 17 BP; 6 A; 3 C; 4 G; 4 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
2640 TTGTTCCTCAGCAGAT 2655
17 TTGTCTACAGCAGAT 2

Db 17 TTGTCTACAGCAGAT 2

RESULT 376
ABT35577
ID ABT35577 standard; DNA; 17 BP.
XX
XX ABT35577;
AC
XX 12-JUN-2003 (first entry)
DT
XX
XX Tumour suppression related human fukutin oligo SEQ ID No 1214.
DE
XX
XX Cytostatic; viroinucle; neuroprotective; nootropic; neuroleptic; gene chip;
KM antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KM schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
XX Homo sapiens.
OS
XX WO2003025175-A2.
PN
XX 27-MAR-2003.
PD
XX 17-SEP-2002; 2002MO-IB04208.
PE
XX 17-SEP-2001; 2001FR-0011978.
PR
XX (MOLE-) MOLECULAR ENGINES LAB.
PA
XX Tejerman A, Amson R, Tuijnder M;
PI
XX WPI; 2003-313353/30.
DR
XX
XX New isolated nucleic acid, useful for treating viral diseases
PT associated with tumors and cell degeneration, also related
PT polypeptides, antibodies and transfected cells -
PS
XX Disclosure; Page 175; 720pp; French.
PS
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15
CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
CC sequence that hybridizes to them under highly stringent conditions, or
CC the complement of any of them, or the corresponding RNA. The novel
CC isolated nucleic acids of the invention are useful as probes and primers
CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
CC and for production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention.
XX
XX Sequence 17 BP; 4 A; 4 C; 3 G; 6 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2358 GATCTTCATTAGG 2373
||| |||||
Db 1 GATCATCACTTTATCG 16

RESULT 377
ABT36389/C
ID ABT36389 standard; DNA; 17 BP.
XX
AC ABT36389;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 2026.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN MO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB04208.
XX
PR 17-SEP-2001; 2001FR-0011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases
PT associated with tumors and cell degeneration, also related
PT polypeptides, antibodies and transfected cells -
XX
PS Disclosure; Page 269; 720pp; French.

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15
CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
CC sequence that hybridizes to them under highly stringent conditions, or
CC the complement of any of them, or the corresponding RNA. The novel
CC isolated nucleic acids of the invention are useful as probes and primers
CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
CC and for production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention.
XX
SQ Sequence 17 BP; 5 A; 1 C; 5 G; 6 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1849 AAAGACCTTCTGATC 1864
||| |||||
Db 16 AAACAACCTTCTGATC 1

RESULT 378
ABT37484
ID ABT37484 standard; DNA; 17 BP.
XX
AC ABT37484;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 3121.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN MO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB04208.
XX
PR 17-SEP-2001; 2001FR-0011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases
PT associated with tumors and cell degeneration, also related
PT polypeptides, antibodies and transfected cells -
XX
PS Disclosure; Page 398; 720pp; French.

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15
CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
CC sequence that hybridizes to them under highly stringent conditions, or
CC the complement of any of them, or the corresponding RNA. The novel
CC isolated nucleic acids of the invention are useful as probes and primers
CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
CC and for production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention.
XX
SQ Sequence 17 BP; 7 A; 1 C; 5 G; 4 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2525 AGCAGTGGTAGAGA 2540
| ||||| |||||

DB 2 ATCACTGTGTAAGA 17

RESULT 379
ID ABT37821/C
XX ABT37821 standard; DNA; 17 BP.
XX
XX ABT37821;
XX
XX 12-JUN-2003 (first entry)
XX
XX Tumour suppression related human fukutin oligo SEQ ID No 3458.
XX
XX
XX Cyclostatin; vinorelbine; neuroprotective; nocotropic; neuroleptic; gene chip;
XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
XX schizophrénia; protein chip; gene therapy; tumour suppression;
XX human fukutin; de.
XX
XX Homo sapiens.
XX
XX WO2003025175-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002MO-IB04208.
XX
XX 17-SEP-2001; 2001FR-0011978.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313353/30.
XX
XX New isolated nucleic acid, useful for treating viral diseases
XX associated with tumors and cell degeneration, also related
XX polypeptides, antibodies and transfected cells -
XX
XX
XX Disclosure; Page 438; 720pp; French.
XX
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
XX given in the specification, a sequence containing at least 15
XX consecutive nucleotides from the 17 mer sequence, a sequence with, after
XX optimal alignment, at least 80 % identity to the 17 mer sequence, a
XX sequence that hybridizes to them under highly stringent conditions, or
XX the complement of any of them, or the corresponding RNA. The novel
XX isolated nucleic acids of the invention are useful as probes and primers
XX for detecting, identifying, quantifying and/or amplifying a nucleic acid,
XX e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
XX and/or for production of recombinant polypeptides. Any of the nucleic acids,
XX polypeptides, vectors containing the nucleic acids, cells containing the
XX vector or antibodies directed against the polypeptides are useful for
XX preparation of pharmaceuticals for prevention and/or treatment of viral
XX diseases that are characterised by development of tumours or cell
XX degeneration, specifically cancer but also Alzheimer's disease and
XX schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
XX patient samples is useful for diagnosis and/or prognosis of these
XX diseases. The polypeptides can also be used to generate antibodies, and
XX both the polypeptide and antibodies are useful as components of protein
XX chips. The nucleic acid sequences of the invention can be used in gene
XX therapy. This polynucleotide sequence represents a tumour suppression
XX related human fukutin oligonucleotide of the invention.
XX
XX Sequence 17 BP; 6 A; 4 C; 2 G; 5 T; 0 other;
XX
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.5e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0.
XX
XX 1695 GCAGTTTCCAGAGAGT 1710
XX |||||
XX 17 GCAGTTTCCAGAGAGT 2

ID	ABT38000/C
ID	ABT38000 standard; DNA; 17 BP.
XX	
AC	ABT38000;
DT	12-JUN-2003 (first entry)
XX	
DE	Tumour suppression related human fukutin oligo SEQ ID No 3637.
XX	
KW	Cytostatic; virucide; neuroprotective; nootropic; neuropilic; gene chip;
KW	antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW	schizophrenia; protein chip; gene therapy; tumour suppression;
KX	human fukutin; de.
OS	Homo sapiens.
PV	WO2003025175-A2.
PD	27-MAR-2003.
PF	17-SEP-2002; 2002MO-IBO4208.
PR	17-SEP-2001; 2001FR-0011978.
PA	(MOLE-) MOLECULAR ENGINES LAB.
PI	Teleman A, Amson R, Tuijnder M;
DR	WPI; 2003-313353/30.
PT	New isolated nucleic acid, useful for treating viral diseases
PT	associated with tumors and cell degeneration, also related
PP	polypeptides, antibodies and transfected cells -
PS	Disclosure; Page 459; 720pp; French.
XX	
CC	The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC	given in the specification, a sequence containing at least 15
CC	consecutive nucleotides from the 17 mer sequence, a sequence with, after
CC	optimal alignment, at least 80 % identity to the 17 mer sequence, a
CC	sequence that hybridizes to them under highly stringent conditions, or
CC	the complement of any of them, or the corresponding RNA. The novel
CC	isolated nucleic acids of the invention are useful as probes and primers
CC	for detecting, identifying, quantifying and/or amplifying a nucleic acid,
CC	e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
CC	and for production of recombinant polypeptides. Any of the nucleic acids,
CC	polypeptides, vectors containing the nucleic acids, cells containing the
CC	vector or antibodies directed against the polypeptides are useful for
CC	preparation of pharmaceuticals for prevention and/or treatment of viral
CC	diseases that are characterised by development of tumours or cell
CC	degeneration, specifically cancer but also Alzheimer's disease and
CC	schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC	patient samples is useful for diagnosis and/or prognosis of these
CC	diseases. The polypeptides can also be used to generate antibodies, and
CC	both the polypeptide and antibodies are useful as components of protein
CC	chips. The nucleic acid sequences of the invention can be used in gene
CC	therapy. This polynucleotide sequence represents a tumour suppression
CC	related human fukutin oligonucleotide of the invention.
XX	
SO	Sequence 17 BP; 4 A; 7 C; 1 G; 5 T; 0 other;
QY	Query Match 0.9%; Score 12.8; DB 1; Length 17; Best Local Similarity 87.5%; Pred. NO. 2.5e+02; Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
DB	2533 GTAGAAGCTTGATC 2548 16 GTGGAAGTTGCATC 1

RESULT 381

ABT38045
 ID ABT38045 standard; DNA; 17 BP.
 XX
 AC
 XX ABT38045;
 XX
 DT 12-JUN-2003 (first entry)
 XX
 DE Tumour suppression related human fukutin oligo SEQ ID No 3682.
 XX
 KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO2003025175-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB04208.
 XX
 PR 17-SEP-2001; 2001FR-0011978.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-313353/30.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases
 PT associated with tumors and cell degeneration, also related
 PT polypeptides, antibodies and transfected cells -
 XX
 PS Disclosure; Page 464; 720pp; French.
 XX
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15
 CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
 CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
 CC sequence that hybridizes to them under highly stringent conditions, or
 CC the complement of any of them, or the corresponding RNA. The novel
 CC isolated nucleic acids of the invention are useful as probes and primers
 CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
 CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
 CC and for production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention.
 CC
 XX
 SQ Sequence 17 BP; 5 A; 7 C; 3 G; 2 T; 0 other;
 QY Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 DB 1377 GATTACAGTCTGCCCA 1392
 1 GATCAGACTGCCCCA 16

XX
 AC ABT38046;
 XX
 DT 12-JUN-2003 (first entry)
 XX
 DE Tumour suppression related human fukutin oligo SEQ ID No 3683.
 XX
 KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO2003025175-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB04208.
 XX
 PR 17-SEP-2001; 2001FR-0011978.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-313353/30.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases
 PT associated with tumors and cell degeneration, also related
 PT polypeptides, antibodies and transfected cells -
 XX
 PS Disclosure; Page 464; 720pp; French.
 XX
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15
 CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
 CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
 CC sequence that hybridizes to them under highly stringent conditions, or
 CC the complement of any of them, or the corresponding RNA. The novel
 CC isolated nucleic acids of the invention are useful as probes and primers
 CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
 CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
 CC and for production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention.
 CC
 XX
 SQ Sequence 17 BP; 6 A; 1 C; 6 G; 4 T; 0 other;
 QY Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 DB 2318 ATCAGAGTGATGCTG 2333
 2 ATCAGATGAAGTATG 17

RESULT 382
 ABT38046
 ID ABT38046 standard; DNA; 17 BP.

RESULT 383
 ABT39470/C
 ID ABT39470 standard; DNA; 17 BP.
 AC ABT39470;

XX 12-JUN-2003 (first entry)
 DT Tumour suppression related human fukutin oligo SEQ ID No 5107.
 DE
 XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.
 XX Homo sapiens.
 OS
 XX WO2003025175-A2.
 XX
 XX 27-MAR-2003.
 XX
 XX 17-SEP-2002; 2002WO-IB04208.
 XX
 XX 17-SEP-2001; 2001FR-0011978.
 XX
 XX (MOLE-) MOLECULAR ENGINES LAB.
 XX
 XX Tejerman A, Amson R, Tuijnder M;
 XX WPI, 2003-313353/30.
 XX
 XX New isolated nucleic acid, useful for treating viral diseases
 PT associated with tumors and cell degeneration, also related
 PT polypeptides, antibodies and transfected cells -
 PT
 XX
 XX Disclosure; Page 631; 720pp; French.
 XX
 XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15
 CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
 CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
 CC sequence that hybridizes to them under highly stringent conditions, or
 CC the complement of any of them, or the corresponding RNA. The novel
 CC isolated nucleic acids of the invention are useful as probes and primers
 CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
 CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
 CC and for production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention.
 CC
 XX
 XX Sequence 17 BP; 5 A; 1 C; 4 G; 7 T; 0 other;
 SQ
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2238 CTATTACAAAAGACC 2253
 DB 16 CTTTACAAAAGATC 1

XX Tumour suppression related human fukutin oligo SEQ ID No 5408.
 DE
 XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.
 XX Homo sapiens.
 OS
 XX WO2003025175-A2.
 XX
 XX 27-MAR-2003.
 XX
 XX 17-SEP-2002; 2002WO-IB04208.
 XX
 XX 17-SEP-2001; 2001FR-0011978.
 XX
 XX (MOLE-) MOLECULAR ENGINES LAB.
 XX
 XX Tejerman A, Amson R, Tuijnder M;
 XX WPI, 2003-313353/30.
 XX
 XX New isolated nucleic acid, useful for treating viral diseases
 PT associated with tumors and cell degeneration, also related
 PT polypeptides, antibodies and transfected cells -
 PT
 XX
 XX Disclosure; Page 666; 720pp; French.
 XX
 XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15
 CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
 CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
 CC sequence that hybridizes to them under highly stringent conditions, or
 CC the complement of any of them, or the corresponding RNA. The novel
 CC isolated nucleic acids of the invention are useful as probes and primers
 CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
 CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
 CC and for production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention.
 CC
 XX
 XX Sequence 17 BP; 2 A; 5 C; 2 G; 8 T; 0 other;
 SQ
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1364 GAAGGAAAGAGAT 1379
 DB 17 GCAAGAAATGAGAT 2

RESULT 384
 ABT39771/C
 ID ABT39771 standard; DNA; 17 BP.
 XX
 XX ABT39771;
 AC
 XX
 XX 12-JUN-2003 (first entry)
 DT

RESULT 385
 ABT39947/C
 ID ABT39947 standard; DNA; 17 BP.
 XX
 XX ABT39947;
 AC
 XX
 XX 13-JUN-2003 (first entry)
 DT
 XX Tumour suppression related human fukutin oligo SEQ ID No 5584.
 DE

Db 16 CCTGGAGAGAGCCACT 1
 RESULT 387
 ID ACA07798 standard; RNA; 17 BP.
 AC ACA07798;
 XX
 XX 03-JUN-2003 (first entry)
 DE NFkB sub-unit modulating zinzyme substrate #197.
 XX
 KW Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection;
 KM 88.
 XX
 XX Homo sapiens.
 OS
 XX US2002177568-A1.
 PN
 XX 28-NOV-2002.
 PD
 XX 23-MAY-2001; 2001US-0864785.
 PF
 XX 15-AUG-1994; 94US-0291932.
 PR 07-DEC-1992; 92US-0987132.
 PR 18-MAY-1994; 94US-0245466.
 PR 23-DEC-1996; 96US-0777916.
 XX
 XX (STIN/) STINCOMB D T.
 PA (MCSW/) MCSWIGEN J.
 PA (DRAP/) DRAPER K G.
 PA
 PI Stinchcomb DT, Mcswiggen J, Draper KG;
 XX
 XX WPI; 2003-340953/32.
 DR
 XX
 PT Novel enzymatic nucleic acid molecules which down regulates expression
 PT of a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases
 XX
 PS Claim 3; Page 40; 72pp; English.
 XX
 CC The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as

CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury,
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel
 CC enzymatic nucleic acid molecule.
 XX
 SQ Sequence 17 BP; 3 A; 9 C; 5 G; 0 U; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2005 GCCCGAGGCCACCG 2020
 Db 1 GCCCGAGGCCACCG 16
 ID ABR23605 standard; DNA; 17 BP.
 AC ABR23605;
 XX
 XX 22-MAY-2003 (first entry)
 DT
 DE Stabilising reagent method related oligo SEQ ID No 57.
 XX
 XX Stabilising reaction reagent; PCR; primer; RNaseH; long-term storage;
 KW specific amplification; pathogenic microorganism; chimeric;
 KW genetic engineering; clinical medicine; 88.
 XX
 OS Unidentified.
 XX
 XX WO2002101042-A1.
 PN
 XX 19-DEC-2002.
 PD
 XX 12-JUN-2002; 2002WO-JP05832.
 PF
 XX 12-JUN-2001; 2001JP-0177737.
 PR 20-AUG-2001; 2001JP-0249689.
 PR
 XX (TAKA-) TAKARA BIO INC.
 PA
 PI Sagawa H, Uemori T, Mukai H, Yamamoto J, Tomono J, Kobayashi E;
 PI Enoki T, Asada K, Kato I,
 PI
 XX WPI; 2003-148805/14.
 DR
 XX
 PT Method for stabilizing and storing reaction reagents for specific
 PT amplification and detection of nucleic acids particularly in e.g.
 PT identifying pathogenic microorganisms or viruses in sample
 XX
 PS Example 15; Page 126; 177pp; Japanese.
 XX
 CC The invention relates to a novel stabilising reaction reagent for use in
 CC the amplification and/or detection of a target nucleic acid comprising:
 CC preparing a reaction mixture with e.g. a nucleic acid as template, at
 CC least 1 primer and RNaseH, and incubation of the reaction mixture for a
 CC defined period of time to form a reaction product during the
 CC stabilisation and long-term storage of reaction reagents for highly
 CC sensitive and specific amplification and detection of nucleic acids
 CC particularly in identifying pathogenic microorganisms or viruses in a
 CC sample using chimeric oligonucleotide primers, which is useful in genetic
 CC engineering and clinical medicine. This polynucleotide sequence
 CC represents an oligo relating to the novel stabilising reaction reagent
 CC method of the invention.
 XX
 SQ Sequence 17 BP; 3 A; 9 C; 3 G; 1 T; 1 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1752 GCAAGTGTGATGGCG 1767
DB 17 GCAAGTGTGATGGCG 2

RESULT 389
ID ABZ60549 standard; RNA; 17 BP.
AC ABZ60549;
XX
XX 21-MAR-2003 (first entry)
XX
XX Human K-Ras DNAzyme substrate #661.
XX
XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
XX Homo sapiens.
OS
XX WO200297114-A2.
PN
XX 05-DEC-2002.
PD
XX 29-MAY-2002; 2002WO-US16840.
PP
XX 29-MAY-2001; 2001US-294140P.
PR 06-JUN-2001; 2001US-296249P.
PR 10-SEP-2001; 2001US-318471P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Mcswiggen J;
PI
XX WPI; 2003-140484/13.
DR
XX
XX Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX
XX
XX Claim 58; Page 97; 185pp; English.

CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytosstatic, anti-HIV, and
CC anti-rheumatic activity. The nucleic acid molecules are useful for
CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
CC acids are also useful for treating breast, ovarian, colorectal, lung,
CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
CC ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
CC sequences for the human ribozymes of the invention.
XX
XX Sequence 17 BP; 7 A; 2 C; 2 G; 6 U; 0 other;
SQ

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 2.5e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
OY 2151 TTTAGCAGCCGAAAT 2166
DB 2 UUAAGUAAACGAAAU 17

RESULT 390
ABZ60832

ID ABZ60832 standard; RNA; 17 BP.
XX
XX ABZ60832;
AC
XX
XX 21-MAR-2003 (first entry)
DT
XX
XX Human K-Ras DNAzyme substrate #944.
DE
XX
XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
XX Homo sapiens.
OS
XX WO200297114-A2.
PN
XX 05-DEC-2002.
PD
XX 29-MAY-2002; 2002WO-US16840.
PP
XX 29-MAY-2001; 2001US-294140P.
PR 06-JUN-2001; 2001US-296249P.
PR 10-SEP-2001; 2001US-318471P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Mcswiggen J;
PI
XX WPI; 2003-140484/13.
DR
XX
XX Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX
XX
XX Claim 58; Page 103; 185pp; English.

CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytosstatic, anti-HIV, and
CC anti-rheumatic activity. The nucleic acid molecules are useful for
CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
CC acids are also useful for treating breast, ovarian, colorectal, lung,
CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
CC ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
CC sequences for the human ribozymes of the invention.
XX
XX Sequence 17 BP; 8 A; 2 C; 5 G; 2 U; 0 other;
SQ

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2.5e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
OY 2190 GATGAATAATACGAGC 2205
DB 2 GAAGAUAUUGCAGAC 17

RESULT 391
ABZ61775
ID ABZ61775 standard; RNA; 17 BP.
XX
XX ABZ61775;
AC
XX
XX 21-MAR-2003 (first entry)
DT
XX
XX Human H-Ras DNAzyme target #566.
DE
XX
XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.

```

XX OS Homo sapiens.
XX PN WO200297114-A2.
XX PD 05-DEC-2002.
XX PF 29-MAY-2002; 2002WO-US16840.
XX PR 29-MAY-2001; 2001US-294140P.
XX PR 06-JUN-2001; 2001US-296249P.
XX PR 10-SEP-2001; 2001US-318471P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcawiggen J;
XX DR WPI; 2003-140484/13.
XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
XX PT treating cancer, modulates the expression of a nucleic acid encoding
XX PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX PS Claim 58; Page 121; 185pp; English.
XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
XX CC acid molecule or an enzymatic nucleic acid molecule, that modulates
XX CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
XX CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
XX CC acid molecule of the invention has cytosstatic, anti-HIV, and
XX CC anti-rheumatic activity. The nucleic acid molecules are useful for
XX CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
XX CC acids are also useful for treating breast, ovarian, colorectal, lung,
XX CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
XX CC The sequences shown in AB259889 - AB262216, AB264544 - AB265531,
XX CC AB266520 - AB266524, AB266530 - AB266585 represent substrate/target
XX CC sequences for the human ribozymes of the invention.
XX SQ Sequence 17 BP; 3 A; 4 C; 6 G; 4 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.5e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1512 GCCTGTGCACAGCTG 1527
DB 1 GCCTGCGCACAGACTG 16

RESULT 392
AB262111/C
ID AB262111 standard; RNA; 17 BP.
XX AC AB262111;
XX DT 21-MAR-2003 (first entry)
XX DE Human H-Ras DNAzyme target #902.
XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
XX KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;
XX KW anti-rheumatic; cancer; AIDS; ss.
XX OS Homo sapiens.
XX PN WO200297114-A2.
XX PD 05-DEC-2002.
XX PF 29-MAY-2002; 2002WO-US16840.
XX PR 29-MAY-2001; 2001US-294140P.
XX PR 06-JUN-2001; 2001US-296249P.
XX PR 10-SEP-2001; 2001US-318471P.

```

```

PR 10-SEP-2001; 2001US-318471P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcawiggen J;
XX DR WPI; 2003-140484/13.
XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
XX PT treating cancer, modulates the expression of a nucleic acid encoding
XX PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX PS Claim 58; Page 130; 185pp; English.
XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
XX CC acid molecule or an enzymatic nucleic acid molecule, that modulates
XX CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
XX CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
XX CC acid molecule of the invention has cytosstatic, anti-HIV, and
XX CC anti-rheumatic activity. The nucleic acid molecules are useful for
XX CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
XX CC acids are also useful for treating breast, ovarian, colorectal, lung,
XX CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
XX CC The sequences shown in AB259889 - AB262216, AB264544 - AB265531,
XX CC AB266520 - AB266524, AB266530 - AB266585 represent substrate/target
XX CC sequences for the human ribozymes of the invention.
XX SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2393 TTCCGCTGACAGACT 2408
DB 17 TTCCGCTGCTGACT 2

RESULT 393
AB265220
ID AB265220 standard; RNA; 17 BP.
XX AC AB265220;
XX DT 21-MAR-2003 (first entry)
XX DE Human HER2 DNAzyme substrate #677.
XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
XX KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;
XX KW anti-rheumatic; cancer; AIDS; ss.
XX OS Homo sapiens.
XX PN WO200297114-A2.
XX PD 05-DEC-2002.
XX PF 29-MAY-2002; 2002WO-US16840.
XX PR 29-MAY-2001; 2001US-294140P.
XX PR 06-JUN-2001; 2001US-296249P.
XX PR 10-SEP-2001; 2001US-318471P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcawiggen J;
XX DR WPI; 2003-140484/13.
XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
XX PT treating cancer, modulates the expression of a nucleic acid encoding
XX PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -

```

Claim 4; Page 146; 185bp; English.

The invention relates to a novel short interfering RNA (siRNA) nucleic acid molecule or an enzymatic nucleic acid molecule, that modulates expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras, human immunodeficiency virus (HIV) or a component of HIV. The nucleic acid molecule of the invention has cytosstatic, anti-HIV, and anti-thematic activity. The nucleic acid molecules are useful for reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are also useful for treating breast, ovarian, colorectal, lung, prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences shown in ABZ65989 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target sequences for the human ribozymes of the invention.

Sequence 17 BP; 4 A; 4 C; 5 G; 4 U; 0 other;

Query Match **0.9%; Score 12.8; DB 1; Length 17;**
Best Local Similarity 62.5% ; Pred. No. 2.5e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0

Oy 2317 CATCAGATGATGTCT 2312
 |||||::||:
Db 2 CACCAGUGUACUGUCU 17

RESULT 394
ABZ65478/c
ID ABZ65478 standard; RNA; 17 BP.

XX AC ABZ65478;
XX DT 21-MAR-2003 (first entry)
XX DE Human HER2 DNAzyme substrate #935.
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KM enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV,
KN anti-thematic; cancer; AIDS; ss.
OS Homo sapiens.
XX EN WO200297114-A2.
XX PD 05-DEC-2002.
XX PE 29-MAY-2002; 2002MO-US16640.
XX PR 29-MAY-2001; 2001US-294140P.
PR 06-JUN-2001; 2001US-296249P.
PR 10-SEP-2001; 2001US-318471P.
XX RA (RIBO-) RIBOZYME PHARM INC.
PI Mcswiggen J;
DR WPI; 2003-140484/13.
XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
XX HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences
XX PS Claim 4; Page 151; 185bp; English.
XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytosstatic, anti-HIV, and
CC anti-thematic activity. The nucleic acid molecules are useful for
CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
CC acids are also useful for treating breast, ovarian, colorectal, lung,

```

CC prostate bladder, or pancreatic cancer, and HIV infection, and AIDS.
CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
CC ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
CC sequences for the human ribozymes of the invention.
CC
CC
SQ Sequence 17 BP; 2 A; 2 C; 6 G; 7 U; 0 other;

OY Query Match 0.9%; Score 12.6; DB 1; Length 17;
Beat Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0.

2701 CCTCAGTATCCACACA 2716
17 CCTCAGATTCACAAA 2

RESULT 395
ABC41010
ID ABC41010 standard; DNA; 13 BP.
XX
XX ABC41010;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 41027 for detecting SNP TSC0012378.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB00713.
XX
XX 07-APR-2000; 2000DE-1019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olet A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single nucleotide polymorphisms and cytosine
XX methylation status -
XX
XX Claim 1; SEQ ID 41027; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotide are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation.
XX ABC00010-ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and
XX AB100010-AB12073 represent the oligomers described in the invention.
XX NOTE: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 3 A; 1 C; 3 G; 5 T; 1 other;

Query Match 0.9%; Score 12.6; DB 1; Length 13;
Beat Local Similarity 92.3%; Pred. No. 1.9e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0.

2542 TTGATGCAATTC 2554
|||||

```

```

DB          1 TTGGATCGAATTY 13

RESULT 396
ABC41011/C
ID          ABC41011 standard; DNA; 13 BP.
XX
AC          ABC41011;
XX
DT          21-FEB-2002 (first entry)
DE          Oligonucleotide SEQ ID NO 41028 for detecting SNP TSC0012378.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM          peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX          central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS          Homo sapiens.
FN          WO200177384-A2;
PD          18-OCT-2001.
PF          06-APR-2001; 2001WO-IB00713.
PR          07-APR-2000; 2000DE-1019173.
PA          (EPIG-) EPIGENOMICS AG.
PI          Olek A, Piepenbrock C, Berlin K;
XX          WPI; 2001-657177/75.
XX          Set of oligonucleotides, useful for diagnosis and cell typing, is
PT          designed to detect single nucleotide polymorphisms and cytosine
PR          methylation status
XX
PS          Claim 1; SEQ ID 41028; 29pp + Sequence listing; German.
CC          This invention describes novel oligonucleotide primers or peptide nucleic
CC          acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC          and cytosine methylation status in chemically pretreated genomic DNA. The
CC          oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC          range of diseases including immune system, gastrointestinal, respiratory,
CC          central nervous system, cardiovascular and metabolic disorders. The
CC          oligomers are also used for detecting cell type differentiation.
CC          ABC00010-ABR99989, ABR00010-ABR99989, ABR00010-ABR99989 and
CC          ABR100010-ABR182073 represent the oligomers described in the invention.
CC          NOTE: The sequence data for this patent did not form part of the printed
CC          specification, but was obtained in electronic format from WIPO at
CC          ftp.wipo.int/pub/published_pct_sequences.
XX
SQ          Sequence 13 BP; 5 A; 3 C; 1 G; 3 T; 1 other;
XX
Query Match          0.9%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.9e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0
QY          2542 TTGGATCGAATTC 2554
DB          13 TTGGATCGAATTY 1
XX
RESULT 397
ABC76782/C
ID          ABC76782 standard; DNA; 13 BP.
XX
AC          ABC76782;
XX
DT          21-FEB-2002 (first entry)
DE          Oligonucleotide SEQ ID NO 76799 for detecting SNP TSC0019618.
XX
XX

```

KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS	Homo sapiens.
XX	
XX	MO200177384-A2.
PN	
XX	18-OCT-2001.
XX	
XX	06-APR-2001; 2001WO-IB00713.
PF	
XX	07-APR-2000; 2000DE-1019173.
PR	
XX	(EPiG-) EPIGENOMICS AG.
PA	
XX	Olek A. Piepenbrock C, Berlin K;
PI	
XX	WPI; 2001-657177/75.
DR	
XX	
XX	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single nucleotide polymorphisms and cytosine
PT	methylation status -
XX	
XX	Claim 1; SEQ ID 76799; 29pp + Sequence Listing; German.
PS	
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation.
CC	ABCC00010-ABCG9989, ABP00010-ABFG9989, ABH00010-ABH9989 and
CC	ABT00010-ABT82073 represent the oligomers described in the invention.
CC	NOTE: The sequence data for this patent did not form part of the printed
CC	specification, but was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences.
CC	
XX	
XX	Sequence 13 BP; 3 A; 0 C; 2 G; 7 T; 1 other;
SQ	
	Query Match 0.9%; Score 12.6; DB 1; Length 13;
	Best Local Similarity 92.3%; Pred. NO. 1.9e+02;
	Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0.
OY	2236 GACTATTACAAA 2248
Db	13 RACTATTACAAA 1
RESULT 398	
ABC76783	
ID	ABC76783 standard; DNA; 13 BP.
AC	
XX	ABC76783;
XX	
DT	21-FEB-2002 (first entry)
XX	
DE	Oligonucleotide SEQ ID NO 76800 for detecting SNP TSC0019618.
XX	
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS	Homo sapiens.
XX	
XX	MO200177384-A2.
PN	
XX	18-OCT-2001.
XX	
XX	06-APR-2001; 2001WO-IB00713.
PF	
XX	07-APR-2000; 2000DE-1019173.
PR	

```

XX PA (EPiG-) EPIGENOMICS AG.
XX XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX
XX DR WPI; 2001-657177/75.
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single nucleotide polymorphisms and cytosine
XX PT methylation status -
XX PS
XX Claim 1; SEQ ID 76800; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation.
XX CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
XX CC ABH00010-ABH82073 represent the oligomers described in the invention.
XX CC NOTE: The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences.
XX SQ
XX Sequence 13 BP; 7 A; 2 C; 0 G; 3 T; 1 other;
XX
XX Query Match 0.9%; Score 12.6; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred No. 1.9e+02;
XX Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0
XX
XX QY 2236 GACTATTACAAA 2248
XX :|||||
XX 1 RACTATTACAAA 13
XX
XX DB
XX 1 RACTATTACAAA 13
XX
XX RESULT 399
XX ABC79816/C
XX ID ABC79816 standard; DNA; 13 BP.
XX AC
XX ABCT9816;
XX XX
XX DT 21-FEB-2002 (first entry)
XX XX
XX DE Oligonucleotide SEQ ID NO 79833 for detecting SNP TSC0020266.
XX XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX XX
XX OS Homo sapiens.
XX XX
XX PN WO200177384-A2.
XX PD
XX 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB00713.
XX PR
XX 07-APR-2000; 2000DE-1019173.
XX PA
XX (EPiG-) EPIGENOMICS AG.
XX PI
XX Olek A, Piepenbrock C, Berlin K;
XX DR
XX WPI; 2001-657177/75.
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single nucleotide polymorphisms and cytosine
XX PT methylation status -
XX PS
XX Claim 1; SEQ ID 79833; 29pp + Sequence Listing; German.
XX

```

CC	This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation.
CC	ABIC00010-ABI82073 represent the oligomers described in the invention.
CC	NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences.
XX	
SQ	Sequence 13 BP; 1 A; 0 C; 6 G; 5 T; 1 other;
Query Match	0.9%; Score 12.6; DB 1; Length 13;
Best Local Similarity	92.3%; Pred. No. 1.9e+02;
Matches 12; Conservative	1; Mismatches 0; Indels 0; Gaps 0
OY	1587 GAACTCGAAACACC 1599
Ds	13 RAACTCGAACACC 1
RESULT 400	
ABC79817	ABC79817 standard; DNA; 13 BP.
XX	
AC	ABC79817;
XX	
DT	21-FEB-2002 (first entry)
DE	Oligonucleotide SEQ ID NO 79834 for detecting SNP TSCC0020266.
XX	
KM	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS	Homo sapiens.
XX	
PN	WO200177384-A2.
PD	18-OCT-2001.
PF	06-APR-2001; 2001WO-IB00713.
PR	07-APR-2000; 2000DE-1019173.
PA	(EPIG-) EPIGENOMICS AG.
PI	Olek A, Piepenbrock C, Berlin K;
DR	WPI; 2001-657177/75.
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single nucleotide polymorphisms and cytosine
PT	methylation status -
PS	Claim 1; SEQ ID 79834; 29pp + Sequence Listing; German.
XX	
XX	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation.
CC	ABIC00010-ABI82073 represent the oligomers described in the invention.
CC	NOTE: The sequence data for this patent did not form part of the printed
CC	specification, but was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences.
XX	

SQ Sequence 13 BP; 5 A; 6 C; 0 G; 1 T; 1 other;

Query Match 0.9%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.9e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1587 GAAGTCACACAC 1599
 :|||||
 Db 1 RAAGTCACACAC 13

RESULT 401
 ABR84730
 ID ABR84730 standard; DNA; 13 BP.
 AC ABR84730;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 XX Oligonucleotide SEQ ID NO 184727 for detecting SNP TSC0045572.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX MO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 PD
 XX 06-APR-2001; 2001WO-IB00713.
 PF
 XX 07-APR-2000; 2000DE-1019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -
 PT
 XX
 XX Claim 1; SEQ ID 184727; 29pp + Sequence Listing; German.
 PS
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABR00010-ABR99989, ABR00010-ABR99989, ABR00010-ABR99989 and
 CC ABR100010-ABR12073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 CC
 XX
 SQ Sequence 13 BP; 2 A; 0 C; 6 G; 4 T; 1 other;

Query Match 0.9%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.9e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 2341 GGGGTCTAATGT 2353
 :|||||
 Db 1 GGGGTCTAATGT 13

RESULT 402
 ABR84731/C

ID ABR84731 standard; DNA; 13 BP.
 XX
 AC ABR84731;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 XX Oligonucleotide SEQ ID NO 184728 for detecting SNP TSC0045572.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX MO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 PD
 XX 06-APR-2001; 2001WO-IB00713.
 PF
 XX 07-APR-2000; 2000DE-1019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -
 PT
 XX
 XX Claim 1; SEQ ID 184728; 29pp + Sequence Listing; German.
 PS
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABR00010-ABR99989, ABR00010-ABR99989, ABR00010-ABR99989 and
 CC ABR100010-ABR12073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 CC
 XX
 SQ Sequence 13 BP; 4 A; 6 C; 0 G; 2 T; 1 other;

Query Match 0.9%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.9e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 2341 GGGGTCTAATGT 2353
 :|||||
 Db 13 GGGGTCTAATGT 1

RESULT 403
 ABR29758/C
 ID ABR29758 standard; DNA; 13 BP.
 AC ABR29758;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 XX Oligonucleotide SEQ ID NO 229735 for detecting SNP TSC0056037.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.

```
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status
XX
PS Claim 1; SEQ ID 229735; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, cardiovascular, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13; BP; 4 A; 0 C; 1 G; 7 T; 1 other;
XX
Query Match 0.9%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.9e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1908 GAATATCATTAAT 1920
DB 13 RAATATCATTAAT 1
XX
RESULT 404
ABH29759
ID ABH29759 standard; DNA; 13 BP.
XX
AC ABH29759;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 229736 for detecting SNP TSC0056037.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
```

```
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status
XX
PS Claim 1; SEQ ID 229736; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 7 A; 1 C; 0 G; 4 T; 1 other;
XX
Query Match 0.9%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.9e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1908 GAATATCATTAAT 1920
DB 1 RAATATCATTAAT 13
XX
RESULT 405
ABH61844/C
ID ABH61844 standard; DNA; 13 BP.
XX
AC ABH61844;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 261821 for detecting SNP TSC0063523.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status
XX
PS Claim 1; SEQ ID 261821; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
```

CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomeric nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation.
CC	AB000010-AB099989, AB000010-AB099989, AB000010-AB099989 and
CC	AB000010-AB099989 represent the oligomers described in the invention.
CC	NOTE: The sequence data for this patent did not form part of the printed
CC	specification, but was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences.
XX	
XX	Sequence 13 BP; 3 A; 0 C; 2 G; 7 T; 1 other;
XX	
XX	Query Match 0.9%; Score 12.6; DB 1; Length 13;
XX	Best Local Similarity 92.3%; Pred. No. 1.9e+02;
XX	Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0
OY	2237 ACTATTACAAA 2249
DB	13 RCTATTACAAA 1
XX	
XX	RESULT 406
ID	ABH61845 standard; DNA; 13 BP.
AC	ABH61845;
XX	
XX	22-FEB-2002 (first entry)
DT	
DE	Oligonucleotide SEQ ID NO 261822 for detecting SNP TSC0063523.
XX	
XX	SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
XX	Homo sapiens.
XX	
PN	WO2001/77384-A2.
PD	18-OCT-2001.
XX	
XX	06-APR-2001; 2001WO-IB00713.
PF	
PR	07-APR-2000; 2000DE-1019173.
XX	
PA	(EP1G-) EPIGENOMICS AG.
XX	
XX	Olek A, Piepenbrock C, Berlin K;
PI	
DR	WPI; 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single nucleotide polymorphisms and cytosine
PT	methylation status
XX	
PS	Claim 1; SEQ ID 261822; 29pp + Sequence Listing; German.
XX	
XX	This invention describes novel oligonucleotide primers or peptide nucleic
XX	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX	and cytosine methylation status in chemically pretreated genomic DNA. The
XX	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX	range of diseases including immune system, gastrointestinal, respiratory,
XX	central nervous system, cardiovascular and metabolic disorders. The
XX	oligomers are also used for detecting cell type differentiation.
XX	AB000010-AB099989, AB000010-AB099989, AB000010-AB099989 and
XX	AB000010-AB099989 represent the oligomers described in the invention.
XX	NOTE: The sequence data for this patent did not form part of the printed
XX	specification, but was obtained in electronic format from WIPO at
XX	ftp.wipo.int/pub/published_pct_sequences.
XX	
XX	Sequence 13 BP; 7 A; 2 C; 0 G; 3 T; 1 other;
XX	
XX	Query Match 0.9%; Score 12.6; DB 1; Length 13;
XX	Best Local Similarity 92.3%; Pred. No. 1.9e+02;
XX	Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0

OY	2237	ACTATTACAAAA	2249
I	:		
DB	1	RCTAATTCAAAA	13
RESULT	407		
ID	ABK55502/C		
XX	ABK55502 standard; DNA; 15 BP.		
XX	ABK55502;		
DT	18-JUN-2002 (first entry)		
DE	Selectin L Lymphocyte Adhesion Molecule 1 (SELL) oligonucleotide #38.		
KW	Human; Selectin L Lymphocyte Adhesion Molecule 1; SELL;		
KM	neonatal pertussis; whooping cough; haplotyping; primer;		
XX	allele-specific oligonucleotide; ss.		
OS	Homo sapiens.		
PN	WO200216654-A1.		
PD	28-FEB-2002.		
PF	27-AUG-2001; 2001MO-US26675.		
PR	25-AUG-2000; 2000US-228262P.		
PA	(GENA-) GENAISSANCE PHARM INC.		
PI	Anastasio AE, Blegiecki KM, Klieem SE, Koshy B, Kumar AM;		
DR	WPI; 2002-292071/33.		
PT	Novel genetic variants of selectin L lymphocyte adhesion molecule 1		
PT	(SELL) gene useful for therapeutic purposes and for expressing SELL		
PT	protein useful in identifying drugs to treat whooping cough -		
PS	Claim 17; Page 14; 137pp; English.		
CC	The invention relates to an isolated polynucleotide (I) comprising a		
CC	nucleotide sequence which is a polymorphic variant of a reference		
CC	sequence for Selectin L Lymphocyte Adhesion Molecule 1 (SELL) gene.		
CC	SELL polypeptide is useful for screening for drugs targeting the		
CC	polypeptide. Oligonucleotides derived from (I) are used to target SELL		
CC	and a haplotype or haplotype pair of SELL gene. These are useful in		
CC	developing diagnostic tests and therapeutic treatments for neonatal		
CC	pertussis (whooping cough). (I) is useful for studying the expression		
CC	function of SELL and expressing SELL protein for use in screening for		
CC	candidate drugs to treat diseases related to SELL activity. The		
CC	polymorphism and haplotype data are useful for validating whether SELL is		
CC	a suitable target for drugs to treat whooping cough, screening for such		
CC	drugs and reducing bias in clinical trials of such drugs. Establishing		
CC	the SELL haplotype or haplotype pair of an individual is useful for		
CC	improving the efficiency and reliability of several steps in the		
CC	discovery and development of drugs for treating diseases associated with		
CC	SELL activity e.g. neonatal pertussis (whooping cough). The haplotyping		
CC	method is useful to validate SELL as a candidate target for treating a		
CC	specific condition or disease predicted to be associated with SELL		
CC	activity. The method is also useful in screening for compounds		
CC	targeting SELL to treat a specific condition or disease predicted to be		
CC	associated with SELL activity, e.g. detecting which of the SELL		
CC	haplotypes or haplotype pairs present in individual members of a		
CC	population with the specific disease of interest enables one to screen		
CC	for compounds that display the highest desired agonist or antagonist		
CC	activity for each of the most frequent SELL isoforms present in the		
CC	disease population. A polymorphic variant of SELL is useful in studying		
CC	the effect of the variation on the biological activity of SELL, on the		
CC	binding affinity of candidate drugs targeting SELL, for the treatment of		
CC	neonatal pertussis (whooping cough) and in assays to measure the		
CC	binding affinities of one or more candidate drugs targeting the SELL		

CC protein. ABK55465-ABK55559 represent SEHL gene allele-specific
CC oligonucleotides of the invention.

XX Sequence 15 BP; 2 A; 5 C; 4 G; 3 T; 1 other;

Query Match 0.9%; Score 12.6; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 2.3e+02; Indels 0; Gaps 0;

Matches 12; Conservative 1; Mismatches 0;

Db 15 ARCTGACACTGGG 3

1712 AGCTGACACTGGG 1724

AAAD26040 standard; DNA; 15 BP.

AAAD26040;

26-MAR-2002 (first entry)

Human apolipoprotein E (APOE) gene polymorphism detecting ASO probe #5.

Human; antilipemic; neuroprotective; nootropic; genetic variant; APOE;

apolipoprotein E; haplotyping; familial dysbetalipoproteinemia; therapy;

genotyping; type III hyperlipoproteinemia; Alzheimer's disease;

atherosclerosis; polymorphism; allele specific oligonucleotide;

ASO probe; ss.

Homo sapiens.

WO200179234-A2.

25-OCT-2001.

16-APR-2001; 2001WO-US12303.

14-APR-2000; 2000US-197188P.

(GENA-) GENAISSANCE PHARM INC.

Choi JY, Kilem SE, Koshy B, Lee HH;

WPI; 2002-075064/10.

Claim 16; Page 14; 78pp; English.

The patent discloses novel genetic variants of human apolipoprotein

E (APOE) gene. The invention also relates to compositions and methods

for haplotyping and/or genotyping the APOE gene. The haplotyping

methods of the invention are useful for improving the efficacy and

reliability of several steps in the discovery and development of

drugs for treating diseases associated with APOB activity, e.g.

familial dysbetalipoproteinemia, type III hyperlipoproteinemia,

atherosclerosis, and Alzheimer's disease. They are useful to validate

APOE as a candidate agent for treating a specific condition or disease

predicted to be associated with APOE activity and in the design of

clinical trials of candidate drugs for treating a specific condition

or disease predicted to be associated with APOE activity. Genotyping

or haplotyping methods are useful to screen for compounds targeting

APOE to treat a specific condition or disease associated with APOE

activity. The present DNA sequence is an allele specific oligonucleotide

(ASO) probe which is used for detecting human APOE gene polymorphisms.

Sequence 15 BP; 2 A; 5 C; 3 G; 4 T; 1 other;

Query Match 0.9%; Score 12.6; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 2.3e+02;

Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

1392 AGACTACCTGGAG 1404

15 AGACTACTGGAG 3

AAQ41008

AAQ41008 standard; DNA; 14 BP.

AAQ41008;

02-AUG-1993 (first entry)

Sequence around translational start codon of modified gp160-gene

in gp60MN.

Plasmid; cloning; restriction site; ss.

Synthetic.

Key Location/Qualifiers

CDS 3..14

AU9221269-A.

25-AUG-1992; 92AU-0021269.

26-AUG-1991; 91US-0750080.

20-JUL-1992; 92US-0914738.

(IMMO) IMMUNO AG.

Dorner F, Falkner FG, Pfeleiderer M, Scheiflinger F;

WPI; 1993-126461/16.

P-PSDB; AAR34645.

Modified eukaryotic cytoplasmic DNA virus prodn. - involves

direct molecular cloning of modified DNA molecule contg.

cytoplasmic DNA virus genome

Example; Fig 9.5.B; 206pp; English.

The synthetic early/late promoter self was used to express the

gp160-gene of the HIV-1 MN strain. The final plasmid is

pselP-gp160MN.

Sequence 14 BP; 3 A; 4 C; 5 G; 2 T; 0 other;

1811 CCGTGCCCGTGAAG 1824

1 CCAATGCCCGTGAAG 14

AAV95609

AAV95609 standard; RNA; 14 BP.

AAV95609;

24-FEB-1999 (first entry)

Human c-fos target sequence nucleotide position 712.

KW Human; c-fos; hammerhead ribozyme; hairpin ribozyme; target site;
 KW cancer; oncogene; leukaemia; neuroblastoma; diagnosis; genetic drift;
 KW mutation; diseased cell; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9832846-A2.
 XX
 PD 30-JUL-1998.
 XX
 PF 20-JAN-1998; 98WO-US01017.
 XX
 PR 23-JAN-1997; 97US-0037658.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Jarvis T, McSwiggen JA, Stinchcomb DT;
 XX
 DR WPI, 1998-427942/36.
 XX
 PT Enzymatic nucleic acid molecules which specifically cleave RNA
 PT derived from a c-fos gene - useful for treating conditions related
 PT to levels of c-fos, especially cancer
 PS
 PS Claim 5; Page 53; 72pp; English.
 XX
 CC The present invention describes an enzymatic nucleic acid molecule which
 CC specifically cleaves RNA derived from a c-fos gene. AAV95401 to AAV95540
 CC and AAV95541 to AAV95584 represent hammerhead ribozymes and hairpin
 CC ribozymes, respectively, which specifically cleave human c-fos. AAV95261
 CC to AAV95400 and AAV95585 to AAV95628 represent human c-fos target
 CC sequences. The enzymatic nucleic acid molecules can be used for treating
 CC cancer associated with elevated levels of c-fos oncogene, especially
 CC leukaemia, neuroblastomas and lung, breast and colon cancers. The
 CC ribozymes may also be used as diagnostic tools to examine genetic drift
 CC and mutations within diseased cells, or to detect the presence of c-fos
 CC RNA in a cell.
 XX
 SQ Sequence 14 BP; 5 A; 3 C; 4 G; 2 U; 0 other;
 Query Match 0.9%; Score 12.4; DB 1; Length 14;
 Best Local Similarity 78.6%; Pred. No. 2.2e+02;
 Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 2413 AAGCTGCTGAAGCA 2426
 Db 1 AACCTGCTGAAGCA 14
 RESULT 411
 AAV97202/C
 ID AAV97202 standard; RNA; 14 BP.
 XX
 AC AAV97202;
 XX
 DT 01-MAR-1999 (first entry)
 XX
 DE Potato citrate synthase target sequence position 539.
 XX
 KW Solanidine; glucosyltransferase; potato; citrate synthase; target;
 KW hammerhead ribozyme; hairpin ribozyme; alkaloid biosynthesis;
 KW flower formation; cleavage; solanaceous plant; ss.
 XX
 OS Solanum tuberosum.
 XX
 PN WO9832843-A2.
 XX
 PD 30-JUL-1998.
 XX
 PF 14-JAN-1998; 98WO-US00738.
 XX
 PR 24-NOV-1997; 97US-0979416.
 XX
 PR 28-JAN-1997; 97US-0036545.
 PR

PR 28-JAN-1997; 97US-0036599.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI McSwiggen JA, Zwick MG;
 XX
 DR WPI, 1998-427939/36.
 XX
 PT New enzymatic nucleic acid(s) - useful for, e.g. reducing alkaloid
 PT biosynthesis or regulating flowering
 PS
 PS Claim 54; Page 59; 79pp; English.
 XX
 CC The present invention describes enzymatic nucleic acid molecules with
 CC RNA-cleaving activity (e.g. ribozymes) which are capable of modulating
 CC the expression of plant genes: (i) involved in biosynthesis of
 CC alkaloids; or (ii) involved in flower formation. AAV95982 to AAV96334,
 CC and AAV96335 to AAV96354 represent potato solanidine glucosyltransferase
 CC hammerhead and hairpin ribozymes, respectively. AAV95629 to AAV95981,
 CC and AAV96355 to AAV96734 represent potato solanidine glucosyltransferase
 CC target sequences. AAV96773 to AAV97170, and AAV97171 to AAV97195
 CC represent potato citrate synthase hammerhead and hairpin ribozymes,
 CC respectively. AAV96735 to AAV96772, and AAV97196 to AAV97220 represent
 CC potato citrate synthase target sequences. Ribozymes of the present
 CC invention can be used to inhibit the synthesis of toxic alkaloids in
 CC solanaceous plants, particularly potato but also tomato, pepper,
 CC aubergine and datura or to inhibit flowering in potato, lettuce, spinach,
 CC cabbage, brussels sprouts, arugula, kale, collards, chard, beet, turnip,
 CC sweet potato and turf grass. Also the ribozymes can be used for RNA
 CC manipulation in the same way that restriction endonucleases are for DNA,
 CC as well as to examine genetic drift and mutations in plants and to
 CC detect specific RNA. The ribozymes can be targeted to specific genes or
 CC to consensus sequences within a family of related genes, and being
 CC catalytic need to be present at only very low concentrations.
 XX
 SQ Sequence 14 BP; 3 A; 5 C; 1 G; 5 U; 0 other;
 Query Match 0.9%; Score 12.4; DB 1; Length 14;
 Best Local Similarity 92.9%; Pred. No. 2.2e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2473 ATGATGATGACGCA 2486
 Db 14 ATGATGATGACGCA 1
 RESULT 412
 AAA19206
 ID AAA19206 standard; RNA; 14 BP.
 XX
 AC AAA19206;
 XX
 DT 19-JUN-2000 (first entry)
 XX
 DE Human TIF-2 target site SEQ ID NO:2432.
 XX
 KW Human; aryl hydrocarbon nuclear transport; ARNT; TIF-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytoskeletal; anti-diabetic;
 KW ophthalmologic; anti-inflammatory; anti-arthritic; antipsoriatic; ARMD;
 KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; inflammation; neovascular glaucoma;
 KW myopic degeneration; psoriasis; verruca vulgaris; angiodiroma;
 KW tuberculous sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9950403-A2.
 XX
 PD 07-OCT-1999.
 XX
 PR 24-MAR-1999; 99WO-US06507.
 PR

XX 27-MAR-1998; 98US-0079678.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
XX WPI; 1999-591315/50.
XX
XX Novel ribozymes for modulating the synthesis, expression and/or
XX stability of an mRNA encoding an angiogenic factors -
XX
XX Claim 56; Page 139; 305pp; English.
XX
XX The present invention describes enzymatic nucleic acid molecules with
XX RNA cleaving activity, which specifically cleave RNA encoded by an aryl
XX hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
XX gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
XX AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
XX and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
XX corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
XX AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
XX and AAA19155 to AAA19222 represent their corresponding target sequences;
XX AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
XX sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
XX AAA21596 to AAA21688 represent their corresponding target sequences;
XX AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
XX for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
XX AAA23442 represent their corresponding target sequences. The ribozymes of
XX the invention are used for modulating the synthesis, expression and/or
XX stability of an mRNA encoding angiogenic factor, especially ARNT,
XX integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
XX especially used to treat cancer, diabetic retinopathy, age related
XX macular degeneration (AMD), inflammation, and arthritis, as well as
XX neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
XX angiofibroma of tuberosus sclerosis, port-wine stains, Sturge Weber
XX syndrome, Kippel-Trennauay-Weber syndrome, Osler-Weber-Rendu syndrome,
XX and other syndromes and diseases related to the levels of ARNT, Tie-2,
XX integrin subunit alpha-6, or integrin subunit beta-3.
XX
SQ Sequence 14 BP; 4 A; 1 C; 4 G; 5 U; 0 other;

Query Match 0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 64.3%; Pred. No. 2.2e+02;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Oy 2198 TAGCAGACTTGA 2211
Db 1 UAGCAGAUUUUGA 14

RESULT 413
AAA09609
ID AAA09609 standard; RNA; 14 BP.
XX
XX AAA09609;
XX
XX 29-JAN-2001 (first entry)
XX
XX DE Primer SEQ ID 3 used in LEE and CEE production.
XX
XX KW Linear expression element; circular expression element; LEE; CEE;
XX KW gene function; antigen; promoter function; vaccine; antibody production;
XX KW primer; ss.
XX
XX OS Synthetic.
XX
XX WO200056901-A2.
XX
XX 28-SEP-2000.
XX
XX 24-MAR-2000; 2000WO-US07979.
XX

PR 24-MAR-1999; 99US-0125864.
PR 31-MAR-1999; 99US-0127222.
XX
XX (TEXA) UNIV TEXAS SYSTEM.
XX
XX Sykes KF, Johnston SA;
XX WPI; 2000-628266/60.
XX
XX
XX Producing a linear or circular expression element useful for a number
XX of molecular biology protocols, comprises obtaining a DNA segment
XX consisting of an open reading frame and linking it to a promoter and
XX terminator -
XX
XX Disclosure; Page 116; 117pp; English.
XX
XX This invention relates to the production of a linear or circular
XX expression element (LEE or CEE). The method comprises obtaining a DNA
XX segment consisting of an open reading frame (ORF) and linking the ORF to
XX a promoter and a terminator. The LEEs and CEEs are useful for screening
XX gene function, biological effects of gene functions, antigens and
XX promoter functions. LEEs and CEEs are useful for producing antibodies to
XX an ORF and also in developing immunological reagents, and may be used in
XX the production of vaccines. Sequences AAA09607-A09611 represent primers
XX disclosed in the specification.
XX
SQ Sequence 14 BP; 5 A; 0 C; 4 G; 5 U; 0 other;

Query Match 0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 64.3%; Pred. No. 2.2e+02;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Oy 1882 ATGATGAGATGAT 1895
Db 1 AUGAUGAUGAUGAU 14

RESULT 414
AAA09611/c
ID AAA09611 standard; RNA; 14 BP.
XX
XX AAA09611;
XX
XX 29-JAN-2001 (first entry)
XX
XX DE Primer SEQ ID 5 used in LEE and CEE production.
XX
XX KW Linear expression element; circular expression element; LEE; CEE;
XX KW gene function; antigen; promoter function; vaccine; antibody production;
XX KW primer; ss.
XX
XX OS Synthetic.
XX
XX WO200056901-A2.
XX
XX 28-SEP-2000.
XX
XX 24-MAR-2000; 2000WO-US07979.
XX
XX PR 24-MAR-1999; 99US-0125864.
XX PR 31-MAR-1999; 99US-0127222.
XX
XX (TEXA) UNIV TEXAS SYSTEM.
XX
XX Sykes KF, Johnston SA;
XX WPI; 2000-628266/60.
XX
XX Producing a linear or circular expression element useful for a number
XX of molecular biology protocols, comprises obtaining a DNA segment
XX consisting of an open reading frame and linking it to a promoter and
XX terminator -
XX

PS Disclosure; Page 117; 117pp; English.
XX
CC This invention relates to the production of a linear or circular
CC expression element (LEE or CEE). The method comprises obtaining a DNA
CC segment consisting of an open reading frame (ORF) and linking the ORF to
CC a promoter and a terminator. The LEEs and CEEs are useful for screening
CC gene function, biological effects of gene functions, antigens and
CC promoter functions. LEEs and CEEs are useful for producing antibodies to
CC an ORF and also in developing immunological reagents, and may be used in
CC the production of vaccines. Sequences AAA09607-A09611 represent primers
CC disclosed in the specification.
XX
SQ Sequence 14 BP; 5 A; 4 C; 0 G; 5 U; 0 other;
XX
Query Match 0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1882 ATGATGAGATGAT 1895
Db |||||
14 ATGATGATGATGAT 1
XX
RESULT 415
AAA89885
ID AAA89885 standard; DNA; 14 BP.
XX
AC AAA89885;
XX
DT 26-JAN-2001 (first entry)
XX
DE DNA sequence around start codon of modified gp160 gene.
XX
KW Vaccinia; fowlpox; virus; immune response; HIV; gp-160; gag;
KM gag-pol; ds.
XX
OS Human Immunodeficiency virus type 3.
OS Synthetic.
XX
PA US6103244-A.
XX
PD 15-AUG-2000.
XX
PE 22-MAY-1996; 96US-0651472.
XX
PR 19-DEC-1994; 94US-0358928.
PR 26-AUG-1991; 91US-0750080.
PR 20-JUL-1992; 92US-0914738.
XX
PA (IMMO) IMMUNO AG.
XX
PI Pfeleiderer M, Falkner FG, Scheifflinger F, Dörner F;
PI WPI; 2000-557665/51.
DR P-PSDB; AAB15068.
XX
DE Use of modified vaccinia virus and fowlpox virus for generating or
PT priming an immune response against HIV gp160, HIV Gag and HIV Gag-Pol
PT proteins -
XX
PS Example 9; Fig 99; 172pp; English.
XX
CC The present invention relates to the use of modified vaccinia virus and
CC fowlpox virus for generating or priming an immune response against a
CC heterologous protein in a vertebrate. Suitable proteins include HIV
CC proteins such as HIV gp160, HIV Gag and HIV Gag-Pol proteins. The
CC present sequence was associated with the generation or use of the
CC modified viruses.
XX
SQ Sequence 14 BP; 3 A; 4 C; 5 G; 2 T; 0 other;
XX
Query Match 0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 2.2e+02;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1811 CCGTGGCCGTGAAG 1824
Db |||||
1 CCATGGCCGTGAAG 14
XX
RESULT 416
AAS12903
ID AAS12903 standard; DNA; 14 BP.
XX
AC AAS12903;
XX
DT 21-NOV-2001 (first entry)
XX
DE Modified gp160MN peptide sequence DNA in vaelp-gp160-virus.
XX
KW Cytoplasmic DNA virus; direct molecular cloning; Vaccinia virus; insect;
KM unique restriction endonuclease cleavage site; infectious virion; ds;
KM helper virus; poxvirus; iridovirus; vertebrate; multiple cloning site;
KM human immunodeficiency virus glycoprotein 160MN; gp160MN; mutant.
XX
OS Human Immunodeficiency Virus.
OS Synthetic.
XX
PA US6265183-B1.
XX
PD 24-JUL-2001.
XX
PE 19-DEC-1994; 94US-0358928.
XX
PR 26-AUG-1991; 91US-0750080.
PR 20-JUL-1992; 92US-0914738.
XX
PA (BAXT) BAXTER AG.
XX
PI Dörner F, Scheifflinger F, Falkner FG, Pfeleiderer M;
PI WPI; 2001-535006/59.
DR P-PSDB; AAU07642.
XX
PT Producing recombinant protein using modified vaccinia viral expression
PT system, comprises directly cloning heterologous insert encoding protein
PT into the viral genome into unique restriction endonuclease cleavage
PT site -
XX
PS Example 9; Fig 9.5B; 172pp; English.
XX
CC The invention relates to a method for producing a modified eukaryotic
CC cytoplasmic DNA virus by direct molecular cloning of a modified DNA
CC molecule comprising a modified cytoplasmic DNA virus genome such as a
CC vaccinia virus, containing a heterologous insert encoding a protein. The
CC method involves molecularly cloning the DNA directly into a host cell via
CC a unique restriction endonuclease cleavage site, to be packaged into
CC infectious virions and then recovering them. The host cell is infected
CC with a helper virus for this purpose. The method is useful for producing
CC recombinant proteins and modified eukaryotic cytoplasmic DNA viruses such
CC as poxviruses and iridoviruses found in vertebrates and insects. This
CC sequence represents a DNA encoding a modified HIV gp160 peptide used in
CC the construction of chimeric vaccinia viruses.
XX
SQ Sequence 14 BP; 3 A; 4 C; 5 G; 2 T; 0 other;
XX
Query Match 0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1811 CCGTGGCCGTGAAG 1824
Db |||||
1 CCATGGCCGTGAAG 14
XX
RESULT 417

```

ABL52817
ID ABL52817 standard; DNA; 14 BP.
XX
XX ABL52817;
XX
XX 01-JUL-2002 (first entry)
XX
XX Light-controlled adenylate cyclase associated primer#3.
DE
XX Light-controlled adenylate cyclase; flagellum; PCR; primer; ss.
XX
XX Euglena gracilis.
OS
XX JP2002017374-A.
XX
XX 22-JAN-2002.
XX
XX 03-JUL-2000; 2000JP-0240426.
XX
XX 03-JUL-2000; 2000JP-0240426.
XX
XX 03-JUL-2000; 2000JP-0240426.
XX
XX (ISEK/) ISEKI M.
XX (WATA/) WATANABE M.
XX
XX WPI; 2002-221713/28.
XX
XX New light-controlled adenylate cyclase, useful for in vivo light switch
XX
XX Example 2; Page 19; 24pp; Japanese.
XX
XX The invention relates to a light-controlled adenylate cyclase which is a
XX polypeptide extracted from the duplicate flagellum body of Euglena or its
XX partial peptide. The adenylate cyclase and the DNA are used in an in vivo
XX light switch. The current sequence represents a light-controlled
XX adenylate cyclase associated primer.
XX
XX Sequence 14 BP; 3 A; 1 C; 6 G; 4 T; 0 other;
SQ
Query Match 0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2345 TGTATATGTGGAG 2358
DB 1 TGTCAATGTGGAG 14
RESULT 418
AAT56846
ID AAT56846 standard; RNA; 15 BP.
XX
XX AAT56846;
XX
XX 25-MAR-2003 (updated)
XX 04-APR-1997 (first entry)
XX
XX RSV 1B hammerhead ribozyme target sequence (nt. position 242).
XX
XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
XX gene expression; downregulation; interleukin-5; IL-5; ICM-1;
XX intercellular adhesion molecule; tel A; tumor necrosis factor;
XX TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
XX translocation; chronic myelogenous leukaemia; CML; cancer;
XX Philadelphia chromosome; inflammation; autoimmune disease;
XX atherosclerosis; myocardial infarction; stroke; restenosis;
XX transplant rejection; rheumatoid arthritis; psoriasis;
XX myocardial ischaemia; Kawasaki disease; septic shock; HIV;
XX human immunodeficiency virus; acquired immune deficiency syndrome;
XX AIDS; ss.
XX
XX Respiratory Syncytial Virus.

```

```

PN MO9523225-A2.
XX
XX 31-AUG-1995.
XX
XX 23-FEB-1995; 95WO-IB00156.
XX
XX 30-JAN-1995; 95US-0380734.
XX 23-FEB-1994; 94US-0201109.
XX 29-MAR-1994; 94US-0218934.
XX 04-APR-1994; 94US-0222795.
XX 07-APR-1994; 94US-0224483.
XX 15-APR-1994; 94US-0227958.
XX 18-MAY-1994; 94US-0228041.
XX 06-JUL-1994; 94US-0245736.
XX 15-AUG-1994; 94US-0271280.
XX 16-AUG-1994; 94US-0291932.
XX 17-AUG-1994; 94US-0291433.
XX 19-AUG-1994; 94US-0293520.
XX 02-SEP-1994; 94US-0300000.
XX 08-SEP-1994; 94US-0303039.
XX 23-SEP-1994; 94US-0311486.
XX 23-SEP-1994; 94US-0311749.
XX 28-SEP-1994; 94US-0314397.
XX 03-OCT-1994; 94US-0316771.
XX 07-OCT-1994; 94US-0319492.
XX 11-OCT-1994; 94US-0321933.
XX 04-NOV-1994; 94US-0334847.
XX 10-NOV-1994; 94US-0337608.
XX 28-NOV-1994; 94US-0345516.
XX 16-DEC-1994; 94US-0357577.
XX 23-DEC-1994; 94US-0363233.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Chowrira B, Drenzo A, Draper KG, Dudycz LW;
XX Grimm S, Karpelesky A, Kisich K, Matulic-adamic J, Mcswiggen JA;
XX Modak A, Pavco P, Belgien U, Sullivan SM, Svedler D;
XX Thompson JD, Tracz D, Usman N, Wincott FE, Woolf T;
XX
XX WPI; 1995-351090/45.
XX
XX Ribozymes having modified bases and methods for producing them
XX for use in inhibiting disease related genes
XX
XX Claim 2; Page 265; 407pp; English.
XX
XX The present sequence represents a preferred target sequence for an
XX enzymatic nucleic acid (i.e. a ribozyme) which cleaves mRNA coding
XX for a protein of respiratory syncytial virus (RSV) at the
XX nucleotide base position indicated in the DE line. Regions of
XX the mRNA that do not form secondary folding structures and that
XX contain potential hammerhead and hairpin ribozyme cleavage sites
XX were identified by computer analysis. Ribozymes directed against
XX these mRNA sequences were designed and synthesised with modifications
XX that improve their nuclease resistance. The ribozymes cleave the
XX target sequences and can be used for treatment and diagnosis of
XX RSV infection.
XX (Updated on 25-MAR-2003 to correct PI field.)
XX
XX Sequence 15 BP; 8 A; 3 C; 1 G; 3 U; 0 other;
SQ
Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 2.4e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 2237 ACTATTACAAAAG 2250
DB 2 ACUAAUACACAAAAG 15
RESULT 419
AAK66621/c

```

ID AAX66621 standard; RNA; 15 BP.
 AC AAX66621;
 DT 20-JUN-1999 (first entry)
 DE Human CD40 hammerhead ribozyme target SEQ ID NO:3253.
 XX
 XX Arthritic condition; graft tolerance; immune response; target; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.
 XX
 OS Homo sapiens.
 XX
 EN MO9618736-A2.
 XX
 PD 20-JUN-1996.
 XX
 PE 22-NOV-1995; 95WO-US15516.
 XX
 XX 05-OCT-1995; 95US-0541365.
 PR 13-DEC-1994; 94US-0354920.
 PR 23-DEC-1994; 94US-0363253.
 PR 17-DEC-1994; 94US-0363254.
 PR 17-FEB-1995; 95US-0390850.
 PR 20-APR-1995; 95US-0426124.
 PR 02-MAY-1995; 95US-0432874.
 PR 04-MAY-1995; 95US-0434509.
 PR 07-JUL-1995; 95US-0000951.
 PR 07-JUL-1995; 95US-0000974.
 PR 07-AUG-1995; 95US-0512861.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PI Draper K, Gustafson J, McSwiggen J, Pavco P, Stinchcomb DT;
 PI Beigelman L, Karpelesky A, Modak A, Uzman N, Burgin A;
 PI Matulic-Adamic U, Jarvis T, Thompson JD, Wincott F;
 XX
 DR WPI; 1996-300653/30.
 XX
 PT Enzymatic nucleic acid molecules having a hammer-head motif - used
 PT for treatment of auto-immune diseases
 PT treatment of auto-immune diseases
 XX
 PS Claim 10; Page 204; 307pp; English.
 XX
 CC The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose
 CC residues; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii)
 CC at least ten 2'-O-methyl modifications; and (iv) a 3'-end modification.
 CC The ENA's can inhibit collagenase and stromelysin production in the
 CC synovial membrane of joints for the treatment or prevention of arthritis,
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention.
 CC
 XX Sequence 15 BP; 2 A; 7 C; 1 G; 5 U; 0 other;
 SQ
 Query Match 0.9%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 2.4e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1887 GAAGATGATGGCA 1900
 Db 14 GAAGATGATGGCA 1
 RESULT 420
 AAT49651/C
 ID AAT49651 standard; RNA; 15 BP.
 AC AAT49651;
 XX
 DT 28-FEB-1997 (first entry)
 DE Human CETP HH ribozyme target sequence #612.
 XX
 XX Hammerhead ribozyme; cholesterol ester transfer protein; mRNA cleavage;
 KW neutral lipid transfer; plasma lipoprotein; atherosclerosis; atherectomy;
 KW reverse cholesterol transport; high density lipoprotein; therapy; CETP;
 KW familial hypercholesterolaemia; dyslipidaemia; hypolipidoproteinaemia;
 KW peripheral vascular disease; hyperbetalipoproteinaemia; RCT; inhibitor;
 KW angioplastic restenosis; low density lipoprotein; diabetes; HDL; human;
 KW LDL; ss.
 XX
 OS Homo sapiens.
 XX
 EN MO9620279-A1.
 XX
 PD 04-JUL-1996.
 XX
 PE 11-DEC-1995; 95WO-US16000.
 PR 23-DEC-1994; 94US-0363240.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PI (WARN) WARNER LAMBERT CO.
 PI Bisgaier C, Couture L, McSwiggen J, Pape M, Stinchcomb D;
 XX
 DR WPI; 1996-321852/32.
 XX
 PT New ribozyme(s) for cleaving cholesterol ester transfer protein mRNA
 PT - useful for preventing or treating initial development, progression
 PT or regression of vascular diseases, esp. familial
 PT hypercholesterolaemia
 XX
 PS Claim 4; Page 30; 72pp; English.
 XX
 CC AAT49608-T49663 represent target sequences for the human cholesterol
 CC ester transfer protein (CETP) hammerhead (HH) ribozymes (see
 CC AAT49861-T50137). CETP is a 74 kD glycoprotein that facilitates neutral
 CC lipid transfer between plasma lipoproteins. The numbering of the targets
 CC refers to the position of the cleavage site in full length CETP. The
 CC ribozyme binds to 5 nucleotides either side of this site, provided the
 CC sequence UH is immediately upstream. The ribozymes are able to cleave
 CC mRNA from the gene encoding CETP, thereby blocking synthesis and/or
 CC expression of the mRNA. By inhibiting CETP, the reverse cholesterol
 CC transport (RCT) pathway can be inhibited (or eliminated) thereby
 CC preventing the reduction in size density of the high density lipoproteins
 CC (HDL), prolonging HDL half life, and therefore increasing HDL levels.
 CC The ribozymes can be used to treat conditions associated with abnormal
 CC levels of CETP, specifically familial hypercholesterolaemia,
 CC atherosclerosis, peripheral vascular disease, hyperbetalipoproteinaemia,
 CC hypolipidoproteinaemia, dyslipidaemia, vascular complications of
 CC diabetes, transplant, atherectomy and angioplastic restenosis. By
 CC inhibiting CETP, the levels of HDL and low density lipoproteins (LDL),
 CC and the HDL:LDL ratio are favourably altered (a decrease in LDL levels,
 CC and a corresponding increase in HDL levels). The HH ribozymes can also
 CC be used diagnostically to study genetic drift and mutations in diseased
 CC cells, and to detect CETP mRNA. As the HH ribozymes target specific
 CC regions of the CETP gene, they have low non-specific activity.
 CC
 XX Sequence 15 BP; 2 A; 5 C; 3 G; 5 U; 0 other;
 SQ

Query Match 0.9%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 2.4e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 1549 AGACAGGTACAGT 1562
 |||||
 DB 15 AGACAGGTACAGT 2

RESULT 421
 ID AAX75723 standard; RNA; 15 BP.
 XX AAX75723;
 AC AAX75723;
 XX 28-JUL-1999 (first entry)
 XX Human f1c-1 and KDR hammerhead ribozyme target site #57.
 XX
 XX Vascular endothelial growth factor receptor; VEGF receptor; f1c-1;
 KM f1c-1; KDR; hammerhead ribozyme; cleavage;
 KM tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KM fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KM foetal liver kinase 1; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO9715662-A2.
 XX
 PD 01-MAY-1997.
 XX
 XX 25-OCT-1996; 96WO-US17480.
 XX
 XX 11-JAN-1996; 96US-0584040.
 PR 26-OCT-1995; 95US-0005974.
 XX
 XX (CHIR) CHIRON CORP.
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Escobedo J, McSwigen J, Pavco P, Stinchcomb D;
 DR WPI, 1997-259017/23.
 XX
 XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
 PT mRNA stability - useful for treating e.g. tumour angiogenesis,
 XX psoriasis, rheumatoid arthritis, etc., in a human patient
 XX
 PS Example 9; Page 191; 218pp; English.
 XX
 XX The present invention describes nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (f1c-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (f1k-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
 CC be treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX75725 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention.
 XX
 SQ Sequence 15 BP; 9 A; 0 C; 3 G; 3 U; 0 other;

Query Match 0.9%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 71.4%; Pred. No. 2.4e+02;
 Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

OY 1822 AAGATCTGAAGA 1835
 |||||
 DB 1 AAAAGUGGAAAGA 14

RESULT 422
 AAT99048/C

ID AAT99048 standard; DNA; 15 BP.
 XX
 XX AAT99048;
 AC
 XX 23-MAR-1998 (first entry)
 DT
 XX Probe 219m8 for drug induced HIV RT gene Q219.
 DE
 XX Reverse transcriptase gene; HIV; RT gene; antiviral drug susceptibility;
 KM virus susceptibility; antiviral drug resistant viral strain; retrovirus;
 KM Hepadnaviridae; HIV RT genotyping; probe; ss.
 XX
 OS Synthetic.
 OS Human immunodeficiency virus type 1.
 XX
 XX WO9727332-A1.
 XX
 PD 31-JUL-1997.
 XX
 XX 17-JAN-1997; 97WO-EP00211.
 PP
 XX 25-JUN-1996; 96EP-0870081.
 PR 26-JAN-1996; 96EP-0870005.
 XX
 XX (INNO-) INNOGENETICS NV.
 PA
 XX Louwagie J, Rossau R, Stuyver L;
 PL WPI; 1997-393716/36.
 DR
 XX Determining susceptibility to antiviral drugs of reverse
 PT transcriptase containing viruses - useful for genotyping HIV RT and
 PT detecting antiviral resistant HIV
 XX
 PS Claim 13; Page 39; 59pp; English.
 XX

XX This sequence represents a probe for a wild type HIV reverse
 CC transcriptase (RT) gene fragment. This sequence can be used in the method
 CC of the invention for determining the susceptibility to antiviral drugs of
 CC viruses which contain RT genes and are present in a biological sample. It
 CC comprises: (1) releasing, isolating or concentrating the polynucleic
 CC acids present in a sample; (2) amplifying the relevant part of the RT
 CC genes present with at least one suitable primer pair; (3) hybridising the
 CC polynucleic acids of step (1) or (2) with at least two RT gene probes,
 CC the probes being applied to known locations on a solid support, and are
 CC capable of simultaneously hybridising to their respective target regions
 CC under appropriate hybridisation and wash condition allowing the detection
 CC of homologous targets, or with the probes hybridising specifically with a
 CC sequence complementary to any of the target sequences; (4) detecting the
 CC hybrids formed in step (3); and (4) inferring the nucleotide sequence at
 CC the codons of interest (codons 38-44, 47-53, 65-72, 73-77, 148-154,
 CC 180-187, 212-216, and 217-220), and/or the amino acids of the codons of
 CC interest and/or antiviral drug resistance spectrum, and possible the type
 CC of viral isolates involved from the differential hybridisation signals
 CC obtained in step (4). The method is specifically used to detect antiviral
 CC drug resistant strains of viruses containing RT genes, especially HIV
 CC retroviruses and Hepadnaviridae. The method can also be used for
 CC genotyping HIV RT.
 XX
 SQ Sequence 15 BP; 8 A; 5 C; 1 G; 1 T; 0 other;

Query Match 0.9%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 2.4e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1856 TTTCGATCTGCTG 1869
 |||||
 DB 14 TTTCGATCTGCTG 1

RESULT 423
 AA207078
 ID AA207078 standard; DNA; 15 BP.

```

XX AA207078;
XX
XX 07-OCT-1999 (first entry)
XX
XX Peptide nucleic acid oligomer #8.
XX
XX Peptide nucleic acid; PNA; polymer; solubility; modulation;
XX synthesis; purification; analysis; ss.
XX
XX Synthetic.
XX
XX Key
XX modified_base
XX 1
XX /tag= a
XX /note= "a is modified to Flu-OR-a where Flu is
XX 5-(6)-carboxyfluorescein, O is
XX 8-amino-3,6-dioxoacetic acid and E is an
XX uncharged ether modifying moiety"
XX
XX modified_base
XX 15
XX /tag= b
XX /note= "g is modified to g-E-NH2, which is an amidated
XX uncharged ether modifying moiety"
XX
XX WO937670-A1.
XX
XX 29-JUL-1999.
XX
XX 19-JAN-1999; 99WO-US01024.
XX
XX 04-JAN-1999; 99US-0225048.
XX 27-JAN-1998; 98US-0072772.
XX
XX (BOST-) BOSTON PROBS INC.
XX
XX Coull JM, Gildea BD;
XX
XX WPI; 1999-479032/40.
XX
XX Branched compositions for improving the solubility of synthetic
XX polymers or minimizing or eliminating polymer self-aggregation,
XX particularly in peptide nucleic acids
XX
XX Example 12; Page 40; 81pp; English.
XX
XX The present invention describes a branched composition (I) which is
XX useful for improving the solubility of synthetic polymers (II) or aids
XX in minimizing or eliminating self-aggregation of (II), where (II) is a
XX nucleic acid (or analogue), peptide, peptide nucleic acid (PNA),
XX polyamide, chimera or a linked polymer. Modification of (II) by (I) can
XX facilitate synthesis, purification and analysis of many insoluble
XX polymers, and particularly purine-rich PNA polymers labeled with
XX hydrophobic labels. The products can be used in research, diagnostic
XX and therapeutic applications. The present sequence represents a PNA
XX used in the exemplification of the present invention.
XX
XX Sequence 15 BP; 5 A; 0 C; 5 G; 5 T; 0 other:
XX
XX Query Match 0.9%; Score 12.4; DB 1; Length 15;
XX Best Local Similarity 92.9%; Pred. No. 2.4e+02;
XX Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 1882 ATGATGAAGATGAT 1895
XX |||||
XX 1 ATGATGATGATGAT 14
XX
XX RESULT 424
XX AAX57566
XX ID AAX57566 standard; DNA; 15 BP.
XX
XX AAX57566;
XX

```

```

DT 16-JUL-1999 (first entry)
XX
XX Antisense oligo #5 to insulin-like growth factor I receptor.
XX
XX Antisense; human; insulin-like growth factor-1 receptor; IGF-1R;
XX expression; inhibition; induction; apoptosis; tumour; liposome; ss.
XX
XX Synthetic.
XX Homo sapiens.
XX
XX WO9923259-A1.
XX
XX 14-MAY-1999.
XX
XX 03-NOV-1998; 98WO-US23418.
XX
XX 04-NOV-1997; 97US-0963886.
XX
XX (INEX-) INEX PHARM CORP.
XX
XX Zon G;
XX
XX WPI; 1999-313361/26.
XX
XX Human insulin-like growth factor-1 receptor gene antisense
XX oligonucleotides
XX
XX Disclosure; Page 16; 23pp; English.
XX
XX Sequences AAX57562-X57571 represent antisense oligonucleotides targeted
XX to a region spanning 4-9 codons downstream of the AUG translation
XX initiation codon of the human insulin-like growth factor-1 receptor
XX (IGF-1R) gene. The antisense oligonucleotides inhibit the expression of
XX IGF-1R, which in turn induces apoptosis, especially in a tumour cell.
XX The oligonucleotides can be administered via a liposome.
XX
XX Sequence 15 BP; 4 A; 4 C; 4 G; 3 T; 0 other:
XX
XX Query Match 0.9%; Score 12.4; DB 1; Length 15;
XX Best Local Similarity 92.9%; Pred. No. 2.4e+02;
XX Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 1488 GAGCCAGACTTCA 1501
XX |||||
XX 1 GGAGCCAGACTTCA 14
XX
XX RESULT 425
XX AAX59271/C
XX ID AAX59271 standard; DNA; 15 BP.
XX
XX AAX59271;
XX
XX 24-MAY-2000 (first entry)
XX
XX Human NR8 gene probe #14.
XX
XX Haemoipoietin receptor family; NR8; antibody; diagnosis;
XX blood formation disorder; fusion protein; probe; ss.
XX
XX Homo sapiens.
XX
XX WO9967290-A1.
XX
XX 29-DEC-1999.
XX
XX 23-JUN-1999; 99WO-JP03351.
XX
XX 24-JUN-1998; 98JP-0214720.
XX 19-OCT-1998; 98JP-0297409.
XX
XX (CHUG-) CHUGAI RES INST MOLECULAR MEDICINE INC.
XX

```

PI Nomura H, Maeda M;
XX WPI; 2000-116933/10.
XX
XX Hemopoietin receptor protein family NR8 used for diagnosis of blood
PT formation disorders -
XX
XX Example 1; Page 38; 176pp; Japanese.
XX
XX The invention relates to the isolation of sequences encoding human
CC haemopoietin receptor protein family NR8 genes. The NR8 family
CC sequences were initially searched for comparison on a nucleic acid
CC database with the nucleic acid probe sequence TGGAGYNNNTGAGY encoding
CC the amino acid sequence Trp-Ser-Xaa-Trp-Ser. The sequences
CC AA259258-259300 and AA290816-290925 represent specific examples of probe
CC sequences used in the search. Antibodies to the NR8 family proteins are
CC used for the diagnosis of blood formation disorders. Compounds identified
CC as binding to the proteins are used for the treatment of such disorders.
XX
SQ Sequence 15 BP; 3 A; 1 C; 7 G; 4 T; 0 other;
Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1581 CTCCATGACTGCA 1594
Db 14 CTCCATGACTGCA 1
RESULT 426
AA259273/c
ID AA259273 standard; DNA; 15 BP.
XX
XX AA259273;
XX
XX 24-MAY-2000. (first entry)
DT
XX
XX Human NR8 gene probe #16.
DE
XX
XX Haemopoietin receptor family; NR8; antibody; diagnosis;
KW blood formation disorder; fusion protein; probe; ss.
XX
XX Homo sapiens.
OS
XX
XX WO967290-A1.
PN
XX
XX 29-DEC-1999.
PD
XX
XX 23-JUN-1999; 99WO-JP03351.
PF
XX
XX 24-JUN-1998; 98JP-0214720.
PR
XX
XX 19-OCT-1998; 98JP-0297409.
PR
XX
XX (CHUG-) CHUGAI RES INST MOLECULAR MEDICINE INC.
PA
XX
XX Nomura H, Maeda M;
PI
XX
XX WPI; 2000-116933/10.
DR
XX
XX Hemopoietin receptor protein family NR8 used for diagnosis of blood
PT formation disorders -
XX
XX Example 1; Page 38; 176pp; Japanese.
XX
XX The invention relates to the isolation of sequences encoding human
CC haemopoietin receptor protein family NR8 genes. The NR8 family
CC sequences were initially searched for comparison on a nucleic acid
CC database with the nucleic acid probe sequence TGGAGYNNNTGAGY encoding
CC the amino acid sequence Trp-Ser-Xaa-Trp-Ser. The sequences
CC AA259258-259300 and AA290816-290925 represent specific examples of probe
CC sequences used in the search. Antibodies to the NR8 family proteins are
CC used for the diagnosis of blood formation disorders. Compounds identified

CC as binding to the proteins are used for the treatment of such disorders.
XX
SQ Sequence 15 BP; 3 A; 2 C; 6 G; 4 T; 0 other;
Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1581 CTCCATGACTGCA 1594
Db 14 CTCCATGACTGCA 1
RESULT 427
AA259278/c
ID AA259278 standard; DNA; 15 BP.
XX
XX AA259278;
XX
XX 24-MAY-2000 (first entry)
DT
XX
XX Human NR8 gene probe #21.
DE
XX
XX Haemopoietin receptor family; NR8; antibody; diagnosis;
KW blood formation disorder; fusion protein; probe; ss.
XX
XX Homo sapiens.
OS
XX
XX WO967290-A1.
PN
XX
XX 29-DEC-1999.
PD
XX
XX 23-JUN-1999; 99WO-JP03351.
PF
XX
XX 24-JUN-1998; 98JP-0214720.
PR
XX
XX 19-OCT-1998; 98JP-0297409.
PR
XX
XX (CHUG-) CHUGAI RES INST MOLECULAR MEDICINE INC.
PA
XX
XX Nomura H, Maeda M;
PI
XX
XX WPI; 2000-116933/10.
DR
XX
XX Hemopoietin receptor protein family NR8 used for diagnosis of blood
PT formation disorders -
XX
XX Example 1; Page 38; 176pp; Japanese.
XX
XX The invention relates to the isolation of sequences encoding human
CC haemopoietin receptor protein family NR8 genes. The NR8 family
CC sequences were initially searched for comparison on a nucleic acid
CC database with the nucleic acid probe sequence TGGAGYNNNTGAGY encoding
CC the amino acid sequence Trp-Ser-Xaa-Trp-Ser. The sequences
CC AA259258-259300 and AA290816-290925 represent specific examples of probe
CC sequences used in the search. Antibodies to the NR8 family proteins are
CC used for the diagnosis of blood formation disorders. Compounds identified
CC as binding to the proteins are used for the treatment of such disorders.
XX
SQ Sequence 15 BP; 3 A; 1 C; 7 G; 4 T; 0 other;
Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1581 CTCCATGACTGCA 1594
Db 14 CTCCATGACTGCA 1
RESULT 428
AA259282/c
ID AA259282 standard; DNA; 15 BP.
XX

```

AC AA259282;
XX
DT 24-MAY-2000 (first entry)
XX
DE Human NR8 gene probe #25.
XX
KM Haemopoietin receptor family; NR8; antibody; diagnosis;
XX blood formation disorder; fusion protein; probe; ss.
XX
OS Homo sapiens.
XX
PN WO967290-A1.
XX
PD 29-DEC-1999.
XX
PF 23-JUN-1999; 99WO-JP03351.
XX
PR 24-JUN-1998; 98JP-0214720.
XX 19-OCT-1998; 98JP-0297409.
XX
PA (CHUG-) CHUGAI RES INST MOLECULAR MEDICINE INC.
XX
PI Nomura H, Maeda M;
XX
DR WPI, 2000-116933/10.
XX
PT Hemopoietin receptor protein family NR8 used for diagnosis of blood
XX formation disorders -
XX
PS Example 1; Page 39; 176pp; Japanese.
XX
CC The invention relates to the isolation of sequences encoding human
CC haemopoietin receptor protein family NR8 genes. The NR8 family
CC sequences were initially searched for comparison on a nucleic acid
CC database with the nucleic acid probe sequence TGGAGYNNNTGAGY encoding
CC the amino acid sequence Trp-Ser-Xaa-Trp-Ser. The sequences
CC AA259288-259300 and AA290816-290925 represent specific examples of probe
CC sequences used in the search. Antibodies to the NR8 family proteins are
CC used for the diagnosis of blood formation disorders. Compounds identified
CC as binding to the proteins are used for the treatment of such disorders.
XX
SQ Sequence 15 BP; 3 A; 1 C; 7 G; 4 T; 0 other;

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1581 CTCGATGAAGTCCA 1594
DB 14 CTCGATGCACTCCA 1

RESULT 429
AA259300/C
ID AA259300 standard; DNA; 15 BP.
XX
AC AA259300;
XX
DT 24-MAY-2000 (first entry)
XX
DE Human NR8 gene probe #43.
XX
KM Haemopoietin receptor family; NR8; antibody; diagnosis;
XX blood formation disorder; fusion protein; probe; ss.
XX
OS Homo sapiens.
XX
PN WO967290-A1.
XX
PD 29-DEC-1999.
XX 23-JUN-1999; 99WO-JP03351.
XX

```

```

PR 24-JUN-1998; 98JP-0214720.
XX 19-OCT-1998; 98JP-0297409.
XX
PA (CHUG-) CHUGAI RES INST MOLECULAR MEDICINE INC.
XX
PI Nomura H, Maeda M;
XX
DR WPI, 2000-116933/10.
XX
PT Hemopoietin receptor protein family NR8 used for diagnosis of blood
XX formation disorders -
XX
PS Example 1; Page 39; 176pp; Japanese.
XX
CC The invention relates to the isolation of sequences encoding human
CC haemopoietin receptor protein family NR8 genes. The NR8 family
CC sequences were initially searched for comparison on a nucleic acid
CC database with the nucleic acid probe sequence TGGAGYNNNTGAGY encoding
CC the amino acid sequence Trp-Ser-Xaa-Trp-Ser. The sequences
CC AA259288-259300 and AA290816-290925 represent specific examples of probe
CC sequences used in the search. Antibodies to the NR8 family proteins are
CC used for the diagnosis of blood formation disorders. Compounds identified
CC as binding to the proteins are used for the treatment of such disorders.
XX
SQ Sequence 15 BP; 4 A; 2 C; 6 G; 3 T; 0 other;

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1581 CTCGATGAAGTCCA 1594
DB 14 CTCGATGCACTCCA 1

RESULT 430
AA290836/C
ID AA290836 standard; DNA; 15 BP.
XX
AC AA290836;
XX
DT 24-MAY-2000 (first entry)
XX
DE Human NR8 gene probe #64.
XX
KM Haemopoietin receptor family; NR8; antibody; diagnosis;
XX blood formation disorder; fusion protein; probe; ss.
XX
OS Homo sapiens.
XX
PN WO967290-A1.
XX
PD 29-DEC-1999.
XX
PF 23-JUN-1999; 99WO-JP03351.
XX
PR 24-JUN-1998; 98JP-0214720.
XX 19-OCT-1998; 98JP-0297409.
XX
PA (CHUG-) CHUGAI RES INST MOLECULAR MEDICINE INC.
XX
PI Nomura H, Maeda M;
XX
DR WPI, 2000-116933/10.
XX
PT Hemopoietin receptor protein family NR8 used for diagnosis of blood
XX formation disorders -
XX
PS Example 1; Page 40; 176pp; Japanese.
XX
CC The invention relates to the isolation of sequences encoding human
CC haemopoietin receptor protein family NR8 genes. The NR8 family
CC sequences were initially searched for comparison on a nucleic acid

```

```
CC database with the nucleic acid probe sequence TGGAGYNNNTGAGY encoding
CC the amino acid sequence Trp-Ser-Xaa-Trp-Ser. The sequences
CC AAZ59258-259300 and AAZ50816-250925 represent specific examples of probe
CC sequences used in the search. Antibodies to the NR8 family proteins are
CC used for the diagnosis of blood formation disorders. Compounds identified
CC as binding to the proteins are used for the treatment of such disorders.
XX
SQ Sequence 15 BP; 3 A; 1 C; 7 G; 4 T; 0 other;

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1581 CTCGATGAAGCTCA 1594
DB 14 CTCGATGACATCTCA 1

RESULT 431
AAZ90837/C
ID AAZ90837 standard; DNA; 15 BP.
XX
AC AAZ90837;
XX
DT 24-MAY-2000 (first entry)
XX
DE Human NR8 gene probe #65.
XX
KW Haemopoietin receptor family; NR8; antibody; diagnosis;
KW blood formation disorder; fusion protein; probe; ss.
XX
OS Homo sapiens.
XX
PN WO9967290-A1.
XX
PD 29-DEC-1999.
XX
PF 23-JUN-1999; 99WO-JP03351.
XX
PR 24-JUN-1998; 98JP-0214720.
PR 19-OCT-1998; 98JP-0297409.
XX
PA (CHUG-) CHUGAI RES INST MOLECULAR MEDICINE INC.
XX
PI Nomura H, Maeda M;
XX
DR WPI; 2000-116933/10.
XX
PT Hemopoietin receptor protein family NR8 used for diagnosis of blood
PT formation disorders -
XX
PS Example 1; Page 41; 176pp; Japanese.
XX
CC The invention relates to the isolation of sequences encoding human
CC haemopoietin receptor protein family NR8 genes. The NR8 family
CC sequences were initially searched for comparison on a nucleic acid
CC database with the nucleic acid probe sequence TGGAGYNNNTGAGY encoding
CC the amino acid sequence Trp-Ser-Xaa-Trp-Ser. The sequences
CC AAZ59258-259300 and AAZ50816-250925 represent specific examples of probe
CC sequences used in the search. Antibodies to the NR8 family proteins are
CC used for the diagnosis of blood formation disorders. Compounds identified
CC as binding to the proteins are used for the treatment of such disorders.
XX
SQ Sequence 15 BP; 3 A; 1 C; 7 G; 4 T; 0 other;

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1581 CTCGATGAAGCTCA 1594
DB 14 CTCGATGACATCTCA 1
```

```
RESULT 432
AAZ90846/C
ID AAZ90846 standard; DNA; 15 BP.
XX
AC AAZ90846;
XX
DT 24-MAY-2000 (first entry)
XX
DE Human NR8 gene probe #74.
XX
KW Haemopoietin receptor family; NR8; antibody; diagnosis;
KW blood formation disorder; fusion protein; probe; ss.
XX
OS Homo sapiens.
XX
PN WO9967290-A1.
XX
PD 29-DEC-1999.
XX
PF 23-JUN-1999; 99WO-JP03351.
XX
PR 24-JUN-1998; 98JP-0214720.
PR 19-OCT-1998; 98JP-0297409.
XX
PA (CHUG-) CHUGAI RES INST MOLECULAR MEDICINE INC.
XX
PI Nomura H, Maeda M;
XX
DR WPI; 2000-116933/10.
XX
PT Hemopoietin receptor protein family NR8 used for diagnosis of blood
PT formation disorders -
XX
PS Example 1; Page 41; 176pp; Japanese.
XX
CC The invention relates to the isolation of sequences encoding human
CC haemopoietin receptor protein family NR8 genes. The NR8 family
CC sequences were initially searched for comparison on a nucleic acid
CC database with the nucleic acid probe sequence TGGAGYNNNTGAGY encoding
CC the amino acid sequence Trp-Ser-Xaa-Trp-Ser. The sequences
CC AAZ59258-259300 and AAZ50816-250925 represent specific examples of probe
CC sequences used in the search. Antibodies to the NR8 family proteins are
CC used for the diagnosis of blood formation disorders. Compounds identified
CC as binding to the proteins are used for the treatment of such disorders.
XX
SQ Sequence 15 BP; 4 A; 0 C; 6 G; 5 T; 0 other;

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1581 CTCGATGAAGCTCA 1594
DB 14 CTCGATTAACTCA 1

RESULT 433
AAZ90861/C
ID AAZ90861 standard; DNA; 15 BP.
XX
AC AAZ90861;
XX
DT 24-MAY-2000 (first entry)
XX
DE Human NR8 gene probe #89.
XX
KW Haemopoietin receptor family; NR8; antibody; diagnosis;
KW blood formation disorder; fusion protein; probe; ss.
XX
OS Homo sapiens.
XX
PN WO9967290-A1.
```

```

XX 29-DEC-1999.
PD 23-JUN-1999; 99WO-JP03351.
XX 24-JUN-1998; 98JP-0214720.
XX 19-OCT-1998; 98JP-0297409.
XX (CHUG-) CHUGAI RES INST MOLECULAR MEDICINE INC.
XX Nomura H, Maeda M;
XX WPI; 2000-116933/10.
XX Hemopoietin receptor protein family NR8 used for diagnosis of blood
XX formation disorders -
XX Example 1; Page 42; 176pp; Japanese.
XX The invention relates to the isolation of sequences encoding human
XX haemopoietin receptor protein family NR8 genes. The NR8 family
XX sequences were initially searched for comparison on a nucleic acid
XX database with the nucleic acid probe sequence TGGAGYNNNTGAGY encoding
XX the amino acid sequence Trp-Ser-Xaa-Trp-Ser. The sequences
XX AA259258-259300 and AA290816-290925 represent specific examples of probe
XX sequences used in the search. Antibodies to the NR8 family proteins are
XX used for the diagnosis of blood formation disorders. Compounds identified
XX as binding to the proteins are used for the treatment of such disorders.
XX Sequence 15 BP; 3 A; 1 C; 7 G; 4 T; 0 other;
XX
XX Query Match 0.9%; Score 12.4; DB 1; Length 15;
XX Best Local Similarity 92.9%; Pred. No. 2.4e+02;
XX Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1581 CTCGATGAAGTCCA 1594
DB 14 CTCGATGAAGTCCA 1
XX
RESULT 434
AA290870/C
XX AA290870 standard; DNA; 15 BP.
XX
AC AA290870;
XX
DT 24-MAY-2000 (first entry)
XX
DE Human NR8 gene probe #98.
XX
XX Haemopoietin receptor family; NR8; antibody; diagnosis;
XX blood formation disorder; fusion protein; probe; ss.
XX
OS Homo sapiens.
XX
XX WO9967290-A1.
XX
XX 29-DEC-1999.
XX
XX 23-JUN-1999; 99WO-JP03351.
XX
XX 24-JUN-1998; 98JP-0214720.
XX
XX 19-OCT-1998; 98JP-0297409.
XX
XX (CHUG-) CHUGAI RES INST MOLECULAR MEDICINE INC.
XX
XX Nomura H, Maeda M;
XX
XX WPI; 2000-116933/10.
XX
XX Hemopoietin receptor protein family NR8 used for diagnosis of blood
XX formation disorders -
XX

```

```

PS Example 1; Page 42; 176pp; Japanese.
XX
XX The invention relates to the isolation of sequences encoding human
XX haemopoietin receptor protein family NR8 genes. The NR8 family
XX sequences were initially searched for comparison on a nucleic acid
XX database with the nucleic acid probe sequence TGGAGYNNNTGAGY encoding
XX the amino acid sequence Trp-Ser-Xaa-Trp-Ser. The sequences
XX AA259258-259300 and AA290816-290925 represent specific examples of probe
XX sequences used in the search. Antibodies to the NR8 family proteins are
XX used for the diagnosis of blood formation disorders. Compounds identified
XX as binding to the proteins are used for the treatment of such disorders.
XX Sequence 15 BP; 3 A; 1 C; 7 G; 4 T; 0 other;
XX
XX Query Match 0.9%; Score 12.4; DB 1; Length 15;
XX Best Local Similarity 92.9%; Pred. No. 2.4e+02;
XX Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1581 CTCGATGAAGTCCA 1594
DB 14 CTCGATGAAGTCCA 1
XX
RESULT 435
AA290883/C
XX AA290883 standard; DNA; 15 BP.
XX
AC AA290883;
XX
DT 24-MAY-2000 (first entry)
XX
DE Human NR8 gene probe #111.
XX
XX Haemopoietin receptor family; NR8; antibody; diagnosis;
XX blood formation disorder; fusion protein; probe; ss.
XX
OS Homo sapiens.
XX
XX WO9967290-A1.
XX
XX 29-DEC-1999.
XX
XX 23-JUN-1999; 99WO-JP03351.
XX
XX 24-JUN-1998; 98JP-0214720.
XX
XX 19-OCT-1998; 98JP-0297409.
XX
XX (CHUG-) CHUGAI RES INST MOLECULAR MEDICINE INC.
XX
XX Nomura H, Maeda M;
XX
XX WPI; 2000-116933/10.
XX
XX Hemopoietin receptor protein family NR8 used for diagnosis of blood
XX formation disorders -
XX
XX Example 1; Page 43; 176pp; Japanese.
XX
XX The invention relates to the isolation of sequences encoding human
XX haemopoietin receptor protein family NR8 genes. The NR8 family
XX sequences were initially searched for comparison on a nucleic acid
XX database with the nucleic acid probe sequence TGGAGYNNNTGAGY encoding
XX the amino acid sequence Trp-Ser-Xaa-Trp-Ser. The sequences
XX AA259258-259300 and AA290816-290925 represent specific examples of probe
XX sequences used in the search. Antibodies to the NR8 family proteins are
XX used for the diagnosis of blood formation disorders. Compounds identified
XX as binding to the proteins are used for the treatment of such disorders.
XX Sequence 15 BP; 3 A; 1 C; 7 G; 4 T; 0 other;
XX
XX Query Match 0.9%; Score 12.4; DB 1; Length 15;
XX Best Local Similarity 92.9%; Pred. No. 2.4e+02;
XX Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX

```

QY 1581 CTCGATGAAGTCCA 1594
 DB 14 CTCGATGACATCCA 1

RESULT 436
 ID AAZ90895/C
 AAZ90895; standard; DNA; 15 BP.

XX AC AAZ90895;
 XX
 XX 24-MAY-2000 (first entry)
 DE Human NR8 gene probe #123.
 XX
 DE Human NR8 gene probe #123.
 XX
 KW Haemopoietin receptor family; NR8; antibody; diagnosis;
 KW blood formation disorder; fusion protein; probe; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO9967290-A1.
 XX
 XX 29-DEC-1999.
 XX
 XX 23-JUN-1999; 99WO-JP03351.
 XX
 XX 24-JUN-1998; 98JP-0214720.
 XX
 XX 19-OCT-1998; 98JP-0297409.
 XX
 PA (CHUG-) CHUGAI RES INST MOLECULAR MEDICINE INC.
 XX
 XX Nomura H, Maeda M;
 XX
 XX WPI; 2000-116933/10.
 DR
 XX
 PT Hemopoietin receptor protein family NR8 used for diagnosis of blood
 PT formation disorders -
 XX
 PS Example 1; Page 44; 176pp; Japanese.

CC The invention relates to the isolation of sequences encoding human
 CC haemopoietin receptor protein family NR8 genes. The NR8 family
 CC sequences were initially searched for comparison on a nucleic acid
 CC database with the nucleic acid probe sequence TGGAGYNNNTGAGY encoding
 CC the amino acid sequence Trp-Ser-Xaa-Trp-Ser. The sequences
 CC AAZ59258-259300 and AAZ90816-290925 represent specific examples of probe
 CC sequences used in the search. Antibodies to the NR8 family proteins are
 CC used for the diagnosis of blood formation disorders. Compounds identified
 CC as binding to the proteins are used for the treatment of such disorders.
 CC
 CC Sequence 15 BP; 3 A; 1 C; 7 G; 4 T; 0 other;
 XX

SQ
 Query Match 0.9%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 2.4e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1581 CTCGATGAAGTCCA 1594
 DB 14 CTCGATGACATCCA 1

RESULT 437
 ID AAZ90902/C
 AAZ90902; standard; DNA; 15 BP.

XX AC AAZ90902;
 XX
 XX 24-MAY-2000 (first entry)
 DE Human NR8 gene probe #130.
 XX
 DE Human NR8 gene probe #130.
 XX
 KW Haemopoietin receptor family; NR8; antibody; diagnosis;

KW blood formation disorder; fusion protein; probe; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO9967290-A1.
 XX
 XX 29-DEC-1999.
 XX
 XX 23-JUN-1999; 99WO-JP03351.
 XX
 XX 24-JUN-1998; 98JP-0214720.
 XX
 XX 19-OCT-1998; 98JP-0297409.
 XX
 PA (CHUG-) CHUGAI RES INST MOLECULAR MEDICINE INC.
 XX
 XX Nomura H, Maeda M;
 XX
 XX WPI; 2000-116933/10.
 DR
 XX
 PT Hemopoietin receptor protein family NR8 used for diagnosis of blood
 PT formation disorders -
 XX
 PS Example 1; Page 44; 176pp; Japanese.

CC The invention relates to the isolation of sequences encoding human
 CC haemopoietin receptor protein family NR8 genes. The NR8 family
 CC sequences were initially searched for comparison on a nucleic acid
 CC database with the nucleic acid probe sequence TGGAGYNNNTGAGY encoding
 CC the amino acid sequence Trp-Ser-Xaa-Trp-Ser. The sequences
 CC AAZ59258-259300 and AAZ90816-290925 represent specific examples of probe
 CC sequences used in the search. Antibodies to the NR8 family proteins are
 CC used for the diagnosis of blood formation disorders. Compounds identified
 CC as binding to the proteins are used for the treatment of such disorders.
 CC
 CC Sequence 15 BP; 2 A; 3 C; 6 G; 4 T; 0 other;
 XX

SQ
 Query Match 0.9%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 2.4e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1581 CTCGATGAAGTCCA 1594
 DB 14 CTCGATGAAGTCCA 1

RESULT 438
 ID AAZ90906/C
 AAZ90906; standard; DNA; 15 BP.

XX AC AAZ90906;
 XX
 XX 24-MAY-2000 (first entry)
 DE Human NR8 gene probe #134.
 XX
 DE Human NR8 gene probe #134.
 XX
 KW Haemopoietin receptor family; NR8; antibody; diagnosis;
 KW blood formation disorder; fusion protein; probe; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO9967290-A1.
 XX
 XX 29-DEC-1999.
 XX
 XX 23-JUN-1999; 99WO-JP03351.
 XX
 XX 24-JUN-1998; 98JP-0214720.
 XX
 XX 19-OCT-1998; 98JP-0297409.
 XX
 PA (CHUG-) CHUGAI RES INST MOLECULAR MEDICINE INC.
 XX
 XX Nomura H, Maeda M;
 XX

DR WPI; 2000-116933/10.
 XX Hemopoietin receptor protein family NR8 used for diagnosis of blood
 PT formation disorders -
 XX
 XX Example 1; Page 44; 176pp; Japanese.
 XX
 CC The invention relates to the isolation of sequences encoding human
 CC haemopoietin receptor protein family NR8 genes. The NR8 family
 CC sequences were initially searched for comparison on a nucleic acid
 CC database with the nucleic acid probe sequence TGGAGYNNNTGAGY encoding
 CC the amino acid sequence Trp-Ser-Xaa-Trp-Ser. The sequences
 CC AA259258-259300 and AA250816-250925 represent specific examples of probe
 CC sequences used in the search. Antibodies to the NR8 family proteins are
 CC used for the diagnosis of blood formation disorders. Compounds identified
 CC as binding to the proteins are used for the treatment of such disorders.
 CC
 SQ Sequence 15 BP; 3 A; 3 C; 6 G; 3 T; 0 other;
 XX
 XX Query Match 0.9%; Score 12.4; DB 1; Length 15;
 XX Best Local Similarity 92.9%; Pred. No. 2.4e+02;
 XX Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1581 CTCGATGAATCTCA 1594
 Db 14 CTCGATGAATCTCA 1
 RESULT 439
 AA290908/C
 ID AA290908 standard; DNA; 15 BP.
 XX
 AC AA290908;
 XX
 DT 24-MAY-2000 (first entry)
 XX
 DE Human NR8 gene probe #136.
 XX
 KW Haemopoietin receptor family; NR8; antibody; diagnosis;
 KW blood formation disorder; fusion protein; probe; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9967290-A1.
 XX
 PD 29-DEC-1999.
 XX
 PF 23-JUN-1999; 99WO-JP03351.
 XX
 PR 24-JUN-1998; 98JP-0214720.
 PR 19-OCT-1998; 98JP-0297409.
 XX
 PA (CHUGAI) CHUGAI RES INST MOLECULAR MEDICINE INC.
 XX
 PI Nomura H, Maeda M;
 XX
 DR WPI; 2000-116933/10.
 XX
 PT Hemopoietin receptor protein family NR8 used for diagnosis of blood
 PT formation disorders -
 XX
 PS Example 1; Page 44; 176pp; Japanese.
 XX
 CC The invention relates to the isolation of sequences encoding human
 CC haemopoietin receptor protein family NR8 genes. The NR8 family
 CC sequences were initially searched for comparison on a nucleic acid
 CC database with the nucleic acid probe sequence TGGAGYNNNTGAGY encoding
 CC the amino acid sequence Trp-Ser-Xaa-Trp-Ser. The sequences
 CC AA259258-259300 and AA250816-250925 represent specific examples of probe
 CC sequences used in the search. Antibodies to the NR8 family proteins are
 CC used for the diagnosis of blood formation disorders. Compounds identified
 CC as binding to the proteins are used for the treatment of such disorders.
 CC

SQ Sequence 15 BP; 2 A; 2 C; 7 G; 4 T; 0 other;
 XX
 XX Query Match 0.9%; Score 12.4; DB 1; Length 15;
 XX Best Local Similarity 92.9%; Pred. No. 2.4e+02;
 XX Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1581 CTCGATGAATCTCA 1594
 Db 14 CTCGATGAATCTCA 1
 RESULT 440
 AAH26020/C
 ID AAH26020 standard; DNA; 15 BP.
 XX
 AC AAH26020;
 XX
 DT 05-SEP-2001 (first entry)
 XX
 DE Stem-loop antisense oligonucleotide targeting rat Syk mRNA.
 XX
 KW Syk; tyrosine kinase; rat; antisense; asthma; gene therapy;
 KW antiasthmatic; inflammation; antiinflammatory; phagocytosis; ss.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT stem_loop 1..60
 FT /tag= a
 FT stem_loop 9..17
 FT /tag= b
 FT stem_loop 36..53
 FT /tag= c
 FT modified_base 1..2
 FT /tag= d
 FT /note= "phosphorothioate linkage"
 FT modified_base 58..60
 FT /tag= e
 FT /note= "phosphorothioate linkage"
 PN US6242427-B1.
 XX
 PD 05-JUN-2001.
 XX
 PF 14-SEP-1998; 98US-0158980.
 XX
 PR 07-JUN-1996; 96US-0657884.
 PR 30-SEP-1993; 93US-0129381.
 PR 30-SEP-1994; 94US-0316425.
 PR 07-JUN-1995; 95US-0483530.
 XX
 PA (UNIV) UNIV PENNSYLVANIA.
 XX
 PI Schreiber AD, Park J;
 XX
 DR WPI; 2001-380484/40.
 XX
 PT Inhibiting the release of a mediator from a Syk-producing cell, useful
 PT in gene therapy for treating inflammatory conditions or asthma, by
 PT introducing into the cell Syk antisense oligonucleotides -
 XX
 PS Example 6; Fig 9; 35pp; English.
 XX
 CC The present sequence is that of a stem-loop rat Syk antisense
 CC oligonucleotide (ODN). The loop domain consists of 3 tandemly
 CC joined antisense ODNs (see AAH26012-14), each targeted to a
 CC different region of rat Syk mRNA. Thus, the stem-loop antisense
 CC ODN can hybridize to 3 different sites of rat Syk mRNA. It was
 CC used in an experiment to demonstrate inhibition of histamine
 CC release from histamine-containing RBL-2H3 rat mast cells using
 CC Syk antisense ODNs. The invention provides a claimed method of
 CC inhibiting the release of a mediator from a Syk-producing cell by
 CC introducing into the cell an antisense construct that targets an

CC Syk encoding sequence such that inhibition is effected. Also
CC claimed is a method of treating an inflammatory condition in a
CC patient by administering an antisense construct that targets Syk
CC encoding sequences and inhibits Syk kinase production.
XX
SQ Sequence 15 BP; 0 A; 3 C; 3 G; 9 T; 0 other;
Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Gy 1783 GACAAAGACAAGCC 1796
Db 15 GACAAAGACAAGAC 2
RESULT 441
AAD05867 standard; DNA; 15 BP.
AC AAD05867;
XX
DT 31-JUL-2001 (first entry)
XX
DE Human cholinergic receptor, muscarinic 3 gene ASO primer #11.
XX
KW Human; cholinergic receptor muscarinic 3; CHRM3; drug screening;
KW single nucleotide polymorphism; forensic application; gene therapy;
KW Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
KW sudden infant death syndrome; genotyping; haplotyping; ASO;
KW chromosome 1q41-q44; allele-specific oligonucleotide; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200129176-A2.
XX
PD 26-APR-2001.
XX
PF 12-OCT-2000; 2000WO-US28247.
XX
PR 15-OCT-1999; 99US-0159860.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Choi JY, Denton RR, Nandabalan K, Stephens JC;
XX
DR WPI; 2001-300326/31.
XX
PT Novel polymorphic variant of reference sequence for human cholinergic
PT receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
PT purposes -
XX
PS Claim 15; Page 19; 54pp; English.
XX
CC The parent relates to polymorphic variants of human cholinergic receptor,
CC muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one
CC single nucleotide polymorphism selected from cytosine at PS1, adenine at
CC PS2 or PS3, and cytosine at PS4. The invention also relates to a method
CC for genotyping and haplotyping the CHRM3 gene for identification of
CC variants. The polymorphic variant is useful for therapeutic purposes,
CC for studying the expression and biological function of CHRM3,
CC as well as for developing drugs targeting the CHRM3 protein.
CC The variant is also useful in diagnostics and forensic applications.
CC The recombinant nonhuman organism transfected with the polymorphic
CC variant is useful for studying expression of CHRM3 isogenes in vivo,
CC for in vivo screening and testing of drugs targeted against CHRM3
CC protein, and for testing the efficacy of therapeutic agents and compounds
CC for Alzheimer's disease, Sjogren's syndrome, disorders associated with
CC smooth muscle contractility and sudden infant death syndrome. The CHRM3
CC protein variant is useful in drug screening assays and its antibodies are
CC useful in immunoassays to detect CHRM3 protein variants in biological
CC samples. The present sequence is an allele-specific oligonucleotide
CC (ASO) primer used for detecting human CHRM3 gene polymorphism.

XX
SQ Sequence 15 BP; 4 A; 2 C; 7 G; 2 T; 0 other;
Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Gy 2053 CCTGAGGACGAT 2066
Db 2 CCTGAGGACGAT 15
RESULT 442
AAH18856 standard; DNA; 15 BP.
ID AAH18856
XX
AC AAH18856;
XX
DT 21-JUN-2001 (first entry)
XX
DE UCP3 polymorphism detection allele specific probe #7.
XX
KW UCP3; uncoupling protein 3; polymorphism; obesity;
KW diabetes mellitus; ss.
XX
OS Homo sapiens.
XX
PN WO200118232-A2.
XX
PD 15-MAR-2001.
XX
PF 08-SEP-2000; 2000WO-US24784.
XX
PR 08-SEP-1999; 99US-0152789.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI (STEP/) STEPHENS J C.
XX
PI Chew A, Choi JY, Denton RR, Nandabalan K;
XX
DR WPI; 2001-218562/22.
XX
PT Nucleic acid encoding uncoupling protein 3 (mitochondrial, proton
PT carrier) (UCP3) proteins comprising single nucleotide polymorphisms,
PT useful for the design of drugs for treating obesity -
XX
PS Claim 15; Page 21; 94pp; English.
XX
CC The present invention relates to the human uncoupling protein 3
CC (mitochondrial, proton carrier) (UCP3) gene and polymorphisms.
CC The polymorphisms are associated with obesity, especially
CC diabetes mellitus associated obesity. They polymorphisms may be
CC identified and analysed to determine whether an individual is
CC susceptible to obesity and may be used as the basis for targeted
CC design of drugs to treat obesity. The present sequence was used in
CC the identification and amplification of UCP3 polymorphisms.
XX
SQ Sequence 15 BP; 4 A; 2 C; 5 G; 4 T; 0 other;
Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Gy 1444 ATGGGTGTAACAGT 1457
Db 2 ATGGGTGTAACAGT 15
RESULT 443
AAF69549 standard; DNA; 15 BP.
ID AAF69549
XX
AC AAF69549;

```

XX 18-APR-2001 (first entry)
XX Human IL4Ralpha gene probe #189.
DE
XX Polymorphism; human; interleukin 4 receptor-alpha; IL4R-alpha;
XX allergic disease; probe; ss.
XX
XX Homo sapiens.
OS
XX WO200104270-A1.
XX
XX 18-JAN-2001.
XX
XX 13-JUL-2000; 2000WO-US19094.
XX
XX 13-JUL-1999; 99US-0143435.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Chew A, Denton RR, Duda A, Nandabalan K, Stephens JC;
PI Windemuth AK;
XX WPI; 2001-103078/11.
XX
XX New isolated polynucleotide useful for the identification of
PT therapeutics in allergic diseases is new -
XX
XX Claim 15; Page 45; 188pp; English.
XX
XX The present invention relates to polymorphisms of the human interleukin 4
CC receptor-alpha gene (IL4R-alpha; see AAF57718 for the reference
CC sequence). Polynucleotides comprising polymorphic gene variants are
CC useful for therapeutic purposes. For example, where a patient may benefit
CC from expression of a particular IL4Ralpha protein isoform, an expression
CC vector encoding the isoform may be administered to the patient. It may
CC desirable to decrease or block expression of a particular IL4Ralpha
CC isogene, which may be done by turning off by transforming a targeted
CC organ, tissue or cell population with an expression vector that expresses
CC high levels of untranslatable mRNA for the isogene. Specific therapeutics
CC identified by these methods may be useful for allergic diseases. The
CC present sequence is a probe for human IL4R-alpha.
XX
XX Sequence 15 BP; 3 A; 3 C; 6 G; 3 T; 0 other;
SQ
Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1543 CTGGGAGACAGCT 1556
DB 1 CTGGGAGACAGCT 14

```

```

OS Homo sapiens.
XX
XX WO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU00693.
XX
XX 21-JUN-1999; 99US-0140345.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
XX Example 6; Page 40; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-745161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids,
CC keratosis, neoplasia, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
XX Sequence 15 BP; 5 A; 7 C; 2 G; 1 T; 0 other;
SQ
Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1586 TGAACCTCCACACC 1599
DB 2 TGAACCTCCACACC 15

```

```

RESULT 444
AAF46143
ID AAF46143 standard; DNA; 15 BP.
XX
XX AAF46143;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGFBP2 oligonucleotide #982.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytoskeletal; dermatological; cardiac; virucide; ophthalmological; keloid;
XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX

```

```

RESULT 445
AAF46144
ID AAF46144 standard; DNA; 15 BP.
XX
XX AAF46144;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGFBP2 oligonucleotide #983.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytoskeletal; dermatological; cardiac; virucide; ophthalmological; keloid;
XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX Homo sapiens.
XX
XX WO200078341-A1.
XX

```

```
BD 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU00693.
XX
XX 21-JUN-1999; 99US-0140345.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by
XX administering UV (ultra-violet) treatment (optional) and an antisense
XX nucleic acid that inhibits or reduces growth factor mediated cell
XX proliferation and/or inflammation -
XX
XX Example 6; Page 40; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects
XX of skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and
XX AAF45153-445161). The method is useful for ameliorating the effects of
XX psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids,
XX keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
XX skin, a hyperneovascular condition such as a neovascular condition of the
XX retina, brain or skin, growth factor-mediated malignancies, other
XX sclerotic disease, kidney disease, hyperproliferation of the inside of
XX blood vessels or any other hyperplasia.
XX
XX Sequence 15 BP; 5 A; 7 C; 2 G; 1 T; 0 other;
XX
XX Query Match 0.9%; Score 12.4; DB 1; Length 15;
XX Best Local Similarity 92.9%; Pred. No. 2.4e+02;
XX Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1586 TGAACCTCCACACC 1599
DB 1 TGAACCTCCACACC 14
XX
RESULT 446
AAF46266
ID AAF46266 standard; DNA; 15 BP.
XX
XX AAF46266;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGFBP2 oligonucleotide #1105.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cyostatic; dermatological; cardiant; vitruide; ophthalmological; keloid;
XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX Homo sapiens.
XX
XX OS
XX WO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU00693.
XX
XX 21-JUN-2000; 2000WO-AU00693.
XX
```

```
BR 21-JUN-1999; 99US-0140345.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by
XX administering UV (ultra-violet) treatment (optional) and an antisense
XX nucleic acid that inhibits or reduces growth factor mediated cell
XX proliferation and/or inflammation -
XX
XX Example 6; Page 41; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects
XX of skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and
XX AAF45153-445161). The method is useful for ameliorating the effects of
XX psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids,
XX keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
XX skin, a hyperneovascular condition such as a neovascular condition of the
XX retina, brain or skin, growth factor-mediated malignancies, other
XX sclerotic disease, kidney disease, hyperproliferation of the inside of
XX blood vessels or any other hyperplasia.
XX
XX Sequence 15 BP; 3 A; 7 C; 5 G; 0 U; 0 other;
XX
XX Query Match 0.9%; Score 12.4; DB 1; Length 15;
XX Best Local Similarity 92.9%; Pred. No. 2.4e+02;
XX Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1500 CAGCAGCCAGCCGG 1513
DB 2 CCGCAGCCAGCCGG 15
XX
RESULT 447
AAF46267
ID AAF46267 standard; DNA; 15 BP.
XX
XX AAF46267;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGFBP2 oligonucleotide #1106.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cyostatic; dermatological; cardiant; vitruide; ophthalmological; keloid;
XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX Homo sapiens.
XX
XX OS
XX WO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU00693.
XX
XX 21-JUN-1999; 99US-0140345.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
```

PI Wraight CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by
 PT administering UV (ultra-violet) treatment (optional) and an antisense
 PT nucleic acid that inhibits or reduces growth factor mediated cell
 PT proliferation and/or inflammation -
 XX
 XX Example 6; Page 41; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects
 CC of skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and
 CC AAF45153-F45161). The method is useful for ameliorating the effects of
 CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids,
 CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
 CC skin, a hyperneovascular condition such as a neovascular condition of the
 CC retina, brain or skin, growth factor-mediated malignancies, other
 CC sclerotic disease, kidney disease, hyperproliferation of the inside of
 CC blood vessels or any other hyperplasia.
 CC
 XX Sequence 15 BP; 2 A; 7 C; 5 G; 1 T; 0 other;
 SQ
 Query Match 0.9%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 2.4e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1500 CAGCAGCCAGCCGG 1513
 Db 1 CCGCAGCCAGCCGG 14
 RESULT 448
 AAF49086/C
 ID AAF49086 standard; DNA; 15 BP.
 XX
 AC AAF49086;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGF-I oligonucleotide #46.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cyrostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU00693.
 XX
 PR 21-JUN-1999; 99US-0140345.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wraight CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 XX
 DR Wraight CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 XX

PT Ameliorating the effects of a disorder, e.g. psoriasis, by
 PT administering UV (ultra-violet) treatment (optional) and an antisense
 PT nucleic acid that inhibits or reduces growth factor mediated cell
 PT proliferation and/or inflammation -
 XX
 XX Example 8; Page 61; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects
 CC of skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and
 CC AAF45153-F45161). The method is useful for ameliorating the effects of
 CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids,
 CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
 CC skin, a hyperneovascular condition such as a neovascular condition of the
 CC retina, brain or skin, growth factor-mediated malignancies, other
 CC sclerotic disease, kidney disease, hyperproliferation of the inside of
 CC blood vessels or any other hyperplasia.
 CC
 XX Sequence 15 BP; 3 A; 4 C; 4 G; 4 T; 0 other;
 SQ
 Query Match 0.9%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 2.4e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1488 GAGCCAGACTTCA 1501
 Db 15 GGAGCCAGACTTCA 2
 RESULT 449
 AAF49087/C
 ID AAF49087 standard; DNA; 15 BP.
 XX
 AC AAF49087;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGF-I oligonucleotide #47.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cyrostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU00693.
 XX
 PR 21-JUN-1999; 99US-0140345.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wraight CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 XX
 DR Wraight CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by
 PT administering UV (ultra-violet) treatment (optional) and an antisense
 PT nucleic acid that inhibits or reduces growth factor mediated cell
 PT proliferation and/or inflammation -

XX Example 8; Page 61; 201pp; English.
PS
XX The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-145161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
SQ Sequence 15 BP; 2 A; 4 C; 5 G; 4 T; 0 other;
Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1488 GAGCGACACTTCA 1501
Db 14 GGAGCGACACTTCA 1
RESULT 450
AAF51575
ID AAF51575 standard; DNA; 15 BP.
AC AAF51575;
XX
XX 30-MAR-2001 (first entry)
DT
XX IGF-I oligonucleotide #2535.
DE
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cyrostatic; dermatological; cardiant; vitruclide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX WO200078341-A1.
PN
XX 28-DEC-2000.
PD
XX 21-JUN-2000; 2000WO-AU00693.
PR
XX 21-JUN-1999; 99US-0140345.
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
PI
XX WPI; 2001-041421/05.
DR
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
XX Example 8; Page 77; 201pp; English.
PS
XX The present invention relates to a method for ameliorating the effects

CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-145161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
SQ Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 other;
Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2060 AGCAGATGACCTTC 2073
Db 1 AGCAGATGACATTC 14
RESULT 451
AAF52664
ID AAF52664 standard; DNA; 15 BP.
AC AAF52664;
XX
XX 30-MAR-2001 (first entry)
DT
XX IGF-I oligonucleotide #3624.
DE
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cyrostatic; dermatological; cardiant; vitruclide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX WO200078341-A1.
PN
XX 28-DEC-2000.
PD
XX 21-JUN-2000; 2000WO-AU00693.
PR
XX 21-JUN-1999; 99US-0140345.
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
PI
XX WPI; 2001-041421/05.
DR
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
XX Example 8; Page 84; 201pp; English.
PS
XX The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,

CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF5151 and
CC AAF5153-P45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.

XX
SQ Sequence 15 BP; 1 A; 4 C; 5 G; 5 T; 0 other;

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2326 GATGTCGTGTCCTT 2339
DB 2 GACGCTGTGTCCTT 15
|||||
|||||

RESULT 452
AAF52781
ID AAF52781 standard; DNA; 15 BP.
XX
AC AAF52781;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #3741.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; vitruide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.

XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
PS Example 8; Page 85; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF5151 and
CC AAF5153-P45161). The method is useful for ameliorating the effects of

CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.

XX
SQ Sequence 15 BP; 6 A; 5 C; 3 G; 1 T; 0 other;

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2443 AAGCCAGCAACTG 2456
DB 2 AAGCCAGCAACTG 15
|||||
|||||

RESULT 453
AAF52782
ID AAF52782 standard; DNA; 15 BP.
XX
AC AAF52782;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #3742.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; vitruide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.

XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
PS Example 8; Page 85; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF5151 and
CC AAF5153-P45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other

CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 6 A; 4 C; 3 G; 2 T; 0 other;
Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2443 AAGCAGCCCACTG 2456
|||||
1 AAGCAGACCACTG 14
Db
RESULT 454
AAFS3986/C
ID AAF53986 standard; DNA; 15 BP.
XX
AC AAF53986;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #4946.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
KM
XX Homo sapiens.
OS
XX WO200078341-A1.
PN
XX 28-DEC-2000.
PD
XX 21-JUN-2000; 2000WO-AU00693.
PF
XX 21-JUN-1999; 99US-0140345.
PR
XX (MURD-) MURDOCH CHILDRENS RES INST.
PA
XX (MURD-) MURDOCH CHILDRENS RES INST.
PI
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
DR
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
XX Example 8; Page 93; 201pp; English.
PS
XX The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation, of
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 3 A; 3 C; 2 G; 7 T; 0 other;

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1845 AGAGAAAGACCTT 1858
|||||
15 AGAGAAAGACCTAT 2
Db
RESULT 455
AAFS3987/C
ID AAF53987 standard; DNA; 15 BP.
XX
AC AAF53987;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #4947.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
KM
XX Homo sapiens.
OS
XX WO200078341-A1.
PN
XX 28-DEC-2000.
PD
XX 21-JUN-2000; 2000WO-AU00693.
PF
XX 21-JUN-1999; 99US-0140345.
PR
XX (MURD-) MURDOCH CHILDRENS RES INST.
PA
XX (MURD-) MURDOCH CHILDRENS RES INST.
PI
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
DR
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
XX Example 8; Page 93; 201pp; English.
PS
XX The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation, of
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 2 A; 4 C; 2 G; 7 T; 0 other;

OY 1845 AGAGAAAGACCTTT 1858
 Db 14 AGAGAAAGACCTTAT 1

RESULT 456
 AAC62187/C
 ID AAC62187 standard; DNA; 15 BP.

AC AAC62187;

DT 06-MAR-2001 (first entry)

DE Oligomer antiparallel to NdhOT mRNA, specific to ovarian tumour cells.

XX Biologically active compound; cellular metabolism; DNA replication;
 KW RNA transcription; RNA translation; RNA elongation; RNA processing;
 KW protein synthesis; protein processing; cellular differentiation;
 KW cell division; ion channel transmission; cellular protein; toxin;
 KW RNA transport; cellular oxidation; tumour suppressor p53;
 KW NdhOT; ss.

XX Synthetic.
 OS Homo sapiens.

PN WO200061775-A1.

PD 19-OCT-2000.

PF 08-APR-1999; 99WO-IB00616.

PR 08-APR-1999; 99WO-IB00616.

PA (SERG/) SERGEEV P.

PI Sergeev P;

XX WPI; 2001-006911/01.

XX Novel methods for the synthesis of biologically active compounds from
 PT inactive precursors in the cells of living organisms, useful for
 PT producing proteins or polynucleotides -

XX Example 10; Page 35; 65pp; English.

XX The specification describes a method of synthesis of biologically active
 CC substances of determined structure directly in the cells of living
 CC organisms containing specific RNA or DNA sequence. The method is based
 CC on the hybridisation of two or more oligomers bound with biologically
 CC inactive substances to specific RNA or DNA in vivo in the cells of
 CC living organisms. After hybridisation of the oligomers, the biologically
 CC inactive precursors bound to the oligomers can interact with each other
 CC to make the active form of the substances. This changing of properties
 CC is due to chemical reactions which bind the biologically inactive
 CC precursors through a chemical bond into a biologically active form of
 CC the whole compound. The methods are useful for producing biologically
 CC active compounds from inactive precursors. These compounds may be
 CC inhibitors or stimulators of cellular metabolism, DNA replication, RNA
 CC transcription, RNA translation, RNA elongation RNA processing, protein
 CC synthesis, protein processing, cellular differentiation, cell division,
 CC ion channel transmission, cellular protein and RNA transport, RNA
 CC processes of cellular oxidation, toxins, proteins or RNAs. Oligomers
 CC AAC62181-94 are used to bind peptides AAB30523-36. The peptides are
 CC fragments of the tumour suppressor p53, and the oligomers are
 CC antiparallel to human NdhOT, which is specific to ovarian cancer cells.
 CC The method of the invention is used to produce the tumour suppressor
 CC protein p53 from the bound peptides and oligomers.

XX Sequence 15 BP; 3 A; 6 C; 3 G; 3 T; 0 other;

Query Match 0.9%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 2.4e+02;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 1649 TGCTGGCAGGCGTC 1662
 Db 15 TGCTGGCAGGATC 2

RESULT 457
 ABX15428/C
 ID ABX15428 standard; DNA; 15 BP.

AC ABX15428;

DT 08-APR-2003 (first entry)

DE Human Syk mRNA target III antisense oligonucleotide.

XX Human; ss; Syk; kinase; immunosuppressive; dermatological;
 KW antiinflammatory; antiarthritic; antirheumatic; antiaesthetic;
 KW phagocytosis; immune complex; kinase inhibitor; autoimmune disease;
 KW immune mediated disease; asthma; systemic lupus erythematosus;
 KW rheumatoid arthritis; antisense.

XX Homo sapiens.

PN US2002068703-A1.

PD 06-JUN-2002.

PF 20-MAR-2001; 2001US-0811492.

PR 14-SEP-1998; 98US-0158980.

PR 30-SEP-1993; 93US-0129381.

PR 07-JUN-1994; 94US-0316425.

PR 07-JUN-1995; 95US-0483530.

PR 07-JUN-1996; 96US-0657884.

PA (UTPE-) UNIV PENNSYLVANIA.

PI Schreiber AD, Park J;

XX WPI; 2003-165571/16.

XX Preventing phagocytosis of immune complexes used for treating e.g.
 PT autoimmune diseases comprises introducing inhibitor of kinase
 PT endogenous to phagocytic cells associated with Fc receptor at membrane
 PT of cells -

XX Example 6; Fig 9; 26pp; English.

XX This invention relates to a novel method for preventing phagocytosis of
 CC immune complexes comprising introducing an inhibitor of a kinase
 CC endogenous to phagocytic cells associated with an Fc receptor at the
 CC membrane of the cells under conditions so that the phagocytic potential
 CC of the cells is inhibited. The method of the invention may have
 CC immunosuppressive, dermatological, antinflammatory, antiarthritic,
 CC antirheumatic and antistimatic activities and may be used as a kinase
 CC inhibitor. The method and compositions of the invention may be used for
 CC modulating the clearance of antibody coated cells, viruses and soluble
 CC antigens by inhibiting phagocytosis and modulating the interaction of
 CC immune complexes with cellular to tissue Fc receptors. The method is
 CC used for treating autoimmune diseases, immune mediated diseases e.g.
 CC asthma and immune complex diseases e.g. lupus erythematosus and
 CC rheumatoid arthritis, and for preventing immune complexes deposition in
 CC tissues e.g. the kidneys and in the joints. The present sequence
 CC represents a human Syk kinase gene target III antisense oligonucleotide
 CC used in the method of the invention.

XX Sequence 15 BP; 0 A; 3 C; 3 G; 9 T; 0 other;

Query Match 0.9%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 2.4e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1783 GACAAAGCAAGCC 1796
|||||
Db 15 GACAAAGCAAGAC 2
|||||
RESULT 458
AAD49046,
ID AAD49046 standard; DNA; 15 BP.
XX
XX AAD49046;
XX
XX 07-MAR-2003 (first entry)
XX
XX MWD gene androgen responsive element (ARE).
XX
XX Androgen receptor; androgen-associated disorder; prostate cancer; acne;
XX benign prostatic hypertrophy; hirsutism; androgen insensitivity syndrome;
XX male pattern baldness; Stein-Leventhal syndrome; infertility; cytostatic;
XX X-linked spinal bulbar muscular atrophy; antihypertensive; dermatological;
XX depilatory; androgen responsive element; ARE; MWD gene; ds.
XX
XX Unidentified.
XX
XX WO200272612-A2.
XX
XX 19-SEP-2002.
XX
XX 12-MAR-2002; 2002WO-US07487.
XX
XX 12-MAR-2001; 2001US-275240P.
XX 28-JAN-2002; 2002US-352399P.
XX
XX (PRAE-) PRAECIS PHARM INC.
XX
XX Joyal JL, Mueller J, Oza VB, Findels MA;
XX
XX WPI; 2003-067363/06.
XX
XX New peptide modulators of androgen receptor, useful for treating
XX androgen-associated disorder, e.g. prostate cancer, particularly
XX hormonally refractive prostate cancer, colon cancer, lung cancer, acne,
XX or hirsutism -
XX
XX Disclosure; Page 26; 68pp; English.
XX
XX The present invention relates to novel peptide modulators of androgen
XX receptor. The peptides of the invention are useful for treating androgen-
XX associated disorders such as prostate cancer, particularly hormonally
XX refractive prostate cancer, colon cancer, lung cancer, benign prostatic
XX hyperplasia, acne, hirsutism, male pattern baldness, Stein-Leventhal
XX syndrome, androgen insensitivity syndrome, infertility, endometrial
XX cancer and X-linked spinal bulbar muscular atrophy. The present DNA
XX sequence is MWD gene androgen responsive element (ARE).
XX
XX Sequence 15 BP; 2 A; 3 C; 3 G; 7 T; 0 other;
XX
XX Query Match 0.9%; Score 12.4; DB 1; Length 15;
XX Best Local Similarity 92.9%; Pred. No. 2.4e+02;
XX Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2633 GAAGTCTGTTGTTCT 2646
|||||
Db 2 GAAGTCTGTTGTTCT 15
|||||
RESULT 459
AAT60192/C
ID AAT60192 standard; DNA; 16 BP.
XX
XX AAT60192;
XX
XX 03-FEB-1998 (first entry)
XX
XX

XX
XX Synthetic PCNA ribozyme recognition site #4.
XX
XX Ribozyme; hairpin; hammerhead; proliferating cell nuclear antigen;
XX growth factor; oncogene; vascular tissue; SMC; PCNA; recognition site;
XX restenosis; smooth muscle cell proliferation; ss.
XX
XX Synthetic.
XX
XX WO9710334-A2.
XX
XX 20-MAR-1997.
XX
XX 12-SEP-1996; 96WO-US14838.
XX
XX 12-SEP-1995; 95US-0527060.
XX
XX (IMMU-) IMMUSOL INC.
XX
XX Goldenberg T, Tritz R;
XX
XX WPI; 1997-202230/18.
XX
XX New hairpin and hammerhead ribozyme(s) - which inhibit abnormal
XX smooth muscle cell proliferation in vascular tissue, partic. for
XX preventing or treating restenosis
XX
XX Example 1; Page 15; 50pp; English.
XX
XX This sequence represents a ribozyme recognition site for the
XX proliferating cell nuclear antigen (PCNA) gene which is cleaved by a
XX hairpin ribozyme at position 867 and by a hammerhead ribozyme at position
XX 869. Novel ribozymes are being investigated for their ability to inhibit
XX the activity of a growth factor (e.g. PCNA) responsible for abnormal
XX smooth muscle cell (SMC) proliferation in vascular tissue leading to
XX restenosis. The ribozymes can also directly block the production of
XX oncogenes and cell regulatory factors involved with SMC growth
XX following vascular injury.
XX
XX Sequence 16 BP; 4 A; 4 C; 1 G; 7 T; 0 other;
XX
XX Query Match 0.9%; Score 12.4; DB 1; Length 16;
XX Best Local Similarity 92.9%; Pred. No. 2.6e+02;
XX Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2169 TTTGTTACAGAAA 2182
|||||
Db 14 TTTGTTACAGAAA 1
|||||
RESULT 460
AAA86559/C
ID AAA86559 standard; DNA; 16 BP.
XX
XX AAA86559;
XX
XX 04-DEC-2000 (first entry)
XX
XX PCNA hairpin ribozyme recognition site #7.
XX
XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic;
XX restenosis; ss.
XX
XX Mammalia.
XX
XX WO200032765-A2.
XX
XX 08-JUN-2000.
XX
XX 06-DEC-1999; 99WO-US28772.
XX
XX 04-DEC-1998; 98US-0110954.
XX
XX

PA (IMMU-) IMMUSOL INC.
XX
PI Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
DR WPI; 2000-412314/35.
XX
PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1 -
XX
PS Example 1; Page 16; 109pp; English.
XX
CC The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AA82415 to AA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells.
CC The ribozyme is resistant to endonuclease activity and hence is
CC efficient in restenosis treatment.
XX
SQ Sequence 16 BP; 4 A; 4 C; 1 G; 7 T; 0 other;
XX
Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2169 TTGGTACAGAAA 2182
Db 14 TTGGTGACAGAAA 1
RESULT 461
AA86780/c
ID AA86780 standard; DNA; 16 BP.
XX
AC AA86780;
XX
DT 04-DEC-2000 (first entry)
XX
DE PCNA hammerhead ribozyme recognition site #5.
XX
KM Ribozyme; hairpin; hammerhead; gene therapy; vasotropic;
KM restenosis; ss.
XX
OS Mammalia.
XX
PN WO200032765-A2.
XX
PD 08-JUN-2000.
XX
PF 06-DEC-1999; 99WO-US28772.
XX
PR 04-DEC-1998; 98US-0110954.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
DR WPI; 2000-412314/35.
XX
PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1 -
XX
PS Example 1; Page 24; 109pp; English.
XX
CC The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AA82415 to AA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells.

CC The ribozyme is resistant to endonuclease activity and hence is
CC efficient in restenosis treatment.
XX
SQ Sequence 16 BP; 4 A; 4 C; 1 G; 7 T; 0 other;
XX
Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2169 TTGGTACAGAAA 2182
Db 14 TTGGTGACAGAAA 1
RESULT 462
AAH61725/c
ID AAH61725 standard; DNA; 16 BP.
XX
AC AAH61725;
XX
DT 10-SEP-2001 (first entry)
XX
DE PCNA hairpin/hammerhead ribozyme recognition site SEQ ID NO:4149.
XX
KM Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KM recognition site; target; ribozyme binding site; eye disease; vulnary;
KM proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KM cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KM matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KM antiproliferative; dermatological; antiseborrheic; antidiabetic; vitruide;
KM antisticking; ophthalmological; keratolytic; gene therapy; viral wart;
KM atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KM basal cell carcinoma; seboreic wart; vitreoretinopathy; scar;
KM sickle cell retinopathy; ss.
XX
OS Homo sapiens.
XX
OS Synthetic.
XX
PN WO200130362-A2.
XX
PD 03-MAY-2001.
XX
PF 26-OCT-2000; 2000WO-US29500.
XX
PR 26-OCT-1999; 99US-0161532.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Robbins JM, Tritz R;
XX
DR WPI; 2001-300427/31.
XX
PT Treating proliferative skin or eye diseases and scarring, using
PT ribozymes that cleave RNA encoding cytokines involved in inflammation,
PT matrix metalloproteinases, growth factors and cell-cycle dependent
PT kinases -
XX
PS Example 1; Page 20; 408pp; English.
XX
CC The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antiproliferative,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisticking,
CC ophthalmological, vulnary, keratolytic and vitruide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative
CC skin diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seboreic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic

CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention.

XX Sequence 16 BP; 4 A; 4 C; 1 G; 7 T; 0 other;

SO Query Match 0.9%; Score 12.4; DB 1; Length 16;

Best Local Similarity 92.9%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2169 TTGTGTACAGAAA 2182
Db 14 TTGTGTACAGAAA 1

RESULT 463

AAH61946/C
ID AAH61946 standard; DNA; 16 BP.

XX AAH61946;

DT 10-SEP-2001 (first entry)

XX PCNA hammerhead ribozyme recognition site SEQ ID NO:4370.

XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
XX recognition site; target; ribozyme binding site; eye disease; vulnary;
XX proliferative disease; skin disease; psoriasis; diabetic retinopathy;
XX cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
XX matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
XX antiproliferative; dermatological; antiseborrheic; antidiabetic; virucide;
XX anticlotting; ophthalmological; keratolytic; gene therapy; viral wart;
XX atopic dermatitis; actinic keratosis; squamous cell carcinoma;
XX basal cell carcinoma; seborrhic wart; vitreoretinopathy; scar;
XX sickle cell retinopathy; ss.

XX Homo sapiens.
OS Synthetic.

XX WO200130362-A2.

XX 03-MAY-2001.

XX 26-OCT-2000; 2000WO-US29500.

XX 26-OCT-1999; 99US-0161532.

XX (IMMU-) IMMUSOL INC.

XX Robbins JM, Tritelz R;

XX WPI, 2001-300427/31.

PT Treating proliferative skin or eye diseases and scarring, using
PT ribozymes that cleave RNA encoding cytokines involved in inflammation,
PT matrix metalloproteinases, growth factors and cell-cycle dependent
PT kinases -

PS Disclosure; Page 394; 408bp; English.

XX The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antiproliferative,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, anticlotting,
CC ophthalmological, vulnary, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative

CC skin diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrhic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention.

XX Sequence 16 BP; 4 A; 4 C; 1 G; 7 T; 0 other;

SO Query Match 0.9%; Score 12.4; DB 1; Length 16;

Best Local Similarity 92.9%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2169 TTGTGTACAGAAA 2182
Db 14 TTGTGTACAGAAA 1

RESULT 464

AAH5233/C
ID AAH5233 standard; DNA; 16 BP.

XX AAH5233;

DT 07-SEP-2001 (first entry)

XX Mycobacterium kansasii oligonucleotide probe KANSASII.

XX Non-tuberculous mycobacteria; rpoB gene fragment; NTM; HIV; PRA; RFLP;
XX PCR-restriction fragment length polymorphism analysis; probe; ss.

XX Mycobacterium kansasii.

XX WO200131061-A1.

XX 03-MAY-2001.

XX 27-OCT-2000; 2000WO-KR01223.

XX 27-OCT-1999; 99KR-0046795.

XX (ERUM-) ERUME BIOTECH CO LTD.

XX Lee H, Park YK, Bai G, Kim S, Cho S, Kim Y, Park HJ;

XX WPI, 2001-300520/31.

PT New DNA fragments from the rpoB gene of mycobacteria, useful for
PT diagnosis and identification of many mycobacterial species by
PT restriction fragment length polymorphism -
PS Disclosure; Page 15; 50bp; English.

XX The present sequence for Mycobacterium kansasii oligonucleotide
CC probe KANSASII can be used to detect M. kansasii. It is 1 of 16
CC oligonucleotide probes (AAH52327-AAH5242) that can be used to
CC detect specific mycobacterial species. The probes are described in an
CC invention relating to the use of rpoB gene fragments (AAH5201-AAH5224)
CC from various Mycobacterium species. These rpoB gene fragments can be used
CC in the diagnosis and identification of Mycobacterium species using a
CC novel PCR-restriction fragment length polymorphism analysis (PRA)
CC method. The method comprises obtaining a restriction fragment length
CC polymorphism (RFLP) pattern of the 24 rpoB gene fragments; isolating,
CC amplifying and digesting the DNA fragment from the microorganism to
CC be identified and comparing the RFLP patterns from the known rpoB gene
CC fragments with the unidentified fragment. The rpoB gene fragments
CC are useful to identify a wide range of Mycobacterium species, e.g. for
CC diagnosis or to obtain epidemiological and pathogenesis information for
CC selection of appropriate therapies, including M. tuberculosis, M. leprae
CC and non-tuberculous mycobacteria (NTM) encountered in subjects infected
CC with human immunodeficiency virus (HIV). Analysis of the rpoB gene

CC other cardiovascular diseases, and sitosterolemia-associated condition
 CC including arthritis, xanthomas and chronic haemolytic anaemia. SSG
 CC expression cassette is useful in the production of transgenic non-human
 CC animals. SSG genes and their homologues are useful as tools for a number
 CC of applications including diagnosing sitosterolemia and other
 CC cardiovascular disorders, for forensics and paternity determinations,
 CC and for treating any of a large number of SSG associated diseases. The
 CC present sequence is human SSG exon splice site.

XX Sequence 16 BP; 3 A; 3 C; 6 G; 4 T; 0 other;

Qy Query Match 0.9%; Score 12.4; DB 1; Length 16;

Best Local Similarity 92.9%; Pred. No. 2.6e+02; Indels 0; Gaps 0;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 1649 TGCTGCGCAGGAGT 1662
 Db 1 TGCTGCGCAGGAGT 14

RESULT 467

ABT33749
 ID ABT33749 standard; DNA; 16 BP.

XX ABT33749;

XX 29-MAY-2003 (first entry)

XX Ribozyme substrate binding sequence SEQ ID No 100.

XX Cyrostatic; gene therapy; apoptosis; cancer growth inhibition;

XX drug screening; ss.

XX Unidentified.

XX WO200292840-A2.

XX 21-NOV-2002.

XX 14-MAY-2002; 2002WO-US15198.

XX 14-MAY-2001; 2001US-290927P.

XX (IMMU-) IMMUSOL INC.

XX Tritz R, Kelly B, Habiba C, Robbins J, Barber J;

XX WPI, 2003-129308/12.

XX New isolated nucleic acid molecule useful for regulating apoptosis
 PT induction in cells, for inhibiting the growth of cancer in subjects,
 PT and for drug screening -

XX Example 3; Page 42; 153pp; English.

XX The invention relates to a novel isolated molecule comprising bases 2-8
 CC or 13-16 of 2 16 base pair sequences, or comprising a 1731 base pair
 CC sequence, all given in the specification or at least 95 % identity with
 CC the 1731 bp sequence. The nucleic acid molecule is useful in regulating
 CC apoptosis in cells and in drug screening. The method is useful in
 CC facilitating the induction of apoptosis in cells, in identifying an agent
 CC that can facilitate the induction of apoptosis in cells, and in
 CC inhibiting the growth of a cancer. This polynucleotide sequence
 CC represents a ribozyme binding substrate sequence relating to the
 CC invention.

XX Sequence 16 BP; 7 A; 3 C; 3 G; 3 T; 0 other;

Qy Query Match 0.9%; Score 12.4; DB 1; Length 16;

Best Local Similarity 92.9%; Pred. No. 2.6e+02; Indels 0; Gaps 0;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2624 CTGACACAGAGT 2637

Db 1 CTGACACAGAGT 14

RESULT 468

AAD48398
 ID AAD48398 standard; DNA; 16 BP.

XX AAD48398;

XX 24-FEB-2003 (first entry)

XX Forward PCR primer #6 used for LOH analysis.

XX Breast tumour; loss of heterozygosity; LOH; tumour; neoplastic disease;

XX PCR; primer; ss.

XX Unidentified.

XX WO200276286-A2.

XX 03-OCT-2002.

XX 20-MAR-2002; 2002WO-US09068.

XX 23-MAR-2001; 2001US-0816460.

XX (CALP-) CALIFORNIA PACIFIC MEDICAL CENT RES INST.

XX Dairkee SH, Li Z;

XX WPI, 2003-046744/04.

XX Determining the likelihood of tumor re-occurrence in a patient
 PT previously diagnosed with a breast tumor to determine treatment
 PT modalities, comprises analyzing the cell sample for loss of
 PT heterozygosity to chromosomal locus 3p24.3 -

XX Example 1; Page 38; 42pp; English.

XX The invention relates to a method of determining the likelihood of
 CC tumour re-occurrence in a patient previously diagnosed with a breast
 CC tumour. The method involves analysing the target cell sample for loss
 CC of heterozygosity (LOH) to chromosomal locus 3p24.3. The method is
 CC useful for determining the likelihood of tumour re-occurrence in a
 CC patient previously diagnosed with a breast tumour and subsequently
 CC useful in determining the degree of aggressive treatment indicated.
 CC The prognostic method is especially useful in making decisions
 CC concerning treatment modalities, including therapeutic intervention,
 CC diagnostic criteria such as disease staging and disease monitoring,
 CC and surveillance for metastasis or recurrence of neoplastic disease.
 CC The present sequence is a PCR primer used for LOH analysis. This
 CC primer is used to illustrate the method of the invention.

XX Sequence 16 BP; 2 A; 5 C; 4 G; 5 T; 0 other;

Qy Query Match 0.9%; Score 12.4; DB 1; Length 16;

Best Local Similarity 92.9%; Pred. No. 2.6e+02; Indels 0; Gaps 0;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2500 GTGCCCTCCAGAG 2513
 Db 1 GTGCCCTCCAGAG 14

Search completed: December 1, 2003, 11:55:07
 Job time : 8 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 1, 2003, 11:57:58 ; Search time 3 Seconds

(without alignments)
4.461 Million cell updates/sec

Title: us-09-954-556-3

Perfect score: 1404
Sequence: 1 tggagatattcttctacctg.....cctcagttatcacacataaa 1404

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 279 seqs, 4766 residues

Total number of hits satisfying chosen parameters: 558

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 279 summaries

Database : rni.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	33	2.4	39	1	US-08-471-570-15 Sequence 15, Appl
2	25.8	1.8	30	1	US-07-997-133-4 Sequence 4, Appl
3	25.8	1.8	30	1	US-07-997-133-4 Sequence 4, Appl
4	22.4	1.6	28	1	US-07-631-717A-5 Sequence 5, Appl
5	22.4	1.6	28	1	US-08-166-717D-5 Sequence 5, Appl
6	21.4	1.5	25	1	US-08-678-039A-4 Sequence 4, Appl
7	21	1.5	21	1	US-07-947-683-14 Sequence 14, Appl
8	21	1.5	21	1	US-08-400-323-13 Sequence 13, Appl
9	21	1.5	21	1	US-08-471-570-16 Sequence 16, Appl
10	19.6	1.4	26	1	US-08-471-570-17 Sequence 17, Appl
11	18.8	1.3	22	1	US-09-014-241-13 Sequence 13, Appl
12	18.6	1.3	20	1	US-09-277-078-39 Sequence 39, Appl
13	18.4	1.3	20	1	US-08-951-923-33 Sequence 33, Appl
14	18.2	1.3	24	1	US-07-741-940-61 Sequence 61, Appl
15	18.2	1.3	24	1	US-08-289-548A-61 Sequence 61, Appl
16	18.2	1.3	24	1	US-08-452-654-61 Sequence 61, Appl
17	18.2	1.3	24	1	US-08-452-655B-61 Sequence 61, Appl
18	18.2	1.3	24	1	US-08-450-582-61 Sequence 61, Appl
19	18.2	1.3	24	1	US-08-449-731-61 Sequence 61, Appl
20	17.8	1.3	21	1	US-08-951-923-26 Sequence 26, Appl
21	17.8	1.3	21	1	US-08-910-629A-62 Sequence 62, Appl
22	17	1.2	20	1	US-09-287-796-62 Sequence 62, Appl
23	17	1.2	20	1	US-09-130-616-62 Sequence 62, Appl
24	16.8	1.2	20	1	US-09-277-078-40 Sequence 40, Appl
25	16.8	1.2	20	1	US-09-798-096-38 Sequence 38, Appl
26	16.4	1.2	20	1	US-09-433-699-42 Sequence 42, Appl
27	16.2	1.2	21	1	US-08-863-639A-44 Sequence 44, Appl
28	16.2	1.2	21	1	US-08-863-639A-65 Sequence 65, Appl
29	15.8	1.1	20	1	US-09-100-398-2 Sequence 2, Appl
30	15.8	1.1	20	1	US-09-226-012-39 Sequence 39, Appl
31	15.8	1.1	20	1	US-09-733-294A-61 Sequence 61, Appl
32	15.4	1.1	17	1	US-08-584-040-7597 Sequence 7597, Ap
33	15.4	1.1	17	1	US-09-371-772B-3391 Sequence 3391, Ap

34	15.4	1.1	17	1	US-09-371-772B-4818 Sequence 4818, Ap
35	15.4	1.1	19	1	US-09-555-889A-5 Sequence 5, Appl
36	15.4	1.1	20	1	US-08-368-704C-89 Sequence 89, Appl
37	15.2	1.1	20	1	US-08-913-050A-3 Sequence 3, Appl
38	15.2	1.1	20	1	US-09-658-688A-24 Sequence 24, Appl
39	15.2	1.1	20	1	US-09-198-452A-5279 Sequence 5279, Ap
40	15.2	1.1	20	1	US-09-944-036-19 Sequence 19, Appl
41	15	1.1	15	1	US-08-585-664B-1805 Sequence 1805, Ap
42	15	1.1	15	1	US-08-585-664B-1806 Sequence 1806, Ap
43	15	1.1	15	1	US-08-585-664B-1807 Sequence 1807, Ap
44	15	1.1	15	1	US-09-038-073-1805 Sequence 1805, Ap
45	15	1.1	15	1	US-09-038-073-1806 Sequence 1806, Ap
46	15	1.1	15	1	US-09-038-073-1807 Sequence 1807, Ap
47	14.8	1.1	18	1	US-08-951-923-51 Sequence 51, Appl
48	14.8	1.1	18	1	US-09-205-113-42 Sequence 42, Appl
49	14.8	1.1	18	1	US-09-632-580A-65 Sequence 65, Appl
50	14.6	1.0	17	1	US-08-149-105-10 Sequence 10, Appl
51	14.6	1.0	17	1	US-08-317-847-10 Sequence 10, Appl
52	14.4	1.0	16	1	US-08-529-878B-20 Sequence 20, Appl
53	14.4	1.0	17	1	US-08-541-950B-17 Sequence 17, Appl
54	14.4	1.0	17	1	US-08-541-950B-20 Sequence 20, Appl
55	14.4	1.0	17	1	US-09-083-756A-17 Sequence 17, Appl
56	14.4	1.0	17	1	US-09-083-756A-20 Sequence 20, Appl
57	14.4	1.0	17	1	US-08-584-040-5715 Sequence 5715, Ap
58	14.4	1.0	17	1	US-09-371-772B-2598 Sequence 2598, Ap
59	14.4	1.0	18	1	US-08-541-950B-23 Sequence 23, Appl
60	14.4	1.0	18	1	US-09-205-922-30 Sequence 30, Appl
61	14.4	1.0	18	1	US-09-083-756A-23 Sequence 23, Appl
62	14.4	1.0	18	1	US-09-658-645A-5 Sequence 5, Appl
63	14	1.0	17	1	US-09-371-772B-4817 Sequence 4817, Ap
64	13.8	1.0	17	1	US-09-218-207-84 Sequence 84, Appl
65	13.8	1.0	17	1	US-08-584-040-4205 Sequence 4205, Ap
66	13.8	1.0	17	1	US-08-584-040-4206 Sequence 4206, Ap
67	13.8	1.0	17	1	US-08-584-040-4206 Sequence 4206, Ap
68	13.8	1.0	17	1	US-08-584-040-4242 Sequence 4242, Ap
69	13.8	1.0	17	1	US-08-584-040-4357 Sequence 4357, Ap
70	13.8	1.0	17	1	US-08-584-040-5714 Sequence 5714, Ap
71	13.8	1.0	17	1	US-08-584-040-5779 Sequence 5779, Ap
72	13.8	1.0	17	1	US-08-584-040-5817 Sequence 5817, Ap
73	13.8	1.0	17	1	US-08-584-040-5817 Sequence 5817, Ap
74	13.8	1.0	17	1	US-08-584-040-7674 Sequence 7674, Ap
75	13.8	1.0	17	1	US-08-584-040-7685 Sequence 7685, Ap
76	13.8	1.0	17	1	US-08-584-040-7685 Sequence 7685, Ap
77	13.8	1.0	17	1	US-08-584-040-7686 Sequence 7686, Ap
78	13.8	1.0	17	1	US-08-584-040-7687 Sequence 7687, Ap
79	13.8	1.0	17	1	US-09-370-644B-21 Sequence 21, Appl
80	13.8	1.0	17	1	US-09-474-432B-385 Sequence 385, App
81	13.8	1.0	17	1	US-09-474-432B-778 Sequence 778, App
82	13.8	1.0	17	1	US-09-371-772B-1972 Sequence 1972, Ap
83	13.8	1.0	17	1	US-09-371-772B-1973 Sequence 1973, Ap
84	13.8	1.0	17	1	US-09-371-772B-2009 Sequence 2009, Ap
85	13.8	1.0	17	1	US-09-371-772B-2124 Sequence 2124, Ap
86	13.8	1.0	17	1	US-09-371-772B-2597 Sequence 2597, Ap
87	13.8	1.0	17	1	US-09-371-772B-2682 Sequence 2682, Ap
88	13.8	1.0	17	1	US-09-371-772B-3455 Sequence 3455, Ap
89	13.8	1.0	17	1	US-09-371-772B-3469 Sequence 3469, Ap
90	13.8	1.0	17	1	US-09-371-772B-3470 Sequence 3470, Ap
91	13.8	1.0	17	1	US-09-371-772B-3471 Sequence 3471, Ap
92	13.8	1.0	17	1	US-09-371-772B-3472 Sequence 3472, Ap
93	13.8	1.0	17	1	US-09-371-772B-4816 Sequence 4816, Ap
94	13.8	1.0	17	1	US-09-371-772B-4816 Sequence 4816, Ap
95	13.8	1.0	17	1	US-09-371-772B-4845 Sequence 4845, Ap
96	13.8	1.0	17	1	US-09-371-772B-4845 Sequence 4845, Ap
97	13.8	1.0	17	1	US-08-143-219-19 Sequence 19, Appl
98	13.8	1.0	18	1	US-08-307-619-33 Sequence 33, Appl
99	13.8	1.0	18	1	US-08-470-837-21 Sequence 21, Appl
100	13.8	1.0	18	1	US-08-541-950B-13 Sequence 13, Appl
101	13.8	1.0	18	1	US-08-350-260A-79 Sequence 79, Appl
102	13.8	1.0	18	1	US-09-205-921-17 Sequence 17, Appl
103	13.8	1.0	18	1	US-08-722-240-4 Sequence 4, Appl
104	13.8	1.0	18	1	US-09-344-521-25 Sequence 25, Appl
105	13.8	1.0	18	1	US-09-205-143-41 Sequence 41, Appl
106	13.8	1.0	18	1	US-09-083-756A-13 Sequence 13, Appl

107	13.8	1.0	18	1	US-09-050-783-13	Sequence 33, Appl	180	12.8	0.9	17	1	US-09-371-772B-3754	Sequence 3754, Ap
C 108	13.8	1.0	18	1	US-08-866-452-21	Sequence 21, Appl	C 181	12.8	0.9	17	1	US-09-371-772B-3889	Sequence 3889, Ap
C 109	13.8	1.0	18	1	US-09-104-337A-79	Sequence 79, Appl	C 182	12.8	0.9	17	1	US-09-371-772B-4555	Sequence 4555, Ap
C 110	13.8	1.0	18	1	US-09-280-030-8	Sequence 8, Appl	C 183	12.8	0.9	17	1	US-09-371-772B-5571	Sequence 5571, Ap
C 111	13.8	1.0	18	1	US-09-280-030-9	Sequence 9, Appl	C 184	12.8	0.9	17	1	US-09-371-772B-6727	Sequence 6727, Ap
C 112	13.8	1.0	18	1	US-09-325-601-3	Sequence 3, Appl	C 185	12.8	0.9	17	1	US-09-371-772B-6753	Sequence 6753, Ap
C 113	13.4	1.0	15	1	US-09-081-646-233	Sequence 233, App	C 186	12.8	0.9	17	1	US-09-371-772B-6762	Sequence 6762, Ap
C 114	13.4	1.0	17	1	US-08-390-850-433	Sequence 433, App	C 187	12.8	0.9	17	1	US-09-371-772B-6888	Sequence 6888, Ap
C 115	13.4	1.0	17	1	US-08-396-008A-5	Sequence 5, Appl	C 188	12.8	0.9	17	1	US-09-099-932-29	Sequence 29, Appl
C 116	13.4	1.0	17	1	US-08-435-634-433	Sequence 433, App	C 189	12.4	0.9	14	1	US-08-651-472-75	Sequence 75, Appl
C 117	13.4	1.0	17	1	US-08-893-333-5	Sequence 5, Appl	C 190	12.4	0.9	14	1	US-08-998-099-249	Sequence 349, App
C 118	13.4	1.0	17	1	US-08-776-900C-10	Sequence 10, Appl	C 191	12.4	0.9	14	1	US-08-358-928-75	Sequence 75, Appl
C 119	13.4	1.0	17	1	US-09-268-195C-10	Sequence 10, Appl	C 192	12.4	0.9	14	1	US-09-535-366C-3	Sequence 3, Appl
C 120	13.4	1.0	17	1	US-08-584-040-4355	Sequence 4355, Ap	C 193	12.4	0.9	14	1	US-09-535-366C-5	Sequence 5, Appl
C 121	13.4	1.0	17	1	US-08-584-040-4356	Sequence 4356, Ap	C 194	12.4	0.9	15	1	US-08-334-847-296	Sequence 296, App
C 122	13.4	1.0	17	1	US-09-474-432B-649	Sequence 649, App	C 195	12.4	0.9	15	1	US-08-353-240A-63	Sequence 63, Appl
C 123	13.4	1.0	17	1	US-09-371-772B-2122	Sequence 2122, Ap	C 196	12.4	0.9	15	1	US-08-657-884-27	Sequence 27, Appl
C 124	13.4	1.0	17	1	US-09-371-772B-2123	Sequence 2123, Ap	C 197	12.4	0.9	15	1	US-08-657-884-31	Sequence 31, Appl
C 125	13	0.9	14	1	US-08-765-340-142	Sequence 142, Ap	C 198	12.4	0.9	15	1	US-08-585-684B-2115	Sequence 2115, Ap
C 126	13	0.9	14	1	5185440-12	Patent No. 5185440	C 199	12.4	0.9	15	1	US-08-716-308-13	Sequence 13, Appl
C 127	13	0.9	17	1	US-08-390-850-566	Sequence 566, App	C 200	12.4	0.9	15	1	US-08-913-833-157	Sequence 157, App
C 128	13	0.9	17	1	US-08-390-850-567	Sequence 567, App	C 201	12.4	0.9	15	1	US-09-038-073-2115	Sequence 2115, Ap
C 129	13	0.9	17	1	US-08-435-634-566	Sequence 566, App	C 202	12.4	0.9	15	1	US-09-158-980-27	Sequence 27, Appl
C 130	13	0.9	17	1	US-08-435-634-567	Sequence 567, App	C 203	12.4	0.9	15	1	US-09-158-980-31	Sequence 31, Appl
C 131	13	0.9	17	1	US-08-479-614-18	Sequence 18, App	C 204	12.4	0.9	15	1	US-09-580-794C-157	Sequence 157, App
C 132	13	0.9	17	1	US-08-678-645-748	Sequence 748, App	C 205	12.4	0.9	15	1	US-08-584-040-8473	Sequence 8473, Ap
C 133	12.8	0.9	16	1	US-09-371-772B-5819	Sequence 5819, Ap	C 206	12.4	0.9	15	1	US-09-371-772B-4118	Sequence 4118, Ap
C 134	12.8	0.9	16	1	US-09-371-772B-5850	Sequence 5850, Ap	C 207	12.4	0.9	16	1	US-08-537-060-14	Sequence 14, Appl
C 135	12.8	0.9	16	1	US-09-371-772B-7080	Sequence 7080, Ap	C 208	12.4	0.9	16	1	US-09-371-772B-5827	Sequence 5827, Ap
C 136	12.8	0.9	17	1	US-08-179-738-23	Sequence 23, Appl	C 209	12	0.9	12	1	US-09-475-947A-85	Sequence 85, Appl
C 137	12.8	0.9	17	1	US-08-390-850-694	Sequence 694, App	C 210	12	0.9	14	1	US-08-998-099-328	Sequence 328, App
C 138	12.8	0.9	17	1	US-08-390-850-695	Sequence 695, App	C 211	12	0.9	14	1	US-08-765-340-141	Sequence 141, App
C 139	12.8	0.9	17	1	US-08-373-124A-416	Sequence 416, App	C 212	12	0.9	15	1	US-07-664-989B-121	Sequence 121, App
C 140	12.8	0.9	17	1	US-08-373-124A-534	Sequence 534, App	C 213	12	0.9	15	1	US-09-177-359-34	Sequence 34, Appl
C 141	12.8	0.9	17	1	US-08-373-124A-1114	Sequence 1114, App	C 214	12	0.9	15	1	US-09-081-646-133	Sequence 133, App
C 142	12.8	0.9	17	1	US-08-373-124A-1116	Sequence 1116, Ap	C 215	12	0.9	15	1	US-09-081-646-708	Sequence 708, App
C 143	12.8	0.9	17	1	US-08-373-124A-2423	Sequence 2423, Ap	C 216	12	0.9	15	1	US-09-081-646-835	Sequence 835, App
C 144	12.8	0.9	17	1	US-08-435-634-694	Sequence 694, App	C 217	12	0.9	15	1	US-09-475-947A-180	Sequence 180, App
C 145	12.8	0.9	17	1	US-08-435-634-695	Sequence 695, App	C 218	12	0.9	16	1	US-08-248-357C-11	Sequence 11, Appl
C 146	12.8	0.9	17	1	US-08-623-891-21	Sequence 21, Appl	C 219	12	0.9	16	1	US-08-282-197C-20	Sequence 20, Appl
C 147	12.8	0.9	17	1	US-08-758-306-123	Sequence 123, App	C 220	12	0.9	16	1	US-08-626-023-4	Sequence 4, Appl
C 148	12.8	0.9	17	1	US-08-435-628-416	Sequence 416, App	C 221	12	0.9	16	1	US-08-626-023-4	Sequence 4, Appl
C 149	12.8	0.9	17	1	US-08-435-628-534	Sequence 534, App	C 222	12	0.9	16	1	US-09-266-409-8	Sequence 8, Appl
C 150	12.8	0.9	17	1	US-08-435-628-1114	Sequence 1114, Ap	C 223	12	0.9	16	1	US-09-678-620-8	Sequence 8, Appl
C 151	12.8	0.9	17	1	US-08-435-628-1116	Sequence 1116, Ap	C 224	11.8	0.8	15	1	US-08-182-968A-35	Sequence 35, Appl
C 152	12.8	0.9	17	1	US-08-435-628-2423	Sequence 2423, Ap	C 225	11.8	0.8	15	1	US-08-182-968A-302	Sequence 302, App
C 153	12.8	0.9	17	1	US-08-541-950B-18	Sequence 18, Appl	C 226	11.8	0.8	15	1	US-08-182-968A-302	Sequence 302, App
C 154	12.8	0.9	17	1	US-08-541-950B-21	Sequence 21, Appl	C 227	11.8	0.8	15	1	US-08-334-847-450	Sequence 450, App
C 155	12.8	0.9	17	1	US-08-541-950B-21	Sequence 21, Appl	C 228	11.8	0.8	15	1	US-08-334-847-450	Sequence 450, App
C 156	12.8	0.9	17	1	US-08-541-950B-22	Sequence 22, Appl	C 229	11.8	0.8	15	1	US-08-363-240A-47	Sequence 47, Appl
C 157	12.8	0.9	17	1	US-08-628-145-23	Sequence 23, Appl	C 230	11.8	0.8	15	1	US-08-363-240A-673	Sequence 673, App
C 158	12.8	0.9	17	1	US-08-985-162-184	Sequence 184, App	C 231	11.8	0.8	15	1	US-08-363-240A-673	Sequence 673, App
C 159	12.8	0.9	17	1	US-08-985-162-326	Sequence 326, App	C 232	11.8	0.8	15	1	US-08-317-432A-5	Sequence 5, Appl
C 160	12.8	0.9	17	1	US-09-083-756A-18	Sequence 18, Appl	C 233	11.8	0.8	15	1	US-08-344-820-9	Sequence 9, Appl
C 161	12.8	0.9	17	1	US-09-083-756A-19	Sequence 19, Appl	C 234	11.8	0.8	15	1	US-08-311-486C-172	Sequence 172, App
C 162	12.8	0.9	17	1	US-09-083-756A-21	Sequence 21, Appl	C 235	11.8	0.8	15	1	US-08-311-486C-172	Sequence 172, App
C 163	12.8	0.9	17	1	US-09-083-756A-22	Sequence 22, Appl	C 236	11.8	0.8	15	1	US-08-311-486C-660	Sequence 660, App
C 164	12.8	0.9	17	1	US-08-584-040-1992	Sequence 1992, Ap	C 237	11.8	0.8	15	1	US-08-292-620A-242	Sequence 242, App
C 165	12.8	0.9	17	1	US-08-584-040-2009	Sequence 2009, Ap	C 238	11.8	0.8	15	1	US-08-292-620A-430	Sequence 430, App
C 166	12.8	0.9	17	1	US-08-584-040-2761	Sequence 2761, Ap	C 239	11.8	0.8	15	1	US-08-292-620A-462	Sequence 462, App
C 167	12.8	0.9	17	1	US-08-584-040-4140	Sequence 4140, Ap	C 240	11.8	0.8	15	1	US-08-292-620A-534	Sequence 534, App
C 168	12.8	0.9	17	1	US-08-584-040-5816	Sequence 5816, Ap	C 241	11.8	0.8	15	1	US-08-292-620A-547	Sequence 547, App
C 169	12.8	0.9	17	1	US-08-584-040-7971	Sequence 7971, Ap	C 242	11.8	0.8	15	1	US-08-292-620A-664	Sequence 664, App
C 170	12.8	0.9	17	1	US-08-584-040-8106	Sequence 8106, Ap	C 243	11.8	0.8	15	1	US-08-292-620A-730	Sequence 730, App
C 171	12.8	0.9	17	1	US-09-340-861-21	Sequence 21, Appl	C 244	11.8	0.8	15	1	US-08-657-884-25	Sequence 25, Appl
C 172	12.8	0.9	17	1	US-09-634-262-21	Sequence 21, Appl	C 245	11.8	0.8	15	1	US-08-657-884-29	Sequence 29, Appl
C 173	12.8	0.9	17	1	US-09-446-301A-31	Sequence 31, Appl	C 246	11.8	0.8	15	1	US-08-774-306A-35	Sequence 35, Appl
C 174	12.8	0.9	17	1	US-09-474-432B-783	Sequence 783, App	C 247	11.8	0.8	15	1	US-08-774-306A-301	Sequence 301, App
C 175	12.8	0.9	17	1	US-09-371-772B-537	Sequence 537, App	C 248	11.8	0.8	15	1	US-08-774-306A-302	Sequence 302, App
C 176	12.8	0.9	17	1	US-09-371-772B-554	Sequence 554, App	C 249	11.8	0.8	15	1	US-08-585-684B-87	Sequence 87, Appl
C 177	12.8	0.9	17	1	US-09-371-772B-1285	Sequence 1285, Ap	C 250	11.8	0.8	15	1	US-08-585-684B-87	Sequence 87, Appl
C 178	12.8	0.9	17	1	US-09-371-772B-1907	Sequence 1907, Ap	C 251	11.8	0.8	15	1	US-08-585-684B-639	Sequence 639, App
C 179	12.8	0.9	17	1	US-09-371-772B-2681	Sequence 2681, Ap	C 252	11.8	0.8	15	1	US-08-585-684B-640	Sequence 640, App


```
RESULT 3
US-07-997-133-4/c
; Sequence 4, Application US/07997133
; GENERAL INFORMATION:
; APPLICANT: Bergonzoni, Laura
; APPLICANT: Mazue, Guy, Antonella
; APPLICANT: Isacchi, Antonella
; APPLICANT: Roncucci, Romeo
; APPLICANT: Sarmientos, Paolo
; TITLE OF INVENTION: Extracellular Form of the Human
; TITLE OF INVENTION: Fibroblast Growth Factor Receptor
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
; ADDRESSEE: P.C.
; STREET: 1755 Jefferson Davis Highway, Fourth Floor
; CITY: Arlington
; STATE: Virginia
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/997,133
; FILING DATE: 28-DEC-1992
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/642,755
; FILING DATE: 18-JAN-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Oblon, Norman F.
; REGISTRATION NUMBER: 24,618
; REFERENCE/DOCKET NUMBER: 769-226-0
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)521-4500
; TELEFAX: (703)486-2347
; TELEX: 24885 OPAT UR
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 30 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-07-997-133-4

Query Match      1.8%; Score 25.8; DB 1; Length 30;
Best Local Similarity 93.1%; Pred. No. 2.4;
Matches 27; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      2488 TGTGGCATGAGTGCCTCCAGAGACC 2516
DB      30  TGCTGGCATGAGTGCCTCCAGAGACC 2

RESULT 4
US-07-631-717A-5/c
; Sequence 5, Application US/07631717A
; GENERAL INFORMATION:
; APPLICANT: Yaron, Avner
; APPLICANT: Ornitz, David M.
; APPLICANT: Klagsbrun, Michael
; APPLICANT: Leder, Philip
; TITLE OF INVENTION: SYSTEM FOR ASSAYING BINDING
; TITLE OF INVENTION: TO A HEPARIN-BINDING GROWTH
; FILING DATE: 12/14/93
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
```

```
ADDRESSEE: Fish & Richardson
STREET: 225 Franklin Street
CITY: Boston
STATE: Massachusetts
COUNTRY: U.S.A.
ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 50Z or 55SX
; OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
; SOFTWARE: WordPerfect (Version 5.0)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/631,717A
; FILING DATE: 19901220
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Paul T. Clark
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00383/018001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-07-631-717A-5
```

```
Query Match      1.6%; Score 22.4; DB 1; Length 28;
Best Local Similarity 95.8%; Pred. No. 8.4;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
OY      1873 GAGATGAGATGATGAGATGATT 1896
DB      28  GAGATGAGATGATGAGATGAT 5
```

```
RESULT 5
US-08-166-717D-5/c
; Sequence 5, Application US/08166717D
; Patent No. 5789182
; GENERAL INFORMATION:
; APPLICANT: Yaron, Avner
; APPLICANT: Ornitz, David M.
; APPLICANT: Klagsbrun, Michael
; APPLICANT: Leder, Philip
; TITLE OF INVENTION: SYSTEM FOR ASSAYING BINDING
; TITLE OF INVENTION: TO A HEPARIN-BINDING GROWTH
; TITLE OF INVENTION: FACTOR RECEPTOR
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Clark & Elbing LLP
; STREET: 176 Federal Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM COMPATIBLE
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WordPerfect (Version 7.0)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/166,717D
; FILING DATE: 12/14/93
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
```

APPLICATION NUMBER: 07/631,717
FILING DATE: 12/20/90
ATTORNEY/AGENT INFORMATION:
NAME: Kristina Bieker-Brady
REGISTRATION NUMBER: 39,109
REFERENCE/DOCKET NUMBER: 00383/017002
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 723-4123
TELEFAX: (617) 723-8962
TELEX:
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 28
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-166-717D-5

Query Match 1.6%; Score 22.4; DB 1; Length 28;
Best Local Similarity 95.8%; Pred. No. 8.4;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1873 GAGATGAGATGATGAGATGATT 1896
DB 28 GAGATGAGATGATGATGATGAT 5

RESULT 6
US-08-678-039A-4/c
Sequence 4, Application US/08678039A
Patent No. 5858662
GENERAL INFORMATION:
APPLICANT: Keating, Mark T.
APPLICANT: Morris, Colleen A.
TITLE OF INVENTION: Diagnosis of Williams Syndrome and
TITLE OF INVENTION: Williams Syndrome Cognitive Profile by Analysis of the
TITLE OF INVENTION: Presence or Absence of a LIM-kinase Gene
NUMBER OF SEQUENCES: 42
CORRESPONDENCE ADDRESS:
ADDRESSEE: Rothwell, Figg, Ermat & Kurz, P.C.
STREET: 555 Thirteenth Street, N.W., Suite 701 East
CITY: Washington
STATE: DC
COUNTRY: U.S.A.
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/678,039A
FILING DATE: 10-JUL-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Saxe, Stephen A.
REGISTRATION NUMBER: 38,609
REFERENCE/DOCKET NUMBER: 2323-120A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-624-1589
TELEFAX: 202-783-6031
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 25 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "Primer sequence"
US-08-678-039A-4

Query Match 1.5%; Score 21.4; DB 1; Length 25;

Best Local Similarity 95.7%; Pred. No. 9.8;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2269 CCAGTCAAGTGATGCTCCAGA 2291
DB 24 CCAGTCAAGTGATGCTCCAGA 2

RESULT 7
US-07-947-683-14/c
Sequence 14, Application US/07947683
Patent No. 5589451
GENERAL INFORMATION:
APPLICANT: WILSON, STEVEN E.
TITLE OF INVENTION: METHODS AND TREATMENTS FOR
TITLE OF INVENTION: CORNEAL HEALING WITH HEPATOCYTE
TITLE OF INVENTION: AND KERATINOCYTE GROWTH FACTORS
NUMBER OF SEQUENCES: 15
CORRESPONDENCE ADDRESS:
ADDRESSEE: ARNOLD, WHITE & DURKEE
STREET: P.O. BOX 4433
CITY: HOUSTON
STATE: TEXAS
COUNTRY: USA
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY DISK
COMPUTER: IBM PC COMPATIBLE
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WORDPERFECT 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/947,683
FILING DATE: SEPTEMBER 21, 1992
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: KITCHELL, BARBARA S.
REGISTRATION NUMBER: 33,928
REFERENCE/DOCKET NUMBER: UTSD:311/KIT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 512-320-7200
TELEFAX: 512-474-7577
TELEX: NOT APPLICABLE
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-07-947-683-14

Query Match 1.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.8;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1322 TATCCTTCACCTGCATGCT 1342
DB 21 TATCCTTCACCTGCATGCT 1

RESULT 8
US-08-400-323-13/c
Sequence 13, Application US/08400323
Patent No. 5703047
GENERAL INFORMATION:
APPLICANT: Wilson, Steven E.
TITLE OF INVENTION: Methods and Treatments for Corneal
TITLE OF INVENTION: Healing with Growth Factors
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSEE: Arnold, White & Durkee
STREET: P. O. Box 4433
CITY: Houston
STATE: TX

COUNTRY: USA
ZIP: 77210-4433
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/400,323
FILING DATE: 09-MAR-1995
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Kitchell, Barbara S.
REGISTRATION NUMBER: 33,928
REFERENCE/DOCKET NUMBER: UTSD:431\KIT
TELECOMMUNICATION INFORMATION:
TELEPHONE: (512) 418-3000
TELEFAX: (512) 474-7577
TELEX: 79-0924
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-400-323-13

Query Match 1.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.6;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1322 TATCCTTCACTGTCGATGTT 1342
Db 21 TATCCTTCACTGTCGATGTT 1

RESULT 9
US-08-471-570-16
Sequence 16, Application US/08471570
Patent No. 5750371
GENERAL INFORMATION:
APPLICANT: IGARASHI, Koichi
APPLICANT: SENOO, Masaharu
APPLICANT: WATANABE, Tatsuya
TITLE OF INVENTION: PROTEIN, DNA AND USE THEREOF
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSEE: DAVID G. CONLIN; DIKE, BRONSTEIN, ROBERTS &
ADDRESS: CUSHMAN
STREET: 130 Water Street
CITY: Boston
STATE: Massachusetts
COUNTRY: US
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/471,570
FILING DATE: 06-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION NUMBER: US/08/149,664
FILING DATE:
APPLICATION NUMBER: US/07/743369
FILING DATE: 16-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: LINEK, Ernest V
REGISTRATION NUMBER: 29822
REFERENCE/DOCKET NUMBER: 40897
TELECOMMUNICATION INFORMATION:

TELEPHONE: (617) 523-3400
TELEFAX: (617) 523-6440
TELEX: 200291 STRE UR
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid, synthetic DNA
US-08-471-570-16

Query Match 1.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.6;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1870 TCAGAGATGAGATGATGAAG 1890
Db 1 TCAGAGATGAGATGATGAAG 21

RESULT 10
US-08-471-570-17/c
Sequence 17, Application US/08471570
Patent No. 5750371
GENERAL INFORMATION:
APPLICANT: IGARASHI, Koichi
APPLICANT: SENOO, Masaharu
APPLICANT: WATANABE, Tatsuya
TITLE OF INVENTION: PROTEIN, DNA AND USE THEREOF
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSEE: DAVID G. CONLIN; DIKE, BRONSTEIN, ROBERTS &
ADDRESS: CUSHMAN
STREET: 130 Water Street
CITY: Boston
STATE: Massachusetts
COUNTRY: US
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/471,570
FILING DATE: 06-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/149,664
FILING DATE:
APPLICATION NUMBER: US/07/743369
FILING DATE: 16-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: LINEK, Ernest V
REGISTRATION NUMBER: 29822
REFERENCE/DOCKET NUMBER: 40897
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 523-3400
TELEFAX: (617) 523-6440
TELEX: 200291 STRE UR
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 26 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid, synthetic DNA
US-08-471-570-17

Query Match 1.4%; Score 19.6; DB 1; Length 26;
Best Local Similarity 84.6%; Pred. No. 22;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;


```

: APPLICANT: ANAND, RAKESH
: APPLICANT: CARLSON, MARY
: APPLICANT: GRODEN, JOANNA
: APPLICANT: HEDGE, PHILIP J.
: APPLICANT: JOSLYN, GEOFF
: APPLICANT: KINZLER, KENNETH
: APPLICANT: MARKHAM, ALEXANDER F.
: APPLICANT: NAKAMURA, YUSUKE
: APPLICANT: THLIVERIS, ANDREW
: TITLE OF INVENTION: INHERITED AND SOMATIC MUTATIONS OF APC
: TITLE OF INVENTION: GENE IN COLORECTAL CANCER IN HUMANS
: NUMBER OF SEQUENCES: 94
: CORRESPONDENCE ADDRESSES:
: ADDRESSEE: Banner, Birch, McKie & Beckett
: STREET: 1001 G Street, NW
: CITY: Washington
: STATE: D.C.
: COUNTRY: USA
: ZIP: 20001-4598
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: OPERATING SYSTEM: IBM PC compatible
: SOFTWARE: Patentin Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/07/741,940
: FILING DATE: 19920109
: CLASSIFICATION: 435
: ATTORNEY/AGENT INFORMATION:
: NAME: Kagan, Sarah A.
: REGISTRATION NUMBER: 32,141
: REFERENCE/DOCKET NUMBER: 1107.035574
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 202-508-9299
: INFORMATION FOR SEQ ID NO: 61:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 24 base pairs
: TYPE: NUCLEIC ACID
: STRANDEDNESS: single
: TOPOLOGY: linear
: MOLECULE TYPE: cDNA
: ORIGINAL SOURCE:
: ORGANISM: Homo sapiens
: US-07-741-940-61

Query Match 1.3%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 32;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2645 CTTGAGAGATGATTCGTGTTT 2667
Db 23 CTTGAGAGATGATTCGTGTTT 1

RESULT 15
US-08-289-548A-61/c
: Sequence 61, Application US/08289548A
: Patent No. 5648212
: GENERAL INFORMATION:
: APPLICANT: ALBERTSEN, HANS
: APPLICANT: ANAND, RAKESH
: APPLICANT: CARLSON, MARY
: APPLICANT: GRODEN, JOANNA
: APPLICANT: HEDGE, PHILIP J.
: APPLICANT: JOSLYN, GEOFF
: APPLICANT: KINZLER, KENNETH
: APPLICANT: MARKHAM, ALEXANDER F.
: APPLICANT: NAKAMURA, YUSUKE
: APPLICANT: THLIVERIS, ANDREW
: TITLE OF INVENTION: INHERITED AND SOMATIC MUTATIONS OF APC
: TITLE OF INVENTION: GENE IN COLORECTAL CANCER IN HUMANS
: NUMBER OF SEQUENCES: 102
```

```

: CORRESPONDENCE ADDRESSES:
: ADDRESSEE: Banner & Allegretti, LTD
: STREET: 1001 G Street, NW
: CITY: Washington
: STATE: D.C.
: COUNTRY: USA
: ZIP: 20001-4598
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: OPERATING SYSTEM: IBM PC compatible
: SOFTWARE: Patentin Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/289,548A
: FILING DATE: 12-AUG-1994
: CLASSIFICATION: 435
: ATTORNEY/AGENT INFORMATION:
: NAME: Kagan, Sarah A.
: REGISTRATION NUMBER: 32,141
: REFERENCE/DOCKET NUMBER: 1107.46943
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 202-508-9299
: INFORMATION FOR SEQ ID NO: 61:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 24 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: MOLECULE TYPE: cDNA
: ORIGINAL SOURCE:
: ORGANISM: Homo sapiens
: US-08-289-548A-61

Query Match 1.3%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 32;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2645 CTTGAGAGATGATTCGTGTTT 2667
Db 23 CTTGAGAGATGATTCGTGTTT 1

RESULT 16
US-08-452-654-61/c
: Sequence 61, Application US/08452654
: Patent No. 5691454
: GENERAL INFORMATION:
: APPLICANT: ALBERTSEN, HANS
: APPLICANT: ANAND, RAKESH
: APPLICANT: CARLSON, MARY
: APPLICANT: GRODEN, JOANNA
: APPLICANT: HEDGE, PHILIP J.
: APPLICANT: JOSLYN, GEOFF
: APPLICANT: KINZLER, KENNETH
: APPLICANT: MARKHAM, ALEXANDER F.
: APPLICANT: NAKAMURA, YUSUKE
: APPLICANT: THLIVERIS, ANDREW
: TITLE OF INVENTION: INHERITED AND SOMATIC MUTATIONS OF APC
: TITLE OF INVENTION: GENE IN COLORECTAL CANCER IN HUMANS
: NUMBER OF SEQUENCES: 94
: CORRESPONDENCE ADDRESSES:
: ADDRESSEE: Banner, Birch, McKie & Beckett
: STREET: 1001 G Street, NW
: CITY: Washington
: STATE: D.C.
: COUNTRY: USA
: ZIP: 20001-4598
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: OPERATING SYSTEM: IBM PC compatible
: SOFTWARE: Patentin Release #1.0, Version #1.25
```

```

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/452,654
FILING DATE: 25-MAY-1995
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/741,940
FILING DATE: 08-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: Kagan, Sarah A.
REGISTRATION NUMBER: 32,141
REFERENCE/DOCKET NUMBER: 1107.035574
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-508-9100
TELEFAX: 202-508-9299
INFORMATION FOR SEQ ID NO: 61:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
US-08-452-654-61

Query Match          1.3%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 32;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      2645 CTTGAGAGATGATTCGTTT 2667
Db      23  CTTGAGAGATGATTCGTTT 1

RESULT 17
US-08-452-655B-61/c
Sequence 61, Application US/08452655B
Patent No. 5783666
GENERAL INFORMATION:
APPLICANT: ALBERTSEN, HANS
APPLICANT: ANAND, RAKESH
APPLICANT: CARLSON, MARY
APPLICANT: GRODEN, JOANNA
APPLICANT: HEDGE, PHILIP J.
APPLICANT: JOSLYN, GEOF.
APPLICANT: KINZLER, KENNETH
APPLICANT: MARKHAM, ALEXANDER F.
APPLICANT: NAKAMURA, YUSUKE
APPLICANT: THLIVERTS, ANDREW
TITLE OF INVENTION: INHERITED AND SOMATIC MUTATIONS OF APC
TITLE OF INVENTION: GENE IN COLORECTAL CANCER IN HUMANS
NUMBER OF SEQUENCES: 102
CORRESPONDENCE ADDRESS:
ADDRESSEE: Banner & Witcoff, Ltd.
STREET: 1001 G Street, NW
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20001-4598
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/452,655B
FILING DATE: 25-MAY-1995
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/289,548
FILING DATE: 12-AUG-1994
ATTORNEY/AGENT INFORMATION:
NAME: Kagan, Sarah A.
REGISTRATION NUMBER: US 07/741,940
APPLICATION NUMBER: US 07/741,940
```

```

FILING DATE: 08-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: Kagan, Sarah A.
REGISTRATION NUMBER: 32,141
REFERENCE/DOCKET NUMBER: 1107.49964
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-508-9100
TELEFAX: 202-508-9299
INFORMATION FOR SEQ ID NO: 61:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
US-08-452-655B-61

Query Match          1.3%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 32;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      2645 CTTGAGAGATGATTCGTTT 2667
Db      23  CTTGAGAGATGATTCGTTT 1

RESULT 18
US-08-452-582-61/c
Sequence 61, Application US/08450582
Patent No. 6114124
GENERAL INFORMATION:
APPLICANT: ALBERTSEN, HANS
APPLICANT: ANAND, RAKESH
APPLICANT: CARLSON, MARY
APPLICANT: GRODEN, JOANNA
APPLICANT: HEDGE, PHILIP J.
APPLICANT: JOSLYN, GEOF.
APPLICANT: KINZLER, KENNETH
APPLICANT: MARKHAM, ALEXANDER F.
APPLICANT: NAKAMURA, YUSUKE
APPLICANT: THLIVERTS, ANDREW
TITLE OF INVENTION: INHERITED AND SOMATIC MUTATIONS OF APC
TITLE OF INVENTION: GENE IN COLORECTAL CANCER IN HUMANS
NUMBER OF SEQUENCES: 102
CORRESPONDENCE ADDRESS:
ADDRESSEE: Banner & Witcoff, Ltd.
STREET: 1001 G Street, NW
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20001-4598
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/450,582
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/452,655
FILING DATE: 25-MAY-1995
APPLICATION NUMBER: US 08/289,548
FILING DATE: 12-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/741,940
FILING DATE: 08-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: Kagan, Sarah A.
REGISTRATION NUMBER: 32,141
```

REFERENCE/DOCKET NUMBER: 1107.49964
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-508-9100
TELEFAX: 202-508-9299
INFORMATION FOR SEQ ID NO: 61:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
US-08-450-582-61

Query Match 1.3%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 32;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2645 CTTGAGGAGATGATTCGTATTT 2667
DB 23 CTTGAGGAGATGATTCGTATTT 1

RESULT 19
US-08-449-731-61/C
Sequence 61, Application US/08449731
Patent No. 6413727
GENERAL INFORMATION:
APPLICANT: ALBERTSEN, HANS
ANAND, RAKESH
CARLSON, MARY
GRODEN, JOANNA
HEDGE, PHILIP J.
JOSLYN, GEOFF
KINZLER, KENNETH
MARKHAM, ALEXANDER F.
NAKAMURA, YUSUKE
THLIVERIS, ANDREW
TITLE OF INVENTION: INHERITED AND SOMATIC MUTATIONS OF APC
GENE IN COLORECTAL CANCER IN HUMANS
NUMBER OF SEQUENCES: 102
CORRESPONDENCE ADDRESS:
ADDRESSEE: Banner & Allegretti, LTD
STREET: 1001 G Street, NW
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20001-4598
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/449,731
FILING DATE: 25-May-1995
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/289,548
FILING DATE: 12-AUG-1994
ATTORNEY/AGENT INFORMATION:
NAME: Kagan, Sarah A.
REGISTRATION NUMBER: 32,141
REFERENCE/DOCKET NUMBER: 1107.46943
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-508-9100
TELEFAX: 202-508-9299
INFORMATION FOR SEQ ID NO: 61:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

TOPOLOGY: linear
MOLECULE TYPE: cDNA
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
SEQUENCE DESCRIPTION: SEQ ID NO: 61:
US-08-449-731-61

Query Match 1.3%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 32;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2645 CTTGAGGAGATGATTCGTATTT 2667
DB 23 CTTGAGGAGATGATTCGTATTT 1

RESULT 20
US-08-951-923-26/C
Sequence 26, Application US/08951923
Patent No. 6048693
GENERAL INFORMATION:
APPLICANT: Bitter, Grant
TITLE OF INVENTION: PHENOTYPIC ASSAYS OF CYCLIN/CYCLIN-DEPENDENT KINASE
NUMBER OF SEQUENCES: 57
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cooley Godward LLP
STREET: 5 Palo Alto Square, 3000 El Camino Real
CITY: Palo Alto
STATE: CA
COUNTRY: US
ZIP: 94306-2155
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/951,923
FILING DATE: October 16, 1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Neeley, Richard L.
REGISTRATION NUMBER: 30,092
REFERENCE/DOCKET NUMBER: BITT-001/020US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650 843-5000
TELEFAX: 650 857-0663
TELEX: 380816COOLEYPA
INFORMATION FOR SEQ ID NO: 26:
SEQUENCE CHARACTERISTICS:
LENGTH: 21
TYPE: nucleic acid
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-951-923-26

Query Match 1.3%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 28;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2203 GACTTTGACTGCGCAGAGAT 2223
DB 21 GACTTTGACTGCGCAGAGAT 1

RESULT 21
US-08-910-629A-62/C
Sequence 62, Application US/08910629A
Patent No. 5877309

```

; GENERAL INFORMATION:
; APPLICANT: Robert A. McKay
; APPLICANT: Nicholas M. Dean
; APPLICANT: Brett Monia
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK
; TITLE OF INVENTION: PROTEINS
; NUMBER OF SEQUENCES: 86
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marilton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB
; MEDIUM TYPE: STORAGE
; COMPUTER: PENTIUM
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.1
; CURRENT APPLICATION NUMBER: US/08/910,629A
; APPLICATION NUMBER: US/08/910,629A
; FILING DATE: August 13, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0215
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 62:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-910-629A-62

Query Match 1.2%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 2642 GTCTTCAGAGATGAT 2658
Db 17 GTCTTCAGAGATGAT 1

RESULT 22
US-09-287-796-62/c
; Sequence 62, Application US/09287796A
; Patent No. 6133246
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
; TITLE OF INVENTION: FOR THE MODULATION OF JNK PROTEINS
; FILE REFERENCE: ISPH-0350
; CURRENT APPLICATION NUMBER: US/09/287,796A
; CURRENT FILING DATE: 1998-04-07
; EARLIER APPLICATION NUMBER: 09/130,616
; EARLIER FILING DATE: 1998-08-07
; EARLIER APPLICATION NUMBER: 08/910,629
; EARLIER FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 165
```

```

; SEQ ID NO 62
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
; US-09-287-796-62

Query Match 1.2%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 2642 GTCTTCAGAGATGAT 2658
Db 17 GTCTTCAGAGATGAT 1

RESULT 23
US-09-130-616-62/c
; Sequence 62, Application US/09130616C
; Patent No. 6221850
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
; TITLE OF INVENTION: FOR THE MODULATION OF JNK PROTEINS
; FILE REFERENCE: ISPH-0318
; CURRENT APPLICATION NUMBER: US/09/130,616C
; CURRENT FILING DATE: 1998-08-07
; EARLIER APPLICATION NUMBER: 08/910,629
; EARLIER FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 178
; SEQ ID NO 62
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
; US-09-130-616-62

Query Match 1.2%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 2642 GTCTTCAGAGATGAT 2658
Db 17 GTCTTCAGAGATGAT 1

RESULT 24
US-09-277-078-40/c
; Sequence 40, Application US/09277078
; Patent No. 6312949
; GENERAL INFORMATION:
; APPLICANT: Sakurada, Kazuhiro
; APPLICANT: Palmer, Theo
; APPLICANT: Gage, Fred H.
; TITLE OF INVENTION: REGULATION OF TYROSINE HYDROXYLASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 07251/031001
; CURRENT APPLICATION NUMBER: US/09/277,078
; CURRENT FILING DATE: 1999-03-26
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PastsEQ for Windows Version 4.0
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for PCR
```

```

; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (0)...(0)
; OTHER INFORMATION: h = A, C, or T; not G
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (0)...(0)
; OTHER INFORMATION: d = A, G, or T; not C
US-09-277-078-40

Query Match          1.2%; Score 16.8; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 38;
Matches 17; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY      2191 ATGAATAAGCAGACTTTGG 2210
        |||||:|||||
Db      20  ATGAAGATGCGDCACTTGG 1

RESULT 25
US-09-798-096-38/C
; Sequence 38, Application US/09798096
; Patent No. 6399378
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; APPLICANT: Andrew T. Walt
; TITLE OF INVENTION: ANTISENSE MODULATION OF RECOL2 EXPRESSION
; FILE REFERENCE: RTS-0207
; CURRENT APPLICATION NUMBER: US/09/798,096
; CURRENT FILING DATE: 2001-03-01
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-798-096-38

Query Match          1.2%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 38;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1882 ATGATGAGATGATGGGAA 1901
        |||||:|||||
Db      20  ATGATGATGATGACTGGGAA 1

RESULT 26
US-09-433-699-42/C
; Sequence 42, Application US/09433699B
; Patent No. 6165786
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowart
; TITLE OF INVENTION: ANTISENSE MODULATION OF NUCLEOLIN EXPRESSION
; FILE REFERENCE: RTS-0109
; CURRENT APPLICATION NUMBER: US/09/433,699B
; CURRENT FILING DATE: 1999-11-03
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-433-699-42

Query Match          1.2%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 45;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      1878 GGAAGTGTGATGAAGATGAT 1895
```

```

Db      19  GAAGATGATGAAGATGAT 2
        |||||:|||||

RESULT 27
US-08-863-639A-44/C
; Sequence 44, Application US/08863639A
; Patent No. 5981185
; GENERAL INFORMATION:
; APPLICANT: Watson, Robert S.
; APPLICANT: Coassin, Peter J.
; APPLICANT: Rampal, Jang B.
; APPLICANT: Caskey, C. T.
; TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESS: Sheldon & Mak
; STREET: 225 South Lake Avenue, 9th Floor
; CITY: Pasadena
; STATE: CA
; COUNTRY: USA
; ZIP: 91101
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Corel WordPerfect 8 version
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/863,639A
; FILING DATE: May 28, 1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph E. Muech
; REGISTRATION NUMBER: 20,532
; REFERENCE/DOCKET NUMBER: 11859-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (626) 796-4000
; TELEFAX: (626) 795-6321
; INFORMATION FOR SEQ ID NO: 44:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
US-08-863-639A-44

Query Match          1.2%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 53;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      1875 GATGAGATGATGAAGATGAT 1895
        |||||:|||||
Db      21  GATGATGATGATGATGATGAT 1

RESULT 28
US-08-863-639A-65
; Sequence 65, Application US/08863639A
; Patent No. 5981185
; GENERAL INFORMATION:
; APPLICANT: Watson, Robert S.
; APPLICANT: Coassin, Peter J.
; APPLICANT: Rampal, Jang B.
; APPLICANT: Caskey, C. T.
; TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESS: Sheldon & Mak
; STREET: 225 South Lake Avenue, 9th Floor
; CITY: Pasadena
; STATE: CA
; COUNTRY: USA
```

```
ZIP: 91101
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Corel Wordperfect 8 version
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/863,639A
; FILING DATE: May 28, 1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph E. Muehl
; REGISTRATION NUMBER: 20,532
; REFERENCE/DOCKET NUMBER: 11859-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (626) 796-4000
; TELEFAX: (626) 795-6321
; INFORMATION FOR SEQ ID NO: 65:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
; US-08-863-639A-65

Query Match 1.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 53;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1875 GATGAGATGATGATGATGAT 1895
Db 1 GATGATGATGATGATGATGAT 21

RESULT 29
US-09-100-398-2/c
; Sequence 2, Application US/09100398
; Patent No. 5865712
; GENERAL INFORMATION:
; APPLICANT: Conrad, Daniel H.
; APPLICANT: Kelly, Ann E.
; TITLE OF INVENTION: LZ-CD3 CHIMERA FOR INHIBITION OF IGE-MEDIATED
; TITLE OF INVENTION: ALLERGIC DISEASE
; FILE REFERENCE: 294066AA
; CURRENT APPLICATION NUMBER: US/09/100,398
; CURRENT FILING DATE: 1998-06-19
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: primer
; US-09-100-398-2

Query Match 1.1%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 56;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1819 GTGAAGATGTGAAGATG 1837
Db 19 GTGAATATGTTGAAGATG 1

RESULT 30
US-09-226-012-39/c
; Sequence 39, Application US/09226012
; Patent No. 6207383
; GENERAL INFORMATION:
; APPLICANT: Keating, Mark T.
; APPLICANT: Splawski, Igor
; TITLE OF INVENTION: MUTATIONS IN AND GENOMIC STRUCTURE OF HERG - A LONG QT
; TITLE OF INVENTION: SYNDROME GENE
```

```
; FILE REFERENCE: 2323-136
; CURRENT APPLICATION NUMBER: US/09/226,012
; CURRENT FILING DATE: 1999-01-06
; EARLIER APPLICATION NUMBER: 09/122,847
; EARLIER FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 116
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-226-012-39

Query Match 1.1%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 56;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2556 CACTCTCACACCAATGAG 2574
Db 19 CACTCTCACGCCAATGAG 1

RESULT 31
US-09-733-294A-61
; Sequence 61, Application US/09733294A
; Patent No. 6492171
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: William Gaarde
; APPLICANT: Susan M. Freiler
; APPLICANT: Edward V. Mancewicz
; TITLE OF INVENTION: ANTISENSE MODULATION OF TERT EXPRESSION
; FILE REFERENCE: ISPH-0527
; CURRENT APPLICATION NUMBER: US/09/733,294A
; CURRENT FILING DATE: 2000-12-07
; PRIOR APPLICATION NUMBER: 09/572,423
; PRIOR FILING DATE: 2000-05-16
; NUMBER OF SEQ ID NOS: 108
; SEQ ID NO 61
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
; US-09-733-294A-61

Query Match 1.1%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 56;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2020 GGGATGGAGTACTCTATG 2038
Db 1 GGGATGGACTATCTCTATG 19

RESULT 32
US-08-584-040-7597
; Sequence 7597, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Bacobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESSES:
; ADDRESS: Lyon & Lyon
; STREET: 633 West Fifth Street
```

STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 7597:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-7597

Query Match 1.1%; Score 15.4; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 47;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1821 GAAGATGTTGAAGATG 1837
|||:|:|:|:|:|:|
Db 1 GAAGAGUGUGAAGAGG 17

RESULT 33
US-09-371-772B-3391
Sequence 3391, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MHB00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
PRIOR FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 3391
LENGTH: 17
TYPE: RNA
ORGANISM: Mus sp.
US-09-371-772B-3391

Query Match 1.1%; Score 15.4; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 47;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1821 GAAGATGTTGAAGATG 1837
|||:|:|:|:|:|:|
Db 1 GAAGAGUGUGAAGAGG 17

RESULT 34
US-09-371-772B-4818
Sequence 4818, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MHB00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
PRIOR FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 4818
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-4818

Query Match 1.1%; Score 15.4; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 47;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2105 CCAGAGCATGAGACTG 2121
|||:|:|:|:|:|:|
Db 1 CCAGAGCATGAGAGG 17

RESULT 35
US-09-555-889A-5/C
Sequence 5, Application US/09555889A
Patent No. 6429299
GENERAL INFORMATION:
APPLICANT: Bowler, Chris
TITLE OF INVENTION: Nucleotide sequence encoding the tomato light
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESS: Robert J. Jondle
STREET: 555 13th Street NW, Suite 701-E
CITY: Washington
STATE: District of Columbia
COUNTRY: USA
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/555,889A
FILING DATE: 09-Apr-2001
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 5;
US-09-555-889A-5

Query Match 1.1%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 59;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1816 GCCGTGAAGATGTGAA 1832
|||
Db 19 GCCGTGAAGATGTGAA 3

RESULT 36
US-08-368-704C-89/c
Sequence 89, Application US/08368704C
Patent No. 6087160

GENERAL INFORMATION:
APPLICANT: Yuan, Junying
APPLICANT: Miura, Masayuki
TITLE OF INVENTION: Programmed Cell Death Genes and Proteins
NUMBER OF SEQUENCES: 95
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sterne, Keseler, Goldstein & Fox
STREET: 1100 New York Avenue, Suite 600
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20005

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/368,704C
FILING DATE: 4-JAN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/258,287
FILING DATE: 10-JUN-1994
CLASSIFICATION: 435

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/080,850
FILING DATE: 24-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Bugaisky, Lawrence B.
REGISTRATION NUMBER: 35,086
REFERENCE/DOCKET NUMBER: 0609.3920002
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 371-2600
TELEFAX: (202) 371-2540
TELEX: 248636 SSK

INFORMATION FOR SEQ ID NO: 89:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: both
TOPOLOGY: both
US-08-368-704C-89

Query Match 1.1%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 66;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1878-GGAGATGATGAAGATGA 1894
|||
Db 20 GGAGTGTATGAAGATGA 4

RESULT 37
US-08-913-050A-3
Sequence 3, Application US/08913050A
Patent No. 5827726

GENERAL INFORMATION:

APPLICANT: NEZU, Jun-ichi
TITLE OF INVENTION: DNA ENCODING PROTEIN KINASE
NUMBER OF SEQUENCES: 10
CORRESPONDENCE ADDRESS:
ADDRESSEE: BROWDY AND NEIMARK, P.L.L.C.
STREET: 419 7th Street N.W., Suite 300
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20004

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/913,050A
FILING DATE: 05-SEP-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 57104/1995
FILING DATE: 16-MAR-1995

PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP PCT/JP96/00660
FILING DATE: 15-MAR-1996
ATTORNEY/AGENT INFORMATION:
NAME: YUN, Allen C.
REGISTRATION NUMBER: 37,971
REFERENCE/DOCKET NUMBER: NEZU=4
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 628-5197
TELEFAX: (202) 737-3528

INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-913-050A-3

Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 70.0%; Pred. No. 71;
Matches 14; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 1813 GTGGCCGTGAAGATGTGAA 1832
|||
Db 1 GTGCGTGNARATGYTAA 20

RESULT 38
US-09-658-688A-24
Sequence 24, Application US/09658688A
Patent No. 6498035

GENERAL INFORMATION:
APPLICANT: Donna T. Ward
APPLICANT: William Gaarde
APPLICANT: Brett P. Monia
APPLICANT: Jacqueline Wyatt
TITLE OF INVENTION: ANTISENSE MODULATION OF MEK3 EXPRESSION
FILE REFERENCE: RFS-0143
CURRENT APPLICATION NUMBER: US/09/658,688A
CURRENT FILING DATE: 2000-09-08
NUMBER OF SEQ ID NOS: 88
SEQ ID NO 24
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-658-688A-24

Query Match 1.1%; Score 15.2; DB 1; Length 20;


```

; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1806:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-585-684B-1806

Query Match 1.1%; Score 15; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 42;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1373 AGGATTACAGCTT 1387
Db 1 AGGAGAUUACAGCUU 15

RESULT 43
US-08-585-684B-1807
; Sequence 1807, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 218/078
; REFERENCE/DOCKET NUMBER: 32,327
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1805:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-585-684B-1807
```

```

; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1807:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-585-684B-1807

Query Match 1.1%; Score 15; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 42;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1374 GGAATTACAGCTTC 1388
Db 1 GGAGAUUACAGCUUC 15

RESULT 44
US-09-038-073-1805
; Sequence 1805, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 218/078
; REFERENCE/DOCKET NUMBER: 32,327
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1805:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-038-073-1805
```

SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1805

Query Match 1.1%; Score 15; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 42;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1373 AGGAGATTACAGCTT 1387
Db 1 AGGAGAUUACAGCUCU 15

RESULT 45

US-09-038-073-1806
Sequence 1806, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038.073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1806:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1806

Query Match 1.1%; Score 15; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 42;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1373 AGGAGATTACAGCTT 1387
Db 1 AGGAGAUUACAGCUCU 15

RESULT 46

US-09-038-073-1807
Sequence 1807, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038.073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1807:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1807

Query Match 1.1%; Score 15; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 42;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1374 GGAGATTACAGCTTC 1388
Db 1 GGAGAUUACAGCUCUC 15

RESULT 47

US-08-951-923-51/c
Sequence 51, Application US/08951923
Patent No. 6048693
GENERAL INFORMATION:
APPLICANT: Bitter, Grant
TITLE OF INVENTION: PHENOTYPIC ASSAYS OF CYCLIN/CYCLIN-DEPENDENT KINASE
TITLE OF INVENTION: FUNCTION
NUMBER OF SEQUENCES: 57
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cooley Godward LLP
STREET: 5 Palo Alto Square, 3000 El Camino Real
CITY: Palo Alto
STATE: CA
COUNTRY: US
ZIP: 94306-2155

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/951,923
FILING DATE: October 16, 1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Neeley, Richard L.
REGISTRATION NUMBER: 30,092
REFERENCE/DOCKET NUMBER: BIRT-001/02US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650 843-5000
TELEFAX: 650 857-0663
TELEX: 380816COOLEYPA
INFORMATION FOR SEQ ID NO: 51:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: nucleic acid
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHEICAL: NO
ANTI-SENSE: NO
US-08-951-923-51

Query Match 1.1%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 67;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2203 GACTTGACCTGCCGACA 2220
Db 18 GACTTGGCTGGCCGACA 1

RESULT 48
US-09-205-143-42/C
Sequence 42, Application US/09205143
Patent No. 6107091
GENERAL INFORMATION:
APPLICANT: Lex M. Cowser
TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-16 EXPRESSION
FILE REFERENCE: R1S-0032
CURRENT APPLICATION NUMBER: US/09/205,143
CURRENT FILING DATE: 1998-12-03
NUMBER OF SEQ ID NOS: 87
SEQ ID NO 42
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense oligonucleotide
US-09-205-143-42

Query Match 1.1%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 67;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1354 CCAGCGCCTGAAGGAA 1371
Db 18 CCAGTGCCTGAAGGAA 1

RESULT 49
US-09-632-580A-65/C
Sequence 65, Application US/09632580A
Patent No. 625511
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
APPLICANT: Lex M. Cowser
TITLE OF INVENTION: ANTISENSE MODULATION OF HER-4 EXPRESSION

FILE REFERENCE: RTS-0054
CURRENT APPLICATION NUMBER: US/09/632,580A
CURRENT FILING DATE: 2000-07-31
NUMBER OF SEQ ID NOS: 93
SEQ ID NO 65
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense oligonucleotide
US-09-632-580A-65

Query Match 1.1%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 67;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1884 GATGAAGATGATGGAA 1901
Db 18 GATGAAGATGATGGAA 1

RESULT 50
US-08-149-105-10
Sequence 10, Application US/08149105
Patent No. 553892
GENERAL INFORMATION:
APPLICANT: Donahoe, Patricia K.
APPLICANT: Gustafson, Michael
APPLICANT: He, Wei W.
APPLICANT: Wang, Xiao-Fan
TITLE OF INVENTION: TGF- TYPE I RECEPTOR
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson
STREET: 225 Franklin Street
CITY: Boston
STATE: Massachusetts
COUNTRY: U.S.A.
ZIP: 02110-2804

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM PS/2 Model 502 or 55SX
OPERATING SYSTEM: MS-DOS (Version 5.0)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/149,105
FILING DATE:
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/029,673
FILING DATE: March 11, 1993
APPLICATION NUMBER: 07/853,396
FILING DATE: March 18, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Clark, Paul T.
REGISTRATION NUMBER: 30,162
REFERENCE/DOCKET NUMBER: 00786/211001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 17
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-149-105-10

Query Match 1.0%; Score 14.6; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 64;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Oy 1813 GTGGCCGTGAAGATGTT 1829
Db 1 GTGGCCGTGAATATTT 17

RESULT 51

US-08-317-847-10
Sequence 10, Application US/08317847
Patent No. 5547854
GENERAL INFORMATION:
APPLICANT: Donahoe, Patricia K.
APPLICANT: Gustafson, Michael
APPLICANT: He, Wei W.
TITLE OF INVENTION: FOUR NOVEL RECEPTORS OF THE TGF-B
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson
STREET: 225 Franklin Street
CITY: Boston
STATE: Massachusetts
COUNTRY: U.S.A.
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM PS/2 Model 502 or 555X
OPERATING SYSTEM: MS-DOS (Version 5.0)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/317,847
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/029,673
FILING DATE: March 11, 1993
APPLICATION NUMBER: 07/853,396
FILING DATE: March 18, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Clark, Paul T.
REGISTRATION NUMBER: 30,162
REFERENCE/DOCKET NUMBER: 00786/127002
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 17
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-317-847-10

Query Match 1.0%; Score 14.6; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 64;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Oy 1813 GTGGCCGTGAAGATGTT 1829
Db 1 GTGGCCGTGAATATTT 17

RESULT 52
US-08-529-878B-20/c
Sequence 20, Application US/08529878B
Patent No. 5932556
GENERAL INFORMATION:
APPLICANT: Tam, Robert C.
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cirockett & Fish

STREET: 3000 S. Augusta Court
CITY: La Habra
STATE: California
COUNTRY: United States of America
ZIP: 90631
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/529,878B
FILING DATE: 13-SEP-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Fish, Robert D.
REGISTRATION NUMBER: 33,880
REFERENCE/DOCKET NUMBER: 213/003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 714-525-3433
TELEFAX: 714-525-3303
TELEX:
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
US-08-529-878B-20

Query Match 1.0%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 61;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1500 CAGCAGCCAGCCGGCT 1515
Db 16 CAGAGCCAGCCGGCT 1

RESULT 53
US-08-541-950B-17
Sequence 17, Application US/08541950B
Patent No. 5821046
GENERAL INFORMATION:
APPLICANT: Karn J, Galt MJ, Heaphy S, Dingwall C
TITLE OF INVENTION: VIRAL (HIV) GROWTH INHIBITION
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Banner & Witcoff, Ltd.
STREET: One Financial Center, 45th floor
CITY: Boston
STATE: MA
ZIP: 02111
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/541,950B
FILING DATE: 10/10/95
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/960,370
FILING DATE: 03/19/93
ATTORNEY/AGENT INFORMATION:
NAME: Williams, Ph.D., Kathleen M.
REGISTRATION NUMBER: 34,380
REFERENCE/DOCKET NUMBER: 3777/57347 (WRC-011AX)
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 345-9100
TELEFAX: (617) 345-9111
INFORMATION FOR SEQ ID NO: 17:

```

; SEQUENCE CHARACTERISTICS:
;   LENGTH: 17 bases
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
;   MOLECULE TYPE: synthetic RNA
;   FEATURE:
;     NAME/KEY: misc_feature
;     LOCATION: 8
;   OTHER INFORMATION: N is 2'-deoxythymidine
;
US-08-541-950B-17

Query Match          1.0%; Score 14.4; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 69;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy      1490 AGCCGAGCTTCAGCAGC 1506
Db      1 AGCCGAGNUTUGAGCAGC 17

RESULT 54
US-08-541-950B-20
; Sequence 20, Application US/08541950B
; Patent No. 5821046
;
; GENERAL INFORMATION:
;   APPLICANT: Kain J, Galt MJ, Heaphy S, Dingwall C
;   TITLE OF INVENTION: VIRAL (HIV) GROWTH INHIBITION
;   NUMBER OF SEQUENCES: 26
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Banner & Witcoff, Ltd.
;     STREET: One Financial Center, 45th Floor
;     CITY: Boston
;     STATE: MA
;     ZIP: 02111
;
; COMPUTER READABLE FORM:
;   MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
;   COMPUTER: IBM PC compatible
;   OPERATING SYSTEM: PC-DOS/MS-DOS
;   SOFTWARE: Wordperfect 6.1
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/08/541,950B
;     FILING DATE: 10/10/95
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER: 07/960,370
;       FILING DATE: 03/19/93
;       ATTORNEY/AGENT INFORMATION:
;         NAME: Williams, Ph.D., Kathleen M.
;         REGISTRATION NUMBER: 34,380
;         REFERENCE/DOCKET NUMBER: 3777/57347 (MRC-O11AX)
;         TELEPHONE: (617) 345-9100
;         TELEFAX: (617) 345-9111
;       INFORMATION FOR SEQ ID NO: 20:
;         SEQUENCE CHARACTERISTICS:
;           LENGTH: 17 bases
;           TYPE: nucleic acid
;           STRANDEDNESS: single
;           TOPOLOGY: linear
;           MOLECULE TYPE: synthetic RNA
;           FEATURE:
;             NAME/KEY: misc_feature
;             LOCATION: 8
;           OTHER INFORMATION: N is 5-bromo-2'-deoxyuridine
;
US-08-541-950B-20

Query Match          1.0%; Score 14.4; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 69;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy      1490 AGCCGAGCTTCAGCAGC 1506
Db      1 AGCCGAGNUTUGAGCAGC 17
```

```

; SEQUENCE CHARACTERISTICS:
;   LENGTH: 17 bases
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
;   MOLECULE TYPE: synthetic RNA
;   FEATURE:
;     NAME/KEY: misc_feature
;     LOCATION: 8
;   OTHER INFORMATION: N is 2'-deoxythymidine
;
US-09-083-756A-17

Query Match          1.0%; Score 14.4; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 69;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy      1490 AGCCGAGCTTCAGCAGC 1506
Db      1 AGCCGAGNUTUGAGCAGC 17

RESULT 55
US-09-083-756A-17
; Sequence 17, Application US/09083756A
; Patent No. 6114109
;
; GENERAL INFORMATION:
;   APPLICANT: Kain J, Galt MJ, Heaphy S, Dingwall C
;   TITLE OF INVENTION: VIRAL (HIV) GROWTH INHIBITION
;   NUMBER OF SEQUENCES: 26
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Banner & Witcoff, Ltd.
;     STREET: One Financial Center, 45th Floor
;     CITY: Boston
;     STATE: MA
;     ZIP: 02111
;
; COMPUTER READABLE FORM:
;   MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
;   COMPUTER: IBM PC compatible
;   OPERATING SYSTEM: PC-DOS/MS-DOS
;   SOFTWARE: Wordperfect 6.1
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/09/083,756A
;     FILING DATE:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER: 08/541,950
;       FILING DATE:
;       ATTORNEY/AGENT INFORMATION:
;         NAME: Williams, Ph.D., Kathleen M.
;         REGISTRATION NUMBER: 34,380
;         REFERENCE/DOCKET NUMBER: 3777/57347 (MRC-O11AX)
;         TELEPHONE: (617) 345-9100
;         TELEFAX: (617) 345-9111
;       INFORMATION FOR SEQ ID NO: 17:
;         SEQUENCE CHARACTERISTICS:
;           LENGTH: 17 bases
;           TYPE: nucleic acid
;           STRANDEDNESS: single
;           TOPOLOGY: linear
;           MOLECULE TYPE: synthetic RNA
;           FEATURE:
;             NAME/KEY: misc_feature
;             LOCATION: 8
;           OTHER INFORMATION: N is 2'-deoxythymidine
;
US-09-083-756A-17

Query Match          1.0%; Score 14.4; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 69;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy      1490 AGCCGAGCTTCAGCAGC 1506
Db      1 AGCCGAGNUTUGAGCAGC 17

RESULT 56
US-09-083-756A-20
; Sequence 20, Application US/09083756A
; Patent No. 6114109
;
; GENERAL INFORMATION:
;   APPLICANT: Kain J, Galt MJ, Heaphy S, Dingwall C
;   TITLE OF INVENTION: VIRAL (HIV) GROWTH INHIBITION
;   NUMBER OF SEQUENCES: 26
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Banner & Witcoff, Ltd.
;     STREET: One Financial Center, 45th Floor
;     CITY: Boston
;     STATE: MA
;     ZIP: 02111
;
; COMPUTER READABLE FORM:
;   MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
;   COMPUTER: IBM PC compatible
```

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/083,756A
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/541,950
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Williams, Ph.D., Kathleen M.
REGISTRATION NUMBER: 34,380
REFERENCE/DOCKET NUMBER: 3777/57347 (MRC-011AX)
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 345-9100
TELEFAX: (617) 345-9111
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: synthetic RNA
FEATURE:
NAME/KEY: misc_feature
LOCATION: 8
OTHER INFORMATION: N is 5-bromo-2'-deoxyuridine
US-09-083-756A-20

Query Match 1.0%; Score 14.4; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 69;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1490 AGCCAGACTTCAGCAGC 1506

Db 1 AGCCAGANUGAGCAGC 17

RESULT 57
US-08-584-040-5715
Sequence 5715, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Scinichomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 5715:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-5715

Query Match 1.0%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 69;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1822 AAGATGTTGAAGAATG 1837

Db 2 AAGAUUGUAAAGAAG 17

RESULT 58
US-09-371-772B-2598
Sequence 2598, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwigen, Jim
APPLICANT: Scinichomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: M8B00, 876-J (237/198)
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US/09/371,772B
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 2598
LENGTH: 17
TYPE: RNA
ORGANISM: Mus gp.
US-09-371-772B-2598

Query Match 1.0%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 69;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1822 AAGATGTTGAAGAATG 1837

Db 2 AAGAUUGUAAAGAAG 17

RESULT 59
US-08-541-950B-23
Sequence 23, Application US/08541950B
Patent No. 5821046
GENERAL INFORMATION:
APPLICANT: Karn J, Gail M, Heaphy S, Dingwall C
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Banner & Witcoff, Ltd.
STREET: One Financial Center, 45th Floor
CITY: Boston

STATE: MA
ZIP: 02111
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/541,950B
FILING DATE: 10/10/95
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/960,370
FILING DATE: 03/19/93
ATTORNEY/AGENT INFORMATION:
NAME: Williams, Ph.D., Kathleen M.
REGISTRATION NUMBER: 34,380
REFERENCE/DOCKET NUMBER: 3777/57347 (MRC-011AX)
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 345-9100
TELEFAX: (617) 345-9111
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: synthetic RNA
FEATURE:
NAME/KEY: misc_feature
LOCATION: 8
OTHER INFORMATION: N is 4-thio-2'-deoxythymidine
US-08-541-950B-23

Query Match 1.0%; Score 14.4; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 78;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1490 AGCCGAGCTTCAGCAGC 1506
DB 1 AGCCGAGNUUGAGCAGC 17

RESULT 60
US-09-205-922-30
Sequence 30, Application US/09205922
Patent No. 5951455
GENERAL INFORMATION:
APPLICANT: Lex M. Cowseart
TITLE OF INVENTION: ANTISENSE MODULATION OF G-APLHA-11 EXPRESSION
FILE REFERENCE: RTS-0030
CURRENT APPLICATION NUMBER: US/09/205,922
CURRENT FILING DATE: 1998-12-04
NUMBER OF SEQ ID NOS: 87
SEQ ID NO 30
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-205-922-30

Query Match 1.0%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1814 TGCCGTAAGATGTT 1829
DB 1 TGCCGTAAGATGTT 16

RESULT 61
US-09-083-756A-23
Sequence 23, Application US/09083756A

Patent No. 6114109
GENERAL INFORMATION:
APPLICANT: Kahn U, Galt M, Heaphy S, Dingwall C
TITLE OF INVENTION: VIRAL (HIV) GROWTH INHIBITION
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Banner & Witcoff, Ltd.
STREET: One Financial Center, 45th Floor
CITY: Boston
STATE: MA
ZIP: 02111
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/083,756A
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/541,950
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Williams, Ph.D., Kathleen M.
REGISTRATION NUMBER: 34,380
REFERENCE/DOCKET NUMBER: 3777/57347 (MRC-011AX)
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 345-9100
TELEFAX: (617) 345-9111
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: synthetic RNA
FEATURE:
NAME/KEY: misc_feature
LOCATION: 8
OTHER INFORMATION: N is 4-thio-2'-deoxythymidine
US-09-083-756A-23

Query Match 1.0%; Score 14.4; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 78;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1490 AGCCGAGCTTCAGCAGC 1506
DB 1 AGCCGAGNUUGAGCAGC 17

RESULT 62
US-09-658-645A-5
Sequence 5, Application US/09658645A
Patent No. 6423518
GENERAL INFORMATION:
APPLICANT: Anderson, Stephen
TITLE OF INVENTION: Design and Production of Mutant 2,5-Diketo-D-gluconic
FILE REFERENCE: RU-0078
CURRENT APPLICATION NUMBER: US/09/658,645A
CURRENT FILING DATE: 2000-09-11
NUMBER OF SEQ ID NOS: 12
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 5
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-658-645A-5

Query Match 1.0%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1356 AGCGCTCGAAGAGA 1371
Db 2 AGCGCTCGAAGAGA 17

RESULT 63
US-09-371-772B-4817
; Sequence 4817, Application US/09371772B
; Patent No. 6566127

GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam

APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

FILE REFERENCE: MHB00, 8/6-J (237/198)

CURRENT APPLICATION NUMBER: US/09/371, 772B

CURRENT FILING DATE: 1999-08-10

PRIOR APPLICATION NUMBER: US 60/005, 974

PRIOR FILING DATE: 1995-10-26

PRIOR APPLICATION NUMBER: US 08/584, 040

PRIOR FILING DATE: 1996-01-08

NUMBER OF SEQ ID NOS: 14225

SOFTWARE: Patentin version 3.0

SEQ ID NO 4817

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-09-371-772B-4817

Query Match 1.0%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 81;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2102 TGGCCAGAGCATG 2115
Db 4 UGCGCAGAGCAG 17

RESULT 64
US-09-338-907-84/c
; Sequence 84, Application US/09338907
; Patent No. 6265546

GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta

APPLICANT: Ilyia, Chumakov
; APPLICANT: Bougueleret, Lydie

TITLE OF INVENTION: PROSTATE CANCER GENE
; TITLE REFERENCE: GENSET, 18CP1CP

CURRENT APPLICATION NUMBER: US/09/338, 907

CURRENT FILING DATE: 1999-06-23

EARLIER APPLICATION NUMBER: 08/996, 306

EARLIER FILING DATE: 1997-12-22

EARLIER APPLICATION NUMBER: 60/099, 658

EARLIER FILING DATE: 1998-09-09

EARLIER APPLICATION NUMBER: 09/218, 207

EARLIER FILING DATE: 1998-12-22

NUMBER OF SEQ ID NOS: 578

SOFTWARE: Patent.pm

SEQ ID NO 84

LENGTH: 17

TYPE: DNA

ORGANISM: Mus Musculus

FEATURE:

NAME/KEY: misc feature

LOCATION: 1..17

OTHER INFORMATION: sequencing oligonucleotide mofGracesR444
US-09-338-907-84

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2092 ACTTACCGCTGGCCAG 2108
Db 17 ACTTACCGCTGGCCAG 1

RESULT 65
US-09-218-207-84/c
; Sequence 84, Application US/09218207
; Patent No. 6346381

GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta

APPLICANT: Ilyia, Chumakov
; APPLICANT: Bougueleret, Lydie

TITLE OF INVENTION: Prostate cancer gene
; TITLE OF INVENTION: GENSET, 018CP1

FILE REFERENCE: GENSET, 018CP1

CURRENT APPLICATION NUMBER: US/09/218, 207

CURRENT FILING DATE: 1998-12-22

EARLIER APPLICATION NUMBER: 08/996, 306

EARLIER FILING DATE: 1997-12-22

EARLIER APPLICATION NUMBER: 60/099, 658

EARLIER FILING DATE: 1998-09-09

NUMBER OF SEQ ID NOS: 578

SOFTWARE: Patent.pm

SEQ ID NO 84

LENGTH: 17

TYPE: DNA

ORGANISM: Mus Musculus

FEATURE:

NAME/KEY: misc feature

LOCATION: 1..17

OTHER INFORMATION: sequencing oligonucleotide mofGracesR444

US-09-218-207-84

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2092 ACTTACCGCTGGCCAG 2108
Db 17 ACTTACCGCTGGCCAG 1

RESULT 66
US-08-584-040-4205
; Sequence 4205, Application US/08584040
; Patent No. 6346398

GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James

APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR

TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL

TITLE OF INVENTION: GROWTH FACTOR

NUMBER OF SEQUENCES: 8502

CORRESPONDENCE ADDRESSES:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Filth Street

STREET: Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 4205:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-4205

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 87;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2112 CATGAGTCTTGCTT 2128
||:||||:|:||||:|
1 CAUGAGUUCUUGGCAU 17

Db 1 CAUGAGUUCUUGGCAU 17

RESULT 67
US-08-584-040-4206
Sequence 4206, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Scinchoomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974

FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 4206:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-4206

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 87;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2113 ATGAGTCTTGCTTC 2129
||:||||:|:||||:|
1 AUGGAGUUCUUGGCAUC 17

Db 1 AUGGAGUUCUUGGCAUC 17

RESULT 68
US-08-584-040-4242
Sequence 4242, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Scinchoomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 4242:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-4242

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 87;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 2323 AGTGATGCTGTCCTT 2339
||:||||:||||:|
Db 1 AGUGACGUCUGUCUUU 17

RESULT 69
US-08-584-040-4357
; Sequence 4357, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Filth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 4357:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-4357

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 87;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
QY 2404 GAACCTTTAAGCTCT 2420
||||:||||:|
Db 1 GAACUUUAAAGCUAU 17

RESULT 70
US-08-584-040-5714
; Sequence 5714, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Filth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5714:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-5714

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 87;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
QY 1813 GTGGCCGTAAGATGT 1829
||:||||:||||:|
Db 1 GUAGCCGCAAGUGUU 17

RESULT 71
US-08-584-040-5779
; Sequence 5779, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE

TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Wardburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 5779:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-5779

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 87;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2112 CATGAGTACTTGCTT 2128
Db 1 CAUGAGUCUUGGCAU 17

RESULT 72
US-08-584-040-5780
Sequence 5780, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: MCSwigen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Bacobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.

ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Wardburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 5780:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-5780

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 87;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2113 ATGAGTACTTGCTT 2129
Db 1 AUGGAGUCUUGGCAUC 17

RESULT 73
US-08-584-040-5817
Sequence 5817, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: MCSwigen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Bacobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:

```

; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5817:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-584-040-5817

Query Match          1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 87;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Qy      2332 TGGTCTTCGGGGTGT 2348
Db      1 UGUCUUCUGGUGUGU 17
      :||:|||||:|:|:|

RESULT 74
US-08-584-040-7674
; Sequence 7674, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Filth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7674:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-584-040-7684
```

```

; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-584-040-7674

Query Match          1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 87;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy      2279 GGATGGCTCCAGAGCC 2295
Db      1 GAUGGCUCCGGAUCC 17
      |||:|||||:|:|:|

RESULT 75
US-08-584-040-7684
; Sequence 7684, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Filth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7684:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-584-040-7684

Query Match          1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 87;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy      2353 TGGAGATCTTCACCTT 2369
      :|||:|||||:|:|:|
```

Db 1 UGGAGAUCCUCCU 17

RESULT 76
US-08-584-040-7685
; Sequence 7685, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7685:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-7685

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 87;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

OY 2355 GGAGATCTTACTTAG 2371
Db 1 GGAGAUCCUCCUCCUAG 17

RESULT 77
US-08-584-040-7686
; Sequence 7686, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7686:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-7686

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 87;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

OY 2356 GGAGATCTTACTTAGG 2372
Db 1 GAGAUCCUCCUCCUAGG 17

RESULT 78
US-08-584-040-7687
; Sequence 7687, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California

COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 7687:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-7687

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 87;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
Qy 2358 GATCTGACTTTAGGGG 2374
Db 1 GAUCCUCCUAGGGG 17

RESULT 79
US-09-370-644B-21
Sequence 21, Application US/09370644B
Patent No. 6433253
GENERAL INFORMATION:
APPLICANT: Kossmann et al.
TITLE OF INVENTION: DEBRANCHING ENZYMES AND DNA SEQUENCES CODING THEM,
TITLE OF INVENTION: SUITABLE FOR CHANGING THE DEGREE OF BRANCHING OF
TITLE OF INVENTION: AMYLOPECTIN STARCH IN PLANTS
FILE REFERENCE: 514413-3771
CURRENT APPLICATION NUMBER: US/09/370,644B
PRIOR FILING DATE: 1999-08-06
PRIOR APPLICATION NUMBER: 08/596,257
PRIOR FILING DATE: 1996-04-18
NUMBER OF SEQ ID NOS: 26
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 21
LENGTH: 17
TYPE: RNA
ORGANISM: Solanum tuberosum
US-09-370-644B-21

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 87;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
Qy 2271 AGTCAAGTGAATGGCTC 2287
Db 1 AUVCAAGUGAUGGCGC 17

RESULT 80
US-09-474-432B-385/c .

Sequence 385, Application US/09474432B
Patent No. 6528640
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Beigelman, Leo
APPLICANT: Burgin, Alex
APPLICANT: Beaudry, Amber
APPLICANT: Karpeisky, Alex
APPLICANT: Adamic, Jasenka
APPLICANT: Sweedler, David
TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
FILE REFERENCE: MBH00-831-B (247/276)
CURRENT APPLICATION NUMBER: US/09/474,432B
PRIOR FILING DATE: 1999-12-19
PRIOR APPLICATION NUMBER: US 60/064,866
PRIOR FILING DATE: 1997-11-05
PRIOR APPLICATION NUMBER: US 60/084,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: US 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: US 09/301,511
PRIOR FILING DATE: 1999-04-28
NUMBER OF SEQ ID NOS: 1526
SOFTWARE: PatentIn version 3.0
SEQ ID NO 385
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-474-432B-385

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1920 TCTTCTTGAGAGCTGCA 1936
Db 17 TCTTCTTGACGACGCA 1

RESULT 81
US-09-474-432B-778
Sequence 778, Application US/09474432B
Patent No. 6528640
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Beigelman, Leo
APPLICANT: Burgin, Alex
APPLICANT: Beaudry, Amber
APPLICANT: Karpeisky, Alex
APPLICANT: Adamic, Jasenka
APPLICANT: Sweedler, David
TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
FILE REFERENCE: MBH00-831-B (247/276)
CURRENT APPLICATION NUMBER: US/09/474,432B
PRIOR FILING DATE: 1999-12-19
PRIOR APPLICATION NUMBER: US 60/064,866
PRIOR FILING DATE: 1997-11-05
PRIOR APPLICATION NUMBER: US 60/084,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: US 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: US 09/301,511
PRIOR FILING DATE: 1999-04-28
NUMBER OF SEQ ID NOS: 1526
SOFTWARE: PatentIn version 3.0
SEQ ID NO 778
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-474-432B-778

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 87;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 2269 CCACTCAAGTGGATGCG 2285
||:||||:||||:
Db 1 CCAUCAAGUGGAGUGGC 17

RESULT 82

US-09-371-772B-1972
; Sequence 1972, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1972
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1972

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 87;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2112 CATGAGTACTTGCTT 2128
||:||||:||||:
Db 1 CAUGAGUCUUGGCAU 17

RESULT 83

US-09-371-772B-1973
; Sequence 1973, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1973
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1973

Query Match 1.0%; Score 13.8; DB 1; Length 17;

Best Local Similarity 58.8%; Pred. No. 87;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2113 ATGAGTACTTGCTTC 2129
||:||||:||||:
Db 1 AUGGAGUCUUGGCAUC 17

RESULT 84

US-09-371-772B-2009
; Sequence 2009, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2009
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-2009

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 87;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 2323 AGTATGTCGTGCTT 2339
||:||||:||||:
Db 1 AGUGAGUCUUGUCUUCU 17

RESULT 85

US-09-371-772B-2124
; Sequence 2124, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2124
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-2124

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 87;

Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 2404 GAACCTTTAGCTGCT 2420

Db 1 GAACUUUAAAGCUGAU 17

RESULT 86

US-09-371-772B-2597

; Sequence 2597, Application US/09371772B

; Patent No. 6566127

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwigen, Jim

; APPLICANT: Stinchcomb, Dan

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re

; FILE REFERENCE: MBHB00,876-J (237/198)

; CURRENT APPLICATION NUMBER: US/09/371,772B

; CURRENT FILING DATE: 1999-08-10

; PRIOR APPLICATION NUMBER: US 60/005,974

; PRIOR FILING DATE: 1995-10-26

; PRIOR APPLICATION NUMBER: US 08/584,040

; PRIOR FILING DATE: 1996-01-08

; NUMBER OF SEQ ID NOS: 14225

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 2597

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Mus sp.

US-09-371-772B-2597

Query Match 1.0%; Score 13.8; DB 1; Length 17;

Best Local Similarity 58.8%; Pred. No. 87;

Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1813 GTGGCCCGAAGATGTT 1829

Db 1 GUAGCCGUCAGAGUGU 17

RESULT 87

US-09-371-772B-2682

; Sequence 2682, Application US/09371772B

; Patent No. 6566127

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwigen, Jim

; APPLICANT: Stinchcomb, Dan

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re

; FILE REFERENCE: MBHB00,876-J (237/198)

; CURRENT APPLICATION NUMBER: US/09/371,772B

; CURRENT FILING DATE: 1999-08-10

; PRIOR APPLICATION NUMBER: US 60/005,974

; PRIOR FILING DATE: 1995-10-26

; PRIOR APPLICATION NUMBER: US 08/584,040

; PRIOR FILING DATE: 1996-01-08

; NUMBER OF SEQ ID NOS: 14225

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 2682

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Mus sp.

US-09-371-772B-2682

Query Match 1.0%; Score 13.8; DB 1; Length 17;

Best Local Similarity 47.1%; Pred. No. 87;

Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Qy 2332 TGGTCTCGGGTGTT 2348

Db 1 UGAGUCUUCGGUGUGU 17

RESULT 88

US-09-371-772B-3459

; Sequence 3459, Application US/09371772B

; Patent No. 6566127

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwigen, Jim

; APPLICANT: Stinchcomb, Dan

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re

; FILE REFERENCE: MBHB00,876-J (237/198)

; CURRENT APPLICATION NUMBER: US/09/371,772B

; CURRENT FILING DATE: 1999-08-10

; PRIOR APPLICATION NUMBER: US 60/005,974

; PRIOR FILING DATE: 1995-10-26

; PRIOR APPLICATION NUMBER: US 08/584,040

; PRIOR FILING DATE: 1996-01-08

; NUMBER OF SEQ ID NOS: 14225

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 3459

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Mus sp.

US-09-371-772B-3459

Query Match 1.0%; Score 13.8; DB 1; Length 17;

Best Local Similarity 76.5%; Pred. No. 87;

Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 2279 GGATGGCTCCGAGAGCC 2295

Db 1 GGAUGGCUUCGAAUCC 17

RESULT 89

US-09-371-772B-3469

; Sequence 3469, Application US/09371772B

; Patent No. 6566127

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwigen, Jim

; APPLICANT: Stinchcomb, Dan

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re

; FILE REFERENCE: MBHB00,876-J (237/198)

; CURRENT APPLICATION NUMBER: US/09/371,772B

; CURRENT FILING DATE: 1999-08-10

; PRIOR APPLICATION NUMBER: US 60/005,974

; PRIOR FILING DATE: 1995-10-26

; PRIOR APPLICATION NUMBER: US 08/584,040

; PRIOR FILING DATE: 1996-01-08

; NUMBER OF SEQ ID NOS: 14225

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 3469

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Mus sp.

US-09-371-772B-3469

Query Match 1.0%; Score 13.8; DB 1; Length 17;

Best Local Similarity 52.9%; Pred. No. 87;

Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 2353 TCGAGATCTTCACCTTT 2369
:||||:|:|:|
Db 1 UCGAGAUCCUCCUAG 17

RESULT 90
US-09-371-772B-3470
; Sequence 3470, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3470
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3470

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 87;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
QY 2355 GGAGATCTTCACCTTAG 2371
||||:|:|:|
Db 1 GGAGAUCCUCCUAG 17

RESULT 91
US-09-371-772B-3471
; Sequence 3471, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3471
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3471

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 87;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
QY 2356 GAGATCTTCACCTTAG 2372

Db 1 GAGAUCCUCCUAGG 17
||||:|:|:|

RESULT 92
US-09-371-772B-3472
; Sequence 3472, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3472
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3472

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 87;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
QY 2358 GATCTTCACCTTAGGG 2374
||||:|:|:|
Db 1 GAUCUCCUCCUAGGG 17

RESULT 93
US-09-371-772B-4816
; Sequence 4816, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4816
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4816

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 87;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 2098 CAGCTGCAGAGGAT 2114
||:|||||

Db 1 CAAGUGGCCAGAGCAU 17

RESULT 94
US-09-371-772B-4845

Sequence 4845, Application US/0931772B
Patent No. 6566127

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Pavco, Pam

APPLICANT: McSwigen, Jim

APPLICANT: Stinchcomb, Dan

APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re

FILE REFERENCE: MEBH00,876-J (237/198)

CURRENT APPLICATION NUMBER: US/09/371,772B

PRIOR FILING DATE: 1999-08-10

PRIOR APPLICATION NUMBER: US 60/005,974

PRIOR FILING DATE: 1995-10-26

PRIOR APPLICATION NUMBER: US 08/584,040

PRIOR FILING DATE: 1996-01-08

NUMBER OF SEQ ID NOS: 14225

SOFTWARE: PatentIn version 3.0

SEQ ID NO 4845

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-09-371-772B-4845

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 87;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 2278 TGATGCTCCAGAGC 2234

Db 1 UGAGUGGCUCCGGAUC 17

RESULT 95
US-09-371-772B-6752

Sequence 6752, Application US/0931772B
Patent No. 6566127

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Pavco, Pam

APPLICANT: McSwigen, Jim

APPLICANT: Stinchcomb, Dan

APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re

FILE REFERENCE: MEBH00,876-J (237/198)

CURRENT APPLICATION NUMBER: US/09/371,772B

PRIOR FILING DATE: 1999-08-10

PRIOR APPLICATION NUMBER: US 60/005,974

PRIOR FILING DATE: 1995-10-26

PRIOR APPLICATION NUMBER: US 08/584,040

PRIOR FILING DATE: 1996-01-08

NUMBER OF SEQ ID NOS: 14225

SOFTWARE: PatentIn version 3.0

SEQ ID NO 6752

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-09-371-772B-6752

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 87;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 2278 TGATGCTCCAGAGC 2234

Db 1 UGAGUGGCUCCGGAUC 17

RESULT 96
US-09-325-601-1

Sequence 1, Application US/09325601
Patent No. 6573045

GENERAL INFORMATION:

APPLICANT: Karn

APPLICANT: Prescott

TITLE OF INVENTION: Methods and Kits for Discovery of RNA-Binding Compounds

FILE REFERENCE: 3950/81235

CURRENT APPLICATION NUMBER: US/09/325,601

PRIOR FILING DATE: 1999-06-03

NUMBER OF SEQ ID NOS: 53

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 1

LENGTH: 17

TYPE: RNA

ORGANISM: Human immunodeficiency virus

US-09-325-601-1

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 87;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1490 AGCCGACTTCAGAGC 1506

Db 1 AGCCAGAUUUGAGCAGC 17

RESULT 97
US-08-143-219-19

Sequence 19, Application US/08143219
Patent No. 5670330

GENERAL INFORMATION:

APPLICANT: Sonnenberg, Nahum

APPLICANT: Katze, Michael G.

APPLICANT: Roy, Sophie

APPLICANT: Koromilas, Antonis E.

APPLICANT: Barber, Glen N.

TITLE OF INVENTION: TUMOR-CELL ASSAY METHOD AND KIT

NUMBER OF SEQUENCES: 27

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 611 West Sixth Street

CITY: Los Angeles

STATE: CA

COUNTRY: USA

ZIP: 90017

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

OPERATING SYSTEM: IBM compatible

SOFTWARE: WordPerfect (Version 5.1)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/143,219

FILING DATE: October 25, 1993

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

PRIOR APPLICATION DATA: including application

APPLICATION NUMBER: 08/141,244

FILING DATE: October 22, 1993

APPLICATION NUMBER: 07/953,681

FILING DATE: September 29, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Douglas E. Olson

REGISTRATION NUMBER: 22,798

REFERENCE/DOCKET NUMBER: 204/139

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

two

INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: COMPLEMENTARY TO THE RNA PROBE FOR
INDIVIDUAL ISOLATE: PR-VII, FIGURE 5
US-08-143-219-19

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 98;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2197 ATAGCAGACTTTGACT 2213
Db 1 ATTGAGACTTTGACT 17

RESULT 98
US-08-307-619-33
Sequence 33, Application US/08307619
Patent No. 5733743
GENERAL INFORMATION:
APPLICANT: Johnson, Kevin S
APPLICANT: Winter, Gregory P
APPLICANT: Griffiths, Andrew D
APPLICANT: Smith, Andrew JH
APPLICANT: Waterhouse, P
TITLE OF INVENTION: Methods for producing members of specific
TITLE OF INVENTION: binding pairs
NUMBER OF SEQUENCES: 67
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borum
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25 (BPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/307,619
FILING DATE: 16-SEP-1994
CLASSIFICATION: 435
CLASSIFICATION: GOIN 33/531, GOIN 33/68
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB93/00605
FILING DATE: 24-MAR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206318.9
FILING DATE: 24-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB92/00883
FILING DATE: 15-MAY-1992
ATTORNEY/AGENT INFORMATION:
NAME: David W. Clough
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 28111/32238
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312-474-6300
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-307-619-33

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 98;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1673 AACTCCAGAGACCCA 1689
Db 1 AACATCCAGATGACCCA 17

RESULT 99
US-08-470-837-21/c
Sequence 21, Application US/08470837
Patent No. 5800811
GENERAL INFORMATION:
APPLICANT: Nimni, Marcel E.
APPLICANT: Hall, Frederick L.
APPLICANT: Tuan, Tai-Lan
APPLICANT: Wu, Lingtao
APPLICANT: Cheung, David T.
TITLE OF INVENTION: Transforming Growth Factor B Fusion
TITLE OF INVENTION: and
TITLE OF INVENTION: their use in wound healing
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSEE: Merchant & Gould
STREET: 1150 Santa Monica Boulevard, Suite 400
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90025-3395
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/470,837
FILING DATE:
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Sharp, Janice A.
REGISTRATION NUMBER: 34,051
REFERENCE/DOCKET NUMBER: 30630-10S01
TELECOMMUNICATION INFORMATION:
TELEPHONE: 310-445-9031
TELEFAX: 310-445-1140
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
FEATURE:
NAME/KEY: CDS
LOCATION: 1..18
FEATURE:
NAME/KEY: mat_peptide
LOCATION: 1
US-08-470-837-21

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 98;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1879 GAGATGATGAGATGAT 1895
Db 18 GTGATGATGATGATGAT 2

RESULT 100
US-08-541-950B-13

Sequence 13, Application US/08541950B
Patent No. 5821046
GENERAL INFORMATION:
APPLICANT: Kain J, Galt MJ, Heaphy S, Dingwall C
TITLE OF INVENTION: VIRAL (HIV) GROWTH INHIBITION
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Banner & Witcoff, Ltd.
STREET: One Financial Center, 45th Floor
CITY: Boston
STATE: MA
ZIP: 02111
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/541,950B
FILING DATE: 10/10/95
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/960,370
FILING DATE: 03/19/93
ATTORNEY/AGENT INFORMATION:
NAME: Williams, Ph.D., Kathleen M.
REGISTRATION NUMBER: 34,380
REFERENCE/DOCKET NUMBER: 3777/57347 (MRC-011AX)
TELEPHONE: (617) 345-9110
TELEFAX: (617) 345-9111
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: synthetic RNA
US-08-541-950B-13

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 98;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1490 AGCCAGACTTACGAGC 1506
Db 1 AGCCAGAUUGAGCAGC 17

RESULT 101
US-08-350-260A-79
Sequence 79, Application US/08350260A
Patent No. 5962255
GENERAL INFORMATION:
APPLICANT: Winter, Gregory Paul
APPLICANT: Griffiths, Andrew David
APPLICANT: Williams, Samuel Cameron
APPLICANT: Waterhouse, Peter
APPLICANT: Nissim, Ahuva
APPLICANT: Johnson, Kevin Stuart
APPLICANT: Smith, Andrew John Hammond
TITLE OF INVENTION: Methods for producing members of specific
TITLE OF INVENTION: binding pairs
NUMBER OF SEQUENCES: 602
CORRESPONDENCE ADDRESS:
ADDRESSEE: David W. Clough
STREET: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: F]oppy disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/350,260A
FILING DATE: 05-DEC-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9110549.4
FILING DATE: 15-MAY-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206318.9
FILING DATE: 24-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB91/01134
FILING DATE: 10-JUL-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB92/00883
FILING DATE: 15-MAY-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB93/00605
FILING DATE: 24-MAR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/150,002
FILING DATE: 31-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/307,619
FILING DATE: 16-SEP-1994
ATTORNEY/AGENT INFORMATION:
NAME: Clough, David W
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 28111/32372
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312-474-6300
INFORMATION FOR SEQ ID NO: 79:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-350-260A-79

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 98;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1673 AACTTCCAGAGACCA 1689
Db 1 AACATCCAGATGACCA 17

RESULT 102
US-09-205-921-17/c
Sequence 17, Application US/09205921A
Patent No. 6008048
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
APPLICANT: ex M. Cowsett
TITLE OF INVENTION: ANTISENSE MODULATION OF EGR-1 EXPRESSION
FILE REFERENCE: RTS-0028
CURRENT APPLICATION NUMBER: US/09/205,921A
CURRENT FILING DATE: 1998-12-04
NUMBER OF SEQ ID NOS: 47
SEQ ID NO 17
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense oligonucleotide
US-09-205-921-17

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 98;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1924 CTTGAGCCTGCACCA 1940
Db 17 CTTGAGCCTGCACCA 1

RESULT 103
US-08-722-240-4
; Sequence 4, Application US/08722240
; Patent No. 6083905
; GENERAL INFORMATION:
; APPLICANT: Voorberg, Johannes Jacobus,
; APPLICANT: van Mourik, Jan Aart
; APPLICANT: Mertens, Koenraad
; TITLE OF INVENTION: Method and means for detecting and treating
; TITLE OF INVENTION: disorders in the blood coagulation cascade
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Michaelson & Wallace
; STREET: 328 Newman Springs Road, P.O. Box 8489
; CITY: Red Bank
; STATE: New Jersey
; ZIP: 07701
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk 3 1/2", 1.44 Mbyte
; OPERATING SYSTEM: Windows NT 4 Workstation
; SOFTWARE: Microsoft Word 97
; CURRENT APPLICATION NUMBER: US/08/722,240
; FILING DATE: January 27, 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Michaelson, Peter L.
; REGISTRATION NUMBER: 30090
; REFERENCE/DOCKET NUMBER: Stichting-10
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (732)530-6671
; TELEFAX: (732)530-6584
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
; HYPOTHEICAL: NO
US-08-722-240-4

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 98;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2531 TGGTAGAGACTTGAT 2547
Db 2 TGGTAGAGACTTGAT 18
RESULT 104
US-09-344-521-25/c
; Sequence 25, Application US/09344521
; Patent No. 610090
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Coweart
; TITLE OF INVENTION: ANTISENSE MODULATION OF PI3K P85 EXPRESSION
; FILE REFERENCE: RFS-0062
; CURRENT APPLICATION NUMBER: US/09/344,521
; FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 25
; LENGTH: 18
; TYPE: DNA

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-521-25

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 98;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2530 TTGTAAGAGACTTGA 2546
Db 17 TTGTAAGAGACTTGA 1

RESULT 105
US-09-205-143-41/c
; Sequence 41, Application US/09205143
; Patent No. 6107091
; GENERAL INFORMATION:
; APPLICANT: Lex M. Coweart
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-16 EXPRESSION
; FILE REFERENCE: RFS-0032
; CURRENT APPLICATION NUMBER: US/09/205,143
; FILING DATE: 1998-12-03
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 41
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-205-143-41

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 98;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1354 CCAGCGCTGAGAGCA 1370
Db 17 CCAGCGCTGAGAGCA 1

RESULT 106
US-09-083-756A-13
; Sequence 13, Application US/09083756A
; Patent No. 6114109
; GENERAL INFORMATION:
; APPLICANT: Karm J, Galt MJ, Heaphy S, Dingwall C
; TITLE OF INVENTION: VIRAL (HIV) GROWTH INHIBITION
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Witcoff, Ltd.
; STREET: One Financial Center, 45th Floor
; CITY: Boston
; STATE: MA
; ZIP: 02111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/083,756A
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/541,950
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Williams, Ph.D., Kathleen M.
; REGISTRATION NUMBER: 34,380
; REFERENCE/DOCKET NUMBER: 3777/57347 (MRC-011AX)
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 345-9100

TELEFAX: (617) 345-9111
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: synthetic RNA
US-09-083-756A-13

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 98;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1490 AGCCAGCTTACGACG 1506
Db 1 AGCCAGATUUGAGCAGC 17

RESULT 107
US-09-050-783-33
; Sequence 33, Application US/09050783
; Patent No. 6140471
; GENERAL INFORMATION:
; APPLICANT: Johnson, Kevin S
; APPLICANT: Winter, Gregory P
; APPLICANT: Griffiths, Andrew D
; APPLICANT: Smith, Andrew JH
; APPLICANT: Waterhouse, P
; TITLE OF INVENTION: Methods for producing members of specific
; TITLE OF INVENTION: binding pairs
; NUMBER OF SEQUENCES: 67
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/050.783
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/307,619
; FILING DATE: 16-SEP-1994
; APPLICATION NUMBER: PCT/GB93/00605
; FILING DATE: 24-MAR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9206318.9
; FILING DATE: 24-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/GB92/00883
; FILING DATE: 15-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: David W. Clough
; REGISTRATION NUMBER: 36,107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312-474-6300
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-050-783-33

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 98;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1673 AACTTCCAGAGACCA 1689
Db 1 AACATCCAGATGACCA 17

RESULT 108
US-08-868-452-21/c
; Sequence 21, Application US/08868452C
; Patent No. 6352972
; GENERAL INFORMATION:
; APPLICANT: Marcel E. Nimni
; APPLICANT: Frederick L. Hall
; APPLICANT: Lingtao Wu
; APPLICANT: Bo Han
; APPLICANT: Edwin Shore
; TITLE OF INVENTION: BONE MORPHOGENETIC PROTEINS AND THEIR
; TITLE OF INVENTION: USE IN BONE GROWTH
; FILE REFERENCE: 17972-11
; CURRENT APPLICATION NUMBER: US/08/868,452C
; CURRENT FILING DATE: 1997-06-03
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 21
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Human
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (1)...(18)
US-08-868-452-21

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 98;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1879 GAGATGATGATGAT 1895
Db 18 GTGATGATGATGAT 2

RESULT 109
US-09-104-337A-79
; Sequence 79, Application US/09104337A
; Patent No. 6492160
; GENERAL INFORMATION:
; APPLICANT: Winter, Gregory Paul
; APPLICANT: Griffiths, Andrew David
; APPLICANT: Williams, Samuel Cameron
; APPLICANT: Waterhouse, Peter
; APPLICANT: Nissim, Ahuva
; APPLICANT: Johnson, Kevin Stuart
; APPLICANT: Smith, Andrew John Hammond
; TITLE OF INVENTION: Methods for producing members of specific
; TITLE OF INVENTION: binding pairs
; NUMBER OF SEQUENCES: 600
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Audrey L. Bartnicki
; STREET: Marshall, Gerstein & Borun
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/104,337A
FILING DATE: 25-Jun-1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/350,260
FILING DATE: 05-DEC-1994
APPLICATION NUMBER: GB 9110549.4
FILING DATE: 15-MAY-1991
APPLICATION NUMBER: GB 9206318.9
FILING DATE: 24-MAR-1992
APPLICATION NUMBER: PCT/GB92/00883
FILING DATE: 15-MAY-1992
APPLICATION NUMBER: PCT/GB93/00605
FILING DATE: 24-MAR-1993
APPLICATION NUMBER: US 08/150,002
FILING DATE: 31-MAR-1994
APPLICATION NUMBER: US 08/307,619
FILING DATE: 16-SEP-1994
ATTORNEY/AGENT INFORMATION:
NAME: Bartnicki, Audrey L.
REGISTRATION NUMBER: 40,499
REFERENCE/DOCKET NUMBER: 28111/32372A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312-474-6300
INFORMATION FOR SEQ ID NO: 79:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 79:
US-09-104-337A-79

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 98;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1673 AACTCCAGAGACCCA 1689
Db 1 AACATCCAGATGACCCA 17

RESULT 110
US-09-280-030-8/c
Sequence 8, Application US/09280030A
Patent No. 6506595
GENERAL INFORMATION:
APPLICANT: Sato, Seiji
APPLICANT: Higashikuni, Naohiko
APPLICANT: Kudo, Toshiyuki
APPLICANT: Kondo, Masaaki
TITLE OF INVENTION: DNAS ENCODING NEW FUSION PROTEINS AND PROCESSES FOR
TITLE OF INVENTION: PREPARING USEFUL POLYPEPTIDES THROUGH EXPRESSION OF THE
FILE REFERENCE: 382.1026
CURRENT APPLICATION NUMBER: US/09/280,030A
CURRENT FILING DATE: 1999-03-26
EARLIER APPLICATION NUMBER: JP10-87339/1998
NUMBER OF SEQ ID NOS: 66
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 8
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Designated is
OTHER INFORMATION: a forward oligonucleotide encoding (His)₆
US-09-280-030-8

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 98;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1879 GAGATGATGAAGATGAT 1895
Db 18 GTGATGATGATGATGAT 2

RESULT 111
US-09-280-030-9
Sequence 9, Application US/09280030A
Patent No. 6506595
GENERAL INFORMATION:
APPLICANT: Sato, Seiji
APPLICANT: Higashikuni, Naohiko
APPLICANT: Kudo, Toshiyuki
APPLICANT: Kondo, Masaaki
TITLE OF INVENTION: DNAS ENCODING NEW FUSION PROTEINS AND PROCESSES FOR THE
TITLE OF INVENTION: PREPARING USEFUL POLYPEPTIDES THROUGH EXPRESSION OF THE
FILE REFERENCE: 382.1026
CURRENT APPLICATION NUMBER: US/09/280,030A
CURRENT FILING DATE: 1999-03-26
EARLIER APPLICATION NUMBER: JP10-87339/1998
NUMBER OF SEQ ID NOS: 66
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 9
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Designated is
OTHER INFORMATION: a reverse oligonucleotide encoding (His)₆
US-09-280-030-9

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 98;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1879 GAGATGATGAAGATGAT 1895
Db 1 GTGATGATGATGATGAT 17

RESULT 112
US-09-325-601-3
Sequence 3, Application US/09325601
Patent No. 6573045
GENERAL INFORMATION:
APPLICANT: Karn
APPLICANT: Prescott
TITLE OF INVENTION: Methods and Kits for Discovery of RNA-Binding Compounds
FILE REFERENCE: 3950/81235
CURRENT APPLICATION NUMBER: US/09/325,601
CURRENT FILING DATE: 1999-06-03
NUMBER OF SEQ ID NOS: 53
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 3
LENGTH: 18
TYPE: RNA
ORGANISM: Human immunodeficiency virus
US-09-325-601-3

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 98;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1490 AGCCAGACTTGACGAC 1506
Db 1 AGCCAGAUUUGAGCAGC 17

RESULT 113
US-09-081-646-233/c
Sequence 233, Application US/09081646

Patent No. 6333152
GENERAL INFORMATION:
APPLICANT: Kinzler, Kenneth
APPLICANT: Vogelstein, Bert
APPLICANT: Zhang, Lin
APPLICANT: Zhou, Wei
TITLE OF INVENTION: Gene Expression Profiles in No. 6333152a1 and
TITLE OF INVENTION: Cancer Cells
FILE REFERENCE: 01107.74664
CURRENT APPLICATION NUMBER: US/09/081,646
CURRENT FILING DATE: 1998-05-20
EARLIER APPLICATION NUMBER: 60/047,352
EARLIER FILING DATE: 1997-05-21
NUMBER OF SEQ ID NOS: 871
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO: 233
LENGTH: 15
TYPE: DNA
ORGANISM: Homo sapiens
US-09-081-646-233

Query Match 1.0%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 79;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1573 TCACGCTCTCCATG 1587
Db 15 TCACGCTCTCCATG 1

RESULT 114
US-08-390-850-433
Sequence 433, Application US/08390850
Patent No. 5612215
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: McSwigen, Pamela
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/390,850
FILING DATE: February 17, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5612215ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 433:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-390-850-433

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 1e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1586 TGAAGTCCACACCC 1600
Db 3 UGACUCCACACACC 17

RESULT 115
US-08-398-008A-5/c
Sequence 5, Application US/08398008A
Patent No. 5665588
GENERAL INFORMATION:
APPLICANT: Kornbluth, Jacki
TITLE OF INVENTION: DNA Encoding Natural Killer Lytic Associated
TITLE OF INVENTION: Protein
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: Gilbreth & Adler, P.C.
STREET: 8011 Candle Lane
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77071
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 inch, 1.44 Mb storage
COMPUTER: MACINTOSH IIcx
OPERATING SYSTEM: Macintosh
SOFTWARE: Microsoft Word 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/398,008A
FILING DATE: March 2, 1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/126,501
FILING DATE: 24-SEP-1993
ATTORNEY/AGENT INFORMATION:
NAME: Adler, Dr. Benjamin Aaron
REGISTRATION NUMBER: 35,423
REFERENCE/DOCKET NUMBER: D5705CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: (713) 777-2321
TELEFAX: (713) 777-6908
TELEX:
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: double-stranded
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHETICAL: no
ANTI-SENSE: no
US-08-398-008A-5

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1375 GAGATTACGCTTCC 1389
Db 16 GTGATTACGCTTCC 2


```
; OTHER INFORMATION: SEQ ID NO: 1 from 695 to 711
US-08-776-900C-10
;
Query Match          1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2465 AACTGTACATGATGA 2479
Db      1 AACTGTGATGATGA 15

RESULT 119
US-09-268-195C-10
; Sequence 10, Application US/09268195C
; Patent No. 6180386
; GENERAL INFORMATION:
; APPLICANT: ROUSSEL UCLAF
; TITLE OF INVENTION: DNA SEQUENCES CODING FOR THE HUMAN
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ROUSSEL UCLAF
; STREET: 102, Route de No. 6180386ey
; CITY: ROMAINVILLE
; COUNTRY: FRANCE
; ZIP: 93230
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patent Release #1.0, Version #1.30 (OEB)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/268.195C
; FILING DATE: 15-MAR-1999
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: FR 9409567
; FILING DATE: AUG-02-1994
; APPLICATION NUMBER: 776,900
; FILING DATE: JANUARY 31, 1998
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17
; TYPE: nucleotide
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
; DESCRIPTION: /desc = "OLIGONUCLEOTIDE"
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 1..17
; OTHER INFORMATION: /note= "SEQ ID NO 1 FROM 695 TO 711"
US-09-268-195C-10
;
Query Match          1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2465 AACTGTACATGATGA 2479
Db      1 AACTGTGATGATGA 15

RESULT 120
US-08-584-040-4355
; Sequence 4355, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
```

```
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" diskette, 1.44 Mb
; MEDIUM TYPE: storage
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELE: 67-3510
; INFORMATION FOR SEQ ID NO: 4355:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-4355
;
Query Match          1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 1e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy      2404 GAACCTTTTAACTG 2418
Db      3 GAACUUVUAAAGCUG 17

RESULT 121
US-08-584-040-4356
; Sequence 4356, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
```

ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Dikette, 1.44 MB
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 4356:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-4356

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 2404 GAACCTTTTAAGCTG 2418
|||:::|||||:
Db 2 GAACUUUAAAGCUG 16

RESULT 122
US-09-474-432B-649
Sequence 649, Application US/09474432B
Patent No. 6528640
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Beigelman, Leo
APPLICANT: Burgin, Alex
APPLICANT: Beaudry, Amber
APPLICANT: Karpelesky, Alex
APPLICANT: Adamic, Jasenka
APPLICANT: Sweedler, David
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
FILE REFERENCE: MHB00-831-B (247/276)
CURRENT APPLICATION NUMBER: US/09/474,432B
CURRENT FILING DATE: 1999-12-19
PRIOR APPLICATION NUMBER: US 60/064,866
PRIOR FILING DATE: 1997-11-05
PRIOR APPLICATION NUMBER: US 60/084,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: US 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: US 09/301,511
PRIOR FILING DATE: 1999-04-28
NUMBER OF SEQ ID NOS: 1526
SOFTWARE: PatentIn version 3.0
SEQ ID NO 649
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-474-432B-649

Query Match 1.0%; Score 13.4; DB 1; Length 17;

Best Local Similarity 73.3%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 2110 GGCATGAGTACTTG 2124
|||:::|||||:
Db 1 GGCAUGAGACACUG 15

RESULT 123
US-09-371-772B-2122
Sequence 2122, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MHB00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 2122
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-2122

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;

Qy 2404 GAACCTTTTAAGCTG 2418
|||:::|||||:
Db 3 GAACUUUAAAGCUG 17

RESULT 124
US-09-371-772B-2123
Sequence 2123, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MHB00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 2123
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-2123

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;

Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 2404 GAACCTTTTAAGCTG 2418
|||||:|||||
Db 2 GAACUUUAAGCUG 16

RESULT 125
US-08-765-340-142
; Sequence 142, Application US/08765340
; Patent No. 6150092
; GENERAL INFORMATION:
; APPLICANT: UCHIDA, K.,
; APPLICANT: UCHIDA, T.,
; APPLICANT: TANAKA, Y.,
; APPLICANT: MATSUDA, Y.,
; APPLICANT: KONDO, S.,
; TITLE OF INVENTION: AN ANTISENSE NUCLEIC ACID
; TITLE OF INVENTION: COMPOUND
; NUMBER OF SEQUENCES: 185
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
; STREET: 345 PARK AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10154
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version
; SOFTWARE: #1.30 (BPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/765,340
; FILING DATE: 23-DEC-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 145146/94
; FILING DATE: 27-JUN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 311130/94
; FILING DATE: 21-NOV-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: SERUNIAN, LESLIE
; REGISTRATION NUMBER: 35,353
; REFERENCE/DOCKET NUMBER: 1452-4005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 758-4800
; TELEFAX: (212) 751-6849
; INFORMATION FOR SEQ ID NO: 142:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "synthetic DNA"
US-08-765-340-142

Query Match 0.9%; Score 13; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 80;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1934 GCACACAGATGG 1946
|||||:|||||
Db 2 GCACACAGATGG 14

RESULT 126
5185440-12
; Patent No. 5185440
; APPLICANT: DAVIS, NANCY L.; WILLIS, LORETTA V.; JOHNSTON,
; ROBERT E.; SMITH, JONATHAN F.

TITLE OF INVENTION: CDNA CLONE CODING FOR VENEZUELAN
; EQUINE ENCEPHALITIS VIRUS AND ATTENUATING MUTATIONS THEREOF
; NUMBER OF SEQUENCES: 14
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/369,023
; FILING DATE: 20-JUN-1989
; SEQ ID NO: 12:
; LENGTH: 14
5185440-12

Query Match 0.9%; Score 13; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 80;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2599 CTCGACAGTATT 2611
|||||:|||||
Db 2 CTCGACAGTATT 14

RESULT 127
US-08-390-850-566/c
; Sequence 566, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 488-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 566:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-390-850-566

Query Match 0.9%; Score 13; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2416 CTGCTGAAGAAG 2428

Db 15 CTGCTGAAGAAG 3

RESULT 128
US-08-390-850-567/c

; Sequence 567, Application US/08390850
; Patent No. 5612215

; GENERAL INFORMATION:

; APPLICANT: Draper, Kenneth G.

; APPLICANT: Pavco, Pamela

; APPLICANT: McSwigen, James

; APPLICANT: Gustofson, John

; APPLICANT: Stinchcomb, Dan T.

; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT

; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS

; NUMBER OF SEQUENCES: 1151

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; CITY: Suite 4700

; STATE: Los Angeles

; COUNTRY: California

; ZIP: 90071

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

; SOFTWARE: FASTSEQ Version 1.5

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/390,850

; FILING DATE: February 17, 1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/354,920

; FILING DATE: December 13, 1994

; APPLICATION NUMBER: 08/152,487

; FILING DATE: No. 5612215ember 12, 1993

; APPLICATION NUMBER: 07/989,848

; FILING DATE: December 7, 1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Wardburg, Richard

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 211/084

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 567:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 17 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; US-08-390-850-567

Query Match 0.9%; Score 13; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.2e+02;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2416 CTGCTGAAGAAG 2428

Db 14 CTGCTGAAGAAG 2

RESULT 129

US-08-435-634-566/c

; Sequence 566, Application US/08435634

; Patent No. 5731295

; GENERAL INFORMATION:

; APPLICANT: Draper, Kenneth G.

; APPLICANT: Pavco, Pamela

; APPLICANT: McSwigen, James

; APPLICANT: Gustofson, John

; APPLICANT: Stinchcomb, Dan T.

; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT

; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS

; NUMBER OF SEQUENCES: 1151

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; CITY: Suite 4700

; STATE: Los Angeles

; COUNTRY: California

; ZIP: 90071

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

; SOFTWARE: FASTSEQ Version 1.5

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/435,634

; FILING DATE: 05-MAY-1995

; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/390,850

; FILING DATE: February 17, 1995

; APPLICATION NUMBER: 08/354,920

; FILING DATE: December 13, 1994

; APPLICATION NUMBER: 08/152,487

; FILING DATE: No. 5731295ember 12, 1993

; APPLICATION NUMBER: 07/989,848

; FILING DATE: December 7, 1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Wardburg, Richard

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 211/084

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 566:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 17 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; US-08-435-634-566

Query Match 0.9%; Score 13; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.2e+02;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2416 CTGCTGAAGAAG 2428

Db 15 CTGCTGAAGAAG 3

RESULT 130

US-08-435-634-567/c

; Sequence 567, Application US/08435634

; Patent No. 5731295

; GENERAL INFORMATION:

; APPLICANT: Draper, Kenneth G.

; APPLICANT: Pavco, Pamela

; APPLICANT: McSwigen, James

; APPLICANT: Gustofson, John

; APPLICANT: Stinchcomb, Dan T.

; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT

```

: TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
:
: NUMBER OF SEQUENCES: 1151
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Lyon & Lyon
: STREET: 633 West Fifth Street
: STREET: Suite 4700
: CITY: Los Angeles
: STATE: California
: COUNTRY: U.S.A.
: ZIP: 90071
:
: COMPUTER READABLE FORM:
: MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
: MEDIUM TYPE: storage
: COMPUTER: IBM Compatible
: OPERATING SYSTEM: IBM P.C. DOS 5.0
: SOFTWARE: FastSeq Version 1.5
:
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/435,634
: FILING DATE: 05-MAY-1995
: CLASSIFICATION: 514
:
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 08/390,850
: FILING DATE: February 17, 1995
: APPLICATION NUMBER: 08/354,920
: FILING DATE: December 13, 1994
: APPLICATION NUMBER: 08/152,487
: FILING DATE: No. 5731295ember 12, 1993
: APPLICATION NUMBER: 07/989,848
: FILING DATE: December 7, 1992
: ATTORNEY/AGENT INFORMATION:
: NAME: Warburg, Richard
: REGISTRATION NUMBER: 32,327
: REFERENCE/DOCKET NUMBER: 211/084
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (213) 489-1600
: TELEFAX: (213) 955-0440
: TELEX: 67-3510
:
: INFORMATION FOR SEQ ID NO: 567:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 17 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
:
: US-08-435-634-567
:
: Query Match 0.9%; Score 13; DB 1; Length 17;
: Best Local Similarity 100.0%; Pred. No. 1.2e+02;
: Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
:
: QY 2416 CTGCTGAGGAAG 2428
: Db 14 CTGCTGAGGAAG 2
:
: RESULT 131
: US-08-479-614-18/c
: Sequence 18, Application US/08479614
: Patent No. 5861294
:
: GENERAL INFORMATION:
: APPLICANT: Cowart, Marion Daniel, Halbert, Donald N.,
: APPLICANT: Kerwin, Jr., James F., McNally, Teresa
: TITLE OF INVENTION: Adenosine Kinase Polypeptides
: NUMBER OF SEQUENCES: 34
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Abbott Laboratories
: STREET: D-377 ApeD, 100 Abbott Park Road
: CITY: Abbott Park
: STATE: Illinois
: COUNTRY: USA
: ZIP: 60064-3500
:
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Diskette, 3.50 inch
: COMPUTER: Macintosh

```

```

: OPERATING SYSTEM: Macintosh System 7.1
: SOFTWARE: Microsoft Word 6.0
:
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/479,614
: FILING DATE: June 7, 1995
: CLASSIFICATION: 536
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER:
: FILING DATE:
: ATTORNEY/AGENT INFORMATION:
: NAME: Thomas D. Brainard
: REGISTRATION NUMBER: 32,459
: REFERENCE/DOCKET NUMBER: 5749.US.D1
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (708) 938-2623
: TELEFAX: (708) 937-4884
:
: INFORMATION FOR SEQ ID NO: 18:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 17 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: MOLECULE TYPE: DNA (genomic)
:
: US-08-479-614-18
:
: Query Match 0.9%; Score 13; DB 1; Length 17;
: Best Local Similarity 66.7%; Pred. No. 1.2e+02;
: Matches 10; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
:
: QY 2400 GGAGGAAGCTTTTAA 2414
: Db 16 GGAGGAAGCTTTTAA 2
:
: RESULT 132
: US-08-679-645-748
: Sequence 748, Application US/08679645
: Patent No. 6350934
:
: GENERAL INFORMATION:
: APPLICANT: Zwick, Michael G.
: APPLICANT: Edington, Brent E.
: APPLICANT: McSwiggen, James A.
: APPLICANT: Merlo, Patricia Ann Owens
: APPLICANT: Guo, Lining
: APPLICANT: Skokut, Thomas A.
: APPLICANT: Young, Scott A.
: APPLICANT: Folkerts, Otto
: APPLICANT: Merlo, Donald J.
:
: TITLE OF INVENTION: COMPOSITION AND METHODS FOR
: TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
: NUMBER OF SEQUENCES: 1263
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Lyon & Lyon
: STREET: 633 West Fifth Street
: CITY: Suite 4700
: CITY: Los Angeles
: STATE: California
: COUNTRY: U.S.A.
: ZIP: 90071-2066
:
: COMPUTER READABLE FORM:
: MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
: MEDIUM TYPE: storage
: COMPUTER: IBM Compatible
: OPERATING SYSTEM: IBM P.C. DOS 5.0
: SOFTWARE: Word Perfect 5.1
:
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/679,645
: FILING DATE: July 12, 1996
: CLASSIFICATION: 800
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 60/001,135
: FILING DATE: July 13, 1995

```

```

; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Waidburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 748:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-679-645-748

Query Match          0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 1.1e+02;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy      1866 GGTGTCAGAGATG 1878
Db      4 GGUGCAGAGATG 16

RESULT 133
US-09-371-772B-5819
; Sequence 5819, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5819
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
;
US-09-371-772B-5819

Query Match          0.9%; Score 12.8; DB 1; Length 16;
Best Local Similarity 68.8%; Pred. No. 1.1e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy      1820 TGAAGATGTTGAAGA 1835
Db      1 UCAAAAUUCUGAAAGA 16

RESULT 134
US-09-371-772B-5850/C
; Sequence 5850, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7080
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
;
US-09-371-772B-7080

Query Match          0.9%; Score 12.8; DB 1; Length 16;
Best Local Similarity 62.5%; Pred. No. 1.1e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy      1820 TGAAGATGTTGAAGA 1835
Db      1 UCAAAAUUCUGAAAGA 16

RESULT 135
US-09-371-772B-7080
; Sequence 7080, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7080
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
;
US-09-371-772B-7080

Query Match          0.9%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1909 AATATCATTAATCTTC 1924
Db      16 AAATCACAATCTTC 1

RESULT 136
US-08-179-738-23/C
; Sequence 23, Application US/08179738
; Patent No. 5578462
; GENERAL INFORMATION:
; APPLICANT: Seizinger, Bernd R.
; APPLICANT: Kley, Nikolai A.
; APPLICANT: Bianchi, Albert B.
; TITLE OF INVENTION: No. 5578462el NP2 Isoforms
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
;
US-08-179-738-23/C
```

ADDRESSEE: Reed & Robins
STREET: 635 Bryant Street
CITY: Palo Alto
STATE: California
COUNTRY: U.S.A.
ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/179,738
FILING DATE: 10-JAN-1994
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: Robins, Roberta L.
REGISTRATION NUMBER: 33,208
REFERENCE/DOCKET NUMBER: 5998-0017
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 617-8999
TELEFAX: (415) 327-3231
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-179-738-23

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1579 TCCCTCAGTACTCCA 1594
Db 17 TTCTCATGTACTCCA 2

RESULT 137
US-08-390-850-694
Sequence 694: Application US/08390850
Patent No. 5612215
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/390,850
FILING DATE: February 17, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994

APPLICATION NUMBER: 08/152,487
FILING DATE: NO. 5612215ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 694:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-390-850-694

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Oy 1694 GGGAGTTTCCAGAGA 1709
Db 2 GGGAGCUCCACGAGA 17

RESULT 138
US-08-390-850-695
Sequence 695: Application US/08390850
Patent No. 5612215
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/390,850
FILING DATE: February 17, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: NO. 5612215ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440

TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 695:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-390-850-695

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Oy 1694 GGAAGTTCCAGAGA 1709
Db 1 GGAAGTCCAGAGA 16

RESULT 139
US-08-373-124A-416/C
Sequence 416, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwigen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 416:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-416

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1866 GGTGTCAAGATGAG 1881
Db 16 GGTGCAAGATGAG 1

RESULT 140
US-08-373-124A-534
Sequence 534, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:

APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwigen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 534:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-534

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Oy 1584 CATGACTCCAGACC 1599
Db 1 CAAGAGTCCAGACC 16

RESULT 141
US-08-373-124A-1114/C
Sequence 1114, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwigen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1114:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-1114
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2240 ATTACAAAAGACCAC 2255
Db 17 ATACAAAAAACAC 2

RESULT 142
US-08-373-124A-1116/C
Sequence 1116, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwigen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1116:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-1116

TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1116:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-1116
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2240 ATTACAAAAGACCAC 2255
Db 16 ATACAAAAAACAC 1

RESULT 143
US-08-373-124A-2423
Sequence 2423, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwigen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1116:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-1116

STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2423:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-2423

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1584 CATGAAGTCCAAACCC 1599
|||::|||
DB 1 CAAGACUCCUACACCC 16

RESULT 144
US-08-435-634-694
Sequence 694, Application US/08435634
Patent No. 5731295
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295, December 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 694:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-694

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1694 GCGAGTTCCAGAGA 1709
|||::|||
DB 2 GCGAGCUCUCCAGAGA 17

RESULT 145
US-08-435-634-695
Sequence 695, Application US/08435634
Patent No. 5731295
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920

;; FILING DATE: December 13, 1994
;; APPLICATION NUMBER: 08/152,487
;; FILING DATE: NO. 573129 September 12, 1993
;; APPLICATION NUMBER: 07/989,848
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 211/084
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;;
;; INFORMATION FOR SEQ ID NO: 695:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;;
US-08-435-634-695

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Oy 1694 GGGAGTTCCAGAGA 1709
Db 1 GGGAGCUCCAGAGA 16

RESULT 146
US-08-623-891-21
; Sequence 21, Application US/08623891
; Patent No. 5795778
; GENERAL INFORMATION:
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HERPES SIMPLEX
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 115
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 611 West Sixth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/623,891
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/238,200
; FILING DATE:
; APPLICATION NUMBER: US/07/987,133
; FILING DATE:
; APPLICATION NUMBER: 07/882,921
; FILING DATE: May 14, 1992
; APPLICATION NUMBER: 07/948,359
; FILING DATE: September 18, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 200/209
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510

;; INFORMATION FOR SEQ ID NO: 21:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;;
US-08-623-891-21

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Oy 2279 GGATGCTCCAGAAC 2294
Db 2 GGGUGCUCCAGAAC 17

RESULT 147
US-08-758-306-123/C
; Sequence 123, Application US/08758306
; Patent No. 5807743
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwigen, James A.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/758,306
; FILING DATE: December 3, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 212/132
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEPHONE: (213) 955-0440
; FILING DATE:
; INFORMATION FOR SEQ ID NO: 123:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-758-306-123

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2156 CAGCAGAAATGTTT 2171
|||||

Db 16 CAGCAGAGATGATT 1

RESULT 148

US-08-435-628-416/C

; Sequence 416, Application US/08435628
; Patent No. 5817796

GENERAL INFORMATION:

APPLICANT: Stinchcomb, Dan T.

APPLICANT: Draper, Kenneth

APPLICANT: McSwigen, James

APPLICANT: Jarvis, Thale

TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR

TREATMENT OF RESTENOSIS AND

CANCER USING RIBOZYMES

NUMBER OF SEQUENCES: 2627

CORRESPONDENCE ADDRESS:

ADDRESSER: Lyon & Lyon

STREET: 633 West Fifth Street

SUITE: Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/435,628

FILING DATE: 05-MAY-1995

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/373,124

FILING DATE: January 13, 1995

APPLICATION NUMBER: 08/245,466

FILING DATE: May 18, 1994

APPLICATION NUMBER: 08/192,943

FILING DATE: February 7, 1994

APPLICATION NUMBER: 07/987,132

FILING DATE: December 7, 1992

APPLICATION NUMBER: 07/936,422

FILING DATE: August 26, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 209/035

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 416:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-435-628-416

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.3e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 16 GGTGACAGATGAG 1881

16 GCTGACAGATGAG 1

RESULT 149

US-08-435-628-534

; Sequence 534, Application US/08435628

; Patent No. 5817796

GENERAL INFORMATION:

APPLICANT: Stinchcomb, Dan T.

APPLICANT: Draper, Kenneth

APPLICANT: McSwigen, James

APPLICANT: Jarvis, Thale

TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR

TREATMENT OF RESTENOSIS AND

CANCER USING RIBOZYMES

NUMBER OF SEQUENCES: 2627

CORRESPONDENCE ADDRESS:

ADDRESSER: Lyon & Lyon

STREET: 633 West Fifth Street

SUITE: Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/435,628

FILING DATE: 05-MAY-1995

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/373,124

FILING DATE: January 13, 1995

APPLICATION NUMBER: 08/245,466

FILING DATE: May 18, 1994

APPLICATION NUMBER: 08/192,943

FILING DATE: February 7, 1994

APPLICATION NUMBER: 07/987,132

FILING DATE: December 7, 1992

APPLICATION NUMBER: 07/936,422

FILING DATE: August 26, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 209/035

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 534:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-435-628-534

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 81.2%; Pred. No. 1.3e+02;

Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Db 1584 CATGAACCAACACC 1599

1 CAAGAACCUCACAC 16

RESULT 150

US-08-435-628-1114/C

; Sequence 1114, Application US/08435628

; Patent No. 5817796

GENERAL INFORMATION:

APPLICANT: Stinchcomb, Dan T.

APPLICANT: Draper, Kenneth

APPLICANT: McSwigen, James

APPLICANT: Jarvis, Thale

TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1114:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-1114
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2240 ATTACAAAAGACCAC 2255
Db 17 ATAACAAAAAACCCAC 2
RESULT 151
US-08-435-628-1116/c
Sequence 1116, Application US/08435628
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwigen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1116:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-1116
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2240 ATTACAAAAGACCAC 2255
Db 16 ATAACAAAAAACCCAC 1
RESULT 152
US-08-435-628-2423
Sequence 2423, Application US/08435628
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwigen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2423:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-2423

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1584 CATGAAGTCCACACCC 1599
DB 1 CAGAGACUCGACACCC 16

RESULT 153
US-08-541-950B-18
Sequence 18, Application US/08541950B
Patent No. 5821046
GENERAL INFORMATION:
APPLICANT: Karm J, Galt MJ, Heaphy S, Dingwall C
TITLE OF INVENTION: VIRAL (HIV) GROWTH INHIBITION
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Banner & Witcoff, Ltd.
STREET: One Financial Center, 45th Floor
CITY: Boston
STATE: MA
ZIP: 02111
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/541,950B
FILING DATE: 10/10/95
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/960,370
FILING DATE: 03/19/93
ATTORNEY/AGENT INFORMATION:
NAME: Williams, Ph.D., Kathleen M.

REGISTRATION NUMBER: 34,380
REFERENCE/DOCKET NUMBER: 3777/57347 (MRC-011AX)
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 345-9100
TELEFAX: (617) 345-9111
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: synthetic RNA
FEATURE:
NAME/KEY: misc_feature
LOCATION: 9
OTHER INFORMATION: N is 2'-deoxythymidine
US-08-541-950B-18

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.3e+02;
Matches 13; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1490 AGCCGAGTCCAGCAGC 1506
DB 1 AGCCGAGTCCAGCAGC 17

RESULT 154
US-08-541-950B-19
Sequence 19, Application US/08541950B
Patent No. 5821046
GENERAL INFORMATION:
APPLICANT: Karm J, Galt MJ, Heaphy S, Dingwall C
TITLE OF INVENTION: VIRAL (HIV) GROWTH INHIBITION
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Banner & Witcoff, Ltd.
STREET: One Financial Center, 45th Floor
CITY: Boston
STATE: MA
ZIP: 02111
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/541,950B
FILING DATE: 10/10/95
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/960,370
FILING DATE: 03/19/93
ATTORNEY/AGENT INFORMATION:
NAME: Williams, Ph.D., Kathleen M.
REGISTRATION NUMBER: 34,380
REFERENCE/DOCKET NUMBER: 3777/57347 (MRC-011AX)
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 345-9111
TELEFAX: (617) 345-9100
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: synthetic RNA
FEATURE:
NAME/KEY: misc_feature
LOCATION: 10
OTHER INFORMATION: N is 2'-deoxythymidine
US-08-541-950B-19

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 76.5%; Pred. No. 1.3e+02;
Matches 13; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1490 AGCCAGACTTCAGCAGC 1506
Db 1 AGCCAGAUUNUGAGCAGC 17

RESULT 155

US-08-541-950B-21

; Sequence 21, Application US/08541950B
; Patent No. 5821046

; GENERAL INFORMATION:

; APPLICANT: Kain J, Galt MJ, Heaphy S, Dingwall C
; TITLE OF INVENTION: VIRAL (HIV) GROWTH INHIBITION
; NUMBER OF SEQUENCES: 26

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Banner & Witcoff, Ltd.
; STREET: One Financial Center, 45th Floor
; CITY: Boston
; STATE: MA
; ZIP: 02111

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Wordperfect 6.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/541,950B
; FILING DATE: 10/10/95
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/960,370
; FILING DATE: 03/19/93

; ATTORNEY/AGENT INFORMATION:

; NAME: Williams, Ph.D., Kathleen M.
; REGISTRATION NUMBER: 34,380

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (617) 345-9110
; INFORMATION FOR SEQ ID NO: 21:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 17 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

; MOLECULE TYPE: synthetic RNA
; FEATURE:

; NAME/KEY: misc_feature
; LOCATION: 9

; OTHER INFORMATION: N is 5-bromo-2'-deoxyuridine
US-08-541-950B-21

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.3e+02;
Matches 13; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1490 AGCCAGACTTCAGCAGC 1506
Db 1 AGCCAGAUUNUGAGCAGC 17

RESULT 156

US-08-541-950B-22

; Sequence 22, Application US/08541950B
; Patent No. 5821046

; GENERAL INFORMATION:

; APPLICANT: Kain J, Galt MJ, Heaphy S, Dingwall C
; TITLE OF INVENTION: VIRAL (HIV) GROWTH INHIBITION
; NUMBER OF SEQUENCES: 26

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Banner & Witcoff, Ltd.
; STREET: One Financial Center, 45th Floor

; CITY: Boston
; STATE: MA
; ZIP: 02111

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Wordperfect 6.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/541,950B
; FILING DATE: 10/10/95
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/960,370
; FILING DATE: 03/19/93

; ATTORNEY/AGENT INFORMATION:

; NAME: Williams, Ph.D., Kathleen M.
; REGISTRATION NUMBER: 34,380

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (617) 345-9110
; INFORMATION FOR SEQ ID NO: 22:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 17 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

; MOLECULE TYPE: synthetic RNA
; FEATURE:

; NAME/KEY: misc_feature
; LOCATION: 10

; OTHER INFORMATION: N is 5-bromo-2'-deoxyuridine
US-08-541-950B-22

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.3e+02;
Matches 13; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1490 AGCCAGACTTCAGCAGC 1506
Db 1 AGCCAGAUUNUGAGCAGC 17

RESULT 157

US-08-628-145-23/c

; Sequence 23, Application US/08628145
; Patent No. 5872214

; GENERAL INFORMATION:

; APPLICANT: Seizinger, Bernd R.
; APPLICANT: Kley, Nikolai A.
; APPLICANT: Bianchi, Albert B.
; TITLE OF INVENTION: NO. 5872214e1 NP2 Isoforms
; NUMBER OF SEQUENCES: 26

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Reed & Robins
; STREET: 635 Bryant Street
; CITY: Palo Alto
; STATE: California
; COUNTRY: U.S.A
; ZIP: 94301

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/628,145
; FILING DATE: 04-APR-1996
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/179,738
; FILING DATE: 10-JAN-1994
; ATTORNEY/AGENT INFORMATION:

; NAME: Williams, Ph.D., Kathleen M.
; REGISTRATION NUMBER: 34,380
; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (617) 345-9110
; INFORMATION FOR SEQ ID NO: 23:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 17 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

; MOLECULE TYPE: synthetic RNA
; FEATURE:

; NAME/KEY: misc_feature
; LOCATION: 10

; OTHER INFORMATION: N is 5-bromo-2'-deoxyuridine
US-08-628-145-23/c

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.3e+02;
Matches 13; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1490 AGCCAGACTTCAGCAGC 1506
Db 1 AGCCAGAUUNUGAGCAGC 17

RESULT 158

US-08-628-145-23/c

; Sequence 23, Application US/08628145
; Patent No. 5872214

; GENERAL INFORMATION:

; APPLICANT: Seizinger, Bernd R.
; APPLICANT: Kley, Nikolai A.
; APPLICANT: Bianchi, Albert B.
; TITLE OF INVENTION: NO. 5872214e1 NP2 Isoforms
; NUMBER OF SEQUENCES: 26

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Reed & Robins
; STREET: 635 Bryant Street
; CITY: Palo Alto
; STATE: California
; COUNTRY: U.S.A
; ZIP: 94301

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/628,145
; FILING DATE: 04-APR-1996
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/179,738
; FILING DATE: 10-JAN-1994
; ATTORNEY/AGENT INFORMATION:

; NAME: Williams, Ph.D., Kathleen M.
; REGISTRATION NUMBER: 34,380
; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (617) 345-9110
; INFORMATION FOR SEQ ID NO: 24:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 17 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

; MOLECULE TYPE: synthetic RNA
; FEATURE:

; NAME/KEY: misc_feature
; LOCATION: 10

; OTHER INFORMATION: N is 5-bromo-2'-deoxyuridine
US-08-628-145-23/c

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.3e+02;
Matches 13; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1490 AGCCAGACTTCAGCAGC 1506
Db 1 AGCCAGAUUNUGAGCAGC 17

NAME: Robins, Roberta L.
REGISTRATION NUMBER: 33,208
REFERENCE/DOCKET NUMBER: 5998-0017
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 617-8999
TELEFAX: (415) 327-3331
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-628-145-23

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1579 TCCTCATGAAGTCCA 1594
Db 17 TTCCTCATGAAGTCCA 2

RESULT 158
US-08-985-162-184/C
Sequence 184, Application US/08985162
Patent No. 6057156
GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwigen, James
TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 184:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-184

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1358 GCCTGTGAAGAGAAAA 1373
Db 16 CGACTGCAAGAGAAAA 1

RESULT 159
US-08-985-162-326
Sequence 326, Application US/08985162
Patent No. 6057156

GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwigen, James
TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440

INFORMATION FOR SEQ ID NO: 326:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-326

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.3e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2323 AGTATGTCGTGCT 2338
Db 1 AGUGAUGUCUGAGCU 16

RESULT 160
US-09-083-756A-18
Sequence 18, Application US/09083756A
Patent No. 6114109

```
GENERAL INFORMATION:
APPLICANT: Kain J, Galt MJ, Heaphy S, Dingwall C
TITLE OF INVENTION: VIRAL (HIV) GROWTH INHIBITION
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Banner & Witcoff, Ltd.
STREET: One Financial Center, 45th Floor
CITY: Boston
STATE: MA
ZIP: 02111
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/083,756A
FILING DATE:
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 08/541,950
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Williams, Ph.D., Kathleen M.
REGISTRATION NUMBER: 34,380
REFERENCE/DOCKET NUMBER: 3777/57347 (MRC-011AX)
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 345-9100
FAX: (617) 345-9111
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: synthetic RNA
FEATURE:
NAME/KEY: misc_feature
LOCATION: 9
OTHER INFORMATION: N is 2'-deoxythymidine
US-09-083-756A-18

Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.3e+02;
Matches 13; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY      1490 AGCCGAGCTCAGCAGC 1506
DB      1 AGCCGAGUNUGAGCAGC 17

RESULT 161
US-09-083-756A-19
Sequence 19, Application US/09083756A
Patent No. 6114109
GENERAL INFORMATION:
APPLICANT: Kain J, Galt MJ, Heaphy S, Dingwall C
TITLE OF INVENTION: VIRAL (HIV) GROWTH INHIBITION
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Banner & Witcoff, Ltd.
STREET: One Financial Center, 45th Floor
CITY: Boston
STATE: MA
ZIP: 02111
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/083,756A
FILING DATE:
PRIORITY APPLICATION DATA:
```

```
APPLICATION NUMBER: 08/541,950
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Williams, Ph.D., Kathleen M.
REGISTRATION NUMBER: 34,380
REFERENCE/DOCKET NUMBER: 3777/57347 (MRC-011AX)
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 345-9100
FAX: (617) 345-9111
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: synthetic RNA
FEATURE:
NAME/KEY: misc_feature
LOCATION: 10
OTHER INFORMATION: N is 2'-deoxythymidine
US-09-083-756A-19

Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.3e+02;
Matches 13; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY      1490 AGCCGAGCTCAGCAGC 1506
DB      1 AGCCGAGUNUGAGCAGC 17

RESULT 162
US-09-083-756A-21
Sequence 21, Application US/09083756A
Patent No. 6114109
GENERAL INFORMATION:
APPLICANT: Kain J, Galt MJ, Heaphy S, Dingwall C
TITLE OF INVENTION: VIRAL (HIV) GROWTH INHIBITION
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Banner & Witcoff, Ltd.
STREET: One Financial Center, 45th Floor
CITY: Boston
STATE: MA
ZIP: 02111
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/083,756A
FILING DATE:
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 08/541,950
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Williams, Ph.D., Kathleen M.
REGISTRATION NUMBER: 34,380
REFERENCE/DOCKET NUMBER: 3777/57347 (MRC-011AX)
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 345-9100
FAX: (617) 345-9111
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: synthetic RNA
FEATURE:
NAME/KEY: misc_feature
LOCATION: 9
```

OTHER INFORMATION: N is 5-bromo-2'-deoxyuridine
US-09-083-756A-21

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.3e+02;
Matches 13; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1490 AGCCAGACTTCAGCAGC 1506
DB 1 AGCCAGAUUNUGAGCAGC 17

RESULT 163
US-09-083-756A-22
Sequence 22, Application US/09083756A
Patent No. 6114109
GENERAL INFORMATION:
APPLICANT: Karm J, Galt MJ, Heaphy S, Dingwall C
TITLE OF INVENTION: VIRAL (HIV) GROWTH INHIBITION
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Banner & Witcoff, Ltd.
STREET: One Financial Center, 45th Floor
CITY: Boston
STATE: MA
ZIP: 02111
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 MB storage
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/083,756A
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/541,950
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Williams, Ph.D., Kathleen M.
REGISTRATION NUMBER: 34,380
REFERENCE/DOCKET NUMBER: 3777/57347 (MRC-011AX)
TELEPHONE: (617) 345-9100
TELEFAX: (617) 345-9111
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: synthetic RNA
FEATURE:
NAME/KEY: misc_feature
LOCATION: 10
OTHER INFORMATION: N is 5-bromo-2'-deoxyuridine
US-09-083-756A-22

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.3e+02;
Matches 13; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1490 AGCCAGACTTCAGCAGC 1506
DB 1 AGCCAGAUUNUGAGCAGC 17

RESULT 164
US-08-584-040-1992/C
Sequence 1992, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
ADDRESSEE: MGSWIGEN, James

APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1992:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-1992

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1909 AATATCATTAATCTTC 1924
DB 17 AAAATCAACAATCTTC 2

RESULT 165
US-08-584-040-2009
Sequence 2009, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
ADDRESSEE: MGSWIGEN, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2009:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-2009

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 2279 GGATGGCTCCAGAACG 2294
Db 1 GAUGGCTCCGCAATC 16

RESULT 166
US-08-584-040-2761/c
Sequence 2761, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESS: Lyon & Lyon
STREET: 633 West Filth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040

FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2761:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-2761

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2422 AAGGAGGACAGCAA 2437
Db 16 ATGAGAGGACAGCAA 1

RESULT 167
US-08-584-040-4140
Sequence 4140, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESS: Lyon & Lyon
STREET: 633 West Filth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440

TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 4140:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-4140

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.3e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1822 AAGATGTTGAAGATG 1837
Db 2 AAAAGUGUAGAAAG 17

RESULT 168
US-08-584-040-5816
; Sequence 5816, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5816:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-5816

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 1.3e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 2332 TGGTCCTCGGGGCT 2347
Db 2 UGCUUCUUGGUGUGU 17

RESULT 169
US-08-584-040-7971/c
; Sequence 7971, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7971:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-7971

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1843 ACAGAGAAAGCCTT 1858
Db 16 ACAGAGAAACCCCTT 1

RESULT 170
US-08-584-040-8106/c
; Sequence 8106, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela

```

APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Walburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 8106:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-8106
Query Match 0.9% Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred No.1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0.
QY 1775 TGGGATTGACAAAGA 1790
||| ||| ||| ||| |||
Db 17 TGGGATTGACAAAGA 2
RESULT 171
US-09-340-861-21
Sequence 21, Application US/09340861
Patent No. 6432704
GENERAL INFORMATION:
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: INHIBITING HERPES SIMPLEX
TITLE OF INVENTION: VIRUS REPLICATION
NUMBER OF SEQUENCES: 115
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 611 West Sixth Street
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:

```

```
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 200/209
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 17
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-634-262-21

Query Match
Best Local Similarity 75.0%; Score 12.8; DB 1; Length 17;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 2279 GGATGGCTCCGAGAAC 2294
Db 2 GGUGGCUCCAGAAC 17

RESULT 173
US-09-446-301A-31/C
Sequence 31, Application US/09446301A
Patent No. 6506893
GENERAL INFORMATION:
APPLICANT: EL SOLH, NEVINE
APPLICANT: ALIGNET, JEANINE
TITLE OF INVENTION: POLYNUCLEOTIDES AND THEIR USE FOR DETECTING RESISTANCE
TITLE OF INVENTION: TO STREPTOGRAMIN A OR TO STREPTOGRAMIN B AND RELATED
FILE REFERENCE: 03715-0059
CURRENT APPLICATION NUMBER: US/09/446,301A
CURRENT FILING DATE: 1999-12-20
NUMBER OF SEQ ID NOS: 51
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 31
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURES:
OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-446-301A-31

Query Match
Best Local Similarity 87.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1741 GGTTCCTTTGGGCAAG 1756
Db 17 GGTTCCTTTGGCAAG 2

RESULT 174
US-09-474-432B-783
Sequence 783, Application US/09474432B
Patent No. 6528640
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Belgelman, Leo
APPLICANT: Burgin, Alex
APPLICANT: Beaudry, Amber
APPLICANT: Karpeisky, Alex
APPLICANT: Adamic, Jasenka
APPLICANT: Sweedler, David
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleo
FILE REFERENCE: MHB00-831-B (247/276)
CURRENT APPLICATION NUMBER: US/09/474,432B
```

```
CURRENT FILING DATE: 1999-12-19
PRIOR APPLICATION NUMBER: US 60/064,866
PRIOR FILING DATE: 1997-11-05
PRIOR APPLICATION NUMBER: US 60/084,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: US 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: US 09/301,511
PRIOR FILING DATE: 1999-04-28
NUMBER OF SEQ ID NOS: 1526
SOFTWARE: PatentIn version 3.0
SEQ ID NO 783
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-474-432B-783

Query Match
Best Local Similarity 62.5%; Score 12.8; DB 1; Length 17;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 2317 CATCAGCTGATGTCT 2332
Db 2 CACCAGAGUGAUGUGU 17

RESULT 175
US-09-371-772B-537/C
Sequence 537, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MHB00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 537
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-537

Query Match
Best Local Similarity 87.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1909 AATATCATTAATCTTC 1924
Db 17 AAATCACAATCTTC 2

RESULT 176
US-09-371-772B-554
Sequence 554, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
```

```
;; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
;; FILE REFERENCE: MHB00,876-J (237/198)
;; CURRENT APPLICATION NUMBER: US/09/371,772B
;; CURRENT FILING DATE: 1999-08-10
;; PRIOR APPLICATION NUMBER: US 60/005,974
;; PRIOR FILING DATE: 1995-10-26
;; PRIOR APPLICATION NUMBER: US 08/584,040
;; PRIOR FILING DATE: 1996-01-08
;; NUMBER OF SEQ ID NOS: 14225
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 554
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-09-371-772B-554

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY      2279 GGATGGCTCCAGAACG 2294
Db      1  GGAUGGCTCCGGAATC 16
      |||:|||||
      |||:|||||

RESULT 177
US-09-371-772B-1285/c
; Sequence 1285, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1285
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1285

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2422 AAGAGAGACACAGA 2437
Db      16  ATGAGAGACACAGA 1
      |||:|||||
      |||:|||||

RESULT 178
US-09-371-772B-1907
; Sequence 1907, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
```

```
;; FILE REFERENCE: MHB00,876-J (237/198)
;; CURRENT APPLICATION NUMBER: US/09/371,772B
;; CURRENT FILING DATE: 1999-08-10
;; PRIOR APPLICATION NUMBER: US 60/005,974
;; PRIOR FILING DATE: 1995-10-26
;; PRIOR APPLICATION NUMBER: US 08/584,040
;; PRIOR FILING DATE: 1996-01-08
;; NUMBER OF SEQ ID NOS: 14225
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 1907
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-09-371-772B-1907

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.3e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      1822 AAGATGTTGAAGATG 1837
Db      2  AAAAUGUGAAAGAAG 17
      |||:|||||
      |||:|||||

RESULT 179
US-09-371-772B-2681
; Sequence 2681, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2681
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2681

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 1.3e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY      2332 TGGTCTTCGGGGTGT 2347
Db      2  UGUUCUUCGUGUGU 17
      |||:|||||
      |||:|||||

RESULT 180
US-09-371-772B-3754/c
; Sequence 3754, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
```

```

; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patentin version 3.0
; SEQ ID NO: 3754
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3754

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

1843 ACAGAGAAAGACCTTT 1858
16 ACAGAGAAACCCCTTT 1

Oy
Db

RESULT 181
US-09-371-772B-3889/c
; Sequence 3889, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patentin version 3.0
; SEQ ID NO: 3889
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3889

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

1775 TGGGAATGACAAGA 1790
17 TGGGAATGACAAGA 2

Oy
Db

RESULT 182
US-09-371-772B-4565/c
; Sequence 4565, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
```

```

; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patentin version 3.0
; SEQ ID NO: 4565
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4565

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

2020 GGGATGAGTACTCCT 2035
16 GGGATGAGTCTCCT 1

Oy
Db

RESULT 183
US-09-371-772B-5571/c
; Sequence 5571, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patentin version 3.0
; SEQ ID NO: 5571
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5571

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

2422 AAGGAGGACACAGA 2437
17 AAGGAGGACACAGA 2

Oy
Db

RESULT 184
US-09-371-772B-6727
; Sequence 6727, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
```

```
;; PRIOR APPLICATION NUMBER: US 60/005,974
;; PRIOR FILING DATE: 1995-10-26
;; PRIOR APPLICATION NUMBER: US 08/584,040
;; PRIOR FILING DATE: 1996-01-08
;; NUMBER OF SEQ ID NOS: 14225
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO: 6727
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-09-371-772B-6727

Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.3e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Oy      2114 TGGAGTACTGGCTTC 2129
Db      1 UGAGUCUCUGGCANC 16

RESULT 185
US-09-371-772B-6753
; Sequence 6753, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 6753
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6753

Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Oy      2279 GGATGGCTCCAGAAC 2294
Db      1 GGAUGCCCCCAGAAC 16

RESULT 186
US-09-371-772B-6762
; Sequence 6762, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974

;; PRIOR FILING DATE: 1995-10-26
;; PRIOR APPLICATION NUMBER: US 08/584,040
;; PRIOR FILING DATE: 1996-01-08
;; NUMBER OF SEQ ID NOS: 14225
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO: 6762
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-09-371-772B-6762

Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 1.3e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Oy      2324 GTGATGCTGCTCTT 2339
Db      1 GUGACUCUCUGUCUU 16

RESULT 187
US-09-371-772B-6888/C
; Sequence 6888, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 6888
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6888

Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      2316 TCATCAGATGATGTC 2331
Db      16 TCATCGAGTGATATC 1

RESULT 188
US-09-099-932-29/C
; Sequence 29, Application US/09099932
; Patent No. 6570001
; GENERAL INFORMATION:
; APPLICANT: El Solh, Nevine
; APPLICANT: Allignet, Jeanine
; TITLE OF INVENTION: POLYNUCLEOTIDES AND THEIR USE FOR DETECTING RESISTANCE
; TITLE OF INVENTION: TO STREPTOGAMIN A OR TO STREPTOGAMIN B AND RELATED
; FILE REFERENCE: 03495,0173-00000
; CURRENT APPLICATION NUMBER: US/09/099,932
; CURRENT FILING DATE: 1998-06-19
; EARLIER APPLICATION NUMBER: 60/050,380
; EARLIER FILING DATE: 1997-06-20
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: PatentIn Ver. 2.0
```

SEQ ID NO 29
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-099-932-29

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1741 GGTTCCTTGGGCAAG 1756
Db 17 GGTTCCTTGGGCAAG 2

RESULT 189
US-08-651-472-75
Sequence 75, Application US/08651472
Patent No. 6103244
GENERAL INFORMATION:
APPLICANT: DORNER, Friedrich
APPLICANT: SCHEIFLINGER, Friedrich
APPLICANT: FALKNER, Faliko Gunter
APPLICANT: PLEIDERER, Michael
TITLE OF INVENTION: DIRECT MOLECULAR CLONING OF CHIMERIC
TITLE OF INVENTION: VIRUSES CONTAINING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
NUMBER OF SEQUENCES: 95
EARLIER FILING DATE: 1994-05-18
CORRESPONDENCE ADDRESS:
ADDRESSEE: Foley & Lardner
STREET: 3000 K Street, N.W., Suite 500
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/651,472
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/914,738
FILING DATE: 20-JUL-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/750,080
FILING DATE: 26-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: BENT, Stephen A.
REGISTRATION NUMBER: 29,768
REFERENCE/DOCKET NUMBER: 30472/166/IMMU
TELEPHONE: (202)672-5300
TELEFAX: (202)672-5399
TELEX: 904136
INFORMATION FOR SEQ ID NO: 75:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid:
DESCRIPTION: Synthetic DNA oligonucleotide
IMMEDIATE SOURCE:
CLONE: gp160 in vswp-gp160 virus
FEATURE:
NAME/KEY: CDS
LOCATION: 3..14

US-08-651-472-75

Query Match 0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1811 CCGTGCCGCTGAAG 1824
Db 1 CCGTGCCGCTGAAG 14

RESULT 190
US-08-998-099-349
Sequence 349, Application US/08998099A
Patent No. 6103890
GENERAL INFORMATION:
APPLICANT: JARVIS, THALE
APPLICANT: MCSWIGEN, JAMES A.
APPLICANT: STINGCOMB, DAN T.
TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF C-FOS
FILE REFERENCE: 231/175
CURRENT APPLICATION NUMBER: US/08/998,099A
CURRENT FILING DATE: 1997-12-24
EARLIER APPLICATION NUMBER: 60/037,658
EARLIER FILING DATE: 1997-01-23
EARLIER APPLICATION NUMBER: 08/373,124
EARLIER FILING DATE: 1995-01-13
EARLIER APPLICATION NUMBER: 08/245,466
EARLIER FILING DATE: 1994-05-18
NUMBER OF SEQ ID NOS: 375
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 349
LENGTH: 14
TYPE: RNA
ORGANISM: Homo sapiens
US-08-998-099-349

Query Match 0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 78.6%; Pred. No. 1e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 2413 AACGTCGGAAGA 2426
Db 1 AACGTCGGAAGA 14

RESULT 191
US-08-358-928-75
Sequence 75, Application US/08358928
Patent No. 6265183
GENERAL INFORMATION:
APPLICANT: DORNER, Friedrich
APPLICANT: SCHEIFLINGER, Friedrich
APPLICANT: FALKNER, Faliko Gunter
APPLICANT: PLEIDERER, Michael
TITLE OF INVENTION: DIRECT MOLECULAR CLONING OF CHIMERIC
TITLE OF INVENTION: VIRUSES CONTAINING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
NUMBER OF SEQUENCES: 95
CORRESPONDENCE ADDRESS:
ADDRESSEE: Foley & Lardner
STREET: 3000 K Street, N.W., Suite 500
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/358,928
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/914,738
FILING DATE: 20-JUL-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/750,080
FILING DATE: 26-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: BENT, Stephen A.
REGISTRATION NUMBER: 29,768
REFERENCE/DOCKET NUMBER: 30472/166/IMMU
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202)672-5300
TELEFAX: (202)672-5399
TELEX: 904136
INFORMATION FOR SEQ ID NO: 75:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid:
DESCRIPTION: Synthetic DNA oligonucleotide
IMMEDIATE SOURCE:
CLONE: gp160-in vswlp-gp160 virus
FEATURE:
NAME/KEY: CDS
LOCATION: 3..14
US-08-358-928-75

Query Match 0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1811 CCGTGGCCGTGAG 1824
Db 1 CCATGGCCGTGAG 14

RESULT 192
US-09-535-366C-3
Sequence 3, Application US/09535366C
Patent No. 6410241
GENERAL INFORMATION:
APPLICANT: SYKES, KATHRYN F.
APPLICANT: JOHNSTON, STEPHEN A.
TITLE OF INVENTION: LINEAR AND CIRCULAR EXPRESSION ELEMENTS
FILE REFERENCE: UTSD:557
CURRENT APPLICATION NUMBER: US/09/535,366C
CURRENT FILING DATE: 2000-03-24
PRIOR APPLICATION NUMBER: 60/125,864
PRIOR FILING DATE: 1999-03-24
NUMBER OF SEQ ID NOS: 5
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 3
LENGTH: 14
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: Primer
US-09-535-366C-3

Query Match 0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 64.3%; Pred. No. 1e+02;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Oy 1882 ATGATGAAGATGAT 1895
Db 1 AUGAUGAUGAUGAU 14

RESULT 193
US-09-535-366C-5/C
Sequence 5, Application US/09535366C
Patent No. 6410241
GENERAL INFORMATION:
APPLICANT: SYKES, KATHRYN F.
APPLICANT: JOHNSTON, STEPHEN A.
TITLE OF INVENTION: LINEAR AND CIRCULAR EXPRESSION ELEMENTS
FILE REFERENCE: UTSD:557
CURRENT APPLICATION NUMBER: US/09/535,366C
CURRENT FILING DATE: 2000-03-24
PRIOR APPLICATION NUMBER: 60/125,864
PRIOR FILING DATE: 1999-03-24
NUMBER OF SEQ ID NOS: 5
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 5
LENGTH: 14
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: Primer
US-09-535-366C-5

Query Match 0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1882 ATGATGAAGATGAT 1895
Db 14 ATGATGAAGATGAT 1

RESULT 194
US-08-334-847-296
Sequence 296, Application US/08334847
Patent No. 5693532
GENERAL INFORMATION:
APPLICANT: MCSWIGEN, James
APPLICANT: DRAPER, Kenneth
APPLICANT: PAVCO, Pam
APPLICANT: WOOLF, Tod
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: INHIBITING RESPIRATORY
NUMBER OF SEQUENCES: 909
CORRESPONDENCE ADDRESS:
ADDRESSEE: LYON & LYON
STREET: 633 West Filth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/334,847
FILING DATE: No. 5693532ember 4, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Waidburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/032
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 296:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-334-847-296

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 1.2e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Oy 2237 ACTATTACAAAAG 2250
Db 2 ACUAAUACAAAG 15

RESULT 195
US-08-363-240A-63/C
Sequence 63, Application US/08363240A
Patent No. 5705388
GENERAL INFORMATION:
APPLICANT: Couture, Larry
APPLICANT: McSwigen, James
APPLICANT: Bisgaier, Charles
APPLICANT: Page, Michael
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: PREVENTION, INHIBITION OF
TITLE OF INVENTION: PROGRESSION AND REGRESSION
TITLE OF INVENTION: OF VASCULAR DISEASES
NUMBER OF SEQUENCES: 1243
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08363,240A
FILING DATE: December 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/096
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 63:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-363-240A-63

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1549 AGACAGGTACAGT 1562
Db 15 AGACAGGTACAGT 2

RESULT 196
US-08-657-884-27/C
Sequence 27, Application US/08657884
Patent No. 5658981
GENERAL INFORMATION:
APPLICANT: SCHREIBER, ALAN D.
APPLICANT: PARK, JONG-GU
TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: NIXON & VANDERHAYE P.C.
STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: U.S.A.
ZIP: 22201-4714
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/657,884
FILING DATE: 07-JUN-1996
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: WILSON, MARY J.
REGISTRATION NUMBER: 32,955
REFERENCE/DOCKET NUMBER: 555-46
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 816-4000
TELEFAX: (703) 816-4100
INFORMATION FOR SEQ ID NO: 27:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-657-884-27

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1783 GACAAAGCAAGCC 1796
Db 15 GACAAAGCAAGAC 2

RESULT 197
US-08-657-884-31/C
Sequence 31, Application US/08657884
Patent No. 5658981
GENERAL INFORMATION:
APPLICANT: SCHREIBER, ALAN D.
APPLICANT: PARK, JONG-GU
TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: NIXON & VANDERHAYE P.C.
STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: U.S.A.
ZIP: 22201-4714
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk

```
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/557,884
FILING DATE: 07-JUN-1996
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: WILSON, MARY J.
REGISTRATION NUMBER: 32,955
REFERENCE/DOCKET NUMBER: 555-46
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 816-4000
TELEFAX: (703) 816-4100
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-557-884-31

Query Match      0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1783 GACAAGACAGACC 1796
DB      15 GACAAGACAGAC 2

RESULT 198
US-08-585-684B-2115/C
Sequence 2115, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESS: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: storage
MEDIUM TYPE: 3.5" Dikette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2115:
```

```
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-2115

Query Match      0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1887 GAAGATGATTGCGA 1900
DB      14 GAAGATGATTGCGA 1

RESULT 199
US-08-716-308-13
Sequence 13, Application US/08716308
Patent No. 5883569
GENERAL INFORMATION:
APPLICANT: Windass, John D.
TITLE OF INVENTION: Biological Insect Control Agent
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESS: ZENECA Inc.
STREET: 1800 Concord Pike
CITY: Wilmington
STATE: DE
COUNTRY: USA
ZIP: 19850
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/716,308
FILING DATE: 24-SEP-1996
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB95/00677
FILING DATE: 27-MAR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9405951.6
FILING DATE: 25-MAR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Hohenschutz, Liza D.
REGISTRATION NUMBER: 33,712
REFERENCE/DOCKET NUMBER: PPD40027X/UST
TELECOMMUNICATION INFORMATION:
TELEPHONE: (302) 886-1699
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-716-308-13

Query Match      0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2166 TGTTCGTACAG 2179
DB      2 TGTTCGTACAG 15

RESULT 200
US-08-913-833-157/C
Sequence 157, Application US/08913833
```

Patent No. 6087093
GENERAL INFORMATION:
APPLICANT: STUYVER, LIEVEN
APPLICANT: LOUWAGIE, JOOST
APPLICANT: ROSSAU, RUDI
TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED
MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE
NUMBER OF SEQUENCES: 164
CORRESPONDENCE ADDRESS:
ADDRESSEE: ARNOLD, WHITE & DURKEE
STREET: P.O. BOX 4433
CITY: HOUSTON
STATE: TEXAS
COUNTRY: USA
ZIP: 77210-4433
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Microsoft Word 6.0 / ASCII text output
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/913.833
FILING DATE: 15 Sep 1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/EP97/00211
FILING DATE: 17 Jan 1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 96870005.4
FILING DATE: 26 Jan 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 96870081.5
FILING DATE: 25 Jun 1996
ATTORNEY/AGENT INFORMATION:
NAME: KAMMERER, PATRICIA A.
REGISTRATION NUMBER: 29,775
REFERENCE/DOCKET NUMBER: INNS:008
INFORMATION FOR SEQ ID NO: 157:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-913-833-157
Query Match: 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1856 TTCTGATCTGATG 1869
DB 14 TTTTGTGATCTGATG 1
RESULT 201
US-09-038-073-2115/c
Sequence 2115, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles

STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038.073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Walburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2115:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-2115
Query Match: 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1887 GAAGTATGATGGA 1900
DB 14 GAAGTATGATGGA 1
RESULT 202
US-09-158-980-27/c
Sequence 27, Application US/09158980
Patent No. 6242427
GENERAL INFORMATION:
APPLICANT: SCHREIBER, ALAN D.
APPLICANT: PARK, JONG-GU
TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: NIXON & VANDERHAYE P.C.
STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: U.S.A.
ZIP: 22201-4714
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/158.980
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/657,884
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: WILSON, MARY J.
REGISTRATION NUMBER: 32,955
REFERENCE/DOCKET NUMBER: 555-46
TELECOMMUNICATION INFORMATION:

TELEPHONE: (703) 816-4000
TELEFAX: (703) 816-4100
INFORMATION FOR SEQ ID NO: 27:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-158-980-27

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1783 GACAAAGACAAGCC 1796
Db 15 GACAAAGACAAGAC 2

RESULT 203
US-09-158-980-31/c
Sequence 31, Application US/09158980
Patent No. 6242427

GENERAL INFORMATION:
APPLICANT: SCHREIBER, ALAN D.
TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: NIXON & VANDERHAYE P.C.
STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: U.S.A.
ZIP: 22201-4714

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/158,980
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/657,884
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: WILSON, MARY J.
REGISTRATION NUMBER: 32,955
REFERENCE/DOCKET NUMBER: 555-46
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 816-4000
TELEFAX: (703) 816-4100
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-158-980-31

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1783 GACAAAGACAAGCC 1796
Db 15 GACAAAGACAAGAC 2

RESULT 204
US-09-580-794C-157/c
Sequence 157, Application US/09580794C
Patent No. 631389
GENERAL INFORMATION:
APPLICANT: Stuyver, Lieven
APPLICANT: Louwaghe, Joost
APPLICANT: Rousseau, Rudi
TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE
TITLE OF INVENTION: TRANSCRIPTASE GENE
FILE REFERENCE: INNS008--2
CURRENT APPLICATION NUMBER: US/09/580,794C
CURRENT FILING DATE: 2000-05-30
PRIOR APPLICATION NUMBER: 08/913,833 now US/6,087,093
PRIOR FILING DATE: 1997-09-15
PRIOR APPLICATION NUMBER: PCT/EP 97/00211
PRIOR FILING DATE: 1997-01-17
PRIOR APPLICATION NUMBER: EP 96870005.4
PRIOR FILING DATE: 1996-01-26
PRIOR APPLICATION NUMBER: EP 96870081.5
PRIOR FILING DATE: 1996-06-25
NUMBER OF SEQ ID NOS: 164
SOFTWARE: Patentin version 3.0
SEQ ID NO 157
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Synthetic Primer
US-09-580-794C-157

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1856 TTTCGATCTGCTG 1869
Db 14 TTTCGATCTGCTG 1

RESULT 205
US-08-584-040-8473
Sequence 8473, Application US/08584040
Patent No. 6346398

GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
;
; TELEFAX: 67-3510
; INFORMATION FOR SEQ ID NO: 8473:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-584-040-8473

Query Match          0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 1.2e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy      1822 AAGATGTGAAGA 1835
Db      1 AAAAUGUGAAAGA 14

RESULT 206
US-09-371-772B-4128
; Sequence 4128, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4128
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-4128

Query Match          0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 1.2e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy      1822 AAGATGTGAAGA 1835
Db      1 AAAAUGUGAAAGA 14

RESULT 207
US-08-527-060-14/c
; Sequence 14, Application US/08527060
; Patent No. 5834440
; GENERAL INFORMATION:
; APPLICANT: Goldenberg, Tavi
; APPLICANT: Tiltz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT
; TITLE OF INVENTION: AND/OR PREVENTION OF RESTENOSIS
```

```

; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSER: SEED and BERRY
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104-7092
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/527,060
; FILING DATE: 12-SEP-1995
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Mcmasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 480124.402C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-527-060-14

Query Match          0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2169 TTGGTACAGAAA 2182
Db      14 TTGGTACAGAAA 1

RESULT 208
US-09-371-772B-5827
; Sequence 5827, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5827
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5827

Query Match          0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 78.6%; Pred. No. 1.3e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy      1924 CTTGAGCTGCAC 1937
```

DB 1 CUGGAGGCTCUGAC 14

RESULT 209

US-09-475-947A-85/c

; Sequence 85, Application US/09475947A

; Patent No. 6472154

; GENERAL INFORMATION:

; APPLICANT: Garner, Harold R.

; APPLICANT: Wren, Jonathan D.

; APPLICANT: Minna, John D.

; TITLE OF INVENTION: Polymorphic Repeats in Human Genes

; FILE REFERENCE: UTS0667

; CURRENT APPLICATION NUMBER: US/09/475,947A

; CURRENT FILING DATE: 1999-12-31

; NUMBER OF SEQ ID NOS: 346

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 85

; LENGTH: 12

; TYPE: DNA

; ORGANISM: human

; US-09-475-947A-85

Query Match

Best Local Similarity 0.9%; Score 12; DB 1; Length 12;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1653 GGCAGGGGTCTC 1664

DB 12 GGCAGGGGTCTC 1

RESULT 210

US-08-998-099-328/c

; Sequence 328, Application US/08998099A

; Patent No. 6103890

; GENERAL INFORMATION:

; APPLICANT: JARVIS, THALE

; APPLICANT: MCSWIGEN, JAMES A.

; APPLICANT: STINCHCOMB, DAN T.

; TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT OF DISEASES

; FILE REFERENCE: 231/175

; CURRENT APPLICATION NUMBER: US/08/998,099A

; CURRENT FILING DATE: 1997-12-24

; EARLIER APPLICATION NUMBER: 60/037,658

; EARLIER FILING DATE: 1997-01-23

; EARLIER APPLICATION NUMBER: 08/373,124

; EARLIER FILING DATE: 1995-01-13

; EARLIER APPLICATION NUMBER: 08/245,466

; EARLIER FILING DATE: 1994-05-18

; NUMBER OF SEQ ID NOS: 375

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 328

; LENGTH: 14

; TYPE: RNA

; ORGANISM: Homo sapiens

; US-08-998-099-328

Query Match

Best Local Similarity 0.9%; Score 12; DB 1; Length 14;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1545 GCGGAGACAGGT 1556

DB 13 GCGGAGACAGGT 2

RESULT 211

US-08-765-340-141

; Sequence 141, Application US/08765340

; Patent No. 6150092

; GENERAL INFORMATION:

; APPLICANT: UCHIDA, K.

; APPLICANT: UCHIDA, T.

; APPLICANT: TANAKA, Y.

; APPLICANT: MATSUDA, Y.

; APPLICANT: KONDO, S.

; TITLE OF INVENTION: AN ANTISENSE NUCLEIC ACID

; TITLE OF INVENTION: COMPOUND

; NUMBER OF SEQUENCES: 185

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: MORGAN & FINNEGAN, L.L.P.

; STREET: 345 PARK AVENUE

; CITY: NEW YORK

; STATE: NEW YORK

; COUNTRY: USA

; ZIP: 10154

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version

; SOFTWARE: #1.30 (EPO)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/765,340

; FILING DATE: 23-DEC-1996

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: JP 145146/94

; FILING DATE: 27-JUN-1994

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: JP 311130/94

; FILING DATE: 21-NOV-1994

; ATTORNEY/AGENT INFORMATION:

; NAME: SERUNIAN, LESLIE

; REGISTRATION NUMBER: 35,353

; REFERENCE/DOCKET NUMBER: 1452-4005

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (212) 758-4800

; TELEFAX: (212) 751-6849

; INFORMATION FOR SEQ ID NO: 141:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 14 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: other nucleic acid

; DESCRIPTION: /desc = "synthetic DNA"

; US-08-765-340-141

Query Match

Best Local Similarity 0.9%; Score 12; DB 1; Length 14;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1935 CACACAGATGG 1946

DB 1 CACACAGATGG 12

RESULT 212

US-07-664-989B-121/c

; Sequence 121, Application US/07664989B

; Patent No. 5223409

; GENERAL INFORMATION:

; APPLICANT: Ladner, Robert Charles

; APPLICANT: Guterman, Sonia Kosow

; APPLICANT: Roberts, Bruce Lindsay

; APPLICANT: Markland, William

; APPLICANT: Ley, Arthur Charles

; APPLICANT: Kent, Rachel Baribault

; TITLE OF INVENTION: Directed Evolution of No. 5223409e1

; TITLE OF INVENTION: Binding Proteins

; NUMBER OF SEQUENCES: 121

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Brody and Neimark

```

: STREET: 419 Seventh Street, N.W.
: STREET: Suite 300
: CITY: Washington,
: STATE: DC
: COUNTRY: USA
: ZIP: 20004
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: WORDPERFECT 4.2
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/07/664,989B
: FILING DATE: 19910301
: CLASSIFICATION: 530
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: PCT/US89/03731
: FILING DATE: 01-SEP-1989
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 07/487,063
: FILING DATE: 02-MAR-1990
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 07/240,160
: FILING DATE: 02-SEP-1988
: ATTORNEY/AGENT INFORMATION:
: NAME: Cooper, Iver P.
: REGISTRATION NUMBER: 28005
: REFERENCE/DOCKET NUMBER: LADNER 7
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 202-628-5197
: TELEFAX: 202-737-3528
: INFORMATION FOR SEQ ID NO: 121:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 15 base pairs
: TYPE: NUCLEIC ACID
: STRANDEDNESS: double
: TOPOLOGY: circular
: MOLECULE TYPE: genomic DNA
: US-07-664-989B-121

Query Match          0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1401 GGAGTAGCCCAT 1412
DB      12 GGAGTAGCCCAT 1

RESULT 213
US-09-177-359-34/c
: Sequence 34, Application US/09177359B
: Patent No. 6183963
: GENERAL INFORMATION:
: APPLICANT: SINNETT, Daniel
: APPLICANT: LABUDA, Daniel
: TITLE OF INVENTION: DETECTION OF CYP1A1, CYP3A4, CYP2D6 AND
: TITLE OF INVENTION: NAT2 VARIANTS BY PCR-ALLELE-SPECIFIC OLIGONUCLEOTIDE (ASO)
: FILE REFERENCE: 12667-17"US" FC/1d
: CURRENT APPLICATION NUMBER: US/09/177,359B
: CURRENT FILING DATE: 1998-10-23
: NUMBER OF SEQ ID NOS: 37
: SOFTWARE: FastSeq for Windows Version 3.0
: SEQ ID NO 34
: LENGTH: 15
: TYPE: DNA
: ORGANISM: Artificial Sequence
: FEATURES:
: OTHER INFORMATION: cDNA for use as probes
US-09-177-359-34

Query Match          0.9%; Score 12; DB 1; Length 15;
```

```

Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1456 GTGATCTGTGTC 1467
DB      14 GTGATCTGTGTC 3

RESULT 214
US-09-081-646-133
: Sequence 133, Application US/09081646
: Patent No. 6333152
: GENERAL INFORMATION:
: APPLICANT: Kinzler, Kenneth
: APPLICANT: Vogelstein, Bert
: APPLICANT: Zhou, Wei
: TITLE OF INVENTION: Gene Expression Profiles in No. 6333152ma1 and
: FILE REFERENCE: 01107.74664
: CURRENT APPLICATION NUMBER: US/09/081,646
: CURRENT FILING DATE: 1998-05-20
: EARLIER APPLICATION NUMBER: 60/047,352
: EARLIER FILING DATE: 1997-05-21
: NUMBER OF SEQ ID NOS: 871
: SOFTWARE: FastSeq for Windows Version 3.0
: SEQ ID NO 133
: LENGTH: 15
: TYPE: DNA
: ORGANISM: Homo sapiens
US-09-081-646-133

Query Match          0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1721 TGGGCAAGCCCC 1732
DB      3 TGGGCAAGCCCC 14

RESULT 215
US-09-081-646-708
: Sequence 708, Application US/09081646
: Patent No. 6333152
: GENERAL INFORMATION:
: APPLICANT: Kinzler, Kenneth
: APPLICANT: Vogelstein, Bert
: APPLICANT: Zhou, Wei
: TITLE OF INVENTION: Gene Expression Profiles in No. 6333152ma1 and
: FILE REFERENCE: 01107.74664
: CURRENT APPLICATION NUMBER: US/09/081,646
: CURRENT FILING DATE: 1998-05-20
: EARLIER APPLICATION NUMBER: 60/047,352
: EARLIER FILING DATE: 1997-05-21
: NUMBER OF SEQ ID NOS: 871
: SOFTWARE: FastSeq for Windows Version 3.0
: SEQ ID NO 708
: LENGTH: 15
: TYPE: DNA
: ORGANISM: Homo sapiens
US-09-081-646-708

Query Match          0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2324 GTGATGCTGTGCT 2335
DB      4 GTGATGCTGTGCT 15
```

```
RESULT 216
US-09-081-646-835
; Sequence 835, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 835
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-835

Query Match
Best Local Similarity 100.0%; Score 12; DB 1; Length 15;
Pred. No. 1.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy 1721 TGGGCAAGCCCC 1732
Db 3 TGGGCAAGCCCC 14

RESULT 217
US-09-475-947A-180/C
; Sequence 180, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Wren, Jonathan D.
; APPLICANT: Minna, John D.
; TITLE OF INVENTION: Polymorphic Repeats in Human Genes
; FILE REFERENCE: UTS0667
; CURRENT APPLICATION NUMBER: US/09/475,947A
; CURRENT FILING DATE: 1999-12-31
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 180
; LENGTH: 15
; TYPE: DNA
; ORGANISM: human
US-09-475-947A-180

Query Match
Best Local Similarity 100.0%; Score 12; DB 1; Length 15;
Pred. No. 1.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy 1837 GATGCCACAGAG 1848
Db 12 GATGCCACAGAG 1

RESULT 218
US-08-248-357C-11
; Sequence 11, Application US/08248357C
; Patent No. 5773225
; GENERAL INFORMATION:
; APPLICANT: Luban, Jeremy
; APPLICANT: Goff, Stephen P.
; TITLE OF INVENTION: Screening Method for the Identification of
; TITLE OF INVENTION: Formation
; NUMBER OF SEQUENCES: 12
```

```
CORRESPONDENCE ADDRESS:
ADDRESSER: Cooper & Dunham LLP
STREET: 1185 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10036

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/248,357C
FILING DATE: 24-MAY-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 44010
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-278-0400
TELEFAX: 212-391-0525
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: N
ANTI-SENSE: N
FRAGMENT TYPE: N-terminal
US-08-248-357C-11

Query Match
Best Local Similarity 100.0%; Score 12; DB 1; Length 16;
Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy 1881 GATGATGAAGAT 1892
Db 2 GATGATGAAGAT 13

RESULT 219
US-08-282-197C-20/C
; Sequence 20, Application US/08282197C
; Patent No. 5871730
; GENERAL INFORMATION:
; APPLICANT: Brzezinski, Ryszard
; APPLICANT: Dery, Claude V.
; APPLICANT: Beaulieu, Carole
; TITLE OF INVENTION: Thermostable Xylanase DNA, Protein and
; NUMBER OF SEQUENCES: 67
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Sterne, Kessler, Goldstein & Fox P.L.L.C.
; STREET: 1100 New York Ave., NW
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20005

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/282,197C
FILING DATE: 29-JUL-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Cimbalia, Michele A
```

REGISTRATION NUMBER: 33,851
REFERENCE/DOCKET NUMBER: 1050.0410000
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-371-2600
TELEFAX: 202-371-2540
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: both
TOPOLOGY: both
US-08-282-197C-20

Query Match 0.9%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1573 TCCAGCTCCTCC 1584
DB 14 TCCAGCTCCTCC 3

RESULT 220
US-08-626-023-2/c
Sequence 2, Application US/08626023
Patent No. 5955266
GENERAL INFORMATION:
APPLICANT: Bray, Paul F.
APPLICANT: Goldschmidt-Clermont, Pascal
APPLICANT: J.
TITLE OF INVENTION: USE OF PLATELET POLYMORPHISM P1A2 TO
TITLE OF INVENTION: DIAGNOSE RISK OF THROMBOTIC DISEASE
NUMBER OF SEQUENCES: 6
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 4225 Executive Square, Suite 1400
CITY: La Jolla
STATE: California
COUNTRY: USA
ZIP: 92037
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/626,023
FILING DATE: 01-APR-1996
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Haile Ph.D., Lisa A.,
REGISTRATION NUMBER: 38,347
REFERENCE/DOCKET NUMBER: 07265/087001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619/678-5070
TELEFAX: 619/678-5099
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: CDS
LOCATION: 1..16
US-08-626-023-2

Query Match 0.9%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2003 GAGCCCGAGGC 2014

DB 13 GAGCCCGAGGC 2

RESULT 221
US-08-626-023-4
Sequence 4, Application US/08626023
Patent No. 5955266
GENERAL INFORMATION:
APPLICANT: Bray, Paul F.
APPLICANT: Goldschmidt-Clermont, Pascal
APPLICANT: J.
TITLE OF INVENTION: USE OF PLATELET POLYMORPHISM P1A2 TO
TITLE OF INVENTION: DIAGNOSE RISK OF THROMBOTIC DISEASE
NUMBER OF SEQUENCES: 6
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 4225 Executive Square, Suite 1400
CITY: La Jolla
STATE: California
COUNTRY: USA
ZIP: 92037
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/626,023
FILING DATE: 01-APR-1996
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Haile Ph.D., Lisa A.,
REGISTRATION NUMBER: 38,347
REFERENCE/DOCKET NUMBER: 07265/087001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619/678-5070
TELEFAX: 619/678-5099
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: CDS
LOCATION: 1..16
US-08-626-023-4

Query Match 0.9%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2003 GAGCCCGAGGC 2014

DB 4 GAGCCCGAGGC 15

RESULT 222
US-09-266-409-8/c
Sequence 8, Application US/09266409
Patent No. 6225061
GENERAL INFORMATION:
APPLICANT: Becker, Thomas
APPLICANT: Sequenom, Inc.
TITLE OF INVENTION: Systems and Methods for Performing Reactions in an Unsealed
FILE REFERENCE: Sequence listing for 24736-2023
PATENT NO. 6225061
CURRENT APPLICATION NUMBER: US/09/266,409
CURRENT FILING DATE: 1999-03-10
NUMBER OF SEQ ID NOS: 8

```

; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 8
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer
; NAME/KEY: primer bind
; LOCATION: (1)..(16)
; OTHER INFORMATION: Sequencing primer for exon 7 of human p53 gene
US-09-266-409-8

Query Match
Best Local Similarity 100.0%; Score 12; DB 1; Length 16;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 AGGATGGGCTTC 1951
Db 12 AGGATGGGCTTC 1

RESULT 223
US-09-678-620-8/c
; Sequence 8, Application US/09678620
; Patent No. 6485913
; GENERAL INFORMATION:
; APPLICANT: Becker, Thomas
; APPLICANT: Hubert K"ster
; APPLICANT: Charles Cantor
; TITLE OF INVENTION: Systems and Methods for Performing Reactions in an Unsealed
; FILE REFERENCE: Sequence listing for 24736-2023B
; Patent No. 6485913
; CURRENT APPLICATION NUMBER: US/09/678,620
; CURRENT FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: 09/266,409
; PRIOR FILING DATE: 1999-03-10
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 8
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer
; NAME/KEY: primer bind
; LOCATION: (1)..(16)
; OTHER INFORMATION: Sequencing primer for exon 7 of human p53 gene
US-09-678-620-8

Query Match
Best Local Similarity 100.0%; Score 12; DB 1; Length 16;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 AGGATGGGCTTC 1951
Db 12 AGGATGGGCTTC 1

RESULT 224
US-08-182-968A-35
; Sequence 35, Application US/08182968A
; Patent No. 5610054
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
```

```

; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/182,968A
; FILING DATE: 13-JANUARY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/882,888
; FILING DATE: 14-MAY-1992
; ATTORNEY/AGENT INFORMATION:

STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/182,968A
FILING DATE: 13-JANUARY-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/882,888
FILING DATE: 14-MAY-1992
ATTORNEY/AGENT INFORMATION:

QY 1946 GGCTCTTATGTC 1960
Db 1 GGCTCTTATGTC 15

RESULT 225
US-08-182-968A-301/c
; Sequence 301, Application US/08182968A
; Patent No. 5610054
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/182,968A
; FILING DATE: 13-JANUARY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/882,888
; FILING DATE: 14-MAY-1992
; ATTORNEY/AGENT INFORMATION:

Query Match
Best Local Similarity 66.7%; Score 11.8; DB 1; Length 15;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1946 GGCTCTTATGTC 1960
Db 1 GGCTCTTATGTC 15

RESULT 225
US-08-182-968A-301/c
; Sequence 301, Application US/08182968A
; Patent No. 5610054
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/182,968A
; FILING DATE: 13-JANUARY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/882,888
; FILING DATE: 14-MAY-1992
; ATTORNEY/AGENT INFORMATION:
```

NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 205/277
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 301:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-182-968A-301

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2436 AATGATAGCCAGC 2450
Db 15 AGTGATAGCCTGC 1

RESULT 226
US-08-182-968A-302/C
Sequence 302 Application US/08182968A
Patent No. 5610054

GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: INHIBITING HEPATITIS C
TITLE OF INVENTION: VIRUS REPLICATION
NUMBER OF SEQUENCES: 497
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/182,968A

FILING DATE: 13-JANUARY-1994

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/882,888

FILING DATE: 14-MAY-1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 205/277

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 302:

SEQUENCE CHARACTERISTICS:

LENGTH: 15

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-182-968A-302

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2435 GAATGATAGCCAG 2449
Db 15 AGTGATAGCCTG 1

RESULT 227
US-08-334-847-295

Sequence 295 Application US/08334847

Patent No. 5693532

GENERAL INFORMATION:

APPLICANT: McSwigen, James

APPLICANT: Draper, Kenneth

APPLICANT: Pavco, Pam

APPLICANT: Wolfe, Tod

TITLE OF INVENTION: METHOD AND REAGENT FOR

TITLE OF INVENTION: INHIBITING RESPIRATORY

TITLE OF INVENTION: SYNCYTIAL VIRUS

NUMBER OF SEQUENCES: 909

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

STREET: Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/334,847

FILING DATE: No. 5693532ember 4, 1994

PRIOR APPLICATION DATA:

APPLICATION NUMBER:

FILING DATE:

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 209/032

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 295:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-334-847-295

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.4e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 2235 AGACTATTGCAAAA 2249
Db 1 AAACUADUACACAA 15

RESULT 228

US-08-334-847-450

Sequence 450 Application US/08334847

Patent No. 5693532

GENERAL INFORMATION:

APPLICANT: McSwigen, James

APPLICANT: Draper, Kenneth

APPLICANT: Pavco, Pam

APPLICANT: Wolfe, Tod

TITLE OF INVENTION: METHOD AND REAGENT FOR
INHIBITING RESPIRATORY
TITLE OF INVENTION: SYNCTYAL VIRUS
NUMBER OF SEQUENCES: 909
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/334,847
FILING DATE: No. 5693532ember 4, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/032
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 450:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-334-847-450
Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.4e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
Qy 2310 ATACATCATCAGAG 2324
Db 1 AUAACUCUACAAGA 15
RESULT 229
US-08-363-240A-17
Sequence 17, Application US/08363240A
Patent No. 5705388
GENERAL INFORMATION:
APPLICANT: Couture, Larry
APPLICANT: McSwigen, James
APPLICANT: Bisgaier, Charles
TITLE OF INVENTION: METHOD AND REAGENT FOR
PREVENTION, INHIBITION OF
PROGRESSION AND REGRESSION
TITLE OF INVENTION: OF VASCULAR DISEASES
NUMBER OF SEQUENCES: 1243
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/363,240A
FILING DATE: December 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/096
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-363-240A-17
Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.4e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
Qy 1454 CAGTCATCTGTGCC 1468
Db 1 CAGGCAUCGUGGCC 15
RESULT 230
US-08-363-240A-47/C
Sequence 47, Application US/08363240A
Patent No. 5705388
GENERAL INFORMATION:
APPLICANT: Couture, Larry
APPLICANT: McSwigen, James
APPLICANT: Bisgaier, Charles
TITLE OF INVENTION: METHOD AND REAGENT FOR
PREVENTION, INHIBITION OF
PROGRESSION AND REGRESSION
TITLE OF INVENTION: OF VASCULAR DISEASES
NUMBER OF SEQUENCES: 1243
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/363,240A
FILING DATE: December 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/096

TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 47:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-363-240A-47

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1488 GAAGCCAGACTTCAG 1502
Db 15 GTAGCCATACCTTCAG 1

RESULT 231
US-08-363-240A-673
Sequence 673, Application US/08363240A
Patent No. 5705388
GENERAL INFORMATION:
APPLICANT: Couture, Larry
APPLICANT: McSwigen, James
APPLICANT: Bisgaler, Charles
APPLICANT: Pape, Michael
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: PREVENTION, INHIBITION OF
TITLE OF INVENTION: PROGRESSION AND REGRESSION
TITLE OF INVENTION: OF VASCULAR DISEASES
NUMBER OF SEQUENCES: 1243
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08363, 240A
FILING DATE: December 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Waipburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/096
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 673:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-363-240A-673

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.4e+02;

Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1917 AAATCTTGTGAGC 1931
Db 1 AAATCTTGTGAGC 15

RESULT 232
US-08-317-432A-5
Sequence 5, Application US/08317432A
Patent No. 5710028
GENERAL INFORMATION:
APPLICANT: Nurit Eyal and Nir Navot
TITLE OF INVENTION: A method of quick screening and
NUMBER OF SEQUENCES: 50
CORRESPONDENCE ADDRESS:
ADDRESSEE: Mark M. Friedman c/o Robert Sheinbein
STREET: 2940 Birchtree lane
CITY: Silver Spring
STATE: Maryland
COUNTRY: United States of America
ZIP: 20906
COMPUTER READABLE FORM:
MEDIUM TYPE: 1.44 megabyte, 3.5" microdisk
COMPUTER: Twinhead* Slimnote-890TX
OPERATING SYSTEM: MS DOS version 6.2,
OPERATING SYSTEM: Windows version 3.11
SOFTWARE: word for windows version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08317, 432A
FILING DATE: 4-Oct-94
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/919, 872
FILING DATE: 27-Jul-92
APPLICATION NUMBER: 08/084, 505
FILING DATE: 1-Jul-93
ATTORNEY/AGENT INFORMATION:
NAME: Friedmam, Mark M.
REGISTRATION NUMBER: 33,883
REFERENCE/DOCKET NUMBER: 128/7
TELECOMMUNICATION INFORMATION:
TELEPHONE: 972-3-5625553
TELEFAX: 972-3-5625554
TELEX:
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-317-432A-5

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2631 AAGAATCTGTGTC 2645
Db 1 AAGAATCTGTGTC 15

RESULT 233
US-08-344-920-9/c
Sequence 9, Application US/08344920
Patent No. 5717085
GENERAL INFORMATION:
APPLICANT: LYTLE, MATTHEW H.
APPLICANT: KAIVAR, LAWRENCE M.
TITLE OF INVENTION: CODON AMIDITES AND METHOD OF USING THEM
TITLE OF INVENTION: TO PRODUCE OLIGONUCLEOTIDES AND MUTAGENESIS LIBRARIES
NUMBER OF SEQUENCES: 21

;; CORRESPONDENCE ADDRESS:
;; ADDRESS: MORRISON & FORBSTER
;; STREET: 2000 Pennsylvania Avenue
;; CITY: Washington
;; STATE: D.C.
;; COUNTRY: USA
;; ZIP: 20006-1812
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patent Release #1.0, Version #1.30
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/344,820
;; FILING DATE: 23-NOV-1994
;; CLASSIFICATION: 530
;; ATTORNEY/AGENT INFORMATION:
;; NAME: DROST, PATRICIA M.
;; REGISTRATION NUMBER: 29,790
;; REFERENCE/DOCKET NUMBER: 2550-0023.00
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (202) 887-1500
;; TELEFAX: (202) 822-0168
;; TELEX: 90-4030
;; INFORMATION FOR SEQ ID NO: 9:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;;
US-08-344-820-9

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1881 GATGATGAAGATGAT 1895
DB 15 GATGATGATCATGAT 1

RESULT 234
US-08-311-486C-171
; Sequence 171, Application US/08311486C
; Patent No. 3811300
; GENERAL INFORMATION:
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth Draper
; APPLICANT: Kevin Kisch
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: TNF- α
; NUMBER OF SEQUENCES: 1157
; CORRESPONDENCE ADDRESS:
; ADDRESS: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,486C
; FILING DATE: September 23, 1994

;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; PRIOR APPLICATION DATA: including application
;; PRIOR APPLICATION DATA: described below:
;; APPLICATION NUMBER: 08/008,895
;; FILING DATE: January 19, 1993
;; APPLICATION NUMBER: 07/989,849
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Wardburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 209/166
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 171:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;;
US-08-311-486C-171

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.4e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1390 CCAGACTACCTGAG 1404
DB 1 CCAGACTUCCTUGAG 15

RESULT 235
US-08-311-486C-172
; Sequence 172, Application US/08311486C
; Patent No. 5811300
; GENERAL INFORMATION:
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth Draper
; APPLICANT: Kevin Kisch
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: TNF- α
; NUMBER OF SEQUENCES: 1157
; CORRESPONDENCE ADDRESS:
; ADDRESS: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,486C
; FILING DATE: September 23, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992

two

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/166
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 172:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-486C-172

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.4e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1391 CAGACTACTGAGCA 1405
Db 1 CAGACUCCUUGAGA 15
|||||:|||||

RESULT 236
US-08-311-486C-660
Sequence 660, Application US/08311486C
Patent No. 5811300
GENERAL INFORMATION:
APPLICANT: Sean Sullivan
APPLICANT: Kenneth Draper
APPLICANT: Kevin Kirsch
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: TNF-
NUMBER OF SEQUENCES: 1157
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,486C
FILING DATE: September 23, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/166
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 955-0440
TELEFAX: 67-3510

INFORMATION FOR SEQ ID NO: 660:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-486C-660

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.4e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 2217 CAGAGATATCAACA 2231
Db 1 CAGACUCCUUGAGA 15
|||||:|||||

RESULT 237
US-08-292-620A-242/C
Sequence 242, Application US/08292620A
Patent No. 5837342
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 242:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-242

Query Match 0.8%; Score 11.8; DB 1; Length 15;

Best Local Similarity 86.7%; Pred. No. 1.4e+02; Mismatches 2; Indels 0; Gaps 0;

OY 2510 AGAGACCAAGCTTCA 2524

Db 15 AGAGACCTATGTCTCA 1

RESULT 238

US-08-292-620A-430/c
; Sequence 430, Application US/08292620A

Patent No. 5837542

GENERAL INFORMATION:

APPLICANT: Susan Grimm

APPLICANT: Dan T. Stinchcomb

APPLICANT: James McSwigen

APPLICANT: Sean Sullivan

APPLICANT: Kenneth G. Draper

TITLE OF INVENTION: RIBOZYME TREATMENT OF

TITLE OF INVENTION: DISEASES OR CONDITIONS

TITLE OF INVENTION: RELATED TO LEVELS OF

TITLE OF INVENTION: INTRACELLULAR ADHESION

TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)

NUMBER OF SEQUENCES: 2390

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/292,620A

FILING DATE: August 17, 1994

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

PRIOR APPLICATION DATA: including application

PRIOR APPLICATION DATA: described below:

APPLICATION NUMBER: 08/008,895

FILING DATE: January 19, 1993

APPLICATION NUMBER: 07/989,849

FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 208/149

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-292-620A-430

Db 15 GCTGTAGAGTCTC 1

RESULT 239

US-08-292-620A-462
; Sequence 462, Application US/08292620A

Patent No. 5837542

GENERAL INFORMATION:

APPLICANT: Susan Grimm

APPLICANT: Dan T. Stinchcomb

APPLICANT: James McSwigen

APPLICANT: Sean Sullivan

APPLICANT: Kenneth G. Draper

TITLE OF INVENTION: RIBOZYME TREATMENT OF

TITLE OF INVENTION: DISEASES OR CONDITIONS

TITLE OF INVENTION: RELATED TO LEVELS OF

TITLE OF INVENTION: INTRACELLULAR ADHESION

TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)

NUMBER OF SEQUENCES: 2390

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/292,620A

FILING DATE: August 17, 1994

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

PRIOR APPLICATION DATA: including application

PRIOR APPLICATION DATA: described below:

APPLICATION NUMBER: 08/008,895

FILING DATE: January 19, 1993

APPLICATION NUMBER: 07/989,849

FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 208/149

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-292-620A-462

Query Match 0.8%; Score 11.8; DB 1; Length 15;

Best Local Similarity 46.7%; Pred. No. 1.4e+02; Mismatches 2; Indels 0; Gaps 0;

OY 2324 GTGATGCTGCTCT 2338

Db 1 GUGCUUAGUGUCCU 15

RESULT 240

US-08-292-620A-534/c
; Sequence 534, Application US/08292620A

Patent No. 5837542

1650 GCTGCGAGGCTTC 1664

* ||||| || |||||

```

GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESS: Lyon & Lyon
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 534:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-534

Query Match          0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1650 GCTGGCAGGGTCTC 1664
Db      15 GCTGGTAGAGTCTC 1

RESULT 241
US-08-292-620A-547
Sequence 547, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
```

```

TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESS: Lyon & Lyon
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 547:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-547

Query Match          0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 46.7%; Pred. No. 1.4e+02;
Matches 7; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY      2324 GTGATGCTGGTCT 2338
Db      1 GUGCUGUAGUGUCU 15

RESULT 242
US-08-292-620A-664/c
Sequence 664, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESS: Lyon & Lyon
```

STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 664:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-664

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

CY 1650 GCTGGCAGGGCTCTC 1664
DB 15 GCTGTTGACGACT 1

RESULT 243
US-08-292-620A-730/c
Sequence 730, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (1-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 730:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-730

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

CY 2295 CCTGTTGATAGT 2309
DB 15 CCTGTTGACGACT 1

RESULT 244
US-08-657-884-25/c
Sequence 25, Application US/08657884
Patent No. 5858981
GENERAL INFORMATION:
APPLICANT: SCHREIBER, ALAN D.
APPLICANT: PARK, JONG-GU
TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: NIXON & VANDERHAYE P.C.
STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: U.S.A.
ZIP: 22201-4714
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/657,884
FILING DATE: 07-JUN-1996
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: WILSON, MARY J.
REGISTRATION NUMBER: 32,955
REFERENCE/DOCKET NUMBER: 555-46
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 816-4000
TELEFAX: (703) 816-4100

```

; INFORMATION FOR SEQ ID NO: 25:
;   SEQUENCE CHARACTERISTICS:
;       LENGTH: 15 base pairs
;       TYPE: nucleic acid
;       STRANDEDNESS: single
;       TOPOLOGY: linear
;   MOLECULE TYPE: DNA (genomic)
;   US-08-657-884-25

Query Match      0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1334 CTGCATGGTGCAG 1348
Db      15 CGGCATGGCTGCAG 1

RESULT 245
US-08-657-884-29/c
; Sequence 29, Application US/08657884
; Patent No. 3858981
; GENERAL INFORMATION:
;   APPLICANT: SCHREIBER, ALAN D.
;   APPLICANT: PARK, JONG-GU
;   TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
;   NUMBER OF SEQUENCES: 31
;   CORRESPONDENCE ADDRESS:
;       ADDRESSEE: NIXON & VANDERHAYE P. C.
;       STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
;       CITY: ARLINGTON
;       STATE: VIRGINIA
;       COUNTRY: U.S.A.
;       ZIP: 22201-4714
;   COMPUTER READABLE FORM:
;       MEDIUM TYPE: Floppy disk
;       COMPUTER: IBM PC compatible
;       OPERATING SYSTEM: PC-DOS/MS-DOS
;       SOFTWARE: Patent in Release #1.0, Version #1.30
;   CURRENT APPLICATION DATA:
;       APPLICATION NUMBER: US/08/657,884
;       FILING DATE: 07-JUN-1996
;       CLASSIFICATION: 424
;   ATTORNEY/AGENT INFORMATION:
;       NAME: WILSON, MARY J.
;       REGISTRATION NUMBER: 32,955
;       REFERENCE/DOCKET NUMBER: 555-46
;       TELECOMMUNICATION INFORMATION:
;           TELEPHONE: (703) 816-4000
;           TELEFAX: (703) 816-4100
;   INFORMATION FOR SEQ ID NO: 29:
;   SEQUENCE CHARACTERISTICS:
;       LENGTH: 15 base pairs
;       TYPE: nucleic acid
;       STRANDEDNESS: single
;       TOPOLOGY: linear
;   MOLECULE TYPE: DNA (genomic)
;   US-08-657-884-29

Query Match      0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1334 CTGCATGGTGCAG 1348
Db      15 CGGCATGGCTGCAG 1

RESULT 246
US-08-774-306A-35
; Sequence 35, Application US/08774306A
; Patent No. 5869253
; GENERAL INFORMATION:
```

```

; APPLICANT: Draper, Kenneth G.
;   TITLE OF INVENTION: METHOD AND REAGENT FOR
;   TITLE OF INVENTION: INHIBITING HEPATITIS C
;   TITLE OF INVENTION: VIRUS REPLICATION
;   NUMBER OF SEQUENCES: 497
;   CORRESPONDENCE ADDRESS:
;       ADDRESSEE: Lyon & Lyon
;       STREET: 633 West Fifth Street
;       STREET: Suite 4700
;       CITY: Los Angeles
;       STATE: California
;       COUNTRY: U.S.A.
;       ZIP: 90071-2066
;   COMPUTER READABLE FORM:
;       MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE: storage

Qy      1946 GGCCTCTATGCA 1960
Db      1 GGCCTCTATGCA 15

RESULT 247
US-08-774-306A-301/c
; Sequence 301, Application US/08774306A
; Patent No. 3869253
; GENERAL INFORMATION:
;   APPLICANT: Draper, Kenneth G.
;   TITLE OF INVENTION: METHOD AND REAGENT FOR
;   TITLE OF INVENTION: INHIBITING HEPATITIS C
;   TITLE OF INVENTION: VIRUS REPLICATION
;   NUMBER OF SEQUENCES: 497
;   CORRESPONDENCE ADDRESS:
;       ADDRESSEE: Lyon & Lyon
;       STREET: 633 West Fifth Street
;       STREET: Suite 4700
;       CITY: Los Angeles
;       STATE: California
;       COUNTRY: U.S.A.
;       ZIP: 90071-2066
;   COMPUTER READABLE FORM:
;       MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE: storage

Query Match      0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.4e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy      1946 GGCCTCTATGCA 1960
Db      1 GGCCTCTATGCA 15
```

COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,306A
FILING DATE: December 26, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/182,968
FILING DATE: January 13, 1994
APPLICATION NUMBER: 07/882,888
FILING DATE: May 14, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/227
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 301:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-306A-301

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2436 AATGATTAAGCCGAC 2450
Db 15 AGTGATTAAGCCTGC 1

RESULT 248
US-08-774-306A-302/c
Sequence 302, Application US/08774306A
Patent No. 5869253
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: METHOD AND REAGENT FOR
INHIBITING HEPATITIS C
TITLE OF INVENTION: VIRUS REPLICATION
NUMBER OF SEQUENCES: 497
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,306A
FILING DATE: December 26, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/182,968
FILING DATE: January 13, 1994
APPLICATION NUMBER: 07/882,888
FILING DATE: May 14, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/227
TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 302:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-306A-302

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2435 GAATGATTAAGCCG 2449
Db 15 GAGTGATTAAGCCTG 1

RESULT 249
US-08-585-684B-87/c
Sequence 87, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: MCSw19gen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 87:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-87

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1782 TGACAAAGACAGCC 1796

Db 15 TGAGAAAGACGACC 1

RESULT 250

US-08-585-684B-638/c
Sequence 638, Application US/08585684B
Patent No. 5877021

GENERAL INFORMATION:

APPLICANT: Stinchcomb, Daniel T.

APPLICANT: Jarvis, Thale

APPLICANT: McSwigen, James

TITLE OF INVENTION: METHOD AND REAGENT FOR THE

TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE

TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES

NUMBER OF SEQUENCES: 2751

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

STREET: Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSeq Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/585,684B

FILING DATE: January 16, 1996

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/000,951

FILING DATE: July 7, 1995

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 218/078

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 638:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-585-684B-638

Query Match 0.8%; Score 11.8; DB 1; Length 15;

Best Local Similarity 86.7%; Pred. No. 1.4e+02;

Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 15 GATGCTAAGATGAT 1

RESULT 251

US-08-585-684B-639/c

Sequence 639, Application US/08585684B

Patent No. 5877021

GENERAL INFORMATION:

APPLICANT: Stinchcomb, Daniel T.

APPLICANT: Jarvis, Thale

APPLICANT: McSwigen, James

TITLE OF INVENTION: METHOD AND REAGENT FOR THE

TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE

TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES

NUMBER OF SEQUENCES: 2751

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

STREET: Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSeq Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/585,684B

FILING DATE: January 16, 1996

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/000,951

FILING DATE: July 7, 1995

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 218/078

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 639:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-585-684B-639

Query Match 0.8%; Score 11.8; DB 1; Length 15;

Best Local Similarity 86.7%; Pred. No. 1.4e+02;

Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 15 AGATGCTAAGATGAT 1

RESULT 252

US-08-585-684B-640/c

Sequence 640, Application US/08585684B

Patent No. 5877021

GENERAL INFORMATION:

APPLICANT: Stinchcomb, Daniel T.

APPLICANT: Jarvis, Thale

APPLICANT: McSwigen, James

TITLE OF INVENTION: METHOD AND REAGENT FOR THE

TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE

TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES

NUMBER OF SEQUENCES: 2751

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

STREET: Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSeq Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/585,684B

```

; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 640:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-585-684B-640

Query Match          0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1880 AGATGATGAAGATGA 1894
Db       15 AGATGCTAAAGATGA 1

RESULT 253
US-08-585-684B-1246
; Sequence 1246, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1246:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-585-684B-1246
```

```

; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-585-684B-1246

Query Match          0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 60.0%; Pred. No. 1.4e+02;
Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      2570 ATGAGGAATCTTGG 2584
Db       1 AUGAGGUUACUUG 15

RESULT 254
US-08-585-684B-2267/c
; Sequence 2267, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2267:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-585-684B-2267

Query Match          0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2398 GTGAGGAACTTTT 2412
Db       15 GTGAGGACTGTTT 1

RESULT 255
US-09-064-156A-35
; Sequence 35, Application US/09064156A
```

```
Patent No. 6132966
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: INHIBITING HEPATITIS C
TITLE OF INVENTION: VIRUS REPLICATION
NUMBER OF SEQUENCES: 498
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/064,156A
FILING DATE: April 21, 1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/774,306
FILING DATE: December 26, 1996
APPLICATION NUMBER: 08/182,968
FILING DATE: January 13, 1994
APPLICATION NUMBER: 07/882,888
FILING DATE: May 14, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 234/083
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-064-156A-35
Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.4e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 1946 GGCCTCTCTATGTC A 1960
Db 1 GGCCCCUCUAGGCA 15
RESULT 256
US-09-064-156A-301/C
Sequence 301, Application US/09064156A
Patent No. 6132966
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: INHIBITING HEPATITIS C
TITLE OF INVENTION: VIRUS REPLICATION
NUMBER OF SEQUENCES: 498
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
```

```
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/064,156A
FILING DATE: April 21, 1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/774,306
FILING DATE: December 26, 1996
APPLICATION NUMBER: 08/182,968
FILING DATE: January 13, 1994
APPLICATION NUMBER: 07/882,888
FILING DATE: May 14, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 234/083
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 301:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-064-156A-301
Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 2436 AATGATTAAGCCAGC 2450
Db 15 AGTGATTAAGCCTGC 1
RESULT 257
US-09-064-156A-302/C
Sequence 302, Application US/09064156A
Patent No. 6132966
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: INHIBITING HEPATITIS C
TITLE OF INVENTION: VIRUS REPLICATION
NUMBER OF SEQUENCES: 498
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/064,156A
FILING DATE: April 21, 1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/774,306
FILING DATE: December 26, 1996
APPLICATION NUMBER: 08/182,968
```

FLING DATE: January 13, 1994
APPLICATION NUMBER: 07/882,888
FILING DATE: May 14, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Wardburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 234/083
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 302:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-064-156A-302

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2435 GAATGATATAGCAG 2449
DB 15 GAGTGGATAGCCTG 1

RESULT 258
US-09-071-845-242/c
Sequence 242, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Wardburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149

TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 242:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-242

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2510 AGAGACCAACGTCA 2524
DB 15 AGAGCCTATGTCA 1

RESULT 259
US-09-071-845-430/c
Sequence 430, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Wardburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 430:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-430

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1650 GCTGCGAGGCTCTC 1664
DB 15 GCTGCTAGAGCTCTC 1

RESULT 260
US-09-071-845-462
Sequence 462, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (1-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071.845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 462:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-462
Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 46.7%; Pred. No. 1.4e+02;

Matches 7; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
QY 2324 GTGATCTGCTGCTC 2338
DB 1 GUGCGUAGGCTCTC 15

RESULT 261
US-09-071-845-534/C
Sequence 534, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (1-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071.845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 534:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-534
Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1650 GCTGCGAGGCTCTC 1664
DB 15 GCTGCTAGAGCTCTC 1

RESULT 262
US-09-071-845-547
Sequence 547, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
RELATED TO LEVELS OF
INTRACELLULAR ADHESION
MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE: December 7, 1992
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 547:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-547

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 46.7%; Pred. No. 1.4e+02;
Matches 7; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 2324 GTGATCTGCTCCT 2338
DB 1 GUGGCUAUGGUCU 15

RESULT 263
US-09-071-845-664/C
Sequence 664, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb

APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
RELATED TO LEVELS OF
INTRACELLULAR ADHESION
MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE: December 7, 1992
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 664:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-664

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1650 GCTGCGAGGCTC 1664
DB 15 GCTGTRAGGCTC 1

RESULT 264
US-09-071-845-730/C
Sequence 730, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
RELATED TO LEVELS OF
INTRACELLULAR ADHESION
MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE: December 7, 1992
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 664:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-664

```

1  TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
2  NUMBER OF SEQUENCES: 2390
3  CORRESPONDENCE ADDRESS:
4  ADDRESSEE: Lyon & Lyon
5  STREET: 633 West Fifth Street
6  CITY: Los Angeles
7  STATE: California
8  COUNTRY: U.S.A.
9  ZIP: 90071-2066
10 COMPUTER READABLE FORM:
11 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
12 MEDIUM TYPE: storage
13 COMPUTER: IBM Compatible
14 OPERATING SYSTEM: IBM P.C. DOS 5.0
15 SOFTWARE: Word Perfect 5.1
16 CURRENT APPLICATION DATA:
17 APPLICATION NUMBER: US/09/071,845
18 FILING DATE:
19 CLASSIFICATION:
20 PRIOR APPLICATION DATA:
21 APPLICATION NUMBER: US/08/292,620
22 FILING DATE: August 17, 1994
23 APPLICATION NUMBER: 08/008,895
24 FILING DATE: January 19, 1993
25 APPLICATION NUMBER: 07/989,849
26 FILING DATE: December 7, 1992
27 ATTORNEY/AGENT INFORMATION:
28 NAME: Warburg, Richard J.
29 REGISTRATION NUMBER: 32,327
30 REFERENCE/DOCKET NUMBER: 208/149
31 TELECOMMUNICATION INFORMATION:
32 TELEPHONE: (213) 489-1600
33 TELEFAX: (213) 955-0440
34 TELEX: 67-3510
35 INFORMATION FOR SEQ ID NO: 730:
36 SEQUENCE CHARACTERISTICS:
37 LENGTH: 15 base pairs
38 TYPE: nucleic acid
39 STRANDEDNESS: single
40 TOPOLOGY: linear
41 US-09-071-845-730
42
43 Query Match 0.8%; Score 11.8; DB 1; Length 15;
44 Best Local Similarity 86.7%; Pred. No. 1.4e+02;
45 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0
46
47 Oy 2295 CCTGTTTGATGACT 2309
48 |||||
49 Db 15 CCTGTTTGACAGACT 1
50
51 RESULT 265
52 US-09-038-073-87/c
53 Sequence 87, Application US/09038073
54 Patent No. 6194150
55 GENERAL INFORMATION:
56 APPLICANT: Stinchcomb, Daniel T.
57 APPLICANT: Jarvis, Thale
58 APPLICANT: McSwigen, James
59 TITLE OF INVENTION: METHOD AND REAGENT FOR THE
60 TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
61 TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
62 NUMBER OF SEQUENCES: 2751
63 CORRESPONDENCE ADDRESS:
64 ADDRESSEE: Lyon & Lyon
65 STREET: 633 West Fifth Street
66 CITY: Los Angeles
67 STATE: California
68 COUNTRY: U.S.A.
69 ZIP: 90071
70 COMPUTER READABLE FORM:

```

```

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 87:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-87

Query Match          0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches   13; Conservative    0; Mismatches    2; Indels      0; Gaps      0.

Oy       1782 TGACAAAGACCAGCC 1796
         ||| ||||| |||
Db        15 TGAGAAGACCAGCC 1

RESULT 266
US-09-038-073-638/c
Sequence 638, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 613 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:

```

TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 638:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-638

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1881 GATGATGAAGATGAT 1895
Db 15 GATGCTAAGATGAT 1

RESULT 267
US-09-038-073-639/c
Sequence 639, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 639:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-639

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1880 AGATGATGAAGATGA 1894
Db 15 AGATGCTAAGATGA 1

Db 15 AGATGCTAAGATGA 1

RESULT 268
US-09-038-073-640/c
Sequence 640, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 640:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-640

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1880 AGATGATGAAGATGA 1894
Db 15 AGATGCTAAGATGA 1

RESULT 269
US-09-038-073-1246
Sequence 1246, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1334 CTGCATGGTTGACAG 1348
|||
Db 15 CGGCATGGCTGACAG 1

RESULT 272
US-09-158-980-29/c
; Sequence 29, Application US/09158980
; Patent No. 6242427

; GENERAL INFORMATION:
; APPLICANT: SCHREIBER, ALAN D.
; APPLICANT: PARK, JONG-GU
; TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHAYE P.C.
; STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714

; COMPUTER READABLE FORM:

; MEDIUM TYPE: FLOPPY disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/158,980

; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/657,884
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: WILSON, MARY J.
; REGISTRATION NUMBER: 32,955
; REFERENCE/DOCKET NUMBER: 555-46
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100

; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-09-158-980-29

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1334 CTGCATGGTTGACAG 1348
|||
Db 15 CGGCATGGCTGACAG 1

RESULT 273
US-09-081-646-26

; Sequence 26, Application US/09081646
; Patent No. 6333152

; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; TITLE OF INVENTION: Cancer Cells

; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 26
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-081-646-26

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1647 CATGCTGCAGGAGT 1661
|||
Db 1 CATGATGCAGAGT 15

RESULT 274
US-09-081-646-331
; Sequence 331, Application US/09081646
; Patent No. 6333152

; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei

; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; TITLE OF INVENTION: Cancer Cells
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 331
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-081-646-331

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2693 CATGCTTCTCAGT 2707
|||
Db 1 CATGCTCTGCTCAGT 15

RESULT 275
US-09-081-646-418
; Sequence 418, Application US/09081646
; Patent No. 6333152

; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; TITLE OF INVENTION: Cancer Cells
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0

SEQ ID NO 418
LENGTH: 15
TYPE: DNA
ORGANISM: Homo sapiens
US-09-081-646-418

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2472 CATGATGATGAGGA 2486
DB 1 CATGATGCTGGCGGA 15

RESULT 276
US-09-081-646-445
Sequence 445, Application US/09081646
Patent No. 6333152
GENERAL INFORMATION:
APPLICANT: Kinzier, Kenneth
APPLICANT: Vogelstein, Bert
APPLICANT: Zhang, Lin
APPLICANT: Zhou, Wei
TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
FILE REFERENCE: 01107.74664
CURRENT APPLICATION NUMBER: US/09/081,646
CURRENT FILING DATE: 1998-05-20
EARLIER APPLICATION NUMBER: 60/047,352
EARLIER FILING DATE: 1997-05-21
NUMBER OF SEQ ID NOS: 871
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 445
LENGTH: 15
TYPE: DNA
ORGANISM: Homo sapiens
US-09-081-646-445

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1647 CATGCTGCAGGGT 1661
DB 1 CATGCTGCACAGGT 15

RESULT 277
US-09-367-007C-1/c
Sequence 1, Application US/09367007C
Patent No. 6416987
GENERAL INFORMATION:
APPLICANT: Bertino, Joseph R.
APPLICANT: Banerjee, Debabrata
APPLICANT: Tong, Youzhi
APPLICANT: Liu-Chen, Xinyue
TITLE OF INVENTION: Mutants of Thymidylate Synthase and Uses Thereof
FILE REFERENCE: D5978
CURRENT APPLICATION NUMBER: US/09/367,007C
CURRENT FILING DATE: 1999-10-15
PRIOR APPLICATION NUMBER: PCT/US98/02145
PRIOR FILING DATE: 1998-01-03
NUMBER OF SEQ ID NOS: 39
SEQ ID NO 1
LENGTH: 15
TYPE: DNA
ORGANISM: artificial sequence
FEATURE:
OTHER INFORMATION: Nucleotide sequence in the 5' coding region of
OTHER INFORMATION: human recombinants cDNA of thymidylate synthase
OTHER INFORMATION: (TS) gene in pET-17(bhrs) vector.
US-09-367-007C-1

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2100 GCTGGCCAGAGCAT 2114
DB 15 GCCGCCACAGGCAT 1

RESULT 278
US-08-826-134-32/c
Sequence 32, Application US/08826134A
Patent No. 6465210
GENERAL INFORMATION:
APPLICANT: Peles, Elior
TITLE OF INVENTION: CASPR/190, A FUNCTIONAL LIGAND FOR RPTD-BETA AND THE
TITLE OF INVENTION: AXONAL CELL RECOGNITION MOLECULE CONTACTIN
FILE REFERENCE: 7683-111
CURRENT APPLICATION NUMBER: US/08/826,134A
CURRENT FILING DATE: 1997-03-26
EARLIER APPLICATION NUMBER: 60/014,199
EARLIER FILING DATE: 1996-03-27
NUMBER OF SEQ ID NOS: 32
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 32
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-826-134-32

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1976 CTAAAGCACTCC 1990
DB 15 CTAAAGGAGACCTCC 1

RESULT 279
US-09-475-947A-69/c
Sequence 69, Application US/09475947A
Patent No. 6472154
GENERAL INFORMATION:
APPLICANT: Garner, Harold R.
APPLICANT: Wren, Jonathan D.
APPLICANT: Minna, John D.
TITLE OF INVENTION: Polymorphic Repeats in Human Genes
FILE REFERENCE: UTS0667
CURRENT APPLICATION NUMBER: US/09/475,947A
CURRENT FILING DATE: 1999-12-31
NUMBER OF SEQ ID NOS: 346
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 69
LENGTH: 15
TYPE: DNA
ORGANISM: human
US-09-475-947A-69

Query Match 0.8%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2637 TTCTTGTTCTTCAGG 2651
DB 15 TTCTTGTTCTTCAGG 1

Search completed: December 1, 2003, 11:58:03
Job time : 5 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 1, 2003, 12:01:43 ; Search time 3 Seconds

(without alignments)
4.588 Million cell updates/sec

Title: us-09-954-556-3

Perfect score: 1404

Sequence: 1 tggagatattccttctactctg.....cctcagttaccacacataaa 1404

Scoring table: IDENTITY_NUC

Gapop 10.0, Gapext 0.5

Searched: 265 seqs, 4902 residues

Total number of hits satisfying chosen parameters: 570

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 285 summaries

Database : rnpb.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	20	1.4	20	1	US-09-073-881-4
C 2	20	1.4	20	1	US-09-954-556-61
C 3	20	1.4	20	1	US-09-954-556-62
C 4	20	1.4	20	1	US-09-954-556-63
C 5	20	1.4	20	1	US-09-954-556-64
C 6	20	1.4	20	1	US-09-954-556-65
C 7	20	1.4	20	1	US-09-954-556-66
C 8	20	1.4	20	1	US-09-954-556-67
C 9	20	1.4	20	1	US-09-954-556-68
C 10	20	1.4	20	1	US-09-954-556-69
C 11	20	1.4	20	1	US-09-954-556-70
C 12	20	1.4	20	1	US-09-954-556-71
C 13	20	1.4	20	1	US-09-954-556-72
C 14	20	1.4	20	1	US-09-954-556-73
C 15	20	1.4	20	1	US-09-954-556-74
C 16	20	1.4	20	1	US-09-954-556-75
C 17	20	1.4	20	1	US-09-954-556-96
C 18	20	1.4	20	1	US-09-954-556-98
C 19	18.8	1.3	23	1	US-09-805-761-42
C 20	18.8	1.3	23	1	US-09-805-761-43
C 21	17.8	1.3	21	1	US-09-953-047-5
C 22	17.2	1.2	22	1	US-10-094-466-79
C 23	17	1.2	22	1	US-09-774-809-62
C 24	17	1.2	22	1	US-09-073-881-21
C 25	16.8	1.2	20	1	US-09-989-339-51
C 26	16.8	1.2	20	1	US-09-953-318-72
C 27	15.8	1.1	20	1	US-09-735-995-39
C 28	15.8	1.1	20	1	US-09-733-294-61
C 29	15.4	1.1	17	1	US-09-848-754A-3493
C 30	15.4	1.1	18	1	US-10-055-728-142
C 31	15.4	1.1	20	1	US-08-459-455-89
C 32	15.4	1.1	20	1	US-09-967-655-59
C 33	15.2	1.1	20	1	US-09-849-901-4
C 34	15.2	1.1	20	1	US-09-944-036-19
C 35	15.2	1.1	20	1	US-09-906-158-67
C 36	15.2	1.1	20	1	US-09-953-318-78
C 37	15.2	1.1	20	1	US-10-400-670-4
C 38	15.2	1.1	20	1	US-10-007-010-59
C 39	15	1.1	15	1	US-10-277-494-59
C 40	15	1.1	15	1	US-10-440-850-753
C 41	15	1.1	15	1	US-10-440-850-754
C 42	15	1.1	17	1	US-09-848-754A-2907
C 43	15	1.1	19	1	US-10-251-117-712
C 44	15	1.1	20	1	US-09-908-410-14
C 45	15	1.1	20	1	US-09-908-410-14
C 46	15	1.1	20	1	US-10-086-156-49
C 47	15	1.1	20	1	US-10-090-011-38
C 48	14.8	1.1	18	1	US-10-309-175-30
C 49	14.8	1.1	19	1	US-09-969-373-2967
C 50	14.8	1.1	19	1	US-09-969-373-4219
C 51	14.4	1.0	16	1	US-10-357-488-32
C 52	14.4	1.0	17	1	US-09-866-108-8374
C 53	14.4	1.0	17	1	US-09-866-108-8375
C 54	14.4	1.0	17	1	US-09-866-108-9001
C 55	14.4	1.0	17	1	US-09-866-108-9002
C 56	14.4	1.0	17	1	US-09-848-754A-2482
C 57	14.4	1.0	17	1	US-10-238-700-3390
C 58	14.4	1.0	17	1	US-10-084-839-3116
C 59	14.4	1.0	17	1	US-10-230-006-789
C 60	14.4	1.0	17	1	US-10-230-006-790
C 61	14	1.0	15	1	US-10-277-494-41
C 62	14	1.0	15	1	US-09-866-108-6888
C 63	14	1.0	17	1	US-09-866-108-6889
C 64	14	1.0	17	1	US-09-866-108-6890
C 65	14	1.0	17	1	US-09-866-108-6891
C 66	14	1.0	17	1	US-09-848-754A-2483
C 67	14	1.0	17	1	US-09-776-474-1034
C 68	14	1.0	17	1	US-09-776-474-1035
C 69	14	1.0	17	1	US-09-776-474-1036
C 70	14	1.0	17	1	US-09-866-108-6312
C 71	13.8	1.0	17	1	US-09-866-108-7673
C 72	13.8	1.0	17	1	US-09-866-108-9075
C 73	13.8	1.0	17	1	US-09-901-484A-84
C 74	13.8	1.0	17	1	US-09-853-526-84
C 75	13.8	1.0	17	1	US-09-853-526-863
C 76	13.8	1.0	17	1	US-09-825-805-384
C 77	13.8	1.0	17	1	US-09-825-805-777
C 78	13.8	1.0	17	1	US-09-825-805-777
C 79	13.8	1.0	17	1	US-09-780-533A-844
C 80	13.8	1.0	17	1	US-09-877-478-1296
C 81	13.8	1.0	17	1	US-09-848-754A-2480
C 82	13.8	1.0	17	1	US-09-848-754A-3492
C 83	13.8	1.0	17	1	US-09-776-474-430
C 84	13.8	1.0	17	1	US-09-930-423-1394
C 85	13.8	1.0	17	1	US-09-780-164-921
C 86	13.8	1.0	17	1	US-09-780-164-921
C 87	13.8	1.0	17	1	US-09-745-237A-1394
C 88	13.8	1.0	17	1	US-10-061-201-122
C 89	13.8	1.0	17	1	US-10-061-201-123
C 90	13.8	1.0	17	1	US-10-339-782-153
C 91	13.8	1.0	17	1	US-10-060-756A-145
C 92	13.8	1.0	17	1	US-10-060-756A-145
C 93	13.8	1.0	17	1	US-10-163-552-303
C 94	13.8	1.0	17	1	US-10-163-552-303
C 95	13.8	1.0	17	1	US-09-280-030-8
C 96	13.8	1.0	18	1	US-09-280-030-9
C 97	13.8	1.0	18	1	US-10-257-848-13
C 98	13.8	1.0	18	1	US-10-004-551-40
C 99	13.8	1.0	18	1	US-10-004-551-43
C 100	13.4	1.0	15	1	US-09-504-221A-999
C 101	13.4	1.0	15	1	US-09-274-553D-999
C 102	13.4	1.0	15	1	US-10-277-494-3
C 103	13.4	1.0	15	1	US-10-277-494-73
C 104	13.4	1.0	17	1	US-09-866-108-8354
C 105	13.4	1.0	17	1	US-09-866-108-8355
C 106	13.4	1.0	17	1	US-09-866-108-8356

C 107	13.4	1.0	17	1	US-09-866-108-8373	Sequence 8373, Ap	C 180	12.8	0.9	17	1	US-09-864-785-664	Sequence 664, App
C 108	13.4	1.0	17	1	US-09-866-108-8376	Sequence 8376, Ap	C 181	12.8	0.9	17	1	US-09-864-785-1617	Sequence 1617, App
C 109	13.4	1.0	17	1	US-09-866-108-8943	Sequence 8943, Ap	C 182	12.8	0.9	17	1	US-09-825-805-782	Sequence 782, App
C 110	13.4	1.0	17	1	US-09-866-108-8944	Sequence 8944, Ap	C 183	12.8	0.9	17	1	US-09-818-875-1760	Sequence 1760, App
C 111	13.4	1.0	17	1	US-09-866-108-8945	Sequence 8945, Ap	C 184	12.8	0.9	17	1	US-09-818-875-1759	Sequence 1759, App
C 112	13.4	1.0	17	1	US-09-866-108-9000	Sequence 9000, Ap	C 185	12.8	0.9	17	1	US-09-818-875-3314	Sequence 3314, Ap
C 113	13.4	1.0	17	1	US-09-866-108-9003	Sequence 9003, Ap	C 186	12.8	0.9	17	1	US-09-818-875-3315	Sequence 3315, App
C 114	13.4	1.0	17	1	US-09-825-805-648	Sequence 648, App	C 187	12.8	0.9	17	1	US-09-780-533A-843	Sequence 843, App
C 115	13.4	1.0	17	1	US-09-780-533A-2375	Sequence 2375, Ap	C 188	12.8	0.9	17	1	US-09-780-533A-845	Sequence 845, App
C 116	13.4	1.0	17	1	US-09-780-533A-2376	Sequence 2376, Ap	C 189	12.8	0.9	17	1	US-09-780-533A-2092	Sequence 2092, App
C 117	13.4	1.0	17	1	US-09-877-478-2182	Sequence 2182, Ap	C 190	12.8	0.9	17	1	US-09-780-533A-2103	Sequence 2103, App
C 118	13.4	1.0	17	1	US-09-877-478-2527	Sequence 2527, Ap	C 191	12.8	0.9	17	1	US-09-780-533A-2231	Sequence 2231, App
C 119	13.4	1.0	17	1	US-09-792-818-96	Sequence 96, App1	C 192	12.8	0.9	17	1	US-09-877-478-2463	Sequence 2463, App
C 120	13.4	1.0	17	1	US-09-792-818-284	Sequence 284, App	C 193	12.8	0.9	17	1	US-09-848-754A-1326	Sequence 1326, App
C 121	13.4	1.0	17	1	US-10-238-700-3194	Sequence 3194, Ap	C 194	12.8	0.9	17	1	US-09-848-754A-1364	Sequence 1364, App
C 122	13.4	1.0	17	1	US-10-230-006-164	Sequence 164, App	C 195	12.8	0.9	17	1	US-09-848-754A-1481	Sequence 1481, Ap
C 123	13.4	1.0	17	1	US-10-230-006-2204	Sequence 2204, Ap	C 196	12.8	0.9	17	1	US-09-848-754A-1481	Sequence 1481, Ap
C 124	13.4	1.0	17	1	US-10-230-006-2205	Sequence 2205, Ap	C 197	12.8	0.9	17	1	US-09-848-754A-2894	Sequence 2894, Ap
C 125	13.4	1.0	17	1	US-10-027-632-58632	Sequence 58632, A	C 198	12.8	0.9	17	1	US-09-848-754A-1364	Sequence 3108, Ap
C 126	13.4	1.0	17	1	US-10-027-632-58632	Sequence 58632, A	C 199	12.8	0.9	17	1	US-09-848-754A-3109	Sequence 3109, App
C 127	13.4	1.0	17	1	US-10-027-632-58640	Sequence 58640, A	C 200	12.8	0.9	17	1	US-09-776-474-76	Sequence 76, App1
C 128	13.4	1.0	17	1	US-10-027-632-58640	Sequence 58640, A	C 201	12.8	0.9	17	1	US-09-776-474-679	Sequence 679, App
C 129	13.4	1.0	17	1	US-10-163-552-289	Sequence 289, App	C 202	12.8	0.9	17	1	US-09-776-474-1087	Sequence 1087, App
C 130	13.4	1.0	17	1	US-10-163-552-667	Sequence 667, App	C 203	12.8	0.9	17	1	US-09-930-423-386	Sequence 386, App
C 131	13.4	1.0	17	1	US-10-163-552-678	Sequence 678, App	C 204	12.8	0.9	17	1	US-09-930-423-660	Sequence 660, App
C 132	13	0.9	13	1	US-09-848-754A-9124	Sequence 9124, Ap	C 205	12.8	0.9	17	1	US-09-930-423-1169	Sequence 1169, App
C 133	13	0.9	15	1	US-10-277-494-54	Sequence 54, App1	C 206	12.8	0.9	17	1	US-09-780-164-225	Sequence 225, App
C 134	13	0.9	16	1	US-10-091-281-150	Sequence 150, App	C 207	12.8	0.9	17	1	US-09-780-164-570	Sequence 570, App
C 135	13	0.9	17	1	US-09-866-108-6887	Sequence 6887, Ap	C 208	12.8	0.9	17	1	US-09-780-164-594	Sequence 594, App
C 136	13	0.9	17	1	US-09-866-108-6892	Sequence 6892, Ap	C 209	12.8	0.9	17	1	US-09-827-395A-198	Sequence 198, App
C 137	13	0.9	17	1	US-09-866-108-8946	Sequence 8946, Ap	C 210	12.8	0.9	17	1	US-09-827-395A-360	Sequence 360, App
C 138	13	0.9	17	1	US-09-866-108-8947	Sequence 8947, Ap	C 211	12.8	0.9	17	1	US-09-827-395A-611	Sequence 611, App
C 139	13	0.9	17	1	US-09-866-108-9030	Sequence 9030, Ap	C 212	12.8	0.9	17	1	US-09-827-395A-691	Sequence 691, App
C 140	13	0.9	17	1	US-09-866-108-9031	Sequence 9031, Ap	C 213	12.8	0.9	17	1	US-09-740-332-99	Sequence 99, App1
C 141	13	0.9	17	1	US-09-866-108-9032	Sequence 9032, Ap	C 214	12.8	0.9	17	1	US-09-740-332-481	Sequence 481, App
C 142	13	0.9	17	1	US-09-866-108-9033	Sequence 9033, Ap	C 215	12.8	0.9	17	1	US-09-740-332-653	Sequence 653, App
C 143	13	0.9	17	1	US-09-866-108-9034	Sequence 9034, Ap	C 216	12.8	0.9	17	1	US-09-740-332-1421	Sequence 1421, App
C 144	13	0.9	17	1	US-09-961-077-748	Sequence 748, App	C 217	12.8	0.9	17	1	US-09-740-332-3105	Sequence 3105, Ap
C 145	13	0.9	17	1	US-09-780-533A-1806	Sequence 1806, Ap	C 218	12.8	0.9	17	1	US-09-740-332-3932	Sequence 3902, Ap
C 146	13	0.9	17	1	US-09-848-754A-2903	Sequence 2903, Ap	C 219	12.8	0.9	17	1	US-09-740-332-4457	Sequence 4457, Ap
C 147	13	0.9	17	1	US-09-848-754A-3486	Sequence 3486, Ap	C 220	12.8	0.9	17	1	US-09-745-237A-385	Sequence 386, App
C 148	13	0.9	17	1	US-09-848-754A-3487	Sequence 3487, Ap	C 221	12.8	0.9	17	1	US-09-745-237A-660	Sequence 660, App
C 149	13	0.9	17	1	US-09-776-474-1033	Sequence 1033, Ap	C 222	12.8	0.9	17	1	US-09-745-237A-1169	Sequence 1169, App
C 150	13	0.9	17	1	US-09-740-332-831	Sequence 831, App	C 223	12.8	0.9	17	1	US-09-745-237A-121	Sequence 121, App
C 151	13	0.9	17	1	US-09-740-332-3724	Sequence 3724, Ap	C 224	12.8	0.9	17	1	US-10-238-700-661	Sequence 661, App
C 152	13	0.9	17	1	US-09-817-879-831	Sequence 831, App	C 225	12.8	0.9	17	1	US-10-238-700-944	Sequence 944, App
C 153	13	0.9	17	1	US-09-817-879-3724	Sequence 3724, Ap	C 226	12.8	0.9	17	1	US-10-238-700-3208	Sequence 3208, Ap
C 154	13	0.9	17	1	US-10-230-006-1403	Sequence 1403, Ap	C 227	12.8	0.9	17	1	US-10-238-700-3544	Sequence 3544, Ap
C 155	12.8	0.9	16	1	US-09-829-855-177	Sequence 177, App	C 228	12.8	0.9	17	1	US-10-253-904-31	Sequence 31, App1
C 156	12.8	0.9	17	1	US-09-866-108-653	Sequence 653, App	C 229	12.8	0.9	17	1	US-10-061-201-121	Sequence 121, App
C 157	12.8	0.9	17	1	US-09-866-108-654	Sequence 654, App	C 230	12.8	0.9	17	1	US-10-061-201-124	Sequence 124, App
C 158	12.8	0.9	17	1	US-09-866-108-1107	Sequence 1107, Ap	C 231	12.8	0.9	17	1	US-09-817-879-99	Sequence 99, App1
C 159	12.8	0.9	17	1	US-09-866-108-1108	Sequence 1108, Ap	C 232	12.8	0.9	17	1	US-09-817-879-481	Sequence 481, App
C 160	12.8	0.9	17	1	US-09-866-108-1112	Sequence 1112, Ap	C 233	12.8	0.9	17	1	US-09-817-879-653	Sequence 653, App
C 161	12.8	0.9	17	1	US-09-866-108-1115	Sequence 1115, Ap	C 234	12.8	0.9	17	1	US-09-817-879-1431	Sequence 1421, Ap
C 162	12.8	0.9	17	1	US-09-866-108-1115	Sequence 1115, Ap	C 235	12.8	0.9	17	1	US-09-817-879-3135	Sequence 3135, Ap
C 163	12.8	0.9	17	1	US-09-866-108-1176	Sequence 1176, Ap	C 236	12.8	0.9	17	1	US-09-817-879-3902	Sequence 3902, Ap
C 164	12.8	0.9	17	1	US-09-866-108-1571	Sequence 1571, Ap	C 237	12.8	0.9	17	1	US-09-817-879-4457	Sequence 4457, Ap
C 165	12.8	0.9	17	1	US-09-866-108-1572	Sequence 1572, Ap	C 238	12.8	0.9	17	1	US-10-332-970-29	Sequence 29, App1
C 166	12.8	0.9	17	1	US-09-866-108-6176	Sequence 6176, Ap	C 239	12.8	0.9	17	1	US-10-339-793-443	Sequence 443, App
C 167	12.8	0.9	17	1	US-09-866-108-6177	Sequence 6177, Ap	C 240	12.8	0.9	17	1	US-10-209-787-1759	Sequence 1759, App
C 168	12.8	0.9	17	1	US-09-866-108-6311	Sequence 6311, Ap	C 241	12.8	0.9	17	1	US-10-209-787-1760	Sequence 1760, Ap
C 169	12.8	0.9	17	1	US-09-866-108-6313	Sequence 6313, Ap	C 242	12.8	0.9	17	1	US-10-209-787-3314	Sequence 3314, Ap
C 170	12.8	0.9	17	1	US-09-866-108-6531	Sequence 6531, Ap	C 243	12.8	0.9	17	1	US-10-209-787-3315	Sequence 3315, Ap
C 171	12.8	0.9	17	1	US-09-866-108-6532	Sequence 6532, Ap	C 244	12.8	0.9	17	1	US-10-060-830-700	Sequence 700, App
C 172	12.8	0.9	17	1	US-09-866-108-7345	Sequence 7345, Ap	C 245	12.8	0.9	17	1	US-10-060-830-701	Sequence 701, App
C 173	12.8	0.9	17	1	US-09-866-108-7345	Sequence 7346, Ap	C 246	12.8	0.9	17	1	US-10-060-756A-144	Sequence 144, App
C 174	12.8	0.9	17	1	US-09-866-108-7672	Sequence 7672, Ap	C 247	12.8	0.9	17	1	US-10-060-756A-146	Sequence 146, App
C 175	12.8	0.9	17	1	US-09-866-108-7674	Sequence 7674, Ap	C 248	12.8	0.9	17	1	US-10-060-756A-1675	Sequence 1675, Ap
C 176	12.8	0.9	17	1	US-09-866-108-9076	Sequence 9076, Ap	C 249	12.8	0.9	17	1	US-10-060-958A-1677	Sequence 1677, Ap
C 177	12.8	0.9	17	1	US-09-866-108-9076	Sequence 9076, Ap	C 250	12.8	0.9	17	1	US-10-060-958-588	Sequence 588, App
C 178	12.8	0.9	17	1	US-09-866-108-10700	Sequence 10700, A	C 251	12.8	0.9	17	1	US-10-060-958-589	Sequence 589, App
C 179	12.8	0.9	17	1	US-09-866-108-10701	Sequence 10701, A	C 252	12.8	0.9	17	1	US-10-163-552-677	Sequence 677, App

Db 20 GGGATCTTCTCATCTGC 1

RESULT 4
US-09-954-556-63/c
; Sequence 63, Application US/09954556
; Publication No. US20030078219A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freiler
; APPLICANT: Scott Cooper
; TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 EXPRE
; FILE REFERENCE: RTS-0250
; CURRENT APPLICATION NUMBER: US/09/954,556
; CURRENT FILING DATE: 2001-09-14
; NUMBER OF SEQ ID NOS: 108
; SEQ ID NO 63
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-954-556-63

Query Match 1.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Gaps 0;
Indels 0;
Oy 1411 ATTACTGATAGGGGCTT 1430
Db 20 ATTACTGATAGGGGCTT 1

RESULT 5
US-09-954-556-64/c
; Sequence 64, Application US/09954556
; Publication No. US20030078219A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freiler
; APPLICANT: Scott Cooper
; TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 EXPRE
; FILE REFERENCE: RTS-0250
; CURRENT APPLICATION NUMBER: US/09/954,556
; CURRENT FILING DATE: 2001-09-14
; NUMBER OF SEQ ID NOS: 108
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-954-556-64

Query Match 1.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Gaps 0;
Indels 0;
Oy 1421 TAGGGGCTTCTTAATCGCC 1440
Db 20 TAGGGGCTTCTTAATCGCC 1

RESULT 6
US-09-954-556-65/c
; Sequence 65, Application US/09954556
; Publication No. US20030078219A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freiler
; APPLICANT: Scott Cooper
; TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 EXPRE

FILE REFERENCE: RTS-0250
; CURRENT APPLICATION NUMBER: US/09/954,556
; CURRENT FILING DATE: 2001-09-14
; NUMBER OF SEQ ID NOS: 108
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-954-556-65

Query Match 1.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Gaps 0;
Indels 0;
Oy 1479 CACGACCAAGAGCCAGACT 1498
Db 20 CACGACCAAGAGCCAGACT 1

RESULT 7
US-09-954-556-66/c
; Sequence 66, Application US/09954556
; Publication No. US20030078219A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freiler
; APPLICANT: Scott Cooper
; TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 EXPRE
; FILE REFERENCE: RTS-0250
; CURRENT APPLICATION NUMBER: US/09/954,556
; CURRENT FILING DATE: 2001-09-14
; NUMBER OF SEQ ID NOS: 108
; SEQ ID NO 66
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-954-556-66

Query Match 1.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Gaps 0;
Indels 0;
Oy 1484 CCAAGAGCCAGACTCAGC 1503
Db 20 CCAAGAGCCAGACTCAGC 1

RESULT 8
US-09-954-556-67/c
; Sequence 67, Application US/09954556
; Publication No. US20030078219A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freiler
; APPLICANT: Scott Cooper
; TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 EXPRE
; FILE REFERENCE: RTS-0250
; CURRENT APPLICATION NUMBER: US/09/954,556
; CURRENT FILING DATE: 2001-09-14
; NUMBER OF SEQ ID NOS: 108
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-954-556-67

Query Match 1.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1489 AAGCAGACTTGACAGCCA 1508
|||||

Db 20 AAGCAGACTTGACAGCCA 1

RESULT 9

US-09-954-556-68/c

; Sequence 68, Application US/09954556

; Publication No. US20030078219A1

; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia

; APPLICANT: Susan M. Freiler

; APPLICANT: Scott Cooper

; TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 EXPRE

; FILE REFERENCE: RTS-0250

; CURRENT APPLICATION NUMBER: US/09/954,556

; CURRENT FILING DATE: 2001-09-14

; NUMBER OF SEQ ID NOS: 108

; SEQ ID NO 68

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-954-556-68

Query Match 1.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2023 ATGAGTACTCTTATGACAT 2042
|||||

Db 20 ATGAGTACTCTTATGACAT 1

RESULT 10

US-09-954-556-69/c

; Sequence 69, Application US/09954556

; Publication No. US20030078219A1

; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia

; APPLICANT: Susan M. Freiler

; APPLICANT: Scott Cooper

; TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 EXPRE

; FILE REFERENCE: RTS-0250

; CURRENT APPLICATION NUMBER: US/09/954,556

; CURRENT FILING DATE: 2001-09-14

; NUMBER OF SEQ ID NOS: 108

; SEQ ID NO 69

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-954-556-69

Query Match 1.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2028 GTACTCTATGACATTAAAC 2047
|||||

Db 20 GTACTCTATGACATTAAAC 1

RESULT 11

US-09-954-556-70/c

; Sequence 70, Application US/09954556

; Publication No. US20030078219A1

; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freiler
; APPLICANT: Scott Cooper
; TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 EXPRE
; FILE REFERENCE: RTS-0250
; CURRENT APPLICATION NUMBER: US/09/954,556
; CURRENT FILING DATE: 2001-09-14
; NUMBER OF SEQ ID NOS: 108
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-954-556-70

Query Match 1.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2032 TCCTATGACATTAAACCGTGT 2051
|||||

Db 20 TCCTATGACATTAAACCGTGT 1

RESULT 12

US-09-954-556-71/c

; Sequence 71, Application US/09954556

; Publication No. US20030078219A1

; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia

; APPLICANT: Susan M. Freiler

; APPLICANT: Scott Cooper

; TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 EXPRE

; FILE REFERENCE: RTS-0250

; CURRENT APPLICATION NUMBER: US/09/954,556

; CURRENT FILING DATE: 2001-09-14

; NUMBER OF SEQ ID NOS: 108

; SEQ ID NO 71

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-954-556-71

Query Match 1.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2387 CAGGATTCCTGAGGAA 2406
|||||

Db 20 CAGGATTCCTGAGGAA 1

RESULT 13

US-09-954-556-72/c

; Sequence 72, Application US/09954556

; Publication No. US20030078219A1

; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia

; APPLICANT: Susan M. Freiler

; APPLICANT: Scott Cooper

; TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 EXPRE

; FILE REFERENCE: RTS-0250

; CURRENT APPLICATION NUMBER: US/09/954,556

; CURRENT FILING DATE: 2001-09-14

; NUMBER OF SEQ ID NOS: 108

; SEQ ID NO 72

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

OTHER INFORMATION: Antisense Oligonucleotide
US-09-954-556-72

Query Match 1.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2536 GAAGACTTGATCGAATTC 2555

Db 20 GAAGACTTGATCGAATTC 1

RESULT 14
US-09-954-556-73/c
Sequence 73, Application US/09954556
Publication No. US20030078219A1
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
APPLICANT: Susan M. Freiler

APPLICANT: Scott Cooper
TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 EXPRESSION
FILE REFERENCE: RTS-0250
CURRENT APPLICATION NUMBER: US/09/954,556
CURRENT FILING DATE: 2001-09-14
NUMBER OF SEQ ID NOS: 108
SEQ ID NO 73
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-954-556-73

Query Match 1.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2557 ACTCTGACACCAATGAGGA 2576

Db 20 ACTCTGACACCAATGAGGA 1

RESULT 15
US-09-954-556-74/c
Sequence 74, Application US/09954556
Publication No. US20030078219A1
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
APPLICANT: Susan M. Freiler

APPLICANT: Scott Cooper
TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 EXPRESSION
FILE REFERENCE: RTS-0250
CURRENT APPLICATION NUMBER: US/09/954,556
CURRENT FILING DATE: 2001-09-14
NUMBER OF SEQ ID NOS: 108
SEQ ID NO 74
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-954-556-74

Query Match 1.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2562 CACAACCAATGAGCAATACT 2581

Db 20 CACAACCAATGAGCAATACT 1

RESULT 16

US-09-954-556-75/c
Sequence 75, Application US/09954556
Publication No. US20030078219A1
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
APPLICANT: Susan M. Freiler

APPLICANT: Scott Cooper
TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 EXPRESSION
FILE REFERENCE: RTS-0250
CURRENT APPLICATION NUMBER: US/09/954,556
CURRENT FILING DATE: 2001-09-14
NUMBER OF SEQ ID NOS: 108
SEQ ID NO 75
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-954-556-75

Query Match 1.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2701 CCTCAGTATCCACATATA 2720

Db 20 CCTCAGTATCCACATATA 1

RESULT 17
US-09-954-556-96/c
Sequence 96, Application US/09954556
Publication No. US20030078219A1
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
APPLICANT: Susan M. Freiler

APPLICANT: Scott Cooper
TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 EXPRESSION
FILE REFERENCE: RTS-0250
CURRENT APPLICATION NUMBER: US/09/954,556
CURRENT FILING DATE: 2001-09-14
NUMBER OF SEQ ID NOS: 108
SEQ ID NO 96
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-954-556-96

Query Match 1.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2591 GCCAACCTTCGACAGTAT 2610

Db 20 GCCAACCTTCGACAGTAT 1

RESULT 18
US-09-954-556-98/c
Sequence 98, Application US/09954556
Publication No. US20030078219A1
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
APPLICANT: Susan M. Freiler

APPLICANT: Scott Cooper
TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 EXPRESSION
FILE REFERENCE: RTS-0250
CURRENT APPLICATION NUMBER: US/09/954,556
CURRENT FILING DATE: 2001-09-14
NUMBER OF SEQ ID NOS: 108
SEQ ID NO 98

```

; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-954-556-98
```

```

Query Match          1.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      2470 TACATGATGATGAGGACTG 2489
Db      20  TACATGATGATGAGGACTG 1
```

```

RESULT 19
US-09-805-761-42
; Sequence 42, Application US/09805761
; Patent No. US20020165174A1
; GENERAL INFORMATION:
; APPLICANT: Gill, Parkesh
; APPLICANT: Masood, Rizwan
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ANTISENSE
; FILE REFERENCE: 21327-701CON2
; CURRENT APPLICATION NUMBER: US/09/805,761
; PRIOR FILING DATE: 2001-03-13
; PRIOR APPLICATION NUMBER: PCT/US01/00019
; PRIOR FILING DATE: 2001-01-19
; PRIOR APPLICATION NUMBER: US 09/487,023
; PRIOR FILING DATE: 2000-01-19
; PRIOR APPLICATION NUMBER: US 09/016,541
; PRIOR FILING DATE: 2000-11-24
; PRIOR APPLICATION NUMBER: US 09/016,541
; PRIOR FILING DATE: 1998-01-30
; PRIOR APPLICATION NUMBER: US 60/037,004
; PRIOR FILING DATE: 1997-01-31
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 42
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: VEGFR-1 gene specific primers for RT-PCR
US-09-805-761-42
```

```

Query Match          1.3%; Score 18.8; DB 1; Length 23;
Best Local Similarity 90.9%; Pred. No. 47;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      2098 CAGCTGGCCAGAGCGATGAGT 2119
Db      1  CAAGTGGCCAGAGCGATGAGT 22
```

```

RESULT 20
US-09-805-761-43
; Sequence 43, Application US/09805761
; Patent No. US20020165174A1
; GENERAL INFORMATION:
; APPLICANT: Gill, Parkesh
; APPLICANT: Masood, Rizwan
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ANTISENSE
; FILE REFERENCE: 21327-701CON2
; CURRENT APPLICATION NUMBER: US/09/805,761
; PRIOR FILING DATE: 2001-03-13
; PRIOR APPLICATION NUMBER: PCT/US01/00019
; PRIOR FILING DATE: 2001-01-19
; PRIOR APPLICATION NUMBER: US 09/487,023
; PRIOR FILING DATE: 2000-01-19
```

```

; PRIOR APPLICATION NUMBER: US 09/016,541
; PRIOR FILING DATE: 2000-11-24
; PRIOR APPLICATION NUMBER: US 09/016,541
; PRIOR FILING DATE: 1998-01-30
; PRIOR APPLICATION NUMBER: US 60/037,004
; PRIOR FILING DATE: 1997-01-31
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 43
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: VEGFR-1 gene specific primers for RT-PCR
US-09-805-761-43
```

```

Query Match          1.3%; Score 18.8; DB 1; Length 23;
Best Local Similarity 90.9%; Pred. No. 47;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      2098 CAGCTGGCCAGAGCGATGAGT 2119
Db      1  CAAGTGGCCAGAGCGATGAGT 22
```

```

RESULT 21
US-09-953-047-5/c
; Sequence 5, Application US/09953047
; Publication No. US20030087854A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 3 EXPRE
; FILE REFERENCE: RTS-0157
; CURRENT APPLICATION NUMBER: US/09/953,047
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 95
; SEQ ID NO 5
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-09-953-047-5
```

```

Query Match          1.3%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 54;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1822 AAGATGTTGAAAGATGATGCC 1842
Db      21  AAGATGCTGAAAGAGCATGCC 1
```

```

RESULT 22
US-10-094-466-79
; Sequence 79, Application US/10094466
; Publication No. US20030203363A1
; GENERAL INFORMATION:
; APPLICANT: Spytek et al.
; TITLE OF INVENTION: NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM
; FILE REFERENCE: 21402-290D
; CURRENT APPLICATION NUMBER: US/10/094,466
; PRIOR FILING DATE: 2002-03-07
; PRIOR APPLICATION NUMBER: 60/274,281
; PRIOR FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: 60/288,148
; PRIOR FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: 60/274,849
; PRIOR FILING DATE: 2001-03-09
; PRIOR APPLICATION NUMBER: 60/275,235
```

```

; PRIOR FILING DATE: 2001-03-12
; PRIOR APPLICATION NUMBER: 60/338,375
; PRIOR FILING DATE: 2001-12-04
; PRIOR APPLICATION NUMBER: 60/275,579
; PRIOR FILING DATE: 2001-03-13
; PRIOR APPLICATION NUMBER: 60/335,302
; PRIOR FILING DATE: 2001-10-31
; PRIOR APPLICATION NUMBER: 60/275,601
; PRIOR FILING DATE: 2001-03-13
; PRIOR APPLICATION NUMBER: 60/276,000
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: 60/277,338
; PRIOR FILING DATE: 2001-03-20
; PRIOR APPLICATION data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 114
; SOFTWARE: Patin 2.1
; SEQ ID NO 79
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Forward Primer
US-10-094-466-79

Query Match          1.2%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 71;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy      1886 TGAAGATGATTGGGAACACAA 1907
Db      1 TGAACATGTTTGGAAACACAA 22

RESULT 23
US-09-774-809-62/c
; Sequence 62, Application US/09774809
; Publication No. US20030004120A1
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
; TITLE OF INVENTION: FOR THE MODULATION OF JNK PROTEINS
; FILE REFERENCE: ISPH-0412
; CURRENT APPLICATION NUMBER: US/09/774,809
; CURRENT FILING DATE: 2001-01-31
; PRIOR APPLICATION NUMBER: 09/396,902
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 09/130,616
; PRIOR FILING DATE: 1998-08-07
; PRIOR APPLICATION NUMBER: 08/910,629
; PRIOR FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 62
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-774-809-62

Query Match          1.2%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      2642 GTTCTTCAGAGATGAT 2658
Db      17 GTTCTTCAGAGATGAT 1

RESULT 24

US-09-073-881-21
; Sequence 21, Application US/09073881
; Patent No. US20020045251A1
; GENERAL INFORMATION:
; APPLICANT: Rao, Mahendra S.
; APPLICANT: Mujtaba, Tahmina
; TITLE OF INVENTION: A Common Neural Progenitor for the CNS and PNS
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESS: Thorpe, No. US20020045251A1th & Western, L.L.P.
; STREET: P.O. Box 1219
; CITY: Sandy
; STATE: Utah
; COUNTRY: USA
; ZIP: 84091-1219
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch, 1.44 Mb storage
; COMPUTER: Compaq Presario 4540
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Word Perfect 8.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/073,881
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/852,744
; FILING DATE: 07-MAY-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Alan J. Howarth
; REGISTRATION NUMBER: 36,553
; REFERENCE/DOCKET NUMBER: T4903.CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (801)566-6633
; TELEFAX: (801)566-0750
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-073-881-21

Query Match          1.2%; Score 17; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 75;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      1873 GAGATGAGATGATGAA 1889
Db      6 GAGATGAGATGATGAA 22

RESULT 25
US-09-989-339-51
; Sequence 51, Application US/09989339
; Publication No. US20030088866A1
; GENERAL INFORMATION:
; APPLICANT: Falco, Saverio Carl
; APPLICANT: Famodu, Iayo
; APPLICANT: Rafalski, Jan A.
; APPLICANT: Ramaker, Michael
; APPLICANT: Tarczyński, Mitchell C.
; APPLICANT: Thorpe, Catherine
; TITLE OF INVENTION: PLANT METHIONINE SYNTHASE GENE AND METHODS FOR INCREASING THE
; TITLE OF INVENTION: METHIONINE CONTENT OF THE SEEDS OF PLANTS
; FILE REFERENCE: BB-1067-B
; CURRENT APPLICATION NUMBER: US/09/989,339
; CURRENT FILING DATE: 2002-05-31
; PRIOR APPLICATION NUMBER: 08/703,829
; PRIOR FILING DATE: 1996-08-27
; NUMBER OF SEQ ID NOS: 55
; SOFTWARE: Microsoft Office 97
; SEQ ID NO 51
; LENGTH: 20
```

FILE REFERENCE: 5244US (REN/P55190US00)

```

; CURRENT APPLICATION NUMBER: US/10/055,728
; CURRENT FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: 60/325,722
; PRIOR FILING DATE: 2001-09-28
; PRIOR APPLICATION NUMBER: EP 0120373.2
; PRIOR FILING DATE: 2001-09-28
; PRIOR APPLICATION NUMBER: EP 01200228.3
; PRIOR FILING DATE: 2001-01-23
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 142
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 3'TAG019GENE-2
US-10-055-728-142

Query Match          1.1%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 85;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy      2413 AAGCTGCTGAAGGAGG 2429
Db      18  AAGCTGCTGAAGGAGG 2

RESULT 31
US-08-459-455-89/c
; Sequence 89, Application US/08459455
; Publication No. US20030124105A1
; GENERAL INFORMATION:
; APPLICANT: Yuan, Junying
; APPLICANT: Miura, Masayuki
; TITLE OF INVENTION: Programmed Cell Death Genes and Proteins
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sterne, Kessler, Goldstein & Fox
; STREET: 1100 New York Avenue, Suite 600
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/459,455
; FILING DATE: 2-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/368,704
; FILING DATE: 4-JAN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/258,287
; FILING DATE: 10-JUN-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/080,850
; FILING DATE: 24-JUN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Bugalsky, Lawrence B.
; REGISTRATION NUMBER: 35,086
; REFERENCE/DOCKET NUMBER: 0609.3920003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 371-2600
; TELEFAX: (202) 371-2540
; TELEX: 248636 SSK
; INFORMATION FOR SEQ ID NO: 89:
; SEQUENCE CHARACTERISTICS:

; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: both
; TOPOLOGY: both
US-08-459-455-89

Query Match          1.1%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy      1878 GGAGATGATGAAGATGA 1894
Db      20  GGAGTGTATGAAGATGA 4

RESULT 32
US-09-967-655-59/c
; Sequence 59, Application US/09967655
; Publication No. US20030092649A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPT
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0227
; CURRENT APPLICATION NUMBER: US/09/967,655
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 95
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
US-09-967-655-59

Query Match          1.1%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy      2110 GGCAATGAGTACTTGGC 2126
Db      18  GGCAATGAGTCTTGGC 2

RESULT 33
US-09-849-901-4/c
; Sequence 4, Application US/09849901
; Patent No. US20020045227A1
; GENERAL INFORMATION:
; APPLICANT: Wagoner, Christoph
; TITLE OF INVENTION: Method for Detecting Mutated Alleles
; FILE REFERENCE: 4121-111 CIP
; CURRENT APPLICATION NUMBER: US/09/849,901
; CURRENT FILING DATE: 2001-05-03
; PRIOR APPLICATION NUMBER: US 09/390,545
; PRIOR FILING DATE: 1999-09-02
; PRIOR APPLICATION NUMBER: DE19708758.2
; PRIOR FILING DATE: 1997-03-04
; PRIOR APPLICATION NUMBER: PCT/DE98/00676
; PRIOR FILING DATE: 1998-03-04
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Sense primer
US-09-849-901-4

Query Match          1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
```

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2424 GGAAGACACAGATGATA 2443
|||||
DB 20 GGAAGACACAGATGATA 1

RESULT 34

US-09-944-036-19
; Sequence 19, Application US/09944036
; Patent No. US20020055095A1
; GENERAL INFORMATION:
; APPLICANT: YANG, Yeasing Y.
; APPLICANT: BRENTANO, Steven T.
; APPLICANT: BABOLA, Odile
; APPLICANT: TRAN, Nathalie
; APPLICANT: VERNET, Guy
; TITLE OF INVENTION: AMPLIFICATION OF HIV-1 SEQUENCES FOR DETECTION OF
; FILE REFERENCE: GP114-02.UT
; CURRENT APPLICATION NUMBER: US/09/944,036
; PRIOR FILING DATE: 2001-08-31
; PRIOR APPLICATION NUMBER: US 60/229,790
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: Oligonucleotide primer for Protease target
; NAME/KEY: modified_base
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-O-methyladenosine
; NAME/KEY: modified_base
; LOCATION: (3)..(4)
; OTHER INFORMATION: gm
US-09-944-036-19

Query Match 1.1%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2422 AAGGAGACACAGATGAA 2441
|||||

DB 1 AAGGAGACACCAATGAA 20
|||||

RESULT 35

US-09-906-158-67/c
; Sequence 67, Application US/09906158
; Publication No. US20030078217A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR-BETA 3 EXPRES
; FILE REFERENCE: RTS-0257
; CURRENT APPLICATION NUMBER: US/09/906,158
; CURRENT FILING DATE: 2001-07-14
; NUMBER OF SEQ ID NOS: 168
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-906-158-67

Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2423 AGGAAGACACAGATGAT 2442
|||||
DB 20 AGGAAGGCGCAGATGGCT 1

RESULT 36

US-09-953-318-78/c
; Sequence 78, Application US/09953318
; Publication No. US20030105036A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPT
; FILE REFERENCE: RTS-0232
; CURRENT APPLICATION NUMBER: US/09/953,318
; CURRENT FILING DATE: 2001-09-13
; NUMBER OF SEQ ID NOS: 154
; SEQ ID NO 78
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-953-318-78

Query Match 1.1%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2275 AAGTGATGCTCCAGAAC 2294
|||||

DB 20 AATGATGCTCCCGAATC 1
|||||

RESULT 37

US-10-400-670-4/c
; Sequence 4, Application US/10400670
; Publication No. US20030215854A1
; GENERAL INFORMATION:
; APPLICANT: CLAUSEN, PETER A.
; TITLE OF INVENTION: DETECTION OF DNA-BINDING PROTEINS
; FILE REFERENCE: 39147-0013
; CURRENT APPLICATION NUMBER: US/10/400,670
; CURRENT FILING DATE: 2003-06-28
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-400-670-4

Query Match 1.1%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1718 CACTGGGCGAAGCCCTGGGA 1737
|||||

DB 20 CACTGGGGAATCCCTTGA 1
|||||

RESULT 38

US-10-007-010-59/c
; Sequence 59, Application US/10007010
; Publication No. US20030125275A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers

```

; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF HCK EXPRESSION
; FILE REFERENCE: RTS-0345
; CURRENT APPLICATION NUMBER: US/10/007,010
; CURRENT FILING DATE: 2001-12-04
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-007-010-59

Query Match          1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      2275 AAGTGATGCTCCAGAGC 2294
Db      20 AAGTGACAGCTCTGAAAC 1

RESULT 39
US-10-277-494-59
; Sequence 59, Application US/10277494
; Publication No. US20030186309A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related To Level
; FILE REFERENCE: MBHB00-958-K (400/064)
; CURRENT APPLICATION NUMBER: US/10/277,494
; CURRENT FILING DATE: 2002-10-21
; NUMBER OF SEQ ID NOS: 446
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 59
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-277-494-59

Query Match          1.1%; Score 15; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 68;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      2320 CAGAGTGTCTCTGG 2334
Db      1 CAGAGUGAUGUCUG 15

RESULT 40
US-10-440-850-753
; Sequence 753, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Reversal
; FILE REFERENCE: 250/130 (MBHB00-900-A)
; CURRENT APPLICATION NUMBER: US/10/440,850
; CURRENT FILING DATE: 2003-05-19
; PRIOR APPLICATION NUMBER: US/09/650,012
; PRIOR FILING DATE: 2000-08-28
; PRIOR APPLICATION NUMBER: US 08/585,684
; PRIOR FILING DATE: 1996-01-12
; PRIOR APPLICATION NUMBER: US 60/000,951
; PRIOR FILING DATE: 1995-07-07
; PRIOR APPLICATION NUMBER: US 09/038,073
```

```

; PRIOR FILING DATE: 1998-03-11
; NUMBER OF SEQ ID NOS: 2285
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 753
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-440-850-753

Query Match          1.1%; Score 15; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 68;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      1373 AGGAGTTACAGCTT 1387
Db      1 AGGAGAUUACAGCUU 15

RESULT 41
US-10-440-850-754
; Sequence 754, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Reversal
; FILE REFERENCE: 250/130 (MBHB00-900-A)
; CURRENT APPLICATION NUMBER: US/10/440,850
; CURRENT FILING DATE: 2003-05-19
; PRIOR APPLICATION NUMBER: US/09/650,012
; PRIOR FILING DATE: 2000-08-28
; PRIOR APPLICATION NUMBER: US 08/585,684
; PRIOR FILING DATE: 1996-01-12
; PRIOR APPLICATION NUMBER: US 60/000,951
; PRIOR FILING DATE: 1995-07-07
; PRIOR APPLICATION NUMBER: US 09/038,073
; PRIOR FILING DATE: 1998-03-11
; NUMBER OF SEQ ID NOS: 2285
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 754
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-440-850-754

Query Match          1.1%; Score 15; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 68;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      1374 GGAGATTACAGCTT 1388
Db      1 GGAGAUUACAGCTT 15

RESULT 42
US-09-848-754A-2907
; Sequence 2907, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related To Level
; FILE REFERENCE: MBHB00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 2907
; LENGTH: 17
; TYPE: RNA
```

```
/ ORGANISM: Homo sapiens
US-09-848-754A-2907

Query Match      1.1%; Score 15; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 86;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Oy      2320 CAGAGTGTGTCTGG 2334
      |||||:||||:||||
Db      2 CAGAGUGAUGUCUG 16

RESULT 43
US-10-251-117-712
; Sequence 712, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; FILE REFERENCE: 900/042 (MEHB02-468-A)
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US/10/251,117
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 712.
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense r
US-10-251-117-712

Query Match      1.1%; Score 15; DB 1; Length 19;
Best Local Similarity 73.3%; Pred. No. 1.1e+02;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Oy      2320 CAGAGTGTGTCTGG 2334
      |||||:||||:||||
Db      2 CAGAGUGAUGUCUG 16

RESULT 44
US-10-251-117-1019/C
; Sequence 1019, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; FILE REFERENCE: 900/042 (MEHB02-468-A)
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US/10/251,117
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
```

```
/ PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1019
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-251-117-1019

Query Match      1.1%; Score 15; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      2320 CAGAGTGTGTCTGG 2334
      |||||:||||:||||
Db      18 CAGAGTGTGTCTGG 4

RESULT 45
US-09-908-410-14
; Sequence 14, Application US/09908410
; Publication No. US20030104382A1
; GENERAL INFORMATION:
; APPLICANT: Hogan, Kirk J.
; APPLICANT: Brunson, David B.
; APPLICANT: Roberts, Monica C.
; APPLICANT: Mickelson, James R.
; TITLE OF INVENTION: Assay for Propensity for Canine Malignant Hyperthermia
; FILE REFERENCE: 960296.98148
; CURRENT FILING DATE: US/09/908,410
; CURRENT FILING DATE: 2001-07-18
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: oligonucleotide
; NAME/KEY: misc feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: Human RYR bases 6686-6667.
US-09-908-410-14

Query Match      1.1%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      2529 GTTGSTAGAGACTT 2543
      |||||:||||:||||
Db      5 GTTGSTAGAGACTT 19

RESULT 46
US-10-086-156-49
; Sequence 49, Application US/10086156
; Publication No. US20030054989A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: POLYNUCLEOTIDE ENCODING TWO NOVEL HUMAN POTASSIUM CHANNEL BETA-SU
; FILE REFERENCE: D0115NP
; CURRENT FILING DATE: K+betam4 and K+betam5
; CURRENT FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: US/10/086,156
; PRIOR FILING DATE: 2001-02-28
; PRIOR APPLICATION NUMBER: US 60/272,190
; PRIOR FILING DATE: 2001-03-07
; PRIOR APPLICATION NUMBER: US 60/274,258
; NUMBER OF SEQ ID NOS: 98
; SOFTWARE: Patentin version 3.0
```

SEQ ID NO 49
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens
US-10-086-156-49

Query Match 1.1%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1691 AATGGAGTTTCCAA 1705
Db 6 AATGGAGTTTCCAA 20

RESULT 47
US-10-090-011-38/c
Sequence 38, Application US/10090011
Publication No. US20030082810A1
GENERAL INFORMATION:
APPLICANT: Serup, Palle
APPLICANT: Heimberg, Harry
APPLICANT: Gradwohl, Gerard
TITLE OF INVENTION: Methods For Generating Insulin-Secreting
TITLE OF INVENTION: Cells Suitable for Transplantation
FILE REFERENCE: 6246.200-US
CURRENT APPLICATION NUMBER: US/10/090.011
CURRENT FILING DATE: 2002-02-26
PRIOR APPLICATION NUMBER: US 60/271,474
PRIOR FILING DATE: 2001-02-26
NUMBER OF SEQ ID NOS: 70
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 38
LENGTH: 20
TYPE: DNA
ORGANISM: Homo Sapien
US-10-090-011-38

Query Match 1.1%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1807 GTCACCGTGGCCGTG 1821
Db 16 GTCACCGTGGCCGTG 2

RESULT 48
US-10-309-175-30/c
Sequence 30, Application US/10309175
Publication No. US20030148347A1
GENERAL INFORMATION:
APPLICANT: Georg A. HOLLANDER
TITLE OF INVENTION: NUCLEAR PROTEIN
FILE REFERENCE: 117-427 / N84006
CURRENT APPLICATION NUMBER: US/10/309,175
CURRENT FILING DATE: 2002-12-04
PRIOR APPLICATION NUMBER: US 60/336,176
PRIOR FILING DATE: 2001-12-06
NUMBER OF SEQ ID NOS: 32
SOFTWARE: MS Word
SEQ ID NO 30
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
NAME/KEY: misc feature
OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-309-175-30

Query Match 1.1%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2546 ATCGAATTCACCTCTCA 2563
Db 18 ATCGAATTCACCTCTCA 1

RESULT 49
US-09-969-373-2967/c
Sequence 2967, Application US/09969373
Patent No. US20020133852A1
GENERAL INFORMATION:
APPLICANT: Effeertz, Roger J.
APPLICANT: Hauge, Brian M.
TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
FILE REFERENCE: 38-10(52679)A
CURRENT APPLICATION NUMBER: US/09/969,373
CURRENT FILING DATE: 2001-10-02
PRIOR APPLICATION NUMBER: US 09/754,853
PRIOR FILING DATE: 2001-01-05
PRIOR APPLICATION NUMBER: US 09/760,427
PRIOR FILING DATE: 2001-01-13
PRIOR APPLICATION NUMBER: US 09/855,768
PRIOR FILING DATE: 2001-05-15
NUMBER OF SEQ ID NOS: 4593
SEQ ID NO 2967
LENGTH: 19
TYPE: DNA
ORGANISM: Glycine max
US-09-969-373-2967

Query Match 1.1%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2192 TGAATAAGCAGACTTG 2209
Db 18 TGAATAAGCAGACTTG 1

RESULT 50
US-09-969-373-4219
Sequence 4219, Application US/09969373
Patent No. US20020133852A1
GENERAL INFORMATION:
APPLICANT: Effeertz, Roger J.
APPLICANT: Hauge, Brian M.
TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
FILE REFERENCE: 38-10(52679)A
CURRENT APPLICATION NUMBER: US/09/969,373
CURRENT FILING DATE: 2001-10-02
PRIOR APPLICATION NUMBER: US 09/754,853
PRIOR FILING DATE: 2001-01-05
PRIOR APPLICATION NUMBER: US 09/760,427
PRIOR FILING DATE: 2001-01-13
PRIOR APPLICATION NUMBER: US 09/855,768
PRIOR FILING DATE: 2001-05-15
NUMBER OF SEQ ID NOS: 4593
SEQ ID NO 4219
LENGTH: 19
TYPE: DNA
ORGANISM: Glycine max
US-09-969-373-4219

Query Match 1.1%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1879 GAGATGATGAAGATGATT 1896
Db 2 GTGATGATGAAGATGATT 19

RESULT 51

```
US-10-357-488-32
; Sequence 32, Application US/10357488
; Publication No. US20030194730A1
; GENERAL INFORMATION:
; APPLICANT: Centre For DNA Fingerprinting and Diagnostics
; TITLE OF INVENTION: No. US20030194730A1 FISSR-PCR primers and markers and a method
; TITLE OF INVENTION: primers and markers for identifying genetic constitution and bre
; FILE REFERENCE: 782-Indian
; CURRENT APPLICATION NUMBER: US/10/357,488
; PRIOR FILING DATE: 2003-02-04
; PRIOR APPLICATION NUMBER: 260/MAS/2002
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 32
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: A novel FISSR-PCR primer for genotyping eukaryotes
US-10-357-488-32

Query Match      1.0%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2473 ATGATGATGAGGACT 2488
Db      1 ATGATGATGAGGACT 16

RESULT 52
US-09-866-108-8374/c
; Sequence 8374, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
```

```
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aeo mica Sequence Listing Engine
;; SEQ ID NO 8374
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-8374

Query Match      1.0%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1506 CCAGCCGCTGTGCAC 1521
Db      17 CCAGCTGCTGTGCAC 2

RESULT 53
US-09-866-108-8375/c
; Sequence 8375, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeo mica Sequence Listing Engine
; SEQ ID NO 8375
; LENGTH: 17
; TYPE: DNA
```

ORGANISM: Homo sapiens
US-09-866-108-8375

Query Match 1.0%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1506 CCAGCCGGCTGTGCAC 1521
DB 16 CCAGCTGCTGTGCAC 1

RESULT 54

US-09-866-108-9001
; Sequence 9001, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ABOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: AboMica Sequence Listing Engine
; SEQ ID NO 9001
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9001

Query Match 1.0%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1505 GCCAGCCGGCTGTGCA 1520
DB 2 GCCAGCCGGCTGTGCA 17

RESULT 55
US-09-866-108-9002
; Sequence 9002, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ABOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: AboMica Sequence Listing Engine
; SEQ ID NO 9002
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9002

Query Match 1.0%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1505 GCCAGCCGGCTGTGCA 1520
DB 1 GCCAGCCGGCTGTGCA 16

RESULT 56
US-09-848-754A-2482
; Sequence 2482, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Levels of Epidermal Growth Factor Receptors

```

? FILE REFERENCE: MH000-956-I (400/018)
? CURRENT APPLICATION NUMBER: US/09/848, 754A
? CURRENT FILING DATE: 2001-05-03
? NUMBER OF SEQ ID NOS: 9645
? SOFTWARE: PatentIn version 3.0
? SEQ ID NO 2482
? LENGTH: 17
? TYPE: RNA
? ORGANISM: Homo sapiens
US-03-848-754A-2482

```

```
Query Match      1.0%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

QY	2317	CATCAGAGTGATGTC	2332
		: :	
Db	2	CACCAGAGUGAUGUCU	17

```

RESULT 57
US-10-238-700-3390/c
? Sequence 3390, Application US/10238700
? Publication No. US20030153521A1
? GENERAL INFORMATION:
? APPLICANT: Ribozyme Pharmaceuticals, Inc.
? APPLICANT: McSwiggen, James
? TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Leve
? FILE REFERENCE: 400/057 (MEHB01-1158-A)
? CURRENT APPLICATION NUMBER: US/10/238,700
? CURRENT FILING DATE: 2002-09-18
? PRIOR APPLICATION NUMBER: PCT/US 02/16840
? PRIOR FILING DATE: 2002-05-29
? PRIOR APPLICATION NUMBER: US 60/3318,471
? PRIOR FILING DATE: 2001-09-10
? NUMBER OF SEQ ID NOS: 4666
? SOFTWARE: PatentIn version 3.0
? SEQ ID NO 3390
? LENGTH: 17
? TYPE: RNA
? ORGANISM: Homo sapiens
US-10-238-700-3390

```

Query Match	1.0%;	Score 14.4;	DB 1;	Length 17;
Best Local Similarity	93.8%;	Pred. No. 1e+02;		
Matches 15; Conservative	0;	Mismatches 1;	Indels 0;	Gaps 0;

Qy	1722	GGGCAAGCCCCCTGGGA	1737
Db	16	GGGCAAGCCCCCTTGA	1

RESULT 58
US-10-084-839-3116/c
: Sequence 3116, Application US/10084839
: Publication No. US20030186238A1
: GENERAL INFORMATION:
: APPLICANT: Third Wave Technologies
: APPLICANT: Allawi, Hatim
: APPLICANT: Argue, Brad T.
: APPLICANT: Bartholomew, Christian T.
: APPLICANT: Chehak, LuAnne
: APPLICANT: Curtis, Michelle L.
: APPLICANT: Eis, Peggy S.
: APPLICANT: Hall, Jeff G.
: APPLICANT: Ip, Hon S.
: APPLICANT: Ji, Lin
: APPLICANT: Kaiser, Michael
: APPLICANT: Kwiatkowski, Jr., Robert W.
: APPLICANT: Lukowski, Andrew A.
: APPLICANT: Lyamichev, Victor
: APPLICANT: Lymaicheva, Natalie E.
: APPLICANT: Ma, Wupo

```

1  APPLICANT: Neil, Bruce P.
2  APPLICANT: Olson, Sarah M.
3  APPLICANT: Olson-Wunoz, Marilyn C.
4  APPLICANT: Schaefer, James J.
5  APPLICANT: Skrzypczynski, Zbigniew
6  APPLICANT: Takova, Tseltso Y.
7  APPLICANT: Thompson, Lisa C.
8  APPLICANT: Vedvik, Kevin L.
9  TITLE OF INVENTION: RNA Detection Assays
10 FILE REFERENCE: FOR-06666
11 CURRENT APPLICATION NUMBER: US10/084,833
12 CURRENT FILING DATE: 2002-02-26
13 NUMBER OF SEQ ID NOS: 4004
14 SOFTWARE: PatentIn version 3.1
15 SEQ ID NO 3116
16 LENGTH: 17
17 TYPE: DNA
18 ORGANISM: Artificial Sequence
19 FEATURE:
20 OTHER INFORMATION: Synthetic
21 US-10-084-839-3116

```

```
Query Match      1.0%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

Qy	1572	GTCCAGCTCCTCCATG	1587
Db	17	GTCCAGCTCCTCCCTG	2

```

RESULT 59
US-10-230-006-789
: Sequence 789, Application US/10230006
: Publication No. US2003019107A1
: GENERAL INFORMATION:
: APPLICANT: Ribozyme Pharmaceuticals, Inc.
: APPLICANT: Fonaugh, Kathy
: APPLICANT: Meswigen, Jim
: TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDID
: FILE REFERENCE: 400/056 (MBH01-1110)
: CURRENT APPLICATION NUMBER: US/10/230, 006
: CURRENT FILING DATE: 2002-11-18
: PRIOR APPLICATION NUMBER: US 60/315,315
: PRIOR FILING DATE: 2001-08-28
: NUMBER OF SEQ ID NOS: 2678
: SOFTWARE: PatentIn version 3.0
: SEQ ID NO 789
: LENGTH: 17
: TYPE: RNA
: ORGANISM: Homo sapiens
: US-10-230-006-789

```

Query Match	1.0%;	Score 14.4;	DB 1;	length 17;
Best Local Similarity	87.5%;	Pred. No. 1e+02;		
Matches 14; Conservative	1;	Mismatches	1;	Indels 0; Gaps 0;

Qy	1992	AGAATACCTCCGAGCC	2007
		:	
Db	2	AGAAGACCUCCGAGCC	17

RESULT 60
US-10-230-006-790
Sequence 790, Application US/10230006
Publication No. US20030191077A1
GENERAL INFORMATION:
APPLICANT: Ribozyne Pharmaceuticals, Inc.
APPLICANT: Fomnaghen, Kathy
APPLICANT: Fomnaghen, Jim
TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
FILE REFERENCE: 400/056 (MHB01-1110)
CURRENT APPLICATION NUMBER: US/10/230,006

```

; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 790
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-790

Query Match          1.0%; Score 14.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1e+02;
Matches 14; Conservative 1; Mismatches 0; Gaps 0;

Qy      1992 AGAATACCTCCGAGCC 2007
      |||||:|||||
Db      1 AGAAGACCCGCGAGCC 16

RESULT 61
US-10-277-494-41
; Sequence 41, Application US/10277494
; Publication No. US20030186909A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related To Level
; FILE REFERENCE: MBH800-958-K (400/064)
; CURRENT APPLICATION NUMBER: US/10/277,494
; CURRENT FILING DATE: 2002-10-21
; NUMBER OF SEQ ID NOS: 446
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 41
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-277-494-41

Query Match          1.0%; Score 14; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 93;
Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      2320 CAGAGTGATGTCGTG 2333
      |||||:|||||
Db      2 CAGAGUGAUGUCUG 15

RESULT 62
US-10-277-494-46
; Sequence 46, Application US/10277494
; Publication No. US20030186909A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related To Level
; FILE REFERENCE: MBH800-958-K (400/064)
; CURRENT APPLICATION NUMBER: US/10/277,494
; CURRENT FILING DATE: 2002-10-21
; NUMBER OF SEQ ID NOS: 446
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 46
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-277-494-46

Query Match          1.0%; Score 14; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 93;
Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```

Qy      2321 AGAGTGATGTCGTG 2334
      |||||:|||||
Db      1 AGAGUGAUGUCUG 14

RESULT 63
US-09-866-108-6888/C
; Sequence 6888, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6888
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6888

Query Match          1.0%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1358 GCCTGGAAGAGAA 1371
      |||||:|||||
Db      17 GCCTGGAAGAGAA 4

RESULT 64
US-09-866-108-6889/C
; Sequence 6889, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
```

```

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6889
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6889

Query Match      1.0%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1358 GCCTGGAAGAGAA 1371
DB      16 GCCTGGAAGAGAA 3

RESULT 65
US-09-866-108-6890/c
; Sequence 6890, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
```

```

; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6890
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6890

Query Match      1.0%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1358 GCCTGGAAGAGAA 1371
DB      15 GCCTGGAAGAGAA 2

RESULT 66
US-09-866-108-6891/c
; Sequence 6891, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO: 6891
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-6891

Query Match      1.0%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1358 CGCCTGGAAGAGAA 1371
DB      14  CGCCTGGAAGAGAA 1

RESULT 67
US-09-848-754A-2483
; Sequence 2483, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MHB00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 2483
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-848-754A-2483

Query Match      1.0%; Score 14; DB 1; Length 17;
Best Local Similarity 71.4%; Pred. No. 1.2e+02;
Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      2321 AGAGTAGTGTCTGG 2334
DB      1  AGAGTAGTGTCTGG 14

RESULT 68
US-09-776-474-1034
; Sequence 1034, Application US/09776474
; Publication No. US20030087847A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale

; PRIOR FILING DATE: 2001-02-02
; APPLICANT: Bocher, Robert
; APPLICANT: Holman, Patricia
; APPLICANT: Faltae, All
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Checkpoint Kinase-1 (CHK
; FILE REFERENCE: MHB00-955-A (400/008)
; CURRENT APPLICATION NUMBER: US/09/776,474
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,983
; PRIOR FILING DATE: 2000-03-02
; NUMBER OF SEQ ID NOS: 2992
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 1034
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; US-09-776-474-1034

Query Match      1.0%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1730 CCCTGGGAGAGGT 1743
DB      3  CCCTGGGAGAGGT 16

RESULT 69
US-09-776-474-1035
; Sequence 1035, Application US/09776474
; Publication No. US20030087847A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Bocher, Robert
; APPLICANT: Holman, Patricia
; APPLICANT: Faltae, All
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Checkpoint Kinase-1 (CHK
; FILE REFERENCE: MHB00-955-A (400/008)
; CURRENT APPLICATION NUMBER: US/09/776,474
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,983
; PRIOR FILING DATE: 2000-03-02
; NUMBER OF SEQ ID NOS: 2992
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 1035
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; US-09-776-474-1035

Query Match      1.0%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1730 CCCTGGGAGAGGT 1743
DB      3  CCCTGGGAGAGGT 16

RESULT 70
US-09-776-474-1036
; Sequence 1036, Application US/09776474
; Publication No. US20030087847A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
```

```
APPLICANT: Jarvis, Thale
APPLICANT: Boohar, Robert
APPLICANT: Holman, Patricia
APPLICANT: Fattaey, Ali
APPLICANT: McSwigen, Jim
TITLE OF INVENTION: Method and Reagent for the Inhibition of Checkpoint Kinase-1 (CHK)
FILE REFERENCE: MBH00-955-A (400/008)
CURRENT APPLICATION NUMBER: US/09/776,474
CURRENT FILING DATE: 2001-02-02
PRIOR APPLICATION NUMBER: US 60/179,983
PRIOR FILING DATE: 2000-03-02
NUMBER OF SEQ ID NOS: 2992
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1036
LENGTH: 17
TYPE: RNA.
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-776-474-1036
```

```
Query Match 1.0%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1730 CCCTGGGAGGAGGT 1743
Db 1 CCCTGGGAGGAGGU 14
```

```
RESULT 71
US-09-866-108-6312
Sequence 6312, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
```

```
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeoica Sequence Listing Engine
SEQ ID NO 6312
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-6312
```

```
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 2090 GCACCTACACAGTGGCC 2106
Db 1 GCACCTCCACGACAGGCC 17
```

```
RESULT 72
US-09-866-108-7673/c
Sequence 7673, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeoica Sequence Listing Engine
SEQ ID NO 7673
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
```

US-09-866-108-7673

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2658 TTCTGTTTTCTCCAG 2674
Db 17 TTCTGCTCTCTCCAG 1

RESULT 73

US-09-866-108-9075
Sequence 9075, Application US/09866108
Patent No. US2002004800A1
GENERAL INFORMATION:
APPLICANT: JI, Yonggang
APPLICANT: GU, Yizhong
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AECOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 9075
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-9075

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1397 ACCTGAGATAGCCATT 1413
Db 1 ACCTGAGATAGCCATT 17

RESULT 74

US-09-901-484A-84/C
Sequence 84, Application US/09901484A
Patent No. US20020119460A1
GENERAL INFORMATION:

APPLICANT: Blumenfeld, Marta
APPLICANT: Chumakov, Ilya
APPLICANT: Bouguetelret, Lydie
TITLE OF INVENTION: Prostate Cancer Gene
FILE REFERENCE: GEN-T11XC3D2
CURRENT APPLICATION NUMBER: US/09/901,484A
CURRENT FILING DATE: 2001-07-09
PRIOR APPLICATION NUMBER: US 08/996,306
PRIOR FILING DATE: 1997-12-22
PRIOR APPLICATION NUMBER: US 60/099,658
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: US 09/218,207
PRIOR FILING DATE: 1998-12-22
PRIOR APPLICATION NUMBER: US 09/338,907
PRIOR FILING DATE: 1999-06-23
PRIOR APPLICATION NUMBER: US 09/853,526
PRIOR FILING DATE: 2001-05-11
NUMBER OF SEQ ID NOS: 578
SOFTWARE: PatentIn version 3.1
SEQ ID NO 84
LENGTH: 17
TYPE: DNA
ORGANISM: Mus musculus
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(17)
OTHER INFORMATION: sequencing oligonucleotide mopGracesR444
US-09-901-484A-84

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2092 ACCTACGAGCTGGCCAG 2108
Db 17 ACCTACCTGCTGGCTG 1

RESULT 75

US-09-853-526-84/C
Sequence 84, Application US/09853526
Patent No. US20020165345A1
GENERAL INFORMATION:
APPLICANT: Cohen, Daniel
APPLICANT: Blumenfeld, Marta
APPLICANT: Ilya, Chumakov
APPLICANT: Bouguetelret, Lydie
TITLE OF INVENTION: PROSTATE CANCER GENE
FILE REFERENCE: GENSET.18CPLCP
CURRENT APPLICATION NUMBER: US/09/853,526
CURRENT FILING DATE: 2001-05-11
PRIOR APPLICATION NUMBER: 09/338,907
PRIOR FILING DATE: 1999-06-23
PRIOR APPLICATION NUMBER: 08/996,306
PRIOR FILING DATE: 1997-12-22
PRIOR APPLICATION NUMBER: 60/099,658
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 09/218,207
PRIOR FILING DATE: 1998-12-22
NUMBER OF SEQ ID NOS: 578
SOFTWARE: Patent.pm
SEQ ID NO 84
LENGTH: 17
TYPE: DNA
ORGANISM: Mus Musculus
FEATURE:

NAME/KEY: misc.feature
LOCATION: 1..17
OTHER INFORMATION: sequencing oligonucleotide m0grace5R444
US-09-853-526-84

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2092 ACCTACCGCTGGCCAG 2108
DB 17 ACCTACCGCTGGCCCTG 1

RESULT 76
US-09-864-785-2863
Sequence 2863, Application US/09864785
Patent No. US20020177568A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Stinchcomb, Dan
APPLICANT: Draper, Ken
APPLICANT: McSwiggen, Jim
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
FILE REFERENCE: 400/022 (MBH00-812-D)
CURRENT APPLICATION NUMBER: US/09/864,785
CURRENT FILING DATE: 2001-05-23
NUMBER OF SEQ ID NOS: 3929
SOFTWARE: Patent version 3.0
SEQ ID NO 2863
LENGTH: 17
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-2863

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2004 AGCCGAGGCCACCCG 2020
DB 1 AGCCGAGGCCACCCCG 17

RESULT 77
US-09-825-805-384/c
Sequence 384, Application US/09825805
Publication No. US20030004122A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Belgelman, Leo
APPLICANT: Beaudry, Amber
APPLICANT: Karpelesky, Alex
APPLICANT: Adamic, Jasenka Matulic
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
FILE REFERENCE: MBH00-831-F (400/009)
CURRENT APPLICATION NUMBER: US/09/825,805
CURRENT FILING DATE: 2001-09-27
PRIOR APPLICATION NUMBER: 09/578,223
PRIOR FILING DATE: 2000-05-23
PRIOR APPLICATION NUMBER: 09/476,387
PRIOR FILING DATE: 1999-12-30
PRIOR APPLICATION NUMBER: 09/474,432
PRIOR FILING DATE: 1999-12-29
PRIOR APPLICATION NUMBER: 09/301,511
PRIOR FILING DATE: 1999-04-28
PRIOR APPLICATION NUMBER: 09/186,675
PRIOR FILING DATE: 1998-11-04

PRIOR APPLICATION NUMBER: 60/083,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/064,866
PRIOR FILING DATE: 1997-11-05
NUMBER OF SEQ ID NOS: 1558
SOFTWARE: Patent version 3.0
SEQ ID NO 384
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-825-805-384

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1920 TCTTCTTGAGGCTGCA 1936
DB 17 TCTTCTTGAGGCGACA 1

RESULT 78
US-09-825-805-777
Sequence 777, Application US/09825805
Publication No. US20030004122A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Belgelman, Leo
APPLICANT: Beaudry, Amber
APPLICANT: Karpelesky, Alex
APPLICANT: Adamic, Jasenka Matulic
APPLICANT: Sweedler, Dave
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
FILE REFERENCE: MBH00-831-F (400/009)
CURRENT APPLICATION NUMBER: US/09/825,805
CURRENT FILING DATE: 2001-09-27
PRIOR APPLICATION NUMBER: 09/578,223
PRIOR FILING DATE: 2000-05-23
PRIOR APPLICATION NUMBER: 09/476,387
PRIOR FILING DATE: 1999-12-30
PRIOR APPLICATION NUMBER: 09/474,432
PRIOR FILING DATE: 1999-12-29
PRIOR APPLICATION NUMBER: 09/301,511
PRIOR FILING DATE: 1999-04-28
PRIOR APPLICATION NUMBER: 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: 60/083,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/064,866
PRIOR FILING DATE: 1997-11-05
NUMBER OF SEQ ID NOS: 1558
SOFTWARE: Patent version 3.0
SEQ ID NO 777
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-825-805-777

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.2e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

OY 2269 CCAGTCAAGTCAGTCGC 2285
DB 1 CCAGTCAAGTCAGTCGC 17

RESULT 79
US-09-780-533A-844/c
Sequence 844, Application US/09780533A
Publication No. US20030060611A1
GENERAL INFORMATION:

```

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrita, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MHB00-878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 844
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-844

Query Match          1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1650 GCTGCGAGGCGTCCG 1666
DB      17  GCGCGAGGGGTCCCG 1

RESULT 80
US-09-877-478-1296
; Sequence 1296, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1296
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-1296

Query Match          1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.2e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      2191 ATGAAATAGCAGACTT 2207
DB      1  AUGAAACAGAGACU 17
```

```

US-09-848-754A-2480
; Sequence 2480, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MHB00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2480
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2480

Query Match          1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.2e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      2269 CCAGTCAAGTGATGCC 2285
DB      1  CCUACCAAGUGAUGGC 17

RESULT 82
US-09-848-754A-3492
; Sequence 3492, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
; FILE REFERENCE: MHB00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3492
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-3492

Query Match          1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.2e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      2314 ACTCATCAGAGTAGGT 2330
DB      1  ACCCAACAGAGUAGU 17

RESULT 83
US-09-776-474-430
; Sequence 430, Application US/09776474
; Publication No. US20030087847A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Booher, Robert
; APPLICANT: Holman, Patricia
; APPLICANT: Fattaey, Ali
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Checkpoint Kinase-1 (CHK1)
; FILE REFERENCE: MHB00-955-A (400/008)
; CURRENT APPLICATION NUMBER: US/09/776,474
```

```
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,983
; PRIOR FILING DATE: 2000-03-02
; NUMBER OF SEQ ID NOS: 2992
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 430
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-776-474-430

Query Match
Best Local Similarity 64.7%; DB 1; Length 17;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2194 AAAATAGCAGACTTGG 2210
|||||
Db 1 AAAAUCGACGACUUGG 17

RESULT 84
US-09-930-423-1394
; Sequence 1394, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBBH00-918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1394
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-1394

Query Match
Best Local Similarity 1.0%; Score 13.8; DB 1; Length 17;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2025 GGAGTACTCTATGACA 2041
|||||
Db 1 GGAGUACAACUAGACA 17

RESULT 85
US-09-780-164-921
; Sequence 921, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 921
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-921
```

```
Query Match
Best Local Similarity 1.0%; Score 13.8; DB 1; Length 17;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1701 TCCAAGAGATAGCTGA 1717
|||||
Db 1 UCCAGAGACGACUGCA 17

RESULT 86
US-09-780-164-1056
; Sequence 1056, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1056
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-1056

Query Match
Best Local Similarity 1.0%; Score 13.8; DB 1; Length 17;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1700 TTCCAAGATATAGCTG 1716
|||||
Db 1 UCCAGAGACGACUGCG 17

RESULT 87
US-09-745-237A-1394
; Sequence 1394, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1394
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-1394

Query Match
Best Local Similarity 1.0%; Score 13.8; DB 1; Length 17;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2025 GGAGTACTCTATGACA 2041
|||||
Db 1 GGAGUACAACUAGACA 17

RESULT 88
US-10-061-201-122/c
; Sequence 122, Application US/10061201
; Publication No. US20030166229A1
```

```

; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10

; ORGANISM: Homo sapiens
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-122

Query Match      1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1564 TCGGCTGAGTCCAGCTC 1580
Db      17 TCTGCTGAGTTCAGCTC 1

RESULT 89
US-10-061-201-123/c
; Sequence 123, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10

```

```

; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 123
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-123

Query Match      1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1563 TTGGCTGAGTCCAGCT 1579
Db      17 TCTGCTGAGTTCAGCT 1

RESULT 90
US-10-339-782-153/c
; Sequence 153, Application US/10339782
; Publication No. US20030166026A1
; GENERAL INFORMATION:
; APPLICANT: Lynx Therapeutics, Inc.
; APPLICANT: Bowman, Benjamin A
; TITLE OF INVENTION: Identification of Specific Biomarkers for Breast Cancer Cells
; FILE REFERENCE: 37-000110US
; CURRENT APPLICATION NUMBER: US/10/339,782
; CURRENT FILING DATE: 2003-01-08
; NUMBER OF SEQ ID NOS: 495
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 153
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-339-782-153

Query Match      1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2532 GGTAGAAGACTTGATC 2548
Db      17 GGTGAAGACTTGATC 1

RESULT 91
US-10-060-756A-145
; Sequence 145, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804

```

SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 145
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-060-756A-145

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1518 GCACAGCTGACCAAC 1534
DB 1 GCCCAAGCTCACCAAC 17

RESULT 92
US-10-060-756A-1676/c
Sequence 1676, Application US/10060756A
Publication No. US20030046717A1
GENERAL INFORMATION:
APPLICANT: Zhang, Jian
TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
FILE REFERENCE: PB0177
CURRENT APPLICATION NUMBER: US/10/060,756A
CURRENT FILING DATE: 2002-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 09/864,761
PRIOR FILING DATE: 2001-05-23
PRIOR APPLICATION NUMBER: US 60/327,898
PRIOR FILING DATE: 2001-10-09
NUMBER OF SEQ ID NOS: 4804
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 1676
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-060-756A-1676

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2186 ATGTGATGAATAAGCA 2202
DB 17 ATGTATAAATAAGCA 1

RESULT 93
US-10-163-552-303/c
Sequence 303, Application US/10163552
Publication No. US20030105051A1
GENERAL INFORMATION:
APPLICANT: McSwigen, Jim
TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
FILE REFERENCE: MHB01-1653-A (400/014)
CURRENT APPLICATION NUMBER: US/10/163,552
CURRENT FILING DATE: 2002-06-06
NUMBER OF SEQ ID NOS: 1997
SOFTWARE: PatentIn version 3.0

SEQ ID NO 303
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-163-552-303

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1920 TCTTCTTGAGCCTGCA 1936
DB 17 TCTTCTTGAGCCTGCA 1

RESULT 94
US-10-163-552-666
Sequence 666, Application US/10163552
Publication No. US20030105051A1
GENERAL INFORMATION:
APPLICANT: McSwigen, Jim
TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
FILE REFERENCE: MHB01-1653-A (400/014)
CURRENT APPLICATION NUMBER: US/10/163,552
CURRENT FILING DATE: 2002-06-06
NUMBER OF SEQ ID NOS: 1997
SOFTWARE: PatentIn version 3.0
SEQ ID NO 666
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-163-552-666

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.2e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2269 CCAGTCAAGTGATGCG 2285
DB 1 CCCAUCAGUGAUGGC 17

RESULT 95
US-09-280-030-8/c
Sequence 8, Application US/09280030A
Patent No. US20010021515A1
GENERAL INFORMATION:
APPLICANT: Sato, Seiji
APPLICANT: Higashikuni, Naohiko
APPLICANT: Kudo, Toshiyuki
APPLICANT: Kondo, Masaki
TITLE OF INVENTION: DNAs ENCODING NEW FUSION PROTEINS AND PROCESSES FOR THE
TITLE OF INVENTION: PREPARING USEFUL POLYPEPTIDES THROUGH EXPRESSION OF THE
TITLE OF INVENTION: DNAs
FILE REFERENCE: 382.1026
CURRENT APPLICATION NUMBER: US/09/280,030A
CURRENT FILING DATE: 1999-03-26
EARLIER APPLICATION NUMBER: JP10-87339/1998
EARLIER FILING DATE: 1998-03-31
NUMBER OF SEQ ID NOS: 66
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 8
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Designated is
US-09-280-030-8
Query Match 1.0%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1879 GAGATGATGAGATGAT 1895
18 GTGATGATGATGATCAT 2

RESULT 96
US-09-280-030-9

; Sequence 9, Application US/09280030A
; Patent No. US20010021515A1
; GENERAL INFORMATION:

; APPLICANT: Sato, Seiji

; APPLICANT: Higashikuni, Naohiko

; APPLICANT: Kondo, Toshiyuki

; TITLE OF INVENTION: DNAS ENCODING NEW FUSION PROTEINS AND PROCESSES FOR
; TITLE OF INVENTION: PREPARING USEFUL POLYPEPTIDES THROUGH EXPRESSION OF THE

; FILE REFERENCE: 382.1026

; CURRENT APPLICATION NUMBER: US/09/280,030A

; EARLIER FILING DATE: 1999-03-26

; EARLIER APPLICATION NUMBER: JP10-87339/1998

; NUMBER OF SEQ ID NOS: 66

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 9

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Designated is

US-09-280-030-9

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1879 GAGATGATGAGATGAT 1895
1 GTGATGATGATGATCAT 17

Db 1 GTGATGATGATGATCAT 17

RESULT 97
US-10-257-848-13

; Sequence 13, Application US/10257848
; Publication No. US20030158381A1
; GENERAL INFORMATION:

; APPLICANT: ITOH, Yasuaki

; APPLICANT: SUZUKI, No. US20030158381A1uhiro

; APPLICANT: NISHI, Kazunori

; APPLICANT: KIZAMA, Hideki

; APPLICANT: HARADA, Masataka

; TITLE OF INVENTION: No. US20030158381A1e1 Insulin/IGF/relaxin Family Polypeptide and

; FILE REFERENCE: 2717 USOP
; CURRENT APPLICATION NUMBER: US/10/257,848
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: PCT/JP01/03399
; PRIOR FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: JP 12-126340
; PRIOR FILING DATE: 2000-04-21
; PRIOR APPLICATION NUMBER: JP 12-205587
; PRIOR FILING DATE: 2000-07-03
; PRIOR APPLICATION NUMBER: JP 12-247962
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: JP 12-395050
; PRIOR FILING DATE: 2000-12-22
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 13
; LENGTH: 18

TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Primer
US-10-257-848-13

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1653 GGCAGGGGCTCTCCAGT 1669
2 GGCAGGGGCTCTCTGT 18

Db 2 GGCAGGGGCTCTCTGT 18

RESULT 98
US-10-004-551-40

; Sequence 40, Application US/10004551
; Publication No. US20030004310A1
; GENERAL INFORMATION:

; APPLICANT: SHIMKETS, RICHARD A

; APPLICANT: FERNANDES, ELMA

; TITLE OF INVENTION: POLYNUCLEOTIDES AND POLYPEPTIDES ENCODED THEREBY

; FILE REFERENCE: 15966-559

; CURRENT APPLICATION NUMBER: US/10/004,551

; CURRENT FILING DATE: 2001-12-05

; PRIOR APPLICATION NUMBER: 09/635,949

; PRIOR FILING DATE: 2000-08-10

; NUMBER OF SEQ ID NOS: 110

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 40

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: PCR PRIMER
US-10-004-551-40

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1481 CGACCAAGAGCCGAC 1497
2 CTACCAAGAGCCGAC 18

Db 2 CTACCAAGAGCCGAC 18

RESULT 99
US-10-004-551-43/C

; Sequence 43, Application US/10004551
; Publication No. US20030004310A1
; GENERAL INFORMATION:

; APPLICANT: SHIMKETS, RICHARD A

; APPLICANT: FERNANDES, ELMA

; TITLE OF INVENTION: POLYNUCLEOTIDES AND POLYPEPTIDES ENCODED THEREBY

; FILE REFERENCE: 15966-559

; CURRENT APPLICATION NUMBER: US/10/004,551

; CURRENT FILING DATE: 2001-12-05

; PRIOR APPLICATION NUMBER: 09/635,949

; PRIOR FILING DATE: 2000-08-10

; NUMBER OF SEQ ID NOS: 110

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 43

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: PCR PRIMER
US-10-004-551-43

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY	1481	CGACCAAGAGCCAGAC	1497
Db	17	CTACCAAGAGCCAGCC	1

```

RESULT 100
US-09-504-231A-999/C
; Sequence 999, Application US/09504231A
; Patent No. US20020013458A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Lawrence
; APPLICANT: McSwiggen, James
; APPLICANT: Roberts, Beth
; APPLICANT: Pawco, Pamela
; APPLICANT: Masejak, Dennis
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: HEPATITIS C VIRUS INFECTION
; FILE REFERENCE: rpl 247/282
; CURRENT APPLICATION NUMBER: US/09/504,231A
; CURRENT FILING DATE: 2000-02-15
; PRIOR APPLICATION NUMBER: 09/274,553
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3242
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 999
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Nucleic Acid Target
US-09-504-231A-999

```

Query Match	1.0%;	Score 13.4;	DB 1;	Length 15;
Best Local Similarity	93.3%;	Pred. No. 1.1e+02;		
Matches 14; Conservative	0;	Mismatches 1;	Indels 0;	Gaps 0;

Qy	2433	CAGAATGGATAAGCC	2447
Db	15	CAGAGTGGATAAGCC	1

```

1      RESULT 101
2      US-09-274-553D-999/c
3      Sequence 999, Application US/09274553D
4      Patent No. US20020082225A1
5      GENERAL INFORMATION:
6      APPLICANT: Blact, Lawrence
7      APPLICANT: McSwiggen, James
8      APPLICANT: Robertcs, Beth
9      APPLICANT: Pavco, Pamela
10     APPLICANT: Macejak, Dennis
11     TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
12     TITLE OF INVENTION: HEPATITIS C VIRUS INFECTION
13     FILE REFERENCE: rpi 247/282
14     CURRENT APPLICATION NUMBER: US/09/274,553D
15     CURRENT FILING DATE: 1999-03-23
16     PRIOR APPLICATION NUMBER: 09/257,608
17     PRIOR FILING DATE: 1999-02-24
18     PRIOR APPLICATION NUMBER: 60/100,842
19     PRIOR FILING DATE: 1998-09-18
20     PRIOR APPLICATION NUMBER: 60/083,217
21     PRIOR FILING DATE: 1998-04-27
22     NUMBER OF SEQ ID NOS: 3148
23     SOFTWARE: PatentIn version 3.0
24     SEQ ID NO 999
25     LENGTH: 15

```

```

; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-274-553D-999

```

Query Match	1.0%	Score 13.4;	DB 1;	Length 15;
Best Local Similarity	93.3%	Pred. No. 1.1e+02;		
Matches 14; Conservative	0;	Mismatches 1;	Indels 0;	Gaps 0;

QY 2433 CAGATGGATAAGCC 2447
|||
Db 15 CAGACTGATAAGCC 1

```

RESULT 102
US-10-277-494-3
; Sequence 3, Application US/10277494
; Publication No. US20030186909A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related To Level
; TITLE OF INVENTION: Epidermal Growth Factor Receptors
; FILE REFERENCE: MEMB00-958-K (400/064)
; CURRENT APPLICATION NUMBER: US/10/277,494
; CURRENT FILING DATE: 2002-10-21
; NUMBER OF SEQ ID NOS: 446
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-277-494-3

```

Query Match	1.0%	Score 13.4	DB 1	length 15;
Best Local Similarity	66.7%	Pred. No. 1.1e+02;		
Matches 10; Conservative	4;	Mismatches 1;	Indels 0;	Gaps 0;

```
QY      2318 ATCAGAGTGATGTC 2332
          |||||:|:|:|
Db      1 ACCAGAGUGAUGUCU 15
```

```

RESULT 103
US-10-277-494-73
: Sequence 73, Application US/10277494
: Publication No. US20030186909A1
: GENERAL INFORMATION:
: APPLICANT: Ribozyme Pharmaceuticals, Inc.
: APPLICANT: McSwiggen, Jim
: TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related To Level
: TITLE OF INVENTION: Epidermal Growth Factor Receptors
: FILE REFERENCE: MBH00-358-K (400/064)
: CURRENT APPLICATION NUMBER: US/10/277,494
: NUMBER OF SEQ ID NOS: 446
: SOFTWARE: PatentIn version 3.0
: SEQ ID NO 73
: LENGTH: 15
: TYPE: RNA
: ORGANISM: Homo sapiens
US-10-277-494-73

```

```
Query Match      1.0%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.1e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

Qy	2317	CATCAGAGTGATGTC	2331
Db	1	CACCAGAGUGAUGUC	15

```
RESULT 104
US-09-866-108-8354/c
; Sequence 8354, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8354
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8354

Query Match      1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1573 TCCAGCTCTCTCCATG 1587
Db      17  TCCAGCTCTCTCTTG 3
```

```
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8355
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8355

Query Match      1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1573 TCCAGCTCTCTCCATG 1587
Db      16  TCCAGCTCTCTCTTG 2
```

```
RESULT 105
US-09-866-108-8355/c
; Sequence 8355, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8354
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8354
```

```
RESULT 106
US-09-866-108-8356/c
; Sequence 8356, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8355
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8355
```

```

; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8356
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8356

```

```

Query Match          1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy      1573 TCCAGCTCTCTCATG 1587
Db      15   TCCAGCTCTCTCTTG 1

```

```

RESULT 107
US-09-866-108-8373/c
; Sequence 8373, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR APPLICATION NUMBER: 2001-05-25
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30

```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8373
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8373

```

```

Query Match          1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy      1507 CAGCGGCTGTGCAC 1521
Db      17   CAGCGGCTGTGCAC 3

```

```

RESULT 108
US-09-866-108-8376/c
; Sequence 8376, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR APPLICATION NUMBER: 2001-05-25
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30

```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8376
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8376

Query Match      1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy      1506 CCAGCGCGCTGTGCA 1520
Db      15 CCAGCTGCTGTGCA 1

RESULT 109
US-09-866-108-8943
; Sequence 8943, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8943
; LENGTH: 17
```

```

; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8943

Query Match      1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy      1355 CAGCGCCTGGAAGAG 1369
Db      3 CGGCGCCTGGAAGAG 17

RESULT 110
US-09-866-108-8944
; Sequence 8944, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8944
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8944

Query Match      1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy      1355 CAGCGCCTGGAAGAG 1369
Db      3 CGGCGCCTGGAAGAG 17
```

Db 2 CGGCGCTGGAAG 16

RESULT 111

US-09-866-108-8945

; Sequence 8945, Application US/09866108

; Patent No. US20020048800A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharon G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108

; PRIOR FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00662

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00661

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00670

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: US 60/234,687

; PRIOR FILING DATE: 2000-09-21

; PRIOR APPLICATION NUMBER: US 60/266,860

; PRIOR FILING DATE: 2001-02-05

; NUMBER OF SEQ ID NOS: 15752

; SOFTWARE: AeoMica Sequence Listing Engine

; SEQ ID NO 8945

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

; US-09-866-108-8945

; Db 1 CGGCGCTGGAAG 15

RESULT 112

US-09-866-108-9000

; Sequence 9000, Application US/09866108

; Patent No. US20020048800A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharon G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

```

; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: AeoMica Sequence Listing Engine
; SEQ ID NO 9000
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-9000

```

Qy 1505 GCCAGCGCGCTGTC 1519

Db 3 GCCAGCGCGCGCTGC 17

RESULT 113

US-09-866-108-9003

; Sequence 9003, Application US/09866108

; Patent No. US20020048800A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharon G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108

; PRIOR FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

```

; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 9003
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9003

Query Match          1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy      1506 CCAGCCGGCTGTGCA 1520
Db      1 CCAGCCGGCTGTGCA 15

RESULT 114
US-09-825-805-648
; Sequence 648, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Vaseka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MBH00-831-F (400/009)
; CURRENT APPLICATION NUMBER: US/09/825,805
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
```

```

; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: Patent version 3.0
; SEQ ID NO 648
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-648

Query Match          1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.4e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Cy      2110 GGCATGAGACTTG 2124
Db      1 GGCATGAGACTTG 15

RESULT 115
US-09-780-533A-2375/c
; Sequence 2375, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowirita, Bharat
; APPLICANT: Haeblerl, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00-878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: Patent version 3.0
; SEQ ID NO 2375
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2375

Query Match          1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy      1573 TCCAGCTCTCCATG 1587
Db      17 TCCAGCTCTCCAG 3

RESULT 116
US-09-780-533A-2376/c
; Sequence 2376, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowirita, Bharat
; APPLICANT: Haeblerl, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00-878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: Patent version 3.0
; SEQ ID NO 2376
; LENGTH: 17
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2376

Query Match
Best Local Similarity 1.0%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1573 TCCAGCTCTCCATG 1587
Db 16 TCCAGCTCTCCAGG 2

RESULT 117
US-09-877-478-2182
; Sequence 2182, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; PRIOR FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2182
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2182

Query Match
Best Local Similarity 1.0%; Score 13.4; DB 1; Length 17;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2479 ATGAGGACTGTGG 2493
Db 2 AUGGGGAGCUGUGG 16

RESULT 118
US-09-877-478-2527
; Sequence 2527, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
```

```
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2527
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2527

Query Match
Best Local Similarity 1.0%; Score 13.4; DB 1; Length 17;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2479 ATGAGGACTGTGG 2493
Db 3 AUGGGGAGCUGUGG 17

RESULT 119
US-09-792-818-96/c
; Sequence 96, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlwiltz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insee
; FILE REFERENCE: MBH00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 96
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-96

Query Match
Best Local Similarity 1.0%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1868 TGTGAGAGTGA 1882
Db 16 TGACAGAGTGA 2

RESULT 120
US-09-792-818-284/c
; Sequence 284, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```

; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Inse
; TITLE OF INVENTION: (GRID) Gene
; FILE REFERENCE: MEBH00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 284
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-284

Query Match          1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy      1868 TGTGACAGATGAGCA 1882
Db      15  TGACAGAGATGAGCA 1

RESULT 121
US-10-238-700-3194/c
; Sequence 3194, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MEBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3194
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-3194

Query Match          1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy      2283 GGCTCCAGAGCCCT 2297
Db      17  GGCTCCAGAGCCCT 3

RESULT 122
US-10-230-006-164
; Sequence 164, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
; FILE REFERENCE: 400/056 (MEBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
```

```

; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 164
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-164

Query Match          1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Cy      1993 GAATACCTCCGAGCC 2007
Db      1  GAAGACCCCGAGCC 15

RESULT 123
US-10-230-006-2204/c
; Sequence 2204, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
; FILE REFERENCE: 400/056 (MEBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2204
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-2204

Query Match          1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy      1573 TCCAGCTCTCCAGC 1587
Db      17  TCCAGCTCTCCAGC 3

RESULT 124
US-10-230-006-2205/c
; Sequence 2205, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
; FILE REFERENCE: 400/056 (MEBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2205
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-2205

Query Match          1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

Qy 1573 TCCAGCTCTCCATG 1587
| | | | | | | | | |
Db 16 TCCAGCTCTCCAGG 2

RESULT 125

US-10-027-632-58632/c
; Sequence 58632, Application US/10027632
; Publication No. US20030204075A9
; GENERAL INFORMATION:

; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632

;; PRIOR FILING DATE: 2002-04-30
;; PRIOR APPLICATION NUMBER: US 60/218,006
;; PRIOR FILING DATE: 2000-07-12
;; PRIOR APPLICATION NUMBER: US 60/198,676
;; PRIOR FILING DATE: 2000-04-20
;; PRIOR APPLICATION NUMBER: US 60/193,483
;; PRIOR FILING DATE: 2000-03-29
;; PRIOR APPLICATION NUMBER: US 60/185,218
;; PRIOR FILING DATE: 2000-02-24
;; PRIOR APPLICATION NUMBER: US 60/167,363
;; PRIOR FILING DATE: 1999-11-23
;; PRIOR APPLICATION NUMBER: US 60/156,358
;; PRIOR FILING DATE: 1999-09-28
;; PRIOR APPLICATION NUMBER: US 60/146,002
;; PRIOR FILING DATE: 1999-08-09
;; NUMBER OF SEQ ID NOS: 325720
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO: 58632
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Human

US-10-027-632-58632

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2326 GATGCTGTCCTTC 2340
| | | | | | | | | |
Db 15 GATGCTGTCCTTC 1

US-10-027-632-58632/c

;; Sequence 58632, Application US/10027632
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632

;; PRIOR FILING DATE: 2002-04-30
;; PRIOR APPLICATION NUMBER: US 60/218,006
;; PRIOR FILING DATE: 2000-07-12
;; PRIOR APPLICATION NUMBER: US 60/198,676
;; PRIOR FILING DATE: 2000-04-20
;; PRIOR APPLICATION NUMBER: US 60/193,483
;; PRIOR FILING DATE: 2000-03-29
;; PRIOR APPLICATION NUMBER: US 60/185,218
;; PRIOR FILING DATE: 2000-02-24
;; PRIOR APPLICATION NUMBER: US 60/167,363
;; PRIOR FILING DATE: 1999-11-23
;; PRIOR APPLICATION NUMBER: US 60/156,358
;; PRIOR FILING DATE: 1999-09-28
;; PRIOR APPLICATION NUMBER: US 60/146,002
;; PRIOR FILING DATE: 1999-08-09
;; NUMBER OF SEQ ID NOS: 325720

;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO: 58632
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Human

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2326 GATGCTGTCCTTC 2340
| | | | | | | | | |
Db 15 GATGCTGTCCTTC 1

US-10-027-632-58640/c
; Sequence 58640, Application US/10027632
; Publication No. US20030204075A9
; GENERAL INFORMATION:

; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
;; PRIOR FILING DATE: 2002-04-30
;; PRIOR APPLICATION NUMBER: US 60/218,006
;; PRIOR FILING DATE: 2000-07-12
;; PRIOR APPLICATION NUMBER: US 60/198,676
;; PRIOR FILING DATE: 2000-04-20
;; PRIOR APPLICATION NUMBER: US 60/193,483
;; PRIOR FILING DATE: 2000-03-29
;; PRIOR APPLICATION NUMBER: US 60/185,218
;; PRIOR FILING DATE: 2000-02-24
;; PRIOR APPLICATION NUMBER: US 60/167,363
;; PRIOR FILING DATE: 1999-11-23
;; PRIOR APPLICATION NUMBER: US 60/156,358
;; PRIOR FILING DATE: 1999-09-28
;; PRIOR APPLICATION NUMBER: US 60/146,002
;; PRIOR FILING DATE: 1999-08-09
;; NUMBER OF SEQ ID NOS: 325720
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO: 58640
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Human

US-10-027-632-58640

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2326 GATGCTGTCCTTC 2340
| | | | | | | | | |
Db 15 GATGCTGTCCTTC 1

US-10-027-632-58640/c
; Sequence 58640, Application US/10027632
; GENERAL INFORMATION:

; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
;; PRIOR FILING DATE: 2002-04-30
;; PRIOR APPLICATION NUMBER: US 60/218,006
;; PRIOR FILING DATE: 2000-07-12
;; PRIOR APPLICATION NUMBER: US 60/198,676
;; PRIOR FILING DATE: 2000-04-20
;; PRIOR APPLICATION NUMBER: US 60/193,483

```

; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; PRIOR FILING DATE: 1999-08-09
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO: 58640
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Human
US-10-027-632-58640

Query Match
Best Local Similarity 93.3%; Pred. No. 1.4e+02; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2326 GATGCTGCTCCTTC 2340
Db 15 GATGCTGCTCCTTC 1

RESULT 129
US-10-163-552-289
; Sequence 289, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE REFERENCE: MHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 289
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-289

Query Match
Best Local Similarity 1.0%; Score 13.4; DB 1; Length 17;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 2110 GGCATGAGTACTTG 2124
Db 1 GGCATGAGTACTTG 15

RESULT 130
US-10-163-552-667
; Sequence 667, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE REFERENCE: MHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 667
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens

US-10-163-552-667
Query Match
Best Local Similarity 1.0%; Score 13.4; DB 1; Length 17;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 2273 TCAAGTGATGGC 2287
Db 1 UCAAGUGGAGCGC 15

RESULT 131
US-10-163-552-678
; Sequence 678, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE REFERENCE: MHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 678
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-678

Query Match
Best Local Similarity 1.0%; Score 13.4; DB 1; Length 17;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2320 CAGAGTGATGCTGG 2334
Db 2 CAGAGUGAGUGUGG 16

RESULT 132
US-09-848-754A-9124
; Sequence 9124, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MHB00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 9124
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Enzymatic Nucleic acid
US-09-848-754A-9124

Query Match
Best Local Similarity 0.9%; Score 13; DB 1; Length 13;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2273 TCAAGTGATGGC 2285
Db 1 UCAAGUGGAGCGC 13

RESULT 133
US-10-277-494-54
; Sequence 54, Application US/10277494
```

Publication No. US20030186909A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: McSwiggen, Jim
TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or conditions Related To Level
TITLE OF INVENTION: Epidermal Growth Factor Receptors
FILE REFERENCE: MBH00-958-K (400/064)
CURRENT APPLICATION NUMBER: US/10/277,494
CURRENT FILING DATE: 2002-10-21
NUMBER OF SEQ ID NOS: 446
SOFTWARE: PatentIn version 3.0
SEQ ID NO 54
LENGTH: 15
TYPE: RNA
ORGANISM: Homo sapiens
US-10-277-494-54

Query Match 0.9%; Score 13; DB 1; Length 15;
Best Local Similarity 69.2%; Pred. No. 1.3e+02;
Matches 9; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 2322 GAGTATGCTCTGG 2334
|||:|:|:|:|:|
1 GAGUGAGUGUCUGG 13

Db 1 GAGUGAGUGUCUGG 13

RESULT 134
US-10-091-281-150/c
Sequence 150, Application US/10091281
Publication No. US20030190617A1
GENERAL INFORMATION:
APPLICANT: RAYMOND, VINCENT
APPLICANT: SI, ERWIN
TITLE OF INVENTION: OPTINEURIN NUCLEIC ACID MOLECULES AND USES THEREOF
FILE REFERENCE: 13587.338
CURRENT APPLICATION NUMBER: US/10/091,281
CURRENT FILING DATE: 2002-03-06
NUMBER OF SEQ ID NOS: 463
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 150
LENGTH: 16
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: Putative LYMF/TH1E47.01 motif
US-10-091-281-150

Query Match 0.9%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2668 TCTCCAGACCCCA 2680
|||||
15 TCTCCAGACCCCA 3

Db 15 TCTCCAGACCCCA 3

RESULT 135
US-09-866-108-6887/c
Sequence 6887, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wenheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOmica-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: AeoMica Sequence Listing Engine
SEQ ID NO 6887
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-6887

Query Match 0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1359 GCGTGGAGAGAA 1371
|||||
17 GCGTGGAGAGAA 5

Db 17 GCGTGGAGAGAA 5

RESULT 136
US-09-866-108-6892/c
Sequence 6892, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wenheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOmica-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667

```

; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6892
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-6892

Query Match          0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      1358 GCGCTGGAAGAGA 1370
Db      13  GCGCTGGAAGAGA 1

RESULT 137
US-09-866-108-8946
; Sequence 8946, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8946
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-8946

Query Match          0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      1357 GCGCTGGAAGAG 1369
Db      2  GCGCTGGAAGAG 14

RESULT 138
US-09-866-108-8947
; Sequence 8947, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
```

NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 8947
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-8947

Query Match 0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1357 GCGCCTGGAGAG 1369
Db 1 GCGCCTGGAGAG 13

RESULT 139
US-09-866-108-9030
Sequence 9030, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263, 6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 9030
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-9030

Query Match 0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2397 CGTGAGAACTT 2409
Db 5 CGTGAGAACTT 17

RESULT 140
US-09-866-108-9031
Sequence 9031, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263, 6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 9031
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-9031

Query Match 0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2397 CGTGAGAACTT 2409
Db 4 CGTGAGAACTT 16

RESULT 141
US-09-866-108-9032
Sequence 9032, Application US/09866108

```
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AECOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 9032
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-9032

Query Match      0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2397 CGTGAGGAACTT 2409
Db      3 CGTGAGGAACTT 15

RESULT 142
US-09-866-108-9033
Sequence 9033, Application US/09866108
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
```

```
FILE REFERENCE: AECOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 9033
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-9033

Query Match      0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2397 CGTGAGGAACTT 2409
Db      2 CGTGAGGAACTT 14

RESULT 143
US-09-866-108-9034
Sequence 9034, Application US/09866108
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AECOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
```

PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 9034
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-9034

Query Match 0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2397 CGTGAGGAGACTT 2409
DB 1 CGTGAGGAGACTT 13

RESULT 144
US-09-961-077-748
Sequence 748, Application US/09961077
Publication No. US20030014775A1
GENERAL INFORMATION:
APPLICANT: Zwick, Michael G.
Edington, Brent B.
McSwiggen, James A.
Merlo, Patricia Ann Owens
Guo, Lining
Skokut, Thomas A.
Young, Scott A.
Folkerts, Otto
Merlo, Donald J.
TITLE OF INVENTION: COMPOSITION AND METHODS FOR
MODULATION OF GENE EXPRESSION
IN PLANTS
NUMBER OF SEQUENCES: 1263
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/961,077
FILING DATE: 21-Sep-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/679,645
FILING DATE: July 12, 1996
APPLICATION NUMBER: 60/001,135
FILING DATE: July 13, 1995
APPLICATION NUMBER: 08/100,726
FILING DATE: September 2, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 219/247
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 748:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 748:
US-09-961-077-748

Query Match 0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 1.6e+02;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1866 GGTCTCAGAGATG 1878
DB 4 GGTCTCAGAGATG 16

RESULT 145
US-09-780-533A-1806/C
Sequence 1806, Application US/09780533A
Publication No. US20030060611A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
Blatt, Larry
APPLICANT: McSwiggen, Jim
Chowrira, Bharat
APPLICANT: Haeblerli, Pete
TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
FILE REFERENCE: MHB00,878-A (400/011)
CURRENT APPLICATION NUMBER: US/09/780,533A
CURRENT FILING DATE: 2001-02-09
PRIOR APPLICATION NUMBER: US 60/181,797
PRIOR FILING DATE: 2000-02-11
NUMBER OF SEQ ID NOS: 6679
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1806
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-780-533A-1806

Query Match 0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1573 TCCAGCTCCTCCA 1585
DB 14 TCCAGCTCCTCCA 2

RESULT 146
US-09-848-754A-2903
Sequence 2903, Application US/09848754A
Publication No. US20030073207A1

```
;; GENERAL INFORMATION:
;; APPLICANT: Ribozyme Pharmaceuticals, Inc.
;; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;; FILE REFERENCE: MHB00-958-1 (400/018)
;; CURRENT APPLICATION NUMBER: US/09/848,754A
;; CURRENT FILING DATE: 2001-05-03
;; NUMBER OF SEQ ID NOS: 9645
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 2903
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-09-848-754A-2903

Query Match          0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 1.6e+02;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      2273 TCAAGTGGATGCG 2285
DB      1 UCAAGUGGAGUGGC 13

RESULT 147
US-09-848-754A-3486
; Sequence 3486, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MHB00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3486
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-3486

Query Match          0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 1.6e+02;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      2273 TCAAGTGGATGCG 2285
DB      3 UCAAGUGGAGUGGC 15

RESULT 148
US-09-848-754A-3487
; Sequence 3487, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MHB00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3487
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-3487

Query Match          0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 1.6e+02;
```

```
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      2273 TCAAGTGGATGCG 2285
DB      2 UCAAGUGGAGUGGC 14

RESULT 149
US-09-776-474-1033
; Sequence 1033, Application US/09776474
; Publication No. US20030087847A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Boohet, Robert
; APPLICANT: Holman, Patricia
; APPLICANT: Fattaey, Ali
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Checkpoint Kinase-1 (CHK
; FILE REFERENCE: MHB00-955-A (400/008)
; CURRENT APPLICATION NUMBER: US/09/776,474
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,983
; NUMBER OF SEQ ID NOS: 2992
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1033
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-776-474-1033

Query Match          0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 1.6e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1730 CCTGTGGAGGAGG 1742
DB      5 CCCUGGAGGAGG 17

RESULT 150
US-09-740-332-831/c
; Sequence 831, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 831
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-831

Query Match          0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1545 GCGGAGACAGCTA 1557
DB      1 GCGGAGACAGCTA 1557
```

```
Db      16 GCGGAGACAGGTA 4
RESULT 151
US-09-740-332-3724
; Sequence 3724, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: RPI 400/003
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3724
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3724

Query Match      0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 1.6e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Oy      1545 GCGGAGACAGGTA 1557
Db      3 GCGGAGACAGGUA 15
RESULT 152
US-09-817-879-831/c
; Sequence 831, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MHB00-801-F
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 831
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-831

Query Match      0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      1545 GCGGAGACAGGTA 1557
Db      16 GCGGAGACAGGTA 4
RESULT 153
US-09-817-879-3724
; Sequence 3724, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MHB00-801-F
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3724
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3724

Query Match      0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 1.6e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Oy      1545 GCGGAGACAGGTA 1557
Db      3 GCGGAGACAGGUA 15
RESULT 154
US-10-230-006-1403/c
; Sequence 1403, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fossnaugh, Kathy
; APPLICANT: McSwiggan, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
; FILE REFERENCE: 400/056 (MHB01-1110)
; CURRENT FILING DATE: 2002-11-18
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1403
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-1403

Query Match      0.9%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      1573 TCCAGCTCTCCCA 1585
Db      14 TCCAGCTCTCCCA 2
RESULT 155
US-09-829-855-177
; Sequence 177, Application US/09829855
; Patent No. US20020065609A1
; GENERAL INFORMATION:
; APPLICANT: Matchew, Ashby N.
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; FILE REFERENCE: ASHBY-1
; CURRENT FILING DATE: 2001-04-10
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
```



```
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AECOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 1107
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-1107

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy      1725 CAAGCCCTGGAGAA 1740
Db      2 CAATCCCTGGAGAA 17

RESULT 159
US-09-866-108-1108
Sequence 1108, Application US/09866108
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
```

```
FILE REFERENCE: AECOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 1108
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-1108

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy      1725 CAAGCCCTGGAGAA 1740
Db      1 CAATCCCTGGAGAA 16

RESULT 160
US-09-866-108-1112
Sequence 1112, Application US/09866108
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AECOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
```

```
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aeomica Sequence Listing Engine
;; SEQ ID NO 1112
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-1112
```

```
Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      1730 CCCTGGGAGAAAGTTG 1745
Db      2 CCCTGGGAGAAAGTGG 17
```

```
RESULT 161
US-09-866-108-1113
;; Sequence 1113, Application US/09866108
;; Patent No. US2002004800A1
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: PENN, Sharon G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AEOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108
;; PRIOR FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
```

```
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aeomica Sequence Listing Engine
;; SEQ ID NO 1113
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-1113
```

```
Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      1730 CCCTGGGAGAAAGTTG 1745
Db      1 CCCTGGGAGAAAGTGG 16
```

```
RESULT 162
US-09-866-108-1175
;; Sequence 1175, Application US/09866108
;; Patent No. US2002004800A1
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: PENN, Sharon G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AEOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108
;; PRIOR FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
```

;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aecomica Sequence Listing Engine
;; SEQ ID NO 1175
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-1175

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2425 GAAGGACACAGAAATGG 2440
Db 2 GAAGGACAAAGAGG 17

RESULT 163
US-09-866-108-1176
; Sequence 1176, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1176
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1176

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2425 GAAGGACACAGAAATGG 2440
Db 1 GAAGGACAAAGAGG 16

RESULT 164
US-09-866-108-1571
; Sequence 1571, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1571
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1571

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1503 CAGCCAGCCGCTGTG 1518
Db 2 CAGCCAGCTCTCTG 17

```
RESULT 165
US-09-866-108-1572
; Sequence 1572, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1572
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1572

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
RESULT 167
US-09-866-108-6176
; Sequence 6176, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6176
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6176

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6311
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6177
```

```

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY      1784 ACAAGACAGCCCA 1799
Db      1 ACAGAGCCAGCCCA 16
```

```

RESULT 168
US-09-866-108-6311
; Sequence 6311, Application US/09866108
; Patent No. US2002004800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6311
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6311
```

```

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY      2090 GCACCTACAGCTGAC 2105
Db      2 GCACCTCCAGCAGGC 17
```

```

RESULT 169
US-09-866-108-6313
; Sequence 6313, Application US/09866108
; Patent No. US2002004800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6313
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-6313

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2091 CACCTACGCGCGCC 2106
Db      1 CACCTCCGAGCGGCC 16

RESULT 170
; Sequence 6531, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6531
; LENGTH: 17
```

```

; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-6531

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1359 GCGTGAGAGAGAAG 1374
Db      2 GCGTGAGAGAGAAG 17

RESULT 171
; Sequence 6532, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6532
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-6532

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1359 GCGTGAGAGAGAAG 1374
Db      2 GCGTGAGAGAGAAG 17
```

Db 1 GCCTGTAGACAG 16

RESULT 172

US-09-866-108-7345

Sequence 7345, Application US/09866108

Patent No. US20020048800A1

GENERAL INFORMATION:

APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharon G.

APPLICANT: HANZEL, David K.

APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng

APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: AEOMICA-7

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00662

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00661

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00670

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: US 60/234,687

PRIOR FILING DATE: 2000-09-21

PRIOR APPLICATION NUMBER: US 60/266,860

PRIOR FILING DATE: 2001-02-05

NUMBER OF SEQ ID NOS: 15752

SOFTWARE: Aeomica Sequence Listing Engine

SEQ ID NO 7345

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-09-866-108-7345

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2524 AACGAGTGTGAG 2539

Db 2 AACGAGTGTGAG 17

RESULT 173

US-09-866-108-7346

Sequence 7346, Application US/09866108

Patent No. US20020048800A1

GENERAL INFORMATION:

APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharon G.

APPLICANT: HANZEL, David K.

APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng

APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: AEOMICA-7

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00662

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00661

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00670

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: US 60/234,687

PRIOR FILING DATE: 2000-09-21

PRIOR APPLICATION NUMBER: US 60/266,860

PRIOR FILING DATE: 2001-02-05

NUMBER OF SEQ ID NOS: 15752

SOFTWARE: Aeomica Sequence Listing Engine

SEQ ID NO 7346

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-09-866-108-7346

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2524 AACGAGTGTGAG 2539

Db 1 AACGAGTGTGAG 16

RESULT 174

US-09-866-108-7672/c

Sequence 7672, Application US/09866108

Patent No. US20020048800A1

GENERAL INFORMATION:

APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharon G.

APPLICANT: HANZEL, David K.

APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng

APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: AEOMICA-7

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

```
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aeomica Sequence Listing Engine
;; SEQ ID NO 7672
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-7672
```

```
Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Oy      2659 TCTGTTTCTCCAG 2674
Db      17 TCTGCTTCTCTCCAG 2
```

```
RESULT 175
US-09-866-108-7674/C
;; Sequence 7674, Application US/09866108
;; Patent No. US20020048800A1
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharon G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AEOMICA-7
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
```

```
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aeomica Sequence Listing Engine
;; SEQ ID NO 7674
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-7674
```

```
Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Oy      2658 TTCTGTTTCTTCTCA 2673
Db      16 TTCTGCTTCTTCTCA 1
```

```
RESULT 176
US-09-866-108-9074
;; Sequence 9074, Application US/09866108
;; Patent No. US20020048800A1
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharon G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AEOMICA-7
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecmica Sequence Listing Engine
; SEQ ID NO 9074
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-9074

Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1397 ACCTGAGATGACCAT 1412
DB      2 ACCTGAGACATCCAT 17

RESULT 177
US-09-866-108-9076
; Sequence 9076, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecmica Sequence Listing Engine
; SEQ ID NO 9074
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-10700

Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1398 CCTGAGATGACCAT 1413
DB      1 CCTGAGACATCCAT 16

RESULT 178
US-09-866-108-10700
; Sequence 10700, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecmica Sequence Listing Engine
; SEQ ID NO 10700
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-10700

Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

; SOFTWARE: Aecmica Sequence Listing Engine
; SEQ ID NO 9076
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-9076

Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1398 CCTGAGATGACCAT 1413
DB      1 CCTGAGACATCCAT 16

RESULT 178
US-09-866-108-10700
; Sequence 10700, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecmica Sequence Listing Engine
; SEQ ID NO 10700
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-10700

Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

OY 1833 AGATGATGCCACAG 1848
DB 2 AGATGATGCCACAG 17

RESULT 179

US-09-866-108-10701

; Sequence 10701, Application US/09866108

; Patent No. US20020048800A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharon G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AECOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263,6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00662

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00661

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00670

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: US 60/234,687

; PRIOR FILING DATE: 2000-09-21

; PRIOR APPLICATION NUMBER: US 60/266,860

; PRIOR FILING DATE: 2001-02-05

; NUMBER OF SEQ ID NOS: 15752

; SOFTWARE: Aecomica Sequence Listing Engine

; SEQ ID NO 10701

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

; US-09-866-108-10701

; Query Match 0.9%; Score 12.8; DB 1; Length 17;

; Best Local Similarity 87.5%; Pred. No. 1.7e+02;

; Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1833 AGATGATGCCACAG 1848
DB 1 AGATGATGCCACAG 16

RESULT 180

US-09-864-785-664/c

; Sequence 664, Application US/09864785

; Patent No. US20020177568A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Draper, Ken

; APPLICANT: McSwigen, Jim

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; FILE REFERENCE: 400/022 (MEHB00-812-D)

; CURRENT APPLICATION NUMBER: US/09/864,785

; CURRENT FILING DATE: 2001-05-23

; NUMBER OF SEQ ID NOS: 3929

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 664

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid

US-09-864-785-664

; Query Match 0.9%; Score 12.8; DB 1; Length 17;

; Best Local Similarity 87.5%; Pred. No. 1.7e+02;

; Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1398 CCTGAGATAGCAGT 1413
DB 16 CCTGAGAGAGCCAGT 1

RESULT 181

US-09-864-785-1617

; Sequence 1617, Application US/09864785

; Patent No. US20020177568A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Draper, Ken

; APPLICANT: McSwigen, Jim

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; FILE REFERENCE: 400/022 (MEHB00-812-D)

; CURRENT APPLICATION NUMBER: US/09/864,785

; CURRENT FILING DATE: 2001-05-23

; NUMBER OF SEQ ID NOS: 3929

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1617

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid

US-09-864-785-1617

; Query Match 0.9%; Score 12.8; DB 1; Length 17;

; Best Local Similarity 87.5%; Pred. No. 1.7e+02;

; Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2005 GCCCGAGGCCACCG 2020
DB 1 GCCCGAGGCCACCG 16

RESULT 182

US-09-825-805-782

; Sequence 782, Application US/09825805

; Publication No. US20030004122A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Beigelman, Leo

; APPLICANT: Beaudry, Amber

; APPLICANT: Karpelesky, Alex

; APPLICANT: Adamic, Jasenka Matulic

; APPLICANT: Sweedler, Dave

```
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleo
FILE REFERENCE: MBBH00-831-F (400/0609)
CURRENT APPLICATION NUMBER: US/09/825,805
PRIOR FILING DATE: 2001-09-27
PRIOR APPLICATION NUMBER: 09/578,223
PRIOR FILING DATE: 2000-05-23
PRIOR APPLICATION NUMBER: 09/476,387
PRIOR FILING DATE: 1999-12-30
PRIOR APPLICATION NUMBER: 09/474,432
PRIOR FILING DATE: 1999-12-29
PRIOR APPLICATION NUMBER: 09/301,511
PRIOR FILING DATE: 1999-04-28
PRIOR APPLICATION NUMBER: 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: 60/083,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/064,866
PRIOR FILING DATE: 1997-11-05
NUMBER OF SEQ ID NOS: 1558
SOFTWARE: PatentIn version 3.0
SEQ ID NO 782
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-825-805-782
```

```
Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.7e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      2317 CATCAGATGATGCT 2332
Db      2   CACGAGUGAGUGUGU 17
```

```
RESULT 183
US-09-818-875-1759
Sequence 1759, Application US/09818875
Publication No. US20030051270A1
GENERAL INFORMATION:
APPLICANT: Kmiec, Eric B.
APPLICANT: Gamper, Howard B.
APPLICANT: Rice, Michael C.
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
FILE REFERENCE: Napro-4
CURRENT APPLICATION NUMBER: US/09/818,875
CURRENT FILING DATE: 2001-03-27
PRIOR APPLICATION NUMBER: US 60/192,176
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/192,179
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/208,538
PRIOR FILING DATE: 2000-06-01
PRIOR APPLICATION NUMBER: US 60/244,989
PRIOR FILING DATE: 2000-10-30
NUMBER OF SEQ ID NOS: 4385
SOFTWARE: Friedman macro Napro4
SEQ ID NO 1759
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-818-875-1759
```

```
Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      1880 AGATGATGAGATGAT 1895
Db      1   AGATGATTCAGATGAT 16
```

```
RESULT 184
US-09-818-875-1760/C
Sequence 1760, Application US/09818875
Publication No. US20030051270A1
GENERAL INFORMATION:
APPLICANT: Kmiec, Eric B.
APPLICANT: Gamper, Howard B.
APPLICANT: Rice, Michael C.
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
FILE REFERENCE: Napro-4
CURRENT APPLICATION NUMBER: US/09/818,875
CURRENT FILING DATE: 2001-03-27
PRIOR APPLICATION NUMBER: US 60/192,176
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/192,179
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/208,538
PRIOR FILING DATE: 2000-06-01
PRIOR APPLICATION NUMBER: US 60/244,989
PRIOR FILING DATE: 2000-10-30
NUMBER OF SEQ ID NOS: 4385
SOFTWARE: Friedman macro Napro4
SEQ ID NO 1760
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-818-875-1760
```

```
Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      1880 AGATGATGAGATGAT 1895
Db      17 AGATGATTCAGATGAT 2
```

```
RESULT 185
US-09-818-875-3314
Sequence 3314, Application US/09818875
Publication No. US20030051270A1
GENERAL INFORMATION:
APPLICANT: Kmiec, Eric B.
APPLICANT: Gamper, Howard B.
APPLICANT: Rice, Michael C.
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
FILE REFERENCE: Napro-4
CURRENT APPLICATION NUMBER: US/09/818,875
CURRENT FILING DATE: 2001-03-27
PRIOR APPLICATION NUMBER: US 60/192,176
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/192,179
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/208,538
PRIOR FILING DATE: 2000-06-01
PRIOR APPLICATION NUMBER: US 60/244,989
PRIOR FILING DATE: 2000-10-30
NUMBER OF SEQ ID NOS: 4385
SOFTWARE: Friedman macro Napro4
SEQ ID NO 3314
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-818-875-3314
```

```
Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      1686 CCCAAATGGAGATT 1701
```

Db 1 ||||| ||||| |||||
1 CCCAATTGGGTGTT 16

RESULT 186
US-09-818-875-3315/c
; Sequence 3315, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3315
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3315

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1666 CCCAATGGAGTTT 1701
Db 17 CCCAATTGGGTGTT 2

RESULT 187
US-09-780-533A-843/c
; Sequence 843, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH800,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 843
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-843

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1651 CTCGACGGGCTCTCCG 1666
Db 17 CCGGACGGGCTCTCCG 2

RESULT 188
US-09-780-533A-845/c
; Sequence 845, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH800,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 845
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-845

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1650 GCTGCACGGGCTCTCC 1665
Db 16 GCCGACGGGCTCTCC 1

RESULT 189
US-09-780-533A-2092/c
; Sequence 2092, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH800,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2092
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2092

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1572 GTCCAGCTCTCCATG 1587
Db 16 GTCCAGCTCTCCATG 1

RESULT 190
US-09-780-533A-2103/c
; Sequence 2103, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:

```

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerl, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00, 878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2103
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2103

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1653 GGCAGGGGTCTCCGAG 1668
Db 17 GGCAGGGGTCTCCGAG 2

RESULT 191
US-09-780-533A-2341/C
; Sequence 2341, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerl, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00, 878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2341
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2341

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1572 GTCCAGCTCTCCATG 1587
Db 17 GTCCAGCTCTCCATG 2

RESULT 192
US-09-877-478-2463
; Sequence 2463, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
```

```

; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2463
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2463

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 2192 TGAATAATGCAGACT 2207
Db 1 TGAATAATGCAGACT 16

RESULT 193
US-09-848-754A-184/C
; Sequence 184, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; PRIOR FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 184
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-184

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1358 GGCCTGAGAGAGAAA 1373
Db 16 GGCCTGAGAGAGAAA 1

RESULT 194
US-09-848-754A-326
; Sequence 326, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
```

;; CURRENT FILING DATE: 2001-05-03
;; NUMBER OF SEQ ID NOS: 9645
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO: 326
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-09-848-754A-326

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.7e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

OY 2323 AGTATGTCTGGTCT 2338
DB 1 AGUGAUGUCUGAGCU 16

RESULT 195
US-09-848-754A-1167/c
; Sequence 1167, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MHB00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 1167
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1167

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1358 CGCTGGAAGAGAAA 1373
DB 17 CGACTGCAAGAGAAA 2

RESULT 196
US-09-848-754A-1481
; Sequence 1481, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MHB00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 1481
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1481

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1.7e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

OY 2314 ACTCATGAGTGTG 2329
DB 2 ACCCACAGAGUGAUG 17

RESULT 197
US-09-848-754A-2894
; Sequence 2894, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MHB00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 2894
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2894

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.7e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

OY 2110 GGCATGAGTACTTG 2125
DB 2 GGCAUGAACUACUUG 17

RESULT 198
US-09-848-754A-3108/c
; Sequence 3108, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MHB00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 3108
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-3108

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2664 TTTTCTCCAGAGCCC 2679
DB 17 TTTTCTCCAGAGCCC 2

RESULT 199
US-09-848-754A-3109/c
; Sequence 3109, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MHB00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 3109
; LENGTH: 17
; TYPE: RNA

ORGANISM: Homo sapiens
US-09-848-754A-3109

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2664 TTTTCTCCAGACCCC 2679
Db 16 TTTTCTCCAGACCCC 1

RESULT 200
US-09-776-474-76
Sequence 76, Application US/09776474
Publication No. US20030087847A1

GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Jarvis, Thale
APPLICANT: Boober, Robert
APPLICANT: Holman, Patricia
APPLICANT: Fattaey, Ali
APPLICANT: McSwiggen, Jim
TITLE OF INVENTION: Method and Reagent for the Inhibition of Checkpoint Kinase-1 (CHK)
FILE REFERENCE: MHB00-955-A (400/008)
CURRENT FILING DATE: 2001-02-02
CURRENT APPLICATION NUMBER: US/09/776,474
PRIOR FILING DATE: 2000-03-02
PRIOR APPLICATION NUMBER: US 60/179,983
NUMBER OF SEQ ID NOS: 2992
SOFTWARE: PatentIn version 3.0
SEQ ID NO 76
LENGTH: 17
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-776-474-76

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.7e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 2194 AAAATAGCAGACTTG 2209
Db 2 AAAAUCGACAGCUUG 17

RESULT 201
US-09-776-474-679/c
Sequence 679, Application US/09776474
Publication No. US20030087847A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Jarvis, Thale
APPLICANT: Boober, Robert
APPLICANT: Holman, Patricia
APPLICANT: Fattaey, Ali
APPLICANT: McSwiggen, Jim
TITLE OF INVENTION: Method and Reagent for the Inhibition of Checkpoint Kinase-1 (CHK)
FILE REFERENCE: MHB00-955-A (400/008)
CURRENT FILING DATE: 2001-02-02
CURRENT APPLICATION NUMBER: US/09/776,474
PRIOR FILING DATE: 2000-03-02
PRIOR APPLICATION NUMBER: US 60/179,983
NUMBER OF SEQ ID NOS: 2992
SOFTWARE: PatentIn version 3.0
SEQ ID NO 679
LENGTH: 17
TYPE: RNA
ORGANISM: Artificial Sequence

FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-776-474-679

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2163 AAATGTTTGATACA 2178
Db 17 AAATGTTTGATAAA 2

RESULT 202
US-09-776-474-1087
Sequence 1087, Application US/09776474
Publication No. US20030087847A1

GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Jarvis, Thale
APPLICANT: Boober, Robert
APPLICANT: Holman, Patricia
APPLICANT: Fattaey, Ali
APPLICANT: McSwiggen, Jim
TITLE OF INVENTION: Method and Reagent for the Inhibition of Checkpoint Kinase-1 (CHK)
FILE REFERENCE: MHB00-955-A (400/008)
CURRENT FILING DATE: 2001-02-02
CURRENT APPLICATION NUMBER: US/09/776,474
PRIOR FILING DATE: 2000-03-02
PRIOR APPLICATION NUMBER: US 60/179,983
NUMBER OF SEQ ID NOS: 2992
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1087
LENGTH: 17
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-776-474-1087

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.7e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 2195 AAATAGCAGACTTG 2210
Db 1 AAAUCGACAGCUUG 16

RESULT 203
US-09-930-423-386/c
Sequence 386, Application US/09930423
Publication No. US20030092003A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blatz, Larry
APPLICANT: McSwiggen, Jim
TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
FILE REFERENCE: MHB00-918-A 400/007
CURRENT FILING DATE: 2001-08-15
CURRENT APPLICATION NUMBER: US/09/930,423
NUMBER OF SEQ ID NOS: 4553
SOFTWARE: PatentIn version 3.0
SEQ ID NO 386
LENGTH: 17
TYPE: RNA
ORGANISM: Homo Sapiens
US-09-930-423-386

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1720 CTGGGAGAGCCCTGG 1735
Db 16 CTGGGAGAGCCCTGG 1

RESULT 204
US-09-930-423-660
; Sequence 660, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBB00,918-A 400/027
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 660
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-660

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.7e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

OY 2025 GGAGTACTCTATGAC 2040
Db 2 GGAGTACTCTATGAC 17

RESULT 205
US-09-930-423-1169/c
; Sequence 1169, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBB00,918-A 400/027
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1169
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-1169

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1721 TGGGCAAGCCCTGGG 1736
Db 17 TGGGCAAGCCCTGGG 2

RESULT 206
US-09-780-164-225/c
; Sequence 225, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20

; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 225
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-225

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1362 TGAAGAGAAAGAG 1377
Db 16 TGAAGAGAAAGAG 1

RESULT 207
US-09-780-164-570
; Sequence 570, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 570
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-570

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

OY 1703 CAAGATTAAGCTGAC 1718
Db 1 CAAGATTAAGCTGAC 16

RESULT 208
US-09-780-164-594/c
; Sequence 594, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 594
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens

US-09-780-164-594

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1362 TGAAGAGAGAGAG 1377

DB 17 TGTAGAGAGAGAG 2

RESULT 209

US-09-827-395A-198/C

Sequence 198, Application US/09827395A

Publication No. US20030113891A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Lawrence Blatt

APPLICANT: James McSwigen

APPLICANT: Bharat Chowrira

TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor C

FILE REFERENCE: MEBB00-878-C (400/017)

CURRENT APPLICATION NUMBER: US/09/827,395A

CURRENT FILING DATE: 2001-04-05

PRIOR APPLICATION NUMBER: 09/780,533

PRIOR FILING DATE: 2001-02-09

PRIOR APPLICATION NUMBER: 60/181,797

PRIOR FILING DATE: 2000-02-11

NUMBER OF SEQ ID NOS: 2617

SOFTWARE: PatentIn version 3.0

SEQ ID NO 198

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-09-827-395A-198

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1572 GTCCAGCTCTCCATG 1587

DB 16 GTCCAGCTCTCCAGG 1

RESULT 210

US-09-827-395A-360/C

Sequence 360, Application US/09827395A

Publication No. US20030113891A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Lawrence Blatt

APPLICANT: James McSwigen

APPLICANT: Bharat Chowrira

TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor C

FILE REFERENCE: MEBB00-878-C (400/017)

CURRENT APPLICATION NUMBER: US/09/827,395A

CURRENT FILING DATE: 2001-04-05

PRIOR APPLICATION NUMBER: 09/780,533

PRIOR FILING DATE: 2001-02-09

PRIOR APPLICATION NUMBER: 60/181,797

PRIOR FILING DATE: 2000-02-11

NUMBER OF SEQ ID NOS: 2617

SOFTWARE: PatentIn version 3.0

SEQ ID NO 360

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-09-827-395A-360

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1496 ACTTCAGCAGCCAGCC 1511

DB 17 ACTTCGAGCCAGCC 2

RESULT 211

US-09-827-395A-611/C

Sequence 611, Application US/09827395A

Publication No. US20030113891A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Lawrence Blatt

APPLICANT: James McSwigen

APPLICANT: Bharat Chowrira

TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor C

FILE REFERENCE: MEBB00-878-C (400/017)

CURRENT APPLICATION NUMBER: US/09/827,395A

CURRENT FILING DATE: 2001-04-05

PRIOR APPLICATION NUMBER: 09/780,533

PRIOR FILING DATE: 2001-02-09

PRIOR APPLICATION NUMBER: 60/181,797

PRIOR FILING DATE: 2000-02-11

NUMBER OF SEQ ID NOS: 2617

SOFTWARE: PatentIn version 3.0

SEQ ID NO 611

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-09-827-395A-611

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1573 TCCAGCTCTCCATGA 1588

DB 17 TCCAGCTCTCCAGGA 2

RESULT 212

US-09-827-395A-691/C

Sequence 691, Application US/09827395A

Publication No. US20030113891A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Lawrence Blatt

APPLICANT: James McSwigen

APPLICANT: Bharat Chowrira

TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor C

FILE REFERENCE: MEBB00-878-C (400/017)

CURRENT APPLICATION NUMBER: US/09/827,395A

CURRENT FILING DATE: 2001-04-05

PRIOR APPLICATION NUMBER: 09/780,533

PRIOR FILING DATE: 2001-02-09

PRIOR APPLICATION NUMBER: 60/181,797

PRIOR FILING DATE: 2000-02-11

NUMBER OF SEQ ID NOS: 2617

SOFTWARE: PatentIn version 3.0

SEQ ID NO 691

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-09-827-395A-691

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1496 ACTTCAGCAGCCAGCC 1511

DB 16 ACTTCGAGCCAGCC 1

```
RESULT 213
US-09-740-332-99/c
; Sequence 99, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 99
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-99

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      2452 AACTGACCAACGAAC 2467
DB      16 AACTCCACCAACGATC 1

RESULT 214
US-09-740-332-481/c
; Sequence 481, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 481
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-481

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      2047 CGTGTCTCTGAGGAC 2062
DB      16 CGTGTCTGTTGAGAGC 1

RESULT 215
US-09-740-332-653/c
; Sequence 653, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3135
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
```

```
FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 653
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-653

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1473 GAAGAACCGACCAAG 1488
DB      17 GAAGAACCGAGGAG 2

RESULT 216
US-09-740-332-1421/c
; Sequence 1421, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1421
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1421

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1737 AGAAGTTGCTTTGGG 1752
DB      16 AGAAGGCTGCTTTGGG 1

RESULT 217
US-09-740-332-3135
; Sequence 3135, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3135
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
```

FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3135

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.7e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

OY 1737 AGAGGCTGCTTGGG 1752
DB 1 AGAGGGGUGCUUGGG 16

RESULT 218
US-09-740-332-3902
Sequence 3902, Application US/09740332
Publication No. US20030125270A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
FILE REFERENCE: RPI 400/003
CURRENT APPLICATION NUMBER: US/09/740,332
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9704
SOFTWARE: PatentIn version 3.0
SEQ ID NO 3902
LENGTH: 17
TYPE: RNA
ORGANISM: artificial sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3902

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1473 GAGAGACGACGACGAG 1488
DB 2 GAGAGACGACGAGGAG 17

RESULT 219
US-09-740-332-4457
Sequence 4457, Application US/09740332
Publication No. US20030125270A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
FILE REFERENCE: RPI 400/003
CURRENT APPLICATION NUMBER: US/09/740,332
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9704
SOFTWARE: PatentIn version 3.0
SEQ ID NO 4457
LENGTH: 17
TYPE: RNA
ORGANISM: artificial sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-4457

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1.7e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

OY 2454 CTGGACCAACGAACTG 2469
DB 1 CUCGACCAACGAACTG 16

RESULT 220
US-09-745-237A-386/C
Sequence 386, Application US/09745237A
Publication No. US20030143708A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blatt, Larry
APPLICANT: McSwiggen, Jim
TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
FILE REFERENCE: 400/007 (MBH00-918-A)
CURRENT APPLICATION NUMBER: US/09/745,237A
CURRENT FILING DATE: 2002-04-15
NUMBER OF SEQ ID NOS: 4550
SOFTWARE: PatentIn version 3.0
SEQ ID NO 386
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-745-237A-386

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1720 CTGGGCAAGCCCGCTGG 1735
DB 16 CTGGGCAAGCCCGCG 1

RESULT 221
US-09-745-237A-660
Sequence 660, Application US/09745237A
Publication No. US20030143708A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blatt, Larry
APPLICANT: McSwiggen, Jim
TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
FILE REFERENCE: 400/007 (MBH00-918-A)
CURRENT APPLICATION NUMBER: US/09/745,237A
CURRENT FILING DATE: 2002-04-15
NUMBER OF SEQ ID NOS: 4550
SOFTWARE: PatentIn version 3.0
SEQ ID NO 660
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-745-237A-660

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.7e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

OY 2025 GGAGTACTCCATGAC 2040
DB 2 GGAGTACACUAGAC 17

RESULT 222
US-09-745-237A-1169/C
Sequence 1169, Application US/09745237A
Publication No. US20030143708A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blatt, Larry
APPLICANT: McSwiggen, Jim
TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease

```

; FILE REFERENCE: 400/007 (MBHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745, 237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1169
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-1169

Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1721 TGGGCAAGCCCTGGG 1736
Db      17 TGGGCGACGCCCGGG 2

RESULT 223
US-09-792-818-283/c
; Sequence 283, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlwiltz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Inse
; TITLE OF INVENTION: (GRID) Gene
; FILE REFERENCE: MBHB00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792, 818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 283
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-283

Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1869 GTCAGAGTGGAGAG 1884
Db      17 GACAGAGATGGAGAG 2

RESULT 224
US-10-238-700-661
; Sequence 661, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBHB01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238, 700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318, 471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 661
; LENGTH: 17
; TYPE: RNA

; ORGANISM: Homo sapiens
US-10-238-700-661

Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.7e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      1512 GGCTGTGCACAAGCTG 1527
Db      2 GGCTGTGCACAAGCTG 1527

; ORGANISM: Homo sapiens
US-10-238-700-661

Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.7e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      2151 TTTAGCAGCCGAGAAAT 2166
Db      2 UUUAGUAAACCAGAAAU 17

RESULT 225
US-10-238-700-944
; Sequence 944, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBHB01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238, 700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318, 471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 944
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-944

Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      2190 GATGAATAATGACAGAC 2205
Db      2 GAAGAAUUAUACGAGAC 17

RESULT 226
US-10-238-700-3208
; Sequence 3208, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBHB01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238, 700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318, 471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3208
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-3208

Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.7e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      1512 GGCTGTGCACAAGCTG 1527
Db      2 GGCTGTGCACAAGCTG 1527
```

Db 1 GGCTUGGACAGACUG 16

RESULT 227

US-10-238-700-3544/c

Sequence 3544, Application US/10238700

Publication No. US20030153521A1

GENERAL INFORMATION:

APPLICANT: MGSWIGEN, James

TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level

FILE REFERENCE: 400/057 (MBH01-1158-A)

CURRENT APPLICATION NUMBER: US/10/238,700

PRIOR FILING DATE: 2002-09-18

PRIOR APPLICATION NUMBER: PCT/US 02/16640

PRIOR FILING DATE: 2002-05-29

PRIOR APPLICATION NUMBER: US 60/318,471

PRIOR FILING DATE: 2001-09-10

NUMBER OF SEQ ID NOS: 4666

SOFTWARE: PatentIn version 3.0

SEQ ID NO 3544

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-10-238-700-3544

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2393 TTCCCGTGAGGACT 2408

Db 17 TTCCCGTCTGGAAT 2

RESULT 228

US-10-253-904-31/c

Sequence 31, Application US/10253904

Publication No. US20030158135A1

GENERAL INFORMATION:

APPLICANT: EL SOLH, NEVINE

TITLE OF INVENTION: POLYNUCLEOTIDES AND THEIR USE FOR DETECTING RESISTANCE

TITLE OF INVENTION: TO STREPTOGRAMIN A OR TO STREPTOGRAMIN B AND RELATED

TITLE OF INVENTION: COMPOUNDS

FILE REFERENCE: 03715-0059

CURRENT APPLICATION NUMBER: US/10/253,904

CURRENT FILING DATE: 2002-09-25

NUMBER OF SEQ ID NOS: 51

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 31

LENGTH: 17

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Primer

US-10-253-904-31

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1741 GGTTCCTTTGGCAG 1756

Db 17 GGTTCCTTTGCCAAG 2

RESULT 229

US-10-061-201-121/c

Sequence 121, Application US/10061201

Publication No. US20030166229A1

GENERAL INFORMATION:

APPLICANT: Shannon, Mark

TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1

FILE REFERENCE: PB0178

CURRENT APPLICATION NUMBER: US/10/061,201

PRIOR FILING DATE: 2002-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00670

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: US 09/864,761

PRIOR FILING DATE: 2001-05-23

PRIOR APPLICATION NUMBER: US 60/328,205

PRIOR FILING DATE: 2001-10-10

NUMBER OF SEQ ID NOS: 4162

SOFTWARE: Neomica Sequence Listing Engine

SEQ ID NO 121

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-10-061-201-121

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1565 CGGCTGAGTCAGCTC 1580

Db 17 CTGCTGAGTCAGCTC 2

RESULT 230

US-10-061-201-124/c

Sequence 124, Application US/10061201

Publication No. US20030166229A1

GENERAL INFORMATION:

APPLICANT: Shannon, Mark

TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1

FILE REFERENCE: PB0178

CURRENT APPLICATION NUMBER: US/10/061,201

CURRENT FILING DATE: 2002-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00670

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: US 09/864,761

PRIOR FILING DATE: 2001-05-23

PRIOR APPLICATION NUMBER: US 60/328,205

PRIOR FILING DATE: 2001-10-10

NUMBER OF SEQ ID NOS: 4162

SOFTWARE: Neomica Sequence Listing Engine

SEQ ID NO 124
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-061-201-124

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1563 TTCGCTGAGTCCAGC 1578
DB 16 TTCGCTGAGTCCAGC 1

RESULT 231
US-09-817-879-99/c
Sequence 99, Application US/09817879
Publication No. US20030171311A1

GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
FILE REFERENCE: MBHB00-801-F
CURRENT APPLICATION NUMBER: US/09/817,879
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9703
SOFTWARE: PatentIn version 3.0
SEQ ID NO 99
LENGTH: 17
TYPE: RNA
ORGANISM: artificial sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-99

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2452 AACTGCACCAACGAC 2467
DB 16 AACTGCACCAACGAC 1

RESULT 232
US-09-817-879-481/c
Sequence 481, Application US/09817879
Publication No. US20030171311A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
FILE REFERENCE: MBHB00-801-F
CURRENT APPLICATION NUMBER: US/09/817,879
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9703
SOFTWARE: PatentIn version 3.0
SEQ ID NO 481
LENGTH: 17
TYPE: RNA
ORGANISM: artificial sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-481

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2047 CGTGCTCTGAGGAGC 2062
DB 16 CGTGCTCTGAGGAGC 1

RESULT 233
US-09-817-879-653/c
Sequence 653, Application US/09817879
Publication No. US20030171311A1

GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
FILE REFERENCE: MBHB00-801-F
CURRENT APPLICATION NUMBER: US/09/817,879
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9703
SOFTWARE: PatentIn version 3.0
SEQ ID NO 653
LENGTH: 17
TYPE: RNA
ORGANISM: artificial sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-653

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1473 GAGACACGACCAAG 1488
DB 17 GAGACACGACCAAG 2

RESULT 234
US-09-817-879-1421/c
Sequence 1421, Application US/09817879
Publication No. US20030171311A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
FILE REFERENCE: MBHB00-801-F
CURRENT APPLICATION NUMBER: US/09/817,879
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9703
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1421
LENGTH: 17
TYPE: RNA
ORGANISM: artificial sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1421

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1737 AGAGGCTGCTTGGG 1752
DB 16 AGAGGCTGCTTGGG 1

RESULT 235
US-09-817-879-3135
Sequence 3135, Application US/09817879

```
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3135
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3135

Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.7e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy      1737 AGAAGTGTCTTGGG 1752
Db      1 AGGAGGUGUCUUGGG 16

RESULT 236
US-09-817-879-3902
; Sequence 3902, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3902
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3902

Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1473 GAAGAACGACGACGAG 1488
Db      2 GAAGAACGACGACGAG 17

RESULT 237
US-09-817-879-4457
; Sequence 4457, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
```

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4457
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-4457

Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1.7e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy      2454 CTGCACCAACGACTG 2469
Db      1 CUCCACCAACGACUUG 16

RESULT 238
US-10-392-970-29/c
; Sequence 29, Application US/10392970
; Publication No. US20030176679A1
; GENERAL INFORMATION:
; APPLICANT: Eli Lilly, Nevine
; TITLE OF INVENTION: POLYNUCLEOTIDES AND THEIR USE FOR DETECTING RESISTANCE
; FILE REFERENCE: TO STREPTOGRAMIN A OR TO STREPTOGRAMIN B AND RELATED
; CURRENT APPLICATION NUMBER: US/10/392,970
; CURRENT FILING DATE: 2003-03-21
; PRIOR APPLICATION NUMBER: US/09/099,932
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/050,380
; PRIOR FILING DATE: EARLIER FILING DATE: 1997-06-20
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 29
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-392-970-29

Query Match          0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1741 GGTGCTTGGGCAAG 1756
Db      17 GGTGCTTGGGCAAG 2

RESULT 239
US-10-339-793-443/c
; Sequence 443, Application US/10339793
; Publication No. US20030180764A1
; GENERAL INFORMATION:
; APPLICANT: Lynx Therapeutics, Inc.
; APPLICANT: Bowen, Jin
; TITLE OF INVENTION: GENES AFFECTED BY CHOLESTEROL TREATMENT AND DURING ADIPOGENESIS
; FILE REFERENCE: 37-000310US
; CURRENT APPLICATION NUMBER: US/10/339,793
; CURRENT FILING DATE: 2003-01-08
; NUMBER OF SEQ ID NOS: 443
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 443
; LENGTH: 17
; TYPE: DNA
```

```
; ORGANISM: Homo sapiens
US-10-339-793-443

Query Match
Best Local Similarity 87.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2238 CTATTACAAAAGACC 2253
Db 16 CTTTACAAAAGATC 1

RESULT 240
US-10-209-787-1759
; Sequence 1759, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO: 1759
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-1759

Query Match
Best Local Similarity 87.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1880 AGATGATGAGATGAT 1895
Db 1 AGATGATTCAGATGAT 16

RESULT 241
US-10-209-787-1760/C
; Sequence 1760, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
```

```
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO: 1760
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-1760

Query Match
Best Local Similarity 87.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1880 AGATGATGAGATGAT 1895
Db 17 AGATGATTCAGATGAT 2

RESULT 242
US-10-209-787-3314
; Sequence 3314, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO: 3314
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3314

Query Match
Best Local Similarity 87.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1686 CCCAAATGGAGTTT 1701
Db 1 CCCAAATGGAGTTT 16

RESULT 243
US-10-209-787-3315/C
; Sequence 3315, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
```

;; PRIOR FILING DATE: 2001-03-27
;; PRIOR APPLICATION NUMBER: US 60/192,176
;; PRIOR FILING DATE: 2000-03-27
;; PRIOR APPLICATION NUMBER: US 60/192,179
;; PRIOR FILING DATE: 2000-03-27
;; PRIOR APPLICATION NUMBER: US 60/208,538
;; PRIOR FILING DATE: 2000-06-01
;; PRIOR APPLICATION NUMBER: US 60/244,989
;; PRIOR FILING DATE: 2000-10-30
;; NUMBER OF SEQ ID NOS: 4385
;; SOFTWARE: Friedman macro Napro4
;; SEQ ID NO: 3315
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-209-787-3315

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 1686 CCCAAATGGAGCTT 1701
Db 17 CCCAATTGGCTTT 2

RESULT 244
US-10-060-830-700/c

;; Sequence 700, Application US/10060830
;; Publication No. US20030032154A1
;; GENERAL INFORMATION:
;; APPLICANT: Gu, Yizhong
;; APPLICANT: Nguyen, Cung-Thuong
;; TITLE OF INVENTION: HUMAN LCLL DOMAIN CONTAINING PROTEIN
;; FILE REFERENCE: PB0169
;; CURRENT FILING DATE: 2002-01-30
;; PRIOR FILING DATE: 2002-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 09/864,761
;; PRIOR FILING DATE: 2001-05-23
;; PRIOR APPLICATION NUMBER: US 60/325,062
;; PRIOR FILING DATE: 2001-09-25
;; NUMBER OF SEQ ID NOS: 1123
;; SOFTWARE: Aecomica Sequence Listing Engine
;; SEQ ID NO: 700
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-060-830-700

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 2054 CTGAGAGCAGATGAC 2069
Db 17 CTGAGAGCAGCTGTC 2

RESULT 245
US-10-060-830-701/c
;; Sequence 701, Application US/10060830

;; Publication No. US20030032154A1
;; GENERAL INFORMATION:
;; APPLICANT: Gu, Yizhong
;; APPLICANT: Nguyen, Cung-Thuong
;; TITLE OF INVENTION: HUMAN LCLL DOMAIN CONTAINING PROTEIN
;; FILE REFERENCE: PB0169
;; CURRENT FILING DATE: 2002-01-30
;; PRIOR FILING DATE: 2002-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 09/864,761
;; PRIOR FILING DATE: 2001-05-23
;; PRIOR APPLICATION NUMBER: US 60/325,062
;; PRIOR FILING DATE: 2001-09-25
;; NUMBER OF SEQ ID NOS: 1123
;; SOFTWARE: Aecomica Sequence Listing Engine
;; SEQ ID NO: 701
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-060-830-701

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 2054 CTGAGAGCAGATGAC 2069
Db 16 CTGAGAGCAGCTGTC 1

RESULT 246
US-10-060-756A-144

;; Sequence 144, Application US/10060756A
;; Publication No. US20030046717A1
;; GENERAL INFORMATION:
;; APPLICANT: Zhang, Jian
;; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
;; FILE REFERENCE: PB0177
;; CURRENT FILING DATE: 2002-01-30
;; PRIOR FILING DATE: 2002-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 09/864,761
;; PRIOR FILING DATE: 2001-05-23
;; PRIOR APPLICATION NUMBER: US 60/327,898
;; PRIOR FILING DATE: 2001-10-09
;; NUMBER OF SEQ ID NOS: 4804
;; SOFTWARE: Aecomica Sequence Listing Engine
;; SEQ ID NO: 144
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens

US-10-060-756A-144

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1518 GCACAGCTGACCAAA 1533

Db 2 GCCCAGCTCACCANA 17

RESULT 247

US-10-060-756A-146

; Sequence 146; Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 146
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-146

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1519 CACAAGCTGACCAAC 1534

Db 1 CCCAAGCTCACCANA 16

RESULT 248

US-10-060-756A-1675/C

; Sequence 1675; Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: US 09/864,761

PRIOR FILING DATE: 2001-05-23

PRIOR APPLICATION NUMBER: US 60/327,898

PRIOR FILING DATE: 2001-10-09

NUMBER OF SEQ ID NOS: 4804

SOFTWARE: Aeomica Sequence Listing Engine

SEQ ID NO 1675

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-10-060-756A-1675

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2187 TGTGATGAATAAGCA 2202

Db 17 TGTATATAAATAGCA 2

RESULT 249

US-10-060-756A-1677/C

; Sequence 1677; Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1677
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1677

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2186 ATGTGATGAATAAGC 2201

Db 16 ATGTATATAAATAGC 1

RESULT 250

US-10-060-998-588/C

; Sequence 588; Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong

```

; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 588
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-588

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1692 ATGGAGTTCCACAA 1707
Db 17 ATGGCAGTCCCAAGA 2

RESULT 251
US-10-060-998-589/c
; Sequence 589, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 589
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-589

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1692 ATGGAGTTCCACAA 1707
Db 16 ATGGCAGTCCCAAGA 1

RESULT 252
US-10-163-552-677
; Sequence 677, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; TITLE OF INVENTION: HER2
; FILE REFERENCE: MHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
```

```

; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 677
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-677

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 2317 CATCAGATGATGCT 2332
Db 2 CACCAAGAGUAGUGUU 17

RESULT 253
US-10-163-552-935/c
; Sequence 935, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; TITLE OF INVENTION: HER2
; FILE REFERENCE: MHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 935
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-935

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2701 CCTCAGATCCACAA 2716
Db 17 CCTCAGATCCACAA 2

RESULT 254
US-10-156-306-228/c
; Sequence 228, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 228
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-228

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2645 CTTGAGATGATGATTC 2660
Db 17 CTTGAGATGATGATTC 2
```

```
RESULT 255
US-10-156-306-364
; Sequence 364, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 364
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-364

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2200 GCAGACTTGGACTCG 2215
Db 1 GGAGACUUGGACUUG 17

RESULT 256
US-10-156-306-365
; Sequence 365, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 365
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-365

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2200 GCAGACTTGGACTCG 2215
Db 1 GGAGACUUGGACUUG 16

RESULT 257
US-10-156-306-1457/C
; Sequence 1457, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 1457
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-1457

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2645 CTTGAGAGATGATTC 2660
Db 16 CTTGAGATGATTC 1

RESULT 258
US-10-156-306-1545
; Sequence 1545, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1545
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-1545

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2198 TAGCAGACTTGGACT 2213
Db 1 UUGAGACUUGGACU 16

RESULT 259
US-10-156-306-2834
; Sequence 2834, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2834
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-2834

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2197 ATAGCAGACTTGGAC 2212
Db 2 AUGCAGACUUGGAC 17
```

```
RESULT 260
US-10-156-306-4426
; Sequence 4426, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 4426
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4426

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1574 CCAGCTCCTCCATGAA 1589
DB 1 CCAGCTCCTCCATGAA 16

RESULT 261
US-10-156-306-4950
; Sequence 4950, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 4950
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4950

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 17;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1574 CCAGCTCCTCCATGAA 1589
DB 2 CCAGCTCCTCCATGAA 17

RESULT 262
US-09-263-959-616
; Sequence 616, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESS: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
```

```
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Mcmasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 616:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-263-959-616

Query Match
Best Local Similarity 0.9%; Score 12.4; DB 1; Length 14;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1882 ATGATGATGATGAT 1895
DB 1 ATGATGATGATGAT 14
```

```
RESULT 263
US-09-263-959-638
; Sequence 638, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESS: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Mcmasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 638:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
```

TOPOLOGY: linear
US-09-263-959-638

Query Match
Best Local Similarity 92.9%; Score 12.4; DB 1; Length 14;
Matches 13; Conservative 0; Pred. No. 1.3e+02; Mismatches 1; Indels 0; Gaps 0;

Qy 1882 ATGATGAAGATGAT 1895
Db 1 ATGATGAAGATGAT 14

RESULT 264
US-10-077-508-3

Sequence 3, Application US/10077508
Publication No. US20030138784A1
GENERAL INFORMATION:
APPLICANT: SYKES, KATHRYN F.
APPLICANT: JOHNSTON, STEPHEN A.
TITLE OF INVENTION: LINEAR AND CIRCULAR EXPRESSION ELEMENTS
FILE REFERENCE: UTSID:557
CURRENT FILING DATE: 2002-02-15
CURRENT APPLICATION NUMBER: 09/535,366
PRIOR FILING DATE: 2000-03-24
PRIOR APPLICATION NUMBER: 60/125,864
NUMBER OF SEQ ID NOS: 5
SOFTWARE: Patent In Ver. 2.1
SEQ ID NO 3
LENGTH: 14
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: Primer
US-10-077-508-3

Query Match
Best Local Similarity 64.3%; Score 12.4; DB 1; Length 14;
Matches 9; Conservative 4; Pred. No. 1.3e+02; Mismatches 1; Indels 0; Gaps 0;

Qy 1882 ATGATGAAGATGAT 1895
Db 1 AUGAUGAUGAUGAU 14

RESULT 265
US-10-077-508-5/C

Sequence 5, Application US/10077508
Publication No. US20030138784A1
GENERAL INFORMATION:
APPLICANT: SYKES, KATHRYN F.
APPLICANT: JOHNSTON, STEPHEN A.
TITLE OF INVENTION: LINEAR AND CIRCULAR EXPRESSION ELEMENTS
FILE REFERENCE: UTSID:557
CURRENT FILING DATE: 2002-02-15
CURRENT APPLICATION NUMBER: 09/535,366
PRIOR FILING DATE: 2000-03-24
PRIOR APPLICATION NUMBER: 60/125,864
NUMBER OF SEQ ID NOS: 5
SOFTWARE: Patent In Ver. 2.1
SEQ ID NO 5
LENGTH: 14
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: Primer
US-10-077-508-5

Query Match
Best Local Similarity 92.9%; Score 12.4; DB 1; Length 14;
Matches 13; Conservative 0; Pred. No. 1.3e+02; Mismatches 1; Indels 0; Gaps 0;

Qy 1882 ATGATGAAGATGAT 1895
Db 14 ATGATGAAGATGAT 1

RESULT 266
US-10-277-494-74

Sequence 74, Application US/10277494
Publication No. US20030186903A1
GENERAL INFORMATION:
APPLICANT: McSwiggen, Jim
APPLICANT: Ribozyme Pharmaceuticals, Inc.
TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
FILE REFERENCE: MBH00-958-K (400/064)
CURRENT FILING DATE: 2002-10-21
CURRENT APPLICATION NUMBER: US/10/277,494
NUMBER OF SEQ ID NOS: 446
SOFTWARE: Patent In version 3.0
SEQ ID NO 74
LENGTH: 14
TYPE: RNA
ORGANISM: Homo sapiens
US-10-277-494-74

Query Match
Best Local Similarity 71.4%; Score 12.4; DB 1; Length 14;
Matches 10; Conservative 3; Pred. No. 1.3e+02; Mismatches 1; Indels 0; Gaps 0;

Qy 2317 CATCAGATGATGT 2330
Db 1 CACCAGAGUAGU 14

RESULT 267
US-10-077-621-3

Sequence 3, Application US/10077621
Publication No. US20020146733A1
GENERAL INFORMATION:
APPLICANT: SYKES, KATHRYN F.
APPLICANT: JOHNSTON, STEPHEN A.
TITLE OF INVENTION: LINEAR AND CIRCULAR EXPRESSION ELEMENTS
FILE REFERENCE: UTSID:557
CURRENT FILING DATE: 2002-02-15
CURRENT APPLICATION NUMBER: 09/535,366
PRIOR FILING DATE: 2000-03-24
PRIOR APPLICATION NUMBER: 60/125,864
NUMBER OF SEQ ID NOS: 5
SOFTWARE: Patent In Ver. 2.1
SEQ ID NO 3
LENGTH: 14
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: Primer
US-10-077-621-3

Query Match
Best Local Similarity 64.3%; Score 12.4; DB 1; Length 14;
Matches 9; Conservative 4; Pred. No. 1.3e+02; Mismatches 1; Indels 0; Gaps 0;

Qy 1882 ATGATGAAGATGAT 1895
Db 1 AUGAUGAUGAUGAU 14

```
RESULT 268
US-10-077-621-5/c
; Sequence 5, Application US/10077621
; Publication No. US20020146733A1
; GENERAL INFORMATION:
; APPLICANT: SYKES, KATHRYN F.
; APPLICANT: JOHNSTON, STEPHEN A.
; TITLE OF INVENTION: LINEAR AND CIRCULAR EXPRESSION ELEMENTS
; FILE REFERENCE: UTSD:557
; CURRENT APPLICATION NUMBER: US/10/077,621
; CURRENT FILING DATE: 2002-02-15
; PRIOR APPLICATION NUMBER: 09/535,366
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: 60/125,864
; PRIOR FILING DATE: 1999-03-24
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Primer
US-10-077-621-5

Query Match          0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      1882 ATGATGAAGATGAT 1895
DB      14 ATGATGATGATGAT 1

RESULT 269
US-10-077-232-3
; Sequence 3, Application US/10077232
; Publication No. US20020150940A1
; GENERAL INFORMATION:
; APPLICANT: SYKES, KATHRYN F.
; APPLICANT: JOHNSTON, STEPHEN A.
; TITLE OF INVENTION: LINEAR AND CIRCULAR EXPRESSION ELEMENTS
; FILE REFERENCE: UTSD:557
; CURRENT APPLICATION NUMBER: US/10/077,232
; CURRENT FILING DATE: 2002-02-15
; PRIOR APPLICATION NUMBER: 09/535,366
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: 60/125,864
; PRIOR FILING DATE: 1999-03-24
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Primer
US-10-077-232-3

Query Match          0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 64.3%; Pred. No. 1.3e+02;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

OY      1882 ATGATGAAGATGAT 1895
DB      1 AUGAUGAUGAUGAU 14

RESULT 270
US-10-077-232-5/c
; Sequence 5, Application US/10077232
```

```
; Publication No. US20020150940A1
; GENERAL INFORMATION:
; APPLICANT: SYKES, KATHRYN F.
; APPLICANT: JOHNSTON, STEPHEN A.
; TITLE OF INVENTION: LINEAR AND CIRCULAR EXPRESSION ELEMENTS
; FILE REFERENCE: UTSD:557
; CURRENT APPLICATION NUMBER: US/10/077,232
; CURRENT FILING DATE: 2002-02-15
; PRIOR APPLICATION NUMBER: 09/535,366
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: 60/125,864
; PRIOR FILING DATE: 1999-03-24
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Primer
US-10-077-232-5

Query Match          0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      1882 ATGATGAAGATGAT 1895
DB      14 ATGATGATGATGAT 1

RESULT 271
US-10-077-247-3
; Sequence 3, Application US/10077247
; Publication No. US20020155508A1
; GENERAL INFORMATION:
; APPLICANT: SYKES, KATHRYN F.
; APPLICANT: JOHNSTON, STEPHEN A.
; TITLE OF INVENTION: LINEAR AND CIRCULAR EXPRESSION ELEMENTS
; FILE REFERENCE: UTSD:557
; CURRENT APPLICATION NUMBER: US/10/077,247
; CURRENT FILING DATE: 2002-02-15
; PRIOR APPLICATION NUMBER: 09/535,366
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: 60/125,864
; PRIOR FILING DATE: 1999-03-24
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Primer
US-10-077-247-3

Query Match          0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 64.3%; Pred. No. 1.3e+02;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

OY      1882 ATGATGAAGATGAT 1895
DB      1 AUGAUGAUGAUGAU 14

RESULT 272
US-10-077-247-5/c
; Sequence 5, Application US/10077247
; Publication No. US20020155508A1
; GENERAL INFORMATION:
; APPLICANT: SYKES, KATHRYN F.
```

```

; APPLICANT: JOHNSTON, STEPHEN A.
; TITLE OF INVENTION: LINEAR AND CIRCULAR EXPRESSION ELEMENTS
; FILE REFERENCE: UTSD:557
; CURRENT APPLICATION NUMBER: US/10/077,247
; PRIOR FILING DATE: 2002-02-15
; PRIOR APPLICATION NUMBER: 09/535,366
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: 60/125,864
; PRIOR FILING DATE: 1999-03-24
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: Patentln Ver. 2.1
; SEQ ID NO 5
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Primer
US-10-077-247-5

Query Match          0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1882 ATGATGAAGATGAT 1895
DB      14 ATGATGATGATGAT 1

RESULT 273
US-10-077-392-3
; Sequence 3, Application US/10077392
; Publication No. US20020160402A1
; GENERAL INFORMATION:
; APPLICANT: SYKES, KATHRYN F.
; APPLICANT: JOHNSTON, STEPHEN A.
; TITLE OF INVENTION: LINEAR AND CIRCULAR EXPRESSION ELEMENTS
; FILE REFERENCE: UTSD:557
; CURRENT APPLICATION NUMBER: US/10/077,392
; CURRENT FILING DATE: 2002-02-15
; PRIOR APPLICATION NUMBER: 09/535,366
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: 60/125,864
; PRIOR FILING DATE: 1999-03-24
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: Patentln Ver. 2.1
; SEQ ID NO 3
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Primer
US-10-077-392-3

Query Match          0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 64.3%; Pred. No. 1.3e+02;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      1882 ATGATGAAGATGAT 1895
DB      1 AUGAUGAUGAUGAU 14

RESULT 274
US-10-077-392-5/C
; Sequence 5, Application US/10077392
; Publication No. US20020160402A1
; GENERAL INFORMATION:
; APPLICANT: SYKES, KATHRYN F.
; APPLICANT: JOHNSTON, STEPHEN A.
; TITLE OF INVENTION: LINEAR AND CIRCULAR EXPRESSION ELEMENTS
; FILE REFERENCE: UTSD:557
```

```

; CURRENT APPLICATION NUMBER: US/10/077,392
; CURRENT FILING DATE: 2002-02-15
; PRIOR APPLICATION NUMBER: 09/535,366
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: 60/125,864
; PRIOR FILING DATE: 1999-03-24
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: Patentln Ver. 2.1
; SEQ ID NO 5
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Primer
US-10-077-392-5

Query Match          0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1882 ATGATGAAGATGAT 1895
DB      14 ATGATGATGATGAT 1

RESULT 275
US-09-771-933-174/C
; Sequence 174, Application US/09771933
; Publication No. US20030023387A1
; GENERAL INFORMATION:
; APPLICANT: Gill-Garrison, Rosalynn D
; APPLICANT: Martin, Christopher J
; APPLICANT: Sanchez-Felix, Manuel V
; TITLE OF INVENTION: Computer-assisted Means for Assessing Lifestyle Risk
; TITLE OF INVENTION: Factors
; FILE REFERENCE: 620-130
; CURRENT APPLICATION NUMBER: US/09/771,933
; CURRENT FILING DATE: 2001-01-30
; NUMBER OF SEQ ID NOS: 205
; SOFTWARE: Patentln Ver. 2.1
; SEQ ID NO 174
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Probe
; OTHER INFORMATION: Primer
US-09-771-933-174

Query Match          0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1880 AGATGATGAAGATG 1893
DB      14 AGATGATGAAGATG 1

RESULT 276
US-09-848-754A-9628
; Sequence 9628, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
; FILE REFERENCE: MHB00-958-1 (400/018) 754A
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: Patentln version 3.0
; SEQ ID NO 9628
; LENGTH: 15
```

TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Enzymatic Nucleic acid
US-09-848-754A-9628

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 1.5e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2317 CATCAGAGTGTGT 2330
|||
Db 2 CACGAGAGGAGUGU 15

RESULT 277
US-09-943-983-157/c
Sequence 157, Application US/09943983
Publication No. US2003007575A1
GENERAL INFORMATION:

APPLICANT: STUYVER, LIEVEN
LOUWAGIE, JOOST
ROSSAU, RUDI

TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED
MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE

NUMBER OF SEQUENCES: 164

CORRESPONDENCE ADDRESS:

ADDRESSEE: ARNOLD, WHITE & DURKEE
STREET: P.O. BOX 4433
CITY: HOUSTON
STATE: TEXAS
COUNTRY: USA
ZIP: 77210-4433

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Microsoft Word 6.0 / ASCII text output

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/943,983
FILING DATE: 31-Aug-2001

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/913,833
FILING DATE: 1997-09-15

APPLICATION NUMBER: EP 96870005.4
FILING DATE: 26 Jan 1996

APPLICATION NUMBER: EP 96870081.5
FILING DATE: 25 Jun 1996

ATTORNEY/AGENT INFORMATION:
NAME: KAMMERER, PATRICIA A.

REGISTRATION NUMBER: 29,775

REFERENCE/DOCKET NUMBER: INNS:008

INFORMATION FOR SEQ ID NO: 157:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

HYPOTHETICAL: NO

ANTI-SENSE: NO

SEQUENCE DESCRIPTION: SEQ ID NO: 157:

US-09-943-983-157

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1856 TTTCTGATCTGCTG 1869
|||
Db 14 TTTTGTATCTGCTG 1

RESULT 278
US-10-277-494-57

Sequence 57, Application US/10277494

Publication No. US20030186909A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: McSwigen, Jim

TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or conditions Related To level

FILE REFERENCE: MBH00-958-K (400/064)

CURRENT APPLICATION NUMBER: US/10/277,494

CURRENT FILING DATE: 2002-10-21

NUMBER OF SEQ ID NOS: 446

SOFTWARE: PatentIn version 3.0

SEQ ID NO 57

LENGTH: 15

TYPE: RNA

ORGANISM: Homo sapiens

US-10-277-494-57

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 1.5e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2317 CATCAGAGTGTGT 2330
|||
Db 2 CACGAGAGGAGUGU 15

RESULT 279
US-10-440-850-911/c

Sequence 911, Application US/10440850

Publication No. US20030207837A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Stinchcomb, Dan

APPLICANT: Jarvis, Thale

TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Rever

FILE REFERENCE: 250/130 (MBH00-900-A)

CURRENT APPLICATION NUMBER: US/10/440,850

CURRENT FILING DATE: 2003-05-19

PRIOR APPLICATION NUMBER: US/09/650,012

PRIOR FILING DATE: 2000-08-28

PRIOR APPLICATION NUMBER: US 08/585,684

PRIOR FILING DATE: 1996-01-12

PRIOR APPLICATION NUMBER: US 60/000,951

PRIOR FILING DATE: 1995-07-07

PRIOR APPLICATION NUMBER: US 09/038,073

PRIOR FILING DATE: 1998-03-11

NUMBER OF SEQ ID NOS: 2285

SOFTWARE: PatentIn version 3.0

SEQ ID NO 911

LENGTH: 15

TYPE: RNA

ORGANISM: Homo sapiens

US-10-440-850-911

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1887 GAAGTATGATGCGA 1900
|||
Db 14 GAAGTATGATGCGA 1

RESULT 280
US-10-097-175-50

Sequence 50, Application US/10097175
Publication No. US20030045680A1
GENERAL INFORMATION:

US-10-097-175-50

APPLICANT: JOVAL, JOHN L.
APPLICANT: MUELLER, JOHN
APPLICANT: OZA, VIBHA B.
APPLICANT: FINDERS, MARK A.
TITLE OF INVENTION: PEPTIDIC MODULATORS OF THE ANDROGEN RECEPTOR
FILE REFERENCE: PPI-110
CURRENT APPLICATION NUMBER: US/10/097,175
CURRENT FILING DATE: 2002-03-12
PRIOR APPLICATION NUMBER: 60/275,240
PRIOR FILING DATE: 2001-03-12
PRIOR APPLICATION NUMBER: 60/352,399
PRIOR FILING DATE: 2002-01-28
NUMBER OF SEQ ID NOS: 102
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 50
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Androgen Responsive Element
US-10-097-175-50

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2633 GAAGTTCTGTCT 2646
DB 2 GAAGTTCTGTCT 15

RESULT 281
US-10-010-802-192
Sequence 192, Application US/10010802
Publication No. US20030078220A1
GENERAL INFORMATION:
APPLICANT: Genesee Pharmaceuticals
APPLICANT: Chew, Anne
APPLICANT: Denton, R. Rex
APPLICANT: Duda, Amy
APPLICANT: Nandabalan, Krishnan
APPLICANT: Stephens, J. Claiborne
APPLICANT: Windemuth, Andreas
TITLE OF INVENTION: Drug Target Isogenes: Polymorphisms in the Interleukin
FILE REFERENCE: MMH-0002US2 IL4R alpha
CURRENT FILING DATE: 2001-11-09
PRIOR APPLICATION NUMBER: PCT/US00/19094
PRIOR FILING DATE: 2000-07-13
NUMBER OF SEQ ID NOS: 413
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 192
LENGTH: 15
TYPE: DNA
ORGANISM: Homo sapiens
US-10-010-802-192

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1543 CTGCGAGACAGGT 1556
DB 1 CTGCGAGACAGGT 14

RESULT 282
US-10-287-919-2272/c
Sequence 2272, Application US/10287919
Publication No. US20030085830A1
GENERAL INFORMATION:
APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.

TITLE OF INVENTION: Methanococcus jannaschii complete genome.
FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
CURRENT APPLICATION NUMBER: US/10/287,919
CURRENT FILING DATE: 2002-11-05
NUMBER OF SEQ ID NOS: 2706
SOFTWARE: Proprietary
SEQ ID NO 2272
LENGTH: 15
TYPE: DNA
ORGANISM: Methanococcus jannaschii complete genome.
FEATURE:
LOCATION: (1403144)...(1403158)
OTHER INFORMATION: Chromosome = 1 Strand = positive ConnectorObjectNumber = 2902
US-10-287-919-2272

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2237 ACTATTACAAAAG 2250
DB 14 ACTATTACAAAAG 1

RESULT 283
US-10-287-919-2400/c
Sequence 2400, Application US/10287919
Publication No. US20030085830A1
GENERAL INFORMATION:
APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
TITLE OF INVENTION: Methanococcus jannaschii complete genome.
FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
CURRENT APPLICATION NUMBER: US/10/287,919
CURRENT FILING DATE: 2002-11-05
NUMBER OF SEQ ID NOS: 2706
SOFTWARE: Proprietary
SEQ ID NO 2400
LENGTH: 15
TYPE: DNA
ORGANISM: Methanococcus jannaschii complete genome.
FEATURE:
LOCATION: (1475658)...(1475673)
OTHER INFORMATION: Chromosome = 1 Strand = negative ConnectorObjectNumber = 3071
US-10-287-919-2400

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2237 ACTATTACAAAAG 2250
DB 14 ACTATTACAAAAG 1

RESULT 284
US-09-837-992-29
Sequence 29, Application US/09837992
Patent No. US20020081687A1
GENERAL INFORMATION:
APPLICANT: Tian, Hui
APPLICANT: Schultz, Joshua
APPLICANT: Shan, Bei
APPLICANT: Tularik Inc.
TITLE OF INVENTION: Sitosterolemia Susceptibility Gene (SSG): Compositions
FILE REFERENCE: 018781-006020US
CURRENT APPLICATION NUMBER: US/09/837,992
CURRENT FILING DATE: 2001-04-18
PRIOR APPLICATION NUMBER: US 60/198,465
PRIOR FILING DATE: 2000-04-18
PRIOR APPLICATION NUMBER: US 60/204,234
PRIOR FILING DATE: 2000-05-15
NUMBER OF SEQ ID NOS: 45

SOFTWARE: Patentin Ver. 2.1
 SEQ ID NO 29
 LENGTH: 16
 TYPE: DNA
 ORGANISM: Homo sapiens
 FEATURE:
 OTHER INFORMATION: 5' splicing site for exon 6
 US-09-837-992-29

Query Match 0.9%; Score 12.4; DB 1; Length 16;
 Best Local Similarity 92.9%; Pred. No. 1.7e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1649 TGCTGGCAGAGGTC 1662
 |||||
 Db 1 TGCTGGCAGAGGTC 14

RESULT 285
 US-09-816-460C-26
 Sequence 26, Application US/09816460C
 Publication No. US20030087235A1
 GENERAL INFORMATION:
 APPLICANT: Daikee, Shanaz H.
 TITLE OF INVENTION: PROGNOSTIC METHODS FOR BREAST CANCER
 FILE REFERENCE: CPMC-010/00US
 CURRENT APPLICATION NUMBER: US/09/816,460C
 NUMBER OF SEQ ID NOS: 47
 SOFTWARE: Patentin version 3.1
 SEQ ID NO 26
 LENGTH: 16
 TYPE: DNA
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: synthetic primer
 US-09-816-460C-26

Query Match 0.9%; Score 12.4; DB 1; Length 16;
 Best Local Similarity 92.9%; Pred. No. 1.7e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2500 GTGCCCTCCAGAG 2513
 |||||
 Db 1 GTGCCCTCCAGAG 14

Search completed: December 1, 2003, 12:01:49
 Job time : 5 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 1, 2003, 12:04:41 ; Search time 0.001 Seconds

(without alignments)
67.392 Million cell updates/sec

Title: us-09-954-556-3

Perfect score: 1404

Sequence: 1 tgggataccttcctcctcctg.....cctcagratccacacataaa 1404

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 0.5

Searched: 2 seqs, 24 residues

Total number of hits satisfying chosen parameters: 4

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Listing first 2 summaries

Database: rst.seq*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	10.4	0.7	12	1	BO587288 Accession:BO587288
C 2	10.4	0.7	12	1	BO587706 Accession:BO587706

ALIGNMENTS

RESULT 1
BO587288/c 12 bp mRNA linear EST 06-DEC-2002
LOCUS DEFINITION E012340W-024-010-G19-SP6 MP1Z-ADIS-024-leaf Beta vulgaris cDNA
clone 024-010-G19 5-PRIME, mRNA sequence.
ACCESSION BO587288
VERSION BO587288.1 GI:26116870
KEYWORDS EST.
SOURCE Beta vulgaris
ORGANISM Beta vulgaris
REFERENCE Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Caryophyllales; Amaranthaceae; Beta.
1 (bases 1 to 12)
AUTHORS Herwig,R., Schulz,B., Weishaar,B., Hennig,S., Steinfath,M., Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H. and Radelof,U.
TITLE Construction of a 'unigene' cDNA clone set by oligonucleotide fingerprinting allows access to 25 000 potential sugar beet genes
JOURNAL Plant J. 32 (5), 845-857 (2002)
COMMENT Contact: Weishaar B
ADIS DNA core facility at MP1Z
Max-Planck-Institute for Plant Breeding Research
Carl-von-Linne Weg 10, 50829 Koeln, Germany
Fax: 00492215062851
Email: weishaar@mpiz-koeln.mpg.de

Insert Length: 12 Std Error: 0.00
Plate: 10 row: G column: 19
Seq primer: SP6; CATACGATTAGCTGACACTATAG.
Location/Qualifiers
1. "12
/organism="Beta vulgaris"
/mol_type="mRNA"
/cultivar="KWS2320 (double haploid, monogerm breeding line)"
/db_xref="GABI:185570"
/db_xref="taxon:161934"
/clone="024-010-G19"
/issue_type="leaf"
/lab_host="EMDH10B"
/clone_lib="MP1Z-ADIS-024-leaf"
/note="Vector: pCIVSPORT6; Site 1: SalI; Site 2: NotI; cDNA library from sugar beet, library provided by KWS Kleinvanzlebener Saatzzucht AG Bindeck, Germany, contact: b.schulz@kws.de; cloning sites SalI-NotI, primer sites and orientation:
SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7; Note: Sequencing granted in the context of the GABI-Beet project, local PI: Dr. Katharina Schneider, coordinator: Prof. Christian Jung; Sequence submission managed by RZPD/GABI-Primary database: http://gabi.rzpd.de"

BASE COUNT 1 a 3 c 0 g 8 t

Query Match 0.7%; Score 10.4; DB 1; Length 12;
Best local Similarity 91.7%; Pred. No. 0;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1362 TGGAGAGAAAA 1373

Db 12 TGGAGAGAAAA 1

RESULT 2
BO587706/c 12 bp mRNA linear EST 06-DEC-2002
LOCUS DEFINITION E012340-024-010-G19-SP6 MP1Z-ADIS-024-leaf Beta vulgaris cDNA clone
024-010-G19 5-PRIME, mRNA sequence.
ACCESSION BO587706
VERSION BO587706.1 GI:26117288
KEYWORDS EST.
SOURCE Beta vulgaris
ORGANISM Beta vulgaris
REFERENCE Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Caryophyllales; Amaranthaceae; Beta.
1 (bases 1 to 12)
AUTHORS Herwig,R., Schulz,B., Weishaar,B., Hennig,S., Steinfath,M., Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H. and Radelof,U.
TITLE Construction of a 'unigene' cDNA clone set by oligonucleotide fingerprinting allows access to 25 000 potential sugar beet genes
JOURNAL Plant J. 32 (5), 845-857 (2002)
COMMENT Contact: Weishaar B
ADIS DNA core facility at MP1Z
Max-Planck-Institute for Plant Breeding Research
Carl-von-Linne Weg 10, 50829 Koeln, Germany
Fax: 00492215062851
Email: weishaar@mpiz-koeln.mpg.de
Insert Length: 12 Std Error: 0.00
Plate: 10 row: G column: 19
Seq primer: SP6; CATACGATTAGCTGACACTATAG.
Location/Qualifiers
1. "12
/organism="Beta vulgaris"
/mol_type="mRNA"
/cultivar="KWS2320 (double haploid, monogerm breeding line)"
/db_xref="GABI:185160"
/db_xref="taxon:161934"

```

/clone="024-010-G19"
/tissue_type="leaf"
/lab_host="EMDN10B"
/clone_lib="MP12-ADIS-024-leaf"
/home=vector: PCWVSORT6; Site_1: SalI, Site_2: NotI;
cDNA library from sugar beet, library provided by KWS
Kleinanzelebener Saatzzucht AG Bindeck, Germany, contact:
b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
orientation:
SP6-Sali-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7; Note:
Sequencing granted in the context of the GABI-beet project
, local PI: Dr. Katharina Schneider, coordinator: Prof.
Christian Jung; Sequence submission managed by
RZPD/GABI-Primary database:http://gabi.rzpd.de"

```

Query Match	0.7%	Score 10.4	DB 1	length 12
Best Local Similarity	91.7%	Pred. No. 0		
Matches 11, Conservative	0	Mismatches 1	Indels 0	Gaps 0

QY	1362	TCGAAGAGAAAA	1373
Db	12	TCGAAGAAAAA	1

```
Search completed: December 1, 2003, 12:04:41
Job time : 0.001 secs
```